

Vaginal Birth After Cesarean: New Insights

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10057-I

Prepared by

Oregon Evidence-based Practice Center, Oregon Health & Science University, Portland, Oregon

Investigator Team

Jeanne-Marie Guise, M.D., M.P.H.
Karen Eden, Ph.D.
Cathy Emeis, Ph.D., C.N.M.
Mary Anna Denman, M.D.
Nicole Marshall, M.D.
Rongwei (Rochelle) Fu, Ph.D.
Rosalind Janik, B.A.
Peggy Nygren, M.A.
Miranda Walker, M.A.
Marian McDonagh, Pharm.D.

AHRQ Publication No. 10-E003
March 2010

This information is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10057-I). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and other make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

Suggested Citation:

Guise J-M, Eden K, Emeis C, Denman MA, Marshall N, Fu R, Janik R, Nygren P, Walker M, McDonagh M. Vaginal Birth After Cesarean: New Insights. Evidence Report/Technology Assessment No.191. (Prepared by the Oregon Health & Science University Evidence-based Practice Center under Contract No. 290-2007-10057-I). AHRQ Publication No. 10-E003. Rockville, MD: Agency for Healthcare Research and Quality. March 2010.

No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in this report.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-Based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. This report was requested by the NIH Office of Medical Applications of Research as a background paper for the Consensus Development Conference on Vaginal Birth After Cesarean – New Insights. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions, and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review prior to their release.

AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality.

We welcome written comments on this evidence report. They may be sent to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Beth A. Collins Sharp, R.N., Ph.D.
Director, EPC Program
Agency for Healthcare Research and Quality

Shilpa Amin, M.D., M.B.sc, FAAFP
EPC Program Task Order Officer
Agency for Healthcare Research and Quality

Jennifer Crosswell, M.D., M.P.H.
Acting Director
Office of Medical Applications of Research
National Institutes of Health

Acknowledgments

This systematic evidence review was developed for the National Institutes of Health Consensus Development Conference on Vaginal Birth After Cesarean: New Insights. It was supported by the Office of Medical Applications of Research (OMAR) at the National Institutes of Health and the Agency for Healthcare Research and Quality (AHRQ) and the investigators acknowledge the contributions of Shilpa Amin, M.D., M.B.sc, FAAFP, Task Order Officer, AHRQ; Lata Nerurkar, Ph.D., OMAR, Jennifer Crosswell, M.D., M.P.H, OMAR; and Gary Cunningham, M.D., Chair of the Consensus Development Conference Panel. Investigators thank the Technical Expert Panel members for providing guidance for the project, the peer reviewers for providing feedback on the draft report, Andrew Hamilton, M.L.S., M.S., for conducting the literature searches; and Benjamin Chan, M.S., for providing statistical assistance; Abby Parsons, M.D., for providing abstract and paper review assistance; JoDee Anderson, M.D. for assistance on neonatal outcomes; and Alia Broman for data abstraction assistance.

Structured Abstract

Objectives: To synthesize the published literature on vaginal birth after cesarean (VBAC). Specifically, to review the trends and incidence of VBAC, maternal benefits and harms, infant benefits and harms, relevant factors influencing each, and the directions for future research.

Data Sources: Relevant studies were identified from multiple searches of MEDLINE®; DARE; the Cochrane databases (1966 to September 2009); and from recent systematic reviews, reference lists, reviews, editorials, Web sites, and experts.

Review Methods: Specific inclusion and exclusion criteria were developed to determine study eligibility. The target population includes healthy women of reproductive age, with a singleton gestation, in the U.S. with a prior cesarean who are eligible for a trial of labor (TOL) or elective repeat cesarean delivery (ERCD). All eligible studies were quality rated and data were extracted from good or fair quality studies, entered into tables, summarized descriptively and, when appropriate, pooled for analysis. The primary focus of the report was term pregnancies. However, due to a small number of studies on term pregnancies, general population studies including all gestational ages (GA) were included in appropriate areas.

Results: We identified 3,134 citations and reviewed 963 papers for inclusion, of which 203 papers met inclusion and were quality rated. Studies of maternal and infant outcomes reported data based upon *actual* rather than *intended* route of delivery. The range for TOL and VBAC rates was large (28-82 percent and 49-87 percent, respectively) with the highest rates being reported in studies outside of the U.S. Predictors of women having a TOL were having a prior vaginal delivery and settings of higher-level care (e.g., tertiary care centers). TOL rates in U.S. studies declined in studies initiated after 1996 from 63 to 47 percent, but the VBAC rate remained unimproved. Hispanic and African American women were less likely than their white counterparts to have a vaginal delivery. Overall rates of maternal harms were low for both TOL and ERCD. While rare for both TOL and ERCD, maternal mortality was significantly increased for ERCD at 13.4 per 100,000 versus 3.8 per 100,000 for TOL. The rates of maternal hysterectomy, hemorrhage, and transfusions did not differ significantly between TOL and ERCD. The rate of uterine rupture for all women with prior cesarean is 3 per 1,000 and the risk was significantly increased with TOL (4.7/1,000 versus 0.3/1,000 ERCD). Six percent of uterine ruptures were associated with perinatal death. No models have been able to accurately predict women who are more likely to deliver by VBAC or to rupture. Women with a prior cesarean delivery had a statistically significant increased risk of placenta previa compared with women with no prior cesarean, at a rate of 12 per 1,000 and risk increasing with the number of cesareans. Women with one prior cesarean and previa had a statistically significant increased risk of adverse events compared with previa patients without a prior cesarean delivery: blood transfusion (15 versus 32.2 percent), hysterectomy (0.7 to 4 percent versus 10 percent), and composite maternal morbidity (15 versus 23-30 percent). Perinatal mortality was significantly increased for TOL at 1.3 per 1,000 versus 0.5 per 1,000 for ERCD. Insufficient data were found on nonmedical factors such as medical liability, economics, hospital staffing, structure and setting, which all appear to be important drivers for VBAC.

Conclusions: Each year 1.5 million childbearing women have cesarean deliveries, and this population continues to increase. This report adds stronger evidence that VBAC is a reasonable and safe choice for the majority of women with prior cesarean. Moreover, there is emerging evidence of serious harms relating to multiple cesareans. Relatively unexamined contextual factors such as medical liability, economics, hospital structure, and staffing may need to be addressed to prioritize VBAC services. There is still no evidence to inform patients, clinicians, or policy-makers about the outcomes of *intended* route of delivery because the evidence is based largely on the actual route of delivery. This inception cohort is the equivalent of intention to treat for randomized controlled trials and this gap in information is critical. A list of future research considerations as prioritized by national experts is also highlighted in this report.

Contents

Executive Summary	1
Evidence Report	9
Chapter 1. Introduction	11
Structure of Report and Key Questions	13
Background Questions	13
Key Questions	13
Introduction	13
Background	14
What are the rates and patterns of utilization of trial of labor after prior cesarean, vaginal birth after cesarean, and repeat cesarean delivery in the United States?	14
What are the nonmedical factors (provider type, hospital type, etc) that influence the patterns of utilization of trial of labor after prior cesarean?	17
Chapter 2. Methods	21
Topic Development	21
Analytic Framework and Key Questions	21
Technical Expert Panel and Expert Reviewers	23
Literature Search and Strategy	23
Inclusion and Exclusion Criteria	23
General	24
Key Question 1	24
Key Question 2	25
Key Question 3	25
Key Question 4	26
Special Considerations	26
Data Extraction and Synthesis	27
Quality Rating of Individual Studies	27
Development of Evidence Tables and Data Abstraction Process	27
Strength of Available Evidence	28
Data Synthesis	29
Size of Literature	30
Chapter 3. Results	33
Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?	33
Trial of Labor Rate	33
Predictors of Trial of Labor	36
Vaginal Birth After Cesarean Rate	36
Induction of Labor	36
Predictors of Vaginal Birth After Cesarean	44
Screening Tools for Predicting Vaginal Birth After Cesarean	46

What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?.....	47
Maternal Death.....	47
Uterine Rupture.....	51
Hysterectomy	73
Transfusions/Hemorrhage.....	77
Infection	84
Surgical Injury	84
Hospital Stay.....	88
Pelvic Floor.....	89
Deep Vein Thrombosis	89
Special Considerations.....	90
Adhesions.....	116
Reproductive Health	116
What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?.....	117
Perinatal Mortality	117
Infant Morbidity.....	127
Sepsis	132
Birth Trauma.....	132
Apgar Scores.....	133
Neonatal Intensive Care Unit Admissions.....	133
Breastfeeding	138
Impact of Mode of Delivery on Subsequent Babies	138
Neurological Development.....	139
Special Considerations.....	139
Chapter 4. Discussion	143
What are the critical gaps in the evidence for decision-making, and what are the priority investigations needed to address these gaps?.....	151
National Childbirth Study	151
Prediction Tools.....	152
Maternal Health Outcomes	152
Infant Health Outcomes	153
Cost	153
References and Included Studies	157
Acronyms/Abbreviations	169

Tables

Table 1	Reasons behind women’s decisions for repeat cesarean delivery	17
Table 2	Vaginal birth after cesarean rates by types of induction.....	37
Table 3	Vaginal birth after cesarean and proportion with augmented labor in women induced with prostaglandin E ₂	39
Table 4	Vaginal birth after cesarean rate with oxytocin used for induction versus augmentation.....	42
Table 5	Most commonly reported indications and pooled proportions	43
Table 6	Uterine rupture: trial of labor versus elective repeat cesarean delivery among any gestational age studies.....	51
Table 7	Characteristics of uterine rupture studies of trial of labor and elective repeat cesarean delivery.....	54
Table 8	Rupture associated morbidity	56
Table 9	Effect of oxytocin augmentation on rate of uterine rupture in women receiving prostaglandin E ₂ for induction	65
Table 10	The odds of uterine rupture after cesarean delivery by factor	68
Table 11	Lower uterine segment thickness and uterine defect.....	71
Table 12	Hysterectomy rates of trial of labor versus elective repeat cesarean delivery	75
Table 13	Surgical injury rates for trial of labor versus elective repeat cesarean delivery among any gestational studies	86
Table 14	Abruption based on number of prior cesarean deliveries	91
Table 15	Blood transfusion by number of prior cesarean deliveries	92
Table 16	Overall incidence of placenta previa.....	92
Table 17	Incidence of placenta previa by number of prior cesarean deliveries.....	93
Table 18	Incidence of hysterectomy in women with previa by number of prior cesarean deliveries	97
Table 19	Overall incidence of placenta accreta	97
Table 20	Incidence of placenta accreta by number of prior cesarean deliveries	98
Table 21	Incidence of placenta accreta with placenta previa by number of prior cesarean deliveries	99
Table 22	Multiple cesarean deliveries effect on rates of hemorrhage	101
Table 23	Multiple cesarean deliveries effect on rates of adhesions.....	102
Table 24	Multiple cesarean deliveries effect on rates of surgical injury	103
Table 25	Multiple cesarean deliveries effect on rates of perioperative infection	103
Table 26	Multiple cesarean deliveries effect on rates of wound complications	104
Table 27	Multiple cesarean deliveries effect on rates of hysterectomy	105
Table 28	Impact of direction of scar	107
Table 29	Vaginal birth after cesarean rate in studies with data by body mass index	111
Table 30	Summary of findings on maternal and infant health outcomes for trial of labor and body mass index.....	114
Table 31	Perinatal mortality rate (20 weeks or greater gestation to 7 days of life) among any gestational age studies	119
Table 32	Fetal mortality rate (20 weeks or greater gestation and before birth) among term studies	122
Table 33	Neonatal mortality rate (death occurring in the first 28 days of life) among term studies	124

Table 34	Comparison of cohort studies reporting respiratory morbidity in infants among term studies	128
Table 35	Neonatal intensive care unit admissions among term studies.....	136
Table 36	Summary of evidence for key questions.....	146
Table 37	Future research.....	154

Figures

Figure 1	Rates of vaginal birth after cesarean (VBAC rate), total cesarean deliveries (CD rate), primary cesarean deliveries (Primary CD), and repeat cesarean delivery (RCD)	12
Figure 2	Cesarean delivery by country - percent for live births (2007).....	15
Figure 3	Vaginal birth after cesarean rates by state for 2006.....	16
Figure 4	Analytic Framework	22
Figure 5	Search and Selection of Literature.....	31
Figure 6	Trial of labor in studies conducted in the U.S. and outside the U.S	34
Figure 7	Global trial of labor rates have dropped over time	35
Figure 8	Vaginal birth after cesarean rates with oxytocin induction	41
Figure 9	Rates of maternal death for trial of labor among all studies.....	49
Figure 10	Rates of maternal death for elective repeat cesarean delivery among all studies.....	50
Figure 11	Uterine rupture among studies including both trial of labor and elective repeat cesarean delivery.....	53
Figure 12	Uterine rupture among all trial of labor studies	55
Figure 13	Risk for perinatal death given uterine rupture	57
Figure 14	Uterine rupture with induction of a trial of labor.....	59
Figure 15	Risk of rupture: induction versus spontaneous labor.....	60
Figure 16	Uterine rupture with prostaglandin E ₂ induction	62
Figure 17	Uterine rupture with oxytocin.....	64
Figure 18	Risk of uterine rupture with any induction method	67
Figure 19	Hysterectomy occurrence for trial of labor.....	76
Figure 20	Hysterectomy occurrence for elective repeat cesarean delivery.....	77
Figure 21	Transfusion rates for trial of labor versus elective repeat cesarean among all studies.....	78
Figure 22	Transfusion rates for trial of labor versus elective repeat cesarean delivery among term studies	79
Figure 23	Rates of infection for trial of labor versus elective repeat cesarean delivery among all studies	82
Figure 24	Rates of fever for trial of labor versus elective repeat cesarean delivery among all studies	84
Figure 25	Length of stay for trial of labor versus elective repeat cesarean delivery among any gestational age studies.....	89
Figure 26	Incidence of placenta previa by number of prior cesarean deliveries among any gestational age studies.....	96
Figure 27	Perinatal mortality rate for trial of labor versus elective repeat cesarean delivery among any gestational age studies.....	120
Figure 28	Neonatal mortality rate for trial of labor versus elective repeat cesarean delivery among term studies	128
Figure 29	Need for bag-and-mask resuscitation among term studies	129

Figure 30 Rates of transient tachypnea of the newborn for trial of labor versus elective repeat cesarean delivery among term studies130

Appendixes

Appendix A	Technical Expert Members
Appendix B	Expert Reviewers
Appendix C	Search Strategies
Appendix D	List of Developed Countries
Appendix E	Inclusion and Exclusion Criteria
Appendix F	Excluded Studies List
Appendix G	List of Citations From the Maternal-Fetal Medicine Units Network
Appendix H	Quality Rating Criteria
Appendix I	Individual Quality Rating Tables
Appendix J	Strength of Evidence Table
Appendix K	Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean
Appendix L	Detailed Evaluation of Vaginal Birth After Cesarean Rates
Appendix M	Induction of Labor Additional Figures
Appendix N	Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean
Appendix O	Detailed Maternal Mortality Table
Appendix P	Predictive Tools of Uterine Rupture Table
Appendix Q	Detailed Transfusion/Hemorrhage Table
Appendix R	Detailed Infection Table
Appendix S	Detailed Hospital Stay Table

Appendixes and evidence tables cited in this report are available at <http://www.ahrq.gov/downloads/pub/evidence/pdf/vbacup/vbacup.pdf>.

Executive Summary

Introduction

Despite the Healthy People 2010 national goal¹ to reduce the cesarean delivery rate to 15 percent of births each year, this century has set record rates of cesarean deliveries. When the national rate of cesarean delivery was first measured in 1965, it was 4.5 percent,² in 2007, almost one in three women in the United States (U.S.) delivered by cesarean (32.8 percent cesarean delivery rate in 2007). With almost 1.5 million cesarean surgeries performed every year, cesarean is the most common surgical procedure in the U.S. Vaginal birth after cesarean (VBAC) emerged from the 1980 National Institutes of Health (NIH) Consensus Conference on Cesarean as a mechanism to safely reduce the cesarean delivery rate.³ VBAC proved to be an effective contributor to reduce the use of cesarean through the early 1990s. From 1990 through 1996, the VBAC rate rose from 19.9 to 28.3 percent and the cesarean rate declined from 22.7 to 20.7 percent.⁴ Since 1996, VBAC rates have declined sharply, to the point where over 90 percent of women with a prior cesarean will deliver by repeat cesarean. While primary cesarean accounts for the largest number of cesarean deliveries, the largest single indication for cesarean is prior cesarean accounting for 534,180 cesareans each year, thus the safety of VBAC remains important.¹ The degree to which cesarean deliveries and VBACs are improving or adversely affecting health remains a subject of continued controversy and uncertainty. This systematic review was conducted to inform the 2010 NIH Consensus Development Conference to evaluate emerging issues relating to VBAC.

Key Questions

The key questions reviewed in this report were assigned by the Agency for Healthcare Research and Quality. Questions were based on deliberations of the planning committee for the National Institutes of Health Consensus Development Conference on Vaginal Birth After Cesarean: New Insights convened by the National Institutes of Health's Office of Medical Applications of Research and further refined by a technical expert panel during the evidence report process. Ultimately, four key questions were reviewed for this report:

1. Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?
2. What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?
3. What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?
4. What are the critical gaps in the evidence for decision-making, and what are the priority investigations needed to address these gaps?

Methods

Relevant studies were identified from multiple searches of MEDLINE®; DARE; the Cochrane databases (1966 to September 2009); and from recent systematic reviews, reference lists, reviews, editorials, Web sites, and experts. Retrieved abstracts were entered into an electronic database (EndNote®).

Of the 3,134 citations reviewed from the searches, 2,171 met exclusion criteria at the abstract level and were not reviewed further. After the abstract review process, 963 full-text papers were retrieved and reviewed for inclusion. An additional 37 full-text papers were retrieved from peer review. A total of 203 full-text papers met inclusion after applying paper inclusion/exclusion criteria. Investigators quality rated included studies, and those rated good or fair quality are discussed in this report. For the topics presented, 71 studies provided data on trial of labor (TOL) and VBAC rate, 27 on induction of labor (IOL) or augmentation, 28 on predictors of TOL and VBAC, 14 on scored models for predicting VBAC, 41 on maternal outcomes, 11 on infant outcomes, 28 on uterine rupture, 19 on abnormal placentation, seven on obesity, 12 on multiple cesarean deliveries, and seven on direction of cesarean delivery scar.

Results

Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?

Who attempts a trial of labor? The rates of TOL are highly variable, ranging from 28 to 70 percent with an overall rate of 58 percent in the U.S. The evidence is largely limited to large tertiary teaching hospitals. TOL rates have declined, particularly after 1996, both inside and outside of the U.S. In the U.S. studies that initiated enrollment after 1996, less than half (47 percent) of women had a TOL. TOL is more likely in hospitals with higher delivery volumes, tertiary care centers, and teaching hospitals. Women with a prior vaginal delivery or non-white women were more likely to have a TOL (odds ratio 1.51 to 6.67 and odds ratio 3.5, respectively).

What is the vaginal delivery rate? In 43 U.S. based studies, 74 percent of women who had a TOL delivered vaginally. While TOL rates reported in observational studies have dropped over time, VBAC rates have remained constant for the women who have a TOL.

What are the factors that influence the vaginal delivery rate? All scored predictive models provide reasonable ability to identify women who are good candidates for VBAC, but none have discriminating ability to consistently identify women who are at risk for cesarean delivery.

Antepartum factors

Prior vaginal delivery: A prior history of vaginal delivery was consistently reported to increase likelihood of VBAC approximately three fold (range odds ratio 1.83 to 28). Among women requiring induction of labor, limited evidence also suggests a higher rate of VBAC among those with prior vaginal delivery (OR 6.8; 95 percent CI: 3.04 to 13.9).

Indication for prior cesarean: Women with prior cesarean delivery for malpresentation/breech were more likely to have a VBAC (75 percent, range 60 to 86 percent) compared with women with prior cesarean delivery for fetal distress (60 percent, range 49 to 69 percent) or failure to progress/cephalopelvic disproportion (54 percent, range 48 to 60 percent).

Race: Hispanic and African American women were more likely to have a TOL but less likely to have a VBAC compared with non-Hispanic and white women, respectively (20 to 49 percent).

Location: Women at rural and private hospitals had a decreased likelihood of TOL and a decreased likelihood of VBAC (57 percent versus 66 percent for tertiary care centers).

Macrosomia: There was decreased likelihood of VBAC in infants weighing 4,000 grams or greater (odds ratio 0.62; 95 percent CI: 0.54 to 0.71). Infants weighing 4,500 grams or greater were less likely to be delivered via VBAC (1.3 to 5.8 percent) compared with 4,000 to 4,499g infants (11.6 to 17.4 percent).

Body mass index: VBAC rates ranged from 68 to 77 percent in the studies of obese women. Women with a body mass index (BMI) of less than 40 had VBAC rates of 52.1 to 70 percent.

Intrapartum factors

Progress of labor: A greater progress of labor--as determined by more advanced dilation, lower station, and higher Bishop score--predicted a higher likelihood of VBAC.

Epidural: The effect of epidural use on the likelihood of VBAC is uncertain.

Augmentation: Augmentation of labor with oxytocin was associated with a rate of 68 percent VBAC, although the strength of this evidence was low.

Induction: Sixty-three percent of women with IOL had a VBAC (PGE₂=63 percent, oxytocin=62 percent, misoprostol=61 percent). Fifty-four percent of women induced with a Foley Catheter had a VBAC.

What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

What are the short-term benefits and harms to the mother of TOL versus elective repeat cesarean delivery (ERCD)?

Maternal death. While maternal mortality is rare, with an overall rate of 10.1 per 100,000 for all women with prior cesarean, the risk of maternal mortality is significantly increased with ERCD (3.8 per 100,000 for TOL versus 13.4 per 100,000 ERCD). When limited to term studies, the maternal mortality was 1.9 per 100,000 for TOL and 9.6 per 100,000 for ERCD.

Hysterectomy. Hysterectomy was rare, occurring in less than three percent of all women with prior cesarean. There was no significant difference between the TOL and ERCD with respect to hysterectomy among all studies or when studies were limited to term populations; however hysterectomy was more common among women undergoing ERCD among studies that were open to all gestational ages (GAs).

Transfusion/hemorrhage. When limited to term studies, the rate of transfusion for TOL was 6.6 per 1,000 (95 percent CI: 2.0 to 22.1 per 1,000) and for ERCD was 4.6 per 1,000 (95 percent CI: 1.6 to 13.2 per 1,000). In term patients, TOL is associated with increased risk of transfusion. When all GAs are evaluated, there is an increased risk of transfusion with ERCD, suggesting a risk-modifying effect of preterm delivery on risk of transfusion. In low risk ERCD, there was a statistically significant increase in transfusion with TOL compared with ERCD prior to labor. Spontaneous labor may be protective against hemorrhage, but data are inconsistent.

Infection. For any GA cohorts, the risk for any infection with TOL was 46 per 1,000 (95 percent CI: 15 to 135 per 1,000) and for ERCD was 32 per 1,000 (95 percent CI: 13 to 73 per 1,000). The rate for fever with TOL was 65 per 1,000 (95 percent CI: 44 to 93 per 1,000) and for ERCD was 72 per 1,000 (95 percent CI: 25 to 189 per 1,000). Studies that did not report TOL outcome (VBAC or repeat cesarean delivery [RCD] after a TOL) tend to report increased febrile morbidity associated with TOL. Cesarean delivery, either ERCD or RCD after a TOL, appears to have a higher incidence of any febrile morbidity compared with VBAC but definitive studies are lacking. A trend toward increased endometritis was seen with ERCD compared with TOL; in contrast, chorioamnionitis was increased in TOL compared with ERCD. Increasing BMI was associated with increased fever in patients undergoing TOL.

Surgical injury. Rate of surgical injury may be increased with TOL, but definitive studies are lacking. Vertical skin incision increases risk of surgical injury to the bladder.

Length of stay. Elective repeat cesarean delivery is associated with a longer hospital stay compared with TOL. The mean length of stay for TOL was 2.55 days (95 percent CI: 2.34 to 2.76 days) compared with 3.92 days (95 percent CI: 3.56 to 4.29) for ERCD.

Uterine rupture. The risk of uterine rupture for all women with a prior cesarean delivery regardless of route of delivery is 0.3 percent (95 percent CI: 0.2 to 0.4 percent). The risk of uterine rupture for women undergoing a TOL is significantly elevated at 0.47 percent (95 percent CI: 0.28 to 0.77 percent); compared with women undergoing an ERCD (0.026 percent; 95 percent CI: 0.009 to 0.082 percent).

Maternal morbidity. To date, there have been no maternal deaths reported because of uterine rupture. The risk of hysterectomy due to uterine rupture ranged from 14 to 33 percent.

Neonatal morbidity. The overall risk of perinatal death due to uterine rupture was 6.2 percent. The two studies of women delivering at term that reported perinatal death rates report that 0 to 2.8 percent of all uterine ruptures resulted in a perinatal death. Overall, the literature relating to response time between premonitory signs of uterine rupture and perinatal mortality are insufficient. However, there is suggestion that fetal bradycardia is an ominous sign for fetal extrusion, which is associated with poor perinatal outcomes, and prompt delivery in this setting is warranted.

What factors influence the incidence of uterine rupture?

Direction of scar. Women with a prior classical incision are at increased risk of uterine dehiscence/rupture. Compared with women with prior low transverse cesarean delivery (LTCD), women with prior low vertical cesarean delivery (LVCD) or with an unknown scar are not at a significantly increased risk of uterine dehiscence or rupture.

Induction of labor. The risk of rupture with any IOL method at term was 1.5 percent and 1.0 percent when any GA was considered. At greater than 40 weeks, the rate was highest at 3.2 percent.

Gestational age. Relative to women with spontaneous labor, there was no increase in risk of rupture among those induced at term. Women induced after 40 weeks GA had an increased risk compared with those undergoing spontaneous labor (risk difference 1.8 percent; 95 percent CI: 0.1 to 3.5 percent, NNH 56).

Method of induction. The rate of uterine rupture by induction method--oxytocin, PGE₂, and misoprostol--was 1.1 percent, two percent, six percent, respectively. The risk of uterine rupture with mechanical methods of IOL is understudied.

Can uterine rupture be predicted? Studies of individual factors that may increase or decrease a woman's risk of uterine rupture are largely exploratory.

Protective factors. Women with prior vaginal delivery have lower risk for uterine rupture.

Risk factors. Women undergoing IOL have higher risk of uterine rupture compared with spontaneously laboring women. Women who are postdate may have a higher risk of uterine rupture. Obese and morbidly obese women are more likely to suffer rupture and/or dehiscence. Women with a prior classical incision are at increased risk of uterine rupture.

Predictive measures. No study was able to produce a reliable and robust model to predict uterine rupture. This is likely because uterine rupture is a rare event, and although there are factors associated with uterine rupture, none are of great magnitude. An accurate and reliable tool to predict an individual woman's risk of uterine rupture has not been found.

Imaging. The data regarding ultrasound measurements of uterine thickness and uterine rupture consistently suggest that there may be value to ultrasound measurements of uterine thickness for women with prior cesarean delivery.

What are the long-term benefits and harms to the mother of TOL versus ERCD?

Adhesions. Prior cesarean delivery was associated with a statistically significant increase in adhesions at subsequent cesarean and hysterectomy. Adhesions were associated with increased perioperative complications, time to delivery, and total operative time. It is unclear whether adhesions and complications increase with increasing number of prior cesareans.

General health. No studies evaluated TOL and/or RCD with respect to pelvic pain, risk of ectopic pregnancy, and general health risks, such as diabetes or high blood pressure.

Fertility. Two studies have shown impaired fertility following cesarean delivery. One study found a difference in the ability to conceive in subjects undergoing cesarean delivery compared with instrumented vaginal delivery (odds ratio 0.33; 95 percent CI: 0.12 to 0.98). Another study found a history of cesarean delivery was associated with increased odds of taking greater than 1 year to conceive (odds ratio 1.53; 95 percent CI: 1.09 to 2.14).

Menopause. One case-control study found an increased risk of early menopause in women with multiple cesarean deliveries compared with no pelvic surgery (odds ratio 2.69; 95 percent CI: 1.16 to 6.22).

What are the long-term benefits and harms to the mother of multiple cesarean? Women who do not have a TOL will undergo RCD and, potentially, multiple cesareans.

Hemorrhage/transfusion. The overall rates of hemorrhage/transfusion with multiple cesarean deliveries were less than five percent, but the risk appeared to increase with increasing numbers of cesareans.

Adhesions. The incidence of adhesions increased with increasing numbers of cesareans.

Surgical injury. Bladder, bowel, and ureteral injury are uncommon occurrences that appear to increase with multiple cesareans.

Infection. The risk of postoperative infection with multiple cesareans remains unclear.

Wound complications. The risk of wound complications does not appear to increase with multiple cesarean deliveries.

Hysterectomy. There was a strong correlation between multiple cesareans and hysterectomy. The odds ratio for hysterectomy with one prior cesarean was 0.7 to 2.14, with one or more was 1.4 to 7.9, and two or more was 3.8 to 18.6.

Abnormal placentation

Abruption. The risk of abruption for women with any prior cesarean was 0.10 to 0.15 percent. The risk did not appear to increase with prior cesarean or number of prior cesarean deliveries.

Previa. Women with a prior cesarean delivery had a statistically significant increased risk of placenta previa compared with women with no prior cesarean at a rate of 12 per 1,000 (95 percent CI: 8 to 15 per 1,000). The incidence increased with increasing number of prior cesarean deliveries. Prior cesarean was a significant risk factor for maternal morbidity in women with previa. Compared with previa patients without a prior cesarean delivery, women with one prior cesarean and previa had a statistically significant increased risk of blood transfusion (15 versus 32.2 percent), hysterectomy (0.7 to 4 percent versus 10 percent), and composite maternal morbidity (15 versus 23 to 30 percent). For women with three or more prior cesarean deliveries and previa, the risk of hysterectomy and composite maternal morbidity rose significantly (0.7-4 percent versus 50-67 percent and 15 versus 83 percent, respectively).

Accreta. The incidence of placenta accreta rose with increasing number of prior cesarean deliveries. The results were statistically significant for women with two or more prior cesareans (odds ratio 8.6 to 29.8).

Placenta previa and accreta. Women with placenta previa are at increased risk for placenta accreta, and the risk increased with increasing number of prior cesareans. Women with more than three prior cesareans and previa had a 50-67 percent incidence of accreta.

What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

What are the short-term benefits and harms to the baby of maternal attempt at TOL versus ERCD?

Perinatal death. Perinatal, fetal, and neonatal mortality rates were low in women with a history of prior cesarean delivery. The overall perinatal death rate with TOL was 1.3 per 1,000 (95 percent CI: 0.59 to 3.04 per 1,000) compared with 0.5 per 1,000 (95 percent CI: 0.07 to 3.82 per 1,000) for ERCD. The intrapartum death rates were consistently slightly higher in women who attempt a TOL (0.1 to 0.4 per 1,000) versus ERCD (0 to 0.04 per 1,000). Women with high-risk conditions and indicated repeat cesarean delivery (IRCD) appear to have higher rates of neonatal mortality.

Sepsis. Three studies measured sepsis in the neonate undergoing a TOL versus ERCD; however only one study actually defined and measured “proven” sepsis. This study found no differences in proven sepsis in infants born after TOL versus those delivered by ERCD.

Apgar scores. Four studies found no differences in Apgar scores of less than six and seven at 5 minutes in infants undergoing a TOL versus ERCD. Three studies examined the differences in low Apgars (less than seven) at 5 minutes in VBAC versus RCD after a TOL; two of these studies found no difference in Apgar scores of infants born by VBAC versus RCD after a TOL.

Neonatal intensive care unit (NICU) admission. Six of eight studies found no significant differences in frequency of NICU admissions between TOL and ERCD.

Breastfeeding. No studies were found that explored the effect of a TOL versus an ERCD on breastfeeding initiation or continuation.

Additional short-term outcomes. There was insufficient evidence to determine if rates of respiratory distress, neonatal trauma, or asphyxia/hypoxic-ischemic encephalopathy varied between TOL and ERCD.

Factors related to outcomes. There was insufficient data to determine that fetal presentation or gestational age in term neonates influences benefits or harms to the neonate undergoing TOL versus ERCD.

What are the long-term benefits and harms to the baby of maternal attempt TOL versus ERCD?

Perinatal outcome in future pregnancies. One study showed that prior cesarean delivery increases the risk for unexplained stillbirth in the next pregnancy and another study showed no difference in risk for stillbirth. Both studies are limited by their retrospective design and relied on large perinatal databases while employing various methodologies to overcome confounding.

Neurological development. No studies were found that measured the impact of a TOL versus ERCD on neonatal neurological development.

Discussion

While cesarean deliveries represent a third of all births, they account for almost half of the childbirth-related expenses of hospitalization, at \$7.8 billion annually.¹ A major contributor to the increase in cesareans is the rapid decline in VBACs witnessed over the last decade.

Therefore, the appropriate and safe use of cesarean and VBAC is not only an individual patient- and provider-level concern, but it is also a national health policy concern.

One of the major findings of this report is that the best evidence suggests that VBAC is a reasonable and safe choice for the majority of women with prior cesarean. The occurrence of maternal and infant mortality for women with prior cesarean is not significantly elevated when compared with national rates overall of mortality in childbirth. The majority of women who have TOL will have a VBAC, and they and their infants will be healthy. However, there is a minority of women who will suffer serious adverse consequences of both TOL and ERCD. While TOL rates have decreased over the last decade, VBAC rates and adverse outcomes have not changed suggesting that the reduction is not reflecting improved patient selection. Sophisticated statistical models have not been able to predict those women who will do well and those who will be harmed.

The most dramatic change since the 1980 VBAC report is the number of women with multiple cesareans. This report found that women with three or more prior cesareans are at significantly increased risk of complications, and the risks increase for women with prior cesarean delivery and previa. Since we are unable to determine which women will have previa or to prevent its occurrence, all pregnant women are at risk, and the risk increases with multiple cesareans.

Studies of VBAC versus ERCD have traditionally reported outcomes based upon actual route of delivery rather than intended route, leading to misclassification of patients who intend elective repeat cesarean but go into labor prior to their cesarean or women who intended trial of labor but who are delivered by cesarean. The evidence from these studies is at best indirect and difficult to apply to a woman who plans for either option. Each leaves clinicians and patients uncertain of the ramification for their decisionmaking and masks potential adverse effects of desiring one route of delivery but having another.

Mode of delivery for subsequent pregnancies poses a difficult question for women with prior cesarean and their providers. Some women have already made their decision prior to leaving the hospital after their cesarean, due to factors surrounding that birth. Others will decide early in pregnancy, and still others will remain undecided until presenting in labor. Some women will not have a choice due to provider, hospital, insurance, or medico-legal factors that mandate repeat cesarean. This report suggests that although there are statistically significant differences between ERCD and TOL, there are very few clinically significant differences, and the overall mortality risk is not significantly elevated between women with prior cesarean delivery and women undergoing their first pregnancy. Serious deficiencies were found in the existing literature, however, and this report provides a list of research priorities as prioritized by national experts as well as potential study designs to advance the field and provide important information to patients, clinicians, and policymakers.


Evidence Report

Chapter 1. Introduction

The effective and safe use of cesarean delivery has been a focus of national attention and concern for decades. Thirty years ago the National Institutes of Health (NIH) held a Consensus Conference on Cesarean Childbirth in response to concerns about a three-fold increase in the rate of cesarean deliveries (from 5 to 15.2 percent).^{3,5,6} As a result of that conference, vaginal birth after cesarean (VBAC) was proposed as a mechanism to reduce the use of cesareans. As shown in Figure 1, though it took almost a decade following the conference to gain popularity, VBAC effectively contributed to the reduction in the cesarean rate. As the VBAC rate rose from 19.9 percent in 1990 to 28.3 percent in 1996, the cesarean delivery rate decreased from 22.7 percent to 20.7 percent over the same time period.⁴ However, a complex combination of emerging studies that suggested that the morbidity associated with VBAC, particularly uterine rupture, was higher than initially thought; organizational changes; and liability pressures resulted in a rapid reduction in the practice of VBAC and concomitant increases in cesarean delivery. While primary cesarean accounts for the largest number of cesarean deliveries, the largest single indication for cesarean is prior cesarean, accounting for over a third of all cesareans; thus the safety of VBAC remains important.¹ Despite the national goal, as stated by Healthy People 2010⁷ to reduce the cesarean delivery rate to 15 percent of births, the cesarean delivery rate for 2007 is the highest ever recorded, at 32.8 percent of all births.¹ This systematic review was conducted to inform the 2010 NIH Consensus Development Conference on emerging issues relating to VBAC.

Appendixes and evidence tables cited in this report are available at <http://www.ahrq.gov/downloads/pub/evidence/pdf/vbacup/vbacup.pdf>.

Figure 1. Rates of vaginal birth after cesarean (VBAC rate), total cesarean deliveries (CD rate), primary cesarean deliveries (Primary CD), and repeat cesarean delivery (RCD)^{8, 9}



*ACOG guidelines from 1995 states “In the absence of contraindications, a woman with one previous cesarean delivery with a lower transverse uterine incision is a candidate for VBAC and should be counseled and encouraged to undergo a trial of labor.”

†Landmark paper published by McMahon¹⁰

‡ACOG guidelines from 1999 states “VBAC should be attempted in institutions equipped to respond to emergencies with physicians immediately available to provide emergency care.”

§Landmark paper published by Lydon-Rochelle, 2001¹¹

Structure of Report and Key Questions

An evidence report focuses attention on the strengths and limits of evidence from published studies about the effectiveness and/or harms of a clinical intervention. The development of an evidence report begins with a careful formulation of the problem. The Evidence-based Practice Center (EPC) systematically reviewed the relevant scientific literature on key questions relating to VBAC assigned by the Agency for Healthcare Research and Quality (AHRQ), the Planning Committee for the NIH Consensus Development Conference on VBAC: New Insights, the National Institutes of Health's Office of Medical Applications of Research (OMAR), and further refined by a technical expert panel (TEP). Ultimately, two background questions and four key questions were reviewed for this report:

Background Questions

- What are the rates and patterns of utilization of trial of labor after prior cesarean, vaginal birth after cesarean, and repeat cesarean deliveries in the United States?
- What are the nonmedical factors (provider type, hospital type, etc.) that influence the patterns and utilization of trial of labor after prior cesarean?

Background questions will be addressed in the introduction of the report with information from reputable sources; however, these data are not part of the systematic review process.

Key Questions

1. Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?
2. What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?
3. What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?
4. What are the critical gaps in the evidence for decision-making, and what are the priority investigations needed to address these gaps?

Introduction

The strength and suitability of the evidence regarding the risks of major maternal and infant morbidity and mortality associated with VBAC is the focus of this evidence report. In judging the suitability of evidence, the perspective taken was what a decisionmaker would want to know—that is, whether the risk for complications is higher for women who plan a VBAC versus those who plan an elective repeat cesarean delivery (ERCD), under optimal conditions of care. Some components of obstetric care, as well as some aspects of the setting of this care, might increase the risks of VBAC or ERCD.

The evidence report emphasizes direct evidence between an intervention (e.g., planned VBAC or ERCD) and health outcomes, the quality of individual studies, and the strength of the body of evidence, giving weight to studies that are appropriately designed to answer a question and meet high methodological standards that reduce the likelihood of biased results. To compare two different treatments or management strategies, the results of well-done, randomized

controlled trials (RCTs) are often regarded as better evidence than are results of cohort, case-control, or cross-sectional studies. These designs, in turn, are considered to provide better evidence than do uncontrolled trials or case series. However, it is increasingly becoming recognized that observational studies may provide important information to aid in understanding adverse events when interventions are applied to more heterogeneous populations than are typical of RCTs. In addition, studies—particularly trials—of interventions are often conducted in narrow populations that are more homogeneous and less generalizable than the intended clinical population or they do not include important populations that may be more susceptible to harm. Therefore, observational studies that reflect actual clinical effectiveness in more heterogeneous populations and community settings can provide information that is more generally applicable. Similarly, observational studies can provide quality evidence for assessing diagnostic tests or prediction tools.

Throughout the report, three key comparative effectiveness themes are emphasized: 1) understanding whether *particular populations* have higher likelihood of benefits or harms, 2) whether *particular settings* experience higher benefits or harms, and 3) understanding *the role of study designs* in shaping the understanding of important outcomes or harms from therapies. The approach to the evidence not only reports the findings of studies relating to a key question, but also looks for information that may illuminate important consequences for the intervention being more broadly applied. Sub-questions included in this summary may include:

- Are there important racial, ethnic, socio cultural, genetic, access to healthcare, medical utilization, patient values, patient adherence and compliance differences that affect response to therapy?
- What populations are particularly susceptible to harm?
- Are the results of effectiveness likely to be retained in populations with more heterogeneity, co-morbidities, different age groups, values, preferences, or settings, or other characteristics?

Similarly, this report aims to enhance future research. It is important for researchers to know how their choice of study design may affect their results and what elements of study design portend higher quality. This report provides these details as a step to informing and improving future research.


Background

The following were asked as background questions to this evidence report. Information is summarized from reputable sources, but did not undergo a systematic review process.

What are the rates and patterns of utilization of trial of labor after prior cesarean, vaginal birth after cesarean, and repeat cesarean delivery in the United States?

Cesarean delivery rates continue to rise in the developed world. A recent report from the Organization for Economic Cooperation and Development (OECD) that provides health statistics and indicators for 30 countries, reports that the U.S. has one of the highest cesarean delivery rates in the world (Figure 2).¹²


Figure 2. Cesarean delivery by country - percent for live births (2007)¹²



Note: Data for Norway, Ireland, Australia, United States, and Italy are from 2006

The cesarean delivery rate in the U.S. reached an all time high of 32.8 percent in 2007, far exceeding the national goal of 15 percent.^{1,7} Though there are many potential causes, the decline in VBACs has certainly contributed to this trend. Cesarean delivery and VBAC rates differ considerably by state ranging from 2.5 to 20.9 percent (Figure 3).

Figure 3. Vaginal birth after cesarean rates* by state for 2006⁹



*Percentage of women with a previous cesarean who then have a subsequent vaginal delivery

The effects of declining VBAC on cesarean rates are particularly pronounced after 1996. When the VBAC rate rapidly began to decline from a high of 28.3 percent in 1996 to its current low of 8.7 percent of live births, the cesarean rate climbed by more than 50 percent (from a rate of 20.7 percent in 1996, Figure 1).¹ Increases in cesarean delivery between 2006 and 2007 were reported for all age groups and for the three largest racial groups, white, Black, and Hispanic.⁸ The coupling of this trend with a concomitant increase in the primary cesarean delivery rate portends a continued escalation in the overall national cesarean delivery rate.

Both vaginal deliveries and cesareans hold inherent risks. Thus, mothers and clinicians are faced with complex decisions and must weigh possible risks and benefits associated with VBAC versus ERCD. How these decisions are made could have dramatic effects on the health of mothers and their children.

Patient decisionmaking. Several prior studies reported that up to half (48 percent) of women make decisions about a future trial of labor (TOL) before becoming pregnant again.¹³⁻¹⁷ An additional 34 to 39 percent decide to have a TOL by the midpoint of the pregnancy.^{15, 17, 18}

A prior systematic review¹³ and several recent studies report that patients' birth choices are complex and are driven by multiple competing factors. Women are balancing perceived health risks to themselves and their infants while also processing prior birth experiences and family and societal influences.^{13, 18, 19} Few studies have examined the reasons behind women's decisions for ERCD or VBAC.^{15, 20} Table 1 lists the reasons behind women's decisions for ERCD by study.

Table 1. Reasons behind women's decisions for repeat cesarean delivery

Study, year	Reasons
Kirk, 1990 ¹⁵	Low probability of vaginal delivery Avoid pain in labor Danger of vaginal birth for mother Danger of vaginal birth for infant Knew what to expect
McClain, 1990 ²⁰	Interaction with clinician Their reconstruction of the meaning of cesarean Personal ideas of motherhood and reproduction

A woman's perception of self-efficacy^{21, 22} and inability to fulfill family obligations²² have been cited as reasons for women choosing VBAC. Patient involvement in decisionmaking as well as VBAC counseling and educational programs have also been associated with increased choice for VBAC, in addition to increased patient satisfaction.²³⁻²⁷ The timing of VBAC education seems to be important, with earlier timing of VBAC education in pregnancy being associated with higher TOL rates.^{27, 28} Conversely, two studies, one out of Scotland and one from the U.S., found that a lack of education or discussion with their clinician was associated with ERCD.^{23, 29} Interestingly, discussion of uterine rupture does not appear to have undue negative influence on patient decisionmaking.^{29, 30} Studies examining external influences on a woman's choice for VBAC have found that women highly value the opinion of their healthcare provider^{18, 23, 29} and to a lesser extent sought input from their partners, family, friends, or other outside sources such as the Internet.^{18, 23}

Decision aids/interventions. Recently, decision aids have emerged to help a woman set priorities or understand her childbirth preferences, and ultimately help her make decisions. Decision aids are available in several formats: DVDs, paper booklets, and interactive computer or Web-based decision aids. Studies of VBAC decision aids have shown that they reduce a woman's decisional conflict and increase knowledge scores; however, their impact on actual decisionmaking is uncertain.³¹⁻³⁴

What are the nonmedical factors (provider type, hospital type etc) that influence the patterns and utilization of trial of labor after prior cesarean?

Despite increasing evidence to inform women and clinicians about the medical benefits of a TOL versus ERCD, the rate of TOL attempts continue to decline.⁸ Nonmedical factors that influence the patterns and utilization of TOL after cesarean delivery are numerous, yet relatively little research has been devoted to acknowledging and understanding their influence on the patterns and utilization of TOL after prior cesarean delivery. Nonmedical factors that have been suggested to contribute to this decline include professional liability concerns, professional and institutional policies, patient insurance type, as well as provider and patient attitudes.^{35, 36}

Medical liability and provider decisionmaking. Examination of closed malpractice cases for obstetricians and midwives indicates that VBAC is an important cause of obstetric lawsuits for maternity providers.³⁷⁻⁴⁰ According to a recent American College of Obstetricians and Gynecologists (ACOG) professional liability survey, 91 percent of obstetric and gynecologic physicians responding to the survey reported that they experienced at least one liability claim in their career and 62 percent of those claims related to obstetric care.³⁷ More than half of

respondents reported making changes in their practice due to the availability or affordability of malpractice insurance with 19.5 percent reporting increasing their cesarean rate, 19.0 percent decreasing their VBAC rate, 21 percent decreasing their number of high-risk pregnant patients, and 6 percent stopping obstetric practice entirely.

Though the studies are few, the literature generally supports the association between medical-legal pressures and both increased likelihood to perform cesarean deliveries and reduced likelihood to perform VBACs.^{37, 41-43} Both regional and hospital malpractice claims have been associated with higher cesarean delivery rates. One study of hospitals in New York reported that the odds of cesarean delivery were three times higher in high premium regions compared with low premium regions (95 percent CI: 2.13 to 4.24).⁴¹ Similarly, higher hospital-level claims were significantly associated with higher cesarean rates after controlling for clinical risk (1.26; 95 percent CI: 1.10 to 1.43), and physicians' perceptions of risk of suit was also associated with almost a two-fold increased odds of cesarean (1.96; 95 percent CI: 1.53 to 2.93). One study demonstrated that for each annual \$10,000 increase in medical liability insurance premium, the primary cesarean rate increased by 15.7 per 1,000 for term nulliparous women.⁴² Looking specifically at tort reform, caps on noneconomic damages were the leading predictor of delivery method, in one study, with VBAC rates being significantly higher and cesarean delivery rates significantly lower in states where caps on noneconomic damages existed. A dose response of sorts was found among noneconomic tort caps suggesting that noneconomic caps at \$250,000 would be associated with 9,000 additional VBACs and 12,000 fewer cesarean deliveries.⁴³ Overall the literature supports a connection between malpractice liability and even provider perception of risk of liability and use of cesarean.

Several studies have tried to understand providers' attitudes toward TOL after a prior cesarean delivery.⁴⁴⁻⁴⁹ These studies note disparity in the management approaches of providers in women who desire a TOL as well as a perceived increased risk of liability when caring for women who attempt a VBAC. Upon examination of 109 closed malpractice claims from a single liability insurer, Clark et al concluded that 80 percent of VBAC lawsuits were potentially avoidable by a management style that limited VBAC to spontaneously laboring women without repetitive moderate to severe variables.³⁹ Some authors have suggested checklists, structured guidelines, and simulation of obstetric emergencies to enhance consistency and reduce adverse events, but to date, there is insufficient evidence about their effectiveness.⁵⁰⁻⁵²

More recently, reports of limited access to hospitals and providers willing to provide a TOL after a previous cesarean have emerged.²⁵ Much of this decline in VBAC services is thought to be in response to a shift in professional and hospital guidelines indicating that "VBAC should be attempted in institutions equipped to respond to emergencies with physicians immediately available to provide emergency care."⁵³ Smaller hospitals with limited staff and resources have difficulty meeting these requirements, interpreted as in-house presence of obstetric surgical providers, and many institutions have discontinued offering VBAC services. Declines in rural hospitals offering TOL after cesarean have resulted in VBAC services becoming centralized, many times far away from where women live and work.⁵⁴ In a descriptive, comparative study, Misra et al found that VBAC attempts had declined in Maryland from 2000 to 2005 (4.65 versus 3.58 percent, respectively) while the total (primary and repeat) cesarean rate rose from 21.71 percent in 1995 to 24.03 percent in 2005.⁵⁵ In a study of all institutions (N=312) providing birth services in a four state region, Roberts et al found 30.6 percent of hospitals previously offering VBAC services prior to the 1999 ACOG policy recommendation had ceased doing so.⁵⁶ This study also found that access to VBAC services in smaller or more rural hospitals was

disproportionately affected. The ethical, social, and financial implication of women delivering subsequent pregnancies by cesarean because of limited options for a TOL after cesarean delivery within their community is unstudied.

Several studies have explored the relationship between private and public health insurance and VBAC.⁵⁷⁻⁵⁹ Wagner et al found that Medicaid insured women were more likely than privately insured women to attempt a TOL (64 versus 50 percent, $p=0.001$) and to have a VBAC (62 versus 60 percent, $p=\text{not significant [NS]}$).⁵⁸ In a recent review of state Medicaid coverage and utilization of cesarean delivery, Grant found that an increase in the amount physicians are reimbursed for cesarean deliveries versus vaginal delivery does account for a slight increase in the number of cesareans being performed.⁵⁹ Specifically, a \$1,000 increase in the reimbursement for performing a cesarean increases cesarean delivery rates by 1 percent. A major factor that distinguishes VBAC from ERCD is the labor process that could take hours to days and requires constant provider supervision. The current structure for provider reimbursement reimburses the delivery event (e.g., vaginal versus cesarean delivery) rather than the process. No studies were found that addressed the effect of this structure of reimbursement on provider's willingness to offer VBAC.

In summary, the nonmedical factors that influence the patterns and utilization of TOL after prior cesarean delivery are numerous and complex. Studies consistently suggest that these nonmedical factors play an important role in decisionmaking and patient access. A better understanding of nonmedical issues and the significance of their impact on utilization of VBAC is warranted.

Chapter 2. Methods


Topic Development

Analytic Framework and Key Questions

The Planning Committee for the National Institutes of Health (NIH) Consensus Development Conference on Vaginal Birth After Cesarean (VBAC): New Insights determined the key questions for this evidence report. Key questions examine 1) a chain of evidence about factors that may influence VBAC, 2) maternal and infant benefits and harms of attempting a VBAC versus an elective repeat cesarean delivery (ERCD), and 3) factors that may influence maternal and infant outcomes. Figure 4 presents an analytic framework that illustrates the clinical logic and contextual factors that underlie the key questions of this report. An analytic framework is intended to illustrate relevant clinical logic and other influencing factors, in this case relating to VBAC. It is meant to clarify the context in which decisions about route of delivery are made, clarify direct and indirect associations, and clarify assumptions and disagreements that underlie clinical controversies. Thus, the analytic framework serves as a central conceptual model for what information is being sought (key questions), what the literature tells us, and the information gaps between the two.

The framework starts with the population of interest, in this case women with a prior cesarean delivery. It explicitly aims to understand a woman's initial intended route of delivery and the factors that influence that initial intention. During this evolving decisionmaking process, there may be adverse outcomes that arise from discordance between an initial preference and the actual choices available, or there may be unforeseen benefits. The routes of delivery are listed in some detail with respect to features that may contribute uniquely to risks and benefits. The framework then clarifies the relationship among the route of actual delivery, intermediate outcome measures, and maternal and infant health outcomes. This framework represents both what might be found in the literature and also important considerations for consumers, clinicians, payers, policymakers, and future research. Studies that measure health outcomes, such as maternal and infant mortality, are emphasized over studies of intermediate outcomes (e.g., nonreassuring fetal tracing). Studies providing evidence of a direct association between an intervention (e.g., ERCD) and health outcomes are said to provide direct evidence and are given greater weight than are studies that provide indirect evidence.

Figure 4. Analytic framework



Key Questions

1. Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?
2. What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?
3. What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?
4. What are the critical gaps in the evidence for decision-making, and what are the priority investigations needed to address these gaps?

Abbreviations

CD=cesarean delivery, ERCD=elective repeat cesarean delivery, IRCD=indicated repeat cesarean delivery, TOL=trial of labor, UR=uterine rupture, VBAC=vaginal birth after cesarean

Technical Expert Panel and Expert Reviewers

A technical expert panel (TEP) (Appendix A) was assembled at the start of the evidence report process to provide input from experts and clinicians in the field to ensure that the scope of the project addressed important clinical questions and issues. The panel included obstetrician/gynecologists, internists, pediatricians, family physicians, and researchers. The panel convened for periodic conference calls during the course of the project. Expert reviewers (Appendix B), including several panel members, provided comments on the draft evidence report.

Literature Search and Strategy

Relevant studies were identified from searching MEDLINE, Database of Abstracts of Reviews of Effectiveness (DARE), and the Cochrane Database of Systematic Reviews and Controlled Trials (1966 to September 2009) multiple times over the course of the project (Appendix C). Additional articles were obtained from recent systematic reviews, reference lists, reviews, editorials, hand searching, Web sites, and by consulting experts. Retrieved abstracts were entered into an electronic database (EndNote®).

A total of 3,134 unique citations were reviewed from the searches. Two investigators reviewed a random set of titles and abstracts to select articles for full text review. When an appropriate level of reliability was reached for inclusion/exclusion of studies, the remaining titles and abstracts were divided up and reviewed by one investigator. A research assistant tracked the inclusion status and names of reviewers for each abstract reviewed. The full text articles of citations that had original data about maternal and infant outcomes relevant to a key question in one or more topic area were retrieved.

Inclusion and Exclusion Criteria

The target population includes women of reproductive age in the United States (U.S.) with a prior cesarean delivery who are eligible for a trial of labor (TOL) or ERCD. Settings that were applicable to a U.S. population were included. Therefore, studies were not limited to the U.S.; foreign studies were included if originating from a developed country (Appendix D). This was believed to offer the broadest range of information on maternal and infant outcomes applicable to the U.S. population. The evidence report emphasizes the patient's perspective in choice of mode of delivery, interventions needed for induction and/or augmentation of labor, and potential adverse effects of a specific mode of delivery on maternal and infant outcomes. It also considers the generalizability of efficacy studies performed in controlled settings.

The Planning Committee for the NIH Consensus Development Conference identified their ideal population of interest as term infants (greater than or equal to 37 weeks gestational age [GA]). However, after initial review of the searches, there was concern about the lack of data on term-only infants. Two cohort studies that compared outcomes of term infants with preterm infants were reviewed and showed no difference.^{60, 61} For both of these reasons, general population studies of women with a prior cesarean delivery who delivered at any GA (preterm and term) were included as were studies that focused exclusively on women delivering at term. While this approach was thought to be reasonable for maternal outcomes, infant outcomes are affected by prematurity, and the scope of studies for this topic remained limited to term studies, except where noted.

General

For all key questions, full text studies with data on women with a prior cesarean delivery eligible for a TOL or ERCD and maternal and/or infant outcomes were initially reviewed. They were subsequently included if they met eligibility criteria: 10 or more subjects, participants represented the target population, and data on benefits and harms to the mother or infant given either mode of delivery. Exclusions included studies of women without a prior cesarean delivery, nulliparous patients, breech delivery, exclusive focus on preterm delivery, low birth weight, studies of pregnancies including twins or abortions, studies begun or published before the 1980 NIH Consensus Conference on VBAC, and studies focusing on patients with particular conditions such as gestational diabetes, human immunodeficiency virus, preeclampsia, etc. (Appendix E). Non-English language papers, editorials, letters, studies available exclusively in abstract form, and studies of animals or cadavers were also excluded. Case-control and case series studies meeting similar inclusion/exclusion criteria were examined and included if they reported relevant data. Given that the focus of this report is intended for a U.S. obstetric population, studies conducted in undeveloped or developing countries were excluded (Appendix D). If the authors described their country as “developing” in either the abstract or the article, it was excluded. For a full listing of excluded studies, please see the excluded studies list in Appendix F.

Investigators read the full text version of the retrieved papers and re-applied the initial eligibility criteria. For all topics, articles were excluded if they did not provide sufficient information to determine the methods for selecting subjects and for analyzing data. For some topics, additional criteria were applied to select studies that were systematically reviewed.

For the purposes of this report, the term “rate” is used to describe the proportion of women who experienced a given event (i.e., VBAC, ERCD, etc.). Though this is not always technically correct when expressing summary statistics, it is a term that is used throughout the literature and easily understood by patients and clinicians.

Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?

For this question, full text randomized controlled trials (RCTs) were reviewed in addition to observational studies. This key question was limited to studies with data on women with a prior cesarean delivery having a TOL and vaginal delivery rates and/or factors influencing the delivery rate. For evaluating the rates of TOL and VBAC, studies were included if they explicitly stated the inclusion and exclusion criteria and provided data for computing TOL or VBAC rates.

To evaluate the effect of induction of labor (IOL) on women with a prior cesarean delivery, only studies that reported the number of women who were induced and the corresponding number with VBAC, uterine rupture, or other relevant outcome were included. Of particular interest were those studies that stratified data by the method of IOL, or whether oxytocin was used for IOL or augmentation or both. We included RCTs and observational studies, preferring cohort designs with an inception cohort but also including less rigorous designs (case series) because data from RCTs and cohort studies were sparse.

What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

For this question, the ideal comparison group was intended VBAC versus intended ERCD. However, as no studies of health outcomes measured intent, the primary comparison groups were TOL and ERCD, unless otherwise noted.

An important concern for patients, providers, hospitals, and policymakers regarding VBAC is the potential for uterine rupture, which can have severe maternal and infant morbidity and mortality. To determine how frequently uterine rupture occurs, it is important to have a clear definition for uterine rupture. A prior systematic review of VBAC and uterine rupture found that studies varied widely in their definition and use of terminology surrounding uterine rupture.⁶² This report uses the anatomic definition of uterine rupture that was proposed by the prior evidence report and restated by the TEP for this project. For the purposes of this report, uterine rupture is defined as:

- Complete Uterine Rupture – separation through the entire thickness of the wall including visceral serosa (with or without extrusion of part of all of fetal-placental unit)
- Incomplete Uterine Rupture – separation that was not completely through all layers of the uterine wall (e.g., serosa intact)⁶²

To evaluate the effect of IOL on the outcome of uterine rupture, the definitions given above were used in the primary analysis. Because the number of studies using these definitions was small, the scope of literature was expanded to enable examination of individual factors predicting uterine rupture, predictive tools, and imaging to predict uterine rupture.

What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

For this question, all studies were limited to term infants (greater than or equal to 37 weeks GA), with the exception of fetal macrosomia and perinatal mortality. Studies addressing the influence of fetal macrosomia used fetal weight (greater than or equal to 4,000 grams) for the inclusion criteria instead of GA.

To measure the frequency of perinatal mortality and the corresponding subsets of perinatal death, we used the definitions accepted by the National Center for Vital Statistics.⁶³ The definition of perinatal death (perinatal II) included infants less than 28 days of age and fetal deaths of 20 weeks or more GA. To study the frequency of stillbirth (antepartum and intrapartum) we used both the intermediate and late fetal definitions of fetal death. Intermediate (20-27 weeks GA) and late fetal death (greater than or equal to 28 weeks GA) referred to the intrauterine death of a fetus before delivery. Although most fetal deaths occur early in pregnancy (less than 20 weeks GA), most countries, and in particular the U.S., only report intermediate and late fetal death. Neonatal (infant) mortality was defined as death in the first 28 days of life.⁶³ Rates for perinatal, fetal, and neonatal mortality were reported per 1,000 live births.

To better understand the relationship between perinatal morbidity and mortality with fetuses or infants born to women with a prior cesarean delivery, we excluded studies that did not exclude cases with congenital or lethal anomalies (before or after analyses). If it could be determined in the analysis or discussion section of a study which perinatal deaths were owed to congenital anomalies, we retained the study for inclusion (excluding the deaths attributed to anomalies). To reduce the effects of prematurity on the neonatal mortality rate, we limited our analyses of neonatal mortality to term infants.

What are the critical gaps in the evidence for decisionmaking, and what are the priority investigations needed to address these gaps?

For this question, investigators reviewed the synthesis of their results and compiled a list of relevant areas that were lacking in evidence. During the expert review process, reviewers were asked to prioritize the gaps identified by the investigators. Specifically, experts were asked if stated topic areas were of low, medium, or high priority for future research and to provide additional clarification on their positions. Areas rated as highest priority, meaning 50 percent of the experts rated the domain as high, are discussed in this section.

Special Considerations

There are topics of interest that do not easily fall into the key questions, these include: effect of maternal obesity, multiple cesarean deliveries, and direction of cesarean scar on outcomes. For the effect of maternal obesity on outcomes, full text papers were excluded if the prior cesarean delivery group was not broken out in TOL analysis, VBAC rates were not provided by body mass index (BMI) or weight categories, or if BMI or weight were used as one of many predictors (e.g., regression model, modeling study) without other usable analysis. For the multiple cesarean deliveries, studies were included that specified maternal outcome by number of cesareans. Outcome by exact number of prior cesareans were identified when possible. For the direction of cesarean scar, studies were limited to those that identified direction of scar and specified outcomes by scar direction.

Data Extraction and Synthesis

All eligible studies were reviewed and a “best evidence” approach was applied, in which studies with the highest quality and most rigorous design are emphasized.⁶⁴ Data were extracted from each study, entered directly into evidence tables, and summarized descriptively. Benefits and adverse effects of mode of delivery were considered equally important and both types of outcomes were abstracted.

Studies were included in the synthesis of the evidence report if they achieved a good or fair quality rating as determined by study design, methods, and analysis. When possible, original data were used as presented in the article. When necessary, raw numbers were calculated from given percentages. Data were pooled from studies evaluating the same outcomes of interest. All results are reported as percentages to allow the reader to make direct comparisons of frequency. Because many of the adverse outcomes are rare, percentages were also translated into rates consistent with those reported in vital statistics, for example maternal death is reported per 100,000, while hysterectomy, infection, fever, transfusion, incidence of placenta previa by number of prior cesareans, neonatal mortality, and perinatal mortality are reported per 1,000.

Several included studies came from the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (MFMU) cohort (Appendix G). For synthesis, the most appropriate study is included for the outcome being discussed.

Studies that did not use an anatomic definition for uterine rupture were excluded from analysis of rates of uterine rupture. For other topic areas where studies that used an anatomic definition were not available (predictors, imaging to predict uterine rupture, and timing from symptom to delivery as a predictor of infant outcome), information was provided from existing studies.

Quality Rating of Individual Studies

Reviewers rated the quality of RCTs, cohort, case-control, and case series studies using criteria specific to different study designs developed by the U.S. Preventive Services Task Force (U.S.PSTF) and additional criteria developed by the National Health Service Centre for Reviews and Dissemination, based at the University of York in England (Appendix H).^{65, 66} Two reviewers independently reviewed a small portion of the studies. When reviewers disagreed, a final rating was reached through consensus. When a Kappa of at least 0.60 was met between reviewers, a single reviewer rated the remaining studies.⁶⁷ The Kappa between reviewers for this evidence report was 0.743 (95 percent CI: 0.537 to 0.949). Studies reporting several different outcomes may have different quality ratings for each outcome depending on how accurate the measure used was and how completely it controlled for potential confounders in multi-variable models (Appendix I). Studies determined to be poor quality were not included in the analyses, unless no studies of better quality were available for a given topic.

In addition to the quality criteria for each study design, the evaluation of prediction modeling studies required that they provided a clear definition of prognostic factors. The most important criteria for these studies were comparable groups that included clear inclusion and exclusion criteria; clear definitions of the prognostic factors; and adjustment (as needed, for studies without comparable groups) for confounders. To achieve a rating of good, minimally, the study had to meet these three ratings. A study with comparable groups and no need for adjustment could still meet this standard. For studies that only met two of these three criteria, the highest quality rating they could achieve was fair.

Development of Evidence Tables and Data Abstraction Process

The following information about the patient population, study design, study outcomes, and study quality was extracted from full text, published studies of VBAC and TOL, IOL, ERCD, or uterine rupture and was used to construct evidence tables showing: identifying information (study name, years of observation); setting (population-based, referral clinic-based, other); study design (randomized trial, prospective, etc.); interventions (induction, augmentation medications); outcomes studied (infant, maternal, cost, etc.); length of followup; statistical methods for handling confounders (statistical adjustment, stratification, none) and attrition; numbers of subjects recruited, included, and completing study; and characteristics of the sample (demographic variables, number of previous births, other risk factors). Data were abstracted by one reviewer and verified by a second.

For prediction studies, odds ratios are routinely presented unless noted by another measure of risk (relative risk [RR]). When possible all results are presented using the same reference and outcome. In the prediction sections, the results are presented for predicting TOL and for

predicting VBAC. If a study, for example, predicted repeat cesarean delivery after a TOL, the odds ratios were inverted so that all studies predicted VBAC.

Strength of Available Evidence

We assessed the overall strength of the body of evidence for each key question using the methods described in the Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews used by the Evidence-based Practice Centers.⁶⁵ The purpose of grading the strength of the whole body of evidence is to provide information beyond study design hierarchy and internal validity assessment to other factors that are important to the application of information for clinical practice and policy. Parameters thought important to policymakers include quantity of evidence, assessment of risk of bias, precision, directness, and consistency. Risk of bias was assessed in two ways: first by describing the study designs used and assuming a hierarchy of designs in terms of risk of bias (randomized controlled trials inherently having lower risk of bias than do observational study designs) and secondly by reporting the cumulative internal quality rating of the included studies. In order to have low risk of bias, the studies would be both RCTs and also have good internal quality ratings overall, and bodies of evidence that are based on observational studies with poor internal quality ratings would be determined to have a high risk of bias. Moderate risk of bias would be the many combinations of factors that would fall in between these two extremes. Consistency was evaluated by determining if the majority of study results were trending in a similar direction, such that their point estimates and confidence intervals (CI) may vary, but the overall conclusions are similarly evaluable. The directness of the evidence was assessed by whether there was a direct link between the interventions studied and the outcomes of interest; for example if mortality due to uterine rupture is the outcome of interest, did the studies evaluate these in the same study or were separate bodies of evidence required to answer the question. Precision refers to how sure one can be of the point estimate of effect and was assessed by examining the narrowness of CIs of studies or CI of the point estimate resulting from pooled analysis. The body of evidence was graded for the evidence surrounding the most important outcomes in the report. A table was created presenting the ratings for each of these domains for the following maternal outcomes: VBAC rate, IOL rate (with subcategories of VBAC rate, uterine rupture rate, and other harms—stratified by intervention), maternal mortality, rate of uterine rupture, hysterectomy, transfusion, hemorrhage and blood loss, effect of IOL on hemorrhage, infection, and long-term sequelae (adhesions, pelvic pain, and reproductive health). The following infant outcomes are also captured on the table: perinatal, fetal, and neonatal mortality; transient tachypnea of the newborn (TTN); respiratory morbidity with bag-and-mask ventilation; respiratory morbidity with intubation for meconium; hypoxic-ischemic encephalopathy/asphyxia; neonatal intensive care unit (NICU) admissions; neurologic sequelae (short- and long-term); sepsis; trauma; and breastfeeding (Appendix J). From the assessments of the domains described above, an overall grade of the strength of the body of evidence was determined (high, medium, low, or insufficient). A high strength of evidence reflects a high degree of confidence that the body of evidence presents the true effect and suggests that additional studies and future research would have a low likelihood of changing the estimate. A moderate strength of evidence suggests that the confidence in the body of evidence is moderate and that additional studies may change the estimate. A low strength of evidence suggests that the confidence that the body of evidence is reflecting the true estimate is low and that it is likely that new studies may change the estimate. An insufficient

strength of evidence suggests that there is either no evidence or that the body of evidence does not permit estimating the true effect.

Data Synthesis

In addition to discussion of the findings of the studies overall, meta-analyses were conducted to summarize data and obtain more precise estimates on main outcomes for which studies were homogeneous enough to provide a meaningful combined estimate. Otherwise, the data are summarized qualitatively.

For common events, e.g., TOL and VBAC, where normal approximation applies, estimates of rates and their standard errors were calculated from each study and directly combined. A random effects model⁶⁸ was used to combine the studies while incorporating variations among studies. Statistical heterogeneity was assessed by using the standard Q-test and the I^2 statistic (the proportion of variation in study estimates due to heterogeneity rather than sampling error).⁶⁹ Based on the Cochrane handbook, a rough guide to interpret I^2 is as follows:

- 0 to 40 percent: might not be important;
- 30 to 60 percent: may represent moderate heterogeneity;
- 50 to 90 percent: may represent substantial heterogeneity;
- 75 to 100 percent: considerable heterogeneity.

Furthermore, the importance of the observed value of I^2 depends on (i) magnitude and direction of effects and (ii) strength of evidence for heterogeneity (e.g., P value from the chi-squared test).⁶⁹ The proportion of women in the induced groups who achieved VBAC or who had a uterine rupture was combined using MetaAnalyst (Beta 3.13; Tufts Medical Center).⁷⁰ For the other outcomes, the rates were combined using STATA 10.1[®] (StataCorp, College Station, Texas, 2009).

For rare or relatively rare events—e.g., the number of ruptures, maternal deaths and infant deaths, etc.—normal approximation does not apply well to estimates of rates directly, and we used two slightly different methods to combine them. When studies did not report zero events in the group, we first logit-transformed the rates before combining the studies as the distribution for the logits of rates were usually approximately normal. The studies were then combined using a random effects model,⁶⁸ and the combined rates were obtained by transforming the combined logit-rates to its original scale. Statistical heterogeneity (Q-test and I^2 statistic) was assessed based on the logits of rates for these outcomes. These analyses were performed by using STATA 10.1[®] (StataCorp, College Station, Texas, 2009). When there are studies that reported zero events, a logistic random effects model^{71, 72} was used to include studies without events. This model also applies the logit-transformation of the rates to achieve better statistical property. In this case, statistical heterogeneity was assessed using Fisher's exact test, and analyses were performed using the NLMIXED procedure in SAS v9.2 (SAS Institute Inc., Cary, NC, USA).


Risk ratio and/or risk difference were used to compare various rates between TOL and ERCD groups. Again the studies were combined by using a random effects model⁶⁸ and statistical heterogeneity was assessed using Q-test and I^2 statistic.

Forest plots were presented to graphically summarize the study results and the pooled results.⁷³ To explore heterogeneity, we performed subgroup analyses and meta-regression^{74, 75} to evaluate whether the summary estimates differ by study level characteristics.

Size of Literature

Of the 3,134 citations reviewed from the searches, 2,171 met exclusion criteria at the abstract level and were not reviewed further. After the abstract review process, 963 full text papers were retrieved and reviewed for inclusion. An additional 37 full text papers were retrieved during the peer review process. After applying inclusion/exclusion criteria, a total of 203 full text papers met inclusion. Investigators quality rated included studies, and those rated good or fair quality are discussed in this report. As mentioned previously, poor quality studies are not discussed unless no studies of better quality were available for a given topic. For the topics presented, 71 studies provided data on TOL and VBAC rate, 27 on IOL or augmentation, 28 on predictors of TOL and VBAC, 14 on scored models for predicting VBAC, 41 on maternal outcomes, 28 on uterine rupture, 11 on infant outcomes, 19 on abnormal placentation, seven on obesity, 12 on multiple cesarean deliveries, and seven on direction of cesarean delivery scar (Figure 5).

Figure 5. Search and selection of literature



* Databases searched include MEDLINE, Cochrane and DARE (see Appendix C for search strategies)

[†] See Appendix E for details on inclusion and exclusion criteria

[‡] Many studies are included in more than one topic area

CD=cesarean delivery; TOL=trial of labor; VBAC=vaginal birth after cesarean;

I/A=Induction/Augmentation of Labor

Chapter 3. Results

Among women who attempt a trial of labor after prior cesarean delivery, what is the vaginal delivery rate and the factors that influence it?

In the sections that follow for this question, the rate of trial of labor (TOL) and its predictors are presented followed by the rate of vaginal birth after cesarean (VBAC) with special focus on induction and spontaneous labor. The section closes with a summary of the many factors associated with VBAC and a review of tools that attempt to predict VBAC for women who have a TOL.



Trial of Labor Rate

In order to understand the proportion of women who have a VBAC, the first searches were for studies to estimate the proportion of women attempting a TOL in the United States (U.S.). To be included studies had to be at least fair quality, clearly define eligibility for TOL, as well as provide the number of women eligible for TOL and the number of women who had a TOL. Thirty-five observational studies consisting of 10 prospective cohort studies⁷⁶⁻⁸⁵ and 25 retrospective cohort studies,^{10, 27, 86-108} were combined providing a TOL rate of 61 percent (95 percent CI: 57 to 65 percent). This analysis (and all meta-analyses) was conducted using a random effects model that considers heterogeneity. In this analysis of 35 observational studies that included 661,765 TOL-eligible women, the Q-statistic for heterogeneity was high, with an I^2 for between-heterogeneity of greater than 99 percent. The full range for TOL rates across the studies inside and outside the U.S. was 28 to 82 percent, Figure 6. Further stratification of study subgroups were conducted to assess differences that could explain the heterogeneity. Considered factors included study design (prospective versus retrospective), U.S. versus non-U.S. population, gestational age of the population (term versus any gestational age), and year of study. Among these, gestational age, country of origin, and year of study demonstrated statistically significant differences. Stratification by the study designs (retrospective and prospective) of all 35 studies revealed no significant association with TOL rates.



As shown in Figure 6, the overall TOL rate in studies conducted in the U.S. was 58 percent (95 percent CI: 52 to 65 percent), with a range of 28 to 70 percent, compared with 64 percent (95 percent CI: 59 to 70 percent) among women in studies conducted outside the U.S.

Figure 6. Trial of labor in studies conducted in the United States and outside the United States

Trial of Labor in United States Studies




Trial of Labor in Non-United States Studies



Similarly, fewer women in studies conducted exclusively in term populations both inside and outside the U.S. had a TOL, 53 percent (95 percent CI: 47 to 59 percent) compared with 66 percent (95 percent CI: 61 to 70 percent) for studies that included any gestational age (GA, $p=0.002$). Further stratification by country and by GA (shown in Figure 6) revealed that this relationship was present in both U.S. and non-U.S. studies but was only statistically significant in studies conducted outside the U.S. ($p=0.001$).

Because VBAC rates have changed over time¹⁰⁹ with dramatic decreases after 1996 when new evidence about uterine rupture was published,¹⁰ the studies were grouped by the years when the data were collected: completed before 1996; included 1996; started after 1996. Before 1996, the summary estimate of the TOL rate in the U.S. was 62 percent (95 percent CI: 58 to 67 percent).^{77, 79, 81, 84, 90, 92, 94, 102, 105, 107} The summary estimate for the TOL rate in studies that were started before 1996 but completed during or after 1996 was 63 percent (95 percent CI: 55 to 72 percent).^{97, 98, 110} Finally, the summary estimate for the TOL rate for studies started and completed after 1996 was 47 percent (95 percent CI: 37 to 58 percent).^{78, 80, 87, 88, 93} Thus TOL rates among studies conducted after 1996 were significantly lower than studies conducted prior to 1996 ($p=0.009$) or that included 1996, ($p=0.036$). This pattern was also observed among studies conducted outside the U.S., see Figure 7.

Figure 7. Global trial of labor rates have dropped over time



*US studies started after 1996 reported lower rates of TOL than studies that included 1996 ($p=0.036$) or were completed by 1996 ($p=0.009$)

†Non-US studies started after 1996 reported lower rates of TOL than studies that were completed by 1996 ($p=0.009$).

Almost all of the TOL studies were conducted in tertiary care centers, teaching hospitals with residents and 24-hour anesthesia teams available; therefore, findings have limited applicability to rural settings. Because stratification by setting was not feasible, studies that reported rates across settings were examined to find information for rural settings. Three retrospective studies^{10, 86, 94} reported reduced attempts (TOL rates ranging from 36 to 47 percent) for rural settings compared with urban and/or teaching settings (TOL rates ranged from 53 to 64 percent). Consistent with

this finding, one retrospective study reported that 70 percent of repeat cesarean deliveries (RCD) in rural settings were potentially unnecessary compared with 61 percent in urban teaching settings.¹¹¹

Summary of trial of labor rates. The rates of TOL are highly variable ranging from 28 to 70 percent in the U.S. The evidence is largely limited to large tertiary teaching hospitals. TOL rates have declined, particularly after 1996, both inside and outside of the U.S. In the U.S. studies launched after 1996, less than half (47 percent) of women in the studies had a TOL.

Predictors of Trial of Labor

Eight good or fair quality retrospective cohort studies,^{10, 27, 86, 94, 101, 112-114} and one fair quality retrospective cross sectional study¹¹¹ looked for factors known in the prenatal setting that may predict TOL. Three themes emerged from these studies related to site of delivery, history of prior vaginal delivery, and race. TOL was more likely in hospitals with higher delivery volumes, tertiary care centers, and teaching hospitals.^{10, 86, 94, 111} Women with a prior vaginal delivery had more than double the likelihood of a TOL (odds ratio 1.51 to 6.67).^{10, 86, 101} Finally, non-white women were more likely to have a TOL than white women (odds ratio 3.5).²⁷ Further details and discussion of predictors of TOL can be found in Appendix K.

Vaginal Birth After Cesarean Rate

As the TOL rate is decreasing, it is certainly important to examine what affect, if any, this has on the VBAC rate and what factors are contributing to vaginal delivery. Sixty-seven studies, 14 fair quality prospective cohort studies^{76-85, 115-118} and 53 retrospective cohort studies^{60, 86-93, 110, 119-128, 10, 27, 95-98, 100-108, 129-146} provided an overall summary estimate for VBAC of 74 percent (95 percent CI: 72 to 75 percent). The heterogeneity of this meta-analysis of 67 observational studies that included 368,304 women was high, I^2 greater than 98 percent. The range in VBAC rates across studies inside and outside the US was 49 to 87 percent, Appendix L. To examine this heterogeneity, these studies were stratified and analyzed by study design (prospective versus retrospective; true cohort that included TOL and ERCD versus studies of TOL only), country (U.S. versus non-U.S.), GA (term only versus any GAs) and by years when the data were collected (completed before 1996, during 1996, and started after 1996). None of these factors were found to result in statistically significant differences (see Appendix L for detailed evaluation).

Summary and strength of evidence on vaginal birth after cesarean rates. The overall strength of the body of evidence is moderate. The rates of VBAC are highly variable in these studies. Most evidence of VBAC rates are from studies based in large tertiary care centers. While TOL rates have dropped over time, VBAC rates reported in observational studies have remained constant for the women who have a TOL. In studies based in the U.S., 74 percent (95 percent CI: 72 to 76 percent) of women who had a TOL delivered vaginally.

Induction of Labor

A major area of interest is whether clinical antepartum and intrapartum management strategies such as induction of labor (IOL) influence VBAC rates. Women with a history of a prior cesarean delivery who undergo a TOL may require cervical ripening, induction and/or augmentation of labor. Multiple approaches can be taken including mechanical, pharmacological or combinations. The potential impact of each method on the ultimate VBAC rate, as well as any

harm or benefit to the mother or infant is important to understand. It is particularly important when reviewing medications to consider the impact of type of drug, dose and regimen as well as important characteristics of the mother, the labor, and the fetus. Cervical ripening, which is used when the cervix is determined to be “unfavorable” for induction (generally a Bishop’s score of less than 6), can be accomplished using various mechanical methods including artificial rupture of membranes and the introduction of a Foley catheter into the cervix. The pharmacological approach to cervical ripening is generally accomplished using a prostaglandin—misoprostol (prostaglandin E₁ analog) or prostaglandin E₂—although the progestin blocker, mifepristone, has also been studied. Prostaglandins and oxytocin are used for labor induction, and oxytocin is frequently used to augment labor that is not progressing as expected.

While comparisons are sometimes made between women undergoing IOL to those with spontaneous labor, the reasons that induction is necessary may confound any effect of the drug or mechanical method of induction. However, the realistic comparison group for women undergoing IOL is expectant management as women who present in spontaneous labor are no longer candidates for IOL. Women who are induced may have different risk factors for VBAC and other outcomes; therefore, the proportion of women with VBAC associated with each method of induction is presented as the primary outcome, with comparison to spontaneous labor presented as a secondary outcome. Other maternal outcomes were reported inconsistently such that meaningful analysis of an association with use of oxytocin was not possible.

Of 328 studies screened for inclusion relating to intrapartum and antepartum factors, 27 studies were included in the IOL analysis. The others were not included due to not reporting data on induction or augmentation, reporting data on the proportion induced or augmented in the overall study population but not stratifying the results on these factors, or because they were found to be poor quality.

Any induction method. Twenty-seven fair quality studies involving 11,938 women report on the rate of VBAC among women receiving any type of IOL.^{60, 96, 118, 125, 130, 131, 139, 141, 145, 147-164} Combining these data results in a pooled estimate of VBAC with any method of IOL of 63 percent (95 percent CI: 59 to 67 percent, Table 2, see Appendix M for additional figures). Unlike other datasets in this review, these observational studies found very similar proportions of VBAC whether or not the population was limited to women with term pregnancies. Table 2 also shows the pooled estimates for the individual methods of induction, whose estimates range from a low of 54 percent with mechanical methods to a high of 69 percent with mifepristone.

Table 2. Vaginal birth after cesarean rates by types of induction

	Any Induction Method	Oxytocin	PGE₂	Misoprostol	Mifepristone	Mechanical
% VBAC	63%	62%	63%	61%	69%	54%
95% CI	58% to 67%	53% to 70%	58% to 69%	27% to 90%	41% to 89%	49% to 59%

Abbreviations: CI=confidence interval; VBAC=vaginal birth after cesarean

Prostaglandins. Prostaglandins are used to ripen the cervix and to initiate labor. The two prostaglandins that can be used for this purpose are prostaglandin E₂, which is available in two formulations in the U.S. (Prepidil® gel and Cervidil® insert, both as dinoprostone), and misoprostol, which is an analog of prostaglandin E₁. In general, the prostaglandins are administered cervically or vaginally, with re-application after several hours if cervical ripening has not progressed adequately. Oxytocin may be used following cervical ripening, to augment

labor, if the strength or frequency of contractions is not considered adequate to maintain sufficient labor.

Prostaglandin E₂. Nineteen studies reported the rates of women with a VBAC after receiving prostaglandin E₂ for cervical ripening for a TOL. These were a single trial in term pregnancies, one case control study, seven cohort studies including women delivering at less than 37 weeks GA, four case series of term gestations, and six case series of open GA.^{139, 145, 147-149, 151, 152, 155, 157-159, 161, 163, 165-170} Two were poor quality^{169, 170} -- inadequate reporting of numbers of women included in analyses and lack of control for potential confounding factors--while the rest were fair quality. Also, a nested case-control study did not report data adequately to determine the proportion who received PGE₂ and had a VBAC.¹⁶⁶ Some of these studies compared the women with induction with women experiencing spontaneous labor^{63, 139, 145, 149, 157, 158, 161, 163, 165-169} and others made only comparisons among induction groups.^{147, 148, 151, 152, 155, 159, 170}

Pooling studies with similar design indicates that 63 percent (95 percent CI: 58 to 69 percent) of women undergoing a TOL with IOL with PGE₂ had a VBAC. One outlier is a very small study (N=17)¹⁶³ that reported a low rate of VBAC for spontaneous labor (33 percent), but removing this study does not materially alter the results (Appendix M).

Examining the pooled analysis (Appendix M), it can be seen that including women induced prior to 37 weeks gestation (any GA) appears to reduce the rate of VBAC from 77 percent in term patients to 61 percent and 65 percent in any GA (case series and cohort studies); however the data on term gestations is limited to two case series studies. What role, if any, study design played in vaginal delivery rates was also considered. For this reasons studies are grouped in the plot according to study design. As demonstrated by the figure, vaginal delivery rates did not vary by study design.

Additional data on induction with PGE₂ come from a trial that compared weekly administration of PGE₂ (up to three doses) to expectant management. The VBAC rate with this weekly regimen was 57 percent compared to 55 percent with expectant management. Because this does not reflect usual practice with PGE₂, it may not reflect the VBAC rate found with the more traditional administration.¹⁶¹

Dose of prostaglandin was sporadically reported, and when reported was not consistent in the reporting metric (e.g., mean number of doses versus the number of women receiving two or three doses). Similarly, the number of prior cesarean delivery and the rate of prior vaginal births may have influenced the rate of VBAC with PGE₂ induction, but these covariates were not reported adequately for analysis. A small number of studies did report these variables, but either did not stratify the results by specific induction method¹⁵⁶ or had too few numbers to allow analysis.¹⁵⁷

Augmentation of labor with oxytocin may be an important confounder for VBAC and might be expected to result in improved VBAC rates. The use of oxytocin for augmentation of labor after induction with PGE₂ ranged widely in the 11 studies reporting these data, from 16 to 77 percent (Table 3). Examining the rigorousness of the study design, the inclusion of only term or any GA labors, or the size of the study does not provide further understanding of any potential relationship between these variables.

Table 3. Vaginal birth after cesarean and proportion with augmented labor in women induced with prostaglandin E₂

Study, year	Study Design	Gestation	# Induced with PGE ₂	% VBAC	% Augmented
Rayburn, 1999 ¹⁶¹	RCT Multicenter women desiring VBAC	Term	143	57	32
Norman, 1992 ¹⁵⁹	Case series Women with 1 prior CD	Term	30	73	37
Goldberger, 1989 ¹⁵⁵	Case series women with 1 prior CD	Term	19	84	21
Yogev, 2004 ¹⁴⁵	Cohort women with 1 prior CD with IOL	Any GA	97	64	25
Ben-Aroya, 2002 ¹⁴⁸	Cohort University hospital women in 2nd delivery following a CD	Any GA	55	55	16
Flamm, 1997 ¹⁶⁷	Case series Kaiser hospitals women with a history of CD undergoing TOL	Any GA	453	51	77
Locatelli, 2006 ¹⁶⁸	Case series University hospital women with a previous LTCS	Any GA	310	71	40
Chilaka, 2004 ¹⁵¹	Case series University hospital, women with prior CD, who had IOL	Any GA	130	61	27
Kayani, 2005 ¹⁵⁷	Case series Larger inner city teaching hospital, women with IOL after 1 prior CD	Any GA	149	46	35
Meehan, 1989 ¹⁵⁸	Case series University teaching hospital women with 1 prior CD, nominated for TOL	Any GA	52	79	44
Blanco, 1992 ¹⁴⁹	Case series University hospital women attempting TOL	Any GA	25	72	20

Abbreviations: CD=cesarean delivery; GA=gestational age; IOL=induction of labor; LTCS=low transverse cesarean scar; TOL=trial of labor; PGE₂=prostaglandin E₂; RCT=randomized controlled trial; VBAC=vaginal birth after cesarean


Misoprostol. Evidence on the VBAC rate with cervical ripening and induction using misoprostol in women with history of prior cesarean delivery is extremely limited. The

contributing evidence comes from two small (N=96 combined) fair quality retrospective cohort studies that included women with any GAs. These two studies report widely different proportions of women with VBAC, 78 percent¹⁷¹ and 44 percent,¹⁷² with a pooled estimate of 61 percent (95 percent CI: 27 to 90 percent). Although these are fair quality studies in general, they may not represent similar populations, or because they are small may not have included enough women to be able to prevent sampling error.

Mifepristone. Mifepristone is a progestin blocker that has been studied for use in cervical ripening. A small (N=32), fair quality trial compared mifepristone 200 mg and placebo, each given orally for 2 days to women with a Bishop score of three or less, followed 2 days later by induction with prostaglandins, oxytocin, and/or artificial rupture of membranes as needed. Eligible women were scheduled for IOL due to post-date pregnancy, pre-eclampsia, or severe fetal growth retardation. Although the rate of onset of spontaneous labor was higher in the mifepristone group than in the placebo group (69 versus 12 percent), the rates of vaginal delivery were not statistically significantly different (69 versus 50 percent) although the study may have not had adequate statistical power to determine a difference at a $p < 0.05$ level.¹⁷³ Other findings that were different between the groups were the time between first dose and start of labor (60 hours and 30 minutes versus 82 hours and 50 minutes; $p < 0.01$), and the amount of oxytocin required (2.11 international unit [IU] versus 4.67 IU; $p < 0.01$) for mifepristone and placebo, respectively.

Oxytocin. Oxytocin is used for both IOL as well as augmentation of labor when contractions are inadequate to maintain progression of labor. Seventeen studies reported on the use of oxytocin in women with a prior cesarean delivery (one good quality cohort, nine fair quality cohorts, and five fair quality case series).^{11, 118, 125, 129-131, 141, 154, 156-158, 162, 164, 168, 169, 174, 175} While oxytocin can be used in combination with a prostaglandin, the focus here is on the use of oxytocin alone. Five studies reported VBAC rates with oxytocin alone used only for IOL (not augmentation),^{125, 141, 157, 162, 175} The pooled estimate of VBAC is 62 percent (95 percent CI: 53 to 70 percent). From the forest plot (Figure 8) it can be seen that the studies with lower quality design and including any GA report higher VBAC rates than either better studies (cohort design) or the single case series in term gestations. Additionally, the best quality study in this group reported an odds ratio for VBAC of 1.19 (95 percent CI: 0.93 to 1.53) for women who had IOL with a favorable cervix compared with women with spontaneous labor.¹⁵⁶ It is not clear that this includes only oxytocin induction, however. A fair quality study reported a VBAC rate of 74 percent, but includes oxytocin and/or amniotomy.¹⁶⁹

Figure 8. Vaginal birth after cesarean rates with oxytocin induction



Abbreviation: VBAC= vaginal birth after cesarean

Seven studies reported the rate of VBAC with oxytocin used only for augmentation.^{118, 125, 129, 131, 141, 154, 162} A fair quality case series reported the odds of a VBAC with oxytocin augmentation to be 0.83 (95 percent CI: 0.67 to 1.02) compared with no augmentation.¹²⁹ The other six studies reported data that could be pooled, resulting in a VBAC rate of 68 percent (95 percent CI: 64 to 72 percent, Appendix M).

Among studies reporting data on VBAC rate among women receiving oxytocin for induction separately from those who received oxytocin for augmentation of labor, three of four found higher proportions with VBAC when oxytocin is used for augmentation rather than induction (Table 4). Pooling these data indicates a 12 percent increase in absolute risk of VBAC when augmentation rather than induction is the reason for oxytocin use.

Table 4. Vaginal birth after cesarean rate with oxytocin used for induction versus augmentation

Study	Study Design	Induction	Augmentation
Silver, 1987 ¹⁶²	Cohort Medical center hospital, women at term with a history of one prior CD, who received intrapartum oxytocin	53%	63%
Sakala, 1990 ¹⁴¹	Cohort University hospital, women who underwent TOL and had > 1 prior CD	58%	88%
Flamm, 1987 ¹²⁵	Cohort Kaiser hospitals, women with prior CD who were administered oxytocin	56%	69%
Paul/Horenstein, 1985 ¹³¹	Cohort University hospital, women with prior CD offered TOL	72%	69%
Pooled absolute difference in proportion with VBAC		12% (95% CI 0.3% to 24%)	

Abbreviations: CD=cesarean delivery; CI=confidence interval; TOL=trial of labor; VBAC=vaginal birth after cesarean

Dose of oxytocin (cumulative, maximum rate of infusion) was sporadically reported, and when reported was not consistent in the reporting metric. Similarly, while the number of prior cesarean deliveries may have influenced the rate of VBAC with PGE₂ induction, these covariates were not reported adequately for analysis.

Prostaglandin E₂ versus oxytocin. While the conditions that may lead to using PGE₂ for IOL may differ from those for choosing oxytocin, there may be some value in comparing the benefits and harms of these two drugs, particularly if the reason for induction and underlying obstetric characteristics also can be compared. The best evidence comparing the effect of these two drugs on VBAC rates comes from a good quality cohort study of women at term who had one prior cesarean delivery.¹⁵⁶ In this study of 11,778 women, 3,259 underwent IOL. An analysis of women induced with an unfavorable cervix compared with those experiencing spontaneous labor showed a significantly lower rate of VBAC in the induced group; odds ratio 0.46 (95 percent CI: 0.39 to 0.53). A similar analysis of women induced with a favorable cervix found no significant difference between groups; odds ratio 1.19 (95 percent CI: 0.93 to 1.53). Assuming that PGE₂ (+ oxytocin) was used in those with unfavorable cervixes, and oxytocin used without PGE₂ in those with favorable cervixes, this indicates a higher rate of VBAC with oxytocin alone. However, a small proportion of women were induced without either drug and direct comparisons were not undertaken. A poor quality trial enrolled 42 women and found a higher rate of VBAC with PGE₂ (81 percent) compared with oxytocin (71percent); however the study was too small to find a statistically significant difference and methodological concerns indicate the need to interpret these findings with caution.¹⁷⁶ Two other studies (from three publications) did not report data in a way that would allow comparison of VBAC between PGE₂ and oxytocin groups.^{164, 177, 178}

Mechanical methods of induction. The evidence on the risk or benefits of mechanical methods of cervical ripening in women with a prior cesarean delivery is limited to five studies.^{148, 150, 169, 179, 180} The best of these are two small retrospective cohort studies evaluating the use of a Foley catheter for cervical ripening compared with spontaneous labor.^{148, 150} The proportion of women with VBAC after Foley catheter IOL were 56 percent¹⁵⁰ and 51 percent¹⁴⁸ with a pooled proportion of 54 percent (95 percent CI: 49 to 59 percent).

The first is a good quality study (N=2,479), that also included a group of women with favorable cervixes who received amniotomy. Logistic regression controlling for several factors found that cervical ripening with a transcervical Foley catheter resulted in a slightly lower proportion with VBAC than with spontaneous labor (odds ratio 0.68; 95 percent CI: 0.41 to

1.15), while amniotomy resulted in a slightly higher rate (odds ratio 1.19; 95 percent CI: 0.84 to 1.69); neither was statistically significantly different from spontaneous labor.¹⁵⁰

The other study (N=1,648) included women who received PGE₂ tablets or Foley catheter for cervical ripening compared with spontaneous labor.¹⁴⁸ This study has more flaws than the first, in that the baseline characteristics, such as number or prior cesarean deliveries, previous vaginal deliveries, inter-delivery interval, etc., are not as well described; neither was the dosing of PGE₂ taken into account nor did the analysis control for confounding variables. This study found the rate of VBAC to be significantly lower in the Foley catheter group compared with the spontaneous labor group (51 versus 65 percent, p< 0.01).

In the first study, crude rates of VBAC were also lower in the Foley catheter group, but analysis controlling for confounding factors resulted in a non-significant difference.¹⁵⁰ The authors of both studies note that for the outcome of uterine rupture, the studies were most likely underpowered to find differences between the groups; they estimate that it would require a sample size of greater than 10,000 patients to find a difference. Additional evidence on Foley catheter, a double-balloon device, and breast stimulation were inadequate to make determinations of VBAC rate, risk of uterine rupture, or other outcomes.^{169, 179, 180} No studies of other mechanical methods, e.g., acupuncture, were found.

Influence of prior vaginal delivery and indication for prior cesarean on vaginal birth after cesarean induction. A small case series of women requiring oxytocin induction or augmentation (N=98) did not find a significant difference in the rate of VBAC among those with prior vaginal deliveries compared with those with none among the group induced with oxytocin, but did find that prior vaginal delivery resulted in a higher rate of VBAC among those with oxytocin augmentation compared to those with no prior vaginal deliveries (86 and 56 percent, p<0.05).¹⁶² In this study, a recurrent indication for induction or augmentation resulted in significantly lower rates of VBAC compared with the groups without recurrent indications (38 versus 90 percent, p<0.01 and 81 versus 50 percent, p<0.05, respectively). Comparing the birth weights of current and previous deliveries in the induced and augmented groups resulted in a non-significant difference with those induced, but a difference favoring smaller fetuses among those augmented (84 versus 49 percent, p<0.01). Because this is a small case series, these data should be interpreted as suggestive, rather than conclusive.

In a fair quality study of 205 women with a prior cesarean delivery and who required induction, 41 percent of those with no prior vaginal deliveries had a VBAC, while 82 percent of those who did have prior vaginal delivery had a VBAC (odds ratio 6.8; 95 percent CI: 3.04 to 13.9).¹⁵⁷

The relationship between the reason for the prior cesarean delivery and VBAC when oxytocin is used was examined in three studies (total N=595).^{118, 125, 130} The most commonly reported indications and pooled proportions with VBAC are listed in Table 5 below.

Table 5. Most commonly reported indications and pooled proportions

Indication for Prior cesarean delivery	VBAC Rate
Failure to progress/cephalopelvic Disproportion	54% (48% to 60%)
Fetal Distress	60% (49% to 69%)
Malpresentation/breech	75% (60% to 86%)

Abbreviations: VBAC=vaginal birth after cesarean

Summary and strength of the evidence on induction of labor. Overall, evidence regarding the rate of VBAC among women with IOL is low to moderate strength, indicating that 63 percent of these women will have a VBAC (PGE₂=63 percent, oxytocin=62 percent,

misoprostol=61 percent). Augmentation of labor with oxytocin was associated with a rate of 68 percent VBAC, although the strength of this evidence is low. Evidence was inadequate to make a comparison of VBAC resulting from induction with oxytocin or prostaglandin E₂. Fifty-four percent of women induced with a Foley Catheter had a VBAC, based on moderate strength evidence. Other mechanical methods were not reported adequately to make comparisons or conclusions. Approximately 60 percent of the studies were conducted in university hospital settings, with the smaller studies also including community hospital settings such that the evidence is weighted towards the larger, tertiary care setting. Less than half of these studies were conducted in the U.S., with most of the others being conducted in Canada, Britain, Ireland, Sweden and Israel. For induction, the results were not stratified by age, race, ethnicity, or baseline risk.

Predictors of Vaginal Birth After Cesarean

The impact of individual factors on VBAC discussed above can overlap and interact with each other such that a factor found to have statistically significant influence on VBAC rate may no longer be significant when other key factors are taken into account. Studies that evaluate these factors in concert, using regression analyses for example, can provide a higher level of evidence on the residual influence of individual factors. Four prospective cohort studies,^{85, 167, 181, 182} 18 retrospective cohort studies,^{27, 61, 86, 99, 104, 106, 113, 119, 127, 136, 143, 146, 183-188} and one case-control study¹⁸⁹ addressed predictive factors for VBAC. The key factors considered by these studies were demographic factors that included maternal age, ethnicity, race, and marital status; nonclinical factors that included insurance status, site of delivery, and volume of VBACs; past obstetric factors that included prior vaginal delivery and prior indications for cesarean delivery; pre-existing and current factors that included maternal height, body mass index (BMI), substance abuse, and pre-existing maternal disease; and current obstetric factors related to the infant gender, age and size. In this section, only the strongest predictors (supported by several good or fair cohort studies) that had an overall trend are presented. Full discussion of all predictors can be found in Appendix K.

Demographic factors. Of all demographic predictors that were evaluated, the strongest evidence was found for ethnicity and race. In all four cohort studies reporting on ethnicity and race, Hispanic women had a reduced likelihood of VBAC (by 31 to 49 percent, Appendix K) than non-Hispanic women.^{181, 182, 185, 187} In these same studies, African American women had a reduced likelihood of VBAC (by 20 to 49 percent) compared with white women.^{181, 182, 185, 187} It is interesting to note that non-white women were more likely to have a TOL but less likely to have a VBAC.²⁷ While not included in the meta analysis of VBAC rates because the cohort included twin deliveries, one retrospective cohort study reported that African American women were more likely to fail at VBAC, were more likely to be hypertensive and have diabetes.¹⁹⁰

Nonclinical factors. The site of delivery can play an important role in deciding what kind of birthing options are pursued, (Appendix K). Women at rural and private hospitals that provide obstetric care for lower risk deliveries had a decreased likelihood of VBAC.^{86, 111} This finding is consistent with another finding by the same investigators⁸⁶ that women at rural and private hospitals were less likely to attempt a TOL. Private hospitals in this study had an average VBAC rate of 57 percent compared with a VBAC rate of 66 percent for perinatal centers.⁸⁶

Past obstetric factors. There is particular interest in whether demographic factors, nonclinical and past obstetric factors may predict VBAC since these factors are known prenatally and would allow clinicians to provide information on prognosis early in pregnancy. Investigators from studies have explored prior vaginal delivery, years since prior cesarean delivery, prior labor

experience and prior baby weight as potential factors for predicting VBAC. A prior history of vaginal delivery was consistently reported to increase likelihood of VBAC in all 13 cohort studies^{86, 99, 104, 127, 136, 143, 167, 181-184, 187, 191} and one case-control study (Appendix K).¹⁸⁹ Women with a vaginal delivery after their prior cesarean (prior VBAC) were three to seven times more likely to have a VBAC for their current delivery^{127, 167, 181-184, 189, 191} compared with women with no prior vaginal deliveries. Women who had a vaginal delivery before their cesarean deliveries also had an increased likelihood to have a VBAC.^{143, 167}

One secondary analysis of a retrospective cohort study⁹⁸ of 16 community and university hospitals¹²³ specifically examined the effect of prior vaginal delivery before a cesarean and of a prior VBAC on the current TOL. The VBAC rate for women with no history of vaginal delivery was 65 percent, 83 percent for women with a prior vaginal delivery before a cesarean, and 94 percent for women with a prior VBAC.¹²³ Finally, a secondary analysis of the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (MFMU) cohort data reported that the likelihood of a VBAC increased with each prior VBAC.¹⁹² Women with zero, one, two, three, and four or more prior VBACs had likelihoods of VBAC of 63.3, 87.6, 90.9, 90.6, and 91.6 percent ($p < 0.001$), respectively.

Pre-existing and current obstetric factors. Many pre-existing factors (maternal height, BMI, smoking and substance use, and maternal disease) appear to change the likelihood of VBAC (Appendix K) but were only supported by single or two studies and are discussed in the appendix. Several investigators examined the effect of pre-existing disease on VBAC. In three of four cohort studies, women with a maternal disease (hypertension, diabetes, asthma, seizures, renal disease, thyroid disease, or collagen vascular disease) had a decreased likelihood (by 17 to 58 percent) of VBAC.^{127, 182, 187} By contrast, in a large prospective study by Grobman et al,¹⁸¹ the presence of diabetes, asthma, chronic hypertension, renal disease or heart disease, was not significant in the study's multivariable logistic model.

Many current obstetric factors related to the infant (GA, birth weight and infant gender) predicted VBAC or TOL followed by a cesarean delivery. Of these, the most consistent finding is that as infant weight increases the likelihood of VBAC decreases. Four of five studies reported that women delivering infants weighing more than 4 kilograms (kg) had a reduced likelihood of VBAC (by 41 to 51 percent) than women who delivered smaller infants.^{86, 127, 143, 146, 182} The oldest of these studies¹⁴³ found no relationship between a birth weight over 4 kg and likelihood of VBAC.

Obstetric factors related to the labor itself (dilation, effacement, station, Bishop score, cervix position) consistently predicted VBAC. Three prospective cohort studies,^{167, 182, 184} one retrospective study¹³⁶ and one case-control study¹⁸⁹ provided consistent evidence that women who were more dilated at admission or at rupture of membranes (ROM) were more likely to deliver vaginally. All three studies that examined effacement reported increased likelihood as effacement reached 75 to 100 percent.^{99, 167, 184} Similarly, all three studies that examined head position reported that as the baby's position was vertex, engaged or at a lower station, the likelihood of VBAC increased.^{85, 136, 185} Both studies that examined Bishop's score showed that as the score increased, the likelihood of VBAC increased two¹⁸³ to six times.¹⁴³

Overall impression of prediction studies. With the exception of three studies,^{104, 167, 181} these prognostic studies of VBAC could be described as exploratory.¹⁹³ According to Simon and Altman, studies that report association and identify patients at risk but that have not yet had results confirmed in followup studies with pre-stated hypotheses, do not yet provide sufficient evidence to change clinical practice.¹⁹³ The three studies^{104, 167, 181} that provided this cross-

validation evidence also proposed screening tools for VBAC and are discussed in detail in Appendix N.

Summary of predictors of vaginal birth after cesarean rate. Hispanic and African American women were more likely to have a TOL but less likely to have a VBAC compared with non-Hispanic and white women, respectively. Women at rural and private hospitals had a decreased likelihood of TOL and a decreased likelihood of VBAC. A prior history of vaginal birth was consistently reported to increase likelihood of VBAC. Women delivering infants over 4 kg have a reduced likelihood of VBAC. Greater progress of labor--measured as greater dilation, lower station and higher Bishop score--predicted a higher likelihood of VBAC.

Screening Tools for Predicting Vaginal Birth After Cesarean

The purpose of a screening tool is to help providers and patients to better identify who will have a VBAC (and who is more likely to have a RCD). Currently, most women are told they have a likelihood of 60 to 80 percent for a VBAC.¹⁹⁴ Screening tools are most helpful for women who have an estimate of VBAC outside this range either to discourage or to encourage a TOL. Two prospective cohort studies,^{167, 181} 10 retrospective cohort studies^{104, 107, 116, 120, 122, 128, 142, 143, 183, 184} and two case-control studies^{102, 189} that presented screening tools were identified (Appendix N). These studies combined individual factors to predict the likelihood of VBAC (or RCD) when certain thresholds were reached. Predictive variables (historic, intrapartum or perinatal) of delivery route were first identified by univariate analyses. Significant variables ($p < 0.05$) were included in multiple logistic regression models and/or scored models.

In the strongest studies, the resulting models or scoring systems were then evaluated with a separate validation dataset.¹⁹⁵ Three of the scored models had one or more external validation studies that tested the models with independent cohort datasets. The scored model by Flamm¹⁶⁷ was externally validated by one retrospective cohort study.¹²² The scored model by Grobman 2007¹⁸¹ was externally evaluated with a retrospective study.¹²⁰ The Troyer¹⁰⁷ model was externally validated by two retrospective studies.^{122, 142} In all validation studies, the scored model's performance was similar to the originally reported performance (see shaded rows of Table N-1 in Appendix N). In a retrospective cohort study that evaluated three scored models using the same dataset,^{107, 167, 196} Dinsmoor et al reported that all three models were accurate at predicting which women would have a VBAC but were not accurate at predicting who would have a RCD after a TOL.¹²² Using the three models, 50 percent of women with unfavorable risk factors had vaginal deliveries, suggesting that other factors may be needed to identify women at risk for cesarean delivery. A previous decision analysis of VBAC¹⁹⁷ suggested that a scored model would be most useful clinically if it achieved a sensitivity and specificity greater than 85 percent,¹²² which none of these tools achieved. All scored models are presented and discussed in detail in Appendix N.

Summary of screening tools. Since the VBAC evidence report published in 2003^{62, 194} five scored models have been created and evaluated to identify women for VBAC (or for RCD).^{104, 128, 181, 183, 184} Two of the studies created scored tools that can be used in the prenatal setting.^{128, 181} All scored models provide reasonable ability to identify women who are good candidates for VBAC but none have discriminating ability to consistently identify women who are at risk for RCD.

What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

This section reviews the maternal benefits and harms associated with VBAC compared with ERCD. The goal of this endeavor is not only to describe the current knowledge of risks of each type of delivery, but to highlight important gaps in the literature. As part of this report, the following outcomes were examined: maternal death, uterine rupture, hysterectomy, transfusion and/or hemorrhage, infection, length of hospital stay, surgical injury, and composite morbidity. In addition, factors that may modify the outcomes associated with mode of delivery such as IOL, number of prior cesarean, deliveries and direction of scar are also discussed.

Maternal Death

Maternal mortality rose in the U.S. after the dawn of the 21st century from seven to nine per 100,000 in the 80s and 90s to 12 to 15 per 100,000 since 2003.¹⁹⁸⁻²⁰⁰ Although these rates are still very low, understanding whether choices patients and providers make about route of delivery and clinical management contribute to maternal mortality is critically important.

There were 12 good or fair quality cohort studies totaling 26 maternal deaths among 402,883 patients that reported maternal mortality associated with TOL and ERCD (Appendix O).^{76, 77, 81, 93, 97, 100, 108, 164, 201-204}

The absolute risk of maternal death associated with TOL was 0.0038 percent (95 percent CI: 0.009 to 0.0155 percent) and with ERCD was 0.0134 percent (95 percent CI: 0.0043 to 0.0416 percent). Four studies focused exclusively on women delivering at term.^{93, 97, 108, 204} Among these four studies the maternal mortality was similarly lower for TOL (0.0019 percent; 95 percent CI: 0.0004 to 0.0095 percent) compared with ERCD (0.0096 percent; 95 percent CI: 0.0021 to 0.0432 percent, Figures 9 and 10).


One study from Canada reported differences in maternal mortality with TOL relative to ERCD for low and high volume maternity units. This study deserves mention because it was one of the only studies to evaluate maternal death in a range of institution types. This study evaluated both large tertiary centers as well as community hospitals, demarcating types by the number of deliveries per year.¹⁰⁸ In low volume maternity wards defined as less than 500 deliveries a year, the odds ratio was 2.68 (0.16 to 45.5) for maternal mortality with TOL compared with RCD. High volume maternity wards, defined by greater than 500 deliveries per year, were noted to have an odds ratio of 0.16 (0.02 to 1.29) of mortality with TOL compared with RCD.¹⁰⁸ No other studies stratified maternal death rates by institution size or delivery volume.

Summary and strength of evidence on maternal death. Overall, the strength of evidence regarding the rate of mortality for women with a prior cesarean delivery is high with good consistency and precision. While maternal mortality is rare with an overall rate of 10.1 per 100,000 for all women with prior cesarean, the risk of maternal mortality is significantly increased with ERCD. When combining the TOL group across all studies, the risk of maternal mortality is found to be 0.0038 percent (95 percent CI: 0.0009 to 0.0155 percent). The combined risk for ERCD group across all studies is 0.0134 percent (95 percent CI: 0.0043 to 0.0416 percent). This translates to 3.8 per 100,000 for TOL (95 percent CI: 0.9 to 15.5 per 100,000) and 13.4 per 100,000 for ERCD (95 percent CI: 4.3 to 41.6 per 100,000). When the analysis is limited to term studies, the combined risk of maternal deaths for TOL is 0.0019 percent for TOL

(95 percent CI: 0.0004 to 0.0095 percent) and 0.0096 percent for ERCD (95 percent CI: 0.0021 to 0.0432 percent); translating to 1.9 per 100,000 for TOL (95 percent CI: 0.4 to 9.5 per 100,000) and 9.6 per 100,000 for ERCD (95 percent CI: 2.1 to 43.2 per 100,000). In addition, meta-regression showed that among TOL studies, maternal mortality was significantly lower among studies of term populations compared with studies of any gestational age ($p=0.027$) but there was no significant difference based upon gestational age among ERCD studies ($p=0.141$) (Figures 9 and 10).


While rare for both TOL and ERCD, compared to ERCD, the overall risk of maternal death associated with TOL is significantly lower (RR, 0.33, 95 percent CI: 0.13 to 0.88; $p=0.027$). Using 0.0134 percent as the baseline risk for ERCD, the calculated risk difference is -0.0090 percent (95 percent CI: -0.0117 to 0.0016 percent), translating to 9.0 less deaths per 100,000 (95 percent CI: 1.6 to 11.7 less deaths per 10,000) from the TOL group. Among the four studies focused exclusively on women delivering at term, the maternal mortality risk was similarly lower for TOL (RR: 0.27, 95 percent CI: 0.09 to 0.85; $p=0.025$). Using 0.0096 percent as the baseline risk for ERCD, the calculated risk difference is -0.0070 percent (95 percent CI: -0.0087 to 0.0014 percent), translating to 7.0 less deaths per 100,000 (95 percent CI: 1.4 to 8.7 less deaths per 10,000) from the TOL group, as compared to the ERCD group.

Figure 9. Rates of maternal death for trial of labor among all studies



*95% confidence intervals are exact
 Abbreviation: TOL= trial of labor

Figure 10. Rates of maternal death for elective repeat cesarean delivery among all studies



*95% confidence intervals are exact

Abbreviation: ERCD= elective repeat cesarean delivery

Uterine Rupture

Uterine rupture is a potentially life-threatening complication that has been directly attributed to VBAC. By itself, uterine rupture – defined as complete separation through the entire thickness of the uterine wall (including serosa) – is a visible or palpable anatomic finding rather than a health outcome. However, its association with perinatal and maternal morbidity and mortality raises substantial concerns among patients, clinicians, hospitals, and policymakers. Given this, there is considerable interest in what populations and conditions make VBAC a reasonable option and what if any management factors may reduce either the occurrence of uterine rupture or the severity of consequences. This section summarizes studies reporting on the risk of uterine rupture for women with TOL and ERCD, the risk of perinatal morbidity and mortality associated with uterine rupture, management factors that may contribute to the development of uterine rupture or severity of morbidity or mortality associated with uterine rupture, and techniques and tools proposed to stratify populations of women with prior cesarean for risk of uterine rupture.

Risk of uterine rupture. Estimating the risk of uterine rupture for women with a prior cesarean has been challenging not only because studies report on *actual* rather than *intended* route of delivery but also because studies often mixed true anatomic ruptures with asymptomatic dehiscences. While numerous studies have been published relating to uterine rupture and/or dehiscence (393 articles), only eight cohort studies^{10, 97, 119, 204-208} were good or fair quality, included the population of interest, and used the anatomic definition for uterine rupture contained in this report (See Appendix F for a table of excluded studies). Details of the eight included studies that included cohorts of either TOL alone or TOL and ERCD together are presented in Table 6.

Table 6. Uterine rupture: trial of labor versus elective repeat cesarean delivery among any gestational age studies

Author Year	Design/ population	Direction/Number Scar	N	Uterine rupture
Cahill, 2006 ²⁰⁵	Retrospective Cohort 17 Community & University Centers	Any number LTCD	Total: 6,619 TOL: 5,041 ERCD: 1,578	TOL: 20/5,041 (0.40%) ERCD: 1/1,578 (0.06%)
Caughey, 1999 ^{*119}	Retrospective Cohort 1 University Hospital	1 prior Any Direction	TOL: 3,891	TOL: 36/3,891 (0.9%)
Cowan, 1994 ²⁰⁶	Prospective Cohort TOL only	Any Number Any Direction	TOL 593	TOL: 5/593 (0.8%)
Flamm 1988 ²⁰⁷	Prospective Cohort	Any Number LTCD or unknown scar	TOL: 1,776	TOL: 3/1,776 (.17%)
Flamm, 1990 ²⁰⁸	Prospective Cohort	Any Number LTCD or unknown scar	TOL: 3,957	TOL: 7/3,957 (.18%)
Loebel, 2004 ^{*97}	Retrospective Cohort 1 Community Hospital	1 prior LTCD	Total: 1,408 TOL: 927 ERCD: 481	TOL: 4/927 (0.4%) ERCD: 0
McMahon, 1996 ¹⁰	Retrospective Cohort Population based Longitudinal study	1 prior LTCD	Total: 6,138 TOL: 3,249 ERCD: 2,889	TOL: 10/3,249 (0.31%) ERCD: 1/2,889 (0.03%)

Table 6. Uterine rupture: trial of labor versus elective repeat cesarean delivery among any gestational age studies


Author Year	Design/ population	Direction/Number Scar	N	Uterine rupture
Spong, 2007 ^{*204}	Prospective Cohort MFMU 19 University Hospitals	Any Number Any Direction	Total: 33,037 TOL: 15,323 ERCD:17,714	TOL: 114/15,323 (0.74%) ERCD: 4/17,714 (0.02%)
		Total	57,419	205 (0.36%)

* Studies limited to term population

Abbreviations: ERCD=elective repeat cesarean delivery; LTCD=low transverse cesarean delivery;
TOL=trial of labor

Four studies reported uterine rupture outcomes for both TOL and ERCD.^{10, 97, 204, 205} Among these four studies totaling 47,202 patients, there were 154 uterine ruptures; 96 percent (N=148) of which were incurred by the TOL group. As shown in Figure 11, these four studies indicate that the risk of uterine rupture for all women with a prior cesarean delivery regardless of route of delivery is 0.3 percent (95 percent CI: 0.23 to 0.40 percent).

Figure 11. Uterine rupture among studies including both trial of labor and elective repeat cesarean delivery



Within these four studies, the combined risk of uterine rupture for women undergoing a TOL is 0.47 percent (95 percent CI: 0.28 to 0.77 percent) and 0.026 percent (95 percent CI: 0.009 to 0.082 percent) for women undergoing an ERCD. The increased risk for uterine rupture among the TOL group is largely affected by the Spong et al study, which reports an occurrence of uterine rupture that is double that reported for the other three studies (0.7 percent versus 0.03 to 0.4 percent).^{10, 97, 204, 205} Table 7 presents details regarding the four studies that report uterine ruptures related to both TOL and ERCD to understand factors that may explain the increased risk. The Spong study is the only one to include women with incisional types other than low transverse cesarean delivery (LTCD). However, given the small contribution of these other scar types to the overall dataset, and the fact that the uterine rupture occurrence among women with LTCD in this study was also higher than the other studies (0.75 percent) it is unlikely that this alone explains the difference. Fewer women with a prior cesarean delivery elected TOL in this study at 39 percent. It is difficult to assess whether the years that studies were conducted affected the occurrence of uterine rupture because the two studies conducted after 1996 have very different populations.^{204, 205} Unfortunately, none of the four studies provided details on the proportion of women in the study who underwent IOL, a factor that is known to have large variation and to increase the occurrence of uterine rupture. The effect of IOL upon uterine rupture is considered in detail later in this section. Overall, there is no clear factor that is associated with higher versus lower occurrence of uterine rupture among the four studies providing comparative data.

Table 7. Characteristics of uterine rupture studies of trial of labor and elective repeat cesarean delivery

Author, year	Study Population	Study Years	GA	Uterine Rupture	TOL/ VBAC	Direction/ # prior	Prior Vaginal Delivery	IOL
Cahill, 2006 ²⁰⁵	17 Community & University Centers approximately 50% University	1996-2000	Any	TOL 0.4% ERCD 0.06%	77% / 92%	8% >1prior LTCD	100%	NR
Loebel, 2004 ^{*97}	100% Community 0% University	1995-1998	Term	TOL 0.4% ERCD 0%	66% / 81%	1 prior LTCD	36-38%	NR
McMahon, 1996 ¹⁰	7% community 60% tertiary	1980-1992	Any	TOL 0.3% ERCD 0%	53% / 60%	1 prior LTCD	17%	NR
Spong, 2007 ^{*204}	100% University	1999-2002	Term	TOL 0.74% ERCD 0.02%	39% / 73%	4% >1 prior any direction	49%	NR

Abbreviations: ERCD=elective repeat cesarean delivery; GA=gestational age; IOL=induction of labor; LTCD=low transverse cesarean delivery; NR=not reported; TOL=trial of labor; VBAC=vaginal birth after cesarean

Four additional studies reported on uterine rupture exclusively in women undergoing TOL.^{119, 206-208} A sensitivity analysis was performed to examine whether this difference in cohort assembly (TOL only versus TOL plus ERCD) affected the results for uterine rupture and there was not a statistically significant difference. The increased number of studies available for TOL allows a more detailed examination of factors such as gestational age, direction of scar, year of study, etc., that may be associated with higher risks of uterine rupture.


Figure 12. Uterine rupture among all trial of labor studies

Study Name	N Ruptures	NTOL	Cohort
Term studies			
Caughey, 1999	36	3,891	TOL only
Loebel, 2004	4	927	TOL + ERCD
Spong, 2007	114	15,323	TOL + ERCD
Combined (Test for heterogeneity Q= 2.71, I²= 26.2%, P= 0.258)†			
Any gestational age studies			
Flamm, 1988	3	1,776	TOL only
Flamm, 1990	7	3,957	TOL only
Cowan, 1994	5	593	TOL only
McMahon, 1996	10	3,249	TOL + ERCD
Cahill, 2006	20	5,091	TOL + ERCD
Combined (Test for heterogeneity Q= 9.12, I²= 56.2%, P= 0.058)†			
TOL only studies combined (Test for heterogeneity Q= 22.24, I²= 86.5%, P< 0.001)†			
TOL + ERCD studies combined (Test for heterogeneity Q= 13.39, I²= 77.6%, P= 0.004)†			
All studies combined (Test for heterogeneity Q= 36.25, I²= 80.7%, P< 0.001)†			

*95% confidence intervals are exact

†All tests for heterogeneity are based on logits of rates

Abbreviations: ERCD= elective repeat cesarean delivery; TOL= trial of labor



As shown in Figure 12, the occurrence of uterine rupture for TOL remains relatively unchanged at 0.46 percent. Among TOL studies, the occurrence of uterine rupture is significantly higher for studies limited to term patients compared with studies including patients of any GA (0.78 versus 0.32 percent, $p=0.033$). Looking across all eight studies, the highest occurrence of uterine rupture among TOL patients were reported by studies that included women with any direction of cesarean scar.^{119, 204, 206} Among these, only Spong et al presented details for uterine rupture occurrence according to the direction of incision, with the lowest rate reported in the unknown incision group 0.63 followed by LTCD 0.75, classical T or J 1.59 and low vertical 2.47. There were no uterine ruptures among women who experienced ERCD without labor for any direction of incision. This study also provides additional information relative to presence or absence of labor and indication for cesarean delivery among the groups because of its unique study design. Because it is clinically important to understand the additional risk for uterine rupture given both the number and direction of prior cesareans, studies that specifically addressed this question are presented in further detail later in this report under the section entitled “Special Considerations.”

Morbidity and mortality related to uterine rupture. As shown in Table 8, there were no maternal deaths due to uterine rupture in any of the eight studies.^{10, 97, 119, 204-208} The risk for perinatal death in the event of uterine rupture ranged from 0 to 20 percent with a pooled risk of 6.2 percent and the highest risk experienced by the TOL group. For perinatal death, it is useful to limit to term studies to remove the effect of gestational age. Among the three term studies,^{97, 119, 204} two provided data for the risk of perinatal death given uterine rupture.^{97, 119} They report that 0 to 2.8 percent of all uterine ruptures resulted in a perinatal death. Figure 13 presents uterine rupture related perinatal death among the six studies reporting uterine rupture for populations of women delivering at any gestational age.^{10, 97, 119, 206-208} Four of the eight studies reported the risk of hysterectomy given uterine rupture;^{10, 207-209} only one of which provided comparative data between TOL and ERCD groups.¹⁰ They reported an occurrence of hysterectomy give uterine rupture of 14 to 33 percent.

Table 8. Rupture associated morbidity


Author, Year	Rupture associated neonatal deaths (% of ruptures)	Rupture associated maternal deaths	Rupture associated hysterectomy
Cahill, 2006 ²⁰⁵	Not reported	Not reported	Not reported
Caughey, 1999 ^{*119}	1/36 (2.8%) 1 prior CD TOL [timing not detailed]	0	8/36 (22%)
Cowan, 1994 ²⁰⁶	0	Not reported	Not reported
Flamm, 1988 ²⁰⁷	0	0	1/3 (33.3%)
Flamm, 1990 ²⁰⁸	1/7 (14%) Labored at home without monitoring; 2 prior CD unknown scar FHR 55 at admission	0	1/7 (14%)
Loebel, 2004 ^{*97}	TOL: 0 ERCD: 0	TOL: 0 ERCD: 0	Not reported
McMahon, 1996 ¹⁰	TOL: 2/10 (20%) (no details provided) ERCD: 0/1	NR	TOL: 2/10 (20%) ERCD: 0/1 (0%)
Spong, 2007 ^{*204}	Not reported	TOL: 0 ERCD: 0	Not reported

*Term studies Abbreviations: CD=cesarean delivery; ERCD=elective repeat cesarean delivery; FHR=fetal heart rate; TOL=trial of labor

Figure 13. Risk for perinatal death given uterine rupture

Study Name	N Perinatal Death	N Ruptures	Term
Flamm, 1988	0	3	0
Flamm, 1990	1	7	0
Cowan, 1994	0	5	0
McMahon, 1996	2	10	0
Caughey, 1999	1	36	1
Loebel, 2004	0	4	1
All studies combined (Test for heterogeneity is based on Fisher's exact test P=0.254)			

*95% confidence intervals are exact




Summary and strength of the evidence on risk of uterine rupture. Overall, evidence regarding the rate of uterine rupture for women with a prior cesarean delivery is moderate in strength, indicating that the risk of uterine rupture for women with prior cesarean is 0.3 percent. Compared with women undergoing an ERCD, women undergoing a TOL have a significantly higher risk of uterine rupture (RR 20.74, 95 percent CI: 9.77 to 44.02; $p < 0.0010$). Using 0.026 percent as the baseline risk for ERCD, the calculated risk difference is 0.51 percent (95 percent CI: 0.23 to 1.12 percent) translating to 5.1 additional ruptures per 1,000 (95 percent CI: 2.3 to 11.2 per 1,000) women undergoing TOL. Though the studies are limited in number, there does not appear to be a reduction in the occurrence of uterine rupture in recent years (e.g., after 1996). Overall, studies focused on providing rates of uterine rupture but did not provide important details that would provide insights for management—such as the relationship between length of labor and uterine rupture—to establish whether there is a dose response for labor. To date, there have been no maternal deaths reported because of uterine rupture, and the risk of perinatal death due to uterine rupture is similarly low at 6.2 percent. However, the risk of hysterectomy due to uterine rupture is an important consideration for women planning VBAC, with rates ranging from 14 to 33 percent. There appears to be an increased risk for uterine rupture among women who undergo a TOL at term. Because term may also include postdates and inductions, the section that follows provides further details on the impact of management and GA upon risk for uterine rupture.

Effect of induction of labor on uterine rupture. Women often need interventions such as induction and/or augmentation of labor that may affect a woman's risk for uterine rupture. Seven fair quality studies (four cohort, three case series) including 5,276 women with a prior cesarean delivery who had IOL report uterine rupture using the definition of separation through the entire thickness of the wall including visceral serosa (with or without extrusion of part of all of fetal-placental unit); two studies of PGE₂,^{145, 151} one of foley catheter used for cervical ripening,¹⁵⁰ and four of any IOL method.^{60, 96, 156, 164} However, one of the studies⁶⁰ used a definition of rupture of extrusion of the uterine contents into the peritoneal cavity, and thus likely underestimates the rate of rupture as defined in this report.

These studies indicate that the risk of uterine rupture is 1.5 percent in women receiving IOL and delivering at term and 1.0 percent when women with any GA and receiving IOL are included. These rates are two times greater compared with all women with a prior cesarean delivering at term (1.5 versus 0.7 percent), and three times greater when considering women with any GA (1.0 versus 0.3 percent). Further stratification of the data indicates that there is increased risk of rupture in women delivering at greater than 40 weeks GA (Figure 14) compared with women delivering at term (3.2 versus 1.5 percent). The reason for induction, the dose of induction agents needed, etc., need to be examined more fully to determine the cause of this increased risk. The pooled risk of uterine rupture in the spontaneous labor groups in these studies is 0.8 percent (95 percent CI 0.7 to 1.1), which is higher than the pooled estimate from all TOL studies (0.47 percent; 95 percent CI 0.28 to 0.77 percent), indicating that the baseline risk of rupture is higher in the induction studies overall. This is an important factor, suggesting that indirect comparisons from these studies to the general TOL studies is not possible.

Figure 14. Uterine rupture with induction of a trial of labor




In women delivering at term, the risk of rupture is not statistically significantly greater in women undergoing IOL compared with those with spontaneous labor (odds ratio 1.42; 95 percent CI: 0.57 to 3.52). In examining these studies further, it appears that women at greater than 40 weeks GA have increased risk of rupture while those at term or less than 37 weeks GA do not (Figure 15). Because there were no ruptures in either group in one study⁶⁰ an odds ratio could not be calculated, but the absolute difference in risk shows that only women delivering at greater than 40 weeks GA have an increased risk with IOL over spontaneous labor (risk

difference 1.8 percent; 95 percent CI: 0.1 to 3.5 percent). The number needed to harm (NNH) in this group is 56 (for every 56 women greater than 40 weeks GA whose labor is induced during a TOL, one additional rupture will occur compared with those having spontaneous labor).

However, for women with indication for induction of labor at 40 weeks gestation and beyond, clinicians are faced with the option of induction or ERCD and not spontaneous labor. A better, more useful, comparator for induction of labor would be expectant management. These findings should be interpreted with caution, as one study found similarly increased rates of rupture with induction regardless of GA, while the other found increased risk in the group with greater than 40 weeks GA only.


Figure 15. Risk of rupture: induction versus spontaneous labor



Given that there is such limited evidence regarding the risk of uterine rupture with various methods of IOL, it was decided to evaluate studies that used a broader definition of uterine rupture. While these cannot be compared with those evaluated for the risk of uterine rupture in spontaneous labor, they can be used to make indirect comparisons across IOL methods. The studies included below report that uterine rupture was a primary outcome measure of the study and report clear methods for ascertaining rupture, e.g., individual chart review. Because the definitions used are not limited to the anatomical description of rupture used in the above, these analyses should be considered exploratory only.

Prostaglandin E2. The risk of uterine rupture with PGE2 use for cervical ripening and IOL was reported as a main of outcome interest in 14 studies (six good or fair quality cohort studies, and eight fair quality case series). Two of which included only women at term gestation,^{156, 164} while the rest included women with any GA.^{11, 145, 148, 149, 151, 157, 158, 163, 165, 168-170} Pooled analysis of the proportion of women experiencing a uterine rupture after PGE2 induction provides a point estimate of 2.0 percent (95 percent CI: 1.1 to 3.5 percent, see Figure 16). It is important to note however, that these studies did not define uterine rupture according to the anatomic definition in this report. Therefore, understanding these rates in comparison with other VBAC studies is not possible. The two studies restricting to women with term GA found very different rates; 3.9 percent¹⁶⁴ compared with 0.8 percent.¹⁵⁶ The study with the lower rate was methodologically superior. The studies with more rigorous design report a higher rate of uterine rupture. One study included in this analysis used ICD-9 codes to identify uterine rupture¹¹ – a method that has subsequently been shown to overestimate true rupture rates.²¹⁰ The study reporting the highest rate, 10.3 percent,¹⁷⁰ identified cases by discharge diagnosis of uterine rupture, another method that may overestimate the proportion with true rupture. The validity and reliability of the method used was not tested or reported, and similar to the use of ICD-9 codes, could overestimate true rupture. Additionally, baseline obstetric characteristics of women induced, mean total dose of prostaglandin, and percent receiving oxytocin for augmentation (except for the uterine rupture cases) were not reported such that comparisons to other study populations cannot be made.

Figure 16. Uterine rupture with prostaglandin E₂ induction



*95% confidence intervals are exact

Dose of PGE₂ was sporadically reported, and when reported was not consistent in the reporting metric (e.g., mean number of doses versus the number of women receiving two or three doses). Similarly, while the number of prior cesarean delivery and the rate of prior vaginal deliveries may have influenced the rate of VBAC with PGE₂ induction, these covariates were not reported adequately for analysis. A small number of studies did report these variables, but either did not stratify the results by specific induction method,¹⁵⁶ or had too few numbers to allow analysis.¹⁵⁷

Misoprostol. Evidence for maternal harms with misoprostol is limited to three fair quality cohort studies, including women with any GA.^{11, 172, 211} The largest of these,¹¹ used ICD-9 codes to identify uterine ruptures, a procedure now known to overestimate rupture rates. Additionally, although the study is large (N=20,525), only 366 received prostaglandins of any kind. The data were collected between 1987 and 1996, and it is noted that misoprostol was not used regularly


until 1996, indicating that few of the women described as receiving a prostaglandin had misoprostol. While the actual numbers of women receiving misoprostol are not reported, the relative risk for a uterine rupture in women who received a prostaglandin during 1996 was 12.2 (95 percent CI: 3.4 to 39.6). This compares with a separate analysis of uterine rupture among women who received a prostaglandin during the years 1987 to 1995, relative risk 14.1 (95 percent CI: 6.1 to 33.0; both compared with ERCD).

The other two studies are much smaller, but do report misoprostol data separately. In a small, fair quality, cohort study (N=226) comparing PGE₂ (administered as a gel or pessary) with misoprostol (25 to 50 mcg),²¹¹ only 16 of 145 women in the misoprostol group and nine of 81 in the PGE₂ group had a prior cesarean delivery. Additionally, the data for PGE₂ was obtained retrospectively while the data for misoprostol were obtained prospectively. The results for uterine rupture were stratified by history of a prior cesarean delivery with two of 16 in the misoprostol group (13 percent) and zero of nine in the PGE₂ group having what is described only as a low transverse rupture. One additional patient in the misoprostol group had a scar dehiscence. In both cases of rupture, hysterectomy was performed, with no blood transfusions. The second study of misoprostol made comparisons among women with a history of prior cesarean delivery to those *without* prior cesarean delivery, a comparison that is not relevant to this review.¹⁷² There were no uterine ruptures, and 2.0 percent were reported as having “complications,” including abruption placenta, retained placenta, uterine atony, and blood transfusion.

Mifepristone. In a small (N=32), fair quality trial of mifepristone and placebo, each given for 2 days followed 2 days later by IOL with prostaglandins, oxytocin, and/or artificial rupture of membranes as needed in term GAs,¹⁷³ one uterine scar separation occurred in each group (6.25 percent). Maternal outcomes were not different between groups, except that two patients in the mifepristone group developed fever, compared with none in the placebo group. One wound infection was found in each group.

Oxytocin. The risk of uterine rupture following induction or augmentation of labor with oxytocin was reported as a main outcome measure in eight studies (one good quality cohort study, four fair quality cohort studies, and three fair quality case series).^{11, 125, 156-158, 164, 168, 169} The risk of uterine rupture is 1.1 percent (95 percent CI: 0.9 to 1.5 percent) when data from these studies are pooled (Figure 17).

Figure 17. Uterine rupture with oxytocin



*95% confidence intervals are exact
Abbreviation: GA= gestational age

A case control study of 24 cases of uterine rupture where oxytocin had been given during TOL after prior cesarean delivery and 96 controls that also received oxytocin but had no uterine rupture examined the relationship of oxytocin dose to rupture.¹⁷⁴ The study was powered to find a difference of 40 percent in the duration of oxytocin or a 65 percent increase in total dose. None of the multiple analyses found a statistically significant difference, although the difference in duration of oxytocin (530 minutes in the uterine rupture group compared with 476 in the non-rupture group) achieved a p value of 0.08. The study was small, and the large differences of 40 percent for duration and 65 percent for dose appear to have been set arbitrarily. Further analysis of the impact of dose on uterine rupture rate may be warranted.

Oxytocin augmentation of labor. Augmentation of labor with oxytocin may be an important confounder for uterine rupture; among the 12 studies reporting uterine rupture as a main outcome measure, eight reported the proportion of women receiving augmentation of labor ranging from 16 to 81 percent (Table 9).^{145, 148, 149, 151, 156-158, 168} Meta-regression of these data did not result in oxytocin augmentation to be a statistically significant covariate for uterine rupture with PGE₂ induction (p=0.22). While this evidence may be too limited to make conclusions about an association between proportions of women having both PGE₂ induction and oxytocin

augmentation of labor and increasing uterine rupture rates, there is at least a trend towards increased risk when both drugs are used.

Table 9. Effect of oxytocin augmentation on rate of uterine rupture in women receiving prostaglandin E₂ for induction

Study, year	Study design	GA	N induced with PGE ₂	% Uterine rupture	% Augmented with oxytocin
Grobman, 2007 ¹⁵⁶	Cohort MFMU	Term	754	0.8	0.81
Yogev, 2004 ¹⁴⁵	Cohort women with 1 prior CD with IOL	Any GA	97	0	0.25
Ben-Aroya, 2002 ¹⁴⁸	Cohort University hospital women in 2nd delivery, following a CD	Any GA	55	0	0.16
Meehan, 1989 ¹⁵⁸	Case series University teaching hospital women with 1 prior CD, nominated for TOL	Any GA	52	1.9	0.44
Locatelli, 2006 ¹⁶⁸	Case series University hospital women with a previous CD	Any GA	310	0.3	0.4
Kayani, 2005 ¹⁵⁷	Case series Larger inner city teaching hospital women with IOL after 1 prior CD	Any GA	149	0.7	0.35
Chilaka, 2004 ¹⁵¹	Case series University hospital women with prior CD, who had IOL	Any GA	130	0	0.27
Blanco, 1992 ¹⁴⁹	Case series University hospital women attempting TOL	Any GA	25	0	0.2

Abbreviations: CD=cesarean delivery; GA=gestational age; IOL=induction of labor; MFMU=Maternal-Fetal Medicine Units Network; PGE₂=prostaglandin E₂; TOL=trial of labor


Prostaglandin E₂ versus oxytocin. The best evidence on the risk of uterine rupture with PGE₂ compared with oxytocin when used for IOL comes from a large good quality cohort study of women with term gestations and one prior cesarean delivery.¹⁵⁶ In this study there were no uterine ruptures in the prostaglandin only group, 29 out of 2,421 (1.2 percent) in the oxytocin only group, and six out of 614 in the prostaglandin plus oxytocin group (1 percent). Statistical comparisons were made only with the spontaneous labor group and stratified by prior vaginal delivery or no prior vaginal delivery. The group with no prior vaginal delivery and receiving oxytocin only resulted in a statistically significantly greater risk of uterine rupture (odds ratio 2.19; 95 percent CI: 1.28 to 3.76). Analysis of the other groups compared with spontaneous labor, including PGE₂ only, did not result in significantly increased risk. A second, lower quality cohort study similarly found the risk of uterine rupture to be significantly increased with oxytocin induction (odds ratio 4.6; 95 percent CI: 1.5 to 14.1) but not with PGE₂.¹⁶⁴ The pooled analysis of these results in an odds ratio of 2.7 (95 percent CI: 1.4 to 5.1) compared with

spontaneous labor. Direct comparisons are not available, and the number of women in the prostaglandin only groups is much smaller than in the oxytocin only groups. Using the data presented in the large cohort study for uterine rupture in the oxytocin only group (prior and no prior vaginal delivery combined) compared with prostaglandin only (prior and no prior vaginal delivery combined) yielded an unadjusted odds ratio of 0.29 (95 percent CI: 0.04 to 2.09) indicating no statistically significant difference in risk. However, this is an exploratory analysis and should be interpreted with caution.

Mechanical methods of induction. The evidence on the risk or benefits of mechanical methods of cervical ripening in women with a prior cesarean delivery is very limited.^{148, 150, 169, 179, 180} The best of these are two small retrospective cohort studies evaluating the use of a foley catheter for cervical ripening compared to spontaneous labor.^{148, 150} No cases of uterine rupture occurred in the groups who had foley catheter cervical ripening, although the numbers of patients in the foley catheter groups may have been too small to identify a rupture (N=416). Additionally, while one study was rated good quality and defined uterine rupture clearly, it is not clear that evidence of uterine rupture was routinely sought in all women,¹⁵⁰ and the other study provided no definition for uterine rupture.¹⁴⁸

Any induction method. The risk of uterine rupture associated with a TOL and IOL using any method was assessed using 14 fair quality studies, involving 12,659 women.^{11, 60, 96, 121, 125, 150, 154, 156-158, 160, 164, 167, 169} Combining these data results in a risk of 1.2 percent (95 percent CI: 0.9 to 1.6 percent) as shown below, with one small study reporting no uterine ruptures (0 percent) (Figure 18).

Figure 18. Risk of uterine rupture with any induction method



*95% confidence intervals are exact
Abbreviation: GA= gestational age

Unfortunately, studies that reported the proportion of women with induced or augmented labors reported other maternal outcomes too infrequently to be meaningfully assessed.

Amnioinfusion. One small cohort study of women with prior cesarean delivery compared the rate of uterine rupture, defined as “full thickness separation of scar requiring operative intervention”, in women who underwent amnioinfusion during labor and those who did not.¹³⁸ However, exploration of the uterus was only undertaken among those with VBAC. The total number of women studied was 1,436, with 122 having received amnioinfusion. The rate of rupture was 0.8 percent in the amnioinfusion group and 1.1 percent in the group without amnioinfusion. There was no statistically significant difference in the rate of rupture between the groups, RR 0.72 (0.10 to 5.39). A smaller study reported no ruptures, but the definition and ascertainment of rupture was unclear.²¹²

Summary and strength of the evidence on effect of induction of labor on uterine rupture. The strength of evidence on the risk of uterine rupture with pharmacologic IOL methods was low due to lack of precision in estimates and inconsistency in findings. The overall risk of rupture with any IOL method at term was 1.5 percent and 1.0 percent when any GA is considered. Among women with GA greater than 40 weeks, the rate was highest at 3.2 percent. Evaluation of the evidence on specific methods of IOL reveal that the lowest rate occurs with oxytocin at 1.1 percent, then PGE₂ at 2 percent, and the highest rate with misoprostol at 6 percent. These

findings should be interpreted with caution as there was imprecision and inconsistency in the results among these studies. The risk of uterine rupture with mechanical methods of IOL is understudied. Other harms were inadequately reported to make conclusions. Relative to women with spontaneous labor, there was no increase in risk of rupture among those induced at term. However, the available evidence on women with induced labor after 40 weeks GA indicates an increased risk compared with spontaneous labor (risk difference 1.8 percent; 95 percent CI: 0.1 to 3.5 percent). The NNH in this group is 56 (for every 56 women greater than 40 weeks GA with IOL during a TOL, one additional rupture will occur compared with having spontaneous labor).

Individual factors associated with uterine rupture. The impact of individual factors on uterine rupture can overlap and interact with each other such that a factor found to have statistically significant influence may no longer be significant when other key factors are taken into account. Studies that evaluate these factors in concert, using regression analyses for example, can provide a higher level of evidence on the residual influence of individual factors. Table 10 presents odds ratios reported by 11 good or fair quality studies that examined the relationship between individual factors and uterine rupture using the anatomic definition for uterine rupture.^{60, 80, 119, 150, 213-219} Individual factors associated with uterine rupture were grouped into four general categories: 1) demographic, 2) past obstetric factors, and 3) current obstetric factors. Nonclinical factors such as hospital type, VBAC volume, hospital delivery volume, maternal substance use or maternal medical conditions were only presented in studies that did not use the anatomical definition for uterine rupture or did not present a definition of uterine rupture and are therefore left off the table.

Table 10. The odds of uterine rupture after cesarean delivery by factor

	Studies using anatomical uterine rupture definition	Adjusted odds ratio for uterine rupture[†] (95% CI or p value)
Demographic Maternal Age	Bujold, 2002 ²¹⁴	0.95 ($\geq 35y$): (0.31-2.92)
	Shipp 2003 ^{*218}	13.78 ($>30y$): (1.56-122.05)
	Shipp 2008 ^{*219}	2.6 (30-39 y): (1.1-6.0) 5.8 ($\geq 40y$): (1.6-20.3)
Past obstetric factors Prior vaginal delivery	Grobman, 2008 ^{*215}	0.44: (0.27-0.71)
	Shipp, 2008 ²¹⁹	0.3: (0.1-0.9)
	Bujold 2002 ²¹³	0.42: (0.05-3.17)
	Caughey, 1999 ¹¹⁹	0.26: (0.08-0.88)
	Landon, 2006 ^{*80}	0.62: (0.43-0.82)
Current obstetric factors		
Prior vaginal birth after cesarean	Landon, 2006 ⁸⁰	0.52: (0.34-0.82)
Number of prior cesarean deliveries	Caughey, 1999 ¹¹⁹	4.8 (2 versus 1): (1.8-13.2)
	Landon, 2006 ⁸⁰	1.36 (multiple): (0.69-2.69)

Table 10. The odds of uterine rupture after cesarean delivery by factor

	Studies using anatomical uterine rupture definition	Adjusted odds ratio for uterine rupture[†] (95% CI or p value)
	Shipp, 2008 ²¹⁹	5.3 (2 or more): (2.1-12.9)
Gestational age	Hammoud, 2004 ⁶⁰ Sciscione, 2008 ²¹⁷ Shipp, 2003 ²¹⁸	2.8 (≥ 41 versus 37-40): (1.27-6.42) 2.05 (preterm versus term with ERCD): (1.39-2.55) 1.73 (preterm versus term excl ERCD): (1.17-2.55) 0.24 (>40wks): (0.04-1.43)
Birth weight	Bujold, 2002 ²¹⁴ Bujold, 2002 ²¹³ Landon, 2006 ⁸⁰ Shipp, 2003 ²¹⁸	1.02(>3500g): (0.42-2.47) 2.10 (>4,000g): (0.76-5.88) 1.09 ($\geq 4,000$ g): (0.60-1.97) 2.26 ($\geq 4,000$ g): (0.47-10.82)
Inter-delivery interval	Bujold, 2002 ^{*214} Bujold, 2002 ^{*213} Landon, 2006 ⁸⁰ Shipp, 2008 ²¹⁹	2.65 (≤ 24 mos): (1.08-5.46) 2.31 (≤ 24 mos): (0.97-5.52) 2.05 (≤ 24 mos): (1.41-2.96) 2.4 (<18 mos): (1.0-5.6)
Induction	Bujold, 2002 ²¹⁴	1.82: (0.66-5.04) 0.75(use of oxytocin): (0.26-2.21) 1.81 (foley): (0.59-5.56)
	Bujold, 2004 ¹⁵⁰	0.47 (foley): (0.06-3.59)
	Grobman, 2007 ^{*220}	1.39: (0.62-3.13)
	Kieser, 2002 ²¹⁶	0.71: (0.12-3.81) 0.53 (oxytocin): (0.04-4.38) 0.56 (PG): (0.01-11.81)
	Landon, 2004 ^{*221}	2.86: (1.49-3.93) 3.01 (oxytocin alone): (1.66-5.46) 3.95 (PG \pm oxytocin): (2.01-7.79)
	Landon, 2006 ^{*80}	1.78: (1.24-2.56)
Augmentation	Landon, 2006 ⁸⁰	2.41: (1.49-3.93)
Epidural	Bujold, 2002 ^{*214}	1.83: (0.50-6.67)

Table 10. The odds of uterine rupture after cesarean delivery by factor

	Studies using anatomical uterine rupture definition	Adjusted odds ratio for uterine rupture[†] (95% CI or p value)
	Bujold, 2002 ^{*213}	2.10: (0.76-5.84)
	Landon, 2006 ⁸⁰	1.76: (1.13-2.75)
Layers of closure	Bujold, 2002 ^{*214}	4.33 (single): (1.70-10.98)
	Bujold, 2002 ^{*213}	3.95 (single): (1.35-11.49)

* Uses same data source

[†]Odds ratio considered significant if confidence interval does not include 1.0 or p<0.05

Abbreviations: CI=confidence interval; ERCD=elective repeat cesarean delivery; g=grams; mos=months; PG=prostaglandin; VBAC=vaginal birth after cesarean; wks=weeks; y=year(s)

As shown, prior vaginal delivery and prior VBAC consistently appear to significantly reduce the risk of uterine rupture with odds ratios of 0.26 to 0.62 for prior vaginal delivery and 0.52 for prior VBAC. Inter-delivery interval less than 18 to 24 months and single layer closure appear to increase risk of uterine rupture with odds ratios of 2.05 to 2.65, and 3.95 to 4.33, respectively. However, caution should be used in interpreting the finding for layers of closure as this is based upon one study and the same study reports an increased risk for uterine rupture among preterm births, which is contrary to the reports of TOL and ERCD cohort studies.

Use of imaging to predict uterine rupture. The evidence on the use of various imaging modalities such as ultrasound, X-ray pelvimetry and endoscopy to predict uterine rupture risk is limited and consists of four fair quality cohort studies and six poor quality case series.^{82, 83, 222-229} The best evidence comes from three fair quality prospective cohort studies that measured full thickness lower uterine segment using ultrasound measurements between 35 and 38 6/7 weeks gestation.^{82, 83, 223} The first study conducted in France from 1989 to 1994⁸³ provides the most robust study design of the three to test the value of ultrasound as neither women nor their clinicians were informed of the results prior to delivery, thus removing the potential bias that could result from clinicians directing their patients towards or away from VBAC due to imaging results. In this study, women underwent ultrasound measurements of the lower uterine segment using a standardized method between 36 and 38 weeks and patients were divided into four groups according to full lower uterine segment thickness greater than 4.5 millimeters (mm), 3.6 to 4.5mm, 2.6 to 3.5mm and 1.6 to 2.5mm. There was a significant association between uterine wall thinning and uterine scar defects, defined as uterine rupture or dehiscence. Overall, the relative risk of a defect was 20.1 percent (95 percent CI: 8.3 to 48.9 percent) for lower uterine segment less than or equal to 3.5mm and 6.3 percent (95 percent CI: 2.8 to 13.9 percent) for measurements less than or equal to 2.5mm. While measurements greater than 4.5mm had a negative predictive value of 100 percent given no cases of defect in this group, the positive predictive value for a thickness less than 3.5mm was not good at 11.8 percent (negative predictive value 99.3 percent). Of note, this population included women with multiple prior cesarean deliveries and there was no clear association between number of prior cesareans and uterine thickness measurements. This study did not adjust for other factors that might also contribute to risk such as direction of prior cesarean scar, estimated fetal weight, co-morbidities, indication for prior cesarean delivery, history of prior vaginal delivery etc. While the two additional studies that follow, Rozenberg 1999⁸² and Bujold 2009,²²³ have higher risk of bias as

clinicians were informed of the imaging results prior to delivery, both support the association between uterine thickness and uterine rupture (Table 11).

Table 11. Lower uterine segment thickness and uterine defect

Author, year	Study years/Population	LUS Thickness (mm) and Uterine Defect	Additional Results
Rozenberg, 1996 ⁸³	Prospective Cohort 1989-1994 Single University hospital Paris, France	1.6-2.5mm – 8/51 (16%) 2.6-3.5mm 14/136 (10%) 3.6-4.5mm – 3/177 (2%) 4.5mm – 0/278 (0%)	Cut off 3.5mm Sensitivity 88% Specificity 73.2% PPV 11.8% NPV 99.3%
Bujold, 2009 ²²³	Prospective Cohort 2004-2006 Single University institution Montreal Canada	< 2.0mm – 4/35 (11%) 2.0-2.4 – 2/52 (3.8%) 2.5-2.9 – 1/40 (2.5%) 3.0-3.4 – 1/50 (2%) ≥3.5 - 1/59 (1.7%)	Single layer closure & inter-delivery interval <24 months associated with defect (not rupture) In TOL group LUS thickness of <2.3mm & UR results in Sensitivity 100% Specificity 75% 9.1% UR in TOL

Abbreviations: LUS=lower uterine segment; mm=millimeter; NPV=negative predictive value; PPV=positive predictive value; TOL=trial of labor; UR=uterine rupture

Strength of evidence for individual factors as predictors of uterine rupture. Studies of individual factors that may increase or decrease a woman’s risk of uterine rupture are largely exploratory, as few factors have been confirmed in prospective studies as suggested by Simon and Altman, 1994.¹⁹³ There is cross validating evidence to suggest that women with prior vaginal delivery have lower risk for uterine rupture and women undergoing IOL have higher risk of uterine rupture compared with spontaneously laboring women. Similarly, evidence from IOL studies suggest that women who are postdates may have a higher risk of uterine rupture. The evidence on the role of imaging to predict uterine rupture is low due to limited studies with high-risk for bias; however, the existing data suggest that there may be value to ultrasound measurements of uterine thickness for women with prior cesarean delivery.

Predictive models for uterine rupture. Because uterine rupture is such an important consideration for women with prior cesarean delivery, several investigators have attempted to build predictive tools that would combine the individual predictors to estimate a woman’s risk for uterine rupture. Four studies attempted to develop predictive models for uterine rupture (see Appendix P for study details).^{104, 215, 219, 230} Only two tested their predictive model in a validation group.^{104, 215} No study was able to produce a reliable and robust model to predict uterine rupture.

Signs of uterine rupture and management to reduce uterine rupture related mortality. Given the serious potential consequences for morbidity and mortality given uterine rupture, it would be ideal to understand signs and symptoms of uterine rupture and what, if any interventions might reduce the likelihood of morbidity or mortality in the event that a uterine rupture does occur. As stated in a prior VBAC evidence report, and echoed in studies contained in this report, there is no single sign for the occurrence of uterine rupture; however, fetal heart tracing abnormalities, particularly fetal bradycardia (reported in 33 to 100 percent of all studies) is the most frequently reported sign of uterine rupture.^{62, 206-208} Other signs reported in uterine rupture studies in descending order are maternal vaginal bleeding, maternal pain, and uterine contraction disturbances.⁶²

The next important question is whether there are any management or system factors that might reduce the likelihood for an adverse outcome in the event of uterine rupture. Two fair quality case series^{231, 232} have specifically studied whether time from signal of uterine rupture to delivery predicts perinatal outcomes. Leung et al were the first to perform an exploratory analysis to study risk factors for poor neonatal and maternal outcome; particularly fetal heart rate (FHR) and uterine contraction patterns.²³³ They identified 106 cases of symptomatic uterine rupture from 11,179 TOLs in women with prior cesarean delivery at Los Angeles County University of Southern California Women's Hospital, from which they were able to review 99 records. The scar type was unknown in 99 percent of their population. They categorized cases of uterine rupture based on complete, partial, or no extrusion of the fetus. Combining death, asphyxia, and respiratory distress, they concluded that perinatal morbidity and mortality was significantly greater in cases where the fetus was extruded. Looking for premonitory signs of uterine rupture, they found that prolonged decelerations occurred in 17/41 (41.5 percent) patients with extrusion and 15/58 (25.9 percent) without and that no patient who had prolonged deceleration only as their sign of rupture had significant clinical morbidity when delivery occurred within 17 minutes of the onset of deceleration. Four of six infants (67 percent) who died due to uterine rupture presented to labor and delivery in "fetal distress" and two of six occurred in women undergoing TOL. It is important to note that 57 percent of uterine ruptures with fetal extrusions occurred in women with two or more prior cesarean deliveries; 21 percent in classical or vertical incisions, 21 percent in unknown incisional type, and 58 percent in LTCD.

A second case series of 23 uterine ruptures out of Canada found no relation between time from FHR deceleration and infant outcome.²³¹ As above, the study was conducted in a tertiary care hospital with in-house anesthesia and obstetrics. Fetal heart rate abnormalities—which included tachycardia and late, variable, or prolonged (not defined) decelerations—were the initial sign of uterine rupture in 20/23 (87 percent) of cases (four had pain, one vaginal bleeding, and one hematuria). Prolonged deceleration was the first sign of uterine rupture in 6/6 (100 percent) of the extruded patients versus 8/17 (47 percent) without extrusion. There was one perinatal death that occurred in the non-extruded group (late decelerations more than 25 minutes before delivery, failed vacuum extraction, then cesarean delivery), and three cases of impaired motor development diagnosed as hypoxic-ischemic encephalopathy (HIE), occurring in the extruded group; delivery occurred 15, 16, and 23 minutes from onset of prolonged deceleration. When they looked at metabolic acidosis (their primary outcome, defined as umbilical artery pH less than 7.0 with base deficit greater than 12mMol/L), they found a non-significant trend towards less time between first sign to delivery (18 versus 24 minutes) and decision to delivery (13 versus 17 minutes) in the group with metabolic acidosis compared with those without acidosis ($p=0.11$). In this case, the greater time delays in the group without metabolic acidosis could reflect less concern by the physician and thus a slower overall movement, rather than programmatic delays.

Summary and strength of the evidence on uterine rupture. Overall, the literature relating to response time between premonitory signs of uterine rupture and perinatal mortality are insufficient. This is due to study designs that are more prone to bias, inconsistent findings, imprecision and difficulty accounting for time among women who presented with concerning fetal tracings (e.g. whether the patient had concerning tracing at arrival to the hospital). However, there is suggestion that fetal bradycardia is an ominous sign for fetal extrusion, which is associated with poor perinatal outcomes, and prompt delivery in this setting is warranted.

Hysterectomy

Overall there were 16 cohort studies reporting hysterectomy as a complication of ERCD, VBAC, and RCD after a TOL,^{10, 77, 78, 80, 81, 93, 100, 108, 137, 164, 201, 204, 228, 234-236} eight provided information comparing risks for hysterectomy between TOL and ERCD (Table 12).^{10, 77, 81, 93, 108, 201, 204, 234} As shown in Figures 19 and 20, while the occurrence of hysterectomy was higher for ERCD at 0.28 percent (95 percent CI: 0.12 percent to 0.67 percent) compared to 0.17 percent (95 percent CI: 0.12 to 0.26 percent) for TOL but the difference was not statistically significant. Three of the eight studies focused exclusively on women delivering at term.^{93, 108, 204} Among these studies, the combined risk of hysterectomy was 0.14 percent (95 percent CI: 0.08 to 0.22 percent) in the TOL group and 0.16 percent (95 percent CI: 0.07 to 0.36 percent) in the ERCD group. The risk was not significantly different between the two groups ($p=0.672$). Among the five studies including women delivering at any gestational age, the combined risk of hysterectomy was 0.22 percent (95 percent CI: 0.13 to 0.38 percent) for TOL and 0.43 percent (95 percent CI: 0.11 to 0.17 percent) for ERCD. Compared with ERCD, TOL had a significantly lower risk of hysterectomy (RR, 0.40; 95 percent CI: 0.18 to 0.92, $p=0.03$). Using 0.43 percent as the baseline risk for ERCD, the calculated risk difference was -0.26 percent (95 percent CI: -0.35 to -0.04 percent), translating to 2.6 fewer hysterectomies per 1,000 for TOL.

There was significant heterogeneity among the studies. In particular, Phelan and Eglinton appeared to be outliers for ERCD among term studies and because of its size, Wen is exerting significant effect on all analyses and particularly for ERCD; this study has a low occurrence of hysterectomy. Studies were explored for factors that might explain the observed heterogeneity. Considered factors included setting (university versus community), gestational age, number, and direction of scar, and no clear pattern was observed across the eight studies.

Individual studies looked for factors that may affect the occurrence of hysterectomy among women with prior cesarean. In particular, several publications from the MFMU study, report interesting potential contributors. Grobman et al examined the influence of induction of labor and reported that induction was associated with almost a 4-fold increase in the occurrence of hysterectomy (odds ratio 3.92; 95 percent CI: 1.10 to 13.9) among women without a history of prior vaginal delivery. Mercer et al evaluated the risk of hysterectomy with increasing number of VBACs found a non-significant decrease in the rate of hysterectomy from 0.23 percent with no prior VBAC to 0.016 percent in subjects with two or more previous VBACs ($p=0.15$).¹⁹² Perhaps the most intriguing factors reported from this group is in regards to the influence of multiple prior cesarean deliveries and prior vaginal delivery. In subjects undergoing multiple cesarean deliveries, there was a decrease in hysterectomy rate between the first and second cesarean delivery, followed by an increase from 0.42 percent after two cesarean deliveries to 9.0 percent after six or more previous cesarean deliveries.²³⁶ Only one study evaluating this cohort compared hysterectomy rate among VBAC after one cesarean delivery, VBAC after greater than one cesarean delivery, and ERCD. This study found the lowest proportion of hysterectomy among those with VBAC after a single cesarean delivery (0.2 percent), intermediate levels after ERCD (0.4 percent), and the highest among those with VBAC after multiple previous cesarean deliveries (0.6 percent).⁸⁰ These two studies suggest multiple cesarean deliveries increase risk for hysterectomy at the time of delivery; VBAC may be protective against hysterectomy after multiple cesarean deliveries. However, this comparison is limited by a lack of information about the actual number of previous cesarean deliveries and TOL in the latter article, and therefore a dose-dependent effect of increasing number of cesarean deliveries with TOL and VBAC cannot be determined. Furthermore, the inclusion criteria for ERCD limited its applicability, as only low

risk ERCD candidates were included. Using data from a California state database, Gregory et al found that underlying medical and obstetrical risk may increase a woman's chance for hysterectomy reporting a two-fold increase in hysterectomy for ERCD compared with TOL among women with high-risk pregnancies (0.41 versus 0.22 percent).⁹³

Table 12. Hysterectomy for trial of labor versus elective repeat cesarean delivery

Author, Year	Study description	N	Hysterectomy proportion	Per 10,000
<i>Term</i>				
Gregory,2008 ⁹³	Retrospective cohort Low-risk = absence of maternal complications High-risk = any maternal condition ICD9 codes	41,450	Hysterectomy (rates) Low-risk TOL: 9/8,292 (0.10%) ERCD: 21/20,834 (0.10%) High-risk TOL: 7/3,188 (0.22%) ERCD: 38/9,136 (0.41%)	Low-risk TOL: 10 RCD: 10 High-risk TOL:22 RCD: 41
Spong, 2007 ²⁰⁴	MFMU Cohort 19 university hospitals	39,117	TOL 31/15,323 (0.2%) ERCD (no labor): 40/14,993 (0.27%) ERCD (labor): 9/2,721 (0.33%) IRCD (no labor): 43/5,002 (0.86%) IRCD (labor): 3/1,078 (0.28%)	TOL:20 ERCD (no labor): 27 ERCD (labor): 33 IRCD (no labor): 86 IRCD (labor): 2.8
Wen,2004 ¹⁰⁸	Retrospective cohort Canadian Registry ICD9 codes	308,755	TOL: 127/128,960 (0.10%) RCD: 140/179,795 (0.08%), Adjusted odds ratio 1.26 (0.99-1.61)	TOL: 10 RCD: 08
<i>Any gestational age</i>				
Eglinton,1984 ²⁰¹	Retrospective cohort University Hospital	871	TOL:1/376 0.3% RCD: 6/495 1.2%	TOL: 30 RCD: 120
Flamm, 1994 ⁷⁷	Prospective cohort 10 Kaiser Hospital in CA	7,229	TOL: 6/5,022 (0.12%) RCD: 6/2,208 (0.27%) p= Not significant	TOL:12 RCD: 27
Hibbard, 2001 ²³⁴	Prospective Cohort University Hospital	2,450	TOL: 6/1,324 (0.5%) VBAC: 4/908 (0.44%) TOL-CD: 2/416 (0.93%) RCD: 0/431 (0%)	TOL: 50 VBAC: 44 TOL-CD:93 RCD: 0
McMahon,1996 ¹⁰	Retrospective cohort Population based Longitudinal study	6,138	TOL: 5/3429 (0.15%) RCD: 6/2,889 (0.2%)	TOL: 15 RCD: 20
Phelan, 1987 ⁸¹	Prospective Cohort University hospital ≥2 prior CD only	2,643	TOL: 5/1796 (0.3%) RCD: 14/847 (1.7%)	TOL: 30 RCD: 170

Abbreviations: CA=California; CD=cesarean delivery; ERCD=elective repeat cesarean delivery; IRCD=indicated repeat cesarean delivery; MFMU=Maternal-Fetal Medicine Units Network; RCD=repeat cesarean delivery; TOL=trial of labor; TOL-CD=trial of labor followed by a cesarean delivery; VBAC=vaginal birth after cesarean

Figure 19. Hysterectomy occurrence for trial of labor





Figure 20. Hysterectomy occurrence for elective repeat cesarean delivery




Summary of hysterectomy. Hysterectomy is rare with either ERCD or TOL, occurring in less than 3 percent of deliveries for women with a prior cesarean delivery. There was no significant difference in the occurrence of hysterectomy based upon route of delivery overall or among women delivering at term; however there was a lower occurrence of hysterectomy among women undergoing a TOL among studies enrolling women of any gestational age.

Transfusion/Hemorrhage


Transfusion. Nine cohort studies of good or fair quality totaling 401,307 patients evaluated the occurrence of transfusion between ERCD and TOL^{10, 76, 77, 93, 95, 97, 108, 204, 234} (see Appendix Q for a detailed description of studies). As shown in Figure 21, the occurrence of transfusion was not significantly different between TOL and ERCD (0.9 versus 1.2 percent, this translates to nine versus 12 per 1,000). There was significant heterogeneity among the studies however with studies varying widely on the frequency of transfusion, with transfusion rates ranging from 0.5 to 4.3 percent for TOL and 0.1 to 5.5 percent for ERCD. Studies were also conflicting on which group had the highest rate of transfusion with five studies reporting greater transfusions with ERCD,^{10, 76, 77, 95, 234} and four reporting greater transfusions in TOL.^{93, 97, 108, 204} The studies were examined for potential factors that may explain the difference. Factors that were reported among studies included gestational age, accuracy of group assignment, maternal conditions particularly underlying high-risk medical conditions, hospital setting, and the influence of prior vaginal delivery.

Figure 21. Transfusion rates for trial of labor versus elective repeat cesarean among all studies



Term studies. Four, of the nine studies focused exclusively on women delivering at term (Figure 22).^{93, 97, 108, 204} All four term studies reported higher rates of transfusion among women who had a TOL, with two reaching statistical significance.^{97, 204} The combined risk of transfusion was 0.7 percent (95 percent CI: 0.2 to 2.2 percent) for TOL and 0.5 percent (95 percent CI: 0.2 to 1.3 percent) for ERCD, translating to seven per 1,000 and five transfusions per 1,000, respectively. When these studies were combined there was a significantly increased risk of transfusion for TOL compared with ERCD (RR, 1.30; 95 percent CI: 1.15-1.47; p<0.001). Using 0.5 percent as the baseline risk for ERCD, the calculated risk difference was 0.14 percent (95 percent CI: 0.07 to 0.22 percent), which is equivalent to 1.4 more transfusion per 1,000 for TOL.

Figure 22. Transfusion rates for trial of labor versus elective repeat cesarean delivery among term studies



When looking at the five studies of women delivering at any gestational age, the combined risk of transfusion was 1.2 percent (95 percent CI: 0.7 to 2.3 percent) for TOL and 2.4 percent (95 percent CI: 1.3 to 4.3 percent) for ERCD, translating to 12 per 1,000 and 24 transfusions per 1,000 respectively. There was a significantly reduced risk of transfusion for TOL compared with ERCD (RR, 0.48; 95 percent CI: 0.30 to 0.79; p=0.003). Using 2.4 percent as the baseline risk for ERCD, the calculated risk difference was -1.26 percent (95 percent CI: -1.71 to -0.52 percent), which is equivalent to 12.6 fewer transfusions per 1,000 for TOL.

Group assignment. The disparities among the pooled analyses raise questions about whether other factors may be playing a role. Two studies provided separate results for VBAC, ERCD, and cesarean after TOL.^{95, 234} In both studies, VBAC had the lowest rate of transfusion, followed by cesarean after TOL, while ERCD had the highest rate of transfusion. This suggests the influence of term gestational ages may be related to increased transfusions with cesarean after TOL; however, the term gestation delivery studies did not report these outcomes.

Maternal factors. The pooled risk is strongly influenced by the largest study, which included all levels of care as well as relied on ICD-9 codes for data gathering. This study found opposing results to the general trends seen with the other studies in this group, and is likely strongly

contributing to the effect seem with the pooled data.¹⁰⁸ Two studies examined the affect of medical conditions upon transfusion rates.^{93, 204} Both studies found an association between high-risk pregnancies with medical conditions and increased transfusion. Gregory found that among high-risk patients, women who delivered by ERCD had more transfusions than those who had a TOL (0.92 versus 0.78 percent, p=NS) and that the overall rate of transfusions was greater among higher risk pregnancies compared with the low-risk group (0.46 versus 0.33 percent, p=NS).⁹³ Similarly, using data from the MFMU cohort, Spong et al divided the type of cesarean delivery into ERCD and indicated repeat cesarean (IRCD) with and without labor, and found the highest proportion of transfusion with IRCD in the absence of labor, again suggesting an influence of maternal co-morbid conditions contributing to increased transfusion risk.²⁰⁴ An analysis of the MFMU cohort focusing only on low-risk ERCD found a statistically significant increase in transfusion with TOL compared with ERCD prior to labor (one versus 1.7 percent, p<0.001), further supporting the idea that maternal co-morbid conditions influence the risk of transfusion.²²¹ In this same cohort, however, increasing maternal BMI and morbid obesity were not found to be associated with increased risk of transfusion in the MFMU cohort.⁷⁸

Hospital setting. One study evaluated the impact of hospital delivery volume on the risk of transfusion.¹⁰⁸ In low volume hospitals (less than 500 deliveries per year) the odds of transfusion with TOL was 1.39 (1.02 to 1.88) compared with ERCD. In high volume centers (greater than 500 deliveries per year) the odds ratio was 1.66 (1.32 to 2.08) for transfusion with TOL compared with ERCD.¹⁰⁸ This study differs in its findings from other studies as described previously; confounding factors that may contribute to this difference is that this review of a birth registry was based on ICD-9 codes; also, unlike the other studies, this study does report only on Canadian hospitals, and includes multiple different levels of hospital acuity.

Influence of prior deliveries. Within the MFMU cohort, multiple studies evaluated the impact of previous deliveries on the risk of transfusion.^{80, 181, 192, 236} Subjects with only one prior cesarean delivery undergoing TOL had a rate comparable with ERCD (1.6 versus 1.5 percent), while those with multiple prior cesareans undergoing TOL had a higher transfusion rate compared with ERCD (3.2 versus 1.5 percent).⁸⁰ This study did not distinguish those with ERCD undergoing multiple cesareans versus first RCD. However, increasing number of cesareans was found to be a risk factor for transfusion.²³⁶ The MFMU cohort had a decreasing rate of transfusion with increasing number of previous VBACs, implying a protective role for prior vaginal delivery against transfusion (zero prior VBAC: 1.89 percent; one prior VBAC: 0.24 percent; two or more prior VBAC: 0.99 percent; p=0.002).¹⁹² One study of this cohort found no difference in women with a prior vaginal delivery when comparing those who were induced with those who went into spontaneous labor (odds ratio 1.13; 95 percent CI: 0.66 to 1.95). However, in those women without a previous vaginal delivery, there was a higher rate of transfusion in the induced group compared with the spontaneous labor group, suggesting a role of induction as a risk for transfusion in women with no prior vaginal delivery only (odds ratio 1.65; 95 percent CI: 1.10 to 2.48).¹⁵⁶

Hemorrhage. Six fair quality cohort studies report on the occurrence of hemorrhage for TOL versus ERCD.^{76, 93, 95, 100, 203, 234} Among the six studies the rates of hemorrhage with ERCD ranged from 0.3 percent to as high as 29 percent. In general, studies reported increased occurrence of hemorrhage associated with ERCD compared to TOL. However, studies were inconsistent regarding the definition of hemorrhage. Several studies did not report the process by which this outcome was measured; studies that quantified blood loss used different amounts of blood loss to qualify as hemorrhage. The highest rate of hemorrhage was from a study that defined hemorrhage as greater than 500mL blood loss.⁷⁶ Further complicating evaluation of these

data is the known difficulty in recording blood loss. Multiple studies demonstrate physician perception of blood loss differs from actual blood loss, impeding accurate recording of this measure.^{237, 238} All studies found a trend toward increased blood loss with ERCD. However, none of the studies found a statistically significant difference between hemorrhage rates for TOL and ERCD. Because these studies did not define hemorrhage similarly, these data were not pooled for analysis. Interesting findings from individual studies are discussed below.

Term studies. Only one of the six studies,⁹³ provided data regarding hemorrhage specifically in term pregnancies. In this study, low-risk patients were separated from high-risk patients based on antenatal conditions. The low-risk group had a lower rate of hemorrhage with TOL compared with ERCD (2.36 versus 6.82 percent, $p=NS$); however in the high-risk group, there was an increase in hemorrhage with TOL compared with ERCD (3.26 versus 1.57 percent). In the one study that reported both, the rates of transfusion are in direct opposition to the rates of hemorrhage for every subset, such that in groups with higher rates of hemorrhage, there were overall fewer transfusions given.⁹³ This was a study that used an administrative database and demonstrates the difficulty in reporting and interpreting a subjective term such as hemorrhage.

Group assignment. Three studies separated the TOL data by VBAC and cesarean after a TOL.^{95, 203, 234} Rates of hemorrhage for VBAC ranged from 0.3 to 6 percent, compared with cesarean after TOL which ranged from 0.86 to 14.8 percent. In three of these studies, cesarean after a TOL had the highest rate of hemorrhage compared to VBAC and ERCD. One study found a statistically significant increase in hemorrhage with ERCD compared to cesarean after a TOL and VBAC (0.91 versus 0.64 versus 0.81 percent, $p<0.001$).⁹⁵ This study did not define hemorrhage; in addition, this university-based Israeli study focused on a grand multiparous subgroup, possibly confounding the results given the global increased risk of hemorrhage. One database study from Norway described the incidence of postpartum hemorrhage. Though it did not specifically evaluate women undergoing TOL or ERCD, it did find 333 cases of hemorrhage in women with a history of previous cesarean delivery. This study found an increased risk of hemorrhage with both vaginal delivery (odds ratio 1.63; 95 percent CI: 1.34 to 1.98) and emergency cesarean (1.41; 95 percent CI: 1.12 to 1.78) in women with a previous history of cesarean compared to women without a history of cesarean.²³⁹ This study found no difference in hemorrhage between these two groups for pre-labor cesarean; however, for women with prior cesarean, pre-labor cesarean carried a 28 percent higher risk of hemorrhage compared to spontaneous labor delivery.²³⁹


Summary and strength of evidence on transfusion/hemorrhage. Overall, evidence regarding the rate of hemorrhage for TOL and ERCD is low due to inconsistency in definitions and subjectivity in measurement. In general, studies reported increased occurrence of hemorrhage associated with ERCD compared to TOL. There was only one study that provided data for term populations. This study suggested that medical complications may modify the effect of route of delivery upon hemorrhage with low-risk patients similarly having higher hemorrhage rates for ERCD but with high-risk patients experiencing higher rates of hemorrhage for TOL. Further studies are needed to understand the true relationship.

Infection

Twenty-two studies of good or fair quality evaluated infectious morbidity (e.g., fever, infection, endometritis, or chorioamnionitis) in TOL compared with ERCD (see Appendix R for study details).^{10, 76-79, 81, 89, 95, 97, 108, 114, 201-205, 221, 234, 240-243} Ten studies^{10, 89, 95, 97, 108, 202-204, 234, 240} report on infection in some manner. As shown in Figure 23, there was no significant difference in infection between TOL and ERCD.). The I^2 statistic for heterogeneity was 89 percent. However,

the confidence in the magnitude and direction of the estimates from this body of literature is low due to inconsistencies in definitions, indirect evidence, and high risk of bias. Details in the specific infections reported in these studies are described below.

Figure 23. Rates of infection for trial of labor versus elective repeat cesarean delivery among all studies



Endometritis. Six studies of good or fair quality compared endometritis in TOL with ERCD.^{89, 95, 203, 221, 240, 241} Overall, rates of endometritis were higher in TOL when compared with ERCD. Rates of endometritis in TOL ranged from 0.8 to 30 percent. The rates of endometritis in ERCD ranged from 1.2 to 18 percent. The upper ranges of these figures both derive from the same study focusing on morbidly obese patients, suggesting an influence of obesity on the risk of infection.²⁴⁰

The MFMU cohort evaluated endometritis in TOL compared with ERCD (Appendix R).²²¹ A separate report on this same cohort specifically evaluated BMI and the risk of endometritis in morbidly obese patients.⁷⁸ There was a statistically significant increase in the rate of endometritis with increasing BMI in patients undergoing a TOL. Additionally, there was a statistically significant increased odds of endometritis for TOL compared with ERCD in morbidly obese

(BMI greater than 40) subjects. (odds ratio 2.4; 95 percent CI: 1.7 to 3.5).⁷⁸ This again suggests maternal weight influences the risk of endometritis in this population.

In studies where outcomes of TOL were evaluated separately, cesarean after labor patients consistently had a higher rate of endometritis than did VBAC or ERCD patients.^{89, 95, 203} This suggests the increased rates of endometritis seen with TOL may be more associated with cesarean delivery than with the labor itself.


Chorioamnionitis. In total, two cohort studies compared chorioamnionitis rates for TOL and ERCD in deliveries.^{89, 95} Both found a higher rate of chorioamnionitis in the TOL group. Based on this, there is evidence that chorioamnionitis is associated with TOL, regardless of ultimate mode of delivery.

Wound infection. Wound infection was evaluated in three cohort studies.^{10, 203, 240} Two of the three found ERCD to be associated with a higher rate of wound infection,^{10, 203} while one found a higher rate with TOL. This study was limited to women over 300lbs at delivery, which complicates any direct comparison of this data with the others.²⁴⁰ None of these studies reached statistical significance with their findings.

Fever. Ten good or fair quality cohort studies compared maternal fever between TOL and ERCD.^{10, 76, 77, 79, 81, 89, 95, 201, 202, 205} As shown in Figure 24, the combined absolute risk for any fever with TOL was 6.5 percent (95 percent CI: 4.4 to 9.3 percent) which translates to 65 per 1,000 (95 percent CI: 44 to 93 per 1,000) and for ERCD was 7.2 percent (95 percent CI: 2.5 to 18.9 percent) which translates to 72 per 1,000 (95 percent CI: 25 to 189 per 1,000). Compared with ERCD, TOL demonstrated a significant decrease in the risk of fever (RR, 0.63; 95 percent CI: 0.43 to 0.91; $p=0.013$). Using 7.2 percent as the baseline risk for ERCD, the calculated risk difference was -2.7 percent (95 percent CI: -4.10 to -0.68 percent), which is equivalent to 27 fewer fevers per 1,000 from the TOL. There was considerable heterogeneity among studies ($I^2 = 92.7$ percent), which demonstrates the variability in the definition of the term “fever” among studies. Only one study in this pooled analysis defined fever by an absolute number (greater than 38 degrees Celsius); it is interesting to note this study did serve as the most apparent outlier in the pooled analysis.⁷⁹ When this study was excluded from analysis, the combined risk of fever for ERCD group was 11.0 percent and TOL still had a significantly lower risk of fever (RR, 0.58; 95 percent CI: 0.40 to 0.82; $p=0.002$). Using 11.0 percent as the baseline risk for ERCD, the calculated risk difference was -4.68 percent (95 percent CI: -6.58 to -1.95 percent), which is equivalent to 47 fewer fevers per 1,000 for TOL. The I^2 statistic for heterogeneity remained 92.7 percent, demonstrating that this outlier did not explain the heterogeneity seen among studies.

Four cohort studies evaluated maternal fever stratified by outcome of TOL.^{81, 89, 95, 201} Three of the four studies found increased rates of fever in cesarean after a TOL compared with VBAC.^{81, 89, 201} This suggests a higher febrile morbidity associated with cesarean delivery after labor compared with VBAC. However, in all but one of these studies ERCD continued to have the highest rate of febrile morbidity, suggesting surgery as a risk factor for maternal infectious morbidity. This would imply the rate of fever seen with TOL may be influenced by the higher risk of fever with RCD after a TOL and not be associated with VBAC. The one outlier study in this group found a rate of 32 percent for cesarean after a TOL compared with 18 percent for ERCD. However, the population of this study was limited to subjects with two prior cesarean deliveries. Increased complications with second cesarean after labor may have influenced the higher rates seen with ERCD.⁸¹ Within women who underwent a TOL, there appears to be an increased risk for febrile morbidity with operative delivery.

Figure 24. Rates of fever for trial of labor versus elective repeat cesarean delivery among all studies



Summary and strength of evidence on infection. Overall, the evidence regarding rate of both infection (all definitions) and fever for women with a prior cesarean delivery is low in strength with inconsistent definitions, high-risk of bias and indirect evidence. The high heterogeneity in these studies demonstrates the variability in the definition of the term “fever” among studies. Overall there was no significant difference in infection between TOL and ERCD.

Surgical injury

In good or fair quality cohort studies, surgical injury was defined differently between studies and variably reported on. Seven studies compared surgical injury between TOL and ERCD.^{10, 78, 80, 97, 204, 205, 236} Four of these are from the same cohort of patients (MFMU); however they report differently on surgical injury rates and therefore are presented separately (Table 13).^{78, 80, 204, 236}

Overall, these were found to be rare events. None of the stratifications from the MFMU studies found a significant difference between ERCD and TOL for rate of surgical injury.^{78, 80, 204, 236} When a specific injury was evaluated, such as bladder, there did tend to be an increased rate

of injury with a cesarean after a TOL. However, this trend was not found to be statistically significant.²⁰⁵

One case-control study evaluating women with bladder injury at the time of cesarean delivery found attempted VBAC to be proportionately higher in the cases compared with controls (64 versus 22 percent, $p < 0.1$) This study found no difference in type of uterine incision with risk of bladder injury.²⁴⁴

One study of 3,164 women evaluated the impact of skin incision direction on the risk of bowel or bladder injury. This retrospective study found an increased odds ratio of bladder injury with a midline sub-umbilical incision compared with a Pfannenstiel (6.7; 95 percent CI: 2.6 to 16.5). The RR for bowel injury was also increased with vertical incision at five and a half fold risk. After multivariate analysis, vertical abdominal incision remained a significant risk factor for bladder injury at the time of cesarean. There was a trend toward increased injury with increasing numbers of cesarean deliveries, though this was not statistically significant.²⁴⁵

Table 13. Surgical injury rates for trial of labor versus elective repeat cesarean delivery

Author, year, quality rating	Country/ Setting	Study description	N	Surgical injury (per 10,000)							Summary
<i>All studies, all gestational ages</i>											
Cahill, 2006 ²⁰⁵	16 University and community hospitals	Retrospective cohort	6,619	Bladder injury TOL: 26/5041 (51) ERCD: 7/1578(44)							VBAC trial associated with higher rate of injury
Loebel, 2004 ⁹⁷	Community teaching hospital	Retrospective cohort	1,408	Operative injury (includes lacerations of the bowel, bladder, ureter, or uterine artery) TOL: 4/927 (40) ERCD: 2/481 (40)							No difference between groups
McMahon, 1996 ¹⁰	Canada national registry 1986-1992	Retrospective cohort population based longitudinal study	6,138	Extension with laceration of uterine arteries, laceration of bladder, ureters, bowel TOL:41/3429 (130) TOL-CD: 39/1287 (300) ERCD: 18/2889 (60)							TOL tended to have increased complications
<i>Maternal-Fetal Medicine Units network studies</i>											
Silver, 2006 ²³⁶	19 university hospitals U.S. academic 1999-2002	MFMU network cohort	30,132	# RCD	1st	2nd	3rd	4th	5th	6th	The first and second CD are similar in the proportion of complication; overall there is an increase in complications with increasing CD numbers but these are overall rare events
				Bowel injury (per 10,000)	10	5	10	30	0	110	
				Bladder per 10,000	10	9	30	110	190	450	
				Ureter per 10,000	3	1	2	7	40	110	
				Wound De-hiscence Per 10,000	40	10	20	20	80	0	

Table 13. Surgical injury rates for trial of labor versus elective repeat cesarean delivery

Author, year, quality rating	Country/ Setting	Study description	N	Surgical injury (per 10,000)	Summary
Spong, 2007 ²⁰⁴	MFMU Network U.S. academic 1999-2002		39,117	Composite: broad ligament injury, cystotomy, bowel injury, ureteral injury TOL: 57 (37) ERCD (no labor): 45 (30); ERCD (with labor): 14 (51) IRCD (no labor): 23 (46); IRCD (with labor): 6 (56)	In a given situation, the presence of labor increases the small risk of surgical complication
Hibbard, 2006 ⁷⁸	U.S. academic 1999-2002	28,446	TOL: 14,142 ERCD: 14,304	Composite: broad ligament hematoma, cystotomy, bowel injury, or ureteral injury All TOL by BMI a) 18.5-24.9: 6/1344 (44) b) 25.0-29.9: 23/4747 (48) c) 30-39.9: 14/6413(22) d) >40: 10/1638 (61) p = .58	There was no increase in complications with increasing BMI
Landon, 2006 ⁸⁰	MFMU- Network U.S. academic 1999-2002			Composite: broad ligament hematoma, cystotomy, bowel injury, or ureteral injury 1 prior CD: 60/16,915 (40) Multiple prior CD: 4/975 (40) ERCD: 36/6035 (60)	There was no statistically significant differences in surgical injury with single or multiple CD prior to VBAC

Abbreviations: BMI=body mass index; CD=cesarean delivery; ERCD=elective repeat cesarean delivery; IRCD=indicated repeat cesarean delivery; MFMU=Maternal-Fetal Medicine ~~U.S.~~ Network; RCD=repeat cesarean delivery; TOL=trial of labor; TOL-CD=trial of labor followed by a cesarean delivery; U.S.=United States; VBAC=vaginal birth after a cesarean

Summary of surgical injury. Rate of surgical injury may be increased with TOL but definitive studies are lacking. Vertical skin incision increases risk of surgical injury to the bladder.


Hospital Stay

Hospital stay was reported as length of total stay in days. A total of eight cohort studies examined length of stay data in the U.S., comparing ERCD and TOL (Appendix S).^{77, 79, 81, 93, 97, 201, 202, 234} All studies were affiliated with teaching institutions. In general, as expected, ERCD had a longer length of hospital stay compared with TOL. The large MFMU cohort studies did not report length of stay data comparing ERCD with TOL. One study did evaluate the risk of extended stay, defined as greater than 4 days, with ERCD compared with TOL in morbidly obese patients; this study found increased length of stay with ERCD (odds ratio 1.2; 95 percent CI: 1.1 to 1.4).⁷⁸

Pooled analysis of any gestational age studies. For any GA cohorts, the pooled analysis using a random effects model demonstrated that the mean length of stay for TOL was 2.55 days (95 percent CI: 2.34 to 2.76 days). Pooled mean length of stay for ERCD was 3.92 days (95 percent CI: 3.56 to 4.29 days). There was significant heterogeneity among studies ($Q=221.06$, $p<0.001$) and the I^2 statistic for heterogeneity was 98.2 percent (between-study heterogeneity accounts for 98.2 percent of the total heterogeneity) (Figure 25).

Summary of hospital stay. Elective repeat cesarean delivery is associated with a longer hospital stay compared with TOL.

Figure 25. Length of stay for trial of labor versus elective repeat cesarean delivery among any gestational age studies



Pelvic Floor

One study evaluated the effect of VBAC on perineal trauma in deliveries over 36 weeks GA. After controlling for age, parity, and episiotomy, those women who had a VBAC as their second delivery had an odds ratio of 5.46 (95 percent CI: 3.69 to 8.08) of severe perineal trauma compared with women with a previous vaginal delivery. In contrast, the odds ratio for a primiparous woman was 4.08 (95 percent CI: 3.16 to 5.28).²⁴⁶ A second study noted a 34 percent prevalence of third or fourth degree perineal laceration following episiotomy in women undergoing VBAC; however no comparisons were made to RCD after a TOL.¹³⁷ No studies evaluated risk of urinary or fecal incontinence following ERCD versus TOL.

Deep Vein Thrombosis

Three studies evaluated thromboembolic disease between ERCD and TOL.^{192, 203, 221} A multicenter study evaluating maternal risk and thromboembolic disease found the lowest rate of embolic disease with TOL after one prior cesarean delivery compared with subjects undergoing either ERCD or VBAC after multiple cesarean deliveries (0.04 percent versus 0.1 and 0.1 percent).²²¹

Special Considerations

Effect of hospital setting. In total, eight studies reported outcomes in both community and academic centers.^{10, 61, 77, 93, 97, 98, 108, 205} Three of these studies reported on the same cohort of patients.^{61, 98, 205} Of these eight studies, only one specifically described the community data separately.¹⁰⁸ As described previously, this study evaluated maternal risk with ERCD, TOL, VBAC, and RCD using the Canadian birth registry. This evaluation focused specifically on the risks of each mode of delivery in low volume (less than 500 deliveries per year) and high volume (greater than 500 deliveries per year) medical centers. This study demonstrated an increased odds of short-term complications in low volume maternity wards. Specifically, the odds ratio of a particular outcome associated with TOL when compared with ERCD were higher for death (odds ratio 2.68; 95 percent CI: 0.16 to 45.5 versus odds ratio 0.16; 95 percent CI: 0.02 to 1.29) and uterine rupture (odds ratio 4.02; 95 percent CI: 2.48 to 6.51 versus odds ratio 2.30; 95 percent CI: 2.04 to 2.59) in low volume maternity wards.¹⁰⁸

Abnormal placentation. Prior cesarean delivery is a risk factor for abnormal placentation in future pregnancies. As the number of cesarean deliveries continues to rise, the incidence of abnormal placentation, which includes placenta previa, accreta, increta, and percreta, is anticipated to increase as well. Abnormal placentation has been associated with both maternal and neonatal morbidity including need for antepartum hospitalization, preterm delivery, emergent cesarean delivery, hysterectomy, blood transfusion, surgical injury, intensive care unit (ICU) stay, and fetal and maternal death. In order to effectively counsel women about their risk of complications due to the placenta in future pregnancies, it is essential to have a clear understanding of the incidence of these potentially life-threatening complications in women with prior cesarean delivery.

Incidence of abnormal placentation following cesarean section. Eighty-two full text articles were reviewed to evaluate the evidence regarding the incidence and outcomes of pregnancies complicated by abnormal placentation, including abruption, placenta previa, and placenta accreta, following prior cesarean delivery. Nineteen articles met inclusion criteria and consisted of eight good or fair quality cohort studies,^{11, 220, 236, 247-251} seven fair quality case-control studies,^{176, 235, 252-256} and four good or fair quality case series.²⁵⁷⁻²⁶⁰ Individual studies provided evidence for one or more of the separate topics of abruption, previa, and accreta, respectively. The studies that made up the body of evidence for each subset of abnormal placentation are listed below.

Abruption. Six fair quality studies, five cohort studies^{11, 247, 249-251} and one case-control study²³⁵ examined abruption following a prior cesarean delivery. Studies were inconsistent in their definition for placental abruption with three studies relying on ICD-9 coding^{11, 247, 250} and no definition offered by the other three.^{235, 249, 251}

The overall incidence of placental abruption with any prior cesarean delivery was 1.2 to 1.5 percent.^{250, 251} For women with one prior cesarean delivery, the odds ratio for abruption was 1.0 to 1.3 and only one of four studies reached statistical significance. The majority of studies did not find an increased incidence of abruption in women with increasing numbers of prior cesarean delivery (Table 14).

Table 14. Abruptio based on number of prior cesarean deliveries

Studies	N	Adjusted OR (95% CI) or P value	N/# cesarean delivery	per/ 1,000
<i>Any prior cesarean delivery</i>				
Odibo, 2007 ²⁵⁰	25,076		1.2% (309/25076) 13 per 1,000	13
Rouse, 2006 ²⁵¹	57,169		1.5% (504/33683)	
<i>Zero prior cesarean deliveries</i>				
Rouse, 2006 ²⁵¹	57,169		3.4% (807/23486)	
<i>1 prior cesarean delivery</i>				
Hemminki, 2005 ²⁴⁷	72,200	1.21 (0.96 to 1.53)		10.3
Lydon-Rochelle, 2001 ¹¹	96,975	1.3 (1.1 to 1.5)		13.7
Nisenblat, 2006 ²⁴⁹	940		1.02% (5/491)	
Odibo, 2007 ²⁵⁰	25,076	1 (0.9 to 1.0)	1.2% (246/20236)	
<i>≥1 prior cesarean delivery</i>				
Rouse, 2006 ²⁵¹	57,169		1.5% (504/33682)	
<i>2 prior cesarean deliveries</i>				
Hemminki, 2005 ²⁴⁷	72,200	1.01 (0.52 to 1.97)		10.3
Odibo, 2007 ²⁵⁰	25,076	1 (0.8 to 1.3)	1.3% (50/3976)	
<i>≥2 prior cesarean deliveries</i>				
Nisenblat, 2006 ²⁴⁹	940	p>0.9	1.1% (3/277)	
<i>3 prior cesarean deliveries</i>				
Odibo, 2007 ²⁵⁰	25076	1.2 (0.7 to 2.1)	1.5% (13/863)	
<i>≥3 prior cesarean deliveries</i>				
Juntunen, 2004 ²³⁵	73000	p=0.024	3.4% (149)	

Abbreviations: CI=confidence interval; OR=odds ratio

Women with abruptio were more likely to require blood transfusion, but the incidence did not increase with increasing number of cesarean delivery. Of women without a prior cesarean delivery, 14.3 percent required blood transfusion compared with 14.1 percent in women with one or more prior cesarean deliveries without abruptio. Other maternal outcomes such as hemorrhage and hysterectomy were reported inconsistently such that meaningful analysis of an association with abruptio and prior cesarean delivery was not possible (Table 15).²⁵¹

Table 15. Blood transfusion by number of prior cesarean deliveries

Studies	N	Adjusted OR (95% CI) or P value	N/abruption population
<i>Zero prior cesarean deliveries</i>			
Rouse, 2006 ²⁵¹	57,169	2.9 (2.2 to 3.7)	14.3% (115/807)
<i>≥1 prior cesarean deliveries</i>			
Rouse, 2006 ²⁵¹	57,169	2.6 (1.8 to 3.7)	14.1% (71/504)

Abbreviations: CI=confidence interval; OR=odds ratio

Placenta previa. Eight good or fair quality cohort studies,^{11, 220, 236, 247-251} five fair quality case-control studies,^{235, 253, 255, 259, 261} and three good or fair case series^{257, 258, 260} provide the primary body of evidence regarding placenta previa following prior cesarean delivery. Only six studies provided information on the incidence of placenta previa following prior cesarean delivery (Table 16).^{11, 248, 251, 258, 259, 261} Again, studies differed in their definition for placenta previa with two studies using a previa grade scale and the remaining providing individual definitions.

Table 16. Overall incidence of placenta previa

Studies	N	N with previa	Per /1,000
Hershkowitz, 1995 ²⁴⁸	58,633	284	4.8
Lydon-Rochelle, 2001 ¹¹	96,975	1,100	11.5
Miller, 1997 ²⁵⁸	155,670	590	1 in 263 (incidence)
Olive, 2005 ²⁵⁹	375,790	1,612	4.3
Rouse, 2006 ²⁵¹	57,169	900	15.7
Taylor, 1994 ²⁶¹	278,933	Not reported	3.3

Women with a prior cesarean delivery had a statistically significant increased risk of placenta previa compared with women with no prior cesarean delivery (odds ratio 1.48 to 3.95, Table 17). The studies conflicted as to whether the risk increased with increasing cesarean deliveries. The incidence of previa with one prior cesarean delivery was 0.8 to 1.5 percent. Compared with women without a prior cesarean delivery, the odds ratio was 1.2 to 1.9. This was statistically significant in four of seven studies. In women with two prior cesarean deliveries, the incidence of previa was 1.1 to 2.0 percent with an odds ratio of 1.9 to 2.0; this was statistically significant in three of five studies. Two studies limited comparisons to women with one prior cesarean delivery versus multiple cesarean deliveries.^{248, 249} In these studies, no increased risk with additional cesarean deliveries was noted. These studies had limited sample size for women with multiple cesarean deliveries and previa (N=7 and N=20, respectively).^{248, 249} The six studies that specifically identified women with three or more cesarean deliveries all noted a statistically significant increased rate of previa with increasing cesarean deliveries, up to 3.7 percent for women with five or more prior cesarean deliveries.^{235, 236, 248, 250, 253, 258}

Table 17. Incidence of placenta previa by number of prior cesarean deliveries

Studies	N	Adjusted OR (95% CI) or p value	N/p previa population	N/# CD	N/total population	per/1,000
<i>Any number of prior cesarean deliveries</i>						
Gilliam, 2002 ²⁵³	2,367	1.59 (1.21 to 2.08)	28% (87/316)			
Hershkowitz, 1995 ²⁴⁸	58,633	2.25 (1.50 to 3.07)	21% (60/284)			
Laughon, 2005 ²⁵⁵	5,824	3.95 (1.49 to 10.50)	22.7% (20/88)			
Miller, 1997 ²⁵⁸	155,670		31.5% (186/590)			
Odibo, 2007 ²⁵⁰	25,076				361/25,076	15
Olive, 2005 ²⁵⁹	375,790	2.4 (2.1 to 2.8)	19.5% (315/1,612)			
Rouse, 2006 ²⁵¹	57,169			1.2% (394/33,683)		
Taylor, 1994 ²⁶¹	278,933	1.48 (1.13 to 1.95)	20% (99/490)			
<i>Zero prior cesarean deliveries</i>						
Gilliam, 2002 ²⁵³	2,367	1	71% (225/316)			
Hershkowitz, 1995 ²⁴⁸	58,633			0.07% (21/26,302)		
Miller, 1997 ²⁵⁸	155,670	p=<0.01		0.30%		
Silver, 2006 ²³⁶	30,132			6.42% (398/6,201)		
Zelop, 1993 ²⁶⁰	75,656			1.6% (565/35,240)	0.79	
<i>1 prior cesarean delivery</i>						
Gilliam, 2002 ²⁵³	2,367	1.28 (0.82 to 1.99)	16% (49/316)			
Hemminki, 2005 ²⁴⁷	72,200	1.92 (1.20 to 3.07)				2.9
Hershkowitz, 1995 ²⁴⁸	58,633	p<0.0001		1.5% (55/3,573)		15.39
Miller, 1997 ²⁵⁸	155,670	p=<0.01		0.80%		
Nisenblat, 2006 ²⁴⁹	940	Not evaluated		1.2% (6/491)		

Table 17. Incidence of placenta previa by number of prior cesarean deliveries

Studies	N	Adjusted OR (95% CI) or p value	N/previa population	N/# CD	N/total population	per/1,000
Lydon-Rochelle, 2001 ¹¹	96,975	1.4 1.1, 1.6			493/95,630	6.9
Odibo, 2007 ²⁵⁰	25,076	RR: 0.9 (0.8 to 1.0)	72% (260/361)			
Silver, 2006 ²³⁶	30132	Not significant		1.33% (211/15,808)		
<i>2 prior cesarean deliveries</i>						
Gilliam, 2002 ²⁵³	2,367	1.95 (1.13 to 3.39)	9.2% (29/316)			
Hemminki, 2005 ²⁴⁷	72,200	2.06 (0.49 to 8.72)				32.8
Hershkowitz, 1995 ²⁴⁸	58,633	Not significant		1.4% (13/934)		13.91
Miller, 1997 ²⁵⁸	155,670	p<0.01		2.00%		
Silver, 2006 ²³⁶	30,132	p<0.001		1.14% (72/6,324)		
<i>≥2 prior cesarean deliveries</i>						
Nisenblat, 2006 ²⁴⁹	940	p=0.753		1.4% (4/277)		
Lynch, 2003 ²⁵⁷	67,097		4.8% (12/250)			
Odibo, 2007 ²⁵⁰	25,076	RR: 1.2 (0.9 to 1.7)	20.8% (75/361)			
<i>3 prior cesarean deliveries</i>						
Gilliam, 2002 ²⁵³	2,367	4.09 (1.53 to 10.96)	7/316			
Hershkowitz, 1995 ²⁴⁸	58,633	Not significant		1.0% (7/675)		10.37
Silver, 2006 ²³⁶	30,132	p<0.001		2.27% (33/1,452)		
<i>≥3 prior cesarean deliveries</i>						
Juntunen, 2004 ²³⁵	73,000	8.4 (1.0 to 68.0)				
Miller, 1997 ²⁵⁸	155,670	p<0.01		4.20%		
Odibo, 2007 ²⁵⁰	25,076	RR: 1.9 (1.2 to 2.9)	7.2% (26/361)			


Table 17. Incidence of placenta previa by number of prior cesarean deliveries

Studies	N	Adjusted OR (95% CI) or p value	N/previa population	N/# CD	N/total population	per/1,000
<i>4 prior cesarean deliveries</i>						
Silver, 2006 ²³⁶	30,132	p=<0.001		2.33% (6/258)		
<i>≥4 prior cesarean deliveries</i>						
Gilliam, 2002 ²⁵³	2,367	8.76 (1.58 to 48.53)	2/316			
<i>≥5 prior cesarean deliveries</i>						
Silver, 2006 ²³⁶	30,132	p=<0.001		3.37% (3/89)		

Abbreviations: CD=cesarean delivery; CI=confidence interval; OR=odds ratio; RR=relative risk

The pooled analysis using a random effects model demonstrated absolute risk of previa associated with any number of prior cesarean deliveries was 1.2 percent (95 percent CI: 0.8 to 1.5 percent), one prior cesarean delivery was 1 percent (95 percent CI: 0.6 to 1.3 percent), two prior cesarean deliveries was 1.7 percent (95 percent CI: 1.1 to 2.3 percent) two or more cesarean deliveries was 2.3 percent (95 percent CI: 1.1 to 3.4 percent), three or more cesarean deliveries was 2.8 percent (95 percent CI: 1.8 to 3.7 percent, Figure 26). This translates to any number of prior cesarean deliveries was 12 per 1,000 (95 percent CI: 8 to 15 per 1,000), one prior cesarean delivery was 10 per 1,000 (95 percent CI: 6 to 13 per 1,000), two prior cesarean deliveries was 17 per 1,000 (95 percent CI: 11 to 23 per 1,000) two or more cesarean deliveries was 23 percent (95 percent CI: 11 to 34 per 1,000), three or more cesarean deliveries was 28 percent (95 percent CI: 18 to 37 per 1,000).

Figure 26. Incidence of placenta previa by number of prior cesarean deliveries among any gestational age studies



The incidence of hysterectomy increased in women with placenta previa depending on the number of prior cesarean deliveries (Table 18). Women with no prior cesarean delivery and previa required hysterectomy in 0.7 to 4 percent of cases compared with 50 to 67 percent in women with three or more prior cesarean deliveries. Women with prior cesarean delivery and

previa were more likely to require a blood transfusion (odds ratio 15.9; 95 percent CI: 12.0 to 21.0). Two authors also reported composite major maternal morbidity in women with prior cesarean delivery and previa. One study evaluated severe postpartum hemorrhage, acute renal failure, ICU admission, mechanical ventilation, shock, disseminated intravascular coagulopathy, hysterectomy, other procedures to stop bleeding, and/or death.²⁵⁹ Thirty percent of women with prior cesarean delivery and previa experienced major maternal morbidity (odds ratio 3.1; 95 percent CI: 2.0 to 4.7). A second study combined transfusion, hysterectomy, operative injury, coagulopathy, venous thromboembolism, pulmonary edema, and/or death.²²⁰ There was a statistically significant increase in composite major maternal morbidity with increasing number of cesarean delivery from 15 percent with no prior cesarean delivery to 83 percent with three or more prior cesarean deliveries (odds ratio 33.6; 95 percent CI: 14.6 to 77.4).

Table 18. Incidence of hysterectomy in women with previa by number of prior cesarean deliveries

Studies	N	N/# cesarean deliveries
<i>Zero prior cesarean deliveries</i>		
Grobman, 2007 ^{*220}	70,442	4% (488)
Zelop, 1993 ²⁶⁰	75,656	0.7% (4/565)
<i>1 prior cesarean delivery</i>		
Grobman, 2007 ^{*220}	70,442	10% (252)
<i>2 prior cesarean deliveries</i>		
Grobman, 2007 ^{*220}	70,442	45% (76)
<i>≥3 prior cesarean deliveries</i>		
Grobman, 2007 ^{*220}	70,442	67% (52)
Juntunen, 2004 ²³⁵	73,000	50% (4/8)
<i>≥4 prior cesarean deliveries</i>		
Lynch, 2003 ²⁵⁷	67,097	50% (2/4)

*Transfusion, hysterectomy, operative injury, coagulopathy, venous thromboembolism, pulmonary edema, or death

Placenta accreta. Three good or fair quality cohort studies^{236, 249, 258}, one fair quality case-control study,²⁵⁶ and one fair quality case series study²⁶⁰ examined placenta accreta and prior cesarean delivery and the relationship between placenta previa and accreta (Table 19). Two fair quality studies evaluated placenta accreta and hysterectomy.^{252, 254} Studies varied widely on the definition of placenta accreta, with one study limited analysis to cases with histopathologically confirmed accreta,²⁵⁸ two used histopathologic diagnosis or clinical findings of adherent placenta or difficult manual removal,^{236, 256} one used ICD-9 codes,²⁵² and two did not describe diagnostic criteria.^{249, 254}

Table 19. Overall incidence of placenta accreta

Studies	N	Adjusted OR (95% CI) or P value	N/previa population	N/total population	Incidence
Miller, 1997 ²⁵⁸	155,670			62/155,670	1 in 2,510
Silver, 2006 ²³⁶	30,132	1.75 (1.533 to 1.997)			
Wu, 2005 ²⁵⁶	64,359		111/64,359		1 in 533
Zelop 1993 ²⁶⁰	75,656			75/75,656	

Abbreviations: CI=confidence interval; OR=odds ratio

Using the designation of placenta accreta as defined by the authors, the incidence of placenta accreta increased with increasing number of cesarean deliveries (Table 20). The risk was not statistically significant until women had at least two prior cesarean deliveries. Women with one prior cesarean delivery had a rate of accreta of 0.3 to 0.6 percent. In comparison to women with no prior cesarean delivery, the odds ratio for accreta was 1.3 to 2.16, which was not statistically significant. The incidence of accreta rose with increasing prior cesarean deliveries from 1.4 percent in women with two or more prior cesarean deliveries to 6.74 percent for women with five or more prior cesarean deliveries. These results were statistically significant in all three studies. The odds ratio increased from 8.6 to 29.8.

Table 20. Incidence of placenta accreta by number of prior cesarean deliveries

Study	N	Adjusted OR (95% CI) or P value # with previa # with accreta
<i>Any number of prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155,670	OR: 19.39 (11.21 to 33.55) Previa: 22% (186) Accreta: 73% (45/62)
Wu, 2005 ²⁵⁶	64,359	p<0.0001 Accreta: 50% (55/111)
<i>Zero prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155,670	(0.01%) 16/138246 1 in 68,000
Silver, 2006 ²³⁶	30,132	0.24% (15/6201)
<i>1 prior cesarean delivery</i>		
Silver, 2006 ²³⁶	30,132	OR: 1.3 (0.7 to 2.3) 0.31% (49/15808)
Nisenblat, 2006 ²⁴⁹	940	0.6% (3/491)
Wu, 2005 ²⁵⁶	64,359	OR: 2.16 (0.96 to 4.86)
<i>2 prior cesarean deliveries</i>		
Silver, 2006 ²³⁶	30,132	OR: 2.4 (1.3 to 4.3) 0.57% (36/6,324)
<i>>2 prior cesarean deliveries</i>		
Nisenblat, 2006 ²⁴⁹	940	1.4% (4/277)
Wu, 2005 ²⁵⁶	64,359	OR: 8.62 (3.53 to 21.07)
<i>3 prior cesarean deliveries</i>		
Silver, 2006 ²³⁶	30,132	OR: 9 (4.8 to 16.7) 2.13% (31/1,452)
<i>4 prior cesarean deliveries</i>		
Silver, 2006 ²³⁶	30,132	OR: 9.8 (3.8 to 25.5) 2.33% (6/258)
<i>>4 prior cesarean deliveries</i>		

Table 20. Incidence of placenta accreta by number of prior cesarean deliveries

Study	N	Adjusted OR (95% CI) or P value # with previa # with accreta
Nisenblat, 2006 ²⁴⁹	940	p=0.023 4.7% (3/64)
<i>≥5 prior cesarean deliveries</i>		
Silver, 2006 ²³⁶	30,132	OR: 29.8 (11.3 to 78.7) 6.74% (6/89)

Abbreviations: CI=confidence interval; OR=odds ratio

A statistically significant relationship between placenta previa and placenta accreta in women with prior cesarean delivery was noted in two studies.^{236, 258} As the number of prior cesarean deliveries rose, the presence of placenta previa increased the likelihood of placenta accreta from 3.3 to 4 percent in women undergoing their first cesarean delivery to 50 to 67 percent in women with four or more prior cesarean deliveries. Women with accreta had a statistically significant increased risk of hysterectomy (odds ratio 43 to 99.5). Additional maternal outcomes such as surgical injury, hemorrhage, transfusion, and death and neonatal outcomes were reported inconsistently such that meaningful analysis of an association between accreta and prior cesarean delivery was not possible (Table 21).

Table 21. Incidence of placenta accreta with placenta previa by number of prior cesarean deliveries

Study	N	Adjusted OR (95% CI) or P value
<i>Zero prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155,670	4%(15/432)
Silver, 2006 ²³⁶	30,132	3.3% (13/398)
<i>1 prior cesarean delivery</i>		
Miller, 1997 ²⁵⁸	155,670	RR 4.45 2.09, 9.50 14% (15/102)
Silver, 2006 ²³⁶	30,132	11% (23/211)
<i>2 prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155,670	23%
Silver, 2006 ²³⁶	30,132	40% (29/72)
<i>≥2 prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155,670	RR: 11.32 (5.59 to 22.92) 29.7% (25/84)
<i>3 prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155670	35%
Silver, 2006 ²³⁶	30132	61% (20/33)
<i>4 prior cesarean deliveries</i>		
Miller, 1997 ²⁵⁸	155670	50%
Silver, 2006 ²³⁶	30132	67% (4/6)
<i>≥5 prior cesarean deliveries</i>		
Silver, 2006 ²³⁶	30132	67% (2/3)

Abbreviations: CI=confidence interval; OR=odds ratio; RR=relative risk

One of the major limitations in analyzing studies regarding placental abnormalities was the lack of consistent definition among studies, especially for abruption, which may have resulted in misclassification. There was also the potential of surveillance bias as women with prior cesarean delivery may have had additional ultrasounds or observation at the time of delivery in anticipation of possible placental complications compared with women without known risk factors. Studies that used histopathologic diagnosis of accreta were therefore limited to hysterectomy patients and may have missed patients managed with conservative therapy. The majority of studies relied on retrospective data analysis and are therefore limited by the quality and consistency of the original data collection.

This review confirms prior reports of increasing incidence of accreta in women with previa depending on number of prior cesarean deliveries.²⁶² evaluated previa, accreta, and prior cesarean delivery in a 1985 paper which was not included in this report due to case collection prior to 1980. In the 286 women with previa, the incidence of accreta for women with zero to four prior cesarean deliveries was 5, 24, 47, 40, and 67 percent, respectively. Interestingly, the incidence of previa and accreta by prior cesarean delivery was similar to later studies except for women with one prior cesarean delivery. Miller reported an incidence by number of prior cesarean deliveries of 4 percent, 14 percent, 23 percent, 35 percent, and 50 percent,²⁵⁸ and Silver found 3 percent, 11 percent, 40 percent, 61 percent, and 67 percent, respectively.²³⁶ Although the individual patient numbers in each study were limited, the consistent findings suggest that women with previa and prior cesarean delivery are at increased risk of placenta accreta and thus more likely to require hysterectomy at the time of delivery.

The incidence of placenta previa or accreta in women with one or two prior cesarean deliveries was less than 1.5 percent. The highest risk group was women with three or more prior cesarean deliveries with a risk for previa of 3.3 to 4.2 percent and accreta of 4.7 to 6.7 percent. In the women with previa, the incidence of hysterectomy was 50-67 percent, and the OR for a hysterectomy with accreta was 43-99.5.

Further studies need to be performed to better evaluate additional risk factors for the development of placenta accreta and surgical management to minimize uterine scarring. Women desiring large families should be counseled about the risks of abnormal placentation with multiple cesarean delivery. As the number of cesarean delivery continues to rise, continued evaluation needs to be performed to optimize management of women with abnormal placentation and minimize maternal and neonatal morbidity and mortality.

Summary of abnormal placentation. The risk of abruption for women with any prior cesarean ranges from 0.10 to 0.15 percent. The risk does not appear to increase with prior cesarean or number of prior cesarean deliveries. Women with a prior cesarean delivery had a statistically significant increased risk of placenta previa compared with women with no prior cesarean at a rate of 1.2 percent (95 percent CI: 0.8 to 1.5 percent). The incidence increased with increasing number of prior cesarean deliveries. A prior cesarean is a significant risk factor for maternal morbidity in women with previa. Compared with previa patients without a prior cesarean delivery, women with one prior cesarean and previa had a statistically significant increased risk of blood transfusion (15 versus 32.2 percent), hysterectomy (0.7 to 4 percent versus 10 percent), and composite maternal morbidity (15 versus 23 to 30 percent). For women with three or more prior cesarean deliveries and previa, the risk of hysterectomy and composite maternal morbidity rose significantly (0.7 to 4 percent versus 50 to 67 percent and 15 versus 83 percent, respectively). The incidence of placenta accreta rose with an increasing number of prior cesarean deliveries. The results were statistically significant for women with two or more prior cesareans

(odds ratio 8.6 to 29.8). Women with placenta previa are at increased risk for placenta accreta, and the risk increased with the increasing number of prior cesareans. Women with more than three prior cesareans and previa had a 50 to 67 percent incidence of accreta.

Maternal complications associated with multiple cesarean deliveries. As the number of women who attempt TOL decreases, the obvious consequence is an increase in the number of RCD. Conventional wisdom has suggested questioning women with a prior cesarean delivery about their plans for future childbearing as part of the discussion regarding mode of delivery due to the increased risk of multiple cesarean deliveries, but the actual risks remains unclear. Maternal morbidity resulting from multiple cesarean deliveries may consist of adhesions, hemorrhage/transfusion, surgical injury, postoperative infection, hysterectomy, abnormal placentation, and death.

The evidence regarding the outcome of multiple cesarean deliveries is limited and consists of 11 good or fair quality studies.^{81, 220, 235, 236, 249, 251, 252, 254, 257, 260, 263}

Hemorrhage. Three fair quality cohort studies evaluated the impact of multiple cesarean deliveries on maternal hemorrhage and/or blood transfusion rates (Table 22).^{249, 251, 263} Definitions of hemorrhage varied. Rouse et al used MFMU data to identify women who received a transfusion of packed red blood cells prior to hospital discharge.²⁵¹ Among women undergoing primary cesarean delivery, 3.2 percent (762/23486) received a blood transfusion. Of women with a prior cesarean delivery, the percentage of women with blood transfusions increased with increasing number of prior cesarean delivery from 1.8, 2.6, 4.3, 4.6, and 14.6 percent from one prior to five or more cesarean deliveries, respectively. The odds ratio for women with five or more cesarean deliveries was 7.6 (95 percent CI: 4.0 to 14.3). Nisenblat et al compared outcomes for women at a single institution in Israel undergoing a second versus three or more cesarean deliveries.²⁴⁹ Women were identified who experienced “excessive blood loss” of greater than 1000 mL or were transfused two or more units. Among women having their second cesarean delivery, 3.3 percent (16/491) met this definition compared with 7.9 percent (22/277) of those with two or more prior cesarean delivery (odds ratio 2.3; 95 percent CI: 1.1 to 4.5). Macones et al performed a secondary analysis of a multicenter, retrospective cohort study and examined incidence of blood transfusion.²⁶³ In women with two prior cesarean deliveries who did not attempt a TOL, 1.18 percent of 2,888 women received a transfusion (odds ratio 0.54; 95 percent CI: 0.23 to 1.27). These studies suggest that overall rates of hemorrhage/transfusion are less than 5 percent but the risk appears to increase with increasing numbers of cesarean delivery.

Table 22. Multiple cesarean deliveries effect on rates of hemorrhage

Studies	Adjusted odds ratio 95% CI or P value	N
<i>Zero prior cesarean deliveries</i>		
Rouse, 2006 ²⁵¹		3.2% (762/23486)
<i>1 prior cesarean delivery</i>		
Rouse, 2006 ²⁵¹		1.8% (427/23579)
Nisenblat 2006 ²⁴⁹		3.3% (16/491)
<i>2 prior cesarean deliveries</i>		
Rouse, 2006 ²⁵¹		2.6% (202/7902)
Macones 2005 ²⁶³	0.54 (0.23 to 1.27)	1.18% (2888) ERCD versus VBAC
<i>>2 prior cesarean deliveries</i>		
Nisenblat 2006 ²⁴⁹	2.3 (1.1 to 4.5)	7.9% (22/277)

Table 22. Multiple cesarean deliveries effect on rates of hemorrhage

Studies	Adjusted odds ratio 95% CI or P value	N
<i>3 prior cesarean deliveries</i>		
Rouse, 2006 ²⁵¹		4.3% (75/1754)
<i>4 prior cesarean deliveries</i>		
Rouse, 2006 ²⁵¹		4.6% (15/323)
<i>≥5 prior cesarean deliveries</i>		
Rouse, 2006 ²⁵¹	7.6 (4.0 to 14.3)	14.6%(16/110)

Abbreviations: CI=confidence interval; ERCD=elective repeat cesarean delivery; VBAC=vaginal birth after cesarean

Adhesions. Three good or fair quality studies discussed the presence of adhesions after multiple cesarean deliveries (Table 23).^{235, 249, 257} Uniform definitions of adhesions were not used. Nisenblat et al reported adhesions present in 25.6 percent (124/491) of women undergoing their second cesarean delivery versus 46.1 percent (124/277) for women with two or more prior cesarean deliveries (odds ratio 2.5; 95 percent CI: 1.8 to 3.4).²⁴⁹ Lynch et al studied outcomes at a single hospital in Ireland and found a similar rate of adhesions (48.8 percent) in women with two or more prior cesarean deliveries (122/250).²⁵⁷ Women with three or more prior cesarean deliveries at the University of Oulu, Finland were studied to identify outcomes in women with multiple cesarean deliveries.²³⁵ Records were reviewed for 64 women who underwent a total of 341 cesarean deliveries, 149 of which were their fourth or greater cesarean. These women were compared with a control group consisting of the next cesarean in the same situation (elective versus emergency). Intraperitoneal adhesions were noted in 18.2 percent of cases versus 2.7 percent of controls (odds ratio 8.1; 95 percent CI: 2.7 to 23.8). Overall, incidence of adhesions appears to increase with increasing numbers of cesareans.

Table 23. Multiple cesarean deliveries effect on rates of adhesions

Studies	Adjusted odds ratio 95% CI or P value	N
<i>1 prior cesarean delivery</i>		
Nisenblat, 2006 ²⁴⁹		25.6% (124/491)
<i>≥2 prior cesarean deliveries</i>		
Lynch 2003 ²⁵⁷		48.8% (122/250)
Nisenblat, 2006 ²⁴⁹	2.5 p<0.001, (1.8 to 3.4)	46.1% (124/277)
<i>≥3 prior cesarean deliveries</i>		
Juntunen, 2004 ²³⁵	8.1 0.0001 (2.7 to 23.8)	18.2% (149)

Abbreviations: CI=confidence interval

Surgical injury. The data regarding surgical injury and multiple cesarean deliveries is very limited and consists of two good quality studies (Table 24).^{236, 257} Both studies evaluated bladder injuries. Lynch et al found 1.6 percent of women with two or more prior cesareans had a bladder injury (4/250).²⁵⁷ Silver et al noted less than 0.3 percent of women with less than three prior cesareans experienced a bladder injury compared with 4.5 percent of women with five or more prior cesareans.²³⁶ This trend was statistically significant at p<0.001. Risk of bowel and ureteral injury with increasing number of cesareans was also statistically significant, although overall

incidence was less than 1.2 percent. Bladder, bowel, and ureteral injury are uncommon occurrences and appear to increase with multiple cesareans.

Table 24. Multiple cesarean deliveries effect on rates of surgical injury

Studies	N
<i>Zero prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	0.13% (8/6201)
<i>1 prior cesarean delivery</i>	
Silver, 2006 ²³⁶	0.09% (15/15808)
<i>2 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	0.28% (18/6324)
<i>≥2 prior cesarean deliveries</i>	
Lynch, 2003 ²⁵⁷	1.6% (4/250)
<i>3 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	1.17% (17/1452)
<i>4 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	1.94% (5/258)
<i>≥5 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	4.49% (4/89)

Perioperative infection. The data regarding perioperative infection and multiple cesarean deliveries is limited and consists of four good or fair quality studies.^{81, 235, 236, 257} As indicated earlier in the report, there was no uniform definition of infection. Phelan et al reported an incidence of “febrile morbidity” of 19.2 percent (163/847) for women undergoing RCD, but the authors did not define febrile morbidity.⁸¹ Similarly, Juntunen et al. noted 14.1 percent of women with three or more prior cesareans had postoperative infections (odds ratio 0.9; 95 percent CI: 0.5 to 1.8), but the criteria for infection were not defined.²³⁵ Urinary tract infection (UTI) and upper respiratory tract infection (URI) were used by Lynch et al to describe postoperative infectious complications (Table 25).²⁵⁷ Silver et al defined postpartum endometritis clinically on the absence of findings consistent with an extrauterine source.²³⁶ There was a statistically significant increase in endometritis with multiple cesareans (p<0.001). Based on these studies, the risk of postoperative infection with multiple cesareans remains unclear.

Table 25. Multiple cesarean deliveries effect on rates of perioperative infection

Studies	N
<i>Zero prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	Endometritis: 5.98% (371/6,201)
<i>1 prior cesarean delivery</i>	
Silver, 2006 ²³⁶	2.56% (404/15,808)
<i>≥1 prior cesarean delivery</i>	
Phelan, 1987 ⁸¹	"Febrile morbidity": 19.2%(163/847)
<i>2 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	2.81% (178/6,324)
Lynch, 2003 ²⁵⁷	Urinary tract infection, upper respiratory track infection: 11.2% (80)
<i>3 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	2.96% (43/1,452)
Lynch, 2003 ²⁵⁷	10.7% (131)

Table 25. Multiple cesarean deliveries effect on rates of perioperative infection

Studies	N
<i>≥3 prior cesarean deliveries</i>	
Juntunen, 2004 ²³⁵	"Postoperative infections": 14.1% (149) Adjusted odds ratio: 0.9 95% confidence interval: 0.869 (0.5, 1.8)
<i>4 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	1.55% (4/258)
<i>≥4 prior cesarean deliveries</i>	
Lynch, 2003 ²⁵⁷	23% (39)
<i>≥5 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	6.74% (6/89) p=0.001

Wound complications. Two good quality studies report incidence of wound complications with multiple cesarean deliveries.^{236, 257} Silver et al reviewed wound infection and wound dehiscence and found no statistically significant change with multiple cesareans (p=0.09 and 0.18, respectively).²³⁶ Similarly, Lynch et al. found no correlation between number of cesareans and wound problems (Table 26).²⁵⁷

Table 26. Multiple cesarean deliveries effect on rates of wound complications

Studies	N
<i>Zero prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	Dehiscence, infection: 1.9% (118/6201)
<i>1 prior cesarean delivery</i>	
Silver, 2006 ²³⁶	1.05% (165/15808)
<i>2 prior cesarean deliveries</i>	
Lynch, 2003 ²⁵⁷	"Problem": 6.2% (80)
Silver, 2006 ²³⁶	1.69% (107/6324)
<i>3 prior cesarean deliveries</i>	
Lynch, 2003 ²⁵⁷	7.6% (131)
Silver, 2006 ²³⁶	1.52% (22/1452)
<i>4 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	4.23% (11/258)
<i>≥4 prior cesarean deliveries</i>	
Lynch, 2003 ²⁵⁷	5.1% (39)
<i>5 prior cesarean deliveries</i>	
Silver, 2006 ²³⁶	3.37% (3/89)

Hysterectomy. Seven good or fair quality studies evaluated the rate of hysterectomy with multiple cesarean deliveries (Table 27).^{81, 236, 249, 252, 254, 257, 260} Women requiring hysterectomy due to abnormal placentation were discussed previously in this report (see Abnormal Placentation section). There are three population-based, matched case-control studies with women requiring peripartum hysterectomy chosen as cases.^{252, 254, 260} Bodelon et al used the Washington State birth certificate registry. Women undergoing their first cesarean delivery were more likely to require hysterectomy than were women delivering vaginally (odds ratio 4.6; 95 percent CI: 3.5 to 6.0). Women with one or more prior cesarean were significantly more likely to require hysterectomy (odds ratio 7.9; 95 percent CI: 5.8 to 10.7).²⁵² Knight et al used the United Kingdom Obstetric Surveillance System and similarly noted an increased risk for hysterectomy

with primary cesarean (odds ratio 7.13; 95 percent CI: 3.71 to 13.7). The risk of peripartum hysterectomy for women with two or more prior cesareans was significantly higher (odds ratio 18.6; 95 percent CI: 7.67 to 45.4) than for women with one prior cesarean delivery (odds ratio 2.14; 95 percent CI: 1.37 to 3.33).²⁵⁴ Zelop et al used obstetric records at Brigham and Women's Hospital to perform a case series of emergency peripartum hysterectomies between 1983 and 1991. Hysterectomy rates for women undergoing a primary cesarean were 0.062 percent, and increased with one prior cesarean delivery to 0.735 percent. Women with one or more prior cesarean had a hysterectomy rate of 1.08 percent, these rates were statistically significant.²⁶⁰ Nisenblat et al compared women undergoing a second cesarean versus women with two or more prior cesareans. The rate of hysterectomy increased from 0.2 percent (1/491) to 1.1 percent (3/277) in the multiple cesarean group, but the result was not statistically significant.²⁴⁹ Lynch et al found a similar rate of hysterectomy in women with four or more prior cesareans of 1.1 percent (2/170).²⁵⁷ Silver et al used MFMU data and noted increasing incidence of hysterectomy with increasing number of cesareans from 0.65, 0.42, 0.90, 2.41, 3.49, and 8.99 percent with zero to five or more prior cesareans, respectively. Women with five or more prior cesareans were 15 times more likely to require hysterectomy (odds ratio 15.2; 95 percent CI: 6.9 to 33.5), these results were statistically significant.²³⁶ These studies strongly support a correlation between multiple cesareans and hysterectomy. The odds ratio for hysterectomy with one prior cesarean is 0.7 to 2.14, with one or more is 1.4 to 7.9, and two or more is 3.8 to 18.6.

Table 27. Multiple cesarean deliveries effect on rates of hysterectomy

Studies	Adjusted odds ratio 95% Confidence interval or P value	N	Per/1000
<i>Zero prior cesarean deliveries</i>			
Bodelon, 2009 ²⁵²	4.6 (3.5 to 6.0)		
Knight, 2008 ²⁵⁴	7.13 (3.71 to 13.7)		Risk 1:1700 (1:1300- 1:2300)
Silver, 2006 ²³⁶		0.65% (40/6201)	
Zelop, 1993 ²⁶⁰		19/35240	0.62
<i>1 prior cesarean delivery</i>			
Nisenblat, 2006 ²⁴⁹		0.2% (1/491)	
Knight, 2008 ²⁵⁴	2.14 (1.37 to 3.33)	80	Risk 1:1300 (1:1000- 1:1600)
Silver, 2006 ²³⁶	0.7 (0.4 to 0.97)		
Zelop, 1993 ²⁶⁰		29/4366	7.35
<i>>1 prior cesarean delivery</i>			
Bodelon, 2009 ²⁵²	7.9 (5.8 to 10.7)		
Phelan, 1987 ⁸¹		1.7% (14/847)	
Zelop, 1993 ²⁶⁰		70/6694	10.75
<i>2 prior cesarean deliveries</i>			
Silver, 2006 ²³⁶	1.4 (0.9 to 2.1)		
<i>>2 prior cesarean deliveries</i>			

Table 27. Multiple cesarean deliveries effect on rates of hysterectomy

Studies	Adjusted odds ratio 95% Confidence interval or P value	N	Per/1000
Nisenblat, 2006 ²⁴⁹	0.136	1.1% (3/277)	
Knight, 2008 ²⁵⁴	18.6 (7.67 to 45.4)	84	Risk 1:220 (1:180-1:270)
<i>3 prior cesarean deliveries</i>			
Silver, 2006 ²³⁶	3.8 (2.4 to 6.0)		
<i>4 prior cesarean deliveries</i>			
Silver, 2006 ²³⁶	5.6 (2.7 to 11.6)		
<i>≥4 prior cesarean deliveries</i>			
Lynch, 2003 ²⁵⁷		1.1% (2/170)	
<i>≥5 prior cesarean deliveries</i>			
Silver, 2006 ²³⁶	15.2 (6.9 to 33.5)		

Summary of maternal complications associated with multiple cesarean deliveries. Thirty-three percent of births in the U.S. as of 2007 were accomplished via cesarean delivery.¹ Many of these women will have additional children in the future and will be faced with the decision regarding mode of delivery. If she has a RCD, she will most likely have a cesarean for the remainder of her pregnancies. If she has a VBAC, she will likely have additional VBAC and avoid multiple cesareans. One of the fundamental gaps in the literature is intention for future pregnancies. This report supports prior evidence that although maternal morbidity increases with cesarean and neonatal morbidity increases with TOL, the overall incidence is extremely uncommon. The overwhelming majority of second pregnancies will result in a healthy mom and baby regardless of delivery method. This changes for women with multiple cesareans. As the number of prior cesareans increases, the maternal morbidity increases, especially for women with more than three prior cesareans. These women are at statistically significant increased risk of previa, accreta, and hysterectomy. The highest risk group is women with previa and prior cesarean, and the risks increase with increasing number of prior cesarean. Women with three or more prior cesareans and previa had a statistically significant increased risk of accreta (3.3 to 4 percent versus 50 to 67 percent), hysterectomy (0.7 to 4 percent versus 50 to 67 percent), and composite maternal morbidity (15 versus 83 percent) compared with women with previa and no cesarean. The only identified prevention of previa is avoiding uterine instrumentation. The overall incidence of previa is uncommon. The incidence of previa in women with any prior cesarean was 1.2 percent and for women with three or more prior cesareans it was 2.8 percent. There is no identified method for determining which women will develop previa in a subsequent pregnancy. All pregnant women are at risk for previa, women with previa are at increased risk of maternal morbidity, the incidence of previa and risk of morbidity increases with increasing number of prior cesareans, and there is no ability to predict which women will develop these complications. This has substantial implications for VBAC counseling relating to the risks of major morbidity associated with multiple cesareans in future pregnancies, especially for women desiring large families. Unfortunately, women are often unable to predict how many children they will have. Per the CDC (<http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/index.htm>), the unintended

pregnancy rate in the U.S. in 2001 was approximately 50 percent. Therefore, it is not unlikely that women will be facing additional pregnancies following cesarean, even if they were not planning to have more children. The inability to determine which women have completed childbearing and this report’s conclusion that maternal morbidity increases with multiple cesareans supports the ACOG 2004 practice bulletin recommendation that most women with a prior cesarean should be counseled about VBAC and offered a TOL.

Direction of scar. There are three recognized types of uterine incision; the most common approach is the low transverse incision through the lower uterine segment. Some surgeons prefer the low vertical incision, although concern remains that it may enter the muscular portion of the uterus. The classical incision, or high vertical incision, has been strongly associated with increased risk of uterine rupture and is a recognized contraindication to labor. Modifications of low transverse incisions—which require entering the muscular portion of the uterus, known as “T” or “J” incisions—are considered classical incisions for classification purposes. In addition, many women are unaware of what type of incision they had with a prior cesarean delivery, especially if the delivery was performed in countries other than the U.S. where operative reports may not be available. These incisions are classified as unknown. It remains unclear the effect of low vertical or unknown incisions on the risk of uterine rupture.

Impact of direction of scar. The published literature regarding impact of the direction of scar is limited and consists of one good and seven fair quality studies (Table 28).^{80, 84, 175, 203, 233, 264-266} These studies focus on impact of direction of scar and subsequent uterine rupture. As previously defined in this report, complete uterine rupture is a separation through the entire thickness of the wall including visceral serosa (with or without extrusion of part of all of fetal-placental unit). An incomplete uterine rupture is defined as a separation that was not completely through all layers of the uterine wall (e.g., serosa intact). Only one author used these definitions.⁸⁰ All other studies will therefore be listed as “uterine defect” which will encompass both complete and incomplete uterine rupture.

Table 28. Impact of direction of scar

Studies	Uterine Rupture Definition	Type of Scar	Mode of Delivery	Uterine Defect Rate
Landon 2006 ⁸⁰	Dehiscence - disruption of the uterine muscle with intact serosa. Rupture - disruption or tear of the uterine muscle and visceral peritoneum	LVCD	TOL: 102	2 (2.0%)
		LTCD	TOL: 14,483	105 (0.7%)
		Classical	TOL: 105	2 (1.9%)
		Unknown	TOL: 3206	15 (0.5%)

Table 28. Impact of direction of scar

Studies	Uterine Rupture Definition	Type of Scar	Mode of Delivery	Uterine Defect Rate
Paul, 1985 ¹⁷⁵	Dehiscence - nontraumatic separation of the uterine scar without bleeding or extrusion of the fetus into the wound. Rupture - scar separation with bleeding, hematoma formation, or extrusion of the fetus	LVCD	TOL: 50	0
		LTCD	TOL: 701	16 (2.3%)
Martin, 1983 ²⁰³	Dehiscence - palpable and/or visualized uterine defect. Rupture - dehiscence that required intervention	LVCD	VBAC: 6/12 (50%) TOL-CD: 6 ERCD: 64	0 0 0
		LTCD	VBAC: 95/150 (64%) TOL-CD: 55 ERCD: 483	1 (1.1%) 4 (7.2%) 6 (1.2%)
Stovall, 1987 ⁸⁴	Dehiscence - palpable and/or visualized defect in the previous scar. Rupture - dehiscence requiring surgical intervention or blood component.	LVCD	VBAC: 57/64 (89%) TOL-CD: 7	0 0
		LTCD	VBAC: 159/208 (76%) TOL-CD: 49	0 1 (2.0%)
Tahilramaney, 1984 ²⁶⁶ different #s text/table	Dehiscence - silent separation of the uterine scar. Rupture - sudden separation of the scar with hemorrhage requiring immediate intervention.	LVCD	VBAC: 0 CD: 11	0 1 (9%)
		LVCD or fundal	VBAC: 5 CD: 16	0 2 (12%)
		LTCD	VBAC: 156 CD: 218	3 (2.2%) 7 (3.3%)
		Unknown	VBAC: 104 CD: 347	0 11 (3.2%)
Leung, 1993 ²³³	Rupture - symptomatic uterine scar separation that required emergency laparotomy. Asymptomatic dehiscences were excluded.	LTCD	Study of ruptures only	64
		LVCD or classical	Study of ruptures only	11
		Unclassified	Study of ruptures only	24
Lin, 2004 ²⁶⁵	Rupture - uterine scar separation associated with abnormal fetal heart rate tracing, extrusion of fetal parts, or hemorrhage.	LVCD	39	0
		LTCD	1931	0.60%
		Classical	145	0
		Unknown	1312	0.50%
Grubb, 1996 ²⁶⁴	Dehiscence - scar separation noted incidentally in asymptomatic patient. Rupture - scar separation with either fetal distress or maternal complication requiring operative intervention.	Unknown	197	5 (2.5%)

Abbreviations: LTCD=low transverse cesarean delivery; LVCD=low vertical cesarean delivery; TOL=trial of labor; TOL-CD=trial of labor followed by cesarean delivery; VBAC=vaginal birth after cesarean delivery

Uterine rupture. Landon et al 2006 used the MFMU database to study the risk of uterine rupture based on direction of scar for women attempting a TOL.⁸⁰ For women with a prior LTCD in that study, the overall rupture rate was 105/14,483 deliveries (0.7 percent). The rate with a prior LVCD was 2.0 percent (2/102 deliveries). There were also two uterine ruptures in 102 women with prior classical, J, or T incisions who refused cesarean delivery or presented in advanced labor, resulting in a rupture rate of 1.9 percent.

Uterine defect, prior low vertical incision - trial of labor. Three fair quality cohort studies reported on prior LVCS and incidence of uterine defects in women undergoing TOL.^{84, 175, 203} Paul et al examined 16,200 deliveries, of which 751 women had a prior cesarean delivery and attempted a TOL.¹⁷⁵ Fifty women had a prior LVCD, and per the authors, there were no serious complications. Martin et al studied 717 patients with prior cesarean who were separated into groups based on intended mode of delivery.²⁰³ For women who elected a TOL, six had a prior LVCD with no cases of uterine defects. Ninety-five women with a prior LTCD had VBAC deliveries with one uterine defect. Of the 61 women who required abdominal delivery after TOL, six had a prior LVCD with no cases of uterine defects, and 55 women had prior LTCD with four defects. The authors concluded that the evidence did not support the theory that low-vertical incisions are more likely to rupture than LTCD. Stovall et al performed a prospective cohort study of 272 women with a prior cesarean attempting a TOL at the University of Tennessee College of Medicine.⁸⁴ One hundred and fifty-nine out of 208 women with a prior LTCD underwent VBAC deliveries with one uterine defect. Fifty-seven out of 64 women with a prior LVCD underwent VBAC deliveries with no defects. These studies suggest that TOL with a prior LVCD does not have an increased rate of uterine dehiscence compared with prior LTCD, but the total number of TOL attempts with prior LVCD reported in these three studies is 126. This suggests that the sample size may have not been large enough to capture the true risk of uterine defect with a prior LVCD, but it is reassuring that there were no cases of uterine defects in this series.

Uterine defect, prior low vertical incision - elective repeat cesarean delivery. Martin et al studied 717 patients with a prior cesarean delivery separated into groups based on intended mode of delivery.²⁰³ Of the participants, 547 chose ERCD, 483 with a prior LTCD and 64 with a prior LVCD. There were six uterine defects in the LTCD group and no cases in the LVCD group.

Uterine defect, prior low vertical incision - unknown intended mode of delivery. Three fair quality cohort studies evaluated a prior LVCD and incidence of uterine defect but did not discuss intended mode of delivery.^{233, 265, 266} As the authors did not report which patients attempted TOL, it is unclear whether patients with scar disruption presented with asymptomatic defects at the time of ERCD or after attempted TOL. Tahilramaney et al reported defects in 2.8 percent of 374 patients with prior LTCD.²⁶⁶ One hundred and thirty-four women delivered vaginally with uterine defects in three versus 211 delivering via cesarean with seven cases of defect. For the 11 patients with a prior LVCD, all were delivered via cesarean with one defect (9 percent). For the 21 prior classical or vertical incisions of unknown type, there were five vaginal deliveries without complications and two cases of uterine defects with cesarean (14 percent). The authors concluded that type of uterine incision was not statistically significant in regards to uterine dehiscence. Leung et al reviewed cases of uterine defects at one institution over a 10 year period.²³³ There were 16,467 women who had a prior cesarean with 107 cases of uterine defects, 99 with complete records. Per patient history, 90 percent of scar types were unknown, but, when possible, scars were classified at the time of laparotomy. Eleven were recorded as classical/vertical, 64 were transverse, and 24 remained unknown. A database at Emory

University was used by Lin et al to identify patients with a prior cesarean who delivered at greater than 28 weeks and to study the impact of the direction of scar and uterine defects.²⁶⁵ Of 3,533 patients, 145 had a prior classical scar, 1,931 had a LTCD, 39 a LVCD, and 1,312 had an unknown scar. There were 106 patients excluded for unidentified scar. There were no cases of uterine defects with prior LVCD or classical incisions.

Uterine defect, unknown uterine scar. Unknown uterine scar remains a diagnostic challenge. One good and three fair quality studies evaluated outcomes for women with unknown incisions.^{221, 264, 266} Grubb et al performed a RCT of 197 women in latent labor with unknown uterine scars comparing nonintervention to active management.²⁶⁴ In the intervention group, there were five cases of uterine defects. There were no cases in the nonintervention group (0 versus 5 percent, $p=0.03$). Per the author's definition, there was one case of rupture and four uterine dehiscences. The uterine rupture was through a vertical scar (later called a T incision). The four cases of uterine dehiscence were with LVCD, and three were noted on routine exploration of the uterine cavity following VBAC. Tahilramaney et al reviewed 451 patients with unknown incisions, 93 delivered vaginally with no complications, and 319 delivered via cesarean delivery, of which 11 (2.6 percent) experienced uterine defects.²⁶⁶ Lin et al reviewed 1,312 patients with unknown scar. In comparison to patients with a known prior LTCD, there was no increased rate of uterine defects in patients with an unknown scar (0.6 and 0.5 percent, respectively).²⁶⁵ Landon et al found that for women with an unknown scar, there were 15 ruptures in 3,206 deliveries (0.5 percent).²²¹ These studies suggest that women with an unknown scar are not at significantly increased risk of uterine dehiscence or rupture with TOL.

Direction of scar summary. Because the scope of this report started after the NIH conference in 1980, data regarding the risk of uterine defect for classical incision is largely absent and what is there is likely biased as providers in general will not allow a trial of labor among women with prior classical incisions. Studies prior to 1980 suggest that women with prior classical are at substantially increased risk for uterine rupture and should not undergo labor. The evidence regarding prior LVCD is very limited. Of six studies on 336 women with LVCD, there are two reported cases of uterine rupture and one uterine defect. These limited data suggests that women with a prior LVCD are not at a significantly increased risk of uterine dehiscence or rupture compared with women with a prior LTCD. Women with an unknown scar are not at a significantly increased risk of uterine dehiscence or rupture with TOL compared with women with prior LTCD.

Obesity. Because obesity is an increasingly important health problem in the U.S., the impact of BMI and/or weight on VBAC rate was investigated. RCT, cohort, or case series studies that reported weight or BMI for TOL or ERCD groups for VBAC rate, or maternal or infant outcomes were included. Of the 119 full text articles retrieved and assessed for inclusion, seven good or fair quality cohort studies were reviewed.^{78, 110, 126, 135, 240, 267, 268} A number of studies provide context for the data related to maternal BMI from the MFMU cohort,^{80, 221} one highlighting health outcomes by BMI and TOL versus ERCD groups will be discussed here.⁷⁸ Three studies of poor quality were excluded from analysis.²⁶⁹⁻²⁷¹ Most studies stratified BMI in predefined categories,^{78, 110, 126, 267} while others used weight.^{135, 240, 268} The most commonly used definition included four BMI (kg/m²) categories: normal, less than 25; overweight, 25 to 29.9; obese, 30 to 39.9; and morbidly obese greater than 40. BMI cutoffs did vary within categories. One looked only at women eligible for a TOL who weighed more than 300 pounds.²⁴⁰

Overall VBAC rates compared by BMI groups will be discussed (Table 29) along with a brief overview of TOL maternal and infant outcomes by BMI status (Table 30). The largest of

the U.S. cohorts will be emphasized as it provides a comprehensive look at how morbid obesity may affect maternal and infant morbidity, TOL compared with ERCD.⁷⁸

Table 29. Vaginal birth after cesarean rate in studies with data by body mass index

Author/ Year	Overall VBAC Rate%	VBAC Rate BMI (kg/m ²) Categories	VBAC Rate (%)
Bujold, 2005 ²⁶⁷	71.2	a) <25: 636/802; OR Not reported b) 25-29.9: 2463/3309 OR 0.81 (0.67-0.98); p=0.03 c) 30-34.9: 1250/1806 OR 0.66 (0.54-0.80); p<0.01 d) 35-39.9: 325/584 OR 0.38 (0.30-0.49); p=0.03 e) ≥ 40 or more: 113/217 OR 0.39 (0.28-0.54); p<0.001	a) 78 b) 74 c) 69 d) 56 e) 52
Carroll, 2003 ²⁶⁸	68	<i>Weight</i> a) <200 lbs 28.7±2.8: 27/33 p <0.01 b) 200-300 lbs 41.3±5.1: 16/28 OR 3.37, 95% CI 1.06 -10.76 c) >300 lbs 57.5±7.0: 4/69	a) 82 b) 57 c) 13
Durnwald, 2004 ¹¹⁰	66	< 19.8 19.9-24.9 25-29.9 ≥30 comparing b & d p=0.003	a) 84.7 b) 70.5 c) 65.5 d) 54.6
Goodall, 2005 ¹²⁶	79	a) <25: OR 1.00 (reference) p < 0.001 b) 25-29.9: OR 1.57 (0.96-2.55) c) 30-39.9: OR 2.34 (1.47-3.73) d) >40: OR 2.65 (1.42-4.96)	a) 86 b) 80 c) 72 d) 70
Juhasz, 2005 ¹³⁵	77	a) <19.8; OR (reference) b) 19.8 - 26: OR 0.85 (0.51-1.41); p=.519 c) 26.1 - 29: OR 0.65 (0.34-1.26); p=.201 d) > 29: OR 0.53 (0.29-0.98); p=.043 [Linear regression: r= -0.182, P <0.001; As BMI increases, the VBAC rate decreases] > 40 lb weight gain; OR 0.63 (0.42-0.97); p=0.34	a) 83 b) 80 c) 69 d) 68
Hibbard, 2006 ⁷⁸ (MFMU)	73	a) 18.5-24.9: 1140/1344 p <0 .001 b) 25.0-29.9: 3690/4747 c) 30-39.9: 4493/6413 d) >40: 994/1638	a) 85 b) 78 c) 70 d) 61
Chauhan, 2001 ²⁴⁰	NA	Morbidly obese ≥40.0: 4/30 CI 3.7- 30.7	13%

* SL/IA versus ERCD

† Morbid obesity category: 1 prior cesarean delivery (55.3%), >1 prior cesarean delivery (61.2%); elective repeat cesarean delivery (68.3%)

Abbreviations: BMI=body mass index; CI=confidence interval; lbs=pounds; OR=odds ratio; VBAC=vaginal birth after cesarean

Vaginal birth after cesarean rate and body mass index. Overall VBAC rates ranged from 66 to 79 percent in the included obesity studies.^{78, 110, 126, 135, 267, 268} When looking at VBAC rate by BMI, most studies found a greater percentage of normal weight women achieved VBAC when compared with overweight or obese women.^{78, 110, 126, 135, 267, 268} The three studies reporting VBAC based upon BMI of greater than or equal to 40 showed varying VBAC rates: 52.1 percent,²⁶⁷ 61 percent,⁷⁸ and 70 percent.¹²⁶ The two smallest U.S. studies that used weight rather than BMI showed women over 300 pounds had a 13 percent VBAC rate.^{240, 268} In a U.S. retrospective chart review, linear regression revealed that as BMI increases, the VBAC rate decreases (r=-0.182, P=0.001).¹³⁵ The MFMU study shows a relationship between increasing

BMI and decreasing VBAC rate where normal BMI women had an 85 percent VBAC rate while those categorized as morbidly obese had a 61 percent VBAC rate ($p < 0.001$; Table 29).⁷⁸

The MFMU⁷⁸ enrolled over 28,000 eligible women aiming to better understand BMI and the risks of uterine rupture and infant and maternal morbidity associated with a TOL as compared with ERCD. BMI was calculated at delivery using weight in kilograms divided by the square of the height in meters (kg/m^2). The subanalysis includes term (greater than or equal to 37 weeks GA), singleton pregnancy with a prior cesarean delivery and a BMI greater than $18.5\text{kg}/\text{m}^2$ at delivery. The description of the cohort reports a significantly higher BMI in the ERCD group compared with the TOL group (BMI: 32.1 ± 6.6 versus 33.6 ± 7 , $p < 0.001$).⁷⁸ Health outcomes for those with morbid obesity (BMI greater than 20) were compared for TOL and ERCD.

Outcome data from the MFMU TOL versus ERCD groups provide insight into how morbid obesity may contribute to adverse pregnancy outcomes for both mother and infant. Compared with the ERCD group, the TOL group had a greater likelihood of hospital stay (odds ratio 1.2; 95 percent CI: 1.1 to 1.4), endometritis (odds ratio 2.4; 95 percent CI: 1.7 to 3.5), dehiscence (odds ratio 2.4; 95 percent CI: 1.0 to 5.4), rupture/dehiscence (odds ratio 5.6; 95 percent CI: 2.7 to 11.7), composite morbidity (odds ratio 1.2; 95 percent CI: 1.1 to 1.4) composite morbidity (excluding stay, odds ratio 1.8; 95 percent CI: 1.5 to 2.6).⁷⁸ TOL did not have higher risk of transfusion, maternal surgical injury, hysterectomy, wound complications, or thromboembolic disease. Compared with the ERCD group, the TOL infants were at greater risk for 5 minute Apgar scores less than seven (odds ratio 3.1; 95 percent CI: 2.1 to 4.6) and injury (odds ratio 5.1; 95 percent CI: 1.9 to 13.8), but not 5 minute Apgar score less than three, sepsis, NICU admission, or stillbirth/abortion/neonatal death.⁷⁸

Health outcomes by body mass index. Table 30 provides a catalog of statistical findings for those included obesity studies that provide information on maternal and infant health outcomes by BMI or weight status. Data are summarized for between BMI group differences in rates of adverse outcomes as reported in full text papers, with statistical significance also provided.

Maternal health outcomes. Three cohort studies provide information on women experiencing uterine rupture or dehiscence between the BMI groups.^{78, 135, 267} One German cohort study (N=8580) found no difference by BMI group for uterine rupture separation,²⁶⁷ while the largest MFMU study found no differences when uterine rupture and dehiscence were analyzed alone, but when combined, a significantly higher rate in the largest of four BMI groups was found (groups/percent 1) 0.9, 2) 1.5, 3) 1.4, 4) 2.1, respectively, $p=0.03$).⁷⁸ Another study reported uterine rupture rates were higher in the overweight group (3.6 percent) than in the underweight (0.6 percent), normal (1.8 percent), and obese (0 percent) groups, ($p=0.041$); however, when controlling for number of layers of closure, this no longer held true (odds ratio 5.08; 95 percent CI: 0.53 to 48.79, $p=0.159$).¹³⁵

More overweight and obese women compared with normal weight women had trouble with wound healing complications in the included studies. Compared with lower BMI groups, women with greater BMI had statistically significantly more wound infection and fever,²⁶⁷ wound infection or endometritis,²⁶⁸ or wound complications and endometritis.⁷⁸ Alternatively, one U.S. cohort (N=725) did not find a significant difference between BMI groups for infection.¹²⁶ While no differences in surgical injury rates were reported in the MFMU,⁷⁸ those women with lower BMI had significantly more third and fourth degree lacerations than women with higher BMI in another study ($p < 0.01$). Studies reporting hysterectomy data did not find any differences between BMI groups.^{78, 267} In addition, hemorrhage,²⁶⁷ blood loss,²⁶⁸ and transfusion⁷⁸ showed no BMI group differences. The two studies looking at maternal hospital stay found statistically

significantly higher rates of hospital stay with higher BMI.^{78, 268} The MFMU sub analysis showed maternal stay of 4 or more days in the hospital at 30.3 percent in the morbidly obese BMI category, versus 9.4 percent, 12 percent, and 18.9 percent, in the other weight categories respectively, $p < 0.001$.⁷⁸ Finally, there was no significant difference in the adverse event thromboembolism in BMI groups.⁷⁸

Infant health outcomes. Two studies reporting on infant death did not find a statistically significant difference between BMI groups.^{78, 267} The MFMU secondary analysis did note that stillbirth/abortion and neonatal death were the highest in the morbid obesity group (BMI greater than 40 was 0.5 percent versus 0.2, 0.3, and 0.3, in the other weight categories, respectively, $p = 0.14$).⁷⁸ When comparing with lower BMI categories, neonatal resuscitation with intubation²⁶⁷ and NICU admission⁷⁸ were highest in the morbidly obese groups as well (greater than 40 BMI) ($p = 0.03$ and $p < 0.001$, respectively).

GA and birth weight were common outcomes evaluated in all studies with BMI group data; however, results were mixed. Two studies showed no effects for GA,^{135, 268} while two studies indicate that younger GA is associated with lower BMI.^{126, 267} The largest MFMU study found older GA in the overweight and obese BMI groups, when compared with the underweight or normal BMI groups ($p < 0.001$).⁷⁸ Similarly, a U.S. university clinic cohort found older GA in higher BMI patients, compared with lower BMI patients.¹²⁶ A similar picture emerges with infant weight and maternal BMI, where three large U.S. studies showed infant weights greater than 4,000 grams were more likely in the largest BMI categories,^{126, 135, 267} and two where infant weight was higher in high BMI groups.^{78, 126} In contrast, one study reported no infant weight differences in BMI groups.²⁶⁸

Apgar scores less than seven taken at 1 minute following delivery showed no differences by BMI,^{126, 267} while Apgar less than seven taken at 5 minutes were more likely in the high BMI group compared with lower BMI group.²⁶⁷ The MFMU analysis showed 5 minute Apgar scores less than or equal to three were not significantly different between BMI groups.⁷⁸ In addition, infant injury and sepsis were similar for all maternal BMI groups.⁷⁸

Summary of obesity. Assessing the risks and benefits of VBAC using BMI is a complex exercise. Data show that increasing BMI is linked to decreased VBAC, with morbidly obese women and their infants being at the highest risk for adverse outcomes. Compared with normal weight mothers, data suggest that obese and morbidly obese women are more likely to suffer rupture and/or dehiscence, wound infection, and/or increased hospital stay, while their infants may experience more injury and greater weights, specifically greater than 4,000 grams. BMI categories use different cut offs and patient inclusion and exclusion criteria vary. Comparison across studies for VBAC rate and important health outcomes is further complicated by lack of consensus on definitions and priorities. Future research in community practice settings with reproducible and valid outcome measures could provide more insight in this field.

Table 30. Summary of findings on maternal and infant health outcomes for trial of labor and body mass index

Author, Year	N/ Country/GA	Maternal Outcomes BMI Between Group Comparisons	Finding	Infant Outcomes BMI Between Group Comparisons	Finding
Bujold, 2005 ²⁶⁷	8580 Germany Term	UR separation Wound healing 3 rd & 4 th degree laceration Hemorrhage Fever Hysterectomy	NS S+ S - NS S+ NS	Death Resuscitation GA Weight*** Weight >4000g Apgar <7 Apgar 5 min, <7 Apgar 5 min, <4	NS S + S - S S + NS S + NS
Carroll, 2003 ²⁶⁸	138 U.S. NR; all	Maternal hospital stay Endometritis or wound infection Blood loss	S + S + NS	GA Weight	NS NS
Goodall, 2005 ¹²⁶	725 U.S. ≥36 wks	Infection Induction	NS S +	GA (<41 wks) GA (>41 wks) Weight <3500g Weight 3500-3999g** Weight >4000g Apgar, 1 minute <7 Apgar, 5 minute	S - S + S - S S + NS NS
Juhasz, 2005 ¹³⁵	709 U.S. ≥36 wks	UR/layers of closure* One-layer closure Pregnancy complications	S + / NS NS S +	GA Weight*** Weight > 4000g	NS S + NS
Hibbard, 2006 ⁷⁸ NICHHD MFMUN	14,142 TOL 14,304 ERCD U.S. >37 wks	UR Dehiscence UR/dehiscence combined Surgical injury Wound complications Endometritis Transfusion Maternal hospital stay Hysterectomy Thromboembolism	NS NS S + NS S + S + NS NS S + NS NS NS	Stillbirth/abortion/neonatal death @ NICU admission GA \$\$ Weight & Apgar 5 min, ≤ 7 Apgar 5 min, ≤ 3 Injury Sepsis	NS; p=.14 S+ S + S+ S - NS NS NS

Table 30. Summary of findings on maternal and infant health outcomes for trial of labor and body mass index

Author, Year	N/ Country/GA	Maternal Outcomes BMI Between Group Comparisons	Finding	Infant Outcomes BMI Between Group Comparisons	Finding
Chauhan, 2001 ²⁴⁰	69 U.S. NR; all	Endometritis Wound infection Pfannensteil skin incision Maternal hospital stay Operating room time	S 30 percent S 23 percent S 46 percent NS 5.4 +/-3.4 NS 61 +/- 21	Cord pH	NS 7.2 +/- 0.07

Statistical significance key:

NS= not significant

S+ = significant (greater adverse outcome in higher or highest BMI category)

S - = significant (less adverse outcome in higher or highest BMI category)

S = direction or association not clear, additional interpretation needed.

* 4 BMI categories; UR greatest in 3rd category, overweight (BMI 26.1-29); when controlling for number of layers of closure (single layer being associated with UR), it became NS

** 4 BMI categories; weight greatest in 3rd category, obese (BMI 30-39.9): OR 2.34 (1.47-3.73)

*** greater infant weight in higher BMI categories

@ 4 BMI categories; greatest in 4th category, morbidly obese (BMI >40); (0.5 percent vs. 0.2, 0.3, and 0.3 in other 3 categories)

& 4 BMI categories; increasing from category 1, greatest in 4th category, morbidly obese (BMI >40)

\$\$ 4 BMI categories; older GA in 3rd and 4th obesity category, compared with 1st and 2nd:

GA data: a) 18.5-24.9: 39.3 +/- 1.2; b) 25.0-29.9: 39.5 +/- 1.2; c) 30-39.9: 39.7 +/- 1/2; d) >40: 39.7 +/- 1/3

p < .001

Abbreviations: BMI=body mass index; GA=gestational age; NA=not applicable; NR=not reported; UR=uterine rupture; U.S.=United States; wk(s)=week(s);

Effects of management of trial of labor using a protocol on maternal outcomes. In a small cohort study examining the impact of using a strict protocol for managing a trial of labor in 841 women with prior cesarean delivery compared with 467 women undergoing ERCD maternal harms were evaluated.⁹¹ The rate of major complications (uterine rupture, hysterectomy, relaparotomy, operative injury, or greater than two units of blood transfused) was not statistically significantly different between the TOL and ERCD groups (1.8 versus 1.3 percent, $p=0.50$).

Adhesions

One concerning complication from multiple cesarean deliveries is increased complications from adhesive disease. This may result in a more difficult RCD, increased postoperative complications, or increased complications with future gynecological surgeries. Studies looking at adhesions are limited. One study described increased adhesions with increased number of cesarean deliveries at the time of cesarean.²³⁵ Another study found increased perioperative complications with vaginal hysterectomy to be associated with women who underwent one or more cesarean in the past (frequency 18.31 versus 3.58 percent, $p<0.0001$). Specifically, in women with a history of cesarean, there was a 5.63 percent rate of bladder injuries compared with 0.89 percent in women without cesarean delivery ($p=0.01$). A history of cesarean was also associated with increased need for adhesiolysis, intestinal injuries, and longer operating time, but none of these factors were significant. This study did not delineate one versus multiple cesareans, however, and did not evaluate patients with a history of VBAC.²⁷²

A similar study evaluating factors relating to complications during hysterectomy found a history of cesarean delivery to be significantly associated with an increase in complications. Again, however, this study did not evaluate multiple cesareans or VBAC separately.²⁷³ Another study evaluated the benefit of closing the peritoneum at the time of initial cesarean to decrease the incidence of adhesions in future cesareans. This study found a statistically significant increase in the number of patients with severe adhesive disease in those without peritoneal closure compared with those who had closure at the time of RCD. (6 versus 42 percent, $p=0.003$) This study did not report the rate of severe adhesions in those patients undergoing multiple RCDs; however it does provide evidence that even one cesarean can result in significant adhesions. The presence of adhesions can result in complications with subsequent cesareans.²⁷⁴ This finding was supported by a Canadian study evaluating the presence of adhesions in subsequent cesarean. This study found a dose dependent relationship with the prevalence of adhesions with the number of cesareans, from 0 percent at primary cesarean delivery to 47.9 percent at the fourth cesarean.²⁷⁵ In addition, this study found a statistical increase in both delivery time as well as total operative time for deliveries complicated by adhesions compared with those without adhesions. Operative and delivery times did not increase however with increasing number of cesareans.²⁷⁵

One study evaluating the incidence of postoperative small bowel obstruction, thought to be associated with increased adhesive disease, found a smaller rate of obstruction in the cesarean delivery group than among those with hysterectomy, adnexal surgery, or myomectomy (0.05 percent versus 1.63, 0.87, and 0.39 percent; $p<0.001$).²⁷⁶

Reproductive Health

Several studies have attempted to define the impact of cesarean delivery on overall reproductive health. One of the important factors emphasized by clinicians is the ultimate family

plan of patients, due to the increased risk perceived with multiple cesareans. However, there is also a concern for impaired fertility due to surgery on the uterus. However, this is not well studied with only two studies evaluating impaired fertility. One study of fair quality looking at future pregnancies after vaginal delivery, operative vaginal delivery, and cesarean found there to be a statistically significant difference in the ability to conceive in subjects undergoing a cesarean compared with those who underwent an instrumented vaginal delivery (odds ratio 0.33; 95 percent CI: 0.12 to 0.98). This study however, did not distinguish between VBAC and primary deliveries in the cohort.²⁷⁷ The second study of fair quality found a history of cesarean associated with an increased odds of taking greater than one year to conceive after adjusting for confounders including maternal and paternal age, demographics, and BMI (odds ratio 1.53; 95 percent CI: 1.09 to 2.14). Though this study did not evaluate VBAC or multiple cesareans separately, there was an increased risk of delayed fertility with increasing parity, suggesting a continued effect of at least one cesarean (odds ratio 2.97; 95 percent CI: 1.72 to 5.10).²⁷⁸

One case-control study found an increased odds ratio of multiple cesarean deliveries (greater than or equal to two priors) compared with no pelvic surgery in women with early menopause (odds ratio 2.69; 95 percent CI: 1.16 to 6.22) This study however, did not evaluate VBAC and this association was not evaluated in a multivariate model.²⁷⁹ No studies evaluated TOL and/or RCD with respect to pelvic pain, risk of ectopic pregnancy, and general health risks, such as diabetes or high blood pressure.

What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?

This section reviews the infant benefits and harms associated with VBAC compared with ERCD. The goal of this endeavor is not only to describe the current knowledge of risks of each type of delivery, but to highlight important gaps in the literature. As part of this report, the following outcomes were examined: perinatal mortality, respiratory conditions, hypoxic ischemic encephalopathy (HIE)/Asphyxia, Sepsis, Birth Trauma, Apgar scores, NICU admissions, and breastfeeding. In addition factors that may modify the outcomes associated with mode of delivery such as induction of labor, fetal macrosomia and fetal presentation are also discussed.

Perinatal and fetal mortality studies were open to all gestational ages but excluded studies that did not specifically exclude infants with known congenital or lethal anomalies.

Perinatal Mortality

The definitions accepted by the National Center for Vital Statistics⁶³ were used to review and describe the data relating to perinatal mortality and the subsets of fetal and neonatal mortality in women with a prior cesarean delivery. The definition of perinatal mortality (perinatal II) included infants less than 28 days of age and fetal deaths of 20 weeks or more gestation. To study the frequency of stillbirth (antepartum and intrapartum) we used both the intermediate (20 to 27 weeks gestation) and late (28 weeks or greater gestation) fetal definitions of fetal death in an attempt to capture the most studies and allow comparisons to national statistics for the general population. Studies that reported fetal loss less than 20 weeks gestation or less than 500 grams were not included in the review. Neonatal (infant) mortality was defined as death in the first 28

days of life.⁶³ . To reduce the effects of prematurity on the neonatal mortality rate, we limited our analyses of neonatal mortality to term infants. Two studies,^{280, 281} which focused specifically on the risk of a stillbirth in a subsequent pregnancy after prior cesarean delivery (irrespective of mode of delivery in the next pregnancy), were included and are discussed in the section of long-term outcomes and the impact of the mode of delivery on subsequent pregnancies. Eight cohort studies of good or fair quality and reporting data on mortality using at least one of these definitions of mortality are included.^{79, 93, 103, 204, 228, 282-284}

Perinatal morality rate. The U.S. perinatal mortality rate (PMR) for infants 28 weeks gestation to less than 7 days of life was reported to be 0.66 percent for the year 2005, but notably does not exclude infants with congenital anomalies.⁶³ Five good or fair quality cohort studies, involving 76,899 infants reported perinatal mortality associated with TOL and ERCD (Table 31).^{103, 204, 228, 282, 284} The definition of perinatal mortality among the five studies included fetal and neonatal deaths up to 28 days of life. Perinatal mortality was also used to categorize studies if it was unclear if the death occurred during labor or after delivery.²⁸⁴ All five studies focused exclusively on women delivering at term. Three of the studies occurred in tertiary or university settings^{204, 228, 284} and two utilized population databases.^{103, 282}

There were 72 perinatal deaths/41,213 births in women having a TOL. The combined PMR for women undergoing a TOL was 0.13 percent (95 percent CI: 0.06 to 0.3 percent), translating to 1.3 per 1,000 (95 percent CI: 0.6 to 3 per 1,000). There were 46 perinatal deaths/35,686 births for women undergoing an ERCD. The combined PMR for ERCD was 0.05 percent (95 percent CI: 0.007 to 0.38 percent) this translates to 0.5 per 1,000 (95 percent CI: 0.07 to 3.8 per 1,000 (Figure 27)). The risk of perinatal mortality was significantly higher for TOL as compared with ERCD (RR 1.82; 95 percent CI: 1.24 to 2.67; p=0.041). Using 0.05 percent as the baseline risk for ERCD, the calculated risk difference was 0.41 percent (95 percent CI: 0.012 to 0.08 percent) which is equivalent to .41 more deaths among women who attempt TOL. One study²⁰⁴ examined the influence of labor and underlying maternal medical complications (indications) upon perinatal mortality. The PMR was higher among women with underlying medical conditions (indications) with and without labor compared with women without indications. Interestingly, the impact of labor upon perinatal mortality appeared to differ based upon indication status with PMR being higher among the labor group for women without indications (0.22 percent labored versus 0.12 percent no labor) and lower for the labor group for women without indications (0.19 percent labor versus 0.34 percent no labor).²⁰⁴


Table 31. Perinatal mortality rate (20 weeks or greater gestation to 7 days of life) among any gestational age studies

Study, Year	Study Description	Years of Study	N	Comparison	Number of Perinatal Deaths		
					PMR* TOL	PMR* IRCD	PMR* ERCD
Bujold, 2005 ²⁸²	Retrospective cohort, Perinatal Database, Germany	1991-1997	8580 Term infants	TOL versus ERCD	4/6,718 (0.6/1,000) 0.06%		2/1,862 (1.1/1,000) 0.11%
Richardson, 2005 ²⁸⁴	Retrospective cohort Administrative database; 1 tertiary hospital in Canada	1992-2002	3,489 Term infants	TOL versus no labor	3/2,646 (1.1/1,000) 0.11%		0/843 (0/1,000)
Sibony, 2006 ²²⁸	Retrospective cohort; University hospital France	1996-2003	1190 Term infants	TOL versus ERCD	1/1,015 (0.9/1,000) 0.10%		0/175 (0/1,000)
Smith, 2002 ¹⁰³	Population-based retrospective cohort Administrative Database Scotland	1992-1997	24,529 Term infants	TOL versus ERCD	20/15,515 (1.3/1,000) 0.13%		1/9,014 (1.1/1,000) 0.01%
Spong, 2007 ²⁰⁴	Prospective cohort, MFMU Network	1999-2002	39,111 Term infants	TOL versus ERCD with labor TOL versus ERCD (without labor)	44/15,319 (2.9/1,000) 0.29%	Labor: 2/1,077 (1.9/1,000) 0.19% No labor: 17/5,002 (3.4/1,000) 0.34%	All: 43/23,792 (1.8/1,000) 0.18% Labor: 6/2,721 (2.2/1,000) 0.22% No labor: 18/14,992 (1.2/1,000) 0.12%

*Number of deaths per 1,000

Abbreviations: ERCD=elective repeat cesarean delivery; IRCD=indicated repeat cesarean delivery; PMR=perinatal mortality rate; TOL=trial of labor

Figure 27. Perinatal mortality rate for trial of labor versus elective repeat cesarean delivery among all studies



Fetal mortality rate. The fetal mortality rate (FMR; 20 weeks gestation to birth) in the U.S. for the year 2005 was 0.622 percent of live births, leveling off in 2004 (0.620 percent of live births) after two decades of decline from a rate of 0.783 percent of live births.⁶³ To understand the relationship of a prior cesarean delivery on fetal mortality (antepartum and intrapartum death) in women who undergo a TOL versus an ERCD, two good quality studies of women at term^{103, 204} met the inclusion criteria and were reviewed. One study used a retrospective cohort from an administrative database,¹⁰³ while the other used a prospective cohort design.²⁰⁴ The studies also differed in that one study¹⁰³ excluded fetal death prior to the onset of labor. Neither study limited their analyses by number or direction of uterine scar. Overall, the FMR was low in women attempting a TOL in both studies. When comparing only intrapartum stillbirth, the rates of intrapartum fetal demise (IUFD) ranged from 0.01 to 0.04 percent of live births in women attempting a TOL to 0 to 0.004 percent for women having an ERCD. Additionally, Spong (2007) measured antepartum stillbirth and found a rate of 0.21 percent in women undergoing a TOL versus 0.1 percent in women having an ERCD (Table 32).²⁰⁴

Table 32. Fetal mortality rate (20 weeks or greater gestation and before birth) among term studies

Study, Year	Study Description	Years of Study	N	Comparison	Number of Fetal Deaths			Total FMR* CD
					FMR* TOL	FMR* IRCD	FMR* ERCD	
Smith, 2002 ¹⁰³	Population-based retrospective cohort Administrative Database Scotland	1992-1997	24,529 (Intrapartum data only) Term infants	TOL versus ERCD	Intrapartum only stillbirth: 7/15,515 (0.5/1,000) 0.04%		Intrapartum stillbirth only: 0/9,014 (0/1000)	
Spong, 2007 ²⁰⁴	Prospective cohort, MFMU Network	1999-2002	39,111 Term infants	1. TOL versus ERCD with labor 2. TOL versus ERCD (without labor)	Antepartum/ Intrapartum: 32/15,319 (2.3/1,000) 0.21% Intrapartum-only: 2/15,319 (0.13/1,000) 0.01%	Labor: 1.1/1,077 (1.8/1,000) 0.10% No labor: 2.7/5,002 (1.3/1,000) 0.05%	1.3/2,721 (1.1/1,000) 0.05% 212/14,992 (0.8/1,000) 1.4%	23/23,792 (1/1,000) 0.1% Intrapartum-only: 1/23,792 (0.04/1,000) 0.004%

*Number of deaths per 1,000

Abbreviations: ERCD=elective repeat cesarean delivery; FMR=fetal mortality rate; IRCD=indicated repeat cesarean delivery; MFMU=Maternal Fetal Medicine Units Network; TOL=trial of labor

Neonatal morality rate. Six good or fair quality cohort studies reported on the neonatal mortality rate (NMR) in women undergoing a TOL versus an ERCD (Table 33).^{79, 93, 103, 204, 228, 283} There was a wide range of hospital settings among the six studies, with two studies representative of academic medical centers,^{204, 228} two studies representative of population databases,^{92, 103} and two studies representative of a diversity of hospital types.^{79, 283} Overall, the neonatal mortality rate for TOL was low with a total of 51 neonatal deaths in a total of 44,485 subjects, for a combined NMR of 0.11 percent (95 percent CI: 0.06 to 0.2 percent). A total of 40 neonatal deaths occurred in 63,843 women who had either an IRCD or ERCD for a combined NMR of 0.6 percent (95 percent CI: 0.02 to 0.15 percent) in the cesarean delivery group (Figure 28). The risk of neonatal mortality was significantly higher for TOL compared with ERCD with a calculated risk difference of 0.058 percent (95 percent CI 0.019 to 0.117 percent), which is equivalent to .58 additional perinatal deaths per 1,000 for TOL.

Two studies provided insight into classifications of patients who appeared to have higher NMRs when compared with subgroups.^{93, 204} In women who were classified as having high-risk conditions,⁹³ the NMR in the TOL group was 0.38 percent compared with women without high-risk maternal conditions undergoing a TOL (0.13 percent) and women undergoing ERCD (high-risk women: 0.1 percent NMR; no high-risk condition: 0.05 percent NMR). In another study representing the MFMU cohort, Spong et al classified cesarean delivery by IRCD (labor versus no labor) and ERCD (labor versus no labor). In this individual study, the NMR was highest in the IRCD (no labor) at 0.2 percent.²⁰⁴ Overall, there was no difference in the TOL NMR (0.08 percent) versus overall cesarean delivery group NMR (0.08 percent).

While overall rates of perinatal mortality are lower in the reviewed studies in comparison with U.S. data for the general population, a noticeable pattern is the association between country of origin and perinatal death. The three studies conducted in the U.S.^{79, 93, 204} reported higher perinatal, fetal, and neonatal mortality, particularly among TOL patients, compared with studies conducted outside of the U.S. The U.S. does have a higher infant mortality rate compared with either the United Kingdom or Canada (0.626 percent, 0.504 percent and 0.485 percent, respectively).²⁸⁵ The studies do not consistently provide details about demographic, societal, or health systems issues to explore the potential contributors.

Table 33. Neonatal mortality rate (death occurring in the first 28 days of life) among term studies

Study, Year	Study Description	Years of Study	N	Comparison	Number of Neonatal Deaths		
					NMR* TOL	NMR* IRCD	NMR* ERCD
Gregory, 2008 ⁹³	Population-based, retrospective cohort Administrative Database, CA state, U.S.	2002	41,450 Term infants	TOL versus ERCD High-risk condition No high-risk condition	TOL any high-risk condition; 12/3,188 (3.8/1,000) 0.38% TOL no high-risk condition: 11/8,292 (1.3/1,000) 0.13% All TOL: 23/11,480 (2/1,000) 0.20%		ERCD any high-risk condition: 9/9,136 (1/1,000) 0.10% ERCD: no high-risk condition: 10/20,834 (0.5/1,000) 0.05% All ERCD: 19/29,970 (0.6/1,000) 0.06%
Hook, 1997 ⁷⁹	Prospective cohort of 3 U.S. hospitals in Ohio, U.S. (levels 1,2,3; teaching)	1992-1993	989 Term infants	TOL versus ERCD	1/492 (2/1,000) 0.20%		0/497 (0/1,000)
Paterson, 1991 ²⁸³	Retrospective cohort of 17 hospitals Administrative database for NW Thames, UK	1988	1,059 Term infants	TOL versus ERCD	1/664 (1.5/1000) 0.15%		0/395 (0/1,000)
Sibony, 2006 ²²⁸	Retrospective cohort; University hospital France	1996-2003	1190	TOL versus ERCD	1/1,015 (0.9/1,000) 0.09%		0/175 (0/1,000)
Smith, 2002 ¹⁰³	Population-based retrospective cohort Administrative Database Scotland	1992-1997	24,529	TOL versus ERCD	13/15,515 (0.8/1,000) 0.08%		1/9,014 (0.1/1,000) 0.01%


Table 33. Neonatal mortality rate (death occurring in the first 28 days of life) among term studies

Study, Year	Study Description	Years of Study	N	Comparison	Number of Neonatal Deaths		
					NMR* TOL	NMR* IRCD	NMR* ERCD
Spong, 2007 ²⁰⁴	Prospective cohort, MFMU Network	1999-2002	39,111	TOL versus ERCD 1. With labor 2. Without labor	12/15,319 (0.8/1,000) 0.08%	1.1/1,077 (0.9/1,000) 0.09% 2.10/5,002 (2/1,000) 0.2%	3/2,721 (1.1/1,000) 0.11% 6/14,992 (0.4/1,000) 0.04% Total CD: 20/23,792 (0.8/1,000) 0.08%

*Number of deaths per 1,000

Abbreviations: CA=California; CD=cesarean delivery; ERCD=elective repeat cesarean delivery; IRCD=indicated repeat cesarean delivery; MFMU=maternal-Fetal Medicine Units Network; NMR=neonatal mortality rate; TOL=trial of labor; NW=Northwest; UK=United Kingdom; U.S.=United States

Figure 28. Neonatal mortality rate for trial of labor versus elective repeat cesarean delivery among term studies



Summary and strength of the evidence on perinatal death. Overall, the strength of evidence on perinatal mortality was low to moderate. The perinatal, fetal, and neonatal mortality rates reported were low, especially when compared with U.S. perinatal statistics from the CDC. However, CDC perinatal mortality data do not exclude congenital anomalies. While overall, perinatal, fetal, and neonatal mortality rates are low in women with a history of prior cesarean delivery, the death rates are significantly higher in women who attempt a TOL versus ERCD. Women with high-risk conditions and IRCD appear to have higher rates of neonatal mortality.

Infant Morbidity

Because of the association between infant outcomes and prematurity, studies of neonatal morbidity were limited to term neonates and included 11 studies of good or fair quality.^{79, 80, 90, 93, 97, 103, 156, 204, 283, 284, 286}

Respiratory conditions. Respiratory disorders in newborns are common and account for the majority of admissions to the neonatal intensive care unit (NICU) in the immediate newborn period.²⁸⁷ While generally considered an intermediate outcome, the need and level of required respiratory support at birth is an outcome of clinical, parental, and economic interest. Respiratory morbidity can occur regardless of mode of delivery, making conclusions about the relationship to the method of labor and delivery unclear. Determining which respiratory indicators are most representative of morbidity as well as disagreement about the definitions creates further challenges.

While respiratory distress syndrome (RDS) is primarily a disease of prematurity, term neonates can experience respiratory issues at or immediately following birth. Comparisons of studies are challenged by: (a) lack of standardized or mutual agreement on definitions of respiratory conditions; (b) lack of clarity regarding the importance and clinical significance of measures; (c) differences in birth settings; and (d) experience and skill level of available providers and staff. It is also worthwhile to note that significant practice changes have occurred over the course of the past several decades (e.g., the revised approaches to suctioning of an infant with meconium-stained amniotic fluid). These changes make it difficult to draw meaningful conclusions about measurements such as the presence of a pediatrician at delivery or the frequency of intubation for meconium without specific information about the measurement, context, and terminal measure of intermediate variables.

Six term fair quality cohort studies^{79, 90, 93, 97, 284, 286} reported an array of respiratory symptoms and interventions in the neonates of women who underwent TOL after cesarean delivery versus ERCD. Several studies made direct comparisons challenging in that the authors grouped respiratory symptoms or disorders together.^{90, 93, 97} Studies that measured the frequency of transient tachypnea of the newborn (TTN), bag-and-mask ventilation, intubation for meconium and ventilation in infants born after a TOL versus ERCD are found in Table 34.


Table 34. Comparison of cohort studies reporting respiratory morbidity in infants among term studies

Study, year	Setting	TOL/ERCD	Measure	Findings	Significance
Fisler, 2003 ⁹⁰	University hospital	TOL (N=313) ERCD (N=136)	TTN	TOL: 8.1% ERCD: 4.5%	p=0.10
			Bag-and-mask ventilation	TOL: 5.8% ERCD: 2.2%	p=0.10
			Intubation for meconium	TOL: 11.5% ERCD: 1.5%	p≤0.001
Hook, 1997 ⁷⁹	Hospital levels 1, 2, 3	TOL (N=492) ERCD (N=497)	TTN	TOL: 3% ERCD: 6%	p<0.05
			Bag-and-mask ventilation	TOL: 7% ERCD: 2%	p≤0.001
			Intubation for meconium	TOL: 11.5% ERCD: 1.5%	p≤0.001
			Intubation for ventilation	TOL: 2% ERCD: 0.4%	p≤0.001
			Meconium aspiration syndrome	TOL: 1% ERCD: 0.2%	Not significant
Kamath, 2009 ²⁸⁶	University Hospital	TOL (N=329) ERCD (N=343) (3.labor/4.no labor)	Bag-and-mask ventilation	TOL: 3.34% ERCD: 2.33%	Not reported
			Intubation (reason unspecified)	TOL: 2.43% ERCD: 0.583%	Not reported
Richardson, 2005 ²⁸⁴	Tertiary care facility	TOL (N=2646) ERCD (no labor) (N=843)	TTN	TOL: 1.3% ERCD: 2.4%	p<0.02

Abbreviations: ERCD=elective repeat cesarean delivery; TOL=trial of labor; TTN=transient tachypnea of the newborn


Three studies^{79, 90, 286} compared the frequency of bag-and-mask ventilation in the infant when women underwent TOL versus ERCD (Figure 29). The summary estimate of rates for infants needing bag-and-mask ventilation for TOL was 5.4 percent (95 percent CI: 3.5 to 7.6 percent) while the rate for ERCD was 2.5 percent (95 percent CI: 1.6 to 3.6 percent). Infants in the TOL group were significantly more likely to receive bag-and-mask ventilation with a pooled RD for TOL versus ERCD of 2.5 percent (95 percent CI: 0.72 to 5.0 percent.). The I^2 statistic for heterogeneity was 42.9 percent (between study heterogeneity accounts for 42.9 percent of the total heterogeneity). The Q -statistic for heterogeneity was 3.5 (p=0.1736).

Figure 29. Need for bag-and-mask resuscitation among term studies



Three studies reported rates of TTN (Figure 30).^{79, 90, 284} There was significant heterogeneity among the three studies with a Q -statistic of 6.05 $p=0.0485$ and I^2 of 67 percent (indicating the between-study heterogeneity accounts for 67 percent of the total heterogeneity). The pooled absolute risk for TTN in the TOL group was 3.6 percent (95 percent CI: 0.9 to 8.0 percent) and 4.2 percent (95 percent CI: 1.9 to 7.3 percent) for ERCD. There was no statistically significant difference between the risk in the two groups using a random effects model with a pooled RD of -0.83 percent (95 percent CI: -3.35 to 1.7 percent) for TOL versus ERCD.

Figure 30. Rates of transient tachypnea of the newborn for trial of labor versus elective repeat cesarean delivery among term studies



Only two studies^{79, 90} measured respiratory care of the infant with meconium-stained amniotic fluid. While one study⁹⁰ measured intubation for meconium, Hook et al⁷⁹ measured meconium aspiration syndrome. Both studies found respiratory care due to meconium-stained amniotic fluid to be greater in infants undergoing a TOL versus ERCD (Table 34).

One study examined respiratory morbidity occurring in infants born by planned and actual route of delivery (e.g., ERCD with and without labor, VBAC, and TOL resulting in RCD).²⁸⁶ This study found infants born after a TOL resulting in CD required the most bag-and-mask ventilation and intubation, while infants born by ERCD (with or without no labor) required the most oxygen therapy (blow-by oxygen, continuous positive airway pressure).²⁸⁶

Ultimately, there were very few studies that reported on respiratory outcomes for term infants born by VBAC or ERCD. While infants born after a TOL were more likely to require bag-and-mask ventilation compared with infants born by ERCD, other respiratory outcomes revealed no differences between routes of delivery. The fact that there are so few studies that measure respiratory outcomes for term infants is an important issue as respiratory outcomes are very important to clinicians and patients.

Summary and strength of the evidence on infant respiratory morbidity. The strength of evidence on the respiratory morbidity of the infant for VBAC versus ERCD was low due to lack of precision in estimates and inconsistency in findings. Respiratory distress syndrome was not included in this review of the literature because RDS is primarily a disease of prematurity and

neonatal outcomes were primarily focused on term neonates to reduce the confounding by prematurity. Studies were conflicting regarding whether VBAC or ERCD resulted in more TTN. Two studies found significantly more infants required intubation for meconium in infants undergoing TOL versus ERCD. is a general lack of consensus among studies regarding what types of respiratory indicators are most representative of health or morbidity.

Hypoxic-ischemic encephalopathy/asphyxia. Hypoxic ischemic encephalopathy (HIE), neonatal encephalopathy, asphyxia, perinatal asphyxia, and hypoxia are terms used in the literature to describe a potentially serious neonatal complications. These descriptors attempt to link a hypoxic event during birth to intermediate and/or long-term neonatal outcomes. Several challenges exist in trying to capture the frequency and severity of such an outcome including lack of agreement regarding definition, timing, and measurement. Proposed criteria to define an acute intrapartum hypoxic event as sufficient to cause a long-term outcome such as cerebral palsy have been advanced by ACOG and the International Cerebral Palsy Task Force.²⁸⁸ The presence of four essential criteria have been proposed in order to link an intrapartum hypoxic-ischemic insult causing a moderate to severe neonatal encephalopathy resulting in cerebral palsy: 1) evidence of metabolic acidosis in fetal umbilical cord arterial blood obtained at delivery (pH less than 7 and base deficit of 12 mmol/L or more), 2) early onset of severe or moderate neonatal encephalopathy in infants born at 34 or more weeks' gestation, 3) cerebral palsy of the spastic quadriplegic or dyskinetic type, and 4) exclusion of other identifiable etiologies, such as trauma, coagulation disorders, infectious conditions, or genetic disorders.²⁸⁸

Three fair quality cohort studies attempted to measure this phenomenon in some manner.^{80, 93, 284} Gregory et al, in a large, population-based study, measured the frequency of hypoxia (by ICD-9 codes) in high- and low-risk women who underwent TOL and ERCD at term.⁹³ High-risk antepartum conditions contributing to neonatal hypoxia in women with a prior cesarean delivery were antepartum bleeding (odds ratio 2.9; 95 percent CI: 1.3 to 6.6) and oligohydramnios (odds ratio 2.5; 95 percent CI: 1.1 to 5.7). Overall, there was little difference in the frequency of hypoxic events (defined by ICD 9 category codes 768.0,1,2,3,4,5,6,9) in infants born to mothers with no high-risk clinical condition (TOL: 0.89 percent, ERCD: 0.32 percent) versus infants whose mothers had any number of high-risk clinical conditions (TOL: 1.29 percent versus ERCD: 0.20 percent). Landon et al, as part of the MFMU cohort, measured but did not offer a definition of HIE.⁸⁰ This study did not find the frequency of HIE to be significantly different in term women with one prior cesarean delivery compared with those with multiple prior cesarean deliveries (0.1 percent versus 0, p=1.0) or when comparing TOL versus ERCD in women with multiple prior cesarean deliveries (0 versus 0). Richardson et al used a very different approach from either of the other two and measured and reported on umbilical cord pH.²⁸⁴ This study found a slight decrease in the mean cord pH of women undergoing a TOL versus women who had an ERCD with no labor (7.24±0.07 versus 7.27±0.05, p< 0.001). There was a statistically significant difference in base excess in the TOL versus ERCD group (-5.3mmol/L ±3.1 versus -2.9mmol/L±2.5, p< 0.001). There were no significant differences in infants with umbilical artery pH of less than 7.00 in the same groups (TOL: 0.5 percent versus ERCD without labor: 0.1 percent, p=NS).

Summary and strength of the evidence on infant respiratory morbidity The strength of evidence on the HIE of the infant for VBAC versus ERCD was low due to lack of consistency in measurement and few studies. While the studies consistently report higher risk for HIE for TOL compared with ERCD, it is not possible to know the true relationship due to the low strength of overall evidence.

Sepsis

Three fair quality cohort studies were found to address sepsis in the neonates of women who attempted a VBAC versus ERCD.^{79, 90, 97} Fisler et al found that neonates in a university setting who had a TOL had significantly more sepsis evaluations than did infants who underwent ERCD (23.3 versus 12.5 percent, $p=0.0008$) and significantly more antibiotic treatments (11.5 versus 4.4 percent, $p=0.02$).⁹⁰ The absence of predefined criteria for a sepsis evaluation and subsequent antibiotic therapy make interpretation of these results difficult. However, the impact of these interventions are not insignificant as the authors note that an evaluation for sepsis consisted of a complete blood count, blood culture, with lumbar puncture performed at the discretion of the practitioner. Sub analysis of the TOL neonates found increased sepsis evaluations and antibiotic therapy in the TOL group with an epidural compared with TOL neonates without an epidural (29.6 versus 6.0 percent, $p=0.0001$). Loebel et al also measured “suspected” sepsis, but found no significant differences in neonates born after a TOL versus those delivered by ERCD (3.5 versus 2.7 percent, $p=0.38$).⁹⁷

Hook et al similarly reported the incidence of sepsis in neonates who underwent TOL versus those delivered by ERCD. This study was unique in that it was conducted in three hospital settings (Level 1, 2, and 3) and measured the incidence of proven sepsis as well as suspected sepsis.⁷⁹ While suspected sepsis was significantly increased for neonates born by VBAC compared with infants born after a TOL who then delivered by cesarean (12 versus 2 percent, $p=0.001$), there were no statistically significant differences between these groups when the outcome was “proven sepsis” (three infants [two percent] versus one infant [0.3 percent], $p=NS$). Infants without “proven sepsis” still received blood cultures and antibiotic therapy, but were not considered proven to be septic unless a positive blood culture was obtained.

Summary and strength of the evidence on sepsis The overall strength of evidence for the impact of route of delivery upon infant sepsis is low due to imprecise and inconsistent definitions and few studies. While existing studies suggest that there is no significant difference between TOL and ERCD, serious limitations prevent a true understanding of the relationship between route of delivery and sepsis.

Birth Trauma

Two fair quality studies^{90, 93} provided information regarding neonatal trauma. In a large, population based study, Gregory et al found the frequency of trauma to be higher in women who attempted VBAC versus ERCD, regardless of whether the mother had a high-risk clinical condition (3.73 percent attempted VBAC versus 0.77 percent ERCD).⁹³ Subanalyses found that among women who attempt VBAC those with a history of substance abuse were more likely to have neonatal trauma (odds ratio 4.4; 95 percent CI: 1.1 to 18.2) as were those with ruptured membranes longer than 24 hours (odds ratio 4.2; 95 percent CI: 1.7 to 10.2). This study used ICD-9 codes to define trauma (763.1,2,3,4; 7.67.2,3,4,5,6,7,8,9). These codes represented fetal malpositions and varying types of delivery affecting the fetus, as well as skeletal, nerve, and cranial injuries.

In a prospective cohort study comparing neonatal outcome in low-risk women at term undergoing a TOL and low-risk women at term electing a RCD, Fisler et al measured mild bruising (defined as bruising confined to a single extremity) as well as birth injury (not defined).⁹⁰ There was a significant increase in the number of infants who had mild bruising in the TOL group compared with the ERCD group (TOL: 8 percent versus ERCD: 1.5 percent,

p=0.0008); however no statistically significant differences were noted between TOL versus ERCD for birth injury (TOL: 1 percent versus ERCD: 1.5 percent, p=0.6). In this study, birth injury was not defined, but the authors noted three infants in the TOL group had cephalohematoma, while two infants in the ERCD group (no labor; scheduled repeat cesarean delivery group) experienced facial nerve palsy.

Summary and strength of evidence on birth trauma The overall strength of evidence for the impact of route of delivery on birth trauma is low largely due to few studies. While existing studies suggest that there a nonsignificant increase in birth trauma for TOL, serious limitations prevent a true understanding of the risk of birth trauma for VBAC compared with ERCD.

Apgar Scores

While Apgar scores suffer from subjectivity and have little long-term predictive value, it is an established and accepted part of the neonatal assessment at the time of delivery. Four good or fair quality cohort studies^{79, 90, 103, 284} all reported no significant difference in 5 minute Apgar scores between infants in TOL groups versus infants in ERCD groups.

Hook et al found no significant differences in an Apgar score of six or less at 5 minutes in infants who underwent a TOL (6/492, 1 percent) versus ERCD (3/497, 1 percent).⁷⁹ Closer examination of the TOL group found significantly fewer neonates had an Apgar score of six or less at 5 minutes if they underwent a VBAC versus when the TOL resulted in a cesarean delivery (26/336, 8 percent versus 22/156, 14 percent, p<0.05). In a fair quality study, Richardson et al similarly found no significant differences in an Apgar score less than seven at 5 minutes in women who underwent a TOL after cesarean delivery versus those who underwent an ERCD (odds ratio 0.5; CI 95 percent 0.2 to 1.2. p= NS).²⁸⁴ However, in a smaller retrospective cohort, fair quality study, Fisler et al found no significant difference in neonates with an Apgar score of less than seven at 5 minutes between neonates who underwent a TOL (regardless of whether they had a VBAC) versus ERCD (1 percent versus 0, p=0.06).⁹⁰ Smith et al, in a large, fair quality population study, found that while the overall incidence of very low Apgar (less than four) at 5 minutes was rare, it occurred more frequently in infants who underwent a TOL (than among those who were delivered by an ERCD (105/15,515 [0.68 percent] versus 40/9014 [0.44 percent] p=0.02).¹⁰³

Summary and strength of evidence on birth trauma. Four studies found no differences in Apgar scores of less than six and seven at 5 minutes in infants undergoing a TOL versus ERCD. Three studies examined the differences in low Apgars (less than seven) at 5 minutes in VBAC versus RCD after a TOL; two of these studies found no difference in Apgar scores of infants born by VBAC versus RCD after a TOL. Future studies that include Apgar score results in their measures of morbidity could be improved by further followup of infants with low Apgar scores as an Apgar score is an intermediate measure of infant health, as well as close attention to classification of exposure to labor and delivery outcome.

Neonatal Intensive Care Unit Admissions

Admission to the NICU is a frequently measured short-term neonatal outcome and has been used as a proxy for serious morbidity. The significance of admission to the NICU can vary by hospital setting, provider experience, provider availability, and pre-established admission criteria. The amount of time a neonate spends in a NICU can vary from a short observation period to a lengthy stay, reflecting the severity of the neonate's condition.

Eight studies that measured NICU admission met the criteria for review,^{78-80, 90, 97, 156, 284, 286} but none explicated the criteria for NICU admission despite the existence of an American Academy of Pediatrics (AAP) policy statement on levels of neonatal care.²⁸⁹ While admission to a NICU can occur for multiple reasons, it is generally agreed that admission to the NICU results in separation of the neonate from its mother as well as contributing to an increase in the cost of healthcare. Three studies^{78, 80, 156} used reported on the same MFMU cohort. In a fair quality study on risk of uterine rupture in women undergoing TOL, Landon et al isolated term neonates to measure the frequency and likelihood of NICU admission in women who underwent TOL with one previous cesarean delivery compared with women with multiple cesarean deliveries.⁸⁰ Of the 17,898 women in the study, 95 percent had only one prior cesarean; the remainder of women undergoing TOL (N= 975) had two, three, and four prior cesareans. Nine percent of the term neonates whose mothers had one prior cesarean were admitted to the NICU compared with 11.2 percent of the neonates whose mothers had greater than one prior (odds ratio 1.53; 95 percent CI: 1.19 to 1.96, p=0.05); however this study did not find multiple prior cesareans to be predictive of uterine rupture (odds ratio 1.36; 95 percent CI: 0.69 to 2.69, p=0.37). Grobman et al, in a good quality study from the MFMU cohort, examined the effect of IOL on perinatal outcomes in neonates at term with one prior cesarean differentiating between one prior vaginal delivery and no previous vaginal delivery.¹⁵⁶ There were no significant differences in admission to the NICU regardless of type of labor (spontaneous, induced, augmented) or whether women had a previous vaginal delivery (odds ratio 1.19; 95 percent CI: 0 to 1.47) or no prior vaginal delivery (odds ratio 1.03; 95 percent CI: 0.85 to 1.24). In another study of good quality from the MFMU cohort, Hibbard et al set out to determine whether morbidly obese women have greater maternal and perinatal morbidity with TOL compared with ERCD.⁷⁸ In this secondary analysis she found an increased incidence in the frequency of admission of term neonates to the NICU in women who were obese/morbidly obese (10 percent/13.8 percent) compared with women with a normal BMI (7.4 percent) or who were overweight (7.7 percent, p<0.001). However, neonates of morbidly obese women undergoing TOL were no more likely than neonates of women who had ERCD to experience admission to the NICU (13.8 versus 12.6 percent, odds ratio 1.1; 95 percent CI: 0.9 to 1.3 percent).

The remaining five studies^{79, 90, 97, 284, 286} addressing frequency and likelihood of NICU admission are summarized in Table 35. Two studies attempted to distinguish NICU admission after delivery by VBAC or RCD after TOL. In a study of good quality across all three hospital levels, Hook et al found no significant increase in admissions to a Level 3 NICU in neonates born by TOL compared with ERCD (3 versus 2 percent, p=NS), but found significantly more neonates admitted to NICU if they were born by RCD following a TOL compared with those born by VBAC (7 versus 2 percent, p< 0.007).⁷⁹ Similarly, Kamath et al, in a fair quality study, also found that RCD after TOL increased the likelihood of NICU admission (odds ratio 2.26; 95 percent CI: 0.85 to 6.0, p=0.10).²⁸⁶ However, the greatest likelihood of admission to the NICU (adjusted for multiple covariates of maternal education level, chronic disease, amniocentesis, choriamnionitis, non-reassuring fetal heart tones, and GA by week) was for term infants who did not experience labor and were born by ERCD (odds ratio 2.93; 95 percent CI: 1.28 to 6.72, p=0.011).

While costs associated with care vary greatly by setting and region of the U.S., Kamath et al analyzed neonatal length of stay and found neonates born by VBAC stayed 3 days on average compared with 4 days for ERCD (with or without labor) and RCD after TOL (p<0.001).²⁸⁶

Summary and strength of evidence on neonatal intensive care unit admissions. Overall the strength of evidence on the impact of route of delivery on NICU admission is low due to inconsistent and imprecise measures. No studies defined the criteria for admission to the NICU. Six studies found no significant differences in frequency of NICU admissions between TOL and ERCD whereas one reported the greatest risk for NICU admission in infants undergoing an ERCD without labor (odds ratio 2.93) versus a successful VBAC (odds ratio 1.0). Future studies would benefit by description of NICU admission criteria, the reason for admission, and level of support provided to the infant.

Table 35. Neonatal intensive care unit admissions among term studies

Study, year	Design/Population	N	Comparison	NICU measurement	Outcome
Fisler, 2003 ⁹⁰	Prospective cohort University hospital	449	1. TOL versus ERCD 2. TOL with epidural versus TOL without epidural	Any NICU admission	1. TOL (26.2%) versus ERCD (17.6%), p= 0.001 2. TOL w/epidural (5.2%) versus TOL w/o epidural (1.2%), p=0.2
Hook, 1997 ⁷⁹	Prospective cohort Level 1, 2, 3 hospital settings	989	1. TOL versus ERCD 2. VBAC versus TOL-CD	NICU admission	1. TOL (3%) versus ERCD (2%), p=NS 2. VBAC (2%) versus TOL-CD (7%), p< 0.007
Grobman, 2007 ¹⁵⁶	Prospective cohort MFMU 19 academic medical centers	11,778	1.No prior VD (SL v. IOL) 2.Prior VD (SL v. IOL)	Special care nursery admission	1.OR 1.03 2.OR 1.19
Hibbard, 2006 ⁷⁸	Prospective observational cohort MFMU 19 academic medical centers	28,446	TOL versus ERCD in obese women	NICU admission by BMI	Obese TOL (13.8%) versus ERCD (12.6%),OR 1.1
Landon, 2006 ⁸⁰	Observational cohort MFMU 19 academic medical centers	17,890	1.TOL in women with 1 prior CD 2.TOL in women with ≥2 prior CD	NICU admission not specified	1 prior CD (9%) versus multiple prior CD (11.2%), OR 1.28
Loebel, 2004 ⁹⁷	Retrospective cohort Large community hospital affiliated with a university	1,408	1.TOL versus ERCD 2.VBAC versus ERCD 3. TOL-CD versus ERCD	NICU admissions	1. TOL (4.2%) versus ERCD (5.6%), p= 0.24 2.VBAC (3.7%) versus ERCD (5.6%), p= 0.12 3. TOL-CD (6.2%) versus ERCD (5.6%) p= 0.78
Richardson, 2005 ²⁸⁴	Prospective cohort Tertiary care hospital	3,489	TOL versus ERCD (no labor)	1.NICU triage 2.NICU admission 3.NICU stay > 7 days	1.TOL (0.8%) versus ERCD (1.5%), Adjusted OR 2.0, p=0.06 2. TOL (8.8%) versus ERCD (8.3%) Adjusted OR 0.8, p=NS 3. NICU >7 days TOL (0.9%) versus ERCD (0.6%) Adjusted OR: 0.4 (0.1-1.1) p=0.08;

Table 35. Neonatal intensive care unit admissions among term studies

Study, year	Design/Population	N	Comparison	NICU measurement	Outcome
Kamath, 2009 ²⁸⁶	Retrospective cohort university hospital	672	Planned TOL VBAC TOL-CD ERCD Labor No labor	NICU Admission	Planned TOL OR 1.0 OR 1.91 ERCD OR 2.26 OR 2.93

Abbreviations: CD=cesarean delivery; ERCD=elective repeat cesarean delivery; MFMU=Maternal-Fetal Medicine Units Network; NICU=neonatal intensive care unit; NS=not significant; OR=odds ratio; TOL=trial of labor; TOL-CD=trial of labor followed by a cesarean delivery; VBAC=vaginal birth after cesarean; VD=vaginal delivery

Breastfeeding

No studies were found that explored the effect of a TOL versus an ERCD on breastfeeding initiation or continuation.

Impact of the Mode of Delivery on Subsequent Babies

Two fair quality studies were found addressing the impact of a previous cesarean delivery on subsequent unexplained stillbirth in the next pregnancy.^{280, 281} Smith et al, using linked discharge data from a large, population database in Scotland, estimated the risk of antepartum stillbirth in a second pregnancy comparing women with a previous cesarean (N=17,754) to women with no previous cesarean.²⁸¹ The study group included women with a second pregnancy from 1992 to 1998 and excluded fetuses less than 500 grams, deaths due to congenital anomalies, and rhesus isoimmunization. There were 68 stillbirths in the previous cesarean delivery group. After attributed causes for the stillbirths (e.g., toxemia, hemorrhage, mechanical, maternal issues) were noted, there were more unexplained stillbirths found in the previous cesarean delivery group (43 unexplained stillbirths out of 17,754 births or 0.24 percent of births) compared with women without a prior scar (163 unexplained stillbirths out of 102,879 births or 0.16 percent of births). Adjusting for maternal and demographic characteristics did not lessen the association between previous cesarean and unexplained stillbirth. Smith also used time-to-event analyses to predict the prospective risk of a stillbirth at 39 weeks or greater gestation to be 0.11 percent of women compared with 0.05 percent of women without a prior cesarean delivery. The authors noted that despite a wealth of clinical and demographic data in the dataset they did not have access to maternal weight, and therefore were unable to adjust for BMI and obesity as a maternal risk factor.

In another large U.S. dataset, Bahtiyar et al conducted a cross-sectional study of singleton, term pregnancies from 1995 to 1997 in women with a prior cesarean delivery compared with women without a prior cesarean delivery, excluding any underlying maternal or fetal abnormality.²⁸⁰ Women were stratified in order to detect the study group of interest and to reduce potential confounders, with the final group of women with only one prior delivery (cesarean versus vaginal birth). Rate of stillbirth in the subsequent pregnancy was compared between the two groups. While not statistically significant, there were fewer stillbirths in the previous cesarean group compared with women without a prior cesarean in the second pregnancy (0.072 percent of births compared with 0.080 percent of births, RR 0.90; 95 percent CI: 0.076 to 0.106 percent). While this study is strengthened by its large cohort size (1.7 million for comparison in the study group described), it was difficult to determine the exact number of cases in each current pregnancy group. The authors did not attempt to classify stillbirths by cause and based study data on birth and death certificates.

Summary of mode of delivery on subsequent babies. Two studies were reviewed to determine the risk of stillbirth in subsequent pregnancies in women with a prior cesarean delivery. These studies produced conflicting results with one study showing that prior cesarean increases the risk for unexplained stillbirth in next pregnancy and the other study showing no difference in risk for stillbirth in the next pregnancy. One study included early gestations, while the other study was limited to term gestations. Both studies are limited by their retrospective design and relied on large perinatal databases while employing various methodologies to overcome confounding.

Neurological Development

No studies were found that measured the impact of a TOL versus an ERCD on neonatal neurological development. In order to examine the neurological development, studies that extend beyond the immediate postpartum period would be required.

Special Considerations

Impact of induction upon infant outcomes.

Prostaglandin E2. Several studies reported the rate of infants with Apgar scores of less than seven at 5 minutes among those with PGE₂ induction, ranging from 0 to 8 percent, but rates were similar to the control group in each individual study.^{145, 148, 149, 153, 161, 168} Other infant harms were not reported consistently.

Misoprostol. Evidence for infant harms associated with misoprostol used for cervical ripening and labor induction is not adequate to make conclusions. As described in previous sections, a small cohort study (N=226) of term gestations, comparing PGE₂ (administered as a gel or pessary) with misoprostol (25 to 50 mcg) included only 16 of 145 women in the misoprostol group and nine of 81 in the PGE₂ group who had a history of a prior cesarean delivery.²¹¹ Only the results for uterine rupture were stratified by history of a prior cesarean with two of 16 in the misoprostol group (13 percent) and zero of nine in the PGE₂ group having a low transverse rupture. In one case, the Apgar scores were two and seven at 1 and 5 minutes respectively, and the neonate's outcome was good. The other resulted in a stillbirth. The only other study made comparisons among women with a history of prior cesarean delivery to those *without* prior cesarean delivery (with no limit on GA), a comparison that is not relevant to this review.¹⁷² Among the group with a prior cesarean delivery and a TOL with misoprostol for cervical ripening (N=48) fetal distress was reported in 23 percent, and 13 percent of infants had an Apgar score of less than seven at 5 minutes.

Mifepristone. In a small (N=32), fair quality trial of mifepristone compared with placebo—each given for 2 days followed 2 days later by induction with prostaglandins, oxytocin, and/or artificial rupture of membranes as needed in women with term gestations—neonatal outcomes were similar between groups, but one baby in the mifepristone group had hypoglycemia at birth.¹⁷³

Oxytocin versus prostaglandin. None of the studies comparing oxytocin and PGE₂ for induction stratified neonatal outcomes based on which drug was used.

Mechanical methods of induction. Reporting of infant harms was inadequate in the limited number of studies of mechanical induction to allow comparative assessment.

Macrosomia. Fetal macrosomia is a common obstetric condition known to present in approximately 10 percent of all infants in the U.S. and has the potential to influence the route of delivery on infant outcomes. Though there is inconsistency in definitions, macrosomia most commonly is used to refer to fetal weights greater than 4,000 or 4,500 grams. Clinicians are frequently called upon to weigh the risks and benefits of a TOL after a prior cesarean delivery in women with suspected fetal macrosomia. Neither ultrasound nor physical examination is able to accurately estimate fetal weight.

Eleven good or fair quality studies reported on the impact of fetal macrosomia on infant outcomes for VBAC compared with ERCD.^{60, 78, 117, 123, 124, 126, 139, 161, 188, 221, 267} Studies that examined the relationship of fetal macrosomia and uterine rupture as well as the incidence of macrosomia in the presence of maternal obesity are also discussed.

The incidence of macrosomia increases as gestational age increases. Rates of macrosomia increased from 2 percent in a cohort of preterm women to 9.1 percent of women at term to 25.5 percent of women at 41 weeks or greater.⁶⁰

Nine studies were reviewed that addressed the VBAC rate within cohorts when the birth weight exceeded 4,000 grams.^{60, 117, 123, 124, 139, 146, 161, 221, 267} Five of these studies used regression analyses to compute the likelihood of VBAC or RCD after TOL based upon birth weight greater than or less than 4,000 grams.^{123, 124, 139, 146, 267} In a retrospective cohort study of good quality, Bujold et al evaluated VBAC in women according to their BMI (N=8580) and found women who delivered infants weighing 4,000 grams or greater were less likely to have a VBAC (odds ratio 0.62; 95 percent CI: 0.54 to 0.71, $p < 0.001$).²⁶⁷ This study excluded patients with known pregestational diabetes, but did not control for gestational diabetes or for the indication for prior cesarean delivery, which is acknowledged to influence VBAC rate.

The majority of studies reported the relationship of VBAC in infants weighing greater than 4,000 grams with those weighing less than 4,000 grams.^{60, 126, 139, 161, 188, 221, 267} Two fair quality studies^{117, 124} furthered their analyses by examining VBAC rates in mothers whose infants weighed greater than 4,000 grams and less than 4,500 grams. Without controlling for parity, number of prior cesarean deliveries, or vaginal births, El-Sayed et al found a higher VBAC rate in women delivering infants greater than 4,000 grams (11.6 percent) compared with women delivering infants greater than 4,500 grams (1.3 percent, $p < 0.001$).¹²⁴ Birth weight greater than 4,000 grams was associated with a RCD after a TOL (odds ratio 2.65; 95 percent CI: 1.70 to 4.13). Likewise, in a prospective descriptive study of women in 25 free-standing birth centers in the U.S., Lieberman et al found a VBAC rate of 17.4 percent in women whose infants weighed 4,000 to 4,499 grams compared with 5.8 percent in women whose infants weighed 4,500 grams or greater.¹¹⁷

Elkousy et al, in a fair quality study, differentiated VBAC rates in women delivering macrosomic infants into two categories (4,000 to 4,249 grams and 4,250 to 4,500 grams) as well as comparing VBAC rates in women with infants weighing less than 4,000 grams versus those whose infants weighed greater than 4,000 grams and greater than 4,500 grams.¹²³ The adjusted incidence ratios for VBAC were reduced only slightly in each infant weight category: 4,000 to 4,249 grams (0.85; 95 percent CI: 0.77 to 0.93); 4,249 to 4,500 grams (0.77; 95 percent CI: 0.66 to 0.89); greater than 4,500 grams (0.70; 95 percent CI: 0.57 to 0.077).

Three studies examining the relationship of neonatal macrosomia in women with increased BMI and VBAC were reviewed.^{78, 126, 267} The impact of increasing maternal weight gain on VBAC rate was previously discussed in the section on Special Considerations of maternal outcomes. In a good quality retrospective cohort of women (N=6718) undergoing a TOL, Bujold et al noted increases in the mean birth weight of infants and rates of macrosomia as maternal BMI increased.²⁶⁷ Likewise, in a secondary analysis of a prospective good quality study, Hibbard et al noted a significant increase in the birth weights of women of normal BMI (3,196±445 grams), compared with women who were overweight, obese, or morbidly obese (3,370.5±451.3, 3,469.2±471.5, 3,493.8±503.4, $p < 0.001$).⁷⁸ While no separate analysis was performed on infants specifically weighing 4,000 grams or greater in this study, it is clear from these two studies there is positive correlation of increased birth weight with increasing maternal BMI. A fair quality study by Goodall et al also found that compared with women with a normal BMI, morbidly obese women were more likely to have infants greater than 4,000 grams ($p = 0.004$).¹²⁶

There were no studies that examined neonatal trauma in infants whose birth weights exceeded 4,000 grams.

Summary of macrosomia. There is a trend toward an increase in mean birth weight as maternal BMI increases. There is evidence for a decreased likelihood of VBAC in infants weighing 4,000 grams or greater (odds ratio 2.65); this trend is more pronounced in infants weighing 4,500 grams or greater compared with less than 4,500 grams (1.3 percent if greater than 4,500 grams versus 11.6 percent if less than 4,500 grams, $p < 0.001$).

Fetal presentation. No studies were found that measured the impact of fetal presentation on the benefits or harms of a TOL versus an ERCD.

Gestational age. Because of the potential confounding for neonatal harms introduced by preterm gestation, a review of neonatal benefits and harms after a TOL versus an ERCD were limited to term infant outcomes. One fair quality study of term infants by Kamath et al reported selected neonatal outcomes at 37, 38, 39, 40, and greater than or equal to 41 completed weeks of gestation.²⁸⁶ Because neonatal outcomes were compared by GA rather than denoting the intended mode of delivery in this study, it is impossible to draw any conclusions regarding the influence of GA on neonatal outcomes in women who attempt a TOL versus ERCD.²⁸⁶

Recent recommendations by ACOG state that infants not be delivered by ERCD or elective IOL before 39 weeks due to the increased risk of iatrogenic prematurity and the potential for respiratory complications. Likewise, post term pregnancies carry an increased risk of complications (e.g., meconium passage and non-reassuring fetal heart rate patterns), potentially influencing the route of delivery. While the study by Kamath et al stratified neonatal outcomes by GA and found that infants delivered at 37 weeks had the highest rates of oxygen use in the delivery area (38.8 percent, $p = 0.003$) and the most admissions to the NICU (15 percent, $p = 0.018$), they do not go on to stratify those outcomes by the intended or actual mode of delivery. Future studies that examine the influence of GA on VBAC rate compared with RCD after TOL and ERCD are warranted.²⁸⁶

Summary of gestational age. Analysis was limited to term neonates due to the potential for confounding for neonatal harms introduced by preterm gestational age. Only one study reported selected neonatal outcomes by gestational age in the term infant, but did not classify the infant by mode of delivery. There is insufficient data to determine that gestational age in term neonates influences benefits or harms to the neonate undergoing TOL versus ERCD.

Chapter 4. Discussion

Each year 1.5 million childbearing women have cesarean deliveries, and this population continues to increase. While cesarean deliveries represent a third of all births, they account for almost half of the childbirth-related expenses of hospitalization at \$7.8 billion annually.¹ Therefore, the appropriate and safe use of cesarean and vaginal birth after cesarean (VBAC) is not only an individual patient- and provider-level concern but it is also a national health policy concern.

Prior cesarean delivery is the most common indication for cesarean, accounting for over a third (534,180,000) of cesarean deliveries, almost twice the rate of any other indication. Thus, an important contributor to the increase in cesareans is the rapid decline in VBACs witnessed over the last decade. In 2007, only 8.7 percent of childbirth-related hospitalizations among women with a previous cesarean delivery were VBACs, suggesting that over 90 percent of all women with a previous cesarean will deliver by planned or elective repeat cesarean delivery (ERCD).

One of the major findings of this report is that the best evidence suggests that VBAC is a reasonable and safe choice for the majority of women with prior cesarean. Moreover, the report raises concerns over the serious morbidity accruing from multiple cesareans, a result of the increased use of ERCD over VBAC. In addition to health outcomes, some relatively unexamined contextual factors relating to VBAC drive patient, provider, hospital, and policy decisionmaking. Regional-, hospital-, and individual-level liability have all been associated with increased cesarean delivery rates. Even a perception of increased risk for liability was reported to be associated with increased use of cesarean. Similarly, some data suggest that economic incentives appear to affect cesarean delivery rates. It is financially untenable for many rural hospitals to offer the 24-hour in-house availability that is suggested to allow VBAC as an option. Economic incentives may need to be changed to prioritize access to VBAC services. Patients and providers are influenced by the short- and long-term benefits and risks of route of delivery as well as family obligations, costs, societal norms, and regional availability of options. Although studies of VBAC are numerous, the numbers of studies providing high quality information on important clinical questions are limited.

The literature concerning trial of labor (TOL) and ERCD is flawed in several ways: imprecise measurement of outcomes (e.g., maternal infection, perinatal death), making it difficult to determine the portion of events directly attributable to route of delivery; lack of standards for terminology (e.g., no standard classification for severity of health consequences related to uterine rupture); and limited attention to comparability between groups (e.g., studies of ERCD in which it is unclear whether patients were eligible for TOL). Data on maternal and infant outcomes, of great interest to most patients, suffer from a lack of standardization of terminology and measurement. This is especially highlighted by the trends seen with studies reporting both hemorrhage and transfusion in TOL and ERCD. In studies where hemorrhage was reported as higher in one group, the transfusion rates were lower. Additionally, alternative interventions to transfusion, such as IV iron therapy, were not reported. Investigations into the neonatal effects of ERCD and VBAC suffer even greater problems of measurement, lack of standardization, and insufficient data. How, then, are these studies to be interpreted by the individual clinician, much less combined for guidance? Further complicating interpretation are both the unreported societal and monetary costs of intervention associated with these modes of delivery. This highlights a

Appendixes and evidence tables cited in this report are available at <http://www.ahrq.gov/downloads/pub/evidence/pdf/vbacup/vbacup.pdf>.

particular problem with the research in this area; the easiest outcomes to measure are not generally the outcomes most pertinent to the clinician or the patient.

Studies of VBAC versus ERCD have traditionally reported outcomes based upon actual route of delivery rather than intended route, leading to misclassification of patients who intend ERCD but go into labor prior to their cesarean or women who intend TOL but who are delivered by cesarean. A good demonstration of the complexity of this issue comes from the first National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (MFMU) studies. The studies report on 45,988 women with singleton gestation and prior cesarean delivery at term. The original article by Landon published in 2004²²¹ considered women who presented in labor at 4 cm or greater cervical dilation or anyone receiving oxytocin in the TOL group; and women who presented in early labor who subsequently underwent cesarean were excluded. Ultimately, 12,289 women (27 percent of population at term with prior cesarean delivery)--9,013 who had an indicated repeat cesarean delivery (IRCD) and 3,276 women who presented in early labor and subsequently delivered by cesarean delivery--were excluded from the analysis. Thus Landon's analysis presented data for 33,699 women: 17,898 women classified as undergoing TOL and 15,801 undergoing an ERCD. Uterine rupture rates in these two groups were 124/17,898 (0.7 percent) in TOL versus 0/15,801 (0 percent) in ERCD. A subsequent analysis performed by Spong in 2007²⁰⁴ aimed to provide information that would be clinically useful to the clinician providing antepartum counseling for VBAC and classified patients quite differently. She broke the group into three main categories: TOL (15,323), ERCD (17,714, without medical indication), and IRCD (6,080). Ultimately, not only did she include 5,418 additional patients for a total of 39,117, but 2,575 women who were initially considered TOL in Landon's study were now distributed to either IRCD or ERCD with labor. While this reclassification did not change the uterine rupture rate for the TOL group (0.74 percent in Spong²⁰⁴ versus 0.7 percent for Landon²²¹), it substantially changed the uterine rupture rate among the ERCD group (without indication).

The design of most studies, including the largest and widely cited Spong study discussed above, render them unable to identify the ideal population - women who *plan* VBAC or *plan* RCD. The evidence from these studies is at best indirect and difficult to apply to a woman who plans for either option. These studies also lack data concerning important contextual factors such as whether and how hospital structure, setting, staffing, economics, and liability affect processes and outcomes. Each potential bias leaves clinicians and patients uncertain of the ramification for their decisionmaking and masks potential adverse effects of desiring one route of delivery but having another.

A longitudinal study design that begins after first cesarean and measures patient intent would allow measurement of outcomes, preferences, and adverse events throughout the entire spectrum of concepts presented in the analytic framework. Because issues of access and capacity to handle obstetric emergencies, such as uterine rupture, are likely to impact a woman's ability to have the delivery she desires as well as the ultimate outcome of any emergency, a national study that could examine regional variation would be ideal.

Table 36 summarizes the strength of evidence and findings for all key questions reviewed in this report. Briefly, there is moderate evidence that women who have a TOL have a high probability of having a vaginal delivery (74 percent) which can be enhanced by maximizing favorable clinical conditions such as waiting for a favorable cervical examination if possible. Overall, maternal morbidity is reduced from TOL compared with ERCD. Of particular note is the significantly decreased risk of maternal mortality and the serious morbidity associated with

multiple repeat cesareans. Overall--with the exception of perinatal, fetal, and neonatal mortality rates, which are significantly higher for TOL--the literature on neonatal outcomes are insufficient. Therefore, the inherent complexities of weighing maternal and infant risks remain a challenge for clinicians and patients.

A systematic review strives to be patient-centered and to provide both patients and clinicians with meaningful numbers or estimates so they can make informed decisions. Often, however, the data do not allow a direct estimate to calculate the numbers that people desire such as the number of cesareans needed to avoid one uterine rupture related death. The assumptions that are required to make such estimates from the available data introduce additional uncertainty that cannot be quantified. If we make a simplistic assumption that 6 percent of all uterine ruptures result in perinatal death (as found from the summary estimate), the range of estimated numbers of cesareans needed to be performed to prevent one uterine rupture related perinatal death would be 2,400 from the largest study,²⁰⁴ and 3,900-6,100 from the other three studies of uterine rupture for TOL and ERCD.^{10, 97, 205} Taken in aggregate, the evidence suggests that the approximate risks and benefits that would be expected for a hypothetical group of 100,000 women at term gestational age (GA) who plan VBAC rather than ERCD include: 10 fewer maternal deaths, 650 additional uterine ruptures, and 50 additional neonatal deaths. Additionally, it is important to consider the morbidity in future pregnancies that would be averted from multiple cesareans particularly in association with placental abnormalities.

One persistent trend emerging from analysis of the evidence in this report is the influence of GA on vaginal delivery rates and outcomes. There appears to be increased risk of uterine rupture and transfusion among term pregnancies undergoing TOL. Further, limited information from induction studies suggests that risks of induction are particularly increased as GA exceeds 40 weeks. These data together pose a particular challenge for the management of the post-date pregnancy. Mode of delivery for subsequent pregnancies poses a difficult question for women with prior cesarean and their providers. Some women have already made their decision prior to leaving the hospital after their cesarean due to factors surrounding that birth. Others will decide early in pregnancy, and still others will remain undecided until presenting in labor. Some women will not have a choice due to provider, hospital, insurance, or medical-legal factors that mandate RCD. This report suggests that, although there are statistically significant differences between ERCD and TOL, there are few clinically significant differences.

Table 36. Summary of evidence for key questions

Key Question	Study Type*	GRADE of Evidence	Findings
Among women who attempt a trial of labor after prior cesarean, what is the vaginal delivery rate and the factors that influence it?			
<i>Individual Risk Factors</i>	Cohorts	N/A	<ul style="list-style-type: none"> • In U.S. studies launched after 1996, less than half of women had a TOL. • Most evidence of TOL and VBAC rates are from studies based in large tertiary care centers or teaching hospitals. • While TOL rates reported in observational studies have dropped over time, VBAC rates have remained constant for the women who have a TOL. • In studies based in the U.S., 74% of women who had a TOL delivered vaginally.
<i>Predictive Tools</i>	Cohorts	N/A	<ul style="list-style-type: none"> • All scored models provide reasonable ability to identify women who are good candidates for • VBAC but none have discriminating ability to consistently identify women who are at risk for CD.
What are the short- and long-term benefits and harms to the mother of attempting trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?			
<i>Maternal Death</i>	Cohorts	High	<ul style="list-style-type: none"> • Overall, maternal death is a rare event with a rate of approximately 10/100,000 when all studies are combined • Mortality appears to be increased with ERCD compared with TOL, however the difference is not statistically significant • For both TOL and ERCD, a trend was seen of increased maternal mortality in studies including all gestational ages compared with term delivery limited studies

Table 36. Summary of evidence for key questions

Key Question	Study Type*	GRADE of Evidence	Findings
<i>Uterine Rupture</i>	Cohorts	Moderate (Low uterine segment thickness studies only)	<ul style="list-style-type: none"> • The rate of uterine rupture for all women with prior cesarean is very low 0.30% (3/1,000) • the risk of uterine rupture for women undergoing a TOL is 0.47% ten times higher than for women undergoing an ERCD 0.03% • Overall, the risk of perinatal death in the event of a uterine rupture was 6.2% • There were no uterine rupture associated maternal deaths among term studies • The overall risk of rupture with any induction method at term was 1.5% and 1.0% when any gestational age is considered. • Among women with gestational age > 40 weeks, the rate was highest at 3.2%. • There was significant heterogeneity among studies • Study design appeared to play a role in reported frequencies of uterine rupture
<i>Predictors of uterine rupture</i>	Cohorts, case series and case-controls	N/A	<ul style="list-style-type: none"> • Uterine rupture risk is decreased by prior vaginal delivery and prior VBAC • Uterine rupture risk is increased by short inter-delivery intervals <18-24 months and gestational age • There is insufficient or conflicting evidence regarding the role of single layer closure, preterm delivery, maternal age, post-term status, birth weight, oxytocin, prostaglandin and epidural use. • ultrasound measurements of uterine thickness may play a promising role in predicting populations at risk for uterine rupture
<i>Predictive Tool</i>	Cohorts	N/A	<ul style="list-style-type: none"> • Accurate and reliable tool to predict an individual woman's risk of uterine rupture has not been achieved.
<i>Hysterectomy</i>	Cohorts	Medium	<ul style="list-style-type: none"> • Hysterectomy is rare with either ERCD or TOL, occurring in less than 3% of deliveries • Hysterectomy rate for ERCD ranged from 0% to 1.7% • Hysterectomy rates for TOL ranged from 0.1%-0.5% • The majority of studies report a non-significant increase in hysterectomy for ERCD • High-risk populations (maternal complications) may be at increased risk for hysterectomy

Table 36. Summary of evidence for key questions

Key Question	Study Type*	GRADE of Evidence	Findings
<i>Hemorrhage/Transfusion</i>	Cohorts	Medium/Low	<ul style="list-style-type: none"> • Overall hemorrhage rates were higher in the ERCD group 0.3-29% versus 0.6-17% for any gestational age • Transfusion rates in TOL were 0.8% versus 1.2% in ERCD for any gestational age, compared with 0.66% TOL and 0.46% ERCD for term delivery only studies • Transfusion risk appears to be modified by gestational age at delivery • Data on maternal hemorrhage is limited by inconsistent reporting and definition of the term hemorrhage among different studies
<i>Infection</i>	Cohorts	Low (All definitions of infection)	<ul style="list-style-type: none"> • TOL appears to be associated with increased risk of febrile morbidity for populations that include preterm patients but not studies limited to term. • TOL is associated with a decreased risk of maternal fever compared with ERCD (RR= 0.63, 95%CI= 0.43 to 0.91) however significant discrepancies exist in the definition of fever
<i>Surgical Injury</i>	Cohorts	N/A	<ul style="list-style-type: none"> • There is insufficient data regarding risk of surgical injury for TOL and ERCD patients • Prior vertical cesarean is associated with increased risk for bladder injury
<i>Embolic events</i>	Cohorts	N/A	<ul style="list-style-type: none"> • TOL is associated with lower rates of embolic events compared with ERCD (0.04% versus 0.1%) • The risk of embolic events for ERCD is similar regardless of number of prior cesareans at 0.1% • Data is limited for this outcome
<i>Length of stay</i>	Cohorts	N/A	<ul style="list-style-type: none"> • TOL had a mean difference in LOS for all studies compared with ERCD • Mean LOS difference for TOL was -1.3 days (95% CI= -1.6 to -1.0) • Obesity was associated with increased hospital stay but data is limited
<i>Effect of Hospital Setting</i>	Cohorts	N/A	<ul style="list-style-type: none"> • Data are based on only one study which reported increased odds of short term complications in low volume maternity wards (particularly death and uterine rupture) • No studies directly describe the long-term outcomes of TOL, VBAC, and ERCD

Table 36. Summary of evidence for key questions

Key Question	Study Type*	GRADE of Evidence	Findings
<i>Multiple cesareans and placenta</i>	Cohorts	N/A	<ul style="list-style-type: none"> >3 prior CD is associated with increased rates of previa (2.3-4.2%), accreta (4.7-6.7%), and hysterectomy (1.1-9.0%). Prior CD is a significant risk factor for maternal morbidity in women with previa. The risk increases with increasing number of prior CD. Women with ≥3 prior CD and previa had a statistically significant increased risk of accreta (3.3-4% vs. 50-67%), hysterectomy (0.7-4% vs. 50-67%), and composite maternal morbidity (15% vs. 83%) compared with women with previa and no CD.
What are the short- and long-term benefits and harms to the baby of maternal attempt at trial of labor after prior cesarean versus elective repeat cesarean delivery, and what factors influence benefits and harms?			
<i>Apgar scores</i>	Cohorts	N/A	<ul style="list-style-type: none"> There is little to no significant difference between Apgar scores of infants delivered by VBAC and ERCD
<i>Respiratory complications</i>	Cohorts	TTN: Low Bag/Mask: Low Intubation: Moderate	<ul style="list-style-type: none"> Few studies define terms for respiratory complications, there is little consensus between studies regarding safer delivery method (VBAC versus ERCD) in regards to this intermediate outcome.
<i>Sepsis</i>	Cohorts	Low	<ul style="list-style-type: none"> Definition of infantile sepsis is unclear, few studies examine rates of this diagnosis and even fewer measure the confirmation of sepsis.
<i>Asphyxia/HIE</i>	Cohorts	Low	<ul style="list-style-type: none"> There are no consistent definitions of HIE among term studies and few report it. Needed: neonates diagnosed with HIE should be followed to measure associated long-term health outcomes
<i>NICU admissions</i>	Cohorts	Low	<ul style="list-style-type: none"> No consistent definition for NICU admission criteria, no difference between VBAC/ERCD. Currently: NICU admission is an imprecise measure of infant health, as reason for admission could differ greatly between cases. Study findings are often confounded by classification bias
<i>Stillbirth/Infant death</i>	Cohorts	Perinatal: Moderate Fetal: Low Neonatal: Moderate	<ul style="list-style-type: none"> Conflicting evidence of whether a previous CD increases the risk for stillbirth in subsequent pregnancies. Perinatal and infant deaths are rare, but occur significantly less often in ERCD
<i>Neurological Development</i>	Cohorts	Insufficient	<ul style="list-style-type: none"> No studies measure neurologic development; studies that go beyond the immediate postpartum period are necessary to capture neurological development
<i>Macrosomia</i>	Cohorts	N/A	<ul style="list-style-type: none"> Heavier women have heavier babies, macrosomic infants are less likely to be delivered by VBAC, especially in infants > 4,500grams

Table 36. Summary of evidence for key questions

Key Question	Study Type*	GRADE of Evidence	Findings
<i>Fetal presentation</i>	Cohorts	N/A	<ul style="list-style-type: none"> No data on fetal presentation
<i>Gestational age</i>	Cohorts	N/A	<ul style="list-style-type: none"> Analysis for Key Question 3 was limited to term infants, no studies broke down term data by week in a VBAC versus ERCD format
<i>Breastfeeding</i>	Cohorts	Insufficient	<ul style="list-style-type: none"> No studies to determine breastfeeding indicators
What are the critical gaps in the evidence for decision-making, and what are the priority investigations needed to address these gaps?			
	None	N/A	<ul style="list-style-type: none"> Because studies largely report actual route of delivery they are subject to misclassification bias which weakens ability to measure magnitude and direction of risk for TOL versus ERCD Ideal cohort study would construct cohort by intended route of delivery Infant outcomes are poorly defined and addressed Important associations and outcomes for uterine rupture were not addressed Rate and predictors for uterine- rupture associated infant and maternal mortality and morbidity Reliability for signs and symptoms of rupture How hospital staffing, structure, etc impact outcomes for uterine rupture

Abbreviations: CD=cesarean delivery; CI=confidence interval; ERCD=elective repeat cesarean delivery; g=grams; HIE=hypoxic ischemic encephalopathy; LOS=length of stay; N/A=not applicable; NICU=neonatal intensive care unit; RR=relative risk; TOL=trial of labor; TTN=transient tachypnea of the newborn; U.S.=United States; VBAC=vaginal birth after cesarean section; VD=vaginal delivery

What are the critical gaps in the evidence for decisionmaking, and what are the priority investigations needed to address these gaps?

Future research sections of evidence reports have been criticized for not providing sufficient detail to provide researchers the information they need to improve their study designs.²⁹⁰ Further, evidence reports have been dismissed for cataloging all possible research efforts rather than prioritizing future research. To take advantage of the peer review process—which distributes the draft report to federal agencies, including the FDA, CDC, and NIH; maternity and pediatric clinicians; advocacy groups; payers; policymakers; content experts; and researchers—our peer reviewers were asked to provide feedback on both investigator ideas on important gaps in the literature and to provide their own perspectives and priorities for future research. Specifically, experts were asked if stated topic areas were of low, medium, or high priority for future research, and to also provide additional clarification on their positions. Those areas that were rated as highest priority are discussed here (highest priority means that 50 percent of the experts rated the domain as high).

The decision on route of delivery for women with prior cesarean delivery is particularly challenging and complex for patients, providers, and decisionmakers. Patients and providers are influenced by the short- and long-term benefits and risks of route of delivery as well as family obligations, costs, societal norms, and regional availability of options. Although the numbers of studies on VBAC are numerous, the numbers of studies providing high quality information on important clinical questions are limited. An analysis of the areas with the most uncertainty, gaps in the evidence, is presented in Table 37. While many believe the ideal study design for an intervention such as TOL versus ERCD would be a randomized controlled trial, none has been done, and several papers indicate that such a trial is unlikely in the U.S.²⁹¹ The evidence for this systematic review is based almost entirely on observational studies, which are more susceptible to bias. Misclassification of patients and outcomes is a challenge to this literature. Steps to improve these areas in research are necessary to provide clinicians and families with accurate and timely information on route of delivery. In particular, studies of VBAC versus ERCD have traditionally reported outcomes based upon actual route of delivery rather than intended route. This can lead to misclassification of patients who intend ERCD but go into labor prior to their cesarean or women who intended TOL but who are delivered by cesarean delivery. Each leads to misclassification of outcomes for a particular group, and leaves clinicians and patients still uncertain of the ramification for their decisionmaking. It also masks the potential adverse effects of desiring one route of delivery but having another either due to medical complications or other reasons.

National Childbirth Study

Investigators and reviewers agree that the existing evidence is insufficient to adequately answer several questions (Table 37). Additionally, it was agreed that the most effective way to address these gaps in the literature is the undertaking of a large, prospective longitudinal national childbirth randomized trial or cohort study. Participants would need to be enrolled early in their pregnancy, and grouped by their *intended* route of delivery. Whether randomized or a cohort, this landmark study would use clearly defined outcomes, preferences, and risk factors. Such a study would be designed to follow women and their fetuses/infants from early pregnancy to

long-term followup. This type of study would allow researchers and clinicians to establish a cohort at risk. Investigators and experts also agreed on the importance of establishing the appropriate definitions for maternal outcomes (such as, infection, hemorrhage, and surgical injury) and for infant outcomes (such as death or respiratory or neurological issues). A prospective approach is paramount, given the problems with variation in patient classification, outcome definition, and method of measurement found in retrospective studies. Outcome definition was noted as being critical to interpretation of the literature by peer reviewers, and as a main problem in synthesizing existing evidence by reviewers. Composite outcomes are particularly problematic, although even individual outcomes were often poorly defined or defined with wide variation in the existing literature. A consensus conference on health outcome definitions with key leaders in the field should be held prior to conducting such a study. It is recognized that enormous challenges may exist in developing such a large scale effort. These include but are not limited to establishing consensus on definitions; acquiring funding; delineating external influences (litigation; popular press; and societal, patient, and provider assumptions); and obstacles to randomization, IRB approval, and long-term followup.

In addition to, or in support of, such a study, there are specific questions for which an RCT is possible and the best methodological approach. Administrative or other types of databases may be useful in assessing some outcomes, particularly long-term harms. However, methods for using such databases in studying VBAC need to be developed.

Specific areas identified that require additional research included prediction tools, maternal health outcomes, infant health outcomes, and cost.

Prediction Tools

Of priority to the experts surveyed in this domain include the ability to predict uterine rupture, VBAC, or emergency cesarean delivery (failed TOL). This report identifies gaps in the ability of existing prediction tools at selecting women for a successful TOL. Studies need to be large and prospective in nature and should use standard health outcome definitions. Such tools should address non-medical factors associated with a successful or failed TOL; the impact of induction; and whether there are differences among racial, ethnic, or socioeconomic groups. Where differences exist, future research should be designed to identify the reasons for such differences.

Maternal Health Outcomes

Better understanding of the short- and long-term outcomes comparing VBAC with ERCD is needed, particularly in order to inform women's choices, especially among those who will have future pregnancies. This is especially important looking at the proportion of women who have three or more children and the extent of unplanned pregnancies. Future studies must include a full range of reproductive outcomes, including quality of life. Current evidence is lacking in standardization of definitions of short-term outcomes as well as methods of ascertainment and reporting. Examples of short-term outcomes that require better research are infection and surgical injury. Outcomes that affect both mother and infant, such as those related to breastfeeding and parental attachment, have not been studied in relation to VBAC. Comparison of long-term outcomes between VBAC and ERCD are also in need of better examination, with better evaluation of the impact of the age of the mother being taken into account along with multiple other factors.

Uterine rupture. Interpretation of the uterine rupture research is difficult for the many reasons previously described. A potentially promising area of inquiry might be using imaging to predict UR or outcomes; however, the current evidence in this area is insufficient for using ultrasound imaging of the uterine scar or lower uterine segment to predict the risk of uterine rupture with TOL. A large multi-centered RCT could take one of two approaches: randomize patients to ultrasound or no ultrasound, or perform ultrasound on all patients but randomize which providers receive the results prior to delivery.

The impact of setting on the short- and long-term outcomes for mothers and infants has not been well studied. A prospective study of uterine rupture could be created to answer several questions. The study would need to use a standard definition and method of ascertainment to compare events at various types of hospital and non-hospital settings, with variation in staffing and the ability to provide “immediate access to cesarean delivery.” Implementation of a national registry of ruptures and using linked data systems may be a way to approach these questions.

Evidence on the risk of uterine rupture when induction or augmentation is needed is lacking appropriate comparison groups and long- or short-term evidence on infant and maternal harms. Women who are candidates for induction should be compared with similar women who undergo expectant management. Additionally, the role of uterine wall thickness has not been studied in relation to induction for TOL. The best study to answer these questions is an RCT of induction or expectant management. The effect of uterine wall thickness could be examined within such a study or as a separate study.

Infant Health Outcomes

Experts and reviewers agreed that two pressing issues in VBAC continue to be identifying and then studying the most meaningful infant outcomes and agreeing on clear and precise definitions and methods of ascertainment. Although similar issues are seen with maternal outcomes and definitions, those reported as specific to infants include evaluation of variation in gestational age associated with the different delivery methods (ERCD and TOL with and without induction).

Cost

Costs were not examined explicitly in this report, but experts expressed the need to correlate beneficial or harmful outcomes to health-system costs. Economic analyses could be designed to coincide with studies described here. Additional studies to identify the best reimbursement model to provide financial incentives for critical elements of VBAC—which may include increased access in rural areas, 24 hour in-house surgical coverage, etc.—are needed. Again, clear definitions of outcomes are essential.

Table 37. Future research

Research Question	Domains Pertaining to Overall Strength of Evidence	
	Results of Literature Review	Types of Studies Needed to Answer Question
Create standard for referencing predictors	Each study uses different reference in their analysis of predictor making pooling difficult.	Evidence review to propose stand way to compare predictors. E.g., prior CD indication (breach) could always be compared to “not breach” rather than to FTP or fetal indication.
Predicting TOL	Only 2 studies examined this. No evidence on race or ethnicity to determine if there is health disparity	Multi-center prospective cohort study of eligible women for TOL. Measure rates of TOL and rates of ERCD along with predictors including race, ethnicity.
What are the predictors of a cesarean after a TOL?	Current prediction ability is low.	Multi-center prospective cohort study of women eligible for TOL. Record TOL, ERCD and VBAC rates, Emergency CD rates. Measure effect of intervention predictors.
How often do uterine ruptures that occur in hospitals result in serious harms for mother or infant? How does this vary by setting? How does this compare to non-hospital births?	6/6 cohort studies reported on neonatal death 4of 6 cohort studies reported on maternal death	- Multi-centered cohort - National registry of Uterine ruptures
What are the long-term maternal outcomes of VBAC versus ERCD?	Limited data.	Long-term follow-up study, beginning to follow women from their 1 st CD, surveying them regarding future fertility, and follow for 30 to 40 years.
What are the rates and differences of infections of VBAC versus ERCD?	Limited data with un-combinable studies	Large multicenter cohort utilizing standardized definition of endometritis as fever > x 24 hours post delivery requiring IV antibiotics. Other infectious morbidity should also be evaluated, but well defined, specifically x-ray confirmed pneumonia; wound infection defined as fever >100.5, with IV or PO antibiotics required; fever of unknown origin >48 hours.
What is the rate of specific surgical injuries with ERCD and TOL?	None	Large multicenter study, which defines injury specifically by type/organ of injury: bladder; bowel; uterus (includes uterine artery laceration); cervix; 3 rd or 4 th degree perineal laceration. Included in this should be length of surgery time as a marker for complexity of the case.
What are appropriate definitions for maternal outcomes (such as, infection, hemorrhage, surgical injury, etc)?	Definitions are not consistent across studies, making it impossible to combine results & difficult to interpret data.	Consensus conference to determine appropriate definitions.

Table 37. Future research

Research Question	Domains Pertaining to Overall Strength of Evidence	
	Results of Literature Review	Types of Studies Needed to Answer Question
Effect of study design on outcomes	This report found that studies differed substantially though not statistically significantly in their rates of uterine rupture based on study design (30/10,000 versus 52/10,000 risk). This has large implications for what studies are sufficient to based clinical practice and policy.	Conduct 2 cohort studies simultaneously keeping results blinded from other study - One that would define trial of labor and study only trial of labor patients and one that would consider the entire cohort of women with prior cesarean who have TOL versus ERCD
How does TOL versus ERCD effect breastfeeding initiation and continuation?	No evidence	Large cohort study
What is the chance of VBAC when induction is required?	Proportion with VBAC is 54 percent to 69 percent, depending on type of induction, but influence of confounding factors such as dose, prior VD, number of CDs not clear.	RCT with power calculations to insure adequate numbers of subjects and planned univariate and multivariate regression analyses to examine impact of individual and combined potential confounding factors. Comparison group: expectant management
What is the chance of uterine rupture when induction is required?	Rate of rupture is estimated to be 1.2 percent for all induction methods combined, however this is limited by the accuracy of the definition and ascertainment of rupture.	RCT with power calculations to insure adequate numbers of subjects and planned univariate and multivariate regression analyses to examine impact of individual and combined potential confounding factors. Comparison group: expectant management. Uterine rupture must be defined and ascertainment methods should include chart review.
How does the cumulative dose and regimen of induction agent (PGE ₂ , oxytocin, etc.) affect maternal and infant harms?	Insufficient	- RCT of women who are candidates for induction of TOL with 2 groups: induction or expectant management.
How does the cumulative dose and rate of infusion of oxytocin used for augmentation of labor affect infant and maternal harms?	Insufficient	- RCT of women who are candidates for induction of TOL with 2 groups: induction or expectant management..

Table 37. Future research

Research Question	Domains Pertaining to Overall Strength of Evidence	
	Results of Literature Review	Types of Studies Needed to Answer Question
What are appropriate definitions for infant outcomes (death, respiratory, neurological)?	Definitions are not consistent across studies, making it impossible to combine results & difficult to interpret data.	Consensus conference to determine appropriate definitions.

Abbreviations: CD=cesarean delivery; ERCD=elective repeat cesarean delivery; FTP=failure to progress; IV=intravenous; PGE=prostaglandin E₂; PO=orally administered; RCT=randomized controlled trial; TOL=trial of labor; VBAC=vaginal birth after cesarean; VD=vaginal delivery

References

1. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). <http://hcupnet.ahrq.gov/>. Accessed Dec 9, 2009.
2. Taffel SM, Placek PJ, Liss T. Trends in the United States cesarean section rate and reasons for the 1980-85 rise. *Am J Public Health*. 1987;77(8):955-959.
3. Cesarean Childbirth. NIH Consensus Statement Online 1980;3(6):1-30.
4. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S. Births: final data for 2004. *Natl Vital Stat Rep*. 2006;55(1):1-101.
5. Placek PJ, Taffel S, Moien M. Cesarean section delivery rates: United States, 1981. *Am J Public Health*. 1981;73(8):861-862.
6. Placek PJ, Taffel SM. The Frequency of Complications in Cesarean and Noncesarean Deliveries, 1970 and 1978. *Public Health Rep*. 1983;98(4):396-400.
7. Healthy People 2010. <http://www.healthypeople.gov/>. Accessed Dec 4, 2009.
8. Hamilton B, Martin J, Ventura S. *Births: Preliminary data for 2007*. *Natl Vital Stat Rep, Web Release*. Hyattsville, MD: National Center for Vital Statistics; March 18, 2009.
9. Martin JA, Hamilton BE, Sutton PD, et al. Births: Final Data for 2006. *Natl Vital Stat Rep*. 2009;57(7):1-102.
10. McMahan MJ, Luther ER, Bowes WA, Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section. *N Engl J Med*. 1996;335(10):689-695.
11. Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. *N Engl J Med*. 2001;345(1):3-8.
12. Development OfEca. OECD health data 2007: statistics and indicators for 30 countries 2007. 6-30-2009; http://www.oecd.org/document/30/0,2340,en_2649_34631_12968734_1_1_1_1,00.html. Accessed Dec 16, 2009.
13. Eden KB, Hashima JN, Osterweil P, Nygren P, Guise J-M. Childbirth preferences after cesarean birth: a review of the evidence. *Birth*. 2004;31(1):49-60.
14. Fawcett J, Tulman L, Spedden J. Responses to vaginal birth after cesarean section. *J Obstet Gynecol Neonatal Nurs*. 1994;23(3):253-259.
15. Kirk EP, Doyle KA, Leigh J, Garrard ML. Vaginal birth after cesarean or repeat cesarean section: medical risks or social realities? *Am J Obstet Gynecol*. 1990;162(6):1398-1403; discussion 1403-1395.
16. Lau TK, Wong SH, Li CY. A study of patients' acceptance towards vaginal birth after cesarean section. *Aust N Z J Obstet Gynaecol*. 1996;36(2):155-158.
17. Murphy MC, Harvey SM. Choice of a childbirth method after cesarean. *Women Health*. 1989;15(2):67-85.
18. Moffat MA, Bell JS, Porter MA, et al. Decision making about mode of delivery among pregnant women who have previously had a cesarean section: A qualitative study. *BJOG*. 2007;114(1):86-93.
19. Farnworth A, Robson SC, Thomson RG, Watson DB, Murtagh MJ. Decision support for women choosing mode of delivery after a previous cesarean section: a developmental study. *Patient Educ Couns*. 2008;71(1):116-124.
20. McClain CS. The making of a medical tradition: vaginal birth after cesarean. *Soc Sci Med*. 1990;31(2):203-210.
21. Dilks FM, Beal JA. Role of self-efficacy in birth choice. *J Perinat Neonatal Nurs*. 1997;11(1):1-9.
22. Meddings F, Phipps FM, Haith-Cooper M, Haigh J. Vaginal birth after cesarean section (VBAC): exploring women's perceptions. *J Clin Nurs*. 2007;16(1):160-167.
23. Cleary-Goldman J, Cornelisse K, Simpson LL, Robinson JN. Previous cesarean delivery: understanding and satisfaction with mode of delivery in a subsequent pregnancy in patients participating in a formal vaginal birth after cesarean counseling program. *Am J Perinatol*. 2005;22(4):217-221.
24. Lucas A. Information for women after CS: are they getting enough? *RCM Midwives*. 2004;7(11):472-475.
25. Melnikow J, Romano P, Gilbert WM, Schembri M, Keyzer J, Kravitz RL. Vaginal birth after cesarean in California. *Obstet Gynecol*. 2001;98(3):421-426.
26. Norman P, Kostovcik S, Lanning A. Elective repeat cesarean sections: how many could be vaginal births? *CMAJ*. 1993;149(4):431-435.
27. Selo-Ojeme D, Abulhassan N, Mandal R, Tirlapur S, Selo-Ojeme U. Preferred and actual delivery mode after a cesarean in London, UK. *Int J Gynaecol Obstet*. 2008;102(2):156-159.
28. Fraser W, Maunsell E, Hodnett E, Moutquin JM. Randomized controlled trial of a prenatal vaginal birth after cesarean section education and support program. Childbirth Alternatives Post-Cesarean Study Group. *Am J Obstet Gynecol*. 1997;176(2):419-425.
29. Renner RM, Eden KB, Osterweil P, Chan BK, Guise JM. Informational factors influencing patient's childbirth preferences after prior cesarean. *Am J Obstet Gynecol*. 2007;196(5):e14-16.

30. Sur S, Mackenzie IZ. Does discussion of possible scar rupture influence preferred mode of delivery after a caesarean section? *J Obstet Gynaecol.* 2005;25(4):338-341.
31. Eden KB, Dolan JG, Perrin NA, et al. Patients were more consistent in randomized trial at prioritizing childbirth preferences using graphic-numeric than verbal formats. *J Clin Epidemiol.* 2009;62(4):415-424.e413.
32. Montgomery AA, Emmett CL, Fahey T, et al. Two decision aids for mode of delivery among women with previous caesarean section: randomised controlled trial. *BMJ.* 2007;334(7607):1305.
33. Shorten A, Shorten B, Keogh J, West S, Morris J. Making choices for childbirth: a randomized controlled trial of a decision-aid for informed birth after caesarean. *Birth.* 2005;32(4):252-261.
34. Frost J, Shaw A, Montgomery A, Murphy DJ. Women's views on the use of decision aids for decision making about the method of delivery following a previous caesarean section: qualitative interview study. *BJOG.* 2009;116(7):896-905.
35. Caron A, Neuhauser D. The effect of public accountability on hospital performance: trends in rates for caesarean sections and vaginal births after caesarean section in Cleveland, Ohio. *Qual Manag Health Care.* 1999;7(2):1-10.
36. Macones GA. Clinical outcomes in VBAC attempts: what to say to patients? *Am J Obstet Gynecol.* 2008;199(1):1-2.
37. ACOG Releases 2009 Medical Liability Survey. Results Paint Dismal Reality for Ob-Gyns and Their Patients. http://www.acog.org/from_home/publications/press_releases/nr09-11-09.cfm. Accessed Dec 1, 2009.
38. Angelini DJ, Greenwald L. Closed claims analysis of 65 medical malpractice cases involving nurse-midwives. *J Midwifery Womens Health.* 2005;50(6):454-460.
39. Clark SL, Vines VL, Belfort MA. Fetal injury associated with routine vacuum use during caesarean delivery. *Am J Obstet Gynecol.* 2008;198(4):e4.
40. Stalnaker BL, Maher JE, Kleinman GE, Macksey JM, Fishman LA, Bernard JM. Characteristics of successful claims for payment by the Florida Neurologic Injury Compensation Association Fund. *Am J Obstet Gynecol.* 1997;177(2):268-271; discussion 271-263.
41. Localio AR, Lawthers AG, Bengtson JM, et al. Relationship Between Malpractice Claims and Cesarean Delivery. *JAMA.* 1993;269(3):366-373.
42. Murthy K, Grobman WA, Lee TA, Holl JL. Association Between Rising Professional Liability Insurance Premiums and Primary Cesarean Delivery Rates. *Obstet Gynecol.* 2007;110(6):1264-1269.
43. Yang YT, Mello MM, Subramanian SV, Studdert DM. Relationship between malpractice litigation pressure and rates of cesarean section and vaginal birth after cesarean section. *Med Care.* 2009;47(2):234-242.
44. Brill Y, Kingdom J, Thomas J, et al. The management of VBAC at term: a survey of Canadian obstetricians. *J Obstet Gynaecol Can.* 2003;25(4):300-310.
45. Coleman VH, Erickson K, Schulkin J, Zinberg S, Sachs BP. Vaginal birth after cesarean delivery: practice patterns of obstetrician-gynecologists. *J Reprod Med.* 2005;50(4):261-266.
46. Dodd J, Crowther CA. Vaginal birth after Caesarean section: a survey of practice in Australia and New Zealand. *Aust N Z J Obstet Gynaecol.* 2003;43(3):226-231.
47. Kamal P, Dixon-Woods M, Kurinczuk JJ, Oppenheimer C, Squire P, Waugh J. Factors influencing repeat caesarean section: qualitative exploratory study of obstetricians' and midwives' accounts. *BJOG.* 2005;112(8):1054-1060.
48. Kenton K, Brincat C, Mutone M, Brubaker L. Repeat cesarean section and primary elective cesarean section: recently trained obstetrician-gynecologist practice patterns and opinions. *Am J Obstet Gynecol.* 2005;192(6):1872-1875; discussion 1875-1876.
49. Sur S, Murphy KW, Mackenzie IZ. Delivery after caesarean section: consultant obstetricians' professional advice and personal preferences. *J Obstet Gynaecol.* 2009;29(3):212-216.
50. Guise J-M. Anticipating and responding to obstetric emergencies. *Best Pract Res Clin Obstet Gynaecol.* 2007;21(4):625-638.
51. Guise J-M, Segel S. Teamwork in obstetric critical care. *Best Pract Res Clin Obstet Gynaecol.* 2008;22(5):937-951.
52. Veltman L. Vaginal birth after caesarean checklist: an evidence-based approach to improving care during VBAC trials. *J Healthc Risk Manag.* 2009;29(1):22-27.
53. ACOG practice bulletin. Vaginal birth after previous cesarean delivery. Number 5, July 1999 (replaces practice bulletin number 2, October 1998). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. *Int J Gynaecol Obstet.* 1999;66(2):197-204.
54. Pinette MG, Kahn J, Gross KL, Wax JR, Blackstone J, Cartin A. Vaginal birth after Cesarean rates are declining rapidly in the rural state of Maine. *J Matern Fetal Neonatal Med.* 2004;16(1):37-43.
55. Misra A. Impact of the HealthChoice program on cesarean section and vaginal birth after C-section deliveries: a retrospective analysis. *Matern Child Health J.* 2008;12(2):266-274.
56. Roberts RG, Deutchman M, King VJ, Fryer GE, Miyoshi TJ. Changing policies on vaginal birth after cesarean: impact on access. *Birth.* 2007;34(4):316-322.

57. Oleske DM, Linn ES, Nachman KL, Marder RJ, Thompson LD. Cesarean and VBAC delivery rates in Medicaid managed care, Medicaid fee-for-service, and private managed care. *Birth*. 1998;25(2):125-127.
58. Wagner CL, Metts AK. Rates of successful vaginal delivery after cesarean for patients with private versus public insurance. *J Perinatol*. 1999;19(1):14-18.
59. Grant D. Physician financial incentives and cesarean delivery: new conclusions from the healthcare cost and utilization project. *J Health Econ*. 2009;28(1):244-250.
60. Hammoud A, Hendler I, Gauthier RJ, Berman S, Sansregret A, Bujold E. The effect of gestational age on trial of labor after Cesarean section. *J Matern Fetal Neonatal Med*. 2004;15(3):202-206.
61. Quinones JN, Stamilio DM, Pare E, Peipert JF, Stevens E, Macones GA. The effect of prematurity on vaginal birth after cesarean delivery: success and maternal morbidity. *Obstet Gynecol*. 2005;105(3):519-524.
62. Guise JM, McDonagh MS, Hashima J, et al. Vaginal birth after cesarean (VBAC). *Evid Rep Technol Assess (Summ)*. 2003(71):1-8.
63. MacDorman MF, Kirmeyer S, MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. *Natl Vital Stat Rep*. 2009;57(8):1-19.
64. Slavin RE. Best Evidence Synthesis: An Intelligent Alternative to Meta-Analysis. *J Clin Epidemiol*. 1995;48(1):9-18.
65. Agency for Healthcare Research and Quality. *Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0*. Rockville, MD 2007.
66. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. *Health Tech Assess*. 2003;7(27):iii-x, 1-173.
67. Altman DG. *Practical Statistics for Medical Research*. London: Chapman & Hall; 1991.
68. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.
69. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration*. 2009.
70. Tufts Medical Center. MetaAnalyst: Powerful meta-analysis software. http://tuftscaes.org/meta_analyst/. Accessed Dec 8, 2009.
71. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. *Stat Med*. 2000;19:3417-3432.
72. Hamza TH, van Houwelingen HC, Stijnen T, Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. *J Clin Epidemiol*. 2008;61(1):41-51.
73. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. *BMJ*. 2001;322(7300):1479-1480.
74. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. *Methods for Meta-Analysis in Medical Research*. John Wiley & Sons, Inc.; 2000.
75. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. *Stat Med*. 1999;18(20):2693-2708.
76. Bais JM, van der Borden DM, Pel M, et al. Vaginal birth after caesarean section in a population with a low overall caesarean section rate. *Eur J Obstet Gynecol Reprod Biol*. 2001;96(2):158-162.
77. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol*. 1994;83(6):927-932.
78. Hibbard JU, Gilbert S, Landon MB, et al. Trial of labor or repeat cesarean delivery in women with morbid obesity and previous cesarean delivery. *Obstet Gynecol*. 2006;108(1):125-133.
79. Hook B, Kiwi R, Amini SB, Fanaroff A, Hack M. Neonatal morbidity after elective repeat cesarean section and trial of labor. *Pediatrics*. 1997;100(3 Pt 1):348-353.
80. Landon MB, Spong CY, Thom E, et al. Risk of uterine rupture with a trial of labor in women with multiple and single prior cesarean delivery. *Obstet Gynecol*. 2006;108(1):12-20.
81. Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after cesarean. *Am J Obstet Gynecol*. 1987;157(6):1510-1515.
82. Rozenberg P, Goffinet F, Philippe HJ, Nisand I. Thickness of the lower uterine segment: its influence in the management of patients with previous cesarean sections. *Eur J Obstet Gynecol Reprod Biol*. 1999;87(1):39-45.
83. Rozenberg P, Goffinet F, Phillippe HJ, Nisand I. Ultrasonographic measurement of lower uterine segment to assess risk of defects of scarred uterus. *Lancet*. 1996;347(8997):281-284.
84. Stovall TG, Shaver DC, Solomon SK, Anderson GD. Trial of labor in previous cesarean section patients, excluding classical cesarean sections. *Obstet Gynecol*. 1987;70(5):713-717.
85. Strong JM, McQuillan K. Factors affecting mode of delivery in labour following a single previous birth by cesarean. *J Obstet Gynaecol*. 1996;16(5).
86. Cameron CA, Roberts CL, Peat B. Predictors of labor and vaginal birth after cesarean section. *Int J Gynaecol Obstet*. 2004;85(3):267-269.
87. DeFranco EA, Rampersad R, Atkins KL, et al. Do vaginal birth after cesarean outcomes differ based on hospital setting? *Am J Obstet Gynecol*. 2007;197(4):400.e401-406.
88. DiMaio H, Edwards RK, Euliano TY, Treloar RW, Cruz AC. Vaginal birth after cesarean delivery: an historic cohort cost analysis. *Am J Obstet Gynecol*. 2002;186(5):890-892.

89. Durnwald C, Mercer B. Vaginal birth after Cesarean delivery: predicting success, risks of failure. *J Matern Fetal Neonatal Med.* 2004;15(6):388-393.
90. Fisler RE, Cohen A, Ringer SA, Lieberman E. Neonatal outcome after trial of labor compared with elective repeat cesarean section. *Birth.* 2003;30(2):83-88.
91. Gonen R, Nisenblat V, Barak S, Tamir A, Ohel G. Results of a well-defined protocol for a trial of labor after prior cesarean delivery. *Obstet Gynecol.* 2006;107(2 Pt 1):240-245.
92. Gregory KD, Korst LM, Cane P, Platt LD, Kahn K. Vaginal birth after cesarean and uterine rupture rates in California. *Obstet Gynecol.* 1999;94(6):985-989.
93. Gregory KD, Korst LM, Fridman M, et al. Vaginal birth after cesarean: clinical risk factors associated with adverse outcome. *Am J Obstet Gynecol.* 2008;198(4):452.e451-410; discussion 452.e410-452.
94. Hueston WJ, Rudy M. Factors predicting elective repeat cesarean delivery. *Obstet Gynecol.* 1994;83(5 Pt 1):741-744.
95. Kugler E, Shoham-Vardi I, Burstien E, Mazor M, Hershkovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. *Arch Gynecol Obstet.* 2008;277(4):339-344.
96. Locatelli A, Regalia AL, Ghidini A, Ciriello E, Biffi A, Pezzullo JC. Risks of induction of labour in women with a uterine scar from previous low transverse caesarean section. *BJOG.* 2004;111(12):1394-1399.
97. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
98. Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. *Am J Obstet Gynecol.* 2005;193(5):1656-1662.
99. McNally OM, Turner MJ. Induction of labour after 1 previous Caesarean section. *Aust N Z J Obstet Gynaecol.* 1999;39(4):425-429.
100. Obara H, Minakami H, Koike T, Takamizawa S, Matsubara S, Sato I. Vaginal birth after cesarean delivery: results in 310 pregnancies. *J Obstet Gynaecol Res.* 1998;24(2):129-134.
101. Pang MW, Law LW, Leung TY, Lai PY, La TK. Sociodemographic factors and pregnancy events associated with women who declined vaginal birth after cesarean section. *Eur J Obstet Gynecol Reprod Biol.* 2009;143(1):24-28.
102. Pickhardt MG, Martin JN, Jr., Meydrech EF, et al. Vaginal birth after cesarean delivery: are there useful and valid predictors of success or failure? *Am J Obstet Gynecol.* 1992;166(6 Pt 1):1811-1815; discussion 1815-1819.
103. Smith GCS, Pell JP, Cameron AD, Dobbie R. Risk of perinatal death associated with labor after previous cesarean delivery in uncomplicated term pregnancies. *JAMA.* 2002;287(20):2684-2690.
104. Smith GCS, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. *PLoS Med.* 2005;2(9):e252.
105. Socol ML, Peaceman AM. Vaginal birth after cesarean: an appraisal of fetal risk. *Obstet Gynecol.* 1999;93(5 Pt 1):674-679.
106. Spaans WA, Sluijs MB, van Roosmalen J, Bleker OP. Risk factors at caesarean section and failure of subsequent trial of labour. *Eur J Obstet Gynecol Reprod Biol.* 2002;100(2):163-166.
107. Troyer LR, Parisi VM. Obstetric parameters affecting success in a trial of labor: designation of a scoring system. *Am J Obstet Gynecol.* 1992;167(4 Pt 1):1099-1104.
108. Wen SW, Rusen ID, Walker M, et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(4):1263-1269.
109. Martin JA, Hamilton BE, Menacker F, Sutton PD, Mathews JT. *Preliminary births for 2004: Infant and maternal health. Health E-stats.* Hyattsville, MD: National Center for Health Statistics; 2005.
110. Durnwald CP, Ehrenberg HM, Mercer BM. The impact of maternal obesity and weight gain on vaginal birth after cesarean section success. *Am J Obstet Gynecol.* 2004;191(3):954-957.
111. Kabir AA, Pridjian G, Steinmann WC, Herrera EA, Khan MM. Racial differences in cesareans: an analysis of U.S. 2001 National Inpatient Sample Data.[see comment][erratum appears in *Obstet Gynecol.* 2005 Jun;105(6):1495]. *Obstet Gynecol.* 2005;105(4):710-718.
112. Bujold E. Uterine rupture during a trial of labor after a one- versus two-layer closure of low transverse cesarean. *Am J Obstet Gynecol.* 2001;184(suppl)(S18).
113. Chang JJ, Stamilio DM, Macones GA. Effect of hospital volume on maternal outcomes in women with prior cesarean delivery undergoing trial of labor. *Am J Epidemiol.* 2008;167(6):711-718.
114. Harper LM, Cahill AG, Stamilio DM, Odibo AO, Peipert JF, Macones GA. Effect of gestational age at the prior cesarean delivery on maternal morbidity in subsequent VBAC attempt. *Am J Obstet Gynecol.* 2009;200(3):276.e271-276.
115. Hendler I, Bujold E. Effect of prior vaginal delivery or prior vaginal birth after cesarean delivery on obstetric outcomes in women undergoing trial of labor. *Obstet Gynecol.* 2004;104(2):273-277.

116. Jakobi P, Weissman A, Peretz BA, Hocherman I. Evaluation of prognostic factors for vaginal delivery after cesarean section. *J Reprod Med.* 1993;38(9):729-733.
117. Lieberman E, Ernst EK, Rooks JP, Stapleton S, Flamm B. Results of the national study of vaginal birth after cesarean in birth centers. *Obstet Gynecol.* 2004;104(5 Pt 1):933-942.
118. van Gelderen CJ, England MJ, Naylor GA, Katzeff TC. Labour in patients with a caesarean section scar. The place of oxytocin augmentation. *S Afr Med J.* 1986;70(9):529-532.
119. Caughey AB, Shipp TD, Repke JT, Zelop CM, Cohen A, Lieberman E. Rate of uterine rupture during a trial of labor in women with one or two prior cesarean deliveries. *Am J Obstet Gynecol.* 1999;181(4):872-876.
120. Costantine MM, Fox K, Byers BD, et al. Validation of the prediction model for success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2009;114(5):1029-1033.
121. Delaney T, Young DC. Spontaneous versus induced labor after a previous cesarean delivery. *Obstet Gynecol.* 2003;102(1):39-44.
122. Dinsmoor MJ, Brock EL. Predicting failed trial of labor after primary cesarean delivery. *Obstet Gynecol.* 2004;103(2):282-286.
123. Elkousy MA, Sammel M, Stevens E, Peipert JF, Macones G. The effect of birth weight on vaginal birth after cesarean delivery success rates. *Am J Obstet Gynecol.* 2003;188(3):824-830.
124. El-Sayed YY, Watkins MM, Fix M, Druzin ML, Pullen KM, Caughey AB. Perinatal outcomes after successful and failed trials of labor after cesarean delivery. *Am J Obstet Gynecol.* 2007;196(6):583.e581-585; discussion 583.e585.
125. Flamm BL, Goings JR, Fuelberth NJ, Fischermann E, Jones C, Hersh E. Oxytocin during labor after previous cesarean section: results of a multicenter study. *Obstet Gynecol.* 1987;70(5):709-712.
126. Goodall PT, Ahn JT, Chapa JB, Hibbard JU. Obesity as a risk factor for failed trial of labor in patients with previous cesarean delivery. *Am J Obstet Gynecol.* 2005;192(5):1423-1426.
127. Gyamfi C, Juhasz G, Gyamfi P, Stone JL. Increased success of trial of labor after previous vaginal birth after cesarean. *Obstet Gynecol.* 2004;104(4):715-719.
128. Hashima JN, Guise J-M. Vaginal birth after cesarean: a prenatal scoring tool. *Am J Obstet Gynecol.* 2007;196(5):e22-23.
129. Hollard AL, Wing DA, Chung JH, et al. Ethnic disparity in the success of vaginal birth after cesarean delivery. *J Matern Fetal Neonatal Med.* 2006;19(8):483-487.
130. Horenstein JM, Eglinton GS, Tahilramaney MP, Boucher M, Phelan JP. Oxytocin use during a trial of labor in patients with previous cesarean section. *J Reprod Med.* 1984;29(1):26-30.
131. Horenstein JM, Phelan JP. Previous cesarean section: the risks and benefits of oxytocin usage in a trial of labor. *Am J Obstet Gynecol.* 1985;151(5):564-569.
132. Hoskins IA, Gomez JL. Correlation between maximum cervical dilatation at cesarean delivery and subsequent vaginal birth after cesarean delivery. *Obstet Gynecol.* 1997;89(4):591-593.
133. Huang WH, Nakashima DK, Rummey PJ, Keegan KA, Jr., Chan K. Interdelivery interval and the success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2002;99(1):41-44.
134. Johnson C, Oriol N, Flood K. Trial of labor: a study of 110 patients. *J Clin Anesth.* 1991;3(3):216-218; discussion 214-215.
135. Juhasz G, Gyamfi C, Gyamfi P, Tocce K, Stone JL. Effect of body mass index and excessive weight gain on success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2005;106(4):741-746.
136. Learman LA, Evertson LR, Shiboski S. Predictors of repeat cesarean delivery after trial of labor: do any exist? *J Am Coll Surg.* 1996;182(3):257-262.
137. Nguyen TV, Dinh TV, Suresh MS, Kinch RA, Anderson GD. Vaginal birth after cesarean section at the University of Texas. *J Reprod Med.* 1992;37(10):880-882.
138. Ouzounian JG, Miller DA, Paul RH. Amnioinfusion in women with previous cesarean births: a preliminary report. *Am J Obstet Gynecol.* 1996;174(2):783-786.
139. Pathadey SD, Van Woerden HC, Jenkinson SD. Induction of labour after a previous caesarean section: a retrospective study in a district general hospital. *J Obstet Gynaecol.* 2005;25(7):662-665.
140. Raynor BD. The experience with vaginal birth after cesarean delivery in a small rural community practice. *Am J Obstet Gynecol.* 1993;168(1 Pt 1):60-62.
141. Sakala EP, Kaye S, Murray RD, Munson LJ. Oxytocin use after previous cesarean: why a higher rate of failed labor trial? *Obstet Gynecol.* 1990;75(3 Pt 1):356-359.
142. Vinueza CA, Chauhan SP, Barker L, Hendrix NW, Scardo JA. Predicting the success of a trial of labor with a simple scoring system. *J Reprod Med.* 2000;45(4):332-336.
143. Weinstein D, Benshushan A, Tanos V, Zilberstein R, Rojansky N. Predictive score for vaginal birth after cesarean section. *Am J Obstet Gynecol.* 1996;174(1 Pt 1):192-198.
144. Yetman TJ, Nolan TE. Vaginal birth after cesarean section: a reappraisal of risk. *Am J Obstet Gynecol.* 1989;161(5):1119-1123.
145. Yogev Y, Ben-Haroush A, Lahav E, Horowitz E, Hod M, Kaplan B. Induction of labor with prostaglandin E2 in women with previous cesarean section and unfavorable cervix. *Eur J Obstet Gynecol Reprod Biol.* 2004;116(2):173-176.

146. Zelop CM, Shipp TD, Cohen A, Repke JT, Lieberman E. Trial of labor after 40 weeks' gestation in women with prior cesarean. *Obstet Gynecol.* 2001;97(3):391-393.
147. Agnew G, Turner MJ. Vaginal prostaglandin gel to induce labour in women with one previous caesarean section. *J Obstet Gynaecol.* 2009;29(3):209-211.
148. Ben-Aroya Z, Hallak M, Segal D, Friger M, Katz M, Mazor M. Ripening of the uterine cervix in a post-cesarean parturient: prostaglandin E2 versus Foley catheter. *J Matern Fetal Neonatal Med.* 2002;12(1):42-45.
149. Blanco JD, Collins M, Willis D, Prien S. Prostaglandin E2 gel induction of patients with a prior low transverse cesarean section. *Am J Perinatol.* 1992;9(2):80-83.
150. Bujold E, Blackwell SC, Gauthier RJ. Cervical ripening with transcervical foley catheter and the risk of uterine rupture. *Obstet Gynecol.* 2004;103(1):18-23.
151. Chilaka VN, Cole MY, Habayeb OMH, Konje JC. Risk of uterine rupture following induction of labour in women with a previous caesarean section in a large UK teaching hospital. *J Obstet Gynaecol.* 2004;24(3):264-265.
152. Del Valle GO, Adair CD, Sanchez-Ramos L, Gaudier FL, McDyer DC, Delke I. Cervical ripening in women with previous cesarean deliveries. *Int J Gynaecol Obstet.* 1994;47(1):17-21.
153. Flamm BL, Anton D, Goings JR, Newman J. Prostaglandin E2 for cervical ripening: a multicenter study of patients with prior cesarean delivery. *Am J Perinatol.* 1997;14(3):157-160.
154. Gibson DH. Vaginal delivery after caesarean section in primigravidae. *Ir J Med Sci.* 1988;157(9):290-292.
155. Goldberger SB, Rosen DJ, Michaeli G, Markov S, Ben-Nun I, Fejgin MD. The use of PGE2 for induction of labor in parturients with a previous cesarean section scar. *Acta Obstet Gynecol Scand.* 1989;68(6):523-526.
156. Grobman WA, Gilbert S, Landon MB, et al. Outcomes of induction of labor after one prior cesarean. *Obstet Gynecol.* 2007;109(2 Pt 1):262-269.
157. Kayani SI, Alfirevic Z. Uterine rupture after induction of labour in women with previous caesarean section. *BJOG.* 2005;112(4):451-455.
158. Meehan FP, Burke G. Trial of labour following prior section; a 5 year prospective study (1982-1987). *Eur J Obstet Gynecol Reprod Biol.* 1989;31(2):109-117.
159. Norman M, Ekman G. Preinductive cervical ripening with prostaglandin E2 in women with one previous cesarean section. *Acta Obstet Gynecol Scand.* 1992;71(5):351-355.
160. Rageth JC, Juzi C, Grossenbacher H. Delivery after previous cesarean: a risk evaluation. Swiss Working Group of Obstetric and Gynecologic Institutions. *Obstet Gynecol.* 1999;93(3):332-337.
161. Rayburn WF, Gittens LN, Lucas MJ, Gall SA, Martin ME. Weekly administration of prostaglandin E2 gel compared with expectant management in women with previous cesareans. Prepidil Gel Study Group. *Obstet Gynecol.* 1999;94(2):250-254.
162. Silver RK, Gibbs RS. Predictors of vaginal delivery in patients with a previous cesarean section, who require oxytocin. *Am J Obstet Gynecol.* 1987;156(1):57-60.
163. Umeadi UP, Mehta R, Thomas S. Delivery outcome after induction of labour using prostaglandin in women with one previous caesarean section. *J Obstet Gynaecol.* 2007;27(8):810-811.
164. Zelop CM, Shipp TD, Repke JT, Cohen A, Caughey AB, Lieberman E. Uterine rupture during induced or augmented labor in gravid women with one prior cesarean delivery. *Am J Obstet Gynecol.* 1999;181(4):882-886.
165. Ardiet E, Subtil D, Puech F. Cervical ripening with dinoprostone gel and previous cesarean delivery. *Int J Gynaecol Obstet.* 2005;91(3):260-261.
166. Cnattingius R, Hoglund B, Kieler H. Emergency cesarean delivery in induction of labor: an evaluation of risk factors. *Acta Obstet Gynecol Scand.* 2005;84(5):456-462.
167. Flamm BL, Geiger AM. Vaginal birth after cesarean delivery: an admission scoring system. *Obstet Gynecol.* 1997;90(6):907-910.
168. Locatelli A, Ghidini A, Ciriello E, Incerti M, Bonardi C, Regalia AL. Induction of labor: comparison of a cohort with uterine scar from previous cesarean section vs. a cohort with intact uterus. *J Matern Fetal Neonatal Med.* 2006;19(8):471-475.
169. Ravasia DJ, Wood SL, Pollard JK. Uterine rupture during induced trial of labor among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2000;183(5):1176-1179.
170. Taylor DR, Doughty AS, Kaufman H, Yang L, Iannucci TA. Uterine rupture with the use of PGE2 vaginal inserts for labor induction in women with previous cesarean sections. *J Reprod Med.* 2002;47(7):549-554.
171. Katz VL, Farmer RM, Dean CA, Carpenter ME. Use of misoprostol for cervical ripening. *South Med J.* 2000;93(9):881-884.
172. Choy-Hee L, Raynor BD. Misoprostol induction of labor among women with a history of cesarean delivery. *Am J Obstet Gynecol.* 2001;184(6):1115-1117.
173. Lelaidier C, Baton C, Benifla JL, Fernandez H, Bourget P, Frydman R. Mifepristone for labour induction after previous caesarean section. *Br J Obstet Gynaecol.* 1994;101(6):501-503.
174. Goetzl L, Shipp TD, Cohen A, Zelop CM, Repke JT, Lieberman E. Oxytocin dose and the risk of uterine rupture in trial of labor after cesarean. *Obstet Gynecol.* 2001;97(3):381-384.

175. Paul RH, Phelan JP, Yeh SY. Trial of labor in the patient with a prior cesarean birth. *Am J Obstet Gynecol.* 1985;151(3):297-304.
176. Taylor AVG, Sellers S, Ah-Moye M, MacKenzie IZ. A prospective random allocation trial to compare vaginal prostaglandin E2 with intravenous oxytocin for labour induction in women previously delivered by caesarean section. *J Obstet Gynecol.* 1993;13(5):333-336.
177. Hannah ME, Ohlsson A, Farine D, et al. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. *N Engl J Med.* 1996;334(16):1005-1010.
178. Peleg D, Hannah ME, Hodnett ED, Foster GA, Willan AR, Farine D. Predictors of cesarean delivery after prelabor rupture of membranes at term. *Obstet Gynecol.* 1999;93(6):1031-1035.
179. Khotaba S, Volfson M, Tarazova L, et al. Induction of labor in women with previous cesarean section using the double balloon device. *Acta Obstet Gynecol Scand.* 2001;80(11):1041-1042.
180. Segal S, Gemer O, Zohav E, Siani M, Sassoon E. Evaluation of breast stimulation for induction of labor in women with a prior cesarean section and in grandmultiparas. *Acta Obstet Gynecol Scand.* 1995;74(1):40-41.
181. Grobman WA, Lai Y, Landon MB, et al. Development of a nomogram for prediction of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2007;109(4):806-812.
182. Landon MB, Leindecker S, Spong CY, et al. The MFMU Cesarean Registry: factors affecting the success of trial of labor after previous cesarean delivery. *Am J Obstet Gynecol.* 2005;193(3 Pt 2):1016-1023.
183. Bujold E, Blackwell SC, Hendler I, Berman S, Sorokin Y, Gauthier RJ. Modified Bishop's score and induction of labor in patients with a previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(5):1644-1648.
184. Gonen R, Tamir A, Degani S, Ohel G. Variables associated with successful vaginal birth after one cesarean section: a proposed vaginal birth after cesarean section score. *Am J Perinatol.* 2004;21(8):447-453.
185. King DE, Lahiri K. Socioeconomic factors and the odds of vaginal birth after cesarean delivery. *JAMA.* 1994;272(7):524-529.
186. Shipp TD, Zelop CM, Repke JT, Cohen A, Caughey AB, Lieberman E. Labor after previous cesarean: influence of prior indication and parity. *Obstet Gynecol.* 2000;95(6 Pt 1):913-916.
187. Srinivas SK, Stamilio DM, Stevens EJ, Odibo AO, Peipert JF, Macones GA. Predicting failure of a vaginal birth attempt after cesarean delivery. *Obstet Gynecol.* 2007;109(4):800-805.
188. Zelop CM, Shipp TD, Repke JT, Cohen A, Lieberman E. Outcomes of trial of labor following previous cesarean delivery among women with fetuses weighing >4000 g. *Am J Obstet Gynecol.* 2001;185(4):903-905.
189. Macones GA, Hausman N, Edelstein R, Stamilio DM, Marder SJ. Predicting outcomes of trials of labor in women attempting vaginal birth after cesarean delivery: a comparison of multivariate methods with neural networks. *Am J Obstet Gynecol.* 2001;184(3):409-413.
190. Cahill AG, Stamilio DM, Odibo AO, Peipert J, Stevens E, Macones GA. Racial disparity in the success and complications of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2008;111(3):654-658.
191. Caughey AB, Shipp TD, Repke JT, Zelop C, Cohen A, Lieberman E. Trial of labor after cesarean delivery: the effect of previous vaginal delivery. *Am J Obstet Gynecol.* 1998;179(4):938-941.
192. Mercer BM, Gilbert S, Landon MB, et al. Labor outcomes with increasing number of prior vaginal births after cesarean delivery. *Obstet Gynecol.* 2008;111(2 Pt 1):285-291.
193. Simon R, Altman D. Statistical aspects of prognostic factor studies in oncology. *Br J Cancer.* 1994;69:979-985.
194. Hashima JN, Eden KB, Osterweil P, Nygren P, Guise J-M. Predicting vaginal birth after cesarean delivery: a review of prognostic factors and screening tools. *Am J Obstet Gynecol.* 2004;190(2):547-555.
195. Altman D. Prognosis and prognostic research: validating prognostic model. *BMJ.* 2009;338:1430-1435.
196. Alamia VJ, Meyer BA, Selioutski O, Vohra N. Can a VBAC scoring system predict uterine rupture in patients attempting a trial of labor? Paper presented at: ACOG 47th Annual Clinical Meeting; May 19, 1999.
197. Macones GA. The utility of clinical tests of eligibility for a trial of labour following a caesarean section: a decision analysis. *Br J Obstet Gynaecol.* 1999;106(7):642-646.
198. Hoyert DL, Hoyert DL. Maternal mortality and related concepts. *Vital Health Stat [3].* 2007(33):1-13.
199. Kung HC, Hoyert DL, Xu J, et al. Deaths: final data for 2005. *Natl Vital Stat Rep.* 2008;56(10):1-120.
200. Minino AM, Heron MP, Murphy SL, et al. Deaths: final data for 2004. *Natl Vital Stat Rep.* 2007;55(19):1-119.
201. Eglington GS, Phelan JP, Yeh S, Diaz FP, Wallace TM, Paul RH. Outcome of a trial of labor after prior cesarean delivery. *J Reprod Med.* 1984;29(1):3-8.
202. Eriksen NL, Buttino L, Jr. Vaginal birth after cesarean: a comparison of maternal and neonatal morbidity to elective repeat cesarean section. *Am J Perinatol.* 1989;6(4):375-379.

203. Martin JN, Jr., Harris BA, Jr., Huddleston JF, et al. Vaginal delivery following previous cesarean birth. *Am J Obstet Gynecol.* 1983;146(3):255-263.
204. Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstet Gynecol.* 2007;110(4):801-807.
205. Cahill AG, Stamilio DM, Odibo AO, et al. Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery? *Am J Obstet Gynecol.* 2006;195(4):1143-1147.
206. Cowan RK, Kinch RA, Ellis B, Anderson R. Trial of labor following cesarean delivery. *Obstet Gynecol.* 1994;83(6):933-936.
207. Flamm BL, Lim OW, Jones C, Fallon D, Newman LA, Mantis JK. Vaginal birth after cesarean section: results of a multicenter study. *Am J Obstet Gynecol.* 1988;158(5):1079-1084.
208. Flamm BL, Newman LA, Thomas SJ, Fallon D, Yoshida MM. Vaginal birth after cesarean delivery: results of a 5-year multicenter collaborative study. *Obstet Gynecol.* 1990;76(5 Pt 1):750-754.
209. Caughey AB. Maternal mortality: more than just anecdotal evidence.[comment]. *J Perinatol.* 2007;27(10):595-596.
210. Weiss JB, Nannini A, Fogerty S. From the Centers for Disease Control and Prevention. Use of hospital discharge data to monitor uterine rupture--Massachusetts, 1990-1997. *JAMA.* 2000;283(16):2098-2100.
211. Blanchette HA, Nayak S, Erasmus S. Comparison of the safety and efficacy of intravaginal misoprostol (prostaglandin E1) with those of dinoprostone (prostaglandin E2) for cervical ripening and induction of labor in a community hospital. *Am J Obstet Gynecol.* 1999;180(6 Pt 1):1551-1559.
212. Strong TH, Jr., Vega JS, O'Shaughnessy MJ, Feldman DB, Koemptgen JG. Amnioinfusion among women attempting vaginal birth after cesarean delivery. *Obstet Gynecol.* 1992;79(5 (Pt 1)):673-674.
213. Bujold E, Bujold C, Hamilton EF, Harel F, Gauthier RJ. The impact of a single-layer or double-layer closure on uterine rupture. *Am J Obstet Gynecol.* 2002;186(6):1326-1330.
214. Bujold E, Gauthier RJ. Neonatal morbidity associated with uterine rupture: what are the risk factors? *Am J Obstet Gynecol.* 2002;186(2):311-314.
215. Grobman WA, Lai Y, Landon MB, et al. Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. *Am J Obstet Gynecol.* 2008;199(1):30.e31-35.
216. Kieser KE, Baskett TF. A 10-year population-based study of uterine rupture. *Obstet Gynecol.* 2002;100(4):749-753.
217. Sciscione AC, Landon MB, Leveno KJ, et al. Previous preterm cesarean delivery and risk of subsequent uterine rupture. *Obstet Gynecol.* 2008;111(3):648-653.
218. Shipp TD, Zelop C, Cohen A, Repke JT, Lieberman E. Post-cesarean delivery fever and uterine rupture in a subsequent trial of labor. *Obstet Gynecol.* 2003;101(1):136-139.
219. Shipp TD, Zelop C, Lieberman E. Assessment of the rate of uterine rupture at the first prenatal visit: a preliminary evaluation. *J Matern Fetal Neonatal Med.* 2008;21(2):129-133.
220. Grobman WA, Gersnoviez R, Landon MB, et al. Pregnancy outcomes for women with placenta previa in relation to the number of prior cesarean deliveries. *Obstet Gynecol.* 2007;110(6):1249-1255.
221. Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. *N Engl J Med.* 2004;351(25):2581-2589.
222. Asakura H, Nakai A, Ishikawa G, Suzuki S, Araki T. Prediction of uterine dehiscence by measuring lower uterine segment thickness prior to the onset of labor: evaluation by transvaginal ultrasonography. *J Nippon Med Sch.* 2000;67(5):352-356.
223. Bujold E, Jastrow N, Simoneau J, Brunet S, Gauthier R. Prediction of complete uterine rupture by sonographic evaluation of the lower uterine segment. *Am J Obstet Gynecol.* 2009;201(3):320-322.
224. Cheung VYT. Sonographic measurement of the lower uterine segment thickness in women with previous caesarean section. *J Obstet Gynaecol Can.* 2005;27(7):674-681.
225. Gotoh H, Masuzaki H, Yoshida A, Yoshimura S, Miyamura T, Ishimaru T. Predicting incomplete uterine rupture with vaginal sonography during the late second trimester in women with prior cesarean. *Obstet Gynecol.* 2000;95(4):596-600.
226. Michaels WH, Thompson HO, Boutt A, Schreiber FR, Michaels SL, Karo J. Ultrasound diagnosis of defects in the scarred lower uterine segment during pregnancy. *Obstet Gynecol.* 1988;71(1):112-120.
227. Petrikovsky BM. Endoscopic assessment of the integrity of the postcesarean uterine wall before a trial of labor. Transcervical Endoscopy Registry. *J Reprod Med.* 1994;39(6):464-466.
228. Sibony O, Alran S, Oury J-F. Vaginal birth after cesarean section: X-ray pelvimetry at term is informative. *J Perinat Med.* 2006;34(3):212-215.
229. Tanik A, Ustun C, Cil E, Arslan A. Sonographic evaluation of the wall thickness of the lower uterine segment in patients with previous cesarean section. *J Clin Ultrasound.* 1996;24(7):355-357.

230. Macones GA, Cahill AG, Stamilio DM, Odibo A, Peipert J, Stevens EJ. Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted? *Am J Obstet Gynecol.* 2006;195(4):1148-1152.
231. Bujold E, Mehta SH, Bujold C, Gauthier RJ. Interdelivery interval and uterine rupture. *Am J Obstet Gynecol.* 2002;187(5):1199-1202.
232. Leung AS, Farmer RM, Leung EK, Medearis AL, Paul RH. Risk factors associated with uterine rupture during trial of labor after cesarean delivery: a case-control study. *Am J Obstet Gynecol.* 1993;168(5):1358-1363.
233. Leung AS, Leung EK, Paul RH. Uterine rupture after previous cesarean delivery: maternal and fetal consequences. *Am J Obstet Gynecol.* 1993;169(4):945-950.
234. Hibbard JU, Ismail MA, Wang Y, Te C, Karrison T. Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. *Am J Obstet Gynecol.* 2001;184(7):1365-1371; discussion 1371-1363.
235. Juntunen K, Makarainen L, Kirkinen P. Outcome after a high number (4-10) of repeated caesarean sections. *BJOG.* 2004;111(6):561-563.
236. Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. *Obstet Gynecol.* 2006;107(6):1226-1232.
237. Stafford I, Dildy GA, Clark SL, Belfort MA. Visually estimated and calculated blood loss in vaginal and cesarean delivery. *Am J Obstet Gynecol.* 2008;199(5):e1-7.
238. Toledo P, McCarthy RJ, Hewlett BJ, Fitzgerald PC, Wong CA. The accuracy of blood loss estimation after simulated vaginal delivery. *Anesth Analg.* 2007;105(6):1736-1740.
239. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Effects of onset of labor and mode of delivery on severe postpartum hemorrhage. *Am J Obstet Gynecol.* 2009;201(3):273.e271-279.
240. Chauhan SP, Magann EF, Carroll CS, Barrilleaux PS, Scardo JA, Martin JN, Jr. Mode of delivery for the morbidly obese with prior cesarean delivery: vaginal versus repeat cesarean section. *Am J Obstet Gynecol.* 2001;185(2):349-354.
241. Upadhyaya CD, Upadhyaya DM, Carlan SJ. Vaginal birth after cesarean delivery in a small rural community with a solo practice. *Am J Perinatol.* 2003;20(2):63-67.
242. Hansell RS, McMurray KB, Huey GR. Vaginal birth after two or more cesarean sections: a five-year experience. *Birth.* 1990;17(3):146-150; discussion 150-141.
243. Granovsky-Grisaru S, Shaya M, Diamant YZ. The management of labor in women with more than one uterine scar: is a repeat cesarean section really the only "safe" option? *J Perinat Med.* 1994;22(1):13-17.
244. Phipps MG, Watabe B, Clemons JL, Weitzen S, Myers DL. Risk factors for bladder injury during cesarean delivery. *Obstet Gynecol.* 2005;105(1):156-160.
245. Makoha FW, Fathuddien MA, Felimban HM. Choice of abdominal incision and risk of trauma to the urinary bladder and bowel in multiple cesarean sections. *Eur J Obstet Gynecol Reprod Biol.* 2006;125(1):50-53.
246. Richter HE, Brumfield CG, Cliver SP, Burgio KL, Neely CL, Varner RE. Risk factors associated with anal sphincter tear: a comparison of primiparous patients, vaginal births after cesarean deliveries, and patients with previous vaginal delivery. *Am J Obstet Gynecol.* 2002;187(5):1194-1198.
247. Hemminki E, Shelley J, Gissler M. Mode of delivery and problems in subsequent births: a register-based study from Finland. *Am J Obstet Gynecol.* 2005;193(1):169-177.
248. Hershkowitz R, Fraser D, Mazor M, Leiberman JR. One or multiple previous cesarean sections are associated with similar increased frequency of placenta previa. *Eur J Obstet Gynecol Reprod Biol.* 1995;62(2):185-188.
249. Nisenblat V, Barak S, Griness OB, Degani S, Ohel G, Gonen R. Maternal complications associated with multiple cesarean deliveries. *Obstet Gynecol.* 2006;108(1):21-26.
250. Odibo AO, Cahill AG, Stamilio DM, Stevens EJ, Peipert JF, Macones GA. Predicting placental abruption and previa in women with a previous cesarean delivery. *Am J Perinatol.* 2007;24(5):299-305.
251. Rouse DJ, MacPherson C, Landon M, et al. Blood transfusion and cesarean delivery.[erratum appears in *Obstet Gynecol.* 2006 Dec;108(6):1556]. *Obstet Gynecol.* 2006;108(4):891-897.
252. Bodelon C, Bernabe-Ortiz A, Schiff MA, Reed SD. Factors associated with peripartum hysterectomy. *Obstet Gynecol.* 2009;114(1):115-123.
253. Gilliam M, Rosenberg D, Davis F. The likelihood of placenta previa with greater number of cesarean deliveries and higher parity. *Obstet Gynecol.* 2002;99(6):976-980.
254. Knight M, Kurinczuk JJ, Spark P, Brocklehurst P, United Kingdom Obstetric Surveillance System Steering C. Cesarean delivery and peripartum hysterectomy. *Obstet Gynecol.* 2008;111(1):97-105.
255. Laughon SK, Wolfe HM, Visco AG. Prior cesarean and the risk for placenta previa on second-trimester ultrasonography. *Obstet Gynecol.* 2005;105(5 Pt 1):962-965.
256. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. *Am J Obstet Gynecol.* 2005;192(5):1458-1461.

257. Lynch CM, Kearney R, Turner MJ. Maternal morbidity after elective repeat caesarean section after two or more previous procedures. *Eur J Obstet Gynecol Reprod Biol.* 2003;106(1):10-13.
258. Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. *Am J Obstet Gynecol.* 1997;177(1):210-214.
259. Olive EC, Roberts CL, Algert CS, Morris JM. Placenta praevia: maternal morbidity and place of birth. *Aust N Z J Obstet Gynaecol.* 2005;45(6):499-504.
260. Zelop CM, Harlow BL, Frigoletto FD, Jr., Safon LE, Saltzman DH. Emergency peripartum hysterectomy. *Am J Obstet Gynecol.* 1993;168(5):1443-1448.
261. Taylor VM, Kramer MD, Vaughan TL, Peacock S. Placenta previa and prior cesarean delivery: how strong is the association? *Obstet Gynecol.* 1994;84(1):55-57.
262. Clark SL, Koonings PP, Phelan JP. Placenta previa/accrta and prior cesarean section. *Obstet Gynecol.* 1985;66(1):89-92.
263. Macones GA, Cahill A, Pare E, et al. Obstetric outcomes in women with two prior cesarean deliveries: is vaginal birth after cesarean delivery a viable option? *Am J Obstet Gynecol.* 2005;192(4):1223-1228; discussion 1228-1229.
264. Grubb DK, Kjos SL, Paul RH. Latent labor with an unknown uterine scar. *Obstet Gynecol.* 1996;88(3):351-355.
265. Lin C, Raynor BD. Risk of uterine rupture in labor induction of patients with prior cesarean section: an inner city hospital experience. *Am J Obstet Gynecol.* 2004;190(5):1476-1478.
266. Tahilramaney MP, Boucher M, Eglinton GS, Beall M, Phelan JP. Previous cesarean section and trial of labor. Factors related to uterine dehiscence. *J Reprod Med.* 1984;29(1):17-21.
267. Bujold E, Hammoud A, Schild C, Krapp M, Baumann P. The role of maternal body mass index in outcomes of vaginal births after cesarean. *Am J Obstet Gynecol.* 2005;193(4):1517-1521.
268. Carroll CS, Sr., Magann EF, Chauhan SP, Klauser CK, Morrison JC. Vaginal birth after cesarean section versus elective repeat cesarean delivery: Weight-based outcomes. *Am J Obstet Gynecol.* 2003;188(6):1516-1520; discussion 1520-1512.
269. Edwards RK, Harnsberger DS, Johnson IM, Treloar RW, Cruz AC. Deciding on route of delivery for obese women with a prior cesarean delivery. *Am J Obstet Gynecol.* 2003;189(2):385-389; discussion 389-390.
270. Hamel KJ. Incidence of adhesions at repeat cesarean delivery. *Am J Obstet Gynecol.* 2007;196(5):e31-32.
271. Ogunyemi D, Hullett S, Leeper J, Risk A. Prepregnancy body mass index, weight gain during pregnancy, and perinatal outcome in a rural black population. *J Matern Fetal Med.* 1998;7(4):190-193.
272. Boukerrou M, Lambaudie E, Collinet P, Crepin G, Cosson M. A history of cesareans is a risk factor in vaginal hysterectomies. *Acta Obstet Gynecol Scand.* 2003;82(12):1135-1139.
273. David-Montefiore E, Rouzier R, Chapron C, Darai E, Collegiale d'Obstetrique et Gynecologie de Paris-Ile de F. Surgical routes and complications of hysterectomy for benign disorders: a prospective observational study in French university hospitals. *Hum Reprod.* 2007;22(1):260-265.
274. Myers SA, Bennett TL. Incidence of significant adhesions at repeat cesarean section and the relationship to method of prior peritoneal closure. *J Reprod Med.* 2005;50(9):659-662.
275. Tulandi T, Agdi M, Zarei A, Miner L, Sikirica V. Adhesion development and morbidity after repeat cesarean delivery. *Am J Obstet Gynecol.* 2009;201(1):56.e51-56.
276. Al-Took S. Adhesion-related small-bowel obstruction after gynecologic operations. *Am J Obstet Gynecol.* 1999;180(2):313-315.
277. Bahl R, Strachan B, Murphy DJ. Outcome of subsequent pregnancy three years after previous operative delivery in the second stage of labour: cohort study. *BMJ.* 2004;328(7435):311.
278. Murphy DJ, Stirrat GM, Heron J, Team AS. The relationship between Caesarean section and subfertility in a population-based sample of 14 541 pregnancies. *Hum Reprod.* 2002;17(7):1914-1917.
279. Cramer DW, Xu H, Harlow BL. Does "incessant" ovulation increase risk for early menopause? *Am J Obstet Gynecol.* 1995;172(2 Pt 1):568-573.
280. Bahtiyar MO, Julien S, Robinson JN, et al. Prior cesarean delivery is not associated with an increased risk of stillbirth in a subsequent pregnancy: analysis of U.S. perinatal mortality data, 1995-1997. *Am J Obstet Gynecol.* 2006;195(5):1373-1378.
281. Smith GCS, Pell JP, Dobbie R. Caesarean section and risk of unexplained stillbirth in subsequent pregnancy. *Lancet.* 2003;362(9398):1779-1784.
282. Bujold E, Francoeur D. Neonatal morbidity and decision-delivery interval in patients with uterine rupture.[comment]. *J Obstet Gynaecol Can.* 2005;27(7):671-673; author reply 673.
283. Paterson CM, Saunders NJ. Mode of delivery after one caesarean section: audit of current practice in a health region. *BMJ.* 1991;303(6806):818-821.
284. Richardson BS, Czikk MJ, daSilva O, Natale R. The impact of labor at term on measures of neonatal outcome. *Am J Obstet Gynecol.* 2005;192(1):219-226.
285. *The World Factbook 2008.* Washington, D. C.: Central Intelligence Agency; 2008.
286. Kamath BD, Todd JK, Glazner JE, Lezotte D, Lynch AM. Neonatal outcomes after elective cesarean delivery. *Obstet Gynecol.* 2009;113(6):1231-1238.

287. Warren J, Anderson JM. Respiratory Distress in the Term Infant: A Review. [in press]. *Pediatrics*. 2009.
288. Hankin G, Speer M. Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. *Obstet Gynecol*. 2003;102(3):628-636.
289. Committee on Fetus and Newborn. Levels of Neonatal Care. *Pediatrics*. 2004;114(5):1341-1347.
290. Brown P. How to formulate research recommendations. *BMJ*. 2006;333(14):804-806.
291. Ecker JL. Once a pregnancy, always a cesarean? Rationale and feasibility of a randomized controlled trial. *Am J Obstet Gynecol*. 2004;190(2):314-318.

Abbreviations and Acronyms

ACOG	American College of Obstetricians and Gynecologists
AUROC	Area Under the Receiver Operating Characteristic curve
AHRQ	Agency for Healthcare Research and Quality
AAP	American Academy of Pediatrics
BMI	Body mass index
CDC	Centers for Disease Control and Prevention
CI	Confidence interval
DARE	Database of Abstracts of Reviews of Effectiveness
EPC	Evidence-based Practice Center
ERCD	Elective repeat cesarean delivery
FDA	Food and Drug Administration
FHR	Fetal heart rate
FMR	Fetal mortality rate
FTP	Failure to progress
GA	Gestational age
HCUP	Healthcare Cost and Utilization Project
HIE	Hypoxic-ischemic encephalopathy
HMO	Health Maintenance Organizations
I/A	Induction/augmentation
ICD-9	International Classification of Diseases, 9th Edition/Revision
ICU	Intensive care unit
IOL	Induction of labor
IRB	Institutional review board
IRCD	Indicated repeat cesarean delivery
IUFD	Intrapartum fetal demise
kg	Kilograms
LTCD	Low transverse cesarean delivery
	National Institute of Child Health and Human Development Maternal-Fetal Medicine
MFMU	Units
mL	Milliliters
mm	Millimeters
NICU	Neonatal intensive care unit
NIH	National Institutes of Health
NMR	Neonatal mortality rate
NNH	Number needed to harm
NS	Not significant
OMAR	National Institutes of Health Office of Medical Applications of Research
OECD	Organization for Economic Cooperation and Development
OR	Odds ratio
PGE ₂	prostaglandin E ₂
PMR	Perinatal mortality rate
RCD	Repeat cesarean delivery
RCT	Randomized controlled trial
RD	Risk difference
RDS	Respiratory distress syndrome
ROC	Receiver operating characteristic

Abbreviations and Acronyms

ROM	Rupture of the membranes
RR	Relative risk
TEP	Technical expert panel
TTN	Transient tachypnea of the newborn
UK	United Kingdom
US	United States of America
USPSTF	US Preventive Services Task Force
VBAC	Vaginal birth after cesarean section
wk	Week(s)

Appendix A. Technical Expert Panel Members

Technical Expert Panel Members

Eugene Declercq, Ph.D.

Assistant Dean, Doctoral Education Professor, Department of Community Health Sciences at Boston University

Stanley Ip, M.D.

Investigator, TUFTS University Evidence-based Practice Center at New England Medical Center

Amelia Psmythe

Executive Director, Nursing Mothers Counsel of Oregon

Carol Sakala, Ph.D., M.S.P.H.

Director of Programs with Childbirth Connections.

John M. Thorp, Jr., M.D.

Division Director, Professor Adjunct Professor in the Department of Obstetrics and Gynecology at the University of North Carolina

Linda J. Van Marter, M.D., M.P.H.

Associate Professor of Pediatrics at Harvard Medical School, Children's Hospital

Professional Organization Representation

American Academy of Family Physicians

Represented by: Lesley Atwood, M.D.

American Academy of Pediatrics

Represented by: Allen Merritt, M.D., M.P.A:HA

American College of Nurse-Midwives

Represented by: Mary Barger, C.N.M., M.P.H.

American College of Obstetricians and Gynecologists

Represented by: Carolyn Zelop, M.D.

Appendix B. Expert Reviewers

Individuals

Eugene Declercq, Ph.D.

Assistant Dean, Doctoral Education Professor, Department of Community Health Sciences at Boston University

William Grobman, M.D., M.B.A.

Assistant Professor of Obstetrics and Gynecology, Section of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Assistant Professor of Preventative Medicine, Department of Preventative Medicine, Northwestern University Medical School

Stanley Ip, M.D.

Investigator, TUFTS University Evidence-based Practice Center at New England Medical Center

Diana Petitti, M.D., M.P.H.

Professor of Biomedical Informatics at Arizona State University

Amelia Psmythe

Executive Director, Nursing Mothers Counsel of Oregon

Carol Sakala, Ph.D., M.S.P.H.

Director of Programs with Childbirth Connections.

James Scott, M.D.

Professor of Obstetrics and Gynecology in the School of Medicine at the University of Utah and Editor of the Green Journal

Professional Organization Representation

American Academy of Family Physicians

Represented by: Eric Wall, M.D., FAAFP; Senior Medical Director of Qualis Health

American College of Nurse-Midwives

Represented by: Nancy Lowe, C.N.M., Ph.D.; Professor of Nurse-Midwifery in the college of Nursing at the University of Colorado Denver

American College of Obstetricians and Gynecologists

Represented by: Carolyn Zelop, M.D.; St. Francis Care, Department of Maternal Fetal Medicine

Appendix B. Expert Reviewers, continued

Federal Reviewers

Suzanne Haynes, Ph.D.

Senior Science Advisor, Office on Women's Health, US Department of Health and Human Services

Mark Klebanoff, M.D., M.P.H.

Senior Investigator, National Institute of Child Health and Human Development, Epidemiology (EPI) Branch

Miriam Kuppermann, Ph.D., M.P.H.

Professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at the University of California, San Francisco

Susan Meikle, M.D., M.S.P.H.

Contraception & Reproductive Health (CRH) Branch, National Institute of Child Health and Human Development, Contraception & Reproductive Health (CRH) Branch

Jun Zhang, M.D., Ph.D.

Senior Investigator, National Institute of Child Health and Human Development, Epidemiology (EPI) Branch

Appendix C. Search Strategies

Core Search

Database: Ovid MEDLINE(R) <1950 to August Week 4 2009>

- 1 exp Vaginal Birth after Cesarean/ (856)
- 2 vbac.mp. (264)
- 3 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 (cesarean\$ or caesarean\$))).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (1448)
- 4 1 or 3 or 2 (1470)
- 5 exp "Trial of Labor"/ (682)
- 6 (trial of labor or trial of labour).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (937)
- 7 tol.mp. (949)
- 8 6 or 7 (1833)
- 9 exp pregnancy/ or exp pregnancy complications/ (654827)
- 10 exp Infant, Newborn/ (429340)
- 11 exp Obstetrics/ (13288)
- 12 exp Obstetric Surgical Procedures/ (89545)
- 13 11 or 10 or 9 or 12 (981159)
- 14 8 and 13 (947)
- 15 14 or 5 (947)
- 16 exp Cesarean Section, Repeat/ (395)
- 17 ((repeat\$ or multip\$ or another or prior or previous\$) adj3 (cesarean\$ or caesarean\$)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (2585)
- 18 ((second or third) adj cesarean).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (30)
- 19 16 or 17 or 18 (2601)
- 20 4 or 19 or 15 (3607)
- 21 limit 20 to (english language and humans) (2888)

Database: EBM Reviews - Cochrane Central Register of Controlled Trials <3rd Quarter 2009>

- 1 vbac.mp. (6)
- 2 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 (cesarean\$ or caesarean\$))).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (14)
- 3 1 or 2 (17)
- 4 (trial of labor or trial of labour).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (38)
- 5 tol.mp. (16)
- 6 4 or 5 (53)
- 7 ((repeat\$ or multip\$ or another or prior or previous\$) adj3 (cesarean\$ or caesarean\$)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (113)
- 8 ((second or third) adj cesarean).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword] (1)
- 9 7 or 8 (113)
- 10 6 or 3 or 9 (160)

Database: EBM Reviews - Cochrane Database of Systematic Reviews <1st Quarter 2009>

- 1 vbac.mp. (4)
- 2 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 (cesarean\$ or caesarean\$))).mp. [mp=title, abstract, full text, keywords, caption text] (15)
- 3 1 or 2 (16)
- 4 (trial of labor or trial of labour).mp. [mp=title, abstract, full text, keywords, caption text] (13)
- 5 tol.mp. (2)
- 6 4 or 5 (15)

Appendix C. Search Strategies, continued

- 7 ((repeat\$ or multip\$ or another or prior or previous\$) adj3 (cesarean\$ or caesarean\$)).mp. [mp=title, abstract, full text, keywords, caption text] (65)
- 8 ((second or third) adj cesarean).mp. [mp=title, abstract, full text, keywords, caption text] (0)
- 9 7 or 8 (65)
- 10 6 or 3 or 9 (72)

Database: EBM Reviews - Database of Abstracts of Reviews of Effects <3rd Quarter 2009>

- 1 vbac.mp. (2)
- 2 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 (cesarean\$ or caesarean\$))).mp. [mp=title, full text, keywords] (1)
- 3 1 or 2 (3)
- 4 (trial of labor or trial of labour).mp. [mp=title, full text, keywords] (8)
- 5 tol.mp. (3)
- 6 4 or 5 (9)
- 7 ((repeat\$ or multip\$ or another or prior or previous\$) adj3 (cesarean\$ or caesarean\$)).mp. [mp=title, full text, keywords] (17)
- 8 ((second or third) adj cesarean).mp. [mp=title, full text, keywords] (0)
- 9 7 or 8 (17)

Uterine Rupture Specific Search

Database: Ovid MEDLINE(R) <1950 to August Week 4 2009>

- 1 exp Vaginal Birth after Cesarean/ (858)
- 2 vbac.mp. (266)
- 3 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 (cesarean\$ or caesarean\$))).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (1450)
- 4 1 or 3 or 2 (1473)
- 5 exp "Trial of Labor"/ (682)
- 6 (trial of labor or trial of labour).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (937)
- 7 tol.mp. (949)
- 8 6 or 7 (1833)
- 9 exp pregnancy/ or exp pregnancy complications/ (655357)
- 10 exp Infant, Newborn/ (429611)
- 11 exp Obstetrics/ (13301)
- 12 exp Obstetric Surgical Procedures/ (89607)
- 13 11 or 10 or 9 or 12 (981885)
- 14 8 and 13 (947)
- 15 14 or 5 (947)
- 16 exp Cesarean Section, Repeat/ (396)
- 17 ((repeat\$ or multip\$ or another or prior or previous\$) adj3 (cesarean\$ or caesarean\$)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (2587)
- 18 ((second or third) adj cesarean).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (30)
- 19 16 or 17 or 18 (2603)
- 20 4 or 19 or 15 (3610)
- 21 limit 20 to (english language and humans) (2891)
- 22 ((uterine or uterus) adj5 (ruptur\$ or tear\$ or torn or perforat\$ or lacerat\$ or trauma\$ or damag\$ or injur\$)).mp. (5413)
- 23 22 and 21 (611)

Obesity Specific Search

Database: Ovid MEDLINE(R) <1950 to August Week 4 2009>

Appendix C. Search Strategies, continued

- 1 exp Vaginal Birth after Cesarean/ (858)
- 2 vbac.mp. (266)
- 3 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 (cesarean\$ or caesarean\$))).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (1450)
- 4 1 or 3 or 2 (1473)
- 5 exp "Trial of Labor"/ (682)
- 6 (trial of labor or trial of labour).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (937)
- 7 tol.mp. (949)
- 8 6 or 7 (1833)
- 9 exp pregnancy/ or exp pregnancy complications/ (655357)
- 10 exp Infant, Newborn/ (429611)
- 11 exp Obstetrics/ (13301)
- 12 exp Obstetric Surgical Procedures/ (89607)
- 13 11 or 10 or 9 or 12 (981885)
- 14 8 and 13 (947)
- 15 14 or 5 (947)
- 16 exp Cesarean Section, Repeat/ (396)
- 17 ((repeat\$ or multip\$ or another or prior or previous\$) adj3 (cesarean\$ or caesarean\$)).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (2587)
- 18 ((second or third) adj cesarean).mp. [mp=title, original title, abstract, name of substance word, subject heading word] (30)
- 19 16 or 17 or 18 (2603)
- 20 4 or 19 or 15 (3610)
- 21 limit 20 to (english language and humans) (2891)
- 22 exp Obesity/ (91434)
- 23 body weight/ or exp body weight changes/ or exp overweight/ or thinness/ (239228)
- 24 exp "Body Weights and Measures"/ (322374)
- 25 22 or 24 or 23 (342869)
- 26 21 and 25 (207)

Multiple Cesarean Specific Search

Database: Ovid MEDLINE(R) <1950 to October Week 4 2009>

- 1 exp Cesarean Section, Repeat/ (429)
- 2 ((repeat\$ or multip\$ or another) adj3 cesarean).mp. (1041)
- 3 ((second or third) adj cesarean).mp. (32)
- 4 3 or 1 or 2 (1061)
- 5 limit 4 to (english language and humans) (855)
- 6 limit 5 to yr="1980 -Current" (833)
- 7 4 not 1 (632)
- 8 limit 1 to (english language and humans and yr="1980 -Current") (364)
- 9 exp "Outcome and Process Assessment (Health Care)"/ (471672)
- 10 exp Postoperative Complications/ (344232)
- 11 (ae or co).fs. (2302892)
- 12 11 or 10 or 9 (2833102)
- 13 ((repeat\$ or multip\$ or another or subsequent\$ or previous\$ or prior) adj3 cesarean).mp. (2237)
- 14 3 or 13 (2254)
- 15 12 and 14 (910)
- 16 limit 15 to (english language and humans and yr="1980 -Current") (716)
- 17 16 not 8 (535)
- 18 9 and 14 (107)
- 19 limit 18 to (english language and humans and yr="1980 -Current") (96)
- 20 19 not 8 (75)
- 21 17 not 20 (460)

Appendix C. Search Strategies, continued

22 from 21 keep 1-460 (460)

Background Questions Specific Search

Database: Ovid MEDLINE(R) <1950 to October Week 1 2009>

- 1 exp Vaginal Birth after Cesarean/ (888)
- 2 vbac.mp. (275)
- 3 (vagina\$ adj3 (birth\$ or born or deliver\$) adj7 ((after\$ or follow\$ or previous\$ or prior or history) adj3 cesarean)).mp. (1347)
- 4 1 or 2 or 3 (1374)
- 5 exp "Trial of Labor"/ (691)
- 6 (trial adj2 labor).mp. (927)
- 7 tol.mp. (984)
- 8 6 or 7 (1856)
- 9 exp pregnancy/ or exp pregnancy complications/ (655043)
- 10 exp Infant, Newborn/ (431654)
- 11 exp Obstetrics/ (13439)
- 12 exp Obstetric Surgical Procedures/ (89191)
- 13 9 or 10 or 11 or 12 (985177)
- 14 8 and 13 (938)
- 15 5 or 14 (938)
- 16 exp Cesarean Section, Repeat/ (428)
- 17 ((repeat\$ or multip\$ or another) adj3 cesarean).mp. (1039)
- 18 ((second or third) adj cesarean).mp. (32)
- 19 18 or 16 or 17 (1059)
- 20 4 or 19 or 15 (2507)
- 21 exp LEGISLATION as topic/ (55190)
- 22 exp JURISPRUDENCE/ (137951)
- 23 lj.fs. (171704)
- 24 22 or 21 or 23 (295921)
- 25 24 and 20 (68)
- 26 exp bioethical issues/ (3229)
- 27 exp bioethics/ (8140)
- 28 (ethic\$ or bioethic\$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier] (106986)
- 29 27 or 28 or 26 (106986)
- 30 29 and 20 (22)
- 31 exp human rights/ (97424)
- 32 31 and 20 (36)
- 33 25 or 32 or 30 (95)
- 34 Physician's Practice Patterns/ (29292)
- 35 20 and 34 (55)
- 36 exp Attitude to Health/ (216292)
- 37 20 and 36 (138)
- 38 exp Economics/ (415371)
- 39 ec.fs. (262834)
- 40 38 or 39 (490853)
- 41 20 and 40 (112)
- 42 exp Decision Making/ (86984)
- 43 20 and 42 (93)
- 44 exp Counseling/ (26819)
- 45 20 and 44 (14)
- 46 "attitude of health personnel"/ or refusal to treat/ (75034)
- 47 20 and 46 (32)
- 48 exp Health Services Accessibility/ (64701)
- 49 20 and 48 (6)

Appendix C. Search Strategies, continued

50 exp "Health Services Needs and Demand"/ (36937)
51 20 and 50 (5)
52 exp Social Control Policies/ (94601)
53 20 and 52 (16)
54 exp Hospital Administration/ (183749)
55 20 and 54 (35)
56 35 or 33 or 53 or 51 or 41 or 47 or 49 or 37 or 45 or 43 or 55 (424)
57 from 56 keep 1-424 (424)

Appendix D. List of Developed Countries

Excerpt from CIA World Factbook 2008¹

Developed Countries:

The top group in the hierarchy of developed countries (DCs), former USSR/Eastern Europe (former USSR/EE), and less developed countries (LDCs); includes the market-oriented economies of the mainly democratic nations in the Organization for Economic Cooperation and Development (OECD), Bermuda, Israel, South Africa, and the European ministates; also known as the First World, high-income countries, the North, industrial countries; generally have a per capita GDP in excess of \$10,000 although four OECD countries and South Africa have figures well under \$10,000 and two of the excluded OPEC countries have figures of more than \$10,000.

The 34 DCs are:

Andorra	France	Liechtenstein	South Africa
Australia	Germany	Luxembourg	Spain, Sweden
Austria	Greece	Malta	Switzerland
Belgium	Holy See	Monaco	Turkey
Bermuda	Iceland	Netherlands	UK
Canada	Ireland	NZ	US
Denmark	Israel	Norway	
Faroe Islands	Italy	Portugal	
Finland	Japan	San Marino	

1. *The World Factbook 2008*. Washington, D. C.: Central Intelligence Agency; 2008.

Appendix E. Inclusion and Exclusion Criteria

Abstract Review Coding

Inclusions

- IN for a specific key question or topic area
- Background for general, question 1 or question 2

Exclusions

- No data
- Wrong Population (animal study, abortion, multiple gestations, etc)
- Opinion or Letter with No Data
- No previous cesarean
- Developing country

Full-Text Paper Review Coding

Inclusions

- IN for a specific key question or topic area
- In, but no comparator
- Background for general, question 1 or question 2

Exclusions

- No data for topic
- Wrong Population (specify reason: no previous cesarean, animal study, abortion, multiple gestations, pre-existing medical condition, pre-term (<37 weeks), cadavers, etc)
- No full-text paper or Opinion or Letter with No Data
- Cannot isolate our population of interest (specify reason)
- Developing country/Not in English
- < 10 subjects
- Study began or published before 1980
- Insufficient to determine population

Appendix F. Excluded Studies List

Exclusion codes key:

Code	Reason
4	No data for topic
5	Wrong Population (specify reason: no previous cesarean, animal study, abortion, multiple gestations, pre-existing medical condition, pre-term (<37 weeks), cadavers, etc)
6	No full-text paper, opinion or letter with no data
7	Cannot isolate our population of interest (specify reason)
8	Developing country/Not in English
9	Less than 10 subjects
10	Study began or published before 1980
11	Insufficient to determine population

List of studies:

- | | |
|---|---|
| <p>1. <i>Vaginal delivery after cesarean section.</i> Am Fam Physician, 1985. 32(3): p. 90.
Exclusion code: 6</p> | <p>6. <i>Repeat cesarean section vs. VBACs: helping women decide.</i> AWHONN Voice, 1994. 2(8): p. 1.
Exclusion code: 6</p> |
| <p>2. <i>Cesarean births and trial of labor rates.</i> Jama, 1987. 257(20): p. 2757-9.
Exclusion code: 6</p> | <p>7. <i>Trial of labor vs. elective repeat cesarean section.</i> AAFP Task Force on Clinical Policies for Patient Care. Am Fam Physician, 1995. 52(6): p. 1763-5.
Exclusion code: 4</p> |
| <p>3. <i>A method of predicting the likelihood of success or failure in a trial of labor in any given set of circumstances is a laudable goal.[comment].</i> J Reprod Med, 1991. 36(11): p. 829-31.
Exclusion code: 4</p> | <p>8. <i>Vaginal delivery after a previous cesarean birth.</i> ACOG Committee opinion. Number 143-October 1994 (replaces No. 64, October 1988). Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet, 1995. 48(1): p. 127-9.
Exclusion code: 4</p> |
| <p>4. <i>Nonclinical factors and repeat C-section.[comment].</i> Jama, 1991. 265(18): p. 2338-9.
Exclusion code: 6</p> | <p>9. <i>ACOG releases practice guidelines on vaginal delivery after previous cesarean birth.</i> Am Fam Physician, 1996. 53(2): p. 775-6.
Exclusion code: 6</p> |
| <p>5. <i>Improving the timeliness of emergency C-sections at Southwestern Vermont Medical Center leads to improved patient care and increased physician satisfaction.</i> Qual Lett Healthc Lead, 1993. 5(1): p. 6-8.
Exclusion code: 6</p> | <p>10. <i>Vaginal delivery after previous cesarean birth.</i> Number 1--August 1995. Committee on Practice</p> |

Appendix F. Excluded Studies List, continued

- Patterns. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet, 1996. 52(1): p. 90-8.*
Exclusion code: **4**
11. *VBAC (vaginal birth after cesareans): are cost concerns outweighing possible safety risks? Hosp Case Manag, 1996. 4(11): p. 161-4.*
Exclusion code: **6**
12. *What is the right number of caesarean sections? Lancet, 1997. 349(9055): p. 815.*
Exclusion code: **4**
13. *Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 9-1998. Cardiovascular collapse after vaginal delivery in a patient with a history of cesarean section. N Engl J Med, 1998. 338(12): p. 821-6.*
Exclusion code: **9**
14. *Outreach program slashes Florida health network's rate of cesarean sections. Health Care Cost Reengineering Rep, 1998. 3(9): p. 137-8.*
Exclusion code: **6**
15. *Stats & facts. Vaginal births after cesarean sections: a need to revisit. Manag Care Interface, 2001. 14(11): p. 34-5.*
Exclusion code: **4**
16. *Medical discipline--not guilty. N Z Med J, 2004. 117(1188): p. 2 p following U755.*
Exclusion code: **6**
17. *National Institutes of Health state-of-the-science conference statement: Cesarean delivery on maternal request March 27-29, 2006. Obstet Gynecol, 2006. 107(6): p. 1386-97.*
Exclusion code: **4**
18. *NIH State of the Science Conference: cesarean delivery on maternal request. Adv Neonat Care, 2006. 6(4): p. 171-2.*
Exclusion code: **4**
19. *Risks and benefits of caesarean delivery on maternal request. Midwifery, 2006. 22(2): p. 98-9.*
Exclusion code: **6**
20. *Aali, B.S. and B. Motamedi, Women's knowledge and attitude towards modes of delivery in Kerman, Islamic Republic of Iran. East Mediterr Health J, 2005. 11(4): p. 663-72.*
Exclusion code: **5**
21. *Abbas, F., et al., Placenta percreta with bladder invasion as a cause of life threatening hemorrhage. J Urol, 2000. 164(4): p. 1270-4.*
Exclusion code: **9**
22. *Abboud, T.K., et al., Isoflurane or halothane for cesarean section: comparative maternal and neonatal effects. Acta Anaesthesiol Scand, 1989. 33(7): p. 578-81.*
Exclusion code: **5**
23. *Abboud, T.K., et al., Isoflurane or halothane for cesarean section: comparative maternal and neonatal effects. Acta Anaesthesiol Scand,*

Appendix F. Excluded Studies List, continued

1989. **33**(7): p. 578-81.
Exclusion code: **5**
24. Abboud, T.K., et al., *Desflurane: a new volatile anesthetic for cesarean section. Maternal and neonatal effects.* Acta Anaesthesiol Scand, 1995. **39**(6): p. 723-6.
Exclusion code: **5**
25. Abboud, T.K., et al., *Intravenous propofol vs thiamylal-isoflurane for cesarean section, comparative maternal and neonatal effects.* Acta Anaesthesiol Scand, 1995. **39**(2): p. 205-9.
Exclusion code: **5**
26. Abdelhak, Y.E., et al., *Management of cervical cerclage at term: remove the suture in labor?* J Perinat Med, 2000. **28**(6): p. 453-7.
Exclusion code: **5**
27. Abitbol, M.M., et al., *The cephalopelvic disproportion index. Combined fetal sonography and x-ray pelvimetry for early detection of cephalopelvic disproportion.* J Reprod Med, 1991. **36**(5): p. 369-73.
Exclusion code: **4**
28. Abouleish, E., et al., *Combined intrathecal morphine and bupivacaine for cesarean section.* Anesth Analg, 1988. **67**(4): p. 370-4.
Exclusion code: **5**
29. Aboulfalah, A., et al., *Induction of labour with intravaginal misoprostol after prior cesarean delivery.* Afr J Reprod Health, 2001. **5**(2): p. 139-42.
Exclusion code: **4**
30. Abu-Ghazze, Y.M. and R. Barqawi, *An appraisal of computed tomography pelvimetry in patients with previous caesarean section.* East Mediterr Health J, 2000. **6**(2-3): p. 260-4.
Exclusion code: **8**
31. Abu-Heija, A.T. and A.M. Ali, *Induction of labor in grand multiparous women and previous cesarean section: is it safe?* Gynecol Obstet Invest, 2002. **53**(2): p. 121-4.
Exclusion code: **8**
32. Abu-Heija, A.T., F. El-Jallad, and S. Ziadeh, *Placenta previa: effect of age, gravidity, parity and previous caesarean section.* Gynecol Obstet Invest, 1999. **47**(1): p. 6-8.
Exclusion code: **8**
33. Afriat, C.I., *Vaginal birth after cesarean section: a review of the literature.* J Perinat Neonatal Nurs, 1990. **3**(3): p. 1-13.
Exclusion code: **10**
34. Agostini, A., et al., *Risk of bladder injury during vaginal hysterectomy in women with a previous cesarean section.* J Reprod Med, 2005. **50**(12): p. 940-2.
Exclusion code: **6**
35. Al Nuaim, L.A., S. Kattan, and M.S. Mustafa, *Vesicouterine fistula after a previous low vertical cesarean section (DeLee incision).* Int J Gynaecol Obstet, 1996. **55**(2): p. 161-2.
Exclusion code: **4**

Appendix F. Excluded Studies List, continued

36. Al Sakka, M., W. Dauleh, and S. Al Hassani, *Case series of uterine rupture and subsequent pregnancy outcome*. *Int J Fertil Womens Med*, 1999. **44**(6): p. 297-300.
Exclusion code: **8**
37. Al Sakka, M., A. Hamsho, and L. Khan, *Rupture of the pregnant uterus--a 21-year review*. *Int J Gynaecol Obstet*, 1998. **63**(2): p. 105-8.
Exclusion code: **8**
38. Alarab, M., et al., *Singleton vaginal breech delivery at term: still a safe option*. *Obstet Gynecol*, 2004. **103**(3): p. 407-12.
Exclusion code: **5**
39. Albers, L.L., *Safety of VBACs in birth centers: choices and risks*. *Birth*, 2005. **32**(3): p. 229-31.
Exclusion code: **4**
40. Alexander, J.M., et al., *Fetal injury associated with cesarean delivery*. *Obstet Gynecol*, 2006. **108**(4): p. 885-90.
Exclusion code: **5**
41. Alexiadis, G., et al., *Abdominal wall endometriosis--ultrasound research: a diagnostic problem*. *Clin Exp Obstet Gynecol*, 2001. **28**(2): p. 121-2.
Exclusion code: **4**
42. Alfievic, Z., *Oral misoprostol for induction of labour*. [update in *Cochrane Database Syst Rev*. 2001;(2):CD001338; PMID: 11405987][update of *Cochrane Database Syst Rev*. 2000;(2):CD001338; PMID: 10796260]. *Cochrane Database Syst Rev*, 2000(4): p. CD001338.
Exclusion code: **4**
43. Alfievic, Z. and A. Weeks, *Oral misoprostol for induction of labour*. *Cochrane Database Syst Rev*, 2006.
Exclusion code: **4**
44. Algert, C.S., et al., *Labor before a primary cesarean delivery: reduced risk of uterine rupture in a subsequent trial of labor for vaginal birth after cesarean*. *Obstet Gynecol*, 2008. **112**(5): p. 1061-6.
Exclusion code: **6**
45. Al-Kadri, H., et al., *Failed individual and sequential instrumental vaginal delivery: contributing risk factors and maternal-neonatal complications*. [erratum appears in *Acta Obstet Gynecol Scand*. 2003 Oct;82(10):976]. *Acta Obstet Gynecol Scand*, 2003. **82**(7): p. 642-8.
Exclusion code: **8**
46. Alkatib, M., A.V.M. Franco, and M.M. Fynes, *Vesicouterine fistula following Cesarean delivery--ultrasound diagnosis and surgical management*. *Ultrasound Obstet Gynecol*, 2005. **26**(2): p. 183-5.
Exclusion code: **4**
47. Almeida, E.C.S., et al., *Cesarean section as a cause of chronic pelvic pain*. *Int J Gynaecol Obstet*, 2002. **79**(2): p. 101-4.
Exclusion code: **7**
48. Al-Najjar, F.S. and A.M. Al-Shafiai,

Appendix F. Excluded Studies List, continued

- Safety of vaginal breech delivery.* Saudi Med J, 2004. **25**(10): p. 1517-8.
Exclusion code: **5**
49. Alran, S., et al., *Maternal and neonatal outcome of 93 consecutive triplet pregnancies with 71% vaginal delivery.* Acta Obstet Gynecol Scand, 2004. **83**(6): p. 554-9.
Exclusion code: **5**
50. Altman, D., et al., *Symptoms of anal and urinary incontinence following cesarean section or spontaneous vaginal delivery.* Am J Obstet Gynecol, 2007. **197**(5): p. 512.e1-7.
Exclusion code: **5**
51. Al-Took, S., *Adhesion-related small-bowel obstruction after gynecologic operations.* Am J Obstet Gynecol, 1999. **180**(2): p. 313-5.
Exclusion code: **4**
52. Amon, E., B.M. Sibai, and G.D. Anderson, *How perinatologists manage the problem of the presenting breech.* Am J Perinatol, 1988. **5**(3): p. 247-50.
Exclusion code: **4**
53. Andersen, H.F., et al., *Neonatal status in relation to incision intervals, obstetric factors, and anesthesia at cesarean delivery.* Am J Perinatol, 1987. **4**(4): p. 279-83.
Exclusion code: **4**
54. Andersen, J.R., et al., *Decidual prolactin content and secretion at term. Correlations with the clinical data.* Acta Obstet Gynecol Scand, 1987. **66**(7): p. 591-6.
- Exclusion code: **7**
55. Anderson, G. and C. Strong, *The premature breech: caesarean section or trial of labour?* J Med Ethics, 1988. **14**(1): p. 18-24.
Exclusion code: **5**
56. Andrews, W.W., et al., *Effect of type of anesthesia on blood loss at elective repeat cesarean section.* Am J Perinatol, 1992. **9**(3): p. 197-200.
Exclusion code: **4**
57. Angelini, D.J. and L. Greenwald, *Closed claims analysis of 65 medical malpractice cases involving nurse-midwives.* J Midwifery Womens Health, 2005. **50**(6): p. 454-60.
Exclusion code: **6**
58. Annibale, D.J., et al., *Comparative neonatal morbidity of abdominal and vaginal deliveries after uncomplicated pregnancies.* Arch Pediatr Adolesc Med, 1995. **149**(8): p. 862-7.
Exclusion code: **5**
59. Anteby, S.O., A. Birkenfeld, and D. Weinstein, *Post cesarean section urinary tract infections, risk factors and prophylactic antibiotic treatment.* Clin Exp Obstet Gynecol, 1984. **11**(4): p. 161-4.
Exclusion code: **5**
60. Antoine, C. and B.K. Young, *Fetal lactic acidosis with epidural anesthesia.* Am J Obstet Gynecol, 1982. **142**(1): p. 55-9.
Exclusion code: **10**
61. Appleton, B., et al., *Knowledge and*

Appendix F. Excluded Studies List, continued

- attitudes about vaginal birth after Caesarean section in Australian hospitals. VBAC Study Group. Vaginal Birth After Caesarean. Aust N Z J Obstet Gynaecol, 2000. 40(2): p. 195-9.*
Exclusion code: **4**
62. Ardiet, E., D. Subtil, and F. Puech, *Cervical ripening with dinoprostone gel and previous cesarean delivery. Int J Gynaecol Obstet, 2005. 91(3): p. 260-1.*
Exclusion code: **6**
63. Arias, E., et al., *Annual summary of vital statistics--2002. Pediatrics, 2003. 112(6 Pt 1): p. 1215-30.*
Exclusion code: **4**
64. Armstrong, V., et al., *Detection of cesarean scars by transvaginal ultrasound. Obstet Gynecol, 2003. 101(1): p. 61-5.*
Exclusion code: **4**
65. Arraztoa, J.A., et al., *[Delivery conduction in patients with cicatrix of a prior cesarean section. Pilot study]. Revista chilena de obstetricia y ginecologia, 1994. 59(2): p. 95-100; discussion 100-1.*
Exclusion code: **8**
66. Arulkumaran, S., et al., *Uterine activity during spontaneous labour after previous lower-segment caesarean section. Br J Obstet Gynaecol, 1989. 96(8): p. 933-8.*
Exclusion code: **8**
67. Arulkumaran, S., I. Ingemarsson, and S.S. Ratnam, *Oxytocin augmentation in dysfunctional labour after previous caesarean section. Br J Obstet Gynaecol, 1989. 96(8): p. 939-41.*
Exclusion code: **8**
68. Ash, A., A. Smith, and D. Maxwell, *Caesarean scar pregnancy. Bjog, 2007. 114(3): p. 253-63.*
Exclusion code: **4**
69. Ashton, P., et al., *Return to theatre--experience at the Mercy Maternity Hospital, Melbourne 1971-1982. Aust N Z J Obstet Gynaecol, 1985. 25(3): p. 159-69.*
Exclusion code: **7**
70. Asole, S., et al., *Effect of hospital practices on breastfeeding: A survey in the Italian region of Lazio. Journal of Human Lactation, 2009. 25(3): p. 333-340.*
Exclusion code: **7**
71. Atad, J., et al., *Ripening and dilatation of the unfavourable cervix for induction of labour by a double balloon device: experience with 250 cases. Br J Obstet Gynaecol, 1997. 104(1): p. 29-32.*
Exclusion code: **7**
72. Atad, J., et al., *Continuous extraovular prostaglandin F2 alpha instillation for late pregnancy termination in patients with previous caesarean section delivery. Int J Gynaecol Obstet, 1986. 24(4): p. 315-9.*
Exclusion code: **5**
73. Atalla, R.K., et al., *Reactive thrombocytosis after caesarean section and vaginal delivery:*

Appendix F. Excluded Studies List, continued

- implications for maternal thromboembolism and its prevention.* Bjog, 2000. **107**(3): p. 411-4.
Exclusion code: **4**
74. Atug, F., et al., *Delivery of dead fetus from inside urinary bladder with uterine perforation: case report and review of literature.* Urology, 2005. **65**(4): p. 797.
Exclusion code: **9**
75. Austin, S.E., *Childbirth classes for couples desiring VBAC (vaginal birth after cesarean).* MCN Am J Matern Child Nurs, 1986. **11**(4): p. 250-5.
Exclusion code: **4**
76. Avery, J.K., *Loss prevention case of the month. Would guidelines have helped?* Tenn Med, 2003. **96**(10): p. 461-2.
Exclusion code: **9**
77. Avery, J.K., *The obstetrical dilemma.* J Ark Med Soc, 2005. **102**(6): p. 156-7.
Exclusion code: **6**
78. Bader, D., et al., *Breathing patterns in term infants delivered by caesarean section.* Acta Paediatr, 2004. **93**(9): p. 1216-20.
Exclusion code: **7**
79. Bai, S.W., et al., *Peripartum hysterectomy and associated factors.* J Reprod Med, 2003. **48**(3): p. 148-52.
Exclusion code: **7**
80. Bainbridge, J., *Choices after cesarean.* Birth, 2002. **29**(3): p. 203-6.
Exclusion code: **4**
81. Bakshi, S. and B.A. Meyer, *Indications for and outcomes of emergency peripartum hysterectomy. A five-year review.* J Reprod Med, 2000. **45**(9): p. 733-7.
Exclusion code: **7**
82. Barker, G., et al., *Placental water content and distribution.* Placenta, 1994. **15**(1): p. 47-56.
Exclusion code: **4**
83. Barnsley, J.M., et al., *Cesarean section in Ontario: practice patterns and responses to hypothetical cases.* Can J Surg, 1990. **33**(2): p. 128-32.
Exclusion code: **4**
84. Barton, D.P., M.J. Turner, and J.M. Stronge, *Outcome of the second labour in patients whose first labour was prolonged: the Dublin experience.* Eur J Obstet Gynecol Reprod Biol, 1991. **42**(1): p. 15-8.
Exclusion code: **7**
85. Baskett, T.F., *Emergency obstetric hysterectomy.* J Obstet Gynaecol, 2003. **23**(4): p. 353-5.
Exclusion code: **7**
86. Baskett, T.F., *Uterine compression sutures for postpartum hemorrhage: efficacy, morbidity, and subsequent pregnancy.* Obstet Gynecol, 2007. **110**(1): p. 68-71.
Exclusion code: **5**
87. Basson, E., H.J. Odendaal, and D. Grove, *Oxytocin use in South Africa-a review.* Samj, S, 2004. **Suid-**

Appendix F. Excluded Studies List, continued

- Afrikaanse Tydskrif Vir Geneeskunde.** **94**(10): p. 839-45.
Exclusion code: **4**
88. Beall, M., et al., *Vaginal delivery after cesarean section in women with unknown types of uterine scar.* J Reprod Med, 1984. **29**(1): p. 31-5.
Exclusion code: **6**
89. Beckett, V.A. and L. Regan, *Vaginal birth after cesarean: the European experience.* Clin Obstet Gynecol, 2001. **44**(3): p. 594-603.
Exclusion code: **4**
90. Ben Nagi, J., et al., *Reproductive outcomes of women with a previous history of Cesarean scar ectopic pregnancies.* Hum Reprod, 2007. **22**(7): p. 2012-5.
Exclusion code: **5**
91. Ben Shachar, I. and D. Weinstein, *High risk pregnancy outcome by route of delivery.* Curr Opin Obstet Gynecol, 1998. **10**(6): p. 447-52.
Exclusion code: **4**
92. Benedetti, T.J., L. Platt, and M. Druzin, *Vaginal delivery after previous cesarean section for a nonrecurrent cause.* Am J Obstet Gynecol, 1982. **142**(3): p. 358-9.
Exclusion code: **10**
93. Ben-Haroush, A., et al., *Indicated labor induction with vaginal prostaglandin E2 increases the risk of cesarean section even in multiparous women with no previous cesarean section.* J Perinat Med, 2004. **32**(1): p. 31-6.
Exclusion code: **7**
94. Ben-Haroush, A., et al., *Accuracy of sonographically estimated fetal weight in 840 women with different pregnancy complications prior to induction of labor.* Ultrasound Obstet Gynecol, 2004. **23**(2): p. 172-6.
Exclusion code: **5**
95. Benterud, T., *Cesarean section is associated with more frequent pneumothorax and respiratory problems in the neonate.* Acta Obstet Gynecol Scand, 2009. **88**(3): p. 359-61.
Exclusion code: **7**
96. Berard, J., et al., *Fetal macrosomia: risk factors and outcome. A study of the outcome concerning 100 cases >4500 g.* Eur J Obstet Gynecol Reprod Biol, 1998. **77**(1): p. 51-9.
Exclusion code: **5**
97. Berg, C.J., et al., *Overview of Maternal Morbidity During Hospitalization for Labor and Delivery in the United States. 1993-1997 and 2001-2005.* Obstet Gynecol, 2009. **113**(5): p. 1075-1081.
Exclusion code: **4**
98. Bergeron, M.-E., et al., *Sonography of lower uterine segment thickness and prediction of uterine rupture.* Obstet Gynecol, 2009. **113**(2 Pt 2): p. 520-2.
Exclusion code: **9**
99. Bergholt, T., et al., *Prevalence and risk factors of adenomyosis at hysterectomy.* Hum Reprod, 2001.

Appendix F. Excluded Studies List, continued

- 16(11): p. 2418-21.
Exclusion code: **5**
100. Bergholt, T., et al., *Intraoperative surgical complication during cesarean section: an observational study of the incidence and risk factors*. Acta Obstet Gynecol Scand, 2003. **82**(3): p. 251-6.
Exclusion code: **4**
101. Berglund, L. and O. Axelsson, *Breech extraction versus cesarean section for the remaining second twin*. Acta Obstet Gynecol Scand, 1989. **68**(5): p. 435-8.
Exclusion code: **5**
102. Bernstein, P., *Prostaglandin E2 gel for cervical ripening and labour induction: a multicentre placebo-controlled trial.[erratum appears in Can Med Assoc J 1992 Apr 15;146(8):1290]*. Cmaj, 1991. **145**(10): p. 1249-54.
Exclusion code: **5**
103. Bhal, P.S., A. Sharma, and K. Asaad, *Vaginal delivery after cesarean section: factors influencing success rates.[comment]*. Aust N Z J Obstet Gynaecol, 1996. **36**(4): p. 497-8.
Exclusion code: **6**
104. Bhattacharjee, N., R.P. Ganguly, and S.P. Saha, *Misoprostol for termination of mid-trimester post-Caesarean pregnancy*. Aust N Z J Obstet Gynaecol, 2007. **47**(1): p. 23-5.
Exclusion code: **8**
105. Biasucci, G., et al., *Cesarean delivery may affect the early biodiversity of intestinal bacteria*. J Nutr, 2008. **138**(9): p. 1796S-1800S.
Exclusion code: **5**
106. Binder, T., et al., *Conducting labor in women with previous caesarean section in a low gestational week. A prospective case-controlled study*. Gynecol Obstet Invest, 2008. **66**(3): p. 197-202.
Exclusion code: **5**
107. Bingham, P., V. Hird, and R.J. Lilford, *Management of the mature selected breech presentation: an analysis based on the intended method of delivery*. Br J Obstet Gynaecol, 1987. **94**(8): p. 746-52.
Exclusion code: **5**
108. Biswas, A., *Management of previous cesarean section*. Curr Opin Obstet Gynecol, 2003. **15**(2): p. 123-9.
Exclusion code: **6**
109. Bjelic-Radusic, V., et al., *Neonatal outcome of second twins depending on presentation and mode of delivery*. Twin Res Hum Genet, 2007. **10**(3): p. 521-7.
Exclusion code: **5**
110. Black, C., J.A. Kaye, and H. Jick, *Cesarean delivery in the United Kingdom: time trends in the general practice research database*. Obstet Gynecol, 2005. **106**(1): p. 151-5.
Exclusion code: **4**
111. Blackwell, S.C., et al., *Influence of maternal-fetal medicine subspecialization on the frequency of trial of labor in term pregnancies with breech presentation*. J Matern

Appendix F. Excluded Studies List, continued

- Fetal Med, 2000. **9**(4): p. 229-32.
Exclusion code: **5**
112. Blanchette, H., *Comparison of obstetric outcome of a primary-care access clinic staffed by certified nurse-midwives and a private practice group of obstetricians in the same community*. Am J Obstet Gynecol, 1995. **172**(6): p. 1864-8; discussion 1868-71.
Exclusion code: **4**
113. Blumenthal, N.J., et al., *Changing caesarean section rates. Experience at a Sydney obstetric teaching hospital*. Aust N Z J Obstet Gynaecol, 1984. **24**(4): p. 246-51.
Exclusion code: **7**
114. Bolaji, I.I. and F.P. Meehan, *Caesarean section survey in Galway-1973 through 1987*. Eur J Obstet Gynecol Reprod Biol, 1993. **48**(1): p. 1-8.
Exclusion code: **10**
115. Bolaji, I.I. and F.P. Meehan, *Post caesarean section delivery*. Eur J Obstet Gynecol Reprod Biol, 1993. **51**(3): p. 181-92.
Exclusion code: **4**
116. Bossert, R., et al., *Early postpartum discharge at a university hospital. Outcome analysis*. J Reprod Med, 2001. **46**(1): p. 39-43.
Exclusion code: **4**
117. Boucher, M., et al., *Maternal morbidity as related to trial of labor after previous cesarean delivery. A quantitative analysis*. J Reprod Med, 1984. **29**(1): p. 12-6.
Exclusion code: **4**
118. Boulet, S.B., *Macrosomic births in the United States: determinants, outcomes, and proposed grades of risk*. Am J Obstet Gynecol, 2003. **188**: p. 1372-1378.
Exclusion code: **5**
119. Boulet, S.L., H.M. Salihu, and G.R. Alexander, *Mode of delivery and birth outcomes of macrosomic infants*. J Obstet Gynaecol, 2004. **24**(6): p. 622-9.
Exclusion code: **4**
120. Boulvain, M., et al., *Trial of labour after caesarean section in sub-Saharan Africa: a meta-analysis*. Br J Obstet Gynaecol, 1997. **104**(12): p. 1385-90.
Exclusion code: **4**
121. Boulvain, M., A.J. Kelly, and O. Irion, *Intracervical prostaglandins for induction of labour*. Cochrane Database Syst Rev, 2008.
Exclusion code: **4**
122. Boulvain, M., C. Stan, and O. Irion, *Elective delivery in diabetic pregnant women*. Cochrane Database Syst Rev, 2001.
Exclusion code: **4**
123. Bowers, S.K., H.M. MacDonald, and E.D. Shapiro, *Prevention of iatrogenic neonatal respiratory distress syndrome: elective repeat cesarean section and spontaneous labor*. Am J Obstet Gynecol, 1982. **143**(2): p. 186-9.
Exclusion code: **5**

Appendix F. Excluded Studies List, continued

124. Bradley, C.F., S.E. Ross, and J. Warnyca, *A prospective study of mothers' attitudes and feelings following cesarean and vaginal births*. Birth, 1983. **10**(2): p. 79-83.
Exclusion code: **5**
125. Brahams, D., *Caesarean sections by court order*. Lancet, 1996. **348**(9030): p. 770.
Exclusion code: **6**
126. Bricker, L. and M. Luckas, *Amniotomy alone for induction of labour*. Cochrane Database Syst Rev, 2000.
Exclusion code: **4**
127. Brill, Y., et al., *The management of VBAC at term: a survey of Canadian obstetricians*. J Obstet Gynaecol Can, 2003. **25**(4): p. 300-10.
Exclusion code: **4**
128. Brill, Y. and R. Windrim, *Vaginal birth after Cesarean section: review of antenatal predictors of success*. J Obstet Gynaecol Can, 2003. **25**(4): p. 275-86.
Exclusion code: **4**
129. Brink, S., *C-sections rise but may not be the kindest cut*. US News World Rep, 2000. **129**(9): p. 63.
Exclusion code: **6**
130. Brody, C.Z., et al., *Vaginal birth after cesarean section in Hawaii. Experience at Kapiolani Medical Center for Women and Children*. Hawaii Med J, 1993. **52**(2): p. 38-42.
Exclusion code: **7**
131. Brown, C.E., et al., *Puerperal septic pelvic thrombophlebitis: incidence and response to heparin therapy*. Am J Obstet Gynecol, 1999. **181**(1): p. 143-8.
Exclusion code: **4**
132. Brubaker, L., *Outcomes of trial of labor after previous cesarean delivery.[comment]*. Am J Obstet Gynecol, 2002. **186**(5): p. 1104-5.
Exclusion code: **6**
133. Bucklin, B.A., *Vaginal birth after cesarean delivery*. Anesthesiology, 2003. **99**(6): p. 1444-8.
Exclusion code: **6**
134. Buechner, J.S., *Rate of vaginal births among women with previous cesarean deliveries*. Med Health R I, 1997. **80**(2): p. 63-4.
Exclusion code: **4**
135. Buist, R., J. Brown, and T. McNamara, *For whom is the Cesarean section rate high?* N Z Med J, 1999. **112**(1101): p. 469-71.
Exclusion code: **6**
136. Bujold, E., *Uterine rupture and labour after a previous low transverse caesarean section.[comment]*. Bjog, 2006. **113**(11): p. 1337; author reply 1337-8.
Exclusion code: **6**
137. Bujold, E., A. Hammoud, and I. Hendler, *Safety and efficacy of vaginal birth after cesarean delivery attempts at or beyond 40 weeks of gestation.[comment]*. Obstet Gynecol, 2006. **107**(1): p. 205; author reply 205.

Appendix F. Excluded Studies List, continued

Exclusion code: **6**

138. Burda, D., *Motives suspect in caesarean repeats--study*. Mod Healthc, 1991. **21**(1): p. 14.

Exclusion code: **6**

139. Burt, R.D., T.L. Vaughan, and J.R. Daling, *Evaluating the risks of cesarean section: low Apgar score in repeat C-section and vaginal deliveries*. Am J Public Health, 1988. **78**(10): p. 1312-4.

Exclusion code: **7**

140. Cahill, A., et al., *Vaginal birth after cesarean (VBAC) attempt in twin pregnancies: is it safe?* Am J Obstet Gynecol, 2005. **193**(3 Pt 2): p. 1050-5.

Exclusion code: **5**

141. Cahill, A.G. and G.A. Macones, *Vaginal birth after cesarean delivery: evidence-based practice*. Clin Obstet Gynecol, 2007. **50**(2): p. 518-25.

Exclusion code: **6**

142. Cahill, A.G., et al., *Racial disparity in the success and complications of vaginal birth after cesarean delivery*. Obstet Gynecol, 2008. **111**(3): p. 654-8.

Exclusion code: **7**

143. Cahill, A.G., et al., *Does a maximum dose of oxytocin affect risk for uterine rupture in candidates for vaginal birth after cesarean delivery?* Am J Obstet Gynecol, 2007. **197**(5): p. 495.e1-5.

Exclusion code: **7**

144. Cahill, A.G., et al., *Risk factors for bladder injury in patients with a prior hysterotomy*. Obstet Gynecol, 2008. **112**(1): p. 116-20.

Exclusion code: **7**

145. Cahill, A.G., et al., *Higher maximum doses of oxytocin are associated with an unacceptably high risk for uterine rupture in patients attempting vaginal birth after cesarean delivery*. Am J Obstet Gynecol, 2008. **199**(1): p. 32.e1-5.

Exclusion code: **7**

146. Cakmak, H. and S. Kuguoglu, *Comparison of the breastfeeding patterns of mothers who delivered their babies per vagina and via cesarean section: An observational study using the LATCH breastfeeding charting system*. Internation Journal of Nursing Studies, 2006. **44**: p. 1128-1137.

Exclusion code: **8**

147. Carayol, M., et al., *Changes in the rates of caesarean delivery before labour for breech presentation at term in France: 1972-2003*. Eur J Obstet Gynecol Reprod Biol, 2007. **132**(1): p. 20-6.

Exclusion code: **6**

148. Carlomagno, G., et al., *Vaginal birth after caesarean section: further contribution to counteract caesarean section epidemic*. Ann Ig, 1992. **4**(4): p. 199-202.

Exclusion code: **4**

149. Carlsson, C., G. Nybell-Lindahl, and I. Ingemarsson, *Extradural block in patients who have previously*

Appendix F. Excluded Studies List, continued

- undergone caesarean section.* Br J Anaesth, 1980. **52**(8): p. 827-30.
Exclusion code: **10**
150. Caron, A. and D. Neuhauser, *The effect of public accountability on hospital performance: trends in rates for cesarean sections and vaginal births after cesarean section in Cleveland, Ohio.* Qual Manag Health Care, 1999. **7**(2): p. 1-10.
Exclusion code: **4**
151. Carpenter, M.W., et al., *Practice environment is associated with obstetric decision making regarding abnormal labor.* Obstet Gynecol, 1987. **70**(4): p. 657-62.
Exclusion code: **6**
152. Carr, C.A., P. Burkhardt, and M. Avery, *Vaginal birth after cesarean birth: a national survey of U.S. midwifery practice.* J Midwifery Womens Health, 2002. **47**(5): p. 347-52.
Exclusion code: **4**
153. Carroli, G., et al., *Epidemiology of postpartum haemorrhage: a systematic review.* Best Pract Res Clin Obstet Gynaecol, 2008. **22**(6): p. 999-1012.
Exclusion code: **4**
154. Catanzarite, V.A., et al., *Maternal death due to rupture of a low transverse cesarean section incision during labor at home.* West J Med, 1992. **157**(4): p. 454-5.
Exclusion code: **9**
155. Cesario, S.K., *Reevaluation of Friedman's Labor Curve: a pilot study.* J Obstet Gynecol Neonatal Nurs, 2004. **33**(6): p. 713-22.
Exclusion code: **4**
156. Chadha, Y.C., et al., *Breech delivery and epidural analgesia.* Br J Obstet Gynaecol, 1992. **99**(2): p. 96-100.
Exclusion code: **10**
157. Chaim, W., et al., *Prevalence and clinical significance of postpartum endometritis and wound infection.* Infect Dis Obstet Gynecol, 2000. **8**(2): p. 77-82.
Exclusion code: **5**
158. Chang, C., *Trial of labor with prior vertical cesarean incision.* J Fam Pract, 1997. **45**(5): p. 380-1.
Exclusion code: **6**
159. Chang, C.-Y., et al., *Preservation of uterine integrity via transarterial embolization under postoperative massive vaginal bleeding due to cesarean scar pregnancy.* Taiwan, 2006. **45**(2): p. 183-7.
Exclusion code: **5**
160. Chanrachakul, B., S. Hamontri, and Y. Herabutya, *A randomized comparison of postcesarean pain between closure and nonclosure of peritoneum.* Eur J Obstet Gynecol Reprod Biol, 2002. **101**(1): p. 31-5.
Exclusion code: **8**
161. Chattopadhyay, K., et al., *Vaginal birth after cesarean section: management debate.* Int J Gynaecol Obstet, 1988. **26**(2): p. 189-96.
Exclusion code: **8**
162. Chattopadhyay, S.K., H. Kharif, and

Appendix F. Excluded Studies List, continued

- M.M. Sherbeeni, *Placenta praevia and accreta after previous caesarean section*. Eur J Obstet Gynecol Reprod Biol, 1993. **52**(3): p. 151-6.
Exclusion code: **8**
163. Chattopadhyay, S.K., M.M. Sherbeeni, and C.C. Anokute, *Planned vaginal delivery after two previous caesarean sections*. Br J Obstet Gynaecol, 1994. **101**(6): p. 498-500.
Exclusion code: **8**
164. Chauhan, S.P., et al., *Application of learning theory to obstetric maloccurrence*. J Matern Fetal Neonatal Med, 2003. **13**(3): p. 203-7.
Exclusion code: **4**
165. Chauhan, S.P., et al., *Maternal and perinatal complications with uterine rupture in 142,075 patients who attempted vaginal birth after cesarean delivery: A review of the literature*. Am J Obstet Gynecol, 2003. **189**(2): p. 408-17.
Exclusion code: **6**
166. Chauhan, S.P., et al., *Neonatal acidemia with trial of labor among parturients with prior cesarean delivery: a case-control study*. J Matern Fetal Med, 2000. **9**(5): p. 278-81.
Exclusion code: **7**
167. Chazotte, C. and W.R. Cohen, *Catastrophic complications of previous cesarean section*. Am J Obstet Gynecol, 1990. **163**(3): p. 738-42.
Exclusion code: **4**
168. Chelmow, D. and R.K. Laros, Jr., *Maternal and neonatal outcomes after oxytocin augmentation in patients undergoing a trial of labor after prior cesarean delivery*. Obstet Gynecol, 1992. **80**(6): p. 966-71.
Exclusion code: **10**
169. Chen, H.Y., S.J. Chen, and F.J. Hsieh, *Observation of cesarean section scar by transvaginal ultrasonography*. Ultrasound Med Biol, 1990. **16**(5): p. 443-7.
Exclusion code: **4**
170. Chen, K.C. and T.T. Hsieh, *Rupture of gravid uterus: a eight-year clinical analysis and review of the literature*. Changgeng Yi Xue Za Zhi, 1992. **15**(1): p. 15-22.
Exclusion code: **4**
171. Chen, L.H., K.H. Tan, and G.S. Yeo, *A ten-year review of uterine rupture in modern obstetric practice*. Ann Acad Med Singapore, 1995. **24**(6): p. 830-5.
Exclusion code: **8**
172. Cheng, M. and M. Hannah, *Breech delivery at term: a critical review of the literature*. Obstet Gynecol, 1993. **82**(4 Pt 1): p. 605-18.
Exclusion code: **4**
173. Chestnut, D.H., *Does epidural analgesia during labor affect the incidence of cesarean delivery?* Reg Anesth, 1997. **22**(6): p. 495-9.
Exclusion code: **6**
174. Cheung, V.Y.T., *Sonographic measurement of the lower uterine segment thickness: is it truly*

Appendix F. Excluded Studies List, continued

- predictive of uterine rupture?* J Obstet Gynaecol Can, 2008. **30**(2): p. 148-51.
Exclusion code: **9**
175. Chez, R.A., *Cervical ripening and labor induction after previous cesarean delivery*. Clin Obstet Gynecol, 1995. **38**(2): p. 287-92.
Exclusion code: **6**
176. Chigbu, C.O., J.O. Enwereji, and A.C. Ikeme, *Women's experiences following failed vaginal birth after cesarean delivery*. Int J Gynaecol Obstet, 2007. **99**(2): p. 113-6.
Exclusion code: **8**
177. Cho, M.K., Y.H. Kim, and T.B. Song, *Predictive factors for vaginal birth after cesarean delivery*. Int J Gynaecol Obstet, 2004. **86**(3): p. 392-3.
Exclusion code: **11**
178. Christian, S.S., et al., *Vaginal breech delivery: a five-year prospective evaluation of a protocol using computed tomographic pelvimetry*. Am J Obstet Gynecol, 1990. **163**(3): p. 848-55.
Exclusion code: **5**
179. Chua, S. and S. Arulkumaran, *Trial of scar*. Aust N Z J Obstet Gynaecol, 1997. **37**(1): p. 6-11.
Exclusion code: **6**
180. Chuang, J.H. and R.A. Jenders, *Trial of labor versus elective repeat cesarean section for the women with a previous cesarean section: a decision analysis*. Proceedings / AMIA, 1999. **Annual Symposium.**: p. 226-30.
Exclusion code: **4**
181. Chung, A., et al., *Cost-effectiveness of a trial of labor after previous cesarean*. Obstet Gynecol, 2001. **97**(6): p. 932-41.
Exclusion code: **6**
182. Cicinelli, E., et al., *Predictive factors for pain experienced at office fluid minihysteroscopy*. J Minim Invasive Gynecol, 2007. **14**(4): p. 485-8.
Exclusion code: **4**
183. Clark, S.L., *Rupture of the scarred uterus*. Obstet Gynecol Clin North Am, 1988. **15**(4): p. 737-44.
Exclusion code: **6**
184. Clark, S.L., et al., *Reducing obstetric litigation through alterations in practice patterns*. Obstet Gynecol, 2008. **112**(6): p. 1279-83.
Exclusion code: **6**
185. Clark, S.L., P.P. Koonings, and J.P. Phelan, *Placenta previa/accreta and prior cesarean section*. Obstet Gynecol, 1985. **66**(1): p. 89-92.
Exclusion code: **10**
186. Clark, S.L., et al., *Is vaginal birth after cesarean less expensive than repeat cesarean delivery?* Am J Obstet Gynecol, 2000. **182**(3): p. 599-602.
Exclusion code: **6**
187. Clark, S.L., et al., *Emergency hysterectomy for obstetric hemorrhage*. Obstet Gynecol, 1984. **64**(3): p. 376-80.
Exclusion code: **10**

Appendix F. Excluded Studies List, continued

188. Clarke, S.C. and S.M. Taffel, *Rates of cesarean and VBAC delivery, United States, 1994*. Birth, 1996. **23**(3): p. 166-8.
Exclusion code: **6**
189. Clarke, S.C. and S.M. Taffel, *State variation in rates of cesarean and VBAC delivery: 1989 and 1993*. Stat Bull Metrop Insur Co, 1996. **77**(1): p. 28-36.
Exclusion code: **6**
190. Clarkson, C., D.C. Derrick, and M. Newburn, *Vaginal birth after cesarean (part 3)*. Pract Midwife, 2006. **9**(11): p. 34-7.
Exclusion code: **4**
191. Clarkson, C. and M. Newburn, *Vaginal birth after cesarean (part 1)*. Pract Midwife, 2006. **9**(9): p. 22-5.
Exclusion code: **4**
192. Clarkson, C. and M. Newburn, *Vaginal birth after cesarean (part 2)*. Pract Midwife, 2006. **9**(10): p. 26-7.
Exclusion code: **4**
193. Clock, C., et al., *Cesarean risk after successful external cephalic version: a matched, retrospective analysis*. J Perinatol, 2009. **29**(2): p. 96-100.
Exclusion code: **7**
194. Cohain, J.S., *Vaginal births after C-section are not necessarily riskier in a birth center than in the hospital*. Midwifery Today Int Midwife, 2006(77): p. 16-7.
Exclusion code: **6**
195. Cohain, J.S., *VBAC rupture & birth weight*. Midwifery Today Int Midwife, 2007(83): p. 50.
Exclusion code: **6**
196. Cohain, J.S. and S. Bewley, *Vaginal birth after cesarean section versus elective repeat cesarean section: assess neonatal downstream outcomes too.[comment]*. Bjog, 2006. **113**(7): p. 852-3; author reply 853-4.
Exclusion code: **6**
197. Coleman, V.H., et al., *Vaginal birth after cesarean delivery: practice patterns of obstetrician-gynecologists*. J Reprod Med, 2005. **50**(4): p. 261-6.
Exclusion code: **6**
198. Coleman, V.H., H. Lawrence, and J. Schulkin, *Rising cesarean delivery rates: the impact of cesarean delivery on maternal request*. Obstet Gynecol Surv, 2009. **64**(2): p. 115-9.
Exclusion code: **6**
199. Collins, C., *Story of a VBAC rupture*. Midwifery Today Int Midwife, 2007(82): p. 35.
Exclusion code: **6**
200. Combs, C.A., E.L. Murphy, and R.K. Laros, Jr., *Factors associated with hemorrhage in cesarean deliveries*. Obstet Gynecol, 1991. **77**(1): p. 77-82.
Exclusion code: **10**
201. Committee on Obstetric, P., *Induction of labor for vaginal birth after cesarean delivery*. Int J

Appendix F. Excluded Studies List, continued

- Gynaecol Obstet, 2002. **77**(3): p. 303-4.
Exclusion code: **6**
202. Conde-Agudelo, A., A. Rosas-Bermudez, and A.C. Kafury-Goeta, *Effects of birth spacing on maternal health: a systematic review*. Am J Obstet Gynecol, 2007. **196**(4): p. 297-308.
Exclusion code: **4**
203. Coniglio, C. and J.E. Dickinson, *Pregnancy following prior Caesarean scar pregnancy rupture: Lessons for modern obstetric practice*. Aust N Z J Obstet Gynaecol, 2004. **44**(2): p. 162-5.
Exclusion code: **9**
204. Coonrod, D.V., R.C. Bay, and G.Y. Kishi, *The epidemiology of labor induction: Arizona, 1997*. Am J Obstet Gynecol, 2000. **182**(6): p. 1355-62.
Exclusion code: **4**
205. Coulter, C.H. and R. Lehrfeld, *When push comes to shove: implementing VBAC practice guidelines*. Physician Exec, 1995. **21**(6): p. 30-5.
Exclusion code: **6**
206. Crane, J.M., et al., *Maternal complications with placenta previa*. Am J Perinatol, 2000. **17**(2): p. 101-5.
Exclusion code: **5**
207. Crane, S.S., et al., *Association between pre-pregnancy obesity and the risk of cesarean delivery*. Obstet Gynecol, 1997. **89**(2): p. 213-6.
Exclusion code: **6**
208. Crawford, P. and L. Kaufmann, *How safe is vaginal birth after cesarean section for the mother and fetus?* J Fam Pract, 2006. **55**(2): p. 149-51; discussion 149.
Exclusion code: **4**
209. Cunha, M., et al., *Induction of labor by vaginal misoprostol in patients with previous cesarean delivery*. Acta Obstet Gynecol Scand, 1999. **78**(7): p. 653-4.
Exclusion code: **8**
210. Curtin, S.C., L.J. Kozak, and K.D. Gregory, *U.S. cesarean and VBAC rates stalled in the mid-1990s*. Birth, 2000. **27**(1): p. 54-7.
Exclusion code: **6**
211. Daltveit, A.K., et al., *Cesarean delivery and subsequent pregnancies*. Obstet Gynecol, 2008. **111**(6): p. 1327-34.
Exclusion code: **4**
212. Dandolu, V., et al., *Resident education regarding technical aspects of cesarean section*. J Reprod Med, 2006. **51**(1): p. 49-54.
Exclusion code: **4**
213. Danforth, D.N., *Cesarean section*. Jama, 1985. **253**(6): p. 811-8.
Exclusion code: **4**
214. Daponte, A., et al., *The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section*. Contraception, 2006. **74**(4): p. 324-7.
Exclusion code: **5**

Appendix F. Excluded Studies List, continued

215. Daponte, A., et al., *Pregnancy termination using vaginal misoprostol in women with more than one caesarean section*. J Obstet Gynaecol, 2007. **27**(6): p. 597-600.
Exclusion code: **5**
216. Dashow, E.E., J.A. Read, and F.H. Coleman, *Randomized comparison of five irrigation solutions at cesarean section*. Obstet Gynecol, 1986. **68**(4): p. 473-8.
Exclusion code: **4**
217. Daskalakis, G.J., et al., *Misoprostol for second trimester pregnancy termination in women with prior caesarean section*. Bjog, 2005. **112**(1): p. 97-9.
Exclusion code: **5**
218. Dauphinee, J.D., *VBAC: safety for the patient and the nurse.[erratum appears in J Obstet Gynecol Neonatal Nurs. 2004 Nov-Dec;33(6):833]*. J Obstet Gynecol Neonatal Nurs, 2004. **33**(1): p. 105-15.
Exclusion code: **4**
219. Davey, M.R., J. Moodley, and G.J. Hofmeyr, *Labour after caesarean section--the problem of scar dehiscence*. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde, 1987. **71**(12): p. 766-8.
Exclusion code: **8**
220. David, M., et al., *Prior caesarean section--an acceptable risk for vaginal delivery at free-standing midwife-led birth centers? Results of the analysis of vaginal birth after cesarean section (VBAC) in German birth centers*. Eur J Obstet Gynecol Reprod Biol, 2009. **142**(2): p. 106-10.
Exclusion code: **4**
221. David-Montefiore, E., et al., *Surgical routes and complications of hysterectomy for benign disorders: a prospective observational study in French university hospitals*. Hum Reprod, 2007. **22**(1): p. 260-5.
Exclusion code: **5**
222. Davies, G.A., P.M. Hahn, and M.M. McGrath, *Vaginal birth after cesarean. Physicians' perceptions and practice*. J Reprod Med, 1996. **41**(7): p. 515-20.
Exclusion code: **4**
223. Daviss, B.A., *Vaginal delivery after caesarean section. Study's focus on induction v spontaneous labour neglects spontaneous deliver*. Bmj, 2001. **323**(7324): p. 1307.
Exclusion code: **6**
224. de Costa, C., *Vaginal birth after classical Caesarean section*. Aust N Z J Obstet Gynaecol, 2005. **45**(3): p. 182-6.
Exclusion code: **4**
225. de Jong, P., *Trial of labor following cesarean section--a study of 212 patients*. Int J Gynaecol Obstet, 1987. **25**(5): p. 405-11.
Exclusion code: **8**
226. de Muylder, X. and M. Thiery, *The cesarean delivery rate can be safely reduced in a developing country*.

Appendix F. Excluded Studies List, continued

- Obstet Gynecol, 1990. **75**(3 Pt 1): p. 360-4.
Exclusion code: **8**
227. de Regt, R.H., et al., *Relation of private or clinic care to the cesarean birth rate*. N Engl J Med, 1986. **315**(10): p. 619-24.
Exclusion code: **7**
228. Declercq, E., M. Barger, and J.P. O'Grady, *Uterine rupture among women with a prior cesarean delivery*. N Engl J Med, 2002. **346**(2): p. 134-7.
Exclusion code: **6**
229. DeJoy, S., J.P. O'Grady, and R.T. Burkman, *The risks of lowering the cesarean-delivery rate.[comment]*. N Engl J Med, 1999. **341**(1): p. 53-4; author reply 54-5.
Exclusion code: **6**
230. Delaney, T. and D.C. Young, *Trial of labour compared to elective Caesarean in twin gestations with a previous Caesarean delivery*. J Obstet Gynaecol Can, 2003. **25**(4): p. 289-92.
Exclusion code: **5**
231. Delpapa, E.H. and E. Mueller-Heubach, *Pregnancy outcome following ultrasound diagnosis of macrosomia*. Obstet Gynecol, 1991. **78**(3 Pt 1): p. 340-3.
Exclusion code: **5**
232. Demianczuk, N.N., D.J. Hunter, and D.W. Taylor, *Trial of labor after previous cesarean section: prognostic indicators of outcome*. Am J Obstet Gynecol, 1982. **142**(6 Pt 1): p. 640-2.
Exclusion code: **10**
233. Deneux-Tharoux, C., et al., *Postpartum maternal mortality and cesarean delivery*. Obstet Gynecol, 2006. **108**(3 Pt 1): p. 541-8.
Exclusion code: **5**
234. Deutchman, M. and R.G. Roberts, *VBAC: protecting patients, defending doctors*. Am Fam Physician, 2003. **67**(5): p. 931-2.
Exclusion code: **4**
235. Diani, F., *Fetal macrosomia and management of delivery*. Clinical and experimental obstetrics & gynecology, 1997. **24**: p. 212-214.
Exclusion code: **5**
236. Diaz, S.D., et al., *Uterine rupture and dehiscence: ten-year review and case-control study*. South Med J, 2002. **95**(4): p. 431-5.
Exclusion code: **7**
237. Dildy, G.A., et al., *Very advanced maternal age: pregnancy after age 45*. Am J Obstet Gynecol, 1996. **175**(3 Pt 1): p. 668-74.
Exclusion code: **5**
238. Dilks, F.M. and J.A. Beal, *Role of self-efficacy in birth choice*. J Perinat Neonatal Nurs, 1997. **11**(1): p. 1-9.
Exclusion code: **6**
239. DiMaio, H., et al., *Vaginal birth after cesarean delivery: an historic cohort cost analysis*. Am J Obstet Gynecol, 2002. **186**(5): p. 890-2.
Exclusion code: **6**

Appendix F. Excluded Studies List, continued

240. Dodd, J. and C. Crowther, *Induction of labour for women with a previous Caesarean birth: a systematic review of the literature*. Aust N Z J Obstet Gynaecol, 2004. **44**(5): p. 392-5.
Exclusion code: **6**
241. Dodd, J. and C. Crowther, *Vaginal birth after Caesarean versus elective repeat Caesarean for women with a single prior Caesarean birth: a systematic review of the literature*. Aust N Z J Obstet Gynaecol, 2004. **44**(5): p. 387-91.
Exclusion code: **4**
242. Dodd, J. and C.A. Crowther, *Vaginal birth after Caesarean section: a survey of practice in Australia and New Zealand*. Aust N Z J Obstet Gynaecol, 2003. **43**(3): p. 226-31.
Exclusion code: **6**
243. Dodd, J., E. Pearce, and C. Crowther, *Women's experiences and preferences following Caesarean birth*. Aust N Z J Obstet Gynaecol, 2004. **44**(6): p. 521-4.
Exclusion code: **6**
244. Dodd, J.M., E.R. Anderson, and S. Gates, *Surgical techniques for uterine incision and uterine closure at the time of caesarean section*. Cochrane Database Syst Rev, 2008.
Exclusion code: **6**
245. Dodd, J.M. and C.A. Crowther, *Elective repeat caesarean section versus induction of labour for women with a previous caesarean birth*. Cochrane Database Syst Rev, 2006(4): p. CD004906.
Exclusion code: **4**
246. Dodd, J.M., et al., *Birth after caesarean study--planned vaginal birth or planned elective repeat caesarean for women at term with a single previous caesarean birth: protocol for a patient preference study and randomised trial*. BMC Pregnancy Childbirth, 2007. **7**: p. 17.
Exclusion code: **4**
247. Doherty, D.A., et al., *Factors affecting caesarean operative time and the effect of operative time on pregnancy outcomes*. Aust N Z J Obstet Gynaecol, 2008. **48**(3): p. 286-91.
Exclusion code: **5**
248. Doucette, R.C., H.T. Sharp, and S.C. Alder, *Challenging generally accepted contraindications to vaginal hysterectomy*. Am J Obstet Gynecol, 2001. **184**(7): p. 1386-9; discussion 1390-1.
Exclusion code: **4**
249. Duffield, C., et al., *Endometrial and endocervical micro echogenic foci: sonographic appearance with clinical and histologic correlation*. J Ultrasound Med, 2005. **24**(5): p. 583-90.
Exclusion code: **4**
250. Dunn, E.A. and C. O'Herlihy, *Comparison of maternal satisfaction following vaginal delivery after caesarean section and caesarean section after previous vaginal delivery*. Eur J Obstet Gynecol Reprod Biol, 2005. **121**(1): p. 56-60.
Exclusion code: **6**

Appendix F. Excluded Studies List, continued

251. Durnwald, C.P. and B.M. Mercer, *Myometrial thickness according to uterine site, gestational age and prior cesarean delivery*. J Matern Fetal Neonatal Med, 2008. **21**(4): p. 247-50.
Exclusion code: **7**
252. Durnwald, C.P., et al., *The Maternal-Fetal Medicine Units Cesarean Registry: safety and efficacy of a trial of labor in preterm pregnancy after a prior cesarean delivery*. Am J Obstet Gynecol, 2006. **195**(4): p. 1119-26.
Exclusion code: **5**
253. Dyack, C., P.F. Hughes, and J.B. Simbakalia, *Vaginal birth after cesarean section in the grand multipara with a previous lower segment scar*. Int J Gynaecol Obstet, 1996. **55**(2): p. 167-8.
Exclusion code: **6**
254. Dyack, C., P.F. Hughes, and J.B. Simbakalia, *Vaginal delivery in the grand multipara following previous lower segment cesarian section*. J Obstet Gynaecol Res, 1997. **23**(2): p. 219-22.
Exclusion code: **4**
255. Ebell, M.H., *Predicting the likelihood of successful vaginal birth after cesarean delivery*. Am Fam Physician, 2007. **76**(8): p. 1192-4.
Exclusion code: **4**
256. Ecker, J.L. and F.D. Frigoletto, Jr., *Cesarean delivery and the risk-benefit calculus*. N Engl J Med, 2007. **356**(9): p. 885-8.
Exclusion code: **6**
257. Eden, K.B., et al., *Childbirth preferences after cesarean birth: a review of the evidence*. Birth, 2004. **31**(1): p. 49-60.
Exclusion code: **6**
258. Elferink-Stinkens, P.M., R. Brand, and O.J. Van Hemel, *Trends in caesarean section rates among high- and medium-risk pregnancies in The Netherlands 1983-1992*. Eur J Obstet Gynecol Reprod Biol, 1995. **59**(2): p. 159-67.
Exclusion code: **7**
259. Eltabbakh, G.H. and J.D. Watson, *Postpartum hysterectomy*. Int J Gynaecol Obstet, 1995. **50**(3): p. 257-62.
Exclusion code: **5**
260. Emmett, C.L., et al., *Decision-making about mode of delivery after previous caesarean section: development and piloting of two computer-based decision aids*. Health Expect, 2007. **10**(2): p. 161-72.
Exclusion code: **6**
261. Emmett, C.L., et al., *Women's experience of decision making about mode of delivery after a previous caesarean section: the role of health professionals and information about health risks*. Bjog, 2006. **113**(12): p. 1438-45.
Exclusion code: **6**
262. Eniola, O.A., et al., *Obstetric hysterectomy in a population of South East England*. J Obstet Gynaecol, 2006. **26**(2): p. 104-9.

Appendix F. Excluded Studies List, continued

Exclusion code: **4**

263. Escamilla, J.O., *Comments on trial of labor scoring system.[comment]*. Am J Obstet Gynecol, 1993. **169**(4): p. 1076-7.

Exclusion code: **4**

264. Escamilla, J.O., *A VBAC question.[comment]*. Am J Obstet Gynecol, 2002. **186**(4): p. 851; author reply 851.

Exclusion code: **6**

265. Escudero, F. and H. Contreras, *A comparative trial of labor induction with misoprostol versus oxytocin*. Int J Gynaecol Obstet, 1997. **57**(2): p. 139-43.

Exclusion code: **8**

266. Esler, M.D. and J. Douglas, *Planning for hemorrhage Steps an anesthesiologist can take to limit and treat hemorrhage in the obstetric patient*. Anesthesiology Clin N Am, 2003. **21**: p. 127-144.

Exclusion code: **4**

267. Estrade, S., et al., *History of cesarean before 32 weeks' gestation and trial of labor: what is the risk of uterine rupture?* Acta Obstet Gynecol Scand, 2009. **88**(2): p. 149-53.

Exclusion code: **4**

268. Ewen, S.P., R.G. Notley, and P.M. Coats, *Bladder laceration associated with uterine scar rupture during vaginal delivery*. Br J Urol, 1994. **73**(6): p. 712-3.

Exclusion code: **9**

269. Faiz, A.S. and C.V. Ananth, *Etiology and risk factors for placenta previa: an overview and meta-analysis of observational studies*. J Matern Fetal Neonatal Med, 2003. **13**(3): p. 175-90.

Exclusion code: **4**

270. Fang, Y.M.V. and C.M. Zelop, *Vaginal birth after cesarean: assessing maternal and perinatal risks--contemporary management*. Clin Obstet Gynecol, 2006. **49**(1): p. 147-53.

Exclusion code: **6**

271. Farmakides, G., et al., *Vaginal birth after two or more previous cesarean sections*. Am J Obstet Gynecol, 1987. **156**(3): p. 565-6.

Exclusion code: **10**

272. Farmer, R.M., et al., *Uterine rupture during trial of labor after previous cesarean section*. Am J Obstet Gynecol, 1991. **165**(4 Pt 1): p. 996-1001.

Exclusion code: **5**

273. Farnworth, A., et al., *Decision support for women choosing mode of delivery after a previous caesarean section: a developmental study*. Patient Educ Couns, 2008. **71**(1): p. 116-24.

Exclusion code: **6**

274. Fedorkow, D.M., C.A. Nimrod, and P.J. Taylor, *Ruptured uterus in pregnancy: a Canadian hospital's experience*. Cmaj, 1987. **137**(1): p. 27-9.

Exclusion code: **10**

Appendix F. Excluded Studies List, continued

275. Fenwick, J., J. Gamble, and Y. Hauck, *Reframing birth: a consequence of cesarean section*. J Adv Nurs, 2006. **56**(2): p. 121-30; discussion 131-2.
Exclusion code: **6**
276. Fenwick, J., J. Gamble, and Y. Hauck, *Believing in birth--choosing VBAC: the childbirth expectations of a self-selected cohort of Australian women*. J Clin Nurs, 2007. **16**(8): p. 1561-70.
Exclusion code: **6**
277. Fenwick, J., J. Gamble, and J. Mawson, *Women's experiences of Caesarean section and vaginal birth after Caesarian: a Birthrites initiative*. Int J Nurs Pract, 2003. **9**(1): p. 10-7.
Exclusion code: **6**
278. Figueroa, R., D. Garry, and A.P. Mackenzie, *Posterior uterine rupture in a woman with a previous Cesarean delivery*. J Matern Fetal Neonatal Med, 2003. **14**(2): p. 130-1.
Exclusion code: **9**
279. Finley, B.E. and C.E. Gibbs, *Emergent cesarean delivery in patients undergoing a trial of labor with a transverse lower-segment scar*. Am J Obstet Gynecol, 1986. **155**(5): p. 936-9.
Exclusion code: **10**
280. Flamm, B.L., *Vaginal birth after cesarean section: controversies old and new*. Clin Obstet Gynecol, 1985. **28**(4): p. 735-44.
Exclusion code: **4**
281. Flamm, B.L., *Vaginal birth after cesarean (VBAC)*. Best Pract Res Clin Obstet Gynaecol, 2001. **15**(1): p. 81-92.
Exclusion code: **6**
282. Flamm, B.L., *Vaginal birth after cesarean: reducing medical and legal risks*. Clin Obstet Gynecol, 2001. **44**(3): p. 622-9.
Exclusion code: **6**
283. Flamm, B.L., *Vaginal birth after cesarean: what's new in the new millennium?* Curr Opin Obstet Gynecol, 2002. **14**(6): p. 595-9.
Exclusion code: **4**
284. Flamm, B.L., et al., *Prostaglandin E2 for cervical ripening: a multicenter study of patients with prior cesarean delivery*. Am J Perinatol, 1997. **14**(3): p. 157-60.
Exclusion code: **4**
285. Flamm, B.L., et al., *Vaginal delivery following cesarean section: use of oxytocin augmentation and epidural anesthesia with internal tocodynamic and internal fetal monitoring*. Am J Obstet Gynecol, 1984. **148**(6): p. 759-63.
Exclusion code: **10**
286. Flamm, B.L., et al., *External cephalic version after previous cesarean section*. Am J Obstet Gynecol, 1991. **165**(2): p. 370-2.
Exclusion code: **4**
287. Fogelson, N.S., et al., *Neonatal impact of elective repeat cesarean delivery at term: a comment on patient choice cesarean delivery*. Am

Appendix F. Excluded Studies List, continued

- J Obstet Gynecol, 2005. **192**(5): p. 1433-6.
Exclusion code: **5**
288. Ford, A.A.D., B.T. Bateman, and L.L. Simpson, *Vaginal birth after cesarean delivery in twin gestations: a large, nationwide sample of deliveries*. Am J Obstet Gynecol, 2006. **195**(4): p. 1138-42.
Exclusion code: **5**
289. Forna, F., A.M. Miles, and D.J. Jamieson, *Emergency peripartum hysterectomy: a comparison of cesarean and postpartum hysterectomy*. Am J Obstet Gynecol, 2004. **190**(5): p. 1440-4.
Exclusion code: **7**
290. Forsnes, E.V., J.E. Browning, and R.B. Gherman, *Bladder rupture associated with uterine rupture. A report of two cases occurring during vaginal birth after cesarean*. J Reprod Med, 2000. **45**(3): p. 240-2.
Exclusion code: **9**
291. Francois, K., J.M. Johnson, and C. Harris, *Is placenta previa more common in multiple gestations?* Am J Obstet Gynecol, 2003. **188**(5): p. 1226-7.
Exclusion code: **5**
292. Franz, M.B., et al., *Stillbirth following previous cesarean section in Bavaria/Germany 1987-2005*. Arch Gynecol Obstet, 2009. **279**(1): p. 29-36.
Exclusion code: **4**
293. Fraser, W., *Women's mid-pregnancy motivation to attempt VBAC predicts delivery method*. International Journal of Gynecology & Obstetrics, 1994. **46**(32).
Exclusion code: **6**
294. Frederiksen, M.C., R. Glassenberg, and C.S. Stika, *Placenta previa: a 22-year analysis*. Am J Obstet Gynecol, 1999. **180**(6 Pt 1): p. 1432-7.
Exclusion code: **10**
295. French, L., *Trial of labor after cesarean section*. J Fam Pract, 1996. **43**(6): p. 538-9.
Exclusion code: **6**
296. Frost, J., et al., *Women's views on the use of decision aids for decision making about the method of delivery following a previous caesarean section: qualitative interview study*. Bjog, 2009. **116**(7): p. 896-905.
Exclusion code: **6**
297. Fruchter, O., *Trial of labor compared with an elective second cesarean section.[comment]*. N Engl J Med, 1997. **336**(9): p. 658; author reply 659.
Exclusion code: **6**
298. Fylstra, D.L., *Ectopic pregnancy within a cesarean scar: a review*. Obstet Gynecol Surv, 2002. **57**(8): p. 537-43.
Exclusion code: **4**
299. Gagnon, A.J., *Individual or group antenatal education for childbirth/parenthood.[update in Cochrane Database Syst Rev. 2007;(3):CD002869; PMID: 17636711]*. Cochrane Database Syst

Appendix F. Excluded Studies List, continued

- Rev, 2000(4): p. CD002869.
Exclusion code: **4**
300. Gagnon, A.J. and J. Sandall, *Individual or group antenatal education for childbirth or parenthood, or both.*[update of *Cochrane Database Syst Rev. 2000;(4):CD002869; PMID: 11034780*]. *Cochrane Database Syst Rev*, 2007(3): p. CD002869.
Exclusion code: **4**
301. Gamble, J.A. and D.K. Creedy, *Women's preference for a cesarean section: incidence and associated factors.* *Birth*, 2001. **28**(2): p. 101-10.
Exclusion code: **4**
302. Gardeil, F., S. Daly, and M.J. Turner, *Uterine rupture in pregnancy reviewed.* *Eur J Obstet Gynecol Reprod Biol*, 1994. **56**(2): p. 107-10.
Exclusion code: **7**
303. Garg, V.K. and E.N. Ekuma-Nkama, *Vaginal birth following two cesarean sections.* *Int J Gynaecol Obstet*, 2005. **88**(1): p. 53-4.
Exclusion code: **8**
304. Gates, P.E., *Think globally, act locally: an approach to implementation of clinical practice guidelines.* *Jt Comm J Qual Improv*, 1995. **21**(2): p. 71-84.
Exclusion code: **6**
305. Gellman, E., et al., *Vaginal delivery after cesarean section. Experience in private practice.* *Jama*, 1983. **249**(21): p. 2935-7.
Exclusion code: **10**
306. Gerhardstein, L.P., et al., *Reduction in the rate of cesarean birth with active management of labor and intermediate-dose oxytocin.* *J Reprod Med*, 1995. **40**(1): p. 4-8.
Exclusion code: **7**
307. Gherman, R.B., S. McBrayer, and J. Browning, *Uterine rupture associated with vaginal birth after cesarean section: a complication of intravaginal misoprostol?* *Gynecol Obstet Invest*, 2000. **50**(3): p. 212-3.
Exclusion code: **9**
308. Gibbs, C.E., *Planned vaginal delivery following cesarean section.* *Clin Obstet Gynecol*, 1980. **23**(2): p. 507-15.
Exclusion code: **10**
309. Gibbs, C.P., et al., *Obstetric anesthesia: a national survey.* *Anesthesiology*, 1986. **65**(3): p. 298-306.
Exclusion code: **10**
310. Gifford, D.S., E. Keeler, and K.L. Kahn, *Reductions in cost and cesarean rate by routine use of external cephalic version: a decision analysis.* *Obstet Gynecol*, 1995. **85**(6): p. 930-6.
Exclusion code: **7**
311. Gil, A. and C.J. Sultana, *Vesicouterine fistula after vacuum delivery and two previous cesarean sections. A case report.* *J Reprod Med*, 2001. **46**(9): p. 853-5.
Exclusion code: **9**
312. Gilmour, D.T., et al., *Minimizing the*

Appendix F. Excluded Studies List, continued

- urological and psychological morbidity of urinary tract fistulae from VBAC.* J Obstet Gynaecol Can, 2006. **28**(2): p. 132-5.
Exclusion code: **9**
313. Gleicher, N., *Mandatory trial of labor after cesarean delivery: an alternative viewpoint.[comment].* Obstet Gynecol, 1991. **78**(4): p. 727-8.
Exclusion code: **6**
314. Gochnour, G., S. Ratcliffe, and M.B. Stone, *The UTAH VBAC Study.* Matern Child Health J, 2005. **9**(2): p. 181-8.
Exclusion code: **6**
315. Goer, H., *Misoprostol and uterine rupture.* Birth, 2000. **27**(3): p. 224-5.
Exclusion code: **6**
316. Goer, H., *VBAC and the New England Journal of Medicine.* Birth, 2002. **29**(2): p. 150-1.
Exclusion code: **4**
317. Goffman, D., et al., *Predictors of maternal mortality and near-miss maternal morbidity.* J Perinatol, 2007. **27**(10): p. 597-601.
Exclusion code: **7**
318. Goldman, G., et al., *Effects of patient, physician and hospital characteristics on the likelihood of vaginal birth after previous cesarean section in Quebec.* Cmaj, 1990. **143**(10): p. 1017-24.
Exclusion code: **6**
319. Gonzales, G.F. and A. Salirrosas, *Pulse oxygen saturation and neurologic assessment in human neonates after vaginal and cesarean delivery.* Int J Gynaecol Obstet, 1998. **63**(1): p. 63-6.
Exclusion code: **10**
320. Gorgen, H., et al., *Fetal torticollis and upper extremity haematoma after silent uterine rupture: a case report.* Aust N Z J Obstet Gynaecol, 2007. **47**(6): p. 513-4.
Exclusion code: **9**
321. Goyert, G.L., et al., *The physician factor in cesarean birth rates.* N Engl J Med, 1989. **320**(11): p. 706-9.
Exclusion code: **7**
322. Graham, A.R., *Trial labor following previous cesarean section.* Am J Obstet Gynecol, 1984. **149**(1): p. 35-45.
Exclusion code: **10**
323. Granot, M., *Postcesarean section pain prediction by preoperative pressure pain assessment.* Anesthesiology, 2003. **98**: p. 1422-26.
Exclusion code: **4**
324. Gray, R., et al., *Caesarean delivery and risk of stillbirth in subsequent pregnancy: a retrospective cohort study in an English population.* Bjog, 2007. **114**(3): p. 264-70.
Exclusion code: **10**
325. Gregory, K.D., *Maternal and infant complications in high and normal weight infants by method of delivery.* Obstetrics and Gynecology, 1998. **92**: p. 507-513.
Exclusion code: **7**

Appendix F. Excluded Studies List, continued

326. Gregory, K.D., et al., *Repeat cesareans: how many are elective?* *Obstet Gynecol*, 1994. **84**(4): p. 574-8.
Exclusion code: **4**
327. Grobman, W.A., A.M. Peaceman, and M.L. Socol, *Cost-effectiveness of elective cesarean delivery after one prior low transverse cesarean.* *Obstet Gynecol*, 2000. **95**(5): p. 745-51.
Exclusion code: **6**
328. Gross, T., R.J. Sokol, and K.C. King, *Obesity in pregnancy: risks and outcome.* *Obstet Gynecol*, 1980. **56**(4): p. 446-50.
Exclusion code: **6**
329. Gross, T.L., et al., *Avoiding prematurity in elective repeat cesarean section. A role for amniotic fluid phosphatidylglycerol.* *Acta Obstet Gynecol Scand*, 1984. **63**(8): p. 683-6.
Exclusion code: **6**
330. Groutz, A., et al., *Persistent postpartum urinary retention in contemporary obstetric practice. Definition, prevalence and clinical implications.* *J Reprod Med*, 2001. **46**(1): p. 44-8.
Exclusion code: **7**
331. Grunebaum, A.N., et al., *The relationship of maternal antibody levels to post-cesarean section endometritis.* *Am J Obstet Gynecol*, 1983. **147**(8): p. 919-22.
Exclusion code: **5**
332. Gudgeon, C.W., *Uterine rupture and scar dehiscence.[comment].* *Anaesth Intensive Care*, 1997. **25**(4): p. 434.
Exclusion code: **6**
333. Guleria, K., G.I. Dhall, and K. Dhall, *Pattern of cervical dilatation in previous lower segment caesarean section patients.* *J Indian Med Assoc*, 1997. **95**(5): p. 131-4.
Exclusion code: **4**
334. Gupta, A., et al., *Meconium stained urine: an unusual sign of combined uterine and bladder rupture.* *Aust N Z J Obstet Gynaecol*, 2005. **45**(4): p. 334.
Exclusion code: **9**
335. Haas, A.V., *Homebirth after cesarean: the myth & the reality.[erratum appears in Midwifery Today Int Midwife. 2008 Winter;(88):8].* *Midwifery Today Int Midwife*, 2008(86): p. 44-7.
Exclusion code: **6**
336. Habek, D. and R. Becarevic, *Emergency peripartum hysterectomy in a tertiary obstetric center: 8-year evaluation.* *Fetal Diagn Ther*, 2007. **22**(2): p. 139-42.
Exclusion code: **5**
337. Haberman, S., et al., *Variations in compliance with documentation using computerized obstetric records.* *Obstet Gynecol*, 2007. **110**(1): p. 141-5.
Exclusion code: **6**
338. Hales, K., *Influence of labor and route of delivery on the frequency of respiratory morbidity in term*

Appendix F. Excluded Studies List, continued

- neonates*. Int J Gynaecol Obstet, 1993. **43**: p. 35-40.
Exclusion code: **4**
339. Hall, M.H., *Mode of delivery and future fertility*. Br J Obstet Gynaecol, 1989. **96**: p. 1297-1303.
Exclusion code: **4**
340. Hamar, B.D., et al., *Expectant management of uterine dehiscence in the second trimester of pregnancy*. Obstet Gynecol, 2003. **102**(5 Pt 2): p. 1139-42.
Exclusion code: **9**
341. Hammond, H., *Death from obstetrical hemorrhage*. Calif Med, 1972. **117**(2): p. 16-20.
Exclusion code: **10**
342. Hamrick-Turner, J.E., P.E. Cranston, and B.S. Lantrip, *Gravid uterine dehiscence: MR findings*. Abdom Imaging, 1995. **20**(5): p. 486-8.
Exclusion code: **4**
343. Hankins, G.D.V., S.M. Clark, and M.B. Munn, *Cesarean section on request at 39 weeks: impact on shoulder dystocia, fetal trauma, neonatal encephalopathy, and intrauterine fetal demise*. Semin Perinatol, 2006. **30**(5): p. 276-87.
Exclusion code: **4**
344. Haq, C.L., *Vaginal birth after cesarean delivery*. Am Fam Physician, 1988. **37**(6): p. 167-71.
Exclusion code: **4**
345. Harper, L.M. and G.A. Macones, *Predicting success and reducing the risks when attempting vaginal birth after cesarean*. Obstet Gynecol Surv, 2008. **63**(8): p. 538-45.
Exclusion code: **6**
346. Harris, W.J., J.F. Daniell, and J.W. Baxter, *Prior cesarean section. A risk factor for adenomyosis?* J Reprod Med, 1985. **30**(3): p. 173-5.
Exclusion code: **10**
347. Has, R., et al., *Imaging features of postpartum uterine rupture: a case report*. Abdom Imaging, 2008. **33**(1): p. 101-3.
Exclusion code: **4**
348. Hauth, J.C., G.D. Hankins, and L.C. Gilstrap, 3rd, *Uterine contraction pressures achieved in parturients with active phase arrest*. Obstet Gynecol, 1991. **78**(3 Pt 1): p. 344-7.
Exclusion code: **5**
349. Hawe, J.A. and K.S. Olah, *Posterior uterine rupture in a patient with a lower segment caesarean section scar complicating prostaglandin induction of labour*. Br J Obstet Gynaecol, 1997. **104**(7): p. 857-8.
Exclusion code: **9**
350. Hawkins, J.L., *Obstetric anesthesia work force survey, 1981 versus 1992*. Anesthesiology, 1997. **87**: p. 135-43.
Exclusion code: **6**
351. Hawkins, J.L., et al., *Oral intake policies on labor and delivery: A national survey*. J Clin Anesth, 1998. **10**(6): p. 449-451.
Exclusion code: **4**
352. Hawkins, J.L., et al., *A reevaluation of the association between*

Appendix F. Excluded Studies List, continued

- instrument delivery and epidural analgesia*. Reg Anesth, 1995. **20**(1): p. 50-6.
Exclusion code: **7**
353. Hawkins, J.L., et al., *Anesthesia-related deaths during obstetric delivery in the United States, 1979-1990*. Anesthesiology, 1997. **86**(2): p. 277-284.
Exclusion code: **4**
354. Heddleston, L.N. and W.J. Watson, *Vaginal birth after cesarean section in a small hospital*. Mil Med, 1991. **156**(5): p. 239-40.
Exclusion code: **6**
355. Heffner, L.J., *Uterine rupture among women with a prior cesarean delivery*. N Engl J Med, 2002. **346**(2): p. 134-7.
Exclusion code: **6**
356. Hendricks, M.S., et al., *Previous cesarean section and abortion as risk factors for developing placenta previa*. J Obstet Gynaecol Res, 1999. **25**(2): p. 137-42.
Exclusion code: **4**
357. Henrich, W., et al., *Ultrasound finding and operative management of a uterine rupture during vaginal delivery after Cesarean section*. Ultrasound Obstet Gynecol, 2005. **25**(2): p. 203-5.
Exclusion code: **9**
358. Henriksen, T.B., et al., *Cesarean section in twin pregnancies in two Danish counties with different cesarean section rates*. Acta Obstet Gynecol Scand, 1994. **73**(2): p. 123-8.
Exclusion code: **5**
359. Heritage, C.K. and M.D. Cunningham, *Association of elective repeat cesarean delivery and persistent pulmonary hypertension of the newborn*. Am J Obstet Gynecol, 1985. **152**(6 Pt 1): p. 627-9.
Exclusion code: **7**
360. Hicks, P., *Systematic review of the risk of uterine rupture with the use of amnioinfusion after previous cesarean delivery*. South Med J, 2005. **98**(4): p. 458-61.
Exclusion code: **4**
361. Hildingsson, I., et al., *Few women wish to be delivered by caesarean section*. Bjog, 2002. **109**(6): p. 618-23.
Exclusion code: **6**
362. Hill, D.A., et al., *Uterine rupture and dehiscence associated with intravaginal misoprostol cervical ripening*. J Reprod Med, 2000. **45**(10): p. 823-6.
Exclusion code: **9**
363. Hodgkinson, R., *Repeat caesarean section associated with gross obesity*. Br J Anaesth, 1981. **53**(10): p. 1108.
Exclusion code: **6**
364. Hodnett, E.D., et al., *Continuous support for women during childbirth*. Cochrane Database Syst Rev, 2007.
Exclusion code: **4**
365. Hoffman, M.K., et al., *Uterine rupture in patients with a prior*

Appendix F. Excluded Studies List, continued

- cesarean delivery: the impact of cervical ripening.* Am J Perinatol, 2004. **21**(4): p. 217-22.
Exclusion code: **7**
366. Hofmeyr, G.J., et al., *Methods for cervical ripening and labour induction in late pregnancy: generic protocol.* Cochrane Database Syst Rev, 2000.
Exclusion code: **4**
367. Hofmeyr, G.J. and A.M. Gulmezoglu, *Vaginal misoprostol for cervical ripening and induction of labour.* Cochrane Database Syst Rev, 2004.
Exclusion code: **4**
368. Hofmeyr, G.J. and M.E. Hannah, *Planned caesarean section for term breech delivery.* Cochrane Database Syst Rev, 2003.
Exclusion code: **4**
369. Hofmeyr, G.J. and R. Kulier, *External cephalic version for breech presentation at term.* Cochrane Database Syst Rev, 2006.
Exclusion code: **7**
370. Hofmeyr, G.J., L. Say, and A.M. Gulmezoglu, *WHO systematic review of maternal mortality and morbidity: the prevalence of uterine rupture.* Bjog, 2005. **112**(9): p. 1221-8.
Exclusion code: **6**
371. Horey, D., J. Weaver, and H. Russell, *Information for pregnant women about caesarean birth.* Cochrane Database Syst Rev, 2004(1): p. CD003858.
Exclusion code: **6**
372. Howarth, G.R. and D.J. Botha, *Amniotomy plus intravenous oxytocin for induction of labour.* Cochrane Database Syst Rev, 2001.
Exclusion code: **4**
373. Hsu, C.D., et al., *Rupture of uterine scar with extensive maternal bladder laceration after cocaine abuse.* Am J Obstet Gynecol, 1992. **167**(1): p. 129-30.
Exclusion code: **9**
374. Hurry, D.J., B. Larsen, and D. Charles, *Effects of postcesarean section febrile morbidity on subsequent fertility.* Obstet Gynecol, 1984. **64**(2): p. 256-60.
Exclusion code: **10**
375. Hutton, E. and E. Mozurkewich, *Extra-amniotic prostaglandin for induction of labour.* Cochrane Database Syst Rev, 2001.
Exclusion code: **4**
376. Hutton, E.K. and G.J. Hofmeyr, *External cephalic version for breech presentation before term.* Cochrane Database Syst Rev, 2006.
Exclusion code: **4**
377. Iglesias, S., R. Burn, and L.D. Saunders, *Reducing the cesarean section rate in a rural community hospital.[see comment][erratum appears in Can Med Assoc J 1992 May 15;146(10):1701].* Cmaj, 1991. **145**(11): p. 1459-64.
Exclusion code: **4**
378. Imberti, R., et al., *Blood transfusion*

Appendix F. Excluded Studies List, continued

- during cesarean section. A 12 years' retrospective analysis. *Acta Anaesthesiol Belg*, 1990. **41**(2): p. 139-44.
Exclusion code: **7**
379. Imoh-Ita, F. and S. Williams, *Prostaglandin E2 induction of labour proceeding to vaginal delivery after two previous caesarean sections*. *J Obstet Gynaecol*, 2002. **22**(5): p. 559-60.
Exclusion code: **9**
380. Jackson, N. and S. Paterson-Brown, *Physical sequelae of caesarean section*. *Best Pract Res Clin Obstet Gynaecol*, 2001. **15**(1): p. 49-61.
Exclusion code: **6**
381. Jacob, J. and J. Pfenninger, *Cesarean deliveries: when is a pediatrician necessary?* *Obstet Gynecol*, 1997. **89**(2): p. 217-20.
Exclusion code: **7**
382. Jaillard, S., V. Houfflin-Debarge, and L. Storme, *Higher risk of persistent pulmonary hypertension of the newborn after cesarean*. *J Perinat Med*, 2003. **31**(6): p. 538-9.
Exclusion code: **4**
383. Janke, J.R., *Breastfeeding duration following cesarean and vaginal births*. *J Nurse Midwifery*, 1988. **33**(4): p. 159-64.
Exclusion code: **7**
384. Janni, W., et al., *The prognostic impact of a prolonged second stage of labor on maternal and fetal outcome*. *Acta Obstet Gynecol Scand*, 2002. **81**(3): p. 214-21.
Exclusion code: **5**
385. Janssen, P.A., et al., *Outcomes of planned home birth with registered midwife versus planned hospital birth with midwife or physician*. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 2009. **181**(6/7): p. 377-383.
Exclusion code: **4**
386. Jarrell, M.A., G.G. Ashmead, and L.I. Mann, *Vaginal delivery after cesarean section: a five-year study*. *Obstet Gynecol*, 1985. **65**(5): p. 628-32.
Exclusion code: **10**
387. Jastrow, N., et al., *Inter- and intraobserver variability in sonographic measurement of the lower uterine segment after a previous Cesarean section*. *Ultrasound Obstet Gynecol*, 2006. **27**(4): p. 420-4.
Exclusion code: **4**
388. Jerbi, M., et al., *Predictive factors of vaginal birth after cesarean delivery*. *Int J Gynaecol Obstet*, 2006. **94**(1): p. 43-4.
Exclusion code: **8**
389. Jerbi, M., et al., *Previous cesarean scar exploration following vaginal delivery and hemorrhagic morbidity*. *Int J Gynaecol Obstet*, 2006. **92**(2): p. 135-6.
Exclusion code: **8**
390. Johnson, C. and N. Oriol, *The role of epidural anesthesia in trial of labor*. *Reg Anesth*, 1990. **15**(6): p. 304-8.

Appendix F. Excluded Studies List, continued

Exclusion code: **6**

391. Johnson, K.C. and I.M. Gaskin, *Vaginal delivery after caesarean section. Safety of single-layer suturing in caesarean sections must be proved.* *Bmj*, 2001. **323**(7324): p. 1307-8.

Exclusion code: **6**

392. Johnson, S.R., et al., *Obstetric decision-making: responses to patients who request cesarean delivery.* *Obstet Gynecol*, 1986. **67**(6): p. 847-50.

Exclusion code: **4**

393. Jolly, M.C., *Risk factors for macrosomia and its clinical consequences: a study of 350,311 pregnancies.* *European Journal of Obstetrics Gynecology and Reproductive Biology*, 2003. **111**: p. 9-14.

Exclusion code: **7**

394. Jonas, H.A., N. Khalid, and S.M. Schwartz, *The relationship between Caesarean section and neonatal mortality in very-low-birthweight infants born in Washington State, USA.* *Paediatr Perinat Epidemiol*, 1999. **13**(2): p. 170-89.

Exclusion code: **5**

395. Jonas, H.A. and J.M. Lumley, *The effect of mode of delivery on neonatal mortality in very low birthweight infants born in Victoria, Australia: Caesarean section is associated with increased survival in breech-presenting, but not vertex-presenting, infants.* *Paediatr Perinat Epidemiol*, 1997. **11**(2): p. 181-99.

Exclusion code: **7**

396. Jones, R.O., et al., *Rupture of low transverse cesarean scars during trial of labor.* *Obstet Gynecol*, 1991. **77**(6): p. 815-7.

Exclusion code: **9**

397. Joseph, G.F., Jr., C.M. Stedman, and A.G. Robichaux, *Vaginal birth after cesarean section: the impact of patient resistance to a trial of labor.* *Am J Obstet Gynecol*, 1991. **164**(6 Pt 1): p. 1441-4; discussion 1444-7.

Exclusion code: **4**

398. Joura, E.A., *Minimal wound closure at cesarean delivery.* *Geburtsh Frauenheilkd*, 1998. **58**: p. 651-3.

Exclusion code: **4**

399. Joyce, D.N., F. Giwa-Osagie, and G.W. Stevenson, *Role of pelvimetry in active management of labour.* *Br Med J*, 1975. **4**(5995): p. 505-7.

Exclusion code: **10**

400. Kabir, A.A., et al., *Unnecessary cesarean delivery in Louisiana: an analysis of birth certificate data.* *Am J Obstet Gynecol*, 2004. **190**(1): p. 10-9; discussion 3A.

Exclusion code: **6**

401. Kaczmarczyk, M., et al., *Risk factors for uterine rupture and neonatal consequences of uterine rupture: a population-based study of successive pregnancies in Sweden.* *Bjog*, 2007. **114**(10): p. 1208-14.

Exclusion code: **5**

402. Kamal, P., et al., *Factors influencing repeat caesarean section: qualitative*

Appendix F. Excluded Studies List, continued

- exploratory study of obstetricians' and midwives' accounts*. *Bjog*, 2005. **112**(8): p. 1054-60.
Exclusion code: **6**
403. Kaplan, B., et al., *Routine revision of uterine scar after prior cesarean section*. *Acta Obstet Gynecol Scand*, 1994. **73**(6): p. 473-5.
Exclusion code: **7**
404. Kaplan, D.L., *Outcomes associated with a trial of labor after prior cesarean delivery.[comment]*. *N Engl J Med*, 2005. **352**(16): p. 1718-20; author reply 1718-20.
Exclusion code: **6**
405. Karaer, A., F.A. Avsar, and S. Batioglu, *Risk factors for ectopic pregnancy: a case-control study*. *Aust N Z J Obstet Gynaecol*, 2006. **46**(6): p. 521-7.
Exclusion code: **4**
406. Kastner, E.S., et al., *Emergency peripartum hysterectomy: experience at a community teaching hospital*. *Obstet Gynecol*, 2002. **99**(6): p. 971-5.
Exclusion code: **5**
407. Kavak, Z.N., A. Basgul, and N. Ceyhan, *Short-term outcome of newborn infants: spinal versus general anesthesia for elective cesarean section. A prospective randomized study*. *Eur J Obstet Gynecol Reprod Biol*, 2001. **100**(1): p. 50-4.
Exclusion code: **5**
408. Kavanagh, J., A.J. Kelly, and J. Thomas, *Sexual intercourse for cervical ripening and induction of labour*. *Cochrane Database Syst Rev*, 2001.
Exclusion code: **4**
409. Kavanagh, J., A.J. Kelly, and J. Thomas, *Breast stimulation for cervical ripening and induction of labour*. *Cochrane Database Syst Rev*, 2005.
Exclusion code: **4**
410. Kavanagh, J., A.J. Kelly, and J. Thomas, *Corticosteroids for cervical ripening and induction of labour*. *Cochrane Database Syst Rev*, 2006.
Exclusion code: **4**
411. Kavanagh, J., A.J. Kelly, and J. Thomas, *Hyaluronidase for cervical ripening and induction of labour*. *Cochrane Database Syst Rev*, 2006.
Exclusion code: **4**
412. Kayani, S.I. and Z. Alfirevic, *Induction of labour with previous caesarean delivery: where do we stand?* *Curr Opin Obstet Gynecol*, 2006. **18**(6): p. 636-41.
Exclusion code: **4**
413. Keeler, E.B., et al., *Adjusting cesarean delivery rates for case mix*. *Health Serv Res*, 1997. **32**(4): p. 511-28.
Exclusion code: **7**
414. Kelly, A., et al., *Induction of labour in specific clinical situations: generic protocol*. *Cochrane Database Syst Rev*, 2001.
Exclusion code: **4**
415. Kelly, A.J. and J. Kavanagh, *Nitric*

Appendix F. Excluded Studies List, continued

- oxide donors for cervical ripening and induction of labour.* Cochrane Database Syst Rev, 2008.
Exclusion code: **5**
416. Kelly, A.J., J. Kavanagh, and J. Thomas, *Castor oil, bath and/or enema for cervical priming and induction of labour.* Cochrane Database Syst Rev, 2001.
Exclusion code: **4**
417. Kelly, A.J., J. Kavanagh, and J. Thomas, *Relaxin for cervical ripening and induction of labour.* Cochrane Database Syst Rev, 2001.
Exclusion code: **4**
418. Kelly, A.J., J. Kavanagh, and J. Thomas, *Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term.* Cochrane Database Syst Rev, 2003.
Exclusion code: **4**
419. Kelly, A.J. and B. Tan, *Intravenous oxytocin alone for cervical ripening and induction of labour.* Cochrane Database Syst Rev, 2001.
Exclusion code: **4**
420. Kendrick, J.S., et al., *Previous cesarean delivery and the risk of ectopic pregnancy.* Obstet Gynecol, 1996. **87**(2): p. 297-301.
Exclusion code: **5**
421. Khan, K.S. and A. Rizvi, *The partograph in the management of labor following cesarean section.* Int J Gynaecol Obstet, 1995. **50**(2): p. 151-7.
Exclusion code: **8**
422. Khan, K.S., A. Rizvi, and J.H. Rizvi, *Risk of uterine rupture after the partographic 'alert' line is crossed--an additional dimension in the quest towards safe motherhood in labour following caesarean section.* JPMA J Pak Med Assoc, 1996. **46**(6): p. 120-2.
Exclusion code: **8**
423. Kirk, E.P., et al., *Vaginal birth after cesarean or repeat cesarean section: medical risks or social realities?* Am J Obstet Gynecol, 1990. **162**(6): p. 1398-403; discussion 403-5.
Exclusion code: **4**
424. Kirkinen, P., *Multiple caesarean sections: outcomes and complications.* Br J Obstet Gynaecol, 1988. **95**(8): p. 778-82.
Exclusion code: **10**
425. Kirkinen, P., *Ultrasonography of the lower uterine segment after multiple caesarean sections.* Ann Med, 1990. **22**(2): p. 137-9.
Exclusion code: **4**
426. Kishor, T., et al., *Study of vaginal delivery in patients with one previous lower segment caesarean section.* Aust N Z J Obstet Gynaecol, 1986. **26**(4): p. 245-8.
Exclusion code: **8**
427. Kline, J. and F. Arias, *Analysis of factors determining the selection of repeated cesarean section or trial of labor in patients with histories of prior cesarean delivery.* J Reprod Med, 1993. **38**(4): p. 289-92.
Exclusion code: **4**

Appendix F. Excluded Studies List, continued

428. Knight, M., et al., *Cesarean delivery and peripartum hysterectomy*. *Obstet Gynecol*, 2008. **111**(1): p. 97-105.
Exclusion code: **7**
429. Kobelin, C.G., *Intrapartum management of vaginal birth after cesarean section*. *Clin Obstet Gynecol*, 2001. **44**(3): p. 588-93.
Exclusion code: **4**
430. Kolas, T., et al., *Indications for cesarean deliveries in Norway*. *Am J Obstet Gynecol*, 2003. **188**(4): p. 864-70.
Exclusion code: **7**
431. Kolderup, L.B., R.K. Laros, Jr., and T.J. Musci, *Incidence of persistent birth injury in macrosomic infants: association with mode of delivery*. *Am J Obstet Gynecol*, 1997. **177**(1): p. 37-41.
Exclusion code: **10**
432. Kopelman, J.N., et al., *Computed tomographic pelvimetry in the evaluation of breech presentation*. *Obstet Gynecol*, 1986. **68**(4): p. 455-8.
Exclusion code: **5**
433. Koroukian, S.M., *Uterine rupture among women with a prior cesarean delivery*. *N Engl J Med*, 2002. **346**(2): p. 134-7.
Exclusion code: **6**
434. Koroukian, S.M., D. Bush, and A.A. Rimm, *Comparison of cesarean section rates in fee-for-service versus managed care patients in the Ohio Medicaid population, 1992-1997*. *Am J Manag Care*, 2001. **7**(2): p. 134-42.
Exclusion code: **6**
435. Koroukian, S.M. and A.A. Rimm, *Declining trends in cesarean deliveries, Ohio 1989-1996: an analysis by indications*. *Birth*, 2000. **27**(1): p. 12-8.
Exclusion code: **6**
436. Koroukian, S.M., B. Trisel, and A.A. Rimm, *Estimating the proportion of unnecessary Cesarean sections in Ohio using birth certificate data.[erratum appears in J Clin Epidemiol 1999 Apr;52(4):379]*. *J Clin Epidemiol*, 1998. **51**(12): p. 1327-34.
Exclusion code: **6**
437. Korst, L.M., et al., *Hospital rates of maternal and neonatal infection in a low-risk population*. *Matern Child Health J*, 2005. **9**(3): p. 307-16.
Exclusion code: **7**
438. Kotagal, U.R., et al., *The impact of legislation and secular trends on newborn length of stay for Medicaid infants in Ohio*. *J Pediatr*, 2002. **141**(3): p. 392-7.
Exclusion code: **6**
439. Kozak, L.J. and J.D. Weeks, *U.S. trends in obstetric procedures, 1990-2000*. *Birth*, 2002. **29**(3): p. 157-61.
Exclusion code: **6**
440. Krishnamurthy, S., et al., *The role of postnatal x-ray pelvimetry after caesarean section in the management of subsequent delivery*. *Br J Obstet Gynaecol*, 1991. **98**(7): p. 716-8.

Appendix F. Excluded Studies List, continued

Exclusion code: **10**

441. Kuczkowski, K.M., *Vaginal birth after previous cesarean delivery: what are the most common signs of uterine rupture?[comment]*. West Afr J Med, 2004. **23**(4): p. 329.

Exclusion code: **6**

442. Kwee, A., et al., *Uterine rupture and its complications in the Netherlands: a prospective study*. Eur J Obstet Gynecol Reprod Biol, 2006. **128**(1-2): p. 257-61.

Exclusion code: **5**

443. Kwee, A., et al., *Outcome of subsequent delivery after a previous early preterm cesarean section*. J Matern Fetal Neonatal Med, 2007. **20**(1): p. 33-7.

Exclusion code: **5**

444. Lagrew, D.C., Jr. and J.A. Adashek, *Lowering the cesarean section rate in a private hospital: comparison of individual physicians' rates, risk factors, and outcomes*. Am J Obstet Gynecol, 1998. **178**(6): p. 1207-14.

Exclusion code: **6**

445. Lam, C.M., S.F. Wong, and L.Y. Chan, *Labor outcomes of short multiparous women with a previous successful vaginal delivery*. Int J Gynaecol Obstet, 2001. **75**(3): p. 313-4.

Exclusion code: **5**

446. Landon, M.B., *Vaginal birth after cesarean delivery*. Clin Perinatol, 2008. **35**(3): p. 491-504.

Exclusion code: **6**

447. Langer, O., *Shoulder dystocia: should the fetus weighing greater than or equal to 4000 grams be delivered by cesarean section?* Am J Obstet Gynecol, 1991. **165**: p. 831-837.

Exclusion code: **10**

448. Lao, T.T. and B.F. Leung, *Rupture of the gravid uterus*. Eur J Obstet Gynecol Reprod Biol, 1987. **25**(3): p. 175-80.

Exclusion code: **8**

449. Laopaiboon, M., et al., *Music during cesarean section under regional anesthesia for improving maternal and infant outcomes*. Cochrane Database Syst Rev, 2008.

Exclusion code: **4**

450. Laros, R.K., Jr., T.A. Flanagan, and S.J. Kilpatrick, *Management of term breech presentation: a protocol of external cephalic version and selective trial of labor*. Am J Obstet Gynecol, 1995. **172**(6): p. 1916-23; discussion 1923-5.

Exclusion code: **5**

451. Latendresse, G., P.A. Murphy, and J.T. Fullerton, *A description of the management and outcomes of vaginal birth after cesarean birth in the homebirth setting*. J Midwifery Womens Health, 2005. **50**(5): p. 386-91.

Exclusion code: **5**

452. Latthe, P., et al., *Factors predisposing women to chronic pelvic pain: systematic review*. Bmj, 2006. **332**(7544): p. 749-55.

Exclusion code: **4**

Appendix F. Excluded Studies List, continued

453. Lavin, J.P., et al., *Vaginal delivery in patients with a prior cesarean section*. *Obstet Gynecol*, 1982. **59**(2): p. 135-48.
Exclusion code: **4**
454. Leaphart, W.L., M.C. Meyer, and E.L. Capeless, *Labor induction with a prenatal diagnosis of fetal macrosomia*. *J Matern Fetal Med*, 1997. **6**(2): p. 99-102.
Exclusion code: **5**
455. Lee, K.S., et al., *Relationship of cesarean delivery to lower birth weight-specific neonatal mortality in singleton breech infants in the United States*. *Obstet Gynecol*, 1998. **92**(5): p. 769-74.
Exclusion code: **5**
456. Leeman, L. and R. Leeman, *A Native American community with a 7% cesarean delivery rate: does case mix, ethnicity, or labor management explain the low rate?* *Ann Fam Med*, 2003. **1**(1): p. 36-43.
Exclusion code: **6**
457. Lewis, S. and M. Collins, *Induction of vaginal birth after cesarean using intracervical Foley bulb*. *J Midwifery Womens Health*, 2008. **53**(6): p. 563-6.
Exclusion code: **6**
458. Lieberman, E., *Risk factors for uterine rupture during a trial of labor after cesarean*. *Clin Obstet Gynecol*, 2001. **44**(3): p. 609-21.
Exclusion code: **6**
459. Lieberman, E., et al., *Assessing the role of case mix in cesarean delivery rates*. *Obstet Gynecol*, 1998. **92**(1): p. 1-7.
Exclusion code: **5**
460. Linton, A. and M.R. Peterson, *Effect of managed care enrollment on primary and repeat cesarean rates among U.S. Department of Defense health care beneficiaries in military and civilian hospitals worldwide, 1999-2002*. *Birth*, 2004. **31**(4): p. 254-64.
Exclusion code: **6**
461. Linton, A., M.R. Peterson, and T.V. Williams, *Effects of maternal characteristics on cesarean delivery rates among U.S. Department of Defense healthcare beneficiaries, 1996-2002*. *Birth*, 2004. **31**(1): p. 3-11.
Exclusion code: **6**
462. Lipscomb, K.R., K. Gregory, and K. Shaw, *The outcome of macrosomic infants weighing at least 4500 grams: Los Angeles County + University of Southern California experience*. *Obstet Gynecol*, 1995. **85**(4): p. 558-64.
Exclusion code: **5**
463. Liston, F.A., et al., *Neonatal outcomes with caesarean delivery at term*. *Arch Dis Child Fetal Neonatal Ed*, 2008. **93**(3): p. F176-82.
Exclusion code: **7**
464. Little, M.O., et al., *Mode of delivery: toward responsible inclusion of patient preferences*. *Obstet Gynecol*, 2008. **112**(4): p. 913-8.
Exclusion code: **6**

Appendix F. Excluded Studies List, continued

465. Localio, A.R., et al., *Relationship Between Malpractice Claims and Cesarean Delivery*. JAMA : the journal of the American Medical Association, 1993. **269**(3): p. 366-373.
Exclusion code: **4**
466. Lomas, J., et al., *Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous cesarean section*. Jama, 1991. **265**(17): p. 2202-7.
Exclusion code: **6**
467. Longo, D.R., et al., *Consumer reports in health care. Do they make a difference in patient care?* Jama, 1997. **278**(19): p. 1579-84.
Exclusion code: **6**
468. Lucas, A., *Information for women after CS: are they getting enough?* RCM Midwives, 2004. **7**(11): p. 472-5.
Exclusion code: **6**
469. Lurie, S., et al., *Routine previous cesarean scar exploration following successful vaginal delivery. Is it necessary?* Eur J Obstet Gynecol Reprod Biol, 1992. **45**(3): p. 185-6.
Exclusion code: **11**
470. Lyerly, A.D., et al., *Risks, values, and decision making surrounding pregnancy*. Obstet Gynecol, 2007. **109**(4): p. 979-84.
Exclusion code: **6**
471. Lynch, J.C. and J.P. Pardy, *Uterine rupture and scar dehiscence. A five-year survey*. Anaesth Intensive Care, 1996. **24**(6): p. 699-704.
Exclusion code: **6**
472. Macario, A., Y.Y. El-Sayed, and M.L. Druzin, *Cost-effectiveness of a trial of labor after previous cesarean delivery depends on the a priori chance of success*. Clin Obstet Gynecol, 2004. **47**(2): p. 378-85.
Exclusion code: **6**
473. MacDorman, M.F., et al., *Fetal and perinatal mortality, United States, 2005*. Natl Vital Stat Rep, 2009. **57**(8): p. 1-19.
Exclusion code: **6**
474. MacDorman, M.F., F. Menacker, and E. Declercq, *Cesarean birth in the United States: epidemiology, trends, and outcomes*. Clin Perinatol, 2008. **35**(2): p. 293-307.
Exclusion code: **6**
475. MacKenzie, I.Z., S. Bradley, and M.P. Embrey, *Vaginal prostaglandins and labour induction for patients previously delivered by caesarean section*. Br J Obstet Gynaecol, 1984. **91**(1): p. 7-10.
Exclusion code: **5**
476. Macones, G.A., *The utility of clinical tests of eligibility for a trial of labour following a caesarean section: a decision analysis*. Br J Obstet Gynaecol, 1999. **106**(7): p. 642-6.
Exclusion code: **4**
477. Magee, B.D., *Uterine rupture among women with a prior cesarean delivery*. N Engl J Med, 2002. **346**(2): p. 134-7.
Exclusion code: **6**

Appendix F. Excluded Studies List, continued

478. Mahmood, T.A., *Maternal height, birthweight, obstetric conjugate and their influence on the management of parturients with a previous cesarean scar*. Acta Obstet Gynecol Scand, 1989. **68**(7): p. 595-8.
Exclusion code: **10**
479. Mahmood, T.A., *The influence of maternal height, obstetrical conjugate and fetal birth-weight in the management of patients with breech presentation*. Aust N Z J Obstet Gynaecol, 1990. **30**(1): p. 10-4.
Exclusion code: **5**
480. Mahony, R., et al., *Outcome of second delivery after prior macrosomic infant in women with normal glucose tolerance*. Obstet Gynecol, 2006. **107**(4): p. 857-62.
Exclusion code: **5**
481. Makino, S., et al., *Prospective comparison of delivery outcomes of vaginal births after cesarean section versus laparoscopic myomectomy*. J Obstet Gynaecol Res, 2008. **34**(6): p. 952-6.
Exclusion code: **4**
482. Makoha, F.W., et al., *Multiple cesarean section morbidity*. Int J Gynaecol Obstet, 2004. **87**(3): p. 227-32.
Exclusion code: **8**
483. Mankuta, D.D., et al., *Vaginal birth after cesarean section: trial of labor or repeat cesarean section? A decision analysis*. Am J Obstet Gynecol, 2003. **189**(3): p. 714-9.
Exclusion code: **4**
484. Many, A., et al., *Neonatal respiratory morbidity after elective cesarean section*. J Matern Fetal Neonatal Med, 2006. **19**(2): p. 75-8.
Exclusion code: **5**
485. Martel, M.-J., et al., *Guidelines for vaginal birth after previous Caesarean birth*. J Obstet Gynaecol Can, 2004. **26**(7): p. 660-83; quiz 684-6.
Exclusion code: **4**
486. Martel, M.-J., et al., *Guidelines for vaginal birth after previous Caesarean birth*. J Obstet Gynaecol Can, 2005. **27**(2): p. 164-88.
Exclusion code: **4**
487. Martin, J.N., Jr., J.C. Morrison, and W.L. Wisner, *Vaginal birth after cesarean section: the demise of routine repeat abdominal delivery*. Obstet Gynecol Clin North Am, 1988. **15**(4): p. 719-36.
Exclusion code: **4**
488. Martin, J.N., Jr., et al., *The case for trial of labor in the patient with a prior low-segment vertical cesarean incision*. Am J Obstet Gynecol, 1997. **177**(1): p. 144-8.
Exclusion code: **7**
489. Martin, L.F., K.M. Finigan, and T.E. Nolan, *Pregnancy after adjustable gastric banding*. Obstet Gynecol, 2000. **95**(6 Pt 1): p. 927-30.
Exclusion code: **5**
490. Maslow, A.S. and A.L. Sweeny, *Elective induction of labor as a risk*

Appendix F. Excluded Studies List, continued

- factor for cesarean delivery among low-risk women at term.* Obstet Gynecol, 2000. **95**(6 Pt 1): p. 917-22.
Exclusion code: **7**
491. Mastrobattista, J.M., *Vaginal birth after cesarean delivery.* Obstet Gynecol Clin North Am, 1999. **26**(2): p. 295-304.
Exclusion code: **6**
492. Matalon, S., et al., *Relationship of treated maternal hypothyroidism and perinatal outcome.* J Reprod Med, 2006. **51**(1): p. 59-63.
Exclusion code: **7**
493. Mathelier, A.C., *Radiopelvimetry after cesarean section.* J Reprod Med, 1996. **41**(6): p. 427-30.
Exclusion code: **4**
494. Mauldin, J.G. and R.B. Newman, *Prior cesarean: a contraindication to labor induction?* Clin Obstet Gynecol, 2006. **49**(3): p. 684-97.
Exclusion code: **4**
495. Mawson, A.R., *Reducing cesarean delivery rates in managed care organizations.* Am J Manag Care, 2002. **8**(8): p. 730-40.
Exclusion code: **6**
496. Maymon, E., et al., *Peripartum complications in grand multiparous women: para 6-9 versus para > or =10.* Eur J Obstet Gynecol Reprod Biol, 1998. **81**(1): p. 21-5.
Exclusion code: **5**
497. McCarthy, F.P., A. Ades, and W.C. Ang, *Spontaneous combined bladder and uterine rupture in pregnancy.* Aust N Z J Obstet Gynaecol, 2009. **49**(2): p. 234-5.
Exclusion code: **9**
498. McClain, C.S., *Why women choose trial of labor or repeat cesarean section.*[erratum appears in J Fam Pract 1986 Nov;23(5):425]. J Fam Pract, 1985. **21**(3): p. 210-6.
Exclusion code: **4**
499. McClain, C.S., *Patient decision making: the case of delivery method after a previous cesarean section.* Cult Med Psychiatry, 1987. **11**(4): p. 495-508.
Exclusion code: **4**
500. McClain, C.S., *The making of a medical tradition: vaginal birth after cesarean.* Soc Sci Med, 1990. **31**(2): p. 203-10.
Exclusion code: **4**
501. McCracken, L., *Issue 57: Cesarean prevention/VBAC.* Midwifery Today Int Midwife, 2001(58): p. 4.
Exclusion code: **4**
502. McDonagh, M.S., P. Osterweil, and J.-M. Guise, *The benefits and risks of inducing labour in patients with prior caesarean delivery: a systematic review.* Bjog, 2005. **112**(8): p. 1007-15.
Exclusion code: **6**
503. McShane, P.M., P.S. Heyl, and M.F. Epstein, *Maternal and perinatal morbidity resulting from placenta previa.* Obstet Gynecol, 1985. **65**(2): p. 176-82.
Exclusion code: **5**

Appendix F. Excluded Studies List, continued

504. Meddings, F., et al., *Vaginal birth after caesarean section (VBAC): exploring women's perceptions*. J Clin Nurs, 2007. **16**(1): p. 160-7.
Exclusion code: **6**
505. Meehan, F.P., *Delivery following prior cesarean section: an obstetrician's dilemma?* Obstet Gynecol Surv, 1988. **43**(10): p. 582-9.
Exclusion code: **6**
506. Meehan, F.P., *Trial of scar with induction/oxytocin in delivery following prior section*. Clin Exp Obstet Gynecol, 1988. **15**(4): p. 117-23.
Exclusion code: **10**
507. Meehan, F.P., et al., *Delivery following cesarean section and perinatal mortality*. Am J Perinatol, 1989. **6**(1): p. 90-4.
Exclusion code: **10**
508. Meehan, F.P., G. Burke, and J.T. Kehoe, *Update on delivery following prior cesarean section: a 15-year review 1972-1987*. Int J Gynaecol Obstet, 1989. **30**(3): p. 205-12.
Exclusion code: **10**
509. Meehan, F.P., et al., *True rupture/scar dehiscence in delivery following prior section*. Int J Gynaecol Obstet, 1990. **31**(3): p. 249-55.
Exclusion code: **10**
510. Meehan, F.P. and I.M. Magani, *True rupture of the caesarean section scar (a 15 year review, 1972-1987)*. Eur J Obstet Gynecol Reprod Biol, 1989. **30**(2): p. 129-35.
Exclusion code: **10**
511. Megafu, U., *Factors influencing maternal survival in ruptured uterus*. Int J Gynaecol Obstet, 1985. **23**(6): p. 475-80.
Exclusion code: **8**
512. Mehta, S.H., et al., *Shoulder dystocia and the next delivery: outcomes and management*. J Matern Fetal Neonatal Med, 2007. **20**(10): p. 729-33.
Exclusion code: **5**
513. Meikle, S.F., et al., *A national estimate of the elective primary cesarean delivery rate*. Obstet Gynecol, 2005. **105**(4): p. 751-6.
Exclusion code: **5**
514. Menacker, F., E. Declercq, and M.F. Macdorman, *Cesarean delivery: background, trends, and epidemiology*. Semin Perinatol, 2006. **30**(5): p. 235-41.
Exclusion code: **6**
515. Menihan, C.A., *The effect of uterine rupture on fetal heart rate patterns*. J Nurse Midwifery, 1999. **44**(1): p. 40-6.
Exclusion code: **9**
516. Menticoglou, S.M., *Must macrosomic fetuses be delivered by a caesarean section? A review of outcome for 786 babies greater than or equal to 4,500 g*. Aust N Z J Obstet Gynaecol, 1992. **32**: p. 100-103.
Exclusion code: **4**

Appendix F. Excluded Studies List, continued

517. Merrill, B.S. and C.E. Gibbs, *Planned vaginal delivery following cesarean section*. *Obstet Gynecol*, 1978. **52**(1): p. 50-2.
Exclusion code: **10**
518. Meyer, M.C., *Translating data to dialogue: how to discuss mode of delivery with your patient with twins*. *Am J Obstet Gynecol*, 2006. **195**(4): p. 899-906.
Exclusion code: **5**
519. Miller, D.A., et al., *Intrapartum rupture of the unscarred uterus*. *Obstet Gynecol*, 1997. **89**(5 Pt 1): p. 671-3.
Exclusion code: **5**
520. Miller, D.A., et al., *Vaginal birth after cesarean section in twin gestation*. *Am J Obstet Gynecol*, 1996. **175**(1): p. 194-8.
Exclusion code: **5**
521. Miller, E.S., J. Partezana, and R.L. Montgomery, *Vaginal birth after cesarean: a 5-year experience in a family practice residency program*. *J Am Board Fam Pract*, 1995. **8**(5): p. 357-60.
Exclusion code: **6**
522. Miller, P.J., et al., *The relationship between surgeon experience and endometritis after cesarean section*. *Surg Gynecol Obstet*, 1987. **165**(6): p. 535-9.
Exclusion code: **4**
523. Milsom, I., et al., *Influence of maternal, obstetric and fetal risk factors on the prevalence of birth asphyxia at term in a Swedish urban population*. *Acta Obstet Gynecol Scand*, 2002. **81**(10): p. 909-17.
Exclusion code: **7**
524. Minkoff, H. and S. McCalla, *Uterine rupture among women with a prior cesarean delivery*. *N Engl J Med*, 2002. **346**(2): p. 134-7.
Exclusion code: **6**
525. Minkoff, H.L., et al., *The relationship of amniotic fluid phosphate-to-zinc ratios to post-cesarean section infection*. *Am J Obstet Gynecol*, 1982. **142**(8): p. 988-91.
Exclusion code: **4**
526. Misra, A., *Impact of the HealthChoice program on cesarean section and vaginal birth after C-section deliveries: a retrospective analysis*. *Matern Child Health J*, 2008. **12**(2): p. 266-74.
Exclusion code: **6**
527. Mo, A. and M.S. Rogers, *Sonographic examination of uteroplacental separation during the third stage of labor*. *Ultrasound Obstet Gynecol*, 2008. **31**(4): p. 427-31.
Exclusion code: **4**
528. Moffat, M.A., et al., *Decision making about mode of delivery among pregnant women who have previously had a caesarean section: A qualitative study*. *Bjog*, 2007. **114**(1): p. 86-93.
Exclusion code: **6**
529. Molloy, B.G., O. Sheil, and N.M. Duignan, *Delivery after caesarean*

Appendix F. Excluded Studies List, continued

- section: review of 2176 consecutive cases.* British Medical Journal Clinical Research Ed, 1987. **294**(6588): p. 1645-7.
Exclusion code: **10**
530. Montgomery, A.A., et al., *Two decision aids for mode of delivery among women with previous caesarean section: randomised controlled trial.* Bmj, 2007. **334**(7607): p. 1305.
Exclusion code: **6**
531. Mootabar, H., et al., *Vaginal delivery following previous cesarean section in 1983.* Int J Gynaecol Obstet, 1984. **22**(2): p. 155-60.
Exclusion code: **10**
532. Moran, C., et al., *Gastrin levels in mothers and neonates at delivery in various perinatal conditions.* Acta Obstet Gynecol Scand, 1996. **75**(7): p. 608-11.
Exclusion code: **8**
533. Morency, A.-M., N. Brassard, and R.J. Gauthier, *Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted?[comment].* Am J Obstet Gynecol, 2007. **196**(6): p. e6; author reply e6.
Exclusion code: **4**
534. Moriel, E.Z., et al., *Experience with the immediate treatment of iatrogenic bladder injuries and the repair of complex vesico-vaginal fistulae by the transvesical approach.* Arch Gynecol Obstet, 1993. **253**(3): p. 127-30.
Exclusion code: **4**
535. Morin, K.H. and L. Reilly, *Caring for obese pregnant women.* J Obstet Gynecol Neonatal Nurs, 2007. **36**(5): p. 482-9.
Exclusion code: **6**
536. Morrison, J., *Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective cesarean section.* Br J Obstet Gynaecol, 1995. **102**: p. 101-6.
Exclusion code: **4**
537. Mor-Yosef, S., A. Samueloff, and J.G. Schenker, *The Israel perinatal census.* Asia Oceania J Obstet Gynaecol, 1992. **18**(2): p. 139-45.
Exclusion code: **4**
538. Mor-Yosef, S., et al., *Vaginal delivery following one previous cesarean birth: nation wide survey.* Asia Oceania J Obstet Gynaecol, 1990. **16**(1): p. 33-7.
Exclusion code: **5**
539. Mozurkewich, E.L. and E.K. Hutton, *Elective repeat cesarean delivery versus trial of labor: a meta-analysis of the literature from 1989 to 1999.* Am J Obstet Gynecol, 2000. **183**(5): p. 1187-97.
Exclusion code: **10**
540. Muench, M.V., et al., *Gravid hysterectomy: a decade of experience at an academic referral center.* J Reprod Med, 2008. **53**(4): p. 271-8.
Exclusion code: **7**
541. Mulik, V., *The outcome of macrosomic fetuses in a low risk*

Appendix F. Excluded Studies List, continued

- primigravid population*. Int J Gynaecol Obstet, 2003. **80**: p. 15-22.
Exclusion code: **5**
542. Murphy, D.J., *Uterine rupture*. Curr Opin Obstet Gynecol, 2006. **18**(2): p. 135-40.
Exclusion code: **6**
543. Murphy, D.J., et al., *The relationship between Caesarean section and subfertility in a population-based sample of 14 541 pregnancies*. Hum Reprod, 2002. **17**(7): p. 1914-7.
Exclusion code: **4**
544. Murphy, H., *Uterine rupture without previous caesarean section. Review of twelve cases*. Ir Med J, 1976. **69**(20): p. 531-2.
Exclusion code: **10**
545. Murphy, M.C. and S.M. Harvey, *Choice of a childbirth method after caesarean*. Women Health, 1989. **15**(2): p. 67-85.
Exclusion code: **6**
546. Murray, T.M., *Case 9-1998: uterine rupture.[comment]*. N Engl J Med, 1998. **339**(4): p. 268; author reply 269.
Exclusion code: **6**
547. Murta, E.F.C. and R.S. Nomelini, *Is repeated caesarean section a consequence of elective caesarean section?* Lancet, 2004. **364**(9435): p. 649-50.
Exclusion code: **4**
548. Murtha, A.P., et al., *Umbilical venous D-dimer concentrations with and without labor*. Obstet Gynecol, 1998. **92**(2): p. 184-6.
Exclusion code: **5**
549. Murthy, K., et al., *Association Between Rising Professional Liability Insurance Premiums and Primary Cesarean Delivery Rates*. Obstetrics and Gynecology, 2007. **110**(6): p. 1264-1269.
Exclusion code: **4**
550. Myers, S.A. and T.L. Bennett, *Incidence of significant adhesions at repeat cesarean section and the relationship to method of prior peritoneal closure*. J Reprod Med, 2005. **50**(9): p. 659-62.
Exclusion code: **6**
551. Myers, S.A. and N. Gleicher, *A successful program to lower cesarean-section rates*. N Engl J Med, 1988. **319**(23): p. 1511-6.
Exclusion code: **4**
552. Myles, T., *Vaginal birth of twins after a previous Cesarean section*. J Matern Fetal Med, 2001. **10**(3): p. 171-4.
Exclusion code: **5**
553. Nasrat, H. and A. Warda, *X-ray pelvimetry-reappraisal*. Clin Exp Obstet Gynecol, 1991. **18**(1): p. 27-33.
Exclusion code: **8**
554. Nather, A., et al., *Nonclosure of peritoneum at cesarean delivery and future fertility*. Fertil Steril, 2002. **78**(2): p. 424-5.
Exclusion code: **6**
555. Naulty, J.S., et al., *Epidural fentanyl*

Appendix F. Excluded Studies List, continued

- for postcesarean delivery pain management.* Anesthesiology, 1985. **63**(6): p. 694-698.
Exclusion code: **4**
556. Ngu, A. and M.A. Quinn, *Vaginal delivery following caesarean section.* Aust N Z J Obstet Gynaecol, 1985. **25**(1): p. 41-3.
Exclusion code: **10**
557. Ni, H.Y., et al., *Previous abdominal surgery and tubal pregnancy.* Obstet Gynecol, 1990. **75**(6): p. 919-22.
Exclusion code: **4**
558. Nicoll, A.E., et al., *An audit of neonatal respiratory morbidity following elective caesarean section at term.* Scott Med J, 2004. **49**(1): p. 22-5.
Exclusion code: **5**
559. Nielsen, T.F., H. Hagberg, and U. Ljungblad, *Placenta previa and antepartum hemorrhage after previous caesarean section.* Gynecol Obstet Invest, 1989. **27**(2): p. 88-90.
Exclusion code: **4**
560. Nielsen, T.F. and K.H. Hokegard, *The course of subsequent pregnancies after previous caesarean section.* Acta Obstet Gynecol Scand, 1984. **63**(1): p. 13-6.
Exclusion code: **10**
561. Nielsen, T.F., U. Ljungblad, and H. Hagberg, *Rupture and dehiscence of caesarean section scar during pregnancy and delivery.* Am J Obstet Gynecol, 1989. **160**(3): p. 569-73.
Exclusion code: **10**
562. Nordin, A.J. and J.A. Richardson, *Lower segment uterine scar rupture during induction of labour with vaginal prostaglandin E2.* Postgrad Med J, 1993. **69**(813): p. 592.
Exclusion code: **9**
563. Norman, P., S. Kostovcik, and A. Lanning, *Elective repeat caesarean sections: how many could be vaginal births?* Cmaj, 1993. **149**(4): p. 431-5.
Exclusion code: **6**
564. Norris, M.C., *Are combined spinal epidural catheters reliable?* Int, 2000. **9**(1): p. 3-6.
Exclusion code: **4**
565. November, M.T., *Cost analysis of vaginal birth after caesarean.* Clin Obstet Gynecol, 2001. **44**(3): p. 571-87.
Exclusion code: **4**
566. Nuthalapaty, F.S., D.J. Rouse, and J. Owen, *The association of maternal weight with caesarean risk, labor duration, and cervical dilation rate during labor induction.[erratum appears in Obstet Gynecol. 2004 May;103(5 Pt 1):1019].* Obstet Gynecol, 2004. **103**(3): p. 452-6.
Exclusion code: **6**
567. Nwokoro, C.A., et al., *Vaginal birth after primary caesarean section: the fetal size factor.* J Obstet Gynaecol, 2003. **23**(4): p. 392-3.
Exclusion code: **8**
568. O'Brien-Abel, N., *Uterine rupture during VBAC trial of labor: risk factors and fetal response.* J

Appendix F. Excluded Studies List, continued

- Midwifery Womens Health, 2003. **48**(4): p. 249-57.
Exclusion code: **4**
569. Odibo, A.O. and G.A. Macones, *Current concepts regarding vaginal birth after cesarean delivery*. Curr Opin Obstet Gynecol, 2003. **15**(6): p. 479-82.
Exclusion code: **6**
570. O'Driscoll, K., *Rupture of the uterus*. Proceedings of the Royal Society of Medicine, 1966. **59**: p. 65.
Exclusion code: **10**
571. Ofir, K., et al., *Uterine rupture: risk factors and pregnancy outcome*. Am J Obstet Gynecol, 2003. **189**(4): p. 1042-6.
Exclusion code: **5**
572. Ohkuchi, A., et al., *Effect of maternal age on blood loss during parturition: a retrospective multivariate analysis of 10,053 cases*. J Perinat Med, 2003. **31**(3): p. 209-15.
Exclusion code: **5**
573. Ojo, V.A. and J.Y. Aliyu, *Determinant factors in uterine rupture following previous caesarean section*. East Afr Med J, 1988. **65**(5): p. 307-13.
Exclusion code: **8**
574. Okerefor, A., et al., *Patterns of brain injury in neonates exposed to perinatal sentinel events*. Pediatrics, 2008. **121**(5): p. 906-14.
Exclusion code: **7**
575. Ola, E.R., O.D. Imosemi, and O.O. Abudu, *Vaginal birth after one previous Caesarean section-- evaluation of predictive factors*. Afr J Med Med Sci, 2001. **30**(1-2): p. 61-6.
Exclusion code: **8**
576. Oladipo, A. and A. Syed, *The views of obstetricians in the south-west of England on the use of prostaglandins and syntocinon in VBAC*. J Obstet Gynaecol, 2008. **28**(2): p. 177-82.
Exclusion code: **4**
577. Oleske, D.M., et al., *Cesarean and VBAC delivery rates in Medicaid managed care, Medicaid fee-for-service, and private managed care*. Birth, 1998. **25**(2): p. 125-7.
Exclusion code: **6**
578. Olive, E.C., et al., *Placenta praevia: maternal morbidity and place of birth*. Aust N Z J Obstet Gynaecol, 2005. **45**(6): p. 499-504.
Exclusion code: **7**
579. Ollendorff, D.A., et al., *Vaginal birth after cesarean section for arrest of labor: is success determined by maximum cervical dilatation during the prior labor?* Am J Obstet Gynecol, 1988. **159**(3): p. 636-9.
Exclusion code: **4**
580. Onwude, J.L., S. Rao, and D.O. Selo-Ojeme, *Large babies and unplanned Caesarean delivery*. Eur J Obstet Gynecol Reprod Biol, 2005. **118**(1): p. 36-9.
Exclusion code: **5**
581. Ophir, E., et al., *Breech presentation after cesarean section: always a*

Appendix F. Excluded Studies List, continued

- section?* Am J Obstet Gynecol, 1989. **161**(1): p. 25-8.
Exclusion code: **5**
582. Ophir, E., et al., *Delivery mode and maternal rehospitalization*. Arch Gynecol Obstet, 2008. **277**(5): p. 401-4.
Exclusion code: **5**
583. Ophir, E., et al., *Trial of labor following cesarean section: dilemma*. Obstet Gynecol Surv, 1989. **44**(1): p. 19-24.
Exclusion code: **6**
584. O'Sullivan, M.J., et al., *Vaginal delivery after cesarean section*. Clin Perinatol, 1981. **8**(1): p. 131-43.
Exclusion code: **6**
585. Oyelese, Y. and J.C. Smulian, *Placenta previa, placenta accreta, and vasa previa*. Obstet Gynecol, 2006. **107**(4): p. 927-41.
Exclusion code: **6**
586. Ozdemir, I., N. Yucel, and O. Yucel, *Rupture of the pregnant uterus: a 9-year review*. Arch Gynecol Obstet, 2005. **272**(3): p. 229-31.
Exclusion code: **7**
587. Pan, P., *Multifactorial preoperative predictors for postcesarean section pain and analgesic requirement*. Anesthesiology, 2006. **104**: p. 417-25.
Exclusion code: **4**
588. Parazzini, F., et al., *Risk factors for placenta praevia*. Placenta, 1994. **15**(3): p. 321-6.
Exclusion code: **5**
589. Parilla, B.V., et al., *Iatrogenic respiratory distress syndrome following elective repeat cesarean delivery*. Obstet Gynecol, 1993. **81**(3): p. 392-5.
Exclusion code: **5**
590. Penn, Z. and S. Ghaem-Maghani, *Indications for caesarean section*. Best Pract Res Clin Obstet Gynaecol, 2001. **15**(1): p. 1-15.
Exclusion code: **6**
591. Penso, C., *Vaginal birth after cesarean section: an update on physician trends and patient perceptions*. Curr Opin Obstet Gynecol, 1994. **6**(5): p. 417-25.
Exclusion code: **6**
592. Perez-Rios, N., G. Ramos-Valencia, and A.P. Ortiz, *Cesarean Delivery as a Barrier for Breastfeeding Initiation: The Puerto Rican Experience*. Journal of Human Lactation, 2008. **24**(3): p. 293-302.
Exclusion code: **8**
593. Persadie, R.J. and R.J. McDonagh, *Vaginal birth after caesarean section: clinical and legal perspectives*. J Obstet Gynaecol Can, 2003. **25**(10): p. 846-52.
Exclusion code: **6**
594. Perveen, F. and Q. Shah, *Obstetric outcome after one previous caesarean section*. J Obstet Gynaecol Res, 1997. **23**(4): p. 341-6.
Exclusion code: **8**
595. Peschers, U., et al., *Changes in vesical neck mobility following*

Appendix F. Excluded Studies List, continued

- vaginal delivery*. *Obstet Gynecol*, 1996. **88**(6): p. 1001-6.
Exclusion code: **4**
596. Petitti, D.B., *Maternal mortality and morbidity in cesarean section*. *Clin Obstet Gynecol*, 1985. **28**(4): p. 763-9.
Exclusion code: **4**
597. Petitti, D.B., et al., *In-hospital maternal mortality in the United States: time trends and relation to method of delivery*. *Obstet Gynecol*, 1982. **59**(1): p. 6-12.
Exclusion code: **10**
598. Petrikovsky, B.M., *Endoscopic assessment of the integrity of the postcesarean uterine wall before a trial of labor*. *Transcervical Endoscopy Registry*. *J Reprod Med*, 1994. **39**(6): p. 464-6.
Exclusion code: **4**
599. Peyrat, L., et al., *Prevalence and risk factors of urinary incontinence in young and middle-aged women*. *BJU Int*, 2002. **89**(1): p. 61-6.
Exclusion code: **5**
600. Phelan, J.P., *Uterine rupture*. *Clin Obstet Gynecol*, 1990. **33**(3): p. 432-7.
Exclusion code: **10**
601. Phelan, J.P., L.M. Korst, and D.K. Settles, *Uterine activity patterns in uterine rupture: a case-control study*. *Obstet Gynecol*, 1998. **92**(3): p. 394-7.
Exclusion code: **7**
602. Pietrantoni, M., *Peritoneal closure or non-clusure at cesarean*. *Obstetrics and Gynecology*, 1991. **77**(2): p. 293-6.
Exclusion code: **4**
603. Pinette, M.G., et al., *Vaginal birth after Cesarean rates are declining rapidly in the rural state of Maine*. *J Matern Fetal Neonatal Med*, 2004. **16**(1): p. 37-43.
Exclusion code: **6**
604. Piver, M.S. and R.A. Johnston, Sr., *The safety of multiple cesarean sections*. *Obstet Gynecol*, 1969. **34**(5): p. 690-3.
Exclusion code: **10**
605. Placek, P.J., S. Taffel, and M. Moien, *Cesarean section delivery rates: United States, 1981*. *Am J Public Health*, 1981. **73**(8): p. 861-862.
Exclusion code: **6**
606. Placek, P.J. and S.M. Taffel, *The Frequency of Complications in Cesarean and Noncesarean Deliveries, 1970 and 1978*. *Public Health Rep*, 1983. **98**(4): p. 396-400.
Exclusion code: **4**
607. Placek, P.J. and S.M. Taffel, *Recent patterns in cesarean delivery in the United States*. *Obstet Gynecol Clin North Am*, 1988. **15**(4): p. 607-27.
Exclusion code: **6**
608. Placek, P.J. and S.M. Taffel, *Vaginal birth after cesarean (VBAC) in the 1980s*. *Am J Public Health*, 1988. **78**(5): p. 512-5.
Exclusion code: **6**

Appendix F. Excluded Studies List, continued

609. Plauche, W.C., W. Von Almen, and R. Muller, *Catastrophic uterine rupture*. *Obstet Gynecol*, 1984. **64**(6): p. 792-7.
Exclusion code: **10**
610. Plaut, M.M., M.L. Schwartz, and S.L. Lubarsky, *Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section*. *Am J Obstet Gynecol*, 1999. **180**(6 Pt 1): p. 1535-42.
Exclusion code: **9**
611. Pollio, F., et al., *Uterine dehiscence in term pregnant patients with one previous cesarean delivery: growth factor immunorexpression and collagen content in the scarred lower uterine segment*. *Am J Obstet Gynecol*, 2006. **194**(2): p. 527-34.
Exclusion code: **4**
612. Poma, P.A., *Effect of departmental policies on cesarean delivery rates: a community hospital experience*. *Obstet Gynecol*, 1998. **91**(6): p. 1013-8.
Exclusion code: **6**
613. Poma, P.A., *Correlation of birth weights with cesarean rates*. *Int J Gynaecol Obstet*, 1999. **65**(2): p. 117-23.
Exclusion code: **5**
614. Poma, P.A., *Effects of obstetrician characteristics on cesarean delivery rates. A community hospital experience*. *Am J Obstet Gynecol*, 1999. **180**(6 Pt 1): p. 1364-72.
Exclusion code: **6**
615. Poma, P.A., *Rupture of a cesarean-scarred uterus: a community hospital experience*. *J Natl Med Assoc*, 2000. **92**(6): p. 295-300.
Exclusion code: **7**
616. Ponkey, S.E., et al., *Persistent fetal occiput posterior position: obstetric outcomes*. *Obstet Gynecol*, 2003. **101**(5 Pt 1): p. 915-20.
Exclusion code: **5**
617. Porreco, R.P. and J.A. Thorp, *The cesarean birth epidemic: trends, causes, and solutions*. *Am J Obstet Gynecol*, 1996. **175**(2): p. 369-74.
Exclusion code: **6**
618. Porter, T.F., *Survival and neurologic outcome of apparently stillborn infants*. *Am J Obstet Gynecol*, 1997. **176**(1 (2)): p. S15.
Exclusion code: **6**
619. Practice, A.C.o.O., *Committee opinion. Induction of labor for vaginal birth after cesarean delivery*. *Obstet Gynecol*, 2002. **99**(4): p. 679-80.
Exclusion code: **6**
620. Pridjian, G., *Labor after prior cesarean section*. *Clin Obstet Gynecol*, 1992. **35**(3): p. 445-56.
Exclusion code: **4**
621. Pridjian, G., J.U. Hibbard, and A.H. Moawad, *Cesarean: changing the trends*. *Obstet Gynecol*, 1991. **77**(2): p. 195-200.
Exclusion code: **4**
622. Qublan, H.S. and Y. Tahat, *Multiple cesarean section. The impact on*

Appendix F. Excluded Studies List, continued

- maternal and fetal outcome.* Saudi Med J, 2006. **27**(2): p. 210-4.
Exclusion code: **8**
623. Qureshi, B., et al., *Ultrasonographic evaluation of lower uterine segment to predict the integrity and quality of cesarean scar during pregnancy: a prospective study.* Tohoku J Exp Med, 1997. **183**(1): p. 55-65.
Exclusion code: **5**
624. Qureshi, S., *Uterine rupture after induction of labour in women with previous caesarean section.[comment].* Bjog, 2005. **112**(12): p. 1668-9; author reply 1669.
Exclusion code: **4**
625. Rahman, J., et al., *Emergency obstetric hysterectomy in a university hospital: A 25-year review.* J Obstet Gynaecol, 2008. **28**(1): p. 69-72.
Exclusion code: **8**
626. Rasmussen, S., S. Albrechtsen, and K. Dalaker, *Obstetric history and the risk of placenta previa.* Acta Obstet Gynecol Scand, 2000. **79**(6): p. 502-7.
Exclusion code: **4**
627. Rattan, P.K., et al., *Cesarean delivery of the second twin after vaginal delivery of the first twin.* Am J Obstet Gynecol, 1986. **154**(4): p. 936-9.
Exclusion code: **5**
628. Rayburn, W., et al., *Attempted vaginal birth after cesarean section: a multicenter comparison of outpatient prostaglandin E2 gel with expectant management [abstract].* Primary Care Update for Ob/Gyns, 1998. **5**(4): p. 182-183.
Exclusion code: **6**
629. Read, A.W., et al., *Trends in caesarean section in Western Australia, 1980-1987.* Med J Aust, 1990. **153**(6): p. 318-23.
Exclusion code: **5**
630. Read, J.A., *The scheduling of repeat cesarean section operations: prospective management protocol experience.* Am J Obstet Gynecol, 1985. **151**(5): p. 557-63.
Exclusion code: **4**
631. Rees, K.M., et al., *Healthcare professionals' views on two computer-based decision aids for women choosing mode of delivery after previous caesarean section: a qualitative study.* Bjog, 2009. **116**(7): p. 906-14.
Exclusion code: **6**
632. Reime, B., et al., *Do maternity care provider groups have different attitudes towards birth?* Bjog, 2004. **111**(12): p. 1388-93.
Exclusion code: **6**
633. Renner, R.M., et al., *Informational factors influencing patient's childbirth preferences after prior cesarean.* Am J Obstet Gynecol, 2007. **196**(5): p. e14-6.
Exclusion code: **6**
634. Rhodes, J.C., K.C. Schoendorf, and J.D. Parker, *Contribution of excess weight gain during pregnancy and macrosomia to the cesarean delivery*

Appendix F. Excluded Studies List, continued

- rate, 1990-2000. *Pediatrics*, 2003. **111**(5 Part 2): p. 1181-5.
Exclusion code: **6**
635. Ridgeway, J.J., D.L. Weyrich, and T.J. Benedetti, *Fetal heart rate changes associated with uterine rupture*. *Obstet Gynecol*, 2004. **103**(3): p. 506-12.
Exclusion code: **7**
636. Ridley, R.T., et al., *What influences a woman to choose vaginal birth after cesarean?* *J Obstet Gynecol Neonatal Nurs*, 2002. **31**(6): p. 665-72.
Exclusion code: **6**
637. Rinehart, H., *A VBAC primer. Technical issues for midwives*. *Midwifery Today Int Midwife*, 2001(57): p. 16-20.
Exclusion code: **4**
638. Roberts, H., et al., *Ectopic pregnancy in lower segment uterine scar*. *Aust N Z J Obstet Gynaecol*, 1998. **38**(1): p. 114-6.
Exclusion code: **5**
639. Roberts, R.G., et al., *Trial of labor or repeated cesarean section. The woman's choice*. *Arch Fam Med*, 1997. **6**(2): p. 120-5.
Exclusion code: **6**
640. Roberts, R.G., et al., *Changing policies on vaginal birth after cesarean: impact on access*. *Birth*, 2007. **34**(4): p. 316-22.
Exclusion code: **6**
641. Rock, S.M., *Variability and consistency of rates of primary and repeat cesarean sections among hospitals in two states*. *Public Health Rep*, 1993. **108**(4): p. 514-6.
Exclusion code: **4**
642. Rogers, J.F. and W.L. Graves, *Risk factors associated with low Apgar scores in a low-income population*. *Paediatr Perinat Epidemiol*, 1993. **7**(2): p. 205-16.
Exclusion code: **7**
643. Roopnarinesingh, A.J., *Abdominal delivery of the second twin*. *J Obstet Gynaecol*, 2002. **22**(4): p. 379-80.
Exclusion code: **5**
644. Rosen, M.G. and J.C. Dickinson, *Vaginal birth after cesarean: a meta-analysis of indicators for success*. *Obstet Gynecol*, 1990. **76**(5 Pt 1): p. 865-9.
Exclusion code: **6**
645. Rosen, M.G., J.C. Dickinson, and C.L. Westhoff, *Vaginal birth after cesarean: a meta-analysis of morbidity and mortality*. *Obstet Gynecol*, 1991. **77**(3): p. 465-70.
Exclusion code: **6**
646. Rossi, A.C. and V. D'Addario, *Maternal morbidity following a trial of labor after cesarean section vs elective repeat cesarean delivery: a systematic review with metaanalysis*. *Am J Obstet Gynecol*, 2008. **199**(3): p. 224-31.
Exclusion code: **4**
647. Rothman, K.J., S. Greenland, and T. Lash, *Modern Epidemiology*. 3 ed. 2008, Philadelphia: Wolters Kluwer Health/Lippincott Williams &

Appendix F. Excluded Studies List, continued

- Wilkins.
Exclusion code: **4**
648. Roumen, F.J., A.A. Janssen, and F.P. Vrouenraets, *The course of delivery after previous cesarean section*. Eur J Obstet Gynecol Reprod Biol, 1990. **34**(1-2): p. 15-20.
Exclusion code: **10**
649. Rouse, D.J., J. Owen, and J.C. Hauth, *Active-phase labor arrest: oxytocin augmentation for at least 4 hours*. Obstet Gynecol, 1999. **93**(3): p. 323-8.
Exclusion code: **5**
650. Rousseau, J.A., et al., *A randomized study comparing skin closure in cesarean sections: staples vs subcuticular sutures*. American Journal of Obstetrics and Gynecology, 2009. **200**(3): p. 265.e1-4.
Exclusion code: **4**
651. Ruiz-Velasco, V., J. Rosas-Arceo, and T. Quezada-Rocha, *Hazards of multiple Cesarean sections*. Int Surg, 1969. **51**(4): p. 292-8.
Exclusion code: **10**
652. Sachs, B.P., *Vaginal birth after cesarean: a health policy perspective*. Clin Obstet Gynecol, 2001. **44**(3): p. 553-60.
Exclusion code: **6**
653. Sachs, B.P., et al., *The risks of lowering the cesarean-delivery rate*. N Engl J Med, 1999. **340**(1): p. 54-7.
Exclusion code: **6**
654. Sadan, O., et al., *Once a cesarean always a cesarean? A computer-assisted decision analysis*. Arch Gynecol Obstet, 2007. **276**(5): p. 517-21.
Exclusion code: **4**
655. Saglamtas, M., et al., *Rupture of the uterus*. Int J Gynaecol Obstet, 1995. **49**(1): p. 9-15.
Exclusion code: **11**
656. Sahala, D., *A call to action: vaginal birth after cesarean (VBAC) in crisis in Florida*. Midwifery Today Int Midwife, 2005(76): p. 41-2.
Exclusion code: **6**
657. Saldana, L.R., H. Schulman, and L. Reuss, *Management of pregnancy after cesarean section*. Am J Obstet Gynecol, 1979. **135**(5): p. 555-61.
Exclusion code: **10**
658. Salihu, H.M., et al., *Risk of stillbirth following a cesarean delivery: black-white disparity*. Obstet Gynecol, 2006. **107**(2 Pt 1): p. 383-90.
Exclusion code: **10**
659. Salim, R., et al., *Abdominal scar characteristics as a predictor of intra-abdominal adhesions at repeat cesarean delivery*. Fertil Steril, 2008. **90**(6): p. 2324-7.
Exclusion code: **4**
660. Sanchez-Ramos, L., F.L. Gaudier, and A.M. Kaunitz, *Cervical ripening and labor induction after previous cesarean delivery*. Clin Obstet Gynecol, 2000. **43**(3): p. 513-23.
Exclusion code: **6**
661. Sanchez-Ramos, L. and A.M.

Appendix F. Excluded Studies List, continued

- Kaunitz, *Uterine rupture associated with the use of prostaglandin E1 in patients with previous cesarean delivery.[comment]*. Am J Obstet Gynecol, 2000. **182**(4): p. 990-1.
Exclusion code: **6**
662. Sanchez-Ramos, L., et al., *Route of breech delivery and maternal and neonatal outcomes*. Int J Gynaecol Obstet, 2001. **73**(1): p. 7-14.
Exclusion code: **5**
663. Sansregret, A., E. Bujold, and R.J. Gauthier, *Twin delivery after a previous caesarean: a twelve-year experience*. J Obstet Gynaecol Can, 2003. **25**(4): p. 294-8.
Exclusion code: **5**
664. Sarno, A.P., Jr., et al., *Vaginal birth after cesarean delivery. Trial of labor in women with breech presentation*. J Reprod Med, 1989. **34**(10): p. 831-3.
Exclusion code: **5**
665. Saunders, L.D. and G. Flowerdew, *Cesarean sections in Alberta from April 1979 to March 1988*. Cmaj, 1991. **144**(10): p. 1243-9.
Exclusion code: **10**
666. Schimmel, L.M., et al., *The Yolo County Midwifery Service. A descriptive study of 496 singleton birth outcomes, 1990*. J Nurse Midwifery, 1992. **37**(6): p. 398-403.
Exclusion code: **7**
667. Schneider, J., D. Gallego, and R. Benito, *Trial of labour in patients with a prior caesarean section and an intervening vaginal delivery*. Aust N Z J Obstet Gynaecol, 1987. **27**(3): p. 178-9.
Exclusion code: **5**
668. Schnitker, K.A., *Uterine rupture during trial of labor: risk management recommendations*. J Healthc Risk Manag, 1999. **19**(4): p. 12-6.
Exclusion code: **6**
669. Schreiner, R.L., et al., *Respiratory distress associated with elective repeat cesarean section. A two-year experience in one medical community*. Acta Obstet Gynecol Scand, 1981. **60**(3): p. 261-4.
Exclusion code: **10**
670. Schreiner, R.L., et al., *Respiratory distress following elective repeat cesarean section*. Am J Obstet Gynecol, 1982. **143**(6): p. 689-92.
Exclusion code: **10**
671. Sciscione, A.C., et al., *A randomized comparison of transcervical Foley catheter to intravaginal misoprostol for preinduction cervical ripening*. Obstet Gynecol, 2001. **97**(4): p. 603-7.
Exclusion code: **9**
672. Scott, J.R., *Mandatory trial of labor after cesarean delivery: an alternative viewpoint*. Obstet Gynecol, 1991. **77**(6): p. 811-4.
Exclusion code: **4**
673. Scott, J.R., *Avoiding labor problems during vaginal birth after cesarean delivery*. Clin Obstet Gynecol, 1997. **40**(3): p. 533-41.
Exclusion code: **6**

Appendix F. Excluded Studies List, continued

674. Scott, J.R., *Vaginal birth after cesarean section*. Book: Queenan JT, Hobbins JC, Spong CY (eds): *Protocols in High Risk Pregnancy*. 4th Ed., 2005: p. 559-64.
Exclusion code: **4**
675. Segal, S., et al., *Evaluation of breast stimulation for induction of labor in women with a prior cesarean section and in grandmultiparas*. *Acta Obstet Gynecol Scand*, 1995. **74**(1): p. 40-1.
Exclusion code: **8**
676. Sela, H.Y., et al., *Safety and efficacy of external cephalic version for women with a previous cesarean delivery*. *Eur J Obstet Gynecol Reprod Biol*, 2009. **142**(2): p. 111-4.
Exclusion code: **4**
677. Sen, S., S. Malik, and S. Salhan, *Ultrasonographic evaluation of lower uterine segment thickness in patients of previous cesarean section*. *Int J Gynaecol Obstet*, 2004. **87**(3): p. 215-9.
Exclusion code: **8**
678. Seow, K.M., et al., *Cesarean scar pregnancy: issues in management*. *Ultrasound Obstet Gynecol*, 2004. **23**(3): p. 247-53.
Exclusion code: **5**
679. Seow, K.-M., et al., *Subsequent pregnancy outcome after conservative treatment of a previous cesarean scar pregnancy*. *Acta Obstet Gynecol Scand*, 2004. **83**(12): p. 1167-72.
Exclusion code: **8**
680. Shalev, E., et al., *External cephalic version at term--using tocolysis*. *Acta Obstet Gynecol Scand*, 1993. **72**(6): p. 455-7.
Exclusion code: **9**
681. Sheffield, J.S., et al., *Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.[see comment][erratum appears in Obstet Gynecol. 2006 Sep;108(3 Pt 1):695]*. *Obstet Gynecol*, 2006. **108**(1): p. 141-7.
Exclusion code: **4**
682. Sheiner, E., et al., *Identifying risk factors for peripartum cesarean hysterectomy. A population-based study*. *J Reprod Med*, 2003. **48**(8): p. 622-6.
Exclusion code: **5**
683. Sheiner, E., et al., *Failed vacuum extraction. Maternal risk factors and pregnancy outcome*. *J Reprod Med*, 2001. **46**(9): p. 819-24.
Exclusion code: **5**
684. Sherrard, A., et al., *Maternal anthropometric risk factors for caesarean delivery before or after onset of labour*. *Bjog*, 2007. **114**(9): p. 1088-96.
Exclusion code: **10**
685. Shihady, I.R., et al., *Vaginal birth after cesarean: do California hospital policies follow national guidelines?* *J Reprod Med*, 2007. **52**(5): p. 349-58.
Exclusion code: **6**
686. Shin, Y.K., *Shoulder pain in a trial of labor after cesarean delivery*.

Appendix F. Excluded Studies List, continued

- South Med J, 1989. **82**(10): p. 1320.
Exclusion code: **6**
687. Shipp, T.A., *Maternal age as a predictor of symptomatic uterine rupture during a trial of labor after previous cesarean delivery*. Am J Obstet Gynecol, 2001. **184**: p. S186.
Exclusion code: **4**
688. Shorten, A., et al., *Making choices for childbirth: development and testing of a decision-aid for women who have experienced previous cesarean*. Patient Educ Couns, 2004. **52**(3): p. 307-13.
Exclusion code: **6**
689. Shorten, A., D.E. Lewis, and B. Shorten, *Trial of labour versus elective repeat cesarean section: a cost-effectiveness analysis*. Aust Health Rev, 1998. **21**(1): p. 8-28.
Exclusion code: **6**
690. Shorten, A., et al., *Making choices for childbirth: a randomized controlled trial of a decision-aid for informed birth after cesarean*. Birth, 2005. **32**(4): p. 252-61.
Exclusion code: **6**
691. Shukunami, K.-I., K. Nishijima, and F. Kotsuji, *Re: Use of the Atad catheter for the induction of labour in women who have had a previous Caesarean section: a case series.[comment]*. Aust N Z J Obstet Gynaecol, 2006. **46**(1): p. 70; author reply 70.
Exclusion code: **6**
692. Shy, K.K., J.P. LoGerfo, and L.E. Karp, *Evaluation of elective repeat cesarean section as a standard of care: an application of decision analysis*. Am J Obstet Gynecol, 1981. **139**(2): p. 123-9.
Exclusion code: **4**
693. Silberstein, T., et al., *Routine revision of uterine scar after cesarean section: has it ever been necessary?* Eur J Obstet Gynecol Reprod Biol, 1998. **78**(1): p. 29-32.
Exclusion code: **4**
694. Silver, R.K. and J. Minogue, *When does a statistical fact become an ethical imperative?* Am J Obstet Gynecol, 1987. **157**(2): p. 229-33.
Exclusion code: **4**
695. Simon, R. and D. Altman, *Statistical aspects of prognostic factor studies in oncology*. Br J Cancer, 1994. **69**: p. 979-85.
Exclusion code: **4**
696. Singh, P.M., C. Rodrigues, and A.N. Gupta, *Placenta previa and previous cesarean section*. Acta Obstet Gynecol Scand, 1981. **60**(4): p. 367-8.
Exclusion code: **10**
697. Singhal, S.R., et al., *Intrapartum posterior uterine wall rupture in lower segment cesarean section scarred uterus*. Acta Obstet Gynecol Scand, 2005. **84**(2): p. 196-7.
Exclusion code: **9**
698. Skelly, H.R., A.M. Duthie, and R.H. Philpott, *Rupture of the uterus: the preventable factors*. Samj, S, 1976. **Suid-Afrikaanse Tydskrif Vir Geneeskunde**. **50**(13): p. 505-9.

Appendix F. Excluded Studies List, continued

Exclusion code: **10**

699. Smith, G.C.S., *Predicting antepartum stillbirth*. Curr Opin Obstet Gynecol, 2006. **18**(6): p. 625-30.

Exclusion code: **5**

700. Smith, G.C.S., J.P. Pell, and R. Dobbie, *Caesarean section and risk of unexplained stillbirth in subsequent pregnancy*. Lancet, 2003. **362**(9398): p. 1779-84.

Exclusion code: **4**

701. Smith, J.G. and D.C. Merrill, *Oxytocin for induction of labor*. Clin Obstet Gynecol, 2006. **49**(3): p. 594-608.

Exclusion code: **6**

702. Smith, J.G., H.L. Mertz, and D.C. Merrill, *Identifying risk factors for uterine rupture*. Clin Perinatol, 2008. **35**(1): p. 85-99.

Exclusion code: **4**

703. Sobande, A. and M. Eskandar, *Multiple repeat caesarean sections: complications and outcomes*. J Obstet Gynaecol Can, 2006. **28**(3): p. 193-7.

Exclusion code: **8**

704. Songane, F.F., et al., *Balancing the risks of planned cesarean section and trial of vaginal delivery for the mature, selected, singleton breech presentation*. J Perinat Med, 1987. **15**(6): p. 531-43.

Exclusion code: **4**

705. Spaulding, L.B. and D.G. Gallup, *Current concepts of management of*

rupture of the gravid uterus. Obstet Gynecol, 1979. **54**(4): p. 437-41.

Exclusion code: **7**

706. Spellacy, W.N., et al., *Neonatal seizures after cesarean delivery: higher risk with labor*. Am J Obstet Gynecol, 1987. **157**(2): p. 377-9.

Exclusion code: **5**

707. Spetz, J., M.W. Smith, and S.F. Ennis, *Physician incentives and the timing of cesarean sections: evidence from California*. Med Care, 2001. **39**(6): p. 536-50.

Exclusion code: **6**

708. Spurrett, B. and C.M. Cook, *Why we choose caesarean section: a prospective study*. Aust N Z J Obstet Gynaecol, 1997. **37**(3): p. 297-300.

Exclusion code: **6**

709. Stafford, R.S., *The impact of nonclinical factors on repeat cesarean section*. Jama, 1991. **265**(1): p. 59-63.

Exclusion code: **6**

710. Stalnaker, B.L., et al., *Characteristics of successful claims for payment by the Florida Neurologic Injury Compensation Association Fund*. Am J Obstet Gynecol, 1997. **177**(2): p. 268-71; discussion 271-3.

Exclusion code: **6**

711. Stevenson, D.K., et al., *Increased immunoreactive erythropoietin in cord plasma and neonatal bilirubin production in normal term infants after labor*. Obstet Gynecol, 1986. **67**(1): p. 69-73.

Appendix F. Excluded Studies List, continued

Exclusion code: **7**

712. Stone, J.L., et al., *Use of cervical prostaglandin E2 gel in patients with previous cesarean section*. Am J Perinatol, 1994. **11**(4): p. 309-12.

Exclusion code: **5**

713. Strong, T.H., Jr., et al., *Vaginal birth after cesarean delivery in the twin gestation*. Am J Obstet Gynecol, 1989. **161**(1): p. 29-32.

Exclusion code: **5**

714. Stubbs, T.M., *Oxytocin for labor induction*. Clin Obstet Gynecol, 2000. **43**(3): p. 489-94.

Exclusion code: **6**

715. Sumigama, S., et al., *Placenta previa increta/percreta in Japan: a retrospective study of ultrasound findings, management and clinical course*. J Obstet Gynaecol Res, 2007. **33**(5): p. 606-11.

Exclusion code: **7**

716. Sur, S. and I.Z. Mackenzie, *Does discussion of possible scar rupture influence preferred mode of delivery after a cesarean section?* J Obstet Gynaecol, 2005. **25**(4): p. 338-41.

Exclusion code: **6**

717. Sur, S., K.W. Murphy, and I.Z. Mackenzie, *Delivery after cesarean section: consultant obstetricians' professional advice and personal preferences*. J Obstet Gynaecol, 2009. **29**(3): p. 212-6.

Exclusion code: **6**

718. Swaim, L.S., C.S. Holste, and D.K. Waller, *Umbilical cord blood pH*

after prior cesarean delivery. Obstet Gynecol, 1998. **92**(3): p. 390-3.

Exclusion code: **5**

719. Szczesny, W., et al., *Bishop score and the outcome of labor induction with misoprostol*. Acta Obstet Gynecol Scand, 2006. **85**(5): p. 579-82.

Exclusion code: **5**

720. Takayama, T., *Risks associated with cesarean section in women with placenta previa*. J Obstet Gynaecol Res, 1997. **23**: p. 375-9.

Exclusion code: **10**

721. Tammelleo, A.D., *Failure to "fully communicate": catastrophic results. Case in point: Baptist Medical Center v. Wilson 618 So. 2d 1335--AL (1993)*. Regan Rep Nurs Law, 1993. **34**(3): p. 2.

Exclusion code: **9**

722. Tan, P.C., R.N. Subramaniam, and S.Z. Omar, *Predictors for caesarean delivery and neonatal admission after trial of labour in women with one previous lower segment caesarean scar*. Singapore Med J, 2008. **49**(3): p. 188-92.

Exclusion code: **8**

723. Tan, P.C., R.N. Subramaniam, and S.Z. Omar, *Trial of labor after one cesarean: role of the order and number of prior vaginal births on the risk of emergency cesarean delivery and neonatal admission*. Taiwan, 2008. **47**(3): p. 305-11.

Exclusion code: **5**

724. Targett, C., *Caesarean section and*

Appendix F. Excluded Studies List, continued

- trial of scar*. Aust N Z J Obstet Gynaecol, 1988. **28**(4): p. 249-62.
Exclusion code: **10**
725. Tatar, M., et al., *Women's perceptions of caesarean section: reflections from a Turkish teaching hospital*. Soc Sci Med, 2000. **50**(9): p. 1227-33.
Exclusion code: **6**
726. Taylor, V.M., et al., *Placenta previa and prior cesarean delivery: how strong is the association?* Obstet Gynecol, 1994. **84**(1): p. 55-7.
Exclusion code: **5**
727. To, W.W. and W.C. Leung, *Placenta previa and previous cesarean section*. Int J Gynaecol Obstet, 1995. **51**(1): p. 25-31.
Exclusion code: **7**
728. Tripathi, J.B., H.U. Doshi, and P.J. Kotdawala, *Vaginal birth after one caesarean section: analysis of indicators of success*. J Indian Med Assoc, 2006. **104**(3): p. 113-5.
Exclusion code: **8**
729. Tuggy, M.L., *Uterine-vesicular rupture during trial of labor*. J Am Board Fam Pract, 1995. **8**(5): p. 405-9.
Exclusion code: **9**
730. Tuncer, R., et al., *Emergency postpartum hysterectomy*. J Gynecol Surg, 1995. **11**(4): p. 209-13.
Exclusion code: **5**
731. Turner, M.J., *Delivery after one previous cesarean section*. Am J Obstet Gynecol, 1997. **176**(4): p. 741-4.
Exclusion code: **7**
732. Turner, M.J., *Uterine rupture*. Best Pract Res Clin Obstet Gynaecol, 2002. **16**(1): p. 69-79.
Exclusion code: **6**
733. Turner, M.J.A., G. Agnew, and H. Langan, *Uterine rupture after a previous Caesarean section*. Ir Med J, 2005. **98**(8): p. 229-30.
Exclusion code: **4**
734. Turner, M.J.A., G. Agnew, and H. Langan, *Uterine rupture and labour after a previous low transverse caesarean section*. Bjog, 2006. **113**(6): p. 729-32.
Exclusion code: **11**
735. Turnquest, M.A., et al., *Vaginal birth after cesarean section in a university setting*. J Ky Med Assoc, 1994. **92**(6): p. 216-21.
Exclusion code: **4**
736. Tutschek, B., H.G. Bender, and W. Henrich, *Silent uterine rupture during vaginal delivery successfully managed conservatively*. Ultrasound Obstet Gynecol, 2005. **26**(2): p. 199-200.
Exclusion code: **9**
737. Udayasankar, V., R. Padmagirison, and F. Majoko, *National survey of obstetricians in Wales regarding induction of labour in women with a previous caesarean section*. J Obstet Gynaecol, 2008. **28**(1): p. 48-50.
Exclusion code: **6**
738. Udo-Inyang, A., C. Lee, and E.

Appendix F. Excluded Studies List, continued

- Evans, *Gravid uterine rupture following cesarean section and intervening vaginal delivery*. Henry Ford Hosp Med J, 1986. **34**(3): p. 215-7.
Exclusion code: **9**
739. Uppington, J., *Epidural analgesia and previous Caesarean section*. Anaesthesia, 1983. **38**(4): p. 336-41.
Exclusion code: **9**
740. Usta, I.M., et al., *Placenta previa-accreta: risk factors and complications*. Am J Obstet Gynecol, 2005. **193**(3 Pt 2): p. 1045-9.
Exclusion code: **4**
741. Usta, I.M. and A.H. Nassar, *Advanced maternal age. Part I: obstetric complications*. Am J Perinatol, 2008. **25**(8): p. 521-34.
Exclusion code: **5**
742. van Amerongen, D., *Vaginal birth after cesarean section in an HMO*. Hmo Pract, 1989. **3**(3): p. 104-7.
Exclusion code: **4**
743. van Amerongen, D., *Vaginal birth after cesarean section. Experience in a community-based practice*. J Reprod Med, 1989. **34**(8): p. 531-4.
Exclusion code: **4**
744. Van Bogaert, L.J., *The relation between height, foot length, pelvic adequacy and mode of delivery*. Eur J Obstet Gynecol Reprod Biol, 1999. **82**(2): p. 195-9.
Exclusion code: **7**
745. van Bogaert, L.J., *Mode of delivery after one cesarean section*. Int J Gynaecol Obstet, 2004. **87**(1): p. 9-13.
Exclusion code: **4**
746. van Loon, A.J., et al., *Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term*. Lancet, 1997. **350**(9094): p. 1799-804.
Exclusion code: **5**
747. van Roosmalen, J. and C.D. van der Does, *Caesarean birth rates worldwide. A search for determinants*. Trop Geogr Med, 1995. **47**(1): p. 19-22.
Exclusion code: **6**
748. Varner, M.W., et al., *The Maternal-Fetal Medicine Unit cesarean registry: trial of labor with a twin gestation*. Am J Obstet Gynecol, 2005. **193**(1): p. 135-40.
Exclusion code: **5**
749. Varner, M.W., et al., *Trial of labor after one previous cesarean delivery for multifetal gestation*. Obstet Gynecol, 2007. **110**(4): p. 814-9.
Exclusion code: **5**
750. Vause, S. and M. Macintosh, *Evidence based case report: use of prostaglandins to induce labour in women with a caesarean section scar*. Bmj, 1999. **318**(7190): p. 1056-8.
Exclusion code: **9**
751. Veille, J.C., et al., *Human umbilical artery flow velocity waveforms before and after regional anesthesia for cesarean section*. Obstet Gynecol, 1988. **72**(6): p. 890-3.

Appendix F. Excluded Studies List, continued

Exclusion code: **4**

752. Vellekoop, J., E.A.M. Roell-Schorer, and J. van Roosmalen, *Uterine scar rupture after a previous cesarean section and induction of labor with prostaglandins*. Acta Obstet Gynecol Scand, 2006. **85**(2): p. 132-4.

Exclusion code: **9**

753. Veltman, L., *Vaginal birth after cesarean checklist; an evidence-based approach to improving care during VBAC trials*. J Healthc Risk Manag, 2009. **29**(1): p. 22-7.

Exclusion code: **6**

754. Vendittelli, F., et al., *Is a breech presentation at term more frequent in women with a history of cesarean delivery?* Am J Obstet Gynecol, 2008. **198**(5): p. 521.e1-6.

Exclusion code: **5**

755. Vengadasalam, D., *Vaginal delivery following cesarean section*. Singapore Med J, 1986. **27**(5): p. 396-8.

Exclusion code: **4**

756. Veridiano, N.P., N.S. Thorner, and J. Ducey, *Vaginal delivery after cesarean section*. Int J Gynaecol Obstet, 1989. **29**(4): p. 307-11.

Exclusion code: **5**

757. Wadhawan, S. and J.N. Narone, *Outcome of labor following previous cesarean section*. Int J Gynaecol Obstet, 1983. **21**(1): p. 7-10.

Exclusion code: **8**

758. Wagner, M., *What every midwife should know about ACOG and*

VBAC. Critique of ACOG Practice Bulletin #5, July 1999, "Vaginal birth after previous cesarean section". Midwifery Today Int Midwife, 2001(59): p. 41-3.

Exclusion code: **6**

759. Wallace, D.H., et al., *Indirect sonographic guidance for epidural anesthesia in obese pregnant patients*. Reg Anesth, 1992. **17**(4): p. 233-6.

Exclusion code: **6**

760. Wareham, V., C. Bain, and D. Cruickshank, *Caesarean section audit by peer review*. Eur J Obstet Gynecol Reprod Biol, 1993. **48**(1): p. 9-14.

Exclusion code: **4**

761. Warren, L., *A revelation in birth--home VBAC*. Midwifery Today Int Midwife, 2005(74): p. 40-1.

Exclusion code: **4**

762. Wax, J.R., et al., *Pregnancy following gastric bypass surgery for morbid obesity: maternal and neonatal outcomes*. Obes Surg, 2008. **18**(5): p. 540-4.

Exclusion code: **7**

763. Wax, J.R., et al., *Twin vaginal birth after cesarean*. Conn Med, 2000. **64**(4): p. 205-8.

Exclusion code: **5**

764. Wax, J.R., et al., *Interpregnancy interval as a risk factor for placenta accreta*. Conn Med, 2000. **64**(11): p. 659-61.

Exclusion code: **5**

Appendix F. Excluded Studies List, continued

765. Weeks, A., et al., *Misoprostol for induction of labor with a live fetus*. Int J Gynaecol Obstet, 2007. **99 Suppl 2**: p. S194-7.
Exclusion code: **6**
766. Weeks, J.W., T. Pitman, and J.A. Spinnato, 2nd, *Fetal macrosomia: does antenatal prediction affect delivery route and birth outcome?* Am J Obstet Gynecol, 1995. **173**(4): p. 1215-9.
Exclusion code: **5**
767. Weiss, J., A. Nannini, and L. Bartlett, *Uterine rupture among women with a prior cesarean delivery*. N Engl J Med, 2002. **346**(2): p. 134-7.
Exclusion code: **6**
768. Whiteman, M.K., et al., *Incidence and determinants of peripartum hysterectomy*. Obstet Gynecol, 2006. **108**(6): p. 1486-92.
Exclusion code: **4**
769. Whiteside, D.C., C.S. Mahan, and J.C. Cook, *Factors associated with successful vaginal delivery after cesarean section*. J Reprod Med, 1983. **28**(11): p. 785-8.
Exclusion code: **7**
770. Wilson, P.D., R.M. Herbison, and G.P. Herbison, *Obstetric practice and the prevalence of urinary incontinence three months after delivery*. Br J Obstet Gynaecol, 1996. **103**(2): p. 154-61.
Exclusion code: **5**
771. Windrim, R., *Vaginal delivery in birth centre after previous caesarean section*. Lancet, 2005. **365**(9454): p. 106-7.
Exclusion code: **6**
772. Wing, D.A. and C.A.L. Gaffaney, *Vaginal misoprostol administration for cervical ripening and labor induction*. Clin Obstet Gynecol, 2006. **49**(3): p. 627-41.
Exclusion code: **4**
773. Wing, D.A. and R.H. Paul, *Vaginal birth after cesarean section: selection and management*. Clin Obstet Gynecol, 1999. **42**(4): p. 836-48.
Exclusion code: **6**
774. Wood, S.L., et al., *The risk of unexplained antepartum stillbirth in second pregnancies following caesarean section in the first pregnancy*. Bjog, 2008. **115**(6): p. 726-31.
Exclusion code: **7**
775. Woods, J.R., Jr., et al., *The effect of labor on maternal and fetal vitamins C and E*. Am J Obstet Gynecol, 2002. **187**(5): p. 1179-83.
Exclusion code: **5**
776. Yamani, T.Y. and A.A. Rouzi, *Induction of labor with vaginal prostaglandin-E2 in grand multiparous women with one previous cesarean section*. Int J Gynaecol Obstet, 1999. **65**(3): p. 251-3.
Exclusion code: **8**
777. Yamani Zamzami, T.Y., *Indication of emergency peripartum hysterectomy: review of 17 cases*.

Appendix F. Excluded Studies List, continued

- Arch Gynecol Obstet, 2003. **268**(3): p. 131-5.
Exclusion code: **8**
778. Yamani Zamzami, T.Y., *Vaginal birth after cesarean section in grand multiparous women*. Arch Gynecol Obstet, 2004. **270**(1): p. 21-4.
Exclusion code: **8**
779. Yamani-Zamzami, T.Y., *Delivery outcomes at term after one previous cesarean section*. Saudi Med J, 2007. **28**(12): p. 1845-9.
Exclusion code: **8**
780. Yang, J.I., et al., *Sonographic findings of placental lacunae and the prediction of adherent placenta in women with placenta previa totalis and prior Cesarean section*. Ultrasound Obstet Gynecol, 2006. **28**(2): p. 178-82.
Exclusion code: **4**
781. Yang, Y.T., et al., *Relationship between malpractice litigation pressure and rates of cesarean section and vaginal birth after cesarean section*. Med Care, 2009. **47**(2): p. 234-42.
Exclusion code: **6**
782. Yangzom, Y., et al., *Outcome of hospital deliveries of women living at high altitude: a study from Lhasa in Tibet*. Acta Paediatr, 2008. **97**(3): p. 317-21.
Exclusion code: **8**
783. Yap, O.W., E.S. Kim, and R.K. Laros, Jr., *Maternal and neonatal outcomes after uterine rupture in labor*. Am J Obstet Gynecol, 2001. **184**(7): p. 1576-81.
Exclusion code: **10**
784. Yasumizu, T., et al., *Trial of vaginal birth following cesarean section for arrest disorders of labor: analysis of patients with well-documented medical records*. Asia Oceania J Obstet Gynaecol, 1994. **20**(4): p. 407-13.
Exclusion code: **7**
785. Yeh, S., X. Huang, and J.P. Phelan, *Postterm pregnancy after previous cesarean section*. J Reprod Med, 1984. **29**(1): p. 41-4.
Exclusion code: **10**
786. Yogev, Y., et al., *Induction of labor with vaginal prostaglandin E2*. J Matern Fetal Neonatal Med, 2003. **14**(1): p. 30-4.
Exclusion code: **7**
787. Yu, C.K.H., T.G. Teoh, and S. Robinson, *Obesity in pregnancy*. Bjog, 2006. **113**(10): p. 1117-25.
Exclusion code: **6**
788. Yudkin, P.L. and C.W. Redman, *Caesarean section dissected, 1978-1983*. Br J Obstet Gynaecol, 1986. **93**(2): p. 135-44.
Exclusion code: **7**
789. Zagorzycki, M.T. and C.R. Brinkman, 3rd, *The effect of general and epidural anesthesia upon neonatal Apgar scores in repeat cesarean section*. Surg Gynecol Obstet, 1982. **155**(5): p. 641-5.
Exclusion code: **7**
790. Zaideh, S.M., A.T. Abu-Heija, and

Appendix F. Excluded Studies List, continued

- M.F. El-Jallad, *Placenta praevia and accreta: analysis of a two-year experience*. *Gynecol Obstet Invest*, 1998. **46**(2): p. 96-8.
Exclusion code: **8**
791. Zaki, Z.M., et al., *Risk factors and morbidity in patients with placenta previa accreta compared to placenta previa non-accreta*. *Acta Obstet Gynecol Scand*, 1998. **77**(4): p. 391-4.
Exclusion code: **8**
792. Zhang, J. and D.A. Savitz, *Maternal age and placenta previa: a population-based, case-control study*. *Am J Obstet Gynecol*, 1993. **168**(2): p. 641-5.
Exclusion code: **4**
793. Zhuang, Y.L., et al., [*Treatment of pregnancy in a previous caesarean section scar with uterine artery embolization: analysis of 60 cases*]. *Zhonghua yi xue za zhi*, 2008. **88**(33): p. 2372-4.
Exclusion code: **8**
794. Ziadeh, S.M. and A.T. Abu-Heija, *Duration of labor in patients delivered vaginally after one previous lower segment cesarean section*. *Int J Gynaecol Obstet*, 1994. **45**(3): p. 213-5.
Exclusion code: **8**
795. Ziadeh, S.M., M.R. Zakaria, and E.I. Sunna, *Obstetric uterine rupture in north Jordan*. *J Obstet Gynaecol Res*, 1996. **22**(3): p. 209-13.
Exclusion code: **8**
796. Zorlu, C.G., et al., *Vaginal birth following unmonitored labor in patients with prior cesarean section*. *Gynecol Obstet Invest*, 1996. **42**(4): p. 222-6.
Exclusion code: **4**
797. Zweifler, J., et al., *Vaginal birth after cesarean in California: before and after a change in guidelines*. *Ann Fam Med*, 2006. **4**(3): p. 228-34.
Exclusion code: **7**

Appendix F. Excluded Studies List, continued

Studies excluded by specific topics of interest:

Trial of labor and vaginal birth after cesarean rates:

Studies were excluded from the trial of labor and vaginal birth after cesarean rates sections for various reasons, these include: limited population that was not comparable to others included, poor quality studies, examined the same group of cohort as included studies, studies were not specific about all who was eligible for a trial of labor.

1. Blanchette, H., et al., *Is vaginal birth after cesarean safe? Experience at a community hospital.* Am J Obstet Gynecol, 2001. **184**(7): p. 1478-84; discussion 1484-7.
2. Bujold, E., et al., *Modified Bishop's score and induction of labor in patients with a previous cesarean delivery.* Am J Obstet Gynecol, 2004. **191**(5): p. 1644-8.
3. Cahill, A.G., et al., *Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery?* Am J Obstet Gynecol, 2006. **195**(4): p. 1143-7.
4. Carroll, C.S., Sr., et al., *Vaginal birth after cesarean section versus elective repeat cesarean delivery: Weight-based outcomes.* Am J Obstet Gynecol, 2003. **188**(6): p. 1516-20; discussion 1520-2.
5. Chauhan, S.P., et al., *Mode of delivery for the morbidly obese with prior cesarean delivery: vaginal versus repeat cesarean section.* Am J Obstet Gynecol, 2001. **185**(2): p. 349-54.
6. Gibson, D.H., *Vaginal delivery after cesarean section in primigravidae.* Ir J Med Sci, 1988. **157**(9): p. 290-2.
7. Gonen, R., et al., *Variables associated with successful vaginal birth after one cesarean section: a proposed vaginal birth after cesarean section score.* Am J Perinatol, 2004. **21**(8): p. 447-53.
8. Grobman, W.A., et al., *Pregnancy outcomes for women with placenta previa in relation to the number of prior cesarean deliveries.* Obstet Gynecol, 2007. **110**(6): p. 1249-55.
9. Heddleston, L.N. and W.J. Watson, *Vaginal birth after cesarean section in a small hospital.* Mil Med, 1991. **156**(5): p. 239-40.
10. Kabir, A.A., et al., *Racial differences in cesareans: an analysis of U.S. 2001 National Inpatient Sample Data.[see comment][erratum appears in Obstet Gynecol. 2005 Jun;105(6):1495].* Obstet Gynecol, 2005. **105**(4): p. 710-8.
11. King, D.E. and K. Lahiri, *Socioeconomic factors and the odds of vaginal birth after cesarean delivery.* Jama, 1994. **272**(7): p. 524-9.

Appendix F. Excluded Studies List, continued

12. Landon, M.B., et al., *Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery*. N Engl J Med, 2004. **351**(25): p. 2581-9.
13. Leung, A.S., E.K. Leung, and R.H. Paul, *Uterine rupture after previous cesarean delivery: maternal and fetal consequences*. Am J Obstet Gynecol, 1993. **169**(4): p. 945-50.
14. Melnikow, J., et al., *Vaginal birth after cesarean in California*. Obstet Gynecol, 2001. **98**(3): p. 421-6.
15. Mercer, B.M., et al., *Labor outcomes with increasing number of prior vaginal births after cesarean delivery*. Obstet Gynecol, 2008. **111**(2 Pt 1): p. 285-91.
16. Montgomery, A.A., et al., *Two decision aids for mode of delivery among women with previous caesarean section: randomised controlled trial*. Bmj, 2007. **334**(7607): p. 1305.
17. Paterson, C.M. and N.J. Saunders, *Mode of delivery after one caesarean section: audit of current practice in a health region*. Bmj, 1991. **303**(6806): p. 818-21.
18. Paul, R.H., J.P. Phelan, and S.Y. Yeh, *Trial of labor in the patient with a prior cesarean birth*. Am J Obstet Gynecol, 1985. **151**(3): p. 297-304.
19. Peaceman, A.M., et al., *The MFMU Cesarean Registry: impact of fetal size on trial of labor success for patients with previous cesarean for dystocia*. Am J Obstet Gynecol, 2006. **195**(4): p. 1127-31.
20. Quinones, J.N., et al., *The effect of prematurity on vaginal birth after cesarean delivery: success and maternal morbidity*. Obstet Gynecol, 2005. **105**(3): p. 519-24.
21. Rudick, V., et al., *Epidural analgesia for planned vaginal delivery following previous cesarean section*. Obstet Gynecol, 1984. **64**(5): p. 621-3.
22. Shorten, A., et al., *Making choices for childbirth: a randomized controlled trial of a decision-aid for informed birth after cesarean*. Birth, 2005. **32**(4): p. 252-61.
23. Srinivas, S.K., et al., *Predicting failure of a vaginal birth attempt after cesarean delivery*. Obstet Gynecol, 2007. **109**(4): p. 800-5.
24. Stone, C., et al., *Vaginal births after Caesarean (VBAC): a population study*. Paediatr Perinat Epidemiol, 2000. **14**(4): p. 340-8.
25. van der Walt, W.A., H.S. Cronje, and R.H. Bam, *Vaginal delivery after one cesarean section*. Int J Gynaecol Obstet, 1994. **46**(3): p. 271-7.

Appendix F. Excluded Studies List, continued

Uterine rupture

Studies not using the anatomical definition, defined as: *complete uterine rupture* – separation through the entire thickness of the wall including visceral serosa (with or without extrusion of part of all of fetal-placental unit). The following studies were excluded from the risk of uterine rupture section of the report because they did not use this definition.

1. Amir, W., J. Peter, and Z. Etan, *Trial of labor without oxytocin in patients with a previous cesarean section*. Am J Perinatol, 1987. **4**(2): p. 140-3.
2. Bais, J.M., et al., *Vaginal birth after caesarean section in a population with a low overall caesarean section rate*. Eur J Obstet Gynecol Reprod Biol, 2001. **96**(2): p. 158-62.
3. Blanchette, H., et al., *Is vaginal birth after cesarean safe? Experience at a community hospital*. Am J Obstet Gynecol, 2001. **184**(7): p. 1478-84; discussion 1484-7.
4. Bujold, E., S.C. Blackwell, and R.J. Gauthier, *Cervical ripening with transcervical foley catheter and the risk of uterine rupture*. Obstet Gynecol, 2004. **103**(1): p. 18-23.
5. Bujold, E., et al., *The impact of a single-layer or double-layer closure on uterine rupture*. Am J Obstet Gynecol, 2002. **186**(6): p. 1326-30.
6. Eglinton, G.S., et al., *Outcome of a trial of labor after prior cesarean delivery*. J Reprod Med, 1984. **29**(1): p. 3-8.
7. Eriksen, N.L. and L. Buttino, Jr., *Vaginal birth after cesarean: a comparison of maternal and neonatal morbidity to elective repeat cesarean section*. Am J Perinatol, 1989. **6**(4): p. 375-9.
8. Fisler, R.E., et al., *Neonatal outcome after trial of labor compared with elective repeat cesarean section*. Birth, 2003. **30**(2): p. 83-8.
9. Flamm, B.L., et al., *Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study*. Obstet Gynecol, 1994. **83**(6): p. 927-32.
10. Granovsky-Grisaru, S., M. Shaya, and Y.Z. Diamant, *The management of labor in women with more than one uterine scar: is a repeat cesarean section really the only "safe" option?* J Perinat Med, 1994. **22**(1): p. 13-7.
11. Gregory, K.D., et al., *Vaginal birth after cesarean: clinical risk factors associated with adverse outcome*. Am J Obstet Gynecol, 2008. **198**(4): p. 452.e1-10; discussion 452.e10-2.
12. Grossetti, E., et al., *Rupture of the scarred uterus*. Acta Obstet Gynecol Scand, 2007. **86**(5): p. 572-8.
13. Grubb, D.K., S.L. Kjos, and R.H. Paul, *Latent labor with an unknown uterine scar*. Obstet Gynecol, 1996. **88**(3): p. 351-5.
14. Hammoud, A., et al., *The effect of gestational age on trial of labor after Cesarean section*. J Matern Fetal Neonatal Med, 2004. **15**(3): p. 202-6.

Appendix F. Excluded Studies List, continued

15. Hibbard, J.U., et al., *Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity.* Am J Obstet Gynecol, 2001. **184**(7): p. 1365-71; discussion 1371-3.
16. Hollard, A.L., et al., *Ethnic disparity in the success of vaginal birth after cesarean delivery.* J Matern Fetal Neonatal Med, 2006. **19**(8): p. 483-7.
17. Hook, B., et al., *Neonatal morbidity after elective repeat cesarean section and trial of labor.* Pediatrics, 1997. **100**(3 Pt 1): p. 348-53.
18. Juhasz, G., et al., *Effect of body mass index and excessive weight gain on success of vaginal birth after cesarean delivery.* Obstet Gynecol, 2005. **106**(4): p. 741-6.
19. Lieberman, E., et al., *Results of the national study of vaginal birth after cesarean in birth centers.* Obstet Gynecol, 2004. **104**(5 Pt 1): p. 933-42.
20. Lin, C. and B.D. Raynor, *Risk of uterine rupture in labor induction of patients with prior cesarean section: an inner city hospital experience.* Am J Obstet Gynecol, 2004. **190**(5): p. 1476-8.
21. Martin, J.N., Jr., et al., *Vaginal delivery following previous cesarean birth.* Am J Obstet Gynecol, 1983. **146**(3): p. 255-63.
22. Meehan, F.P. and G. Burke, *Trial of labour following prior section; a 5 year prospective study (1982-1987).* Eur J Obstet Gynecol Reprod Biol, 1989. **31**(2): p. 109-17.
23. Meier, P.R. and R.P. Porreco, *Trial of labor following cesarean section: a two-year experience.* Am J Obstet Gynecol, 1982. **144**(6): p. 671-8.
24. Menihan, C.A., *Uterine rupture in women attempting a vaginal birth following prior cesarean birth.* J Perinatol, 1998. **18**(6 Pt 1): p. 440-3.
25. Nguyen, T.V., et al., *Vaginal birth after cesarean section at the University of Texas.* J Reprod Med, 1992. **37**(10): p. 880-2.
26. Obara, H., et al., *Vaginal birth after cesarean delivery: results in 310 pregnancies.* J Obstet Gynaecol Res, 1998. **24**(2): p. 129-34.
27. Phelan, J.P., et al., *Vaginal birth after cesarean.* Am J Obstet Gynecol, 1987. **157**(6): p. 1510-5.
28. Quinones, J.N., et al., *The effect of prematurity on vaginal birth after cesarean delivery: success and maternal morbidity.* Obstet Gynecol, 2005. **105**(3): p. 519-24.
29. Sakala, E.P., et al., *Oxytocin use after previous cesarean: why a higher rate of failed labor trial?* Obstet Gynecol, 1990. **75**(3 Pt 1): p. 356-9.
30. Schneider, J., D. Gallego, and R. Benito, *Trial of labor after an earlier cesarean section. A conservative approach.* J Reprod Med, 1988. **33**(5): p. 453-6.

Appendix F. Excluded Studies List, continued

31. Socol, M.L. and A.M. Peaceman, *Vaginal birth after cesarean: an appraisal of fetal risk*. *Obstet Gynecol*, 1999. **93**(5 Pt 1): p. 674-9.
32. Stovall, T.G., et al., *Trial of labor in previous cesarean section patients, excluding classical cesarean sections*. *Obstet Gynecol*, 1987. **70**(5): p. 713-7.
33. Tahilramaney, M.P., et al., *Previous cesarean section and trial of labor. Factors related to uterine dehiscence*. *J Reprod Med*, 1984. **29**(1): p. 17-21.
34. Upadhyaya, C.D., D.M. Upadhyaya, and S.J. Carlan, *Vaginal birth after cesarean delivery in a small rural community with a solo practice*. *Am J Perinatol*, 2003. **20**(2): p. 63-7.
35. van der Walt, W.A., H.S. Cronje, and R.H. Bam, *Vaginal delivery after one cesarean section*. *Int J Gynaecol Obstet*, 1994. **46**(3): p. 271-7.
36. Wen, S.W., et al., *Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery*. *Am J Obstet Gynecol*, 2004. **191**(4): p. 1263-9.
37. Zwart, J.J., et al., *Uterine rupture in The Netherlands: a nationwide population-based cohort study*. *Bjog*, 2009. **116**(8): p. 1069-78; discussion 1078-80.

Appendix G. List of Citations From the Maternal-Fetal Medicine Units Network Cohort

Overview: This appendix contains the full-text papers used from the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (MFMU) in this report by key question.

Description of overall cohort: The MFMU cohort drew subjects from 19 academic medical centers and report on 45,988 women with singleton gestation and prior cesarean delivery. The Network, established in 1986, was designed to focus on clinical questions in maternal-fetal medicine and obstetrics, particularly with respect to the continuing problem of preterm birth.

Key Question 1

- Grobman, 2007¹
- Landon, 2004²
- Mercer, 2008³
- Peaceman, 2006⁴

Key Question 2

- Grobman, 2007⁵
- Grobman, 2008⁶
- Hibbard, 2006⁷
- Landon, 2004²
- Landon, 2006⁸
- Mercer, 2008³
- Rouse, 2006⁹
- Silver, 2006¹⁰
- Spong, 2007¹¹

Key Question 3

- Grobman, 2007⁵
- Hibbard, 2006⁷
- Landon, 2006⁸
- Spong, 2007¹¹

Appendix G. List of Citations From the Maternal-Fetal Medicine Units Network Cohort, continued

References

1. Grobman WA, Lai Y, Landon MB, et al. Development of a nomogram for prediction of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2007;109(4):806-812.
2. Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. *N Engl J Med.* 2004;351(25):2581-2589.
3. Mercer BM, Gilbert S, Landon MB, et al. Labor outcomes with increasing number of prior vaginal births after cesarean delivery. *Obstet Gynecol.* 2008;111(2 Pt 1):285-291.
4. Peaceman AM, Gersnoviez R, Landon MB, et al. The MFMU Cesarean Registry: impact of fetal size on trial of labor success for patients with previous cesarean for dystocia. *American Journal of Obstetrics & Gynecology.* 2006;195(4):1127-1131.
5. Grobman WA, Gilbert S, Landon MB, et al. Outcomes of induction of labor after one prior cesarean. *Obstet Gynecol.* 2007;109(2 Pt 1):262-269.
6. Grobman WA, Lai Y, Landon MB, et al. Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. *American Journal of Obstetrics & Gynecology.* 2008;199(1):30.e31-35.
7. Hibbard JU, Gilbert S, Landon MB, et al. Trial of labor or repeat cesarean delivery in women with morbid obesity and previous cesarean delivery. *Obstet Gynecol.* 2006;108(1):125-133.
8. Landon MB, Spong CY, Thom E, et al. Risk of uterine rupture with a trial of labor in women with multiple and single prior cesarean delivery. *Obstet Gynecol.* 2006;108(1):12-20.
9. Rouse DJ, MacPherson C, Landon M, et al. Blood transfusion and cesarean delivery.[erratum appears in *Obstet Gynecol.* 2006 Dec;108(6):1556]. *Obstet Gynecol.* 2006;108(4):891-897.
10. Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. *Obstet Gynecol.* 2006;107(6):1226-1232.
11. Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstet Gynecol.* 2007;110(4):801-807.

Appendix H. Quality Rating Criteria

Introduction

Quality assessment of individual studies is a critical and necessary step in conducting an evidence review. Quality assessment is an assessment of a study's internal validity (the study's ability to measure what it intends to measure). If a study is not conducted properly, the results that they produce are unlikely to represent the truth and thus are worthless (the old adage garbage in garbage out). If however, a study is structurally and analytically sound, then the results are valuable. A systematic review, is intended to evaluate the entire literature and distill those studies which are of the highest possible quality and therefore likely to be sound and defensible to affect practice.

Our senior advisory team reviewed the literature around quality assessment including:

We were searching for a system that was able to evaluate the entire breadth of study designs as the Obstetric literature and vaginal birth after cesarean literature spans all study types. Using one system that is able to cover all study designs, makes it easier for the reader to understand quality assessments across study designs that are included in any given topic. For example, the topic of uterine rupture will include randomized controlled trials of induction of labor or other interventions but will also necessarily include cohort, case series, and case control literature.

We concluded that the quality assessment tool that was used in the last report remained the optimal choice for this current review. We felt that this was likely to be widely applicable across clinical reviews, and as such, we have developed a user's guide to the quality assessment tool to increase reliability across staff.

Appendix H. Quality Rating Criteria, continued

Taxonomy of study designs¹

Experimental designs

A study in which the investigator has control over at least some study conditions, particularly decisions concerning the allocation of participants to different intervention groups.

Randomized controlled trial

Participants are randomly allocated to intervention or control groups and followed up over time to assess any differences in outcome rates. Randomization with allocation concealment ensures that on average known and unknown determinants of outcome are evenly distributed between groups.

Observational designs

A study in which natural variation in interventions (or exposure) among study participants is investigated to explore the effect of the interventions (or exposure) on health outcomes.

Cohort study

A follow-up study that compares outcomes between participants who have received an intervention and those who have not. Participants are studied during the same (concurrent) period either prospectively or, more commonly, retrospectively.

Case-control study

Participants with and without a given outcome are identified (cases and controls respectively) and exposure to a given intervention(s) between the two groups compared.

Cross-sectional study


Examination of the relationship between disease and other variables of interest as they exist in a defined population at one particular time point.

Case series

Description of a number of cases of an intervention and outcome (no comparison with a control group).

Appendix H. Quality Rating Criteria, continued

Hierarchy of Study Designs



Appendix H. Quality Rating Criteria, continued

Randomized Controlled Trials Table Example

Quality Criteria	Study, Year	Random assignment	Allocation concealed	Groups comparable at baseline & maintained	Eligibility criteria specified
<p>What should be in the cell</p> <p>Definitions</p>	<p><i>First author, Year of Publication</i></p>	<p><i>Y/N/Unclear</i></p> <p>Yes -computer-generated random numbers -random numbers tables</p> <p>No -use of alternation -case record numbers -birth dates -days of the week -horoscope</p> <p>Unclear reports study as randomized, but provides no details on approach or not reported</p>	<p><i>Y/N/Unclear</i></p> <p>Yes -centralized or pharmacy-controlled -serially-numbered identical containers</p> <p>-on-site computer based system with a randomization sequence that is not readable until allocation</p> <p>No -open random numbers lists -serially numbered envelopes (even sealed opaque envelopes can be subject to manipulation)</p> <p>Unclear not reported or reports study as concealed, but provides no details on approach</p>	<p><i>Y/N/Unclear</i></p> <p>Yes -comparison groups are balanced for relevant baseline characteristics, either described in the text or in a table -comparable groups were maintained throughout the study</p> <p>No (if no, state reason) -there are noted differences between the groups at baseline -authors excluded a group of people after they were randomized</p> <p>Unclear does not state that groups were different, but does not provide data to allow reader to compare groups on baseline characteristics</p>	<p><i>Y/N</i></p> <p>Yes -authors layout explicit eligibility criteria in the methods section -authors reference another article for methods and we are able to pull the information from that article</p> <p>No -authors imply eligibility criteria, but do not explicitly state it</p>

Appendix H. Quality Rating Criteria, continued

Randomized Controlled Trials Table Example, continued

Blinded: Outcome Assessors/ Care Provider/Patient	Report of attrition Differential loss to follow-up	Analysis considerations	Quality Score
<p><i>Y/N/Unclear</i></p> <p><i>Please note: answer for each person; outcome assessors, care providers and patients</i></p> <p>Yes -Blinding is used to keep the participants, investigators and outcome assessors ignorant about the interventions which participants are receiving during a study. Blinding of outcome assessment can often be done even when blinding of participants and caregivers cannot. Blinding is used to protect against performance bias and detection bias. It may also contribute to adequate allocation concealment.</p> <p>No -open label -un-blinded</p> <p>Unclear reports as 'blind' or 'double blind' but no details are provided</p>	<p><i>Attrition rate=%</i> <i>Differential loss to follow-up=%</i></p> <p><i>Report the actual attrition rate, per group</i> - $\leq 20\%$ - Good - $\leq 40\%$ - Fair</p> <p><i>Calculate the differential loss to follow-up</i></p>	<p><i>Y/N/Unclear</i></p> <p>Yes -ITT analysis is followed, not only described but actually followed in the results section -included all who were randomized in the analysis -$\leq 5\%$ missing data without including them in the analysis</p> <p>No -specifically exclude people from the analysis -conduct ONLY a per protocol analysis</p> <p>Unclear reports ITT, but provides no details of who is in analysis</p>	<p><i>Good/Fair/Poor</i></p>

Appendix H. Quality Rating Criteria, continued

Randomized Controlled Trials Descriptors

Random assignment – The process by which study participants are allocated to treatment groups in a trial. Adequate (that is, unbiased) methods of randomization include computer generated schedules and random-numbers tables.

Allocation concealed – The process by which the person determining eligibility, consent, and enrollment is unaware of which group the next patient is to be assigned.

Groups comparable at baseline & maintained - The researchers need to explicitly describe their groups at baseline and how they may or may not differ on important prognostic factors. These types of comparable groups must be maintained throughout the study as well. This becomes very important and can be tricky to assess. We know that some women who end up with a cesarean will have opted for a trial of labor and some who opted for a cesarean prior to trial of labor will go into labor. Thus issues such as inclusion from intended cohort and intention to treat analyses are important.

Eligibility criteria specified – The researchers need to be explicit in laying out the eligibility criteria. This will include what inclusion criteria needed to be met to be eligible for the study as well as the reasons why they excluded particular individuals. This information is important to determine generalizability of the study.

Blinded: Outcome Assessors/Care Provider/Patient – A way of making sure that the people involved in a research study — participants, clinicians, or researchers —do not know which participants are assigned to each study group. Blinding usually is used in research studies that compare two or more types of treatment for an illness. Blinding is used to keep the participants, investigators and outcome assessors ignorant about the interventions which participants are receiving during a study. Blinding of outcome assessment can often be done even when blinding of participants and caregivers cannot. Blinding is used to protect against performance bias and detection bias. It may also contribute to adequate allocation concealment.

Report of attrition/Differential loss to follow-up – For every study, some proportion of participants is likely to dropout or be lost to follow-up due to a number of reasons. Loss to follow-up occurs when there is a loss of contact with some participants, so that researchers cannot complete data collection as planned, and do not know why the participants discontinued. Loss to follow-up is a common cause of missing data, especially in long-term studies. An acceptable attrition rate is $\leq 20\%$ for a good quality rating and $\leq 40\%$ for a fair quality rating.

Analysis considerations – The use of data from a randomized controlled trial in which data from all randomized patients are accounted for in the final results. Trials often incorrectly report results as being based on intention to treat despite the fact that some patients are excluded from the analysis. If co-interventions occurred the researchers need to describe how these were handled in the analysis.

Appendix H. Quality Rating Criteria, continued

Cohort Studies Table Example

Quality Criteria	Study, Year/ Design	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
<p>What should be in the cell</p> <p>Definitions</p>	<p><i>First author, Year of Publication</i></p> <p><i>Study design as determined by investigator</i></p>	<p><i>Y/N/Unclear</i></p> <p>Yes -authors layout explicit eligibility criteria in the methods section -authors reference another article for methods and we are able to pull the information from that article</p> <p>No -authors imply eligibility criteria, but do not explicitly state it</p>	<p><i>Y/N/Unclear</i></p> <p><i>This is analogous to ITT.</i></p> <p>Yes -comparison groups are balanced for relevant baseline characteristics, either described in the text or in a table -relevant, important prognostic factors are similar across groups -comparable groups are maintained throughout the study</p> <p>No (if no, state reason) -there are noted differences between the groups at baseline</p> <p>Unclear does not state that groups were different, but does not provide data to allow reader to compare groups on baseline characteristics</p>	<p><i>Y/N/Unclear</i></p> <p>Yes -validated, standard measurement used</p> <p>No -study uses questions they came up with, but have not validated or standardized</p> <p>Unclear There is mention of a measure used, but it is not described</p>	<p><i>Y/N/Unclear</i></p> <p><i>Studies should attempt to decrease bias in their assessment of data and need to explicitly state it.</i></p> <p>Yes - the researcher recording outcome measure is looking only at outcome data, separated from intervention data</p>

Appendix H. Quality Rating Criteria, continued

Cohort Studies Table Example, continued

Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Clear definition of prognostic factors*	Quality Score
<p>Overall differential loss to follow-up=%</p> <p>Report the actual attrition rate, per group</p> <ul style="list-style-type: none"> - <20% - Good - <40% - Fair <p>Calculate the differential loss to follow-up</p>	<p>Y/N/Unclear</p> <p>Has enough time passed to allow measured outcomes to occur?</p>	<p>Y/N/Unclear/NA</p> <p>Consider</p> <p>Yes</p> <ul style="list-style-type: none"> -descriptions of potential confounders are noted -the authors describe confounders that they are aware of in the groups <p>No</p> <p>no mention of potential confounders</p> <p>Adjust</p> <p>Yes</p> <p>statistical analysis conducted to minimize the affect of potential confounders</p> <p>No</p> <p>no statistical analysis is mentioned</p>	<p>Y/N/Unclear</p>	<p>Good/Fair/Poor</p>

Appendix H. Quality Rating Criteria, continued

Cohort Studies Descriptors

Assembly of groups– In a cohort study, the assembly and maintenance of comparable groups is critical. Sometimes you will hear people talking about inception cohort that is the vision of a group of patients who represent the target population. In most intervention studies, you would want the intervention group to be as similar to the placebo group as possible with the only exception being the intervention. If this is sound, then whatever differences you measure between intervention and non intervention should be based upon the intervention itself. This issue can be difficult in obstetrics, particularly relating to delivery as the intervention in that, patients often self select to groups and there may be systematic reasons why people would choose different options which may also contribute to outcomes. Nonetheless, our goal in a systematic review is to ask were the groups assembled for cesarean versus trial of labor similar to each other. That is, would the group that had the cesarean have been eligible for a trial of labor in the first place? If the group who had a cesarean all had placenta previas, this population would not be eligible for a trial of labor and there are ways in which the group with placenta previa would be expected to differ in outcomes regardless of choice of intervention. The first test should be to examine the populations, look at whatever groups were systematically removed from the cohort assembled, and ensure that what remains in the TOL and Cesarean group are otherwise comparable.

Maintenance of comparable groups – This also becomes very important and can be tricky to assess. We know that some women who end up with a cesarean will have opted for a trial of labor and some who opted for a cesarean prior to trial of labor will go into labor. This topic is analogous to intention to treat analysis. The ideal cohort study would keep the patients in their original groups e.g. trial of labor versus repeat cesarean and report outcomes based upon that “inception cohort.” Doing this allows the study to report on outcomes for real experience that include adverse effects. It may be easier to understand the importance of this by looking at what happens if you don’t follow this. A VBAC study takes all women who intend trial of labor at 35 weeks and then reports on repeat cesarean without labor as the cesarean comparator and places the patients instead into the trial of labor groups reasoning that this group underwent labor. The outcome profile for the cesarean group is likely to be unrealistically positive in that labor increases the opportunity for infection, fetal intolerance of labor etc. Similarly, what a clinician can tell a patient is only what their experience would be if they chose cesarean and never went into labor rather than what the patient and clinician would like to know, what are the chance that I might go into labor anyways before my scheduled cesarean and what would be the implications for that. This maintenance must be maintained through analysis.

Outcome measures reliable and valid – Were the researchers clear and specific about the outcome measures? They should have identified the outcome they were attempting to identify, and then identify the measure(s) they were using to capture that outcome. This may for example, be ICD-9 codes in a study using a database that includes these codes. In this case, the researchers should identify how they determined the validity and reliability of these codes for the outcome measure of interest. If the outcomes were clinical measures abstracted from patient charts, the determination of an outcome should be well defined, and there should be indication that some assessment of the validity and reliability of decisions made by those making the determinations.

Appendix H. Quality Rating Criteria, continued

In the best studies, the researchers will discuss why they selected specific outcome measures, for example, why they selected the HAM-D scale rather than the MADRS scale to measure depression, what change on the scale indicated clinically meaningful improvement or response, and so on.

Outcome assessors blind to exposure status – Were the outcome assessors blinded to which group the patient belonged? Those making determinations of whether an outcome occurred or not should ideally be unaware of which group that patient was in. This can be achieved in most cases. When the outcomes are being assessed retrospectively, the researcher recording outcome measure should be looking only at outcome data, separated from intervention data. If this is truly not possible, for example, the outcome data are described in such a way that the group the patient is in is apparent, then researchers who are not aware of the study purpose at the time of abstracting the outcome measure data can be employed. Blinding of outcome measure assessment is important even when it seems like the determination of the outcome is black and white. Many outcome assessments are in fact subjective, because the data are not perfect such that judgments have to be made along the way. While identifying mortality may be quite clear in most cases, there are situations where the data may be less reliable. More difficult is identifying the cause of death, if that is an outcome measure.

Missing data – For every study, some proportion of participants is likely to dropout or be lost to follow-up due to a number of reasons. Loss to follow-up occurs when there is a loss of contact with some participants, so that researchers cannot complete data collection as planned, and do not know why the participants discontinued. Loss to follow-up is a common cause of missing data, especially in long-term studies. An acceptable attrition rate is $\leq 20\%$ for a good quality rating and $\leq 40\%$ for a fair quality rating.

Follow-up long enough for outcomes to occur – Was the follow-up period long enough? The researchers should indicate that they have thought through the disease process in detail when designing their study, such that the period of follow-up is long enough to allow the outcome to occur. If the outcome is mortality associated with hepatitis C, then a follow-up period of only several weeks is likely to be inadequate. If the researchers have not indicated reasoning for their selection of follow-up period, then you need to consider this determination.

Consider/adjust for potential important confounders – A confounder is a characteristic of study subjects that is a common cause of the exposure and the outcome. Researchers need to identify what potential confounders are possible given their study and when possible adjust for these confounders using statistical analysis.

Clear definition of prognostic factors* – In addition to these quality criteria, the evaluation of prediction modeling studies required that they provided a clear definitions of prognostic factors (1 extra criterion). The most important criteria for these studies were: comparable groups that included clear inclusion and exclusion criteria; clear definitions of the prognostic factors; adjustment (as needed, for studies without comparable groups) for confounders. To achieve a good rating, minimally, the study had to meet these three ratings. A study with comparable groups and no need for adjustment could still meet this standard. For studies that only met 2 of these 3 criteria, the highest rating they could achieve was fair.

Appendix H. Quality Rating Criteria, continued

*For prediction modeling studies only.

Appendix H. Quality Rating Criteria, continued

Case-Control Studies Table Example

Quality Criteria	Author, Year	Explicit definition of cases	Disease state of the cases similar & reliably assessed	Case ascertainment reliable, valid & applied appropriately	Non-biased selection of controls
<p>What should be in the cell</p> <p>Definitions</p>	<p><i>First author, Year of Publication</i></p>	<p><i>Y/N</i></p> <p><i>Authors must clearly state how they defined who is considered a case.</i></p>	<p><i>Y/N/Unclear</i></p> <p><i>Cases should be similar in respect to time course of disease; this may include capturing all cases along a spectrum or focus on cases at a similar point in their progression of the disease/condition.</i></p>	<p><i>Y/N/Unclear</i></p>	<p><i>Y/N/Unclear</i></p> <p>Yes <i>Controls randomly assigned</i></p>

Appendix H. Quality Rating Criteria, continued

Case-Control Studies Table Example, continued

Cases/controls: comparable confounding factors	Study procedures applied equally	Appropriate attention to confounders (consider & adjust)	Appropriate statistical analysis used (matched, unmatched, overmatching)	Quality Score
<p><i>Y/N/Unclear</i></p> <p><i>Were they matched on important factors (i.e., age, SES, # of prior C/S, etc)?</i></p>	<p><i>Y/N/Unclear</i></p> <p><i>Are the procedures & measurement of exposure accurate & applied equally?</i></p>	<p><i>Y/N/Unclear/NA</i></p> <p><i>Consider</i> Yes <i>-descriptions of potential confounders are noted</i> <i>-the authors describe confounders that they are aware of in the groups</i> No <i>no mention of potential confounders</i></p> <p><i>Adjust</i> Yes <i>statistical analysis conducted to minimize the affect of potential confounders</i> No <i>no statistical analysis is mentioned</i></p>	<p><i>Y/N/Unclear</i></p>	<p><i>Good/Fair/Poor</i></p>

Appendix H. Quality Rating Criteria, continued

Case-Control Studies Descriptors

Explicit definition of cases – It is important to ensure that the authors clearly state how they defined who would be considered a case and that these cases are determined by outcome (e.g. cancer). A case definition may not be a definitive health outcome but rather an intermediate outcome such as in the case of uterine rupture for obstetric research.

Disease state of the cases similar and reliably assessed – When there is a spectrum of disease such as in the case of cancer or neurologic injury of a fetus, considerations of whether the cases are similar to one another in relation to time course of disease is important to consider. Depending on the stated objective, you may wish to capture all cases along the spectrum or to focus such that cases are at a similar point in their progression of disease.

Case ascertainment reliable, valid and applied appropriately – How did the authors assess whether the patient was a case, how reliable is this method, and how did they ascertain cases? For example in the case of leukemia research use of ICD-9 codes, not clearly stated, histological evaluation by 2 pathologists, excluded all adopted children (this may be important if you were evaluating the effect of exposure to radiation and this was geographically represented rather than biologically inherited). In the obstetric literature, case control studies have been conducted on cases of uterine rupture. Studies have used ICD-9 codes to ascertain cases, however there are several that may apply. Some of the codes are more specific to uterine rupture while others include not only uterine rupture but also surgical extension of uterine incisions, which is not a uterine rupture. Studies that include the latter would have a consistent mechanism to apply but research has shown that the latter code is unreliable to ascertain cases. The next question once you know what method people use to identify cases is where they apply them. For example, hospitals' discharge summaries in a single institution, identification from a cancer registry, governmental databases, laboratory pathological diagnoses. Similar to the conceptual cohort idea of the cohort study this is where you are asking whether the methods are likely to capture all cases that would be of interest.

Nonbiased selection of controls – The issue of ensuring that controls are comparable to cases is critical to the quality and reliability of a case control study. Selecting a noncomparable control may skew the results and make them uninterpretable.

Cases/controls: comparable confounding factors – The cases and controls should be comparable with respect to potential confounding factors. Otherwise, the results must be interpreted with this bias in mind.

Study procedures applied equally - Are the procedures & measurement of exposure accurate & applied equally? All measurements should be applied to both cases and controls equally and accurately.

Appropriate attention to confounders (consider & adjust) - A confounder is a characteristic of study subjects that is a risk factor (determinant) for the outcome to the putative cause, or is associated (in a statistical sense) with exposure to the putative cause. Researchers need to

Appendix H. Quality Rating Criteria, continued

identify what potential confounders are possible given their study and when possible adjust for these confounders using statistical analysis.

Appropriate statistical analysis used (matched, unmatched, overmatching) – Was the method used for statistical analysis appropriate? Did the researchers match their controls and cases appropriately? Beware of overmatching by researchers as well, when they match the subjects on too many variables making the results uninterruptable as well.

Appendix H. Quality Rating Criteria, continued

Case Series Studies Table Example

Quality Criteria	Author, Year	Representative sample selected from a relevant population	Explicit definition of cases	Sufficient description of distribution of prognostic factors	Follow-up long enough for important events to occur	Outcomes assessed using objective criteria/blinding used	Quality Score
<p>What should be in the cell</p> <p>Definitions</p>	<p><i>First author, Year of Publication</i></p>	<p><i>Y/N/Unclear</i></p> <p><i>Is the population examined relevant to the disease and age group? or atypical?</i></p> <p>Yes</p> <p><i>-randomly selected from registry</i></p> <p><i>-consecutive patients</i></p> <p>No</p> <p><i>-self-selected volunteers</i></p> <p><i>-investigator selected</i></p>	<p><i>Y/N</i></p> <p>Yes</p> <p><i>-authors layout explicit definitions for their cases</i></p> <p><i>-authors reference another article for methods and we are able to pull the information from that article</i></p> <p>No</p> <p><i>-authors imply definition, but do not explicitly state it</i></p>	<p><i>Y/N/Unclear/NA</i></p>	<p><i>Y/N/Unclear</i></p> <p><i>Did the authors allow enough time for the outcomes to occur.</i></p>	<p><i>Y/N/Unclear</i></p> <p><i>Do the methods describe the measures in detail; are they reliable/valid; are references provided?</i></p>	<p><i>Good/Fair/Poor</i></p>

Appendix H. Quality Rating Criteria, continued

Case Series Studies Descriptors

Representative sample selected from a relevant population – For case series studies, the cases being selected must be representative of the overall population. This will require the judgment of experts in the particular subject matter being studied to understand if the cases represent the broader population they are being drawn from. The researchers need to describe the overall population and how their cases are a representative sample of this overall population.

Explicit definition of cases – It is important to ensure that the authors clearly state how they defined who will be considered a case and that these cases are determined by outcome (e.g. cancer). A case definition may not be a definitive health outcome but rather an intermediate outcome such as in the case of uterine rupture for obstetric research.

Sufficient description of distribution of prognostic factors – A prognostic factor is a situation or condition, or a characteristic of a patient, that can be used to estimate the chance of recovery from a disease or the chance of the disease recurring. The researchers should explicitly describe the prognostic factors that are relevant to the group(s).

Follow-up long enough for important outcomes to occur – Was the follow-up period long enough? The researchers should indicate that they have thought through the disease process in detail when designing their study, such that the period of follow-up is long enough to allow the outcome to occur. If the outcome is success of a trial of labor in a pregnant woman with a previous cesarean delivery, then a follow-up period of only several hours is adequate. However, if the outcome is neurological sequelae in the infant, then a much longer period of follow-up is necessary, possibly years are required. If the researchers have not indicated reasoning for their selection of follow-up period, then you will need to consider this determination.

Outcomes assessed using objective criteria/blinding used – Were the outcome assessors blinded to which group the patient belonged? Those making determinations of whether an outcome occurred or not should ideally be unaware of which group that patient was in. This can be achieved in most cases. When the outcomes are being assessed retrospectively, the researcher recording outcome measure should be looking only at outcome data, separated from intervention data. If this is truly not possible, for example, the outcome data are described in such a way that the group the patient is in is apparent, then researches who are not aware of the study purpose at the time of abstracting the outcome measure data can be employed. Blinding of outcome measure assessment is important even when it seems like the determination of the outcome is black and white. Many outcome assessments are in fact subjective, because the data are not perfect such that judgments have to be made along the way. While identifying mortality may be quite clear in most cases, there are situations where the data may be less reliable. More difficult is identifying the cause of death, if that is an outcome measure.

Appendix H. Quality Rating Criteria, continued

Rating Determinations²

Good (low risk of bias). These studies have the least bias and results are considered valid. A study that adheres mostly to the commonly held concepts of high quality including the following: a formal randomized controlled study; clear description of the population, setting, interventions, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytic methods and reporting; no reporting errors; low dropout rate; and clear reporting of dropouts.

Fair. These studies are susceptible to some bias, but it is not sufficient to invalidate the results. They do not meet all the criteria required for a rating of good quality because they have some deficiencies, but no flaw is likely to cause major bias. The study may be missing information, making it difficult to assess limitations and potential problems.

Poor (high risk of bias). These studies have significant flaws that imply biases of various types that may invalidate the results. They have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.

Appendix H. Quality Rating Criteria, continued

References

1. Adapted from: Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. *Health Technology Assessment*. 2003;7(27):iii-x, 1-173.
2. Agency for Healthcare Research and Quality. *Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0*. Rockville, MD 2007.

Appendix I. Quality Ratings of Randomized Controlled Trials

Study, Year	Random assignment	Allocation concealed	Groups comparable at baseline & maintained	Eligibility criteria specified	Blinded: Outcome Assessors/ Care Provider/ Patient	Report of attrition Differential loss to follow-up	Analysis considerations	Quality Score
Grubb, 1996 ¹	Yes	No	Yes	Yes	No/No/No	8/188 lost to follow-up, <20%	Yes	Fair
Peleg, 1999 ²	Yes	Yes	NR	Yes	No/No/No	Unclear	Unclear	Fair
Thubisi, 1993 ³	No. "Allocated alternately by admitting clerks"	No	Yes	Yes	No/No/No	No data given	No	Poor*
Wing, 1998 ⁴	NR	NR	NR/NR	Yes	No/No/No	No data given	No	Poor*

Appendix I. Quality Ratings of Cohort Studies

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Amir, 1987 ⁵	Yes	Yes	Unclear	Unclear
Asakura, 1995 ⁶	Unclear	Unclear	Unclear	No
Bahtiyar, 2006 ⁷	Yes	Yes	No	No
Bais, 2001 ⁸	Yes	Unclear	Yes	Yes
Bashiri, 2008 ⁹	Yes	No	Yes	Yes
Blanchette, 1999 ¹⁰	Yes	Unclear	Unclear	Not reported
Blanchette, 2001 ¹¹	Unclear	No	No	Unclear
Bujold, 2002 ¹²	Yes	No	Unclear	Unclear
Bujold, 2002 ¹³	Yes	Yes	Yes	No
Bujold, 2004 ¹⁴	Yes	Yes	Unclear	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Amir, 1987 ⁵	None	Yes	Yes/No	Fair
Asakura, 1995 ⁶	Unclear	Yes	No/No	Poor*
Bahtiyar, 2006 ⁷	Unclear	Yes	Yes/Yes	Fair
Bais, 2001 ⁸	No	Yes	Yes/No	Fair
Bashiri, 2008 ⁹	No	Yes	Yes/Yes	Good
Blanchette, 1999 ¹⁰	Not reported	Yes	No/No	Poor*
Blanchette, 2001 ¹¹	Unclear	Yes	Yes/Yes for uterine rupture, no for all others	Poor*
Bujold, 2002 ¹²	Unclear	Yes	Yes/Yes	Fair
Bujold, 2002 ¹³	No	Yes	Yes/Yes	Good
Bujold, 2004 ¹⁴	No	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Bujold, 2004 ¹⁵	Yes	Yes	Unclear	No
Bujold, 2005 ¹⁶	Yes	Yes	Yes	Not reported
Cahill, 2006 ¹⁷	Yes	No	Yes	Yes
Carroll, 2003 ¹⁸	Yes	Unclear	Unclear	Unclear
Caughey, 1999 ¹⁹	Yes	Yes	Unclear	Unclear
	Yes	Yes	Yes	No
Chang, 2008 ²⁰				
	Yes	No	Unclear	Unclear
Chapman, 1997 ²¹				
Chauhan, 2001 ²²	Yes	No	Yes	Unclear
Chauhan, 2002 ²³	Yes	Unclear	Unclear	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Bujold, 2004 ¹⁵	No	Yes	Yes/Yes	Fair
Bujold, 2005 ¹⁶	No	Yes	Yes/Yes	Good
Cahill, 2006 ¹⁷	No	Yes	Yes/Yes	Fair
Carroll, 2003 ¹⁸	Unclear	Yes	Yes/Yes	Fair
Caughey, 1999 ¹⁹	<20%	Yes	Yes/Yes	Fair
	None	Yes	Yes/Yes	Good
Chang, 2008 ²⁰	Unclear	Yes	No/No	Poor*
Chapman, 1997 ²¹				
Chauhan, 2001 ²²	No	Yes	Yes/Some	Fair
Chauhan, 2002 ²³	Low, 1/156	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Chestnut, 1985 ²⁴	Unclear	Yes	Unclear	No
Coughlan, 2002 ²⁵	Yes	No	Yes	Unclear
DeFranco, 2007 ²⁶	Yes	Yes	Yes	No
Delaney, 2003 ²⁷	Yes	Yes	Yes	Unclear
Dhall, 1987 ²⁸	Yes	Unclear	Unclear	Unclear
DiMaio, 2002 ²⁹	Yes	No	Yes	Unclear
Dinsmoor, 2004 ³⁰	Yes	No	Yes	Yes
Duff, 1988 ³¹	Yes	Unclear	Yes	Unclear
Durnwald, 2004 ³²	Unclear	Unclear	Yes	Unclear

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Chestnut, 1985 ²⁴	Maternal morbidity for post-op: 25%; Other outcomes: 0% for other outcomes	Yes	Some/No	Poor*
Coughlan, 2002 ²⁵	Unclear	Yes	No/No	Poor*
DeFranco, 2007 ²⁶	None	Yes	Yes/Yes	Good
Delaney, 2003 ²⁷	None	Yes	Yes/No	Fair
Dhall, 1987 ²⁸	Not reported	Yes	Yes/Yes	Poor*
DiMaio, 2002 ²⁹	Not applicable	Yes	No	Fair
Dinsmoor, 2004 ³⁰	Low, 12%	Yes	Yes/Yes	Fair
Duff, 1988 ³¹	Unclear	Yes	No/No	Poor*
Durnwald, 2004 ³²	Unclear	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Durnwald, 2004 ³³	Yes	Yes	No	No
Edwards, 2003 ³⁴	Yes	Unclear	No	No
Eglinton, 1984 ³⁵	Yes	Unclear	Yes	Unclear
Elkousy, 2003 ³⁶	Unclear	Unclear	No	Unclear
El-Sayed, 2007 ³⁷	Unclear	Not applicable	Unclear	No
Eriksen, 1989 ³⁸	Unclear	Yes	Unclear	Unclear
Fisler, 2003 ³⁹	Yes	Yes	Yes	No
Flamm, 1987 ⁴⁰	Yes	Not applicable	Yes	No
Flamm, 1989 ⁴¹	Yes	Unclear	Unclear	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Durnwald, 2004 ³³	No	Yes	No/No	Fair
Edwards, 2003 ³⁴	No	Yes	Yes/No	Poor*
Eglinton, 1984 ³⁵	Low, 5%	Yes	Yes/Yes	Fair
Elkousy, 2003 ³⁶	Unclear	Yes	Yes/Yes	Fair
El-Sayed, 2007 ³⁷	<20%	Yes	Yes/Yes	Fair
Eriksen, 1989 ³⁸	No	Yes	Some/No	Fair
Fisler, 2003 ³⁹	No	Yes	Yes/Yes	Fair
Flamm, 1987 ⁴⁰	Not applicable	Yes	Yes/Yes	Fair
Flamm, 1989 ⁴¹	No	Unclear	No/No	Poor*

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Flamm, 1994 ⁴²	Yes	Not applicable	Yes	No
Flamm, 1997 ⁴³	Yes	Yes	Yes	No
Gemer, 1992 ⁴⁴	Yes	Unclear	Yes	Unclear
Getahun, 2006 ⁴⁵	Unclear	Unclear	Unclear	Unclear
Gibson, 1988 ⁴⁶	Unclear	Unclear	Unclear	No
Gonen, 2006 ⁴⁷	Unclear	No	Yes	No
Gonen, 2007 ⁴⁸	Yes	No	Unclear	Unclear
Goodall, 2005 ⁴⁹	Yes	Unclear	Yes	Unclear
Granovsky-Grisaru, 1994 ⁵⁰	Yes	Unclear	Unclear	Unclear

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Flamm, 1994 ⁴²	Not applicable	Yes	Yes/Yes	Good
Flamm, 1997 ⁴³	Not applicable	Yes	Yes/Yes	Good
Gemer, 1992 ⁴⁴	No	Yes	Yes/No	Poor*
Getahun, 2006 ⁴⁵	Unclear	Yes	Yes/Yes	Poor*
Gibson, 1988 ⁴⁶	None	Yes	No/No	Fair
Gonen, 2006 ⁴⁷	Unclear	Yes	Yes/Yes	Fair
Gonen, 2007 ⁴⁸	Unclear	Yes	No/No	Poor*
Goodall, 2005 ⁴⁹	No	Yes	Yes/Yes	Fair
Granovsky-Grisaru, 1994 ⁵⁰	Not applicable	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Gregory, 1999 ⁵¹	Yes	Not applicable	Yes	Not applicable
Gregory, 2008 ⁵²	Yes	No	No	No
Grobman, 2007 ⁵³	Yes	Unclear	Yes	Yes
Grobman, 2008 ⁵⁴	Yes	Unclear	Yes	No
Grossetti, 2007 ⁵⁵	Unclear	Yes	Unclear	No
Hammoud, 2004 ⁵⁶	Yes	No	Unclear	Unclear
Hansell, 1990 ⁵⁷	Yes	Yes	Yes	Yes
Hashima, 2007 ⁵⁸	Yes	No	Yes	Yes
Hemminki, 2005 ⁵⁹	Yes	Unclear	Unclear	Unclear

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Gregory, 1999 ⁵¹	Not applicable	Not applicable	Yes/Yes	Good
Gregory, 2008 ⁵²	Unclear	Unclear	Yes/Yes	Fair
Grobman, 2007 ⁵³	No	Yes	Yes/Yes	Good
Grobman, 2008 ⁵⁴	Missing 30% of body mass indexes, and 25% of prior birth weights	Yes	Yes/Yes	Good
Grossetti, 2007 ⁵⁵	No	Yes	Unclear	Fair
Hammoud, 2004 ⁵⁶	Unclear	Yes	Yes/Yes	Fair
Hansell, 1990 ⁵⁷	No	Yes	Yes/No	Fair
Hashima, 2007 ⁵⁸	Unclear	Yes	Yes/Yes	Fair
Hemminki, 2005 ⁵⁹	1.20%	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Hershkowitz, 1995 ⁶⁰	Yes	Unclear	Unclear	Unclear
Hibbard, 2001 ⁶¹	Unclear	No	Yes	Unclear
Hibbard, 2006 ⁶²	Yes	Yes	Yes	No
Hollard, 2006 ⁶³	Yes	No	Yes	Yes
Hook, 1997 ⁶⁴	Yes	Yes	Yes	Not reported
Horenstein, 1984 ⁶⁵	Unclear	Yes	Unclear	No
Horenstein, 1985 ⁶⁶	Unclear	Yes	Unclear	No
Hoskins, 1997 ⁶⁷	Yes	Not applicable	Yes	Unclear
Johnson, 1991 ⁶⁸	Yes	Unclear	Yes	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Hershkowitz, 1995 ⁶⁰	Unclear	Yes	Yes/Yes	Fair
Hibbard, 2001 ⁶¹	ERCD: 2.4%; VBAC: 6.9%	Yes	Yes/Yes	Fair
Hibbard, 2006 ⁶²	No	Yes	Yes/Yes	Good
Hollard, 2006 ⁶³	No	Yes	Yes/Yes	Good
Hook, 1997 ⁶⁴	No	Yes	Yes/Yes	Good
Horenstein, 1984 ⁶⁵	No	Yes	Very little/No	Fair
Horenstein, 1985 ⁶⁶	No	Yes	Very little/No	Fair
Hoskins, 1997 ⁶⁷	Not applicable	Yes	No	Fair
Johnson, 1991 ⁶⁸	Unclear	Yes	No/No	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Juhasz, 2005 ⁶⁹	Yes	Unclear	Yes	Unclear
Kamath, 2009 ⁷⁰	Yes	No	Yes	No
Kayani, 2005 ⁷¹	Yes	Yes	Unclear	No
Kugler, 2008 ⁷²	Unclear	Not applicable	No	No
Kwee, 2007 ⁷³	Yes	Unclear	Yes	No
Landon, 2004 ⁷⁴	Yes	No	Yes	No
Landon, 2006 ⁷⁵	Yes	No	Yes	Unclear
Lieberman, 2004 ⁷⁶	Yes	Yes	Unclear	No
Lin, 2004 ⁷⁷	Yes	Yes	Yes	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Juhasz, 2005 ⁶⁹	No	Yes	Yes/Yes	Fair
Kamath, 2009 ⁷⁰	No	Yes	Yes/Yes	Fair
Kayani, 2005 ⁷¹	No	Yes	Very little/No	Fair
Kugler, 2008 ⁷²	No	Yes	No/No	Fair
Kwee, 2007 ⁷³	No	Yes	No/No	Fair
Landon, 2004 ⁷⁴	< 20%	Yes	Yes/Yes	Fair
Landon, 2006 ⁷⁵	<20% - 7% (unknown intent to trial of labor)	Yes	Yes/Yes	Fair
Lieberman, 2004 ⁷⁶	Unclear	Yes	Yes/No	Fair
Lin, 2004 ⁷⁷	No	Yes	Unclear	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Loebel, 2004 ⁷⁸	Unclear	Yes	Unclear	No
Lydon-Rochelle, 2001 ⁷⁹	Yes	No	Unclear	Unclear
Lyndon-Rochelle, 2001 ⁸⁰	Yes	Not applicable	No	No
Macones, 2005 ⁸¹	Yes	Not applicable	Yes	No
Martin, 1983 ⁸²	Yes	Not applicable	Yes. No for fever	No
McMahon, 1996 ⁸³	Yes	Not applicable	Yes	No
Melnikow, 2001 ⁸⁴	Yes	Unclear	Yes	Yes
Miller, 1992 ⁸⁵	Yes	Not applicable	Yes	Yes
Naef, 1995 ⁸⁶	Yes	No	Yes	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Loebel, 2004 ⁷⁸	No	Yes	No/No	Fair
Lydon-Rochelle, 2001 ⁷⁹	No data given	Yes	Yes/Yes	Fair
Lyndon-Rochelle, 2001 ⁸⁰	Not applicable	Yes	Yes/Yes	Poor*
Macones, 2005 ⁸¹	Not applicable	Yes	Yes/No	Fair
Martin, 1983 ⁸²	Not applicable	Yes	No/No	Fair
McMahon, 1996 ⁸³	Not applicable	Yes	Yes/Yes	Good
Melnikow, 2001 ⁸⁴	Low, 73/1662	Not applicable	Not reported	Fair
Miller, 1992 ⁸⁵	Not applicable	Not applicable	No/No	Poor*
Naef, 1995 ⁸⁶	Unclear	Yes	No/No	Poor*

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Nisenblat, 2006 ⁸⁷	Yes	No	Yes	No
Obara, 1998 ⁸⁸	Yes	No	Unclear	Unclear
Odibo, 2007 ⁸⁹	Yes	Unclear	unclear	Unclear
Ogunyemi, 1998 ⁹⁰	Yes	No	Unclear	Not applicable
Ouzounian, 1996 ⁹¹	Unclear	Yes	Yes	No
Paterson, 1991 ⁹²	Yes	Yes	Unclear	Unclear
Pathadey, 2005 ⁹³	Yes	Yes	Unclear	No
Paul, 1985 ⁹⁴	Yes	Not applicable	Yes	No
Peaceman, 2006 ⁹⁵	Yes	No	Yes	Unclear

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Nisenblat, 2006 ⁸⁷	Unclear	Yes	Yes/Yes	Fair
Obara, 1998 ⁸⁸	Unclear	Yes	Yes/No	Fair
Odibo, 2007 ⁸⁹	Unclear	Yes	Yes/Yes	Fair
Ogunyemi, 1998 ⁹⁰	No	Yes	No/No	Poor*
Ouzounian, 1996 ⁹¹	No	Yes	No/No	Fair
Paterson, 1991 ⁹²	Not applicable	Yes	Unclear	Fair
Pathadey, 2005 ⁹³	No	Yes	Yes/No	Fair
Paul, 1985 ⁹⁴	Not applicable	Yes	Yes/No	Fair
Peaceman, 2006 ⁹⁵	Unclear	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Phelan, 1987 ⁹⁶	Yes	Not applicable	Yes	No
Phelan, 1989 ⁹⁷	Yes	Unclear	Yes for uterine rupture. No for fever	Yes
Pruett, 1988 ⁹⁸	Yes	Unclear	Yes	No
Quinones, 2005 ⁹⁹	Unclear	Unclear	Yes	No
Rageth, 1999 ¹⁰⁰	No	Not applicable	No	No
Ravasia, 2000 ¹⁰¹	Unclear	No	No	No
Raynor, 1993 ¹⁰²	Yes	Not applicable	Yes	Unclear
Richardson, 2005 ¹⁰³	Yes	Unclear	Yes	No
Richter, 2002 ¹⁰⁴	Yes	No	Yes	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Phelan, 1987 ⁹⁶	Not applicable	Yes	Yes/No	Fair
Phelan, 1989 ⁹⁷	No	Yes	Yes/No	Poor*
Pruett, 1988 ⁹⁸	Unclear	Yes	No/No	Poor*
Quinones, 2005 ⁹⁹	low	Yes	Yes/Yes	Fair
Rageth, 1999 ¹⁰⁰	Not applicable	Yes	No/No	Poor*
Ravasia, 2000 ¹⁰¹	No	Yes	No/No	Poor*
Raynor, 1993 ¹⁰²	Not applicable	Yes	No	Fair
Richardson, 2005 ¹⁰³	No	Yes	Yes/Yes	Fair
Richter, 2002 ¹⁰⁴	No	Yes	Some/No	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Rozenberg, 1996 ¹⁰⁵	Yes	Yes	Yes	Yes
Rozenberg, 1999 ¹⁰⁶	No	Yes	Yes	No
Rudick, 1984 ¹⁰⁷	Yes	Yes	Unclear	No
Russillo, 2008 ¹⁰⁸	Yes	Unclear	Unclear	Yes
Sakala, 1990 ¹⁰⁹	Yes	Yes	Unclear	No
Sakala, 1990 ¹¹⁰	Unclear	Unclear	Unclear	No
Schneider, 1988 ¹¹¹	Inclusion criteria are described, but methods to ascertain group are not discussed. Elective repeat cesarean group includes medical and obstetric reasons as well as maternal decisions, and methods for ascertaining the reason are not described	Unclear	Unclear	Unclear
Sciscione, 2008 ¹¹²	Yes	No	Yes	Yes
Rozenberg, 1996 ¹⁰⁵	Yes	Yes	Yes	Yes

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Rozenberg, 1996 ¹⁰⁵	No	Yes	Yes/Yes	Good
Rozenberg, 1999 ¹⁰⁶	No	Yes	Yes/Unclear	Fair
Rudick, 1984 ¹⁰⁷	No	Yes	Yes/No	Fair
Russillo, 2008 ¹⁰⁸	No	Yes	Yes/No	Poor*
Sakala, 1990 ¹⁰⁹	No	Yes	Yes/No	Fair
Sakala, 1990 ¹¹⁰	No	Yes	No/No	Poor*
Schneider, 1988 ¹¹¹	No	Yes	Yes/No	Poor*
Sciscione, 2008 ¹¹²	No	Yes	Yes/Yes	Good

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Shipp, 2008 ¹¹³	Yes	No	Yes	Yes
Smith, 2002 ¹¹⁴	Yes	Yes	Yes	No
Socol, 1999 ¹¹⁵	Yes	Unclear	Yes	Unclear
Spaans, 2003 ¹¹⁶	Yes	Unclear	Unclear	Unclear
Spong, 2007 ¹¹⁷	Yes. However, the number (39,177) for term singleton gestation with prior cesarean is different from prior publication (Landon, 2006)	Yes	Yes	No
Stone, 2000 ¹¹⁸	Unclear	Not applicable	Unclear	No
Strong, 1992 ¹¹⁹	Unclear	Yes	No	No
Stovall, 1987 ¹²⁰	Yes	Not applicable	Yes/Yes	Unclear
Tahilramaney, 1984 ¹²¹	Yes	Yes	Unclear	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Shipp, 2008 ¹¹³	No	Yes	Yes/Yes	Fair
Smith, 2002 ¹¹⁴	No	Yes	Yes/Some	Good
Socol, 1999 ¹¹⁵	No	Yes	No/No	Fair
Spaans, 2003 ¹¹⁶	Unclear	Yes	No/No	Poor*
Spong, 2007 ¹¹⁷	Yes	Yes	Yes/Yes	Fair
Stone, 2000 ¹¹⁸	Not applicable	Yes	No/No	Poor*
Strong, 1992 ¹¹⁹	No	Yes	No/No	Poor*
Stovall, 1987 ¹²⁰	Not applicable	Yes	No	Fair
Tahilramaney, 1984 ¹²¹	No	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Tucker, 1993 ¹²²	Yes	Unclear	No	No
Upadhyaya, 2003 ¹²³	Unclear	Unclear	Yes	Unclear
Van der Walt, 1994 ¹²⁴	Unclear	Unclear	Yes	Unclear
Van Gelderen, 1986 ¹²⁵	Unclear	Yes	Unclear	No
Videla, 1995 ¹²⁶	Yes	Unclear	No	No
Weinstein, 1996 ¹²⁷	Yes	Yes	For some, not for others	No
Wen, 2004 ¹²⁸	Unclear	Yes	Unclear	No
Yetman, 1989 ¹²⁹	Yes	Unclear	No	Yes
Yogev, 2004 ¹³⁰	Unclear	Yes	Yes	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Tucker, 1993 ¹²²	No	Yes	No/No	Poor*
Upadhyaya, 2003 ¹²³	Not applicable	Yes	Yes/Yes	Fair
Van der Walt, 1994 ¹²⁴	Yes	Yes	Yes/Yes	Fair
Van Gelderen, 1986 ¹²⁵	No	Yes	No/No	Fair
Videla, 1995 ¹²⁶	Yes	Yes	No/No	Poor*
Weinstein, 1996 ¹²⁷	Not applicable	Yes	Yes/Yes	Fair
Wen, 2004 ¹²⁸	No	Yes	Some/Some	Fair
Yetman, 1989 ¹²⁹	Low, 5%	Yes	No/No	Fair
Yogev, 2004 ¹³⁰	No	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Assembly of Groups	Maintenance of comparable groups	Outcome measures reliable & valid	Outcome assessor blind to exposure status
Zelop, 1999 ¹³¹	Yes	Yes	Yes	No
Zelop, 2000 ¹³²	Yes	Unclear	No	No
Zelop, 2001 ¹³³	Yes	Yes	Yes	No

Appendix I. Quality Ratings of Cohort Studies, continued

Study, Year	Missing data	Follow-up long enough for outcomes to occur	Consider/adjust for potential confounders (obstetric conditions)	Quality Score
Zelop, 1999 ¹³¹	No	Yes	No/No	Fair
Zelop, 2000 ¹³²	Yes	Yes	No/No	Poor*
Zelop, 2001 ¹³³	Not applicable	Yes	Yes/Yes	Fair

Appendix I. Quality Ratings of Case-Control Studies

Study, Year	Explicit definition of cases	Disease state of the cases similar & reliably assessed	Case ascertainment reliable, valid & applied appropriately	Nonbiased selection of controls	Cases/controls: comparable confounding factors	Study procedures applied equally	Appropriate attention to confounders (consider & adjust)	Appropriate statistical analysis used (matched, unmatched, overmatching)	Quality Score
Adair, 1995 ¹³⁴	Yes	Unclear	Unclear	No	No	Unclear	Yes/No	Unmatched	Poor*
Bashiri, 2008 ⁹	Yes	Unclear	No	Yes	No	No	Unclear	Overmatched	Poor*
Bodelon, 2009 ¹³⁵	Yes	Yes	Unclear	Yes	No	Unclear	Yes/Yes	Unclear	Fair
Buhimschi, 2005 ¹³⁶	Yes	Yes	Yes	Yes	Yes	Yes	No/No	Yes	Good
Gilliam, 2002 ¹³⁷	Yes	Yes	No	Yes	No	Yes	Yes/Yes	Yes	Fair
Guihard, 2001 ¹³⁸	Yes	Yes	Yes	Unclear	Unclear	Yes	Yes/Yes	Yes	Fair
Hadley, 1986 ¹³⁹	Somewhat	Yes	Yes	Yes	No	Yes	NA	No	Poor*
Juntunen, 2004 ¹⁴⁰	Yes	Unclear	Yes	Unclear	Unclear	Yes	No/No	Unclear	Fair

Appendix I. Quality Ratings of Case-Control Studies, continued

Study, Year	Explicit definition of cases	Disease state of the cases similar & reliably assessed	Case ascertainment reliable, valid & applied appropriately	Nonbiased selection of controls	Cases/controls: comparable confounding factors	Study procedures applied equally	Appropriate attention to confounders (consider & adjust)	Appropriate statistical analysis used (matched, unmatched, overmatching)	Quality Score
Kacmar, 2003 ¹⁴¹	Yes	Yes	Unclear	Yes	No	Yes	Yes/Yes	Unclear	Fair
Laughon, 2005 ¹⁴²	Yes	Yes	Yes	Yes	No	Yes	Yes/Yes	Unclear	Fair
Leung, 1993 ¹⁴³	Yes	Yes	Unclear	Yes	Unclear	Unclear	No/No	Yes	Fair
Macones, 2001 ¹⁴⁴	Yes	Yes/No	Yes	No	Yes	Yes/No	Yes/Yes	Yes	Fair
Macones, 2005 ⁸¹	Yes	Yes	No	Unclear	Unclear	Yes	Yes/Unclear	Some. 4:1 matching	Fair
Macones, 2006 ¹⁴⁵	Yes	Yes	Yes	Yes	No	Yes	Yes/Yes	Yes. No matching	Good
McMahon, 1997 ¹⁴⁶	Yes	Unclear. Used birth certificate data for previa	Unclear	Yes	No	Unclear	No/No	Unclear	Poor*
Miles, 2000 ¹⁴⁷	Yes	Yes	Unclear	No	Unclear	Unclear	Some/No	Yes	Poor*
Pickhardt, 1992 ¹⁴⁸	Yes	Yes/No	Yes/No	No	Yes	Yes/No	Yes	Yes	Fair

Appendix I. Quality Ratings of Case-Control Studies, continued

Study, Year	Explicit definition of cases	Disease state of the cases similar & reliably assessed	Case ascertainment reliable, valid & applied appropriately	Nonbiased selection of controls	Cases/controls: comparable confounding factors	Study procedures applied equally	Appropriate attention to confounders (consider & adjust)	Appropriate statistical analysis used (matched, unmatched, overmatching)	Quality Score
Rochelson, 2005 ¹⁴⁹	Yes	Yes	Yes	Unclear	Matched on # prior cesarean otherwise non-matched	Yes	No/No	Yes	Poor*
Rouse, 2006 ¹⁵⁰	Yes	Yes	Unclear	Unclear	No	Unclear	Yes/Yes	Unclear	Fair
Seidman, 1994 ¹⁵¹	Yes	Yes	Unclear	Unclear	No	Unclear	Yes/Yes	Unclear	Poor*
Shimonovitz, 2000 ¹⁵²	No	Unclear	No	Yes	Yes	Unclear	Unclear	Unclear	Fair
Shipp, 2003 ¹⁵³	Yes	Yes	Yes	Yes	Yes	Yes	Yes/Yes	Yes	Good
Tikkanen, 2006 ¹⁵⁴	Yes	Unclear	No	No	No	Unclear	Yes/Yes	Unclear	Poor*
Uygur, 2005 ¹⁵⁵	Yes	Yes	Yes	No	No	Yes	No/No	Unclear	Poor*
Uygur, 2005 ¹⁵⁶	Yes	Unclear		No	No	Yes	No/No	Unclear	Poor*
Wu, 2005 ¹⁵⁷	Yes	Yes	No	Yes	No	Unclear	Yes/Yes	Unclear	Fair

Appendix I. Quality Ratings of Case Series Studies

Study, Year	Representative sample selected from a relevant population	Explicit definition of cases	Sufficient description of distribution of prognostic factors	Follow-up long enough for important events to occur	Outcomes assessed using objective criteria/ blinding used	Quality Score
Armstrong, 2004 ¹⁵⁸	Yes	Yes	Yes	Yes	Unclear	Fair
Asakura, 2000 ¹⁵⁹	Unclear	Yes	Yes	Yes	Some/ No	Fair
Blanco, 1992 ¹⁶⁰	Yes	Yes	No	Yes	No	Fair
Bujold, 2002 ¹⁶¹	Yes	Yes	Yes	Yes	No	Fair
Chilaka, 2004 ¹⁶²	Yes	Yes	Unclear	Yes	No	Fair
Gotoh, 2000 ¹⁶³	No	No	Yes	Yes	Yes	Fair
Grobman, 2007 ¹⁶⁴	Yes	Yes	Yes	Yes	Unclear	Good
Kieser, 2002 ¹⁶⁵	Yes	Yes	Yes	Yes	Yes/No	Good
Landon, 2005 ¹⁶⁶	Yes	Yes	Yes	Yes	Unclear	Good

Appendix I. Quality Ratings of Case Series Studies, continued

Study, Year	Representative sample selected from a relevant population	Explicit definition of cases	Sufficient description of distribution of prognostic factors	Follow-up long enough for important events to occur	Outcomes assessed using objective criteria/ blinding used	Quality Score
Leung, 1993 ¹⁶⁷	Yes	Yes	Yes	Yes	Unclear	Fair
Lynch, 2002 ¹⁶⁸	Yes	Yes	Yes	Yes	Unclear	Good
Meehan, 1989 ¹⁶⁹	NR	NR	Somewhat	Yes	No	Fair
Mercer, 2008 ¹⁷⁰	Yes	Yes	Yes	Yes	Unclear	Good
Raynor, 1993 ¹⁰²	Yes	Yes	NA	NA	Yes	Fair
Scott, 2001 ¹⁷¹	Yes	Yes	Yes	Yes	Unclear	Poor*
Sheiner, 2004 ¹⁷²	Yes	Yes	Unclear	Yes	Unclear	Poor*
Shellhaas, 2009	Yes	Yes	Yes	Yes	Unclear	Good
Shipp, 2002 ¹⁷³	Yes	Yes	Somewhat	Yes	Unclear	Fair

Appendix I. Quality Ratings of Case Series Studies, continued

Study, Year	Representative sample selected from a relevant population	Explicit definition of cases	Sufficient description of distribution of prognostic factors	Follow-up long enough for important events to occur	Outcomes assessed using objective criteria/ blinding used	Quality Score
Silver, 2006 ¹⁷⁴	Yes	Yes	Yes	Yes	Unclear	Good
Stovall, 1987 ¹²⁰	Yes	Yes	No	Yes	Unclear	Poor*
Yucel, 2006 ^{175]}	Yes	Yes	No	Yes	Unclear	Poor*
Zelop, 1993 ¹⁷⁶	Yes	Yes	Yes	Yes	Unclear	Fair

Appendix I. Quality Ratings of Cohort Prediction Studies

Study, Year	Comparable Groups Clear inclusion and exclusion criteria for VBAC	Maintenance of comparable groups	Clear definition of prognostic factors	Measures reliable, valid	Unbiased assessment of data and analysis of results	Loss/Drop-out rate	Follow-up long enough for outcomes to occur	Adjust for potential confounders (obstetric conditions)	Quality Score
Bujold, 2001 ¹⁷⁷	No	NA	Yes	Yes/Yes	Unclear	NA	Yes	No	Fair
Bujold, 2004 ¹⁴	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
Cameron, 2004 ¹⁷⁸	Yes	NA	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Chang, 2008 ²⁰	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
Costantine, 2009 ¹⁷⁹	Yes. Unclear for twins	NA	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Dinsmoor, 2004 ³⁰	Yes	NA	Yes	Yes/Yes	Unclear	NA	Yes	No	Fair
Flamm, 1997 ⁴³	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
Gonen, 2004 ¹⁸⁰	Yes	NA	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Good

Appendix I. Quality Ratings of Cohort Prediction Studies, continued

Study, Year	Comparable Groups Clear inclusion and exclusion criteria for VBAC	Maintenance of comparable groups	Clear definition of prognostic factors	Measures reliable, valid	Unbiased assessment of data and analysis of results	Loss/Drop-out rate	Follow-up long enough for outcomes to occur	Adjust for potential confounders (obstetric conditions)	Quality Score
Grobman, 2007 ¹⁶⁴	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
Gyamfi, 2004 ¹⁸¹	Yes	Yes	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Good
Harper, 2009 ¹⁸² (Macones 2005 ⁸¹)	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
Hashima, 2007 ⁵⁸	No. Exclusion not defined	NA	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Fair
Hendler, 2004 ¹⁸³	No. Exclusion not defined	Yes	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Good
Huang, 2002 ¹⁸⁴	No. Exclusion not defined	NA	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Fair
Hueston, 1994 ¹⁸⁵	No. Exclusion not defined. Unclear for twins	NA	No	Yes/Yes	Unclear	NA	Yes	Yes	Fair
Grobman, 2007 ¹⁶⁴	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good

Appendix I. Quality Ratings of Cohort Prediction Studies, continued

Study, Year	Comparable Groups Clear inclusion and exclusion criteria for VBAC	Maintenance of comparable groups	Clear definition of prognostic factors	Measures reliable, valid	Unbiased assessment of data and analysis of results	Loss/Drop-out rate	Follow-up long enough for outcomes to occur	Adjust for potential confounders (obstetric conditions)	Quality Score
Jakobi, 1993 ¹⁸⁶	Yes	Yes	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Kabir, 2005 ¹⁸⁷	Yes	NA	Yes	Yes/Yes	NA	NA	Yes	Yes	Good
King, 1994 ¹⁸⁸	Yes	NA	Yes	Yes/Yes	Unclear	NA	NA	Yes	Good
Landon, 2005 ¹⁶⁶	Yes	NA	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Learman, 1996 ¹⁸⁹	Yes	NA	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Macones, 2001 ¹⁴⁴	Unclear how controls were selected.	NA	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Fair
Macones, 2005 ⁸¹	Yes	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
McMahon, 1996 ⁸³	Yes	Yes	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good

Appendix I. Quality Ratings of Cohort Prediction Studies, continued

Study, Year	Comparable Groups Clear inclusion and exclusion criteria for VBAC	Maintenance of comparable groups	Clear definition of prognostic factors	Measures reliable, valid	Unbiased assessment of data and analysis of results	Loss/Drop-out rate	Follow-up long enough for outcomes to occur	Adjust for potential confounders (obstetric conditions)	Quality Score
Mercer, 2008 ¹⁷⁰	Yes	NA	Yes	Yes/Yes	NA	NA	Yes	No	Fair
Pang, 2009 ¹⁹⁰	Yes	Yes	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Good
Pickhardt, 1992 ¹⁴⁸	No. Exclusion not defined	NA	No	Yes/Yes	Unclear	NA	Yes	Yes	Fair
Quinones, 2005 ⁹⁹	Yes	NA	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Selo-Ojeme, 2008 ¹⁹¹	No. Exclusion not defined	NA	Yes	Yes/Yes	No	NA	Yes	Yes	Fair
Shipp, 2000 ¹⁹²	Unclear comparison between repeat CD and primary CD	NA	Yes	Yes/Yes	Yes	NA	Yes	Yes	Fair
Smith, 2005 ¹⁹³	Yes	Yes	Yes	Yes/Yes	No	NA	Yes	Yes	Good
Spaans, 2002 ¹⁹⁴	Yes	NA	Yes	Yes/Yes	No	NA	Yes	No	Fair

Appendix I. Quality Ratings of Cohort Prediction Studies, continued

Study, Year	Comparable Groups Clear inclusion and exclusion criteria for VBAC	Maintenance of comparable groups	Clear definition of prognostic factors	Measures reliable, valid	Unbiased assessment of data and analysis of results	Loss/Drop-out rate	Follow-up long enough for outcomes to occur	Adjust for potential confounders (obstetric conditions)	Quality Score
Srinivas, 2007 ¹⁹⁵	Yes	Yes	Yes	Yes/Yes	Yes	NA	Yes	Yes	Good
Strong, 1996 ¹⁹⁶	No. Exclusion not defined	Yes	Yes	Yes/Yes	No	NA	Yes	Yes	Fair
Troyer, 1992 ¹⁹⁷	Yes	NA	Yes	Yes/No	Unclear	NA	Yes	No	Fair
Vinueza, 2000 ¹⁹⁸	Yes	NA	Yes	Yes/No	No	NA	Yes	Unclear for prediction	Fair
Weinstein, 1996 ¹²⁷	Yes	NA	Yes	Yes/Yes	Unclear	NA	Yes	Yes	Good

*Poor quality studies are not included in the narrative or synthesis of the final report, unless no studies of better quality were available for a given topic and/or key question.

Abbreviations: CD=cesarean delivery; ERCD=elective repeat cesarean delivery; VBAC=vaginal birth after cesarean

References

1. Grubb DK, Kjos SL, Paul RH. Latent labor with an unknown uterine scar. *Obstet Gynecol.* 1996;88(3):351-355.
2. Peleg D, Hannah ME, Hodnett ED, Foster GA, Willan AR, Farine D. Predictors of cesarean delivery after prelabor rupture of membranes at term. *Obstet Gynecol.* 1999;93(6):1031-1035.
3. Thubisi M, Ebrahim A, Moodley J, Shweni PM. Vaginal delivery after previous cesarean section: is X-ray pelvimetry necessary? *Br J Obstet Gynaecol.* 1993;100(5):421-424.
4. Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. *Obstet Gynecol.* 1998;91(5 Pt 2):828-830.
5. Amir W, Peter J, Etan Z. Trial of labor without oxytocin in patients with a previous cesarean section. *Am J Perinatol.* 1987;4(2):140-143.
6. Asakura H, Myers SA. More than one previous cesarean delivery: a 5-year experience with 435 patients. *Obstet Gynecol.* 1995;85(6):924-929.
7. Bahtiyar MO, Julien S, Robinson JN, et al. Prior cesarean delivery is not associated with an increased risk of stillbirth in a subsequent pregnancy: analysis of U.S. perinatal mortality data, 1995-1997. *Am J Obstet Gynecol.* 2006;195(5):1373-1378.
8. Bais JM, van der Borden DM, Pel M, et al. Vaginal birth after caesarean section in a population with a low overall caesarean section rate. *Eur J Obstet Gynecol Reprod Biol.* 2001;96(2):158-162.
9. Bashiri A, Burstein E, Rosen S, Smolin A, Sheiner E, Mazor M. Clinical significance of uterine scar dehiscence in women with previous cesarean delivery: prevalence and independent risk factors. *J Reprod Med.* 2008;53(1):8-14.
10. Blanchette HA, Nayak S, Erasmus S. Comparison of the safety and efficacy of intravaginal misoprostol (prostaglandin E1) with those of dinoprostone (prostaglandin E2) for cervical ripening and induction of labor in a community hospital. *Am J Obstet Gynecol.* 1999;180(6 Pt 1):1551-1559.
11. Blanchette H, Blanchette M, McCabe J, Vincent S. Is vaginal birth after cesarean safe? Experience at a community hospital. *Am J Obstet Gynecol.* 2001;184(7):1478-1484; discussion 1484-1477.
12. Bujold E, Mehta SH, Bujold C, Gauthier RJ. Interdelivery interval and uterine rupture. *Am J*

- Obstet Gynecol.* 2002;187(5):1199-1202.
13. Bujold E, Bujold C, Hamilton EF, Harel F, Gauthier RJ. The impact of a single-layer or double-layer closure on uterine rupture. *Am J Obstet Gynecol.* 2002;186(6):1326-1330.
 14. Bujold E, Blackwell SC, Hendler I, Berman S, Sorokin Y, Gauthier RJ. Modified Bishop's score and induction of labor in patients with a previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(5):1644-1648.
 15. Bujold E, Hammoud AO, Hendler I, et al. Trial of labor in patients with a previous cesarean section: does maternal age influence the outcome? *Am J Obstet Gynecol.* 2004;190(4):1113-1118.
 16. Bujold E, Hammoud A, Schild C, Krapp M, Baumann P. The role of maternal body mass index in outcomes of vaginal births after cesarean. *Am J Obstet Gynecol.* 2005;193(4):1517-1521.
 17. Cahill AG, Stamilio DM, Odibo AO, et al. Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery? *Am J Obstet Gynecol.* 2006;195(4):1143-1147.
 18. Carroll CS, Sr., Magann EF, Chauhan SP, Klausner CK, Morrison JC. Vaginal birth after cesarean section versus elective repeat cesarean delivery: Weight-based outcomes. *Am J Obstet Gynecol.* 2003;188(6):1516-1520; discussion 1520-1512.
 19. Caughey AB, Shipp TD, Repke JT, Zelop CM, Cohen A, Lieberman E. Rate of uterine rupture during a trial of labor in women with one or two prior cesarean deliveries. *Am J Obstet Gynecol.* 1999;181(4):872-876.
 20. Chang JJ, Stamilio DM, Macones GA. Effect of hospital volume on maternal outcomes in women with prior cesarean delivery undergoing trial of labor. *Am J Epidemiol.* 2008;167(6):711-718.
 21. Chapman SJ, Owen J, Hauth JC. One- versus two-layer closure of a low transverse cesarean: the next pregnancy. *Obstet Gynecol.* 1997;89(1):16-18.
 22. Chauhan SP, Magann EF, Carroll CS, Barrilleaux PS, Scardo JA, Martin JN, Jr. Mode of delivery for the morbidly obese with prior cesarean delivery: vaginal versus repeat cesarean section. *Am J Obstet Gynecol.* 2001;185(2):349-354.
 23. Chauhan SP, Magann EF, Wiggs CD, Barrilleaux PS, Martin JN, Jr. Pregnancy after classic cesarean delivery. *Obstet Gynecol.* 2002;100(5 Pt 1):946-950.
 24. Chestnut DH. Effect of anesthesia for repeat cesarean section on postoperative infectious morbidity. *Obstet Gynecol.* 1985;66(2):199-202.

25. Coughlan C, Kearney R, Turner MJ. What are the implications for the next delivery in primigravidae who have an elective caesarean section for breech presentation? *BJOG: An International Journal of Obstetrics & Gynaecology*. 2002;109(6):624-626.
26. DeFranco EA, Rampersad R, Atkins KL, et al. Do vaginal birth after cesarean outcomes differ based on hospital setting? *Am J Obstet Gynecol*. 2007;197(4):400.e401-406.
27. Delaney T, Young DC. Spontaneous versus induced labor after a previous cesarean delivery. *Obstet Gynecol*. 2003;102(1):39-44.
28. Dhall K, Mittal SC, Grover V, Dhall GI. Childbirth following primary cesarean section--evaluation of a scoring system. *Int J Gynaecol Obstet*. 1987;25(3):199-205.
29. DiMaio H, Edwards RK, Euliano TY, Treloar RW, Cruz AC. Vaginal birth after cesarean delivery: an historic cohort cost analysis. *Am J Obstet Gynecol*. 2002;186(5):890-892.
30. Dinsmoor MJ, Brock EL. Predicting failed trial of labor after primary cesarean delivery. *Obstet Gynecol*. 2004;103(2):282-286.
31. Duff P, Southmayd K, Read JA. Outcome of trial of labor in patients with a single previous low transverse cesarean section for dystocia. *Obstet Gynecol*. 1988;71(3 Pt 1):380-384.
32. Durnwald CP, Ehrenberg HM, Mercer BM. The impact of maternal obesity and weight gain on vaginal birth after cesarean section success. *Am J Obstet Gynecol*. 2004;191(3):954-957.
33. Durnwald C, Mercer B. Vaginal birth after Cesarean delivery: predicting success, risks of failure. *J Matern Fetal Neonatal Med*. 2004;15(6):388-393.
34. Edwards RK, Harnsberger DS, Johnson IM, Treloar RW, Cruz AC. Deciding on route of delivery for obese women with a prior cesarean delivery. *Am J Obstet Gynecol*. 2003;189(2):385-389; discussion 389-390.
35. Eglinton GS, Phelan JP, Yeh S, Diaz FP, Wallace TM, Paul RH. Outcome of a trial of labor after prior cesarean delivery. *J Reprod Med*. 1984;29(1):3-8.
36. Elkousy MA, Sammel M, Stevens E, Peipert JF, Macones G. The effect of birth weight on vaginal birth after cesarean delivery success rates. *Am J Obstet Gynecol*. 2003;188(3):824-830.
37. El-Sayed YY, Watkins MM, Fix M, Druzin ML, Pullen KM, Caughey AB. Perinatal outcomes after successful and failed trials of labor after cesarean delivery.

- Am J Obstet Gynecol.* 2007;196(6):583.e581-585; discussion 583.e585.
38. Eriksen NL, Buttino L, Jr. Vaginal birth after cesarean: a comparison of maternal and neonatal morbidity to elective repeat cesarean section. *Am J Perinatol.* 1989;6(4):375-379.
39. Fisler RE, Cohen A, Ringer SA, Lieberman E. Neonatal outcome after trial of labor compared with elective repeat cesarean section. *Birth.* 2003;30(2):83-88.
40. Flamm BL, Goings JR, Fuelberth NJ, Fischermann E, Jones C, Hersh E. Oxytocin during labor after previous cesarean section: results of a multicenter study. *Obstet Gynecol.* 1987;70(5):709-712.
41. Flamm BL, Goings JR. Vaginal birth after cesarean section: is suspected fetal macrosomia a contraindication? *Obstet Gynecol.* 1989;74(5):694-697.
42. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol.* 1994;83(6):927-932.
43. Flamm BL, Geiger AM. Vaginal birth after cesarean delivery: an admission scoring system. *Obstet Gynecol.* 1997;90(6):907-910.
44. Gemer O, Segal S, Sassoon E. Detection of scar dehiscence at delivery in women with prior cesarean section. *Acta Obstet Gynecol Scand.* 1992;71(7):540-542.
45. Getahun D, Oyelese Y, Salihu HM, Ananth CV. Previous cesarean delivery and risks of placenta previa and placental abruption. *Obstet Gynecol.* 2006;107(4):771-778.
46. Gibson DH. Vaginal delivery after caesarean section in primigravidae. *Ir J Med Sci.* 1988;157(9):290-292.
47. Gonen R, Nisenblat V, Barak S, Tamir A, Ohel G. Results of a well-defined protocol for a trial of labor after prior cesarean delivery. *Obstet Gynecol.* 2006;107(2 Pt 1):240-245.
48. Gonen R, Barak S, Nissenblat V, Ohel G. The outcome and cumulative morbidity associated with the second and third postcesarean delivery. *Am J Perinatol.* 2007;24(8):483-486.
49. Goodall PT, Ahn JT, Chapa JB, Hibbard JU. Obesity as a risk factor for failed trial of labor in patients with previous cesarean delivery. *Am J Obstet Gynecol.* 2005;192(5):1423-1426.
50. Granovsky-Grisaru S, Shaya M, Diamant YZ. The management of labor in women with more than one uterine scar: is a repeat cesarean section really the only "safe" option? *J Perinat Med.* 1994;22(1):13-17.

51. Gregory KD, Korst LM, Cane P, Platt LD, Kahn K. Vaginal birth after cesarean and uterine rupture rates in California. *Obstet Gynecol.* 1999;94(6):985-989.
52. Gregory KD, Korst LM, Fridman M, et al. Vaginal birth after cesarean: clinical risk factors associated with adverse outcome. *Am J Obstet Gynecol.* 2008;198(4):452.e451-410; discussion 452.e410-452.
53. Grobman WA, Gilbert S, Landon MB, et al. Outcomes of induction of labor after one prior cesarean. *Obstet Gynecol.* 2007;109(2 Pt 1):262-269.
54. Grobman WA, Lai Y, Landon MB, et al. Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. *Am J Obstet Gynecol.* 2008;199(1):30.e31-35.
55. Grossetti E, Vardon D, Creveuil C, Herlicoviez M, Dreyfus M. Rupture of the scarred uterus. *Acta Obstet Gynecol Scand.* 2007;86(5):572-578.
56. Hammoud A, Hendler I, Gauthier RJ, Berman S, Sansregret A, Bujold E. The effect of gestational age on trial of labor after Cesarean section. *J Matern Fetal Neonatal Med.* 2004;15(3):202-206.
57. Hansell RS, McMurray KB, Huey GR. Vaginal birth after two or more cesarean sections: a five-year experience. *Birth.* 1990;17(3):146-150; discussion 150-141.
58. Hashima JN, Guise J-M. Vaginal birth after cesarean: a prenatal scoring tool. *Am J Obstet Gynecol.* 2007;196(5):e22-23.
59. Hemminki E, Shelley J, Gissler M. Mode of delivery and problems in subsequent births: a register-based study from Finland. *Am J Obstet Gynecol.* 2005;193(1):169-177.
60. Hershkowitz R, Fraser D, Mazor M, Leiberman JR. One or multiple previous cesarean sections are associated with similar increased frequency of placenta previa. *Eur J Obstet Gynecol Reprod Biol.* 1995;62(2):185-188.
61. Hibbard JU, Ismail MA, Wang Y, Te C, Karrison T. Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. *Am J Obstet Gynecol.* 2001;184(7):1365-1371; discussion 1371-1363.
62. Hibbard JU, Gilbert S, Landon MB, et al. Trial of labor or repeat cesarean delivery in women with morbid obesity and previous cesarean delivery. *Obstet Gynecol.* 2006;108(1):125-133.
63. Hollard AL, Wing DA, Chung JH, et al. Ethnic disparity in the success of vaginal birth after cesarean delivery. *J Matern Fetal Neonatal Med.* 2006;19(8):483-487.

64. Hook B, Kiwi R, Amini SB, Fanaroff A, Hack M. Neonatal morbidity after elective repeat cesarean section and trial of labor. *Pediatrics*. 1997;100(3 Pt 1):348-353.
65. Horenstein JM, Eglinton GS, Tahilramaney MP, Boucher M, Phelan JP. Oxytocin use during a trial of labor in patients with previous cesarean section. *J Reprod Med*. 1984;29(1):26-30.
66. Horenstein JM, Phelan JP. Previous cesarean section: the risks and benefits of oxytocin usage in a trial of labor. *Am J Obstet Gynecol*. 1985;151(5):564-569.
67. Hoskins IA, Gomez JL. Correlation between maximum cervical dilatation at cesarean delivery and subsequent vaginal birth after cesarean delivery. *Obstet Gynecol*. 1997;89(4):591-593.
68. Johnson C, Oriol N, Flood K. Trial of labor: a study of 110 patients. *J Clin Anesth*. 1991;3(3):216-218; discussion 214-215.
69. Juhasz G, Gyamfi C, Gyamfi P, Tocce K, Stone JL. Effect of body mass index and excessive weight gain on success of vaginal birth after cesarean delivery. *Obstet Gynecol*. 2005;106(4):741-746.
70. Kamath BD, Todd JK, Glazner JE, Lezotte D, Lynch AM. Neonatal outcomes after elective cesarean delivery. *Obstet Gynecol*. 2009;113(6):1231-1238.
71. Kayani SI, Alfirevic Z. Uterine rupture after induction of labour in women with previous caesarean section. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2005;112(4):451-455.
72. Kugler E, Shoham-Vardi I, Burstien E, Mazor M, Hershkovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. *Arch Gynecol Obstet*. 2008;277(4):339-344.
73. Kwee A, Bots ML, Visser GHA, Bruinse HW. Obstetric management and outcome of pregnancy in women with a history of caesarean section in the Netherlands. *Eur J Obstet Gynecol Reprod Biol*. 2007;132(2):171-176.
74. Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. *N Engl J Med*. 2004;351(25):2581-2589.
75. Landon MB, Spong CY, Thom E, et al. Risk of uterine rupture with a trial of labor in women with multiple and single prior cesarean delivery. *Obstet Gynecol*. 2006;108(1):12-20.
76. Lieberman E, Ernst EK, Rooks JP, Stapleton S, Flamm B. Results of the national study of

- vaginal birth after cesarean in birth centers. *Obstet Gynecol.* 2004;104(5 Pt 1):933-942.
77. Lin C, Raynor BD. Risk of uterine rupture in labor induction of patients with prior cesarean section: an inner city hospital experience. *Am J Obstet Gynecol.* 2004;190(5):1476-1478.
78. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
79. Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. First-birth cesarean and placental abruption or previa at second birth(1). *Obstet Gynecol.* 2001;97(5 Pt 1):765-769.
80. Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. *N Engl J Med.* 2001;345(1):3-8.
81. Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. *Am J Obstet Gynecol.* 2005;193(5):1656-1662.
82. Martin JN, Jr., Harris BA, Jr., Huddlestone JF, et al. Vaginal delivery following previous cesarean birth. *Am J Obstet Gynecol.* 1983;146(3):255-263.
83. McMahon MJ, Luther ER, Bowes WA, Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section. *N Engl J Med.* 1996;335(10):689-695.
84. Melnikow J, Romano P, Gilbert WM, Schembri M, Keyzer J, Kravitz RL. Vaginal birth after cesarean in California. *Obstet Gynecol.* 2001;98(3):421-426.
85. Miller M, Leader LR. Vaginal delivery after caesarean section. *Aust N Z J Obstet Gynaecol.* 1992;32(3):213-216.
86. Naef RW, 3rd, Ray MA, Chauhan SP, Roach H, Blake PG, Martin JN, Jr. Trial of labor after cesarean delivery with a lower-segment, vertical uterine incision: is it safe? *Am J Obstet Gynecol.* 1995;172(6):1666-1673; discussion 1673-1664.
87. Nisenblat V, Barak S, Grinss OB, Degani S, Ohel G, Gonen R. Maternal complications associated with multiple cesarean deliveries. *Obstet Gynecol.* 2006;108(1):21-26.
88. Obara H, Minakami H, Koike T, Takamizawa S, Matsubara S, Sato I. Vaginal birth after cesarean delivery: results in 310 pregnancies. *J Obstet Gynaecol Res.* 1998;24(2):129-134.
89. Odibo AO, Cahill AG, Stamilio DM, Stevens EJ, Peipert JF,

- Macones GA. Predicting placental abruption and previa in women with a previous cesarean delivery. *Am J Perinatol.* 2007;24(5):299-305.
90. Ogunyemi D, Hullett S, Leeper J, Risk A. Prepregnancy body mass index, weight gain during pregnancy, and perinatal outcome in a rural black population. *J Matern Fetal Med.* 1998;7(4):190-193.
91. Ouzounian JG, Miller DA, Paul RH. Amnioinfusion in women with previous cesarean births: a preliminary report. *Am J Obstet Gynecol.* 1996;174(2):783-786.
92. Paterson CM, Saunders NJ. Mode of delivery after one caesarean section: audit of current practice in a health region. *BMJ.* 1991;303(6806):818-821.
93. Pathadey SD, Van Woerden HC, Jenkinson SD. Induction of labour after a previous caesarean section: a retrospective study in a district general hospital. *J Obstet Gynaecol.* 2005;25(7):662-665.
94. Paul RH, Phelan JP, Yeh SY. Trial of labor in the patient with a prior cesarean birth. *Am J Obstet Gynecol.* 1985;151(3):297-304.
95. Peaceman AM, Gersnoviez R, Landon MB, et al. The MFMU Cesarean Registry: impact of fetal size on trial of labor success for patients with previous cesarean for dystocia. *Am J Obstet Gynecol.* 2006;195(4):1127-1131.
96. Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after cesarean. *Am J Obstet Gynecol.* 1987;157(6):1510-1515.
97. Phelan JP, Ahn MO, Diaz F, Brar HS, Rodriguez MH. Twice a cesarean, always a cesarean? *Obstet Gynecol.* 1989;73(2):161-165.
98. Pruett KM, Kirshon B, Cotton DB, Poindexter AN, 3rd. Is vaginal birth after two or more cesarean sections safe? *Obstet Gynecol.* 1988;72(2):163-165.
99. Quinones JN, Stamilio DM, Pare E, Peipert JF, Stevens E, Macones GA. The effect of prematurity on vaginal birth after cesarean delivery: success and maternal morbidity. *Obstet Gynecol.* 2005;105(3):519-524.
100. Rageth JC, Juzi C, Grossenbacher H. Delivery after previous cesarean: a risk evaluation. Swiss Working Group of Obstetric and Gynecologic Institutions. *Obstet Gynecol.* 1999;93(3):332-337.
101. Ravasia DJ, Wood SL, Pollard JK. Uterine rupture during induced trial of labor among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2000;183(5):1176-1179.
102. Raynor BD. The experience with vaginal birth after cesarean delivery in a small rural

- community practice. *Am J Obstet Gynecol.* 1993;168(1 Pt 1):60-62.
103. Richardson BS, Czikk MJ, daSilva O, Natale R. The impact of labor at term on measures of neonatal outcome. *Am J Obstet Gynecol.* 2005;192(1):219-226.
 104. Richter HE, Brumfield CG, Cliver SP, Burgio KL, Neely CL, Varner RE. Risk factors associated with anal sphincter tear: a comparison of primiparous patients, vaginal births after cesarean deliveries, and patients with previous vaginal delivery. *Am J Obstet Gynecol.* 2002;187(5):1194-1198.
 105. Rozenberg P, Goffinet F, Phillippe HJ, Nisand I. Ultrasonographic measurement of lower uterine segment to assess risk of defects of scarred uterus. *Lancet.* 1996;347(8997):281-284.
 106. Rozenberg P, Goffinet F, Philippe HJ, Nisand I. Thickness of the lower uterine segment: its influence in the management of patients with previous cesarean sections. *Eur J Obstet Gynecol Reprod Biol.* 1999;87(1):39-45.
 107. Rudick V, Niv D, Hetman-Peri M, Geller E, Avni A, Golan A. Epidural analgesia for planned vaginal delivery following previous cesarean section. *Obstet Gynecol.* 1984;64(5):621-623.
 108. Russillo B, Sewitch MJ, Cardinal L, Brassard N. Comparing rates of trial of labour attempts, VBAC success, and fetal and maternal complications among family physicians and obstetricians. *J Obstet Gynaecol Can.* 2008;30(2):123-128.
 109. Sakala EP, Kaye S, Murray RD, Munson LJ. Oxytocin use after previous cesarean: why a higher rate of failed labor trial? *Obstet Gynecol.* 1990;75(3 Pt 1):356-359.
 110. Sakala EP, Kaye S, Murray RD, Munson LJ. Epidural analgesia. Effect on the likelihood of a successful trial of labor after cesarean section. *J Reprod Med.* 1990;35(9):886-890.
 111. Schneider J, Gallego D, Benito R. Trial of labor after an earlier cesarean section. A conservative approach. *J Reprod Med.* 1988;33(5):453-456.
 112. Sciscione AC, Landon MB, Leveno KJ, et al. Previous preterm cesarean delivery and risk of subsequent uterine rupture. *Obstet Gynecol.* 2008;111(3):648-653.
 113. Shipp TD, Zelop C, Lieberman E. Assessment of the rate of uterine rupture at the first prenatal visit: a preliminary evaluation. *J Matern Fetal Neonatal Med.* 2008;21(2):129-133.
 114. Smith GCS, Pell JP, Cameron AD, Dobbie R. Risk of perinatal death associated with labor after previous cesarean delivery in

- uncomplicated term pregnancies. *JAMA*. 2002;287(20):2684-2690.
115. Socol ML, Peaceman AM. Vaginal birth after cesarean: an appraisal of fetal risk. *Obstet Gynecol*. 1999;93(5 Pt 1):674-679.
116. Spaans WA, van der Vliet LME, Roell-Schorer EAM, Bleker OP, van Roosmalen J. Trial of labour after two or three previous caesarean sections. *Eur J Obstet Gynecol Reprod Biol*. 2003;110(1):16-19.
117. Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstet Gynecol*. 2007;110(4):801-807.
118. Stone C, Halliday J, Lumley J, Brennecke S. Vaginal births after Caesarean (VBAC): a population study. *Paediatr Perinat Epidemiol*. 2000;14(4):340-348.
119. Strong TH, Jr., Vega JS, O'Shaughnessy MJ, Feldman DB, Koemptgen JG. Amnioinfusion among women attempting vaginal birth after cesarean delivery. *Obstet Gynecol*. 1992;79(5 (Pt 1)):673-674.
120. Stovall TG, Shaver DC, Solomon SK, Anderson GD. Trial of labor in previous cesarean section patients, excluding classical cesarean sections. *Obstet Gynecol*. 1987;70(5):713-717.
121. Tahilramaney MP, Boucher M, Eglinton GS, Beall M, Phelan JP. Previous cesarean section and trial of labor. Factors related to uterine dehiscence. *J Reprod Med*. 1984;29(1):17-21.
122. Tucker JM, Hauth JC, Hodgkins P, Owen J, Winkler CL. Trial of labor after a one- or two-layer closure of a low transverse uterine incision. *Am J Obstet Gynecol*. 1993;168(2):545-546.
123. Upadhyaya CD, Upadhyaya DM, Carlan SJ. Vaginal birth after cesarean delivery in a small rural community with a solo practice. *Am J Perinatol*. 2003;20(2):63-67.
124. van der Walt WA, Cronje HS, Bam RH. Vaginal delivery after one cesarean section. *Int J Gynaecol Obstet*. 1994;46(3):271-277.
125. van Gelderen CJ, England MJ, Naylor GA, Katzeff TC. Labour in patients with a caesarean section scar. The place of oxytocin augmentation. *Samj, S*. 1986;70(9):529-532.
126. Videla FL, Satin AJ, Barth WH, Jr., Hankins GD. Trial of labor: a disciplined approach to labor management resulting in a high rate of vaginal delivery. *Am J Perinatol*. 1995;12(3):181-184.
127. Weinstein D, Benshushan A, Tanos V, Zilberstein R, Rojansky N. Predictive score for vaginal birth after cesarean section. *Am J*

- Obstet Gynecol.* 1996;174(1 Pt 1):192-198.
128. Wen SW, Rusen ID, Walker M, et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(4):1263-1269.
129. Yetman TJ, Nolan TE. Vaginal birth after cesarean section: a reappraisal of risk. *Am J Obstet Gynecol.* 1989;161(5):1119-1123.
130. Yogev Y, Ben-Haroush A, Lahav E, Horowitz E, Hod M, Kaplan B. Induction of labor with prostaglandin E2 in women with previous cesarean section and unfavorable cervix. *Eur J Obstet Gynecol Reprod Biol.* 2004;116(2):173-176.
131. Zelop CM, Shipp TD, Repke JT, Cohen A, Caughey AB, Lieberman E. Uterine rupture during induced or augmented labor in gravid women with one prior cesarean delivery. *Am J Obstet Gynecol.* 1999;181(4):882-886.
132. Zelop CM, Shipp TD, Repke JT, Cohen A, Lieberman E. Effect of previous vaginal delivery on the risk of uterine rupture during a subsequent trial of labor. *Am J Obstet Gynecol.* 2000;183(5):1184-1186.
133. Zelop CM, Shipp TD, Cohen A, Repke JT, Lieberman E. Trial of labor after 40 weeks' gestation in women with prior cesarean. *Obstet Gynecol.* 2001;97(3):391-393.
134. Adair CD, Sanchez-Ramos L, Gaudier FL, Kaunitz AM, McDyer DC, Briones D. Labor induction in patients with previous cesarean section. *Am J Perinatol.* 1995;12(6):450-454.
135. Bodelon C, Bernabe-Ortiz A, Schiff MA, Reed SD. Factors associated with peripartum hysterectomy. *Obstet Gynecol.* 2009;114(1):115-123.
136. Buhimschi CS, Buhimschi IA, Patel S, Malinow AM, Weiner CP. Rupture of the uterine scar during term labour: contractility or biochemistry? *BJOG: An International Journal of Obstetrics & Gynaecology.* 2005;112(1):38-42.
137. Gilliam M, Rosenberg D, Davis F. The likelihood of placenta previa with greater number of cesarean deliveries and higher parity. *Obstet Gynecol.* 2002;99(6):976-980.
138. Guihard P, Blondel B. Trends in risk factors for caesarean sections in France between 1981 and 1995: lessons for reducing the rates in the future. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2001;108(1):48-55.
139. Hadley CB, Mennuti MT, Gabbe SG. An evaluation of the relative risks of a trial of labor versus

- elective repeat cesarean section. *Am J Perinatol.* 1986;3(2):107-114.
140. Juntunen K, Makarainen L, Kirkinen P. Outcome after a high number (4-10) of repeated cesarean sections. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2004;111(6):561-563.
141. Kacmar J, Bhimani L, Boyd M, Shah-Hosseini R, Peipert J. Route of delivery as a risk factor for emergent peripartum hysterectomy: a case-control study. *Obstet Gynecol.* 2003;102(1):141-145.
142. Laughon SK, Wolfe HM, Visco AG. Prior cesarean and the risk for placenta previa on second-trimester ultrasonography. *Obstet Gynecol.* 2005;105(5 Pt 1):962-965.
143. Leung AS, Farmer RM, Leung EK, Medearis AL, Paul RH. Risk factors associated with uterine rupture during trial of labor after cesarean delivery: a case-control study. *Am J Obstet Gynecol.* 1993;168(5):1358-1363.
144. Macones GA, Hausman N, Edelstein R, Stamilio DM, Marder SJ. Predicting outcomes of trials of labor in women attempting vaginal birth after cesarean delivery: a comparison of multivariate methods with neural networks. *Am J Obstet Gynecol.* 2001;184(3):409-413.
145. Macones GA, Cahill AG, Stamilio DM, Odibo A, Peipert J, Stevens EJ. Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted? *Am J Obstet Gynecol.* 2006;195(4):1148-1152.
146. McMahon MJ, Li R, Schenck AP, Olshan AF, Royce RA. Previous cesarean birth. A risk factor for placenta previa? *J Reprod Med.* 1997;42(7):409-412.
147. Miles AL, Monga M, Waller DK, Dande D, Pschirrer ER. Risk factors for symptomatic uterine rupture during a trial of labor: the 1990s. *Am J Perinatol.* 2000;17(7):385-389.
148. Pickhardt MG, Martin JN, Jr., Meydrech EF, et al. Vaginal birth after cesarean delivery: are there useful and valid predictors of success or failure? *Am J Obstet Gynecol.* 1992;166(6 Pt 1):1811-1815; discussion 1815-1819.
149. Rochelson B, Pagano M, Conetta L, et al. Previous preterm cesarean delivery: identification of a new risk factor for uterine rupture in VBAC candidates. *J Matern Fetal Neonatal Med.* 2005;18(5):339-342.
150. Rouse DJ, Owen J, Hauth JC. Active-phase labor arrest: oxytocin augmentation for at least 4 hours. *Obstet Gynecol.* 1999;93(3):323-328.
151. Seidman DS, Paz I, Nadu A, et al. Are multiple cesarean sections

- safe? *Eur J Obstet Gynecol Reprod Biol.* 1994;57(1):7-12.
152. Shimonovitz S, Botosneano A, Hochner-Celnikier D. Successful first vaginal birth after cesarean section: a predictor of reduced risk for uterine rupture in subsequent deliveries. *Isr Med Assoc J.* 2000;2(7):526-528.
153. Shipp TD, Zelop C, Cohen A, Repke JT, Lieberman E. Post-cesarean delivery fever and uterine rupture in a subsequent trial of labor. *Obstet Gynecol.* 2003;101(1):136-139.
154. Tikkanen M, Nuutila M, Hiilesmaa V, Paavonen J, Ylikorkala O. Prepregnancy risk factors for placental abruption. *Acta Obstet Gynecol Scand.* 2006;85(1):40-44.
155. Uygur D, Gun O, Kelekci S, Ozturk A, Ugur M, Mungan T. Multiple repeat cesarean section: is it safe? *Eur J Obstet Gynecol Reprod Biol.* 2005;119(2):171-175.
156. Uygur D, Tapisiz OL, Mungan T. Multiple repeat cesarean sections: maternal and neonatal outcomes. *Int J Gynaecol Obstet.* 2005;89(3):284-285.
157. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. *Am J Obstet Gynecol.* 2005;192(5):1458-1461.
158. Armstrong CA, Harding S, Matthews T, Dickinson JE. Is placenta accreta catching up with us? *Aust N Z J Obstet Gynaecol.* 2004;44(3):210-213.
159. Asakura H, Nakai A, Ishikawa G, Suzuki S, Araki T. Prediction of uterine dehiscence by measuring lower uterine segment thickness prior to the onset of labor: evaluation by transvaginal ultrasonography. *J Nippon Med Sch.* 2000;67(5):352-356.
160. Blanco JD, Collins M, Willis D, Prien S. Prostaglandin E2 gel induction of patients with a prior low transverse cesarean section. *Am J Perinatol.* 1992;9(2):80-83.
161. Bujold E, Gauthier RJ. Neonatal morbidity associated with uterine rupture: what are the risk factors? *Am J Obstet Gynecol.* 2002;186(2):311-314.
162. Chilaka VN, Cole MY, Habayeb OMH, Konje JC. Risk of uterine rupture following induction of labour in women with a previous cesarean section in a large UK teaching hospital. *J Obstet Gynaecol.* 2004;24(3):264-265.
163. Gotoh H, Masuzaki H, Yoshida A, Yoshimura S, Miyamura T, Ishimaru T. Predicting incomplete uterine rupture with vaginal sonography during the late second trimester in women with prior cesarean. *Obstet Gynecol.* 2000;95(4):596-600.
164. Grobman WA, Lai Y, Landon MB, et al. Development of a nomogram for prediction of vaginal birth after cesarean

- delivery. *Obstet Gynecol.* 2007;109(4):806-812.
165. Kieser KE, Baskett TF. A 10-year population-based study of uterine rupture. *Obstet Gynecol.* 2002;100(4):749-753.
166. Landon MB, Leindecker S, Spong CY, et al. The MFMU Cesarean Registry: factors affecting the success of trial of labor after previous cesarean delivery. *Am J Obstet Gynecol.* 2005;193(3 Pt 2):1016-1023.
167. Leung AS, Leung EK, Paul RH. Uterine rupture after previous cesarean delivery: maternal and fetal consequences. *Am J Obstet Gynecol.* 1993;169(4):945-950.
168. Lynch JC, Pardy JP. Uterine rupture and scar dehiscence. A five-year survey. *Anaesth Intensive Care.* 1996;24(6):699-704.
169. Meehan FP, Burke G. Trial of labour following prior section; a 5 year prospective study (1982-1987). *Eur J Obstet Gynecol Reprod Biol.* 1989;31(2):109-117.
170. Mercer BM, Gilbert S, Landon MB, et al. Labor outcomes with increasing number of prior vaginal births after cesarean delivery. *Obstet Gynecol.* 2008;111(2 Pt 1):285-291.
171. Scott JR. Mandatory trial of labor after cesarean delivery: an alternative viewpoint. *Obstet Gynecol.* 1991;77(6):811-814.
172. Sheiner E, Levy A, Menes TS, Silverberg D, Katz M, Mazor M. Maternal obesity as an independent risk factor for caesarean delivery. *Paediatr Perinat Epidemiol.* 2004;18(3):196-201.
173. Shipp TD, Zelop C, Repke JT, Cohen A, Caughey AB, Lieberman E. The association of maternal age and symptomatic uterine rupture during a trial of labor after prior cesarean delivery. *Obstet Gynecol.* 2002;99(4):585-588.
174. Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. *Obstet Gynecol.* 2006;107(6):1226-1232.
175. Yucel O, Ozdemir I, Yucel N, Somunkiran A. Emergency peripartum hysterectomy: a 9-year review. *Arch Gynecol Obstet.* 2006;274(2):84-87.
176. Zelop CM, Harlow BL, Frigoletto FD, Jr., Safon LE, Saltzman DH. Emergency peripartum hysterectomy. *Am J Obstet Gynecol.* 1993;168(5):1443-1448.
177. Bujold E. Uterine rupture during a trial of labor after a one- versus two-layer closure of low transverse cesarean. *Am J Obstet Gynecol.* 2001;184(suppl)(S18).
178. Cameron CA, Roberts CL, Peat B. Predictors of labor and vaginal

- birth after cesarean section. *Int J Gynaecol Obstet*. 2004;85(3):267-269.
179. Costantine MM, Fox K, Byers BD, et al. Validation of the prediction model for success of vaginal birth after cesarean delivery. *Obstet Gynecol*. 2009;114(5):1029-1033.
180. Gonen R, Tamir A, Degani S, Ohel G. Variables associated with successful vaginal birth after one cesarean section: a proposed vaginal birth after cesarean section score. *Am J Perinatol*. 2004;21(8):447-453.
181. Gyamfi C, Juhasz G, Gyamfi P, Stone JL. Increased success of trial of labor after previous vaginal birth after cesarean. *Obstet Gynecol*. 2004;104(4):715-719.
182. Harper LM, Cahill AG, Stamilio DM, Odibo AO, Peipert JF, Macones GA. Effect of gestational age at the prior cesarean delivery on maternal morbidity in subsequent VBAC attempt. *Am J Obstet Gynecol*. 2009;200(3):276.e271-276.
183. Hendler I, Bujold E. Effect of prior vaginal delivery or prior vaginal birth after cesarean delivery on obstetric outcomes in women undergoing trial of labor. *Obstet Gynecol*. 2004;104(2):273-277.
184. Huang WH, Nakashima DK, Rumney PJ, Keegan KA, Jr., Chan K. Interdelivery interval and the success of vaginal birth after cesarean delivery. *Obstet Gynecol*. 2002;99(1):41-44.
185. Hueston WJ, Rudy M. Factors predicting elective repeat cesarean delivery. *Obstet Gynecol*. 1994;83(5 Pt 1):741-744.
186. Jakobi P, Weissman A, Peretz BA, Hocherman I. Evaluation of prognostic factors for vaginal delivery after cesarean section. *J Reprod Med*. 1993;38(9):729-733.
187. Kabir AA, Pridjian G, Steinmann WC, Herrera EA, Khan MM. Racial differences in cesareans: an analysis of U.S. 2001 National Inpatient Sample Data. *Obstet Gynecol*. 2005;105(4):710-718.
188. Fawcett J, Tulman L, Spedden J. Responses to vaginal birth after cesarean section. *J Obstet Gynecol Neonatal Nurs*. 1994;23(3):253-259.
189. Learman LA, Evertson LR, Shiboski S. Predictors of repeat cesarean delivery after trial of labor: do any exist? *J Am Coll Surg*. 1996;182(3):257-262.
190. Pang MW, Law LW, Leung TY, Lai PY, La TK. Sociodemographic factors and pregnancy events associated with women who declined vaginal birth after cesarean section. *Eur J Obstet Gynecol Reprod Biol*. 2009;143(1):24-28.

191. Selo-Ojeme D, Abulhassan N, Mandal R, Tirlapur S, Selo-Ojeme U. Preferred and actual delivery mode after a cesarean in London, UK. *Int J Gynaecol Obstet.* 2008;102(2):156-159.
192. Shipp TD, Zelop CM, Repke JT, Cohen A, Caughey AB, Lieberman E. Labor after previous cesarean: influence of prior indication and parity. *Obstet Gynecol.* 2000;95(6 Pt 1):913-916.
193. Smith GCS, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. *PLoS Med.* 2005;2(9):e252.
194. Spaans WA, Sluijs MB, van Roosmalen J, Bleker OP. Risk factors at caesarean section and failure of subsequent trial of labour. *Eur J Obstet Gynecol Reprod Biol.* 2002;100(2):163-166.
195. Srinivas SK, Stamilio DM, Stevens EJ, Odibo AO, Peipert JF, Macones GA. Predicting failure of a vaginal birth attempt after cesarean delivery. *Obstet Gynecol.* 2007;109(4):800-805.
196. Strong JM, McQuillan K. Factors affecting mode of delivery in labour following a single previous birth by cesarean. *Journal of Obs & Gyn.* 1996;16(5).
197. Troyer LR, Parisi VM. Obstetric parameters affecting success in a trial of labor: designation of a scoring system. *Am J Obstet Gynecol.* 1992;167(4 Pt 1):1099-1104.
198. Vinueza CA, Chauhan SP, Barker L, Hendrix NW, Scardo JA. Predicting the success of a trial of labor with a simple scoring system. *J Reprod Med.* 2000;45(4):332-336.

Appendix J. Strength of Evidence Table

	Domains pertaining to strength of evidence				Magnitude of effect	Strength of Evidence
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Vaginal Birth After Cesarean Rate	Low, Moderate, High
<i>Vaginal Birth After Cesarean Rate</i>						
67 368,304	Medium 16 cohort (Good Quality); 51 cohort (Fair Quality)	Inconsistent	Direct for delivery outcome	Precise	74% (95% CI: 72% to 75%)	Moderate
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Proportion of Induced Trials of Labor	Low, Moderate, High
<i>Any Induction Method in Trial of Labor: Proportion with Vaginal Birth After Cesarean</i>						
28 11,938	Medium 1 RCT, 19 cohort, 9 case series (Fair Quality)	Consistent	Direct	Precise	63% (95% CI: 59% to 67%)	Moderate
<i>Prostaglandin E₂ Induction in Trial of Labor: Proportion with Vaginal Birth After Cesarean</i>						
5 1671	Medium 11 case series, 4 cohort (Fair Quality)	Inconsistent	Direct	Precise	63% (95% CI: 58% to 69%)	Moderate
<i>Misoprostol Induction in TOL: Proportion with Vaginal Birth After Cesarean</i>						
2 96	Medium Cohort, (Fair Quality)	Inconsistent	Direct	Imprecise	61% (95% CI: 27% to 90%)	Low
<i>Oxytocin Induction in Trial of Labor: Proportion with Vaginal Birth After Cesarean</i>						
5 308	Low 2 cohort, 3 case series (Fair Quality)	Inconsistent	Direct	Imprecise	62% (95% CI: 53% to 70%)	Low
<i>Oxytocin Augmentation in Trial of Labor: Proportion with Vaginal Birth After Cesarean</i>						
7 660*	Medium 5 cohort, 2 case series (Fair Quality)	Inconsistent	Direct	Imprecise	68% (95% CI: 64% to 72%)	Low
<i>Oxytocin versus Prostaglandin E₂ Induction in Trial of Labor: Proportion with Vaginal Birth After Cesarean</i>						
2 3301	1 RCT (Poor Quality) 1 cohort (Fair Quality)	Inconsistent	Indirect	Imprecise	Not applicable	Low
<i>Mechanical Induction in Trial of Labor: Proportion with Vaginal Birth After Cesarean</i>						
Foley Catheter						
2 416	2 cohort (Fair Quality)	Consistent	Direct	Imprecise	54% (95% CI: 49% to 59%)	Moderate

Appendix J. Strength of Evidence, continued

	Domains pertaining to strength of evidence				Magnitude of effect	Strength of Evidence
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Trial of Labor versus Elective Repeat Cesarean Delivery	Low, Moderate, High
Maternal Mortality						
14 405,827	Medium 13 cohort (2 Good, 11 Fair Quality); 1 case control (Fair Quality)	Consistent	Direct	Precise	TOL: 3.8/100,000 (95% CI: 0.9/100,000 to 15.5/100,000) ERCD: 13.4/100,000 (95% CI: 4.3/100,000 to 41.6/100,000)	High
Maternal Outcomes: Uterine Rupture Rate						
8 63,499	Medium 4 prospective cohort; 4 retrospective cohort (4 include both TOL and ERCD)	Consistent	Direct	Precise	Overall: 3% (95% CI: 0.2% to 0.4%) TOL: 0.47% (95% CI: 0.28% to 0.68%) ERCD: 0.04% (95% CI: 0.018% to 0.11%)	Moderate
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Proportion of Induced Trials of Labor	Low, Moderate, High
Any Induction Method in Trial of Labor: Uterine Rupture						
7 5296	Medium 5 cohort, 2 case series (Fair Quality)	Inconsistent	Direct	Imprecise	1.2% (95% CI: 0.7% to 1.9%)	Low
Prostaglandin E₂ Induction in Trial of Labor: Uterine Rupture						
12	6 cohort (5 Fair, 1 Good Quality) 6 case series (Fair Quality)	Inconsistent	Direct	Imprecise	2% (95% CI: 1.1% to 3.5%)	Low
Misoprostol Induction in Trial of Labor: Uterine Rupture						
1 226	Cohort (Fair Quality)	NA	Direct	Imprecise	13%	Low
Oxytocin Induction in Trial of Labor: Uterine Rupture						
9 5713	Medium 1 case control, 5 cohort, 3 case series (Fair Quality)	Inconsistent	Direct	Precise	1.1% (95% CI: 0.9% to 1.5%)	Moderate
Oxytocin Augmentation in Trial of Labor: Uterine Rupture						
Insufficient data to assess						
Oxytocin versus Prostaglandin E₂ Induction in Trial of Labor: Uterine Rupture						
1 3035	Medium 1 cohort (Fair Quality)	NA	Direct	Imprecise	Increased risk found in oxytocin groups	Low
Mechanical Induction in Trial of Labor: Uterine Rupture						
Insufficient data to assess						
Any Induction method in Trial of Labor: Other Harms						
Insufficient data to assess						

Appendix J. Strength of Evidence Table, continued

	Domains pertaining to strength of evidence				Magnitude of effect	Strength of Evidence
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Proportion of Induced Trials of Labor	Low, Moderate, High
Prostaglandin E₂ Induction in Trial of Labor: Other Harms						
Insufficient data to assess						
Misoprostol Induction in Trial of Labor: Other Harms						
Insufficient data to assess						
Oxytocin Induction in Trial of Labor: Other Harms						
Insufficient data to assess						
Oxytocin Augmentation in Trial of Labor: Other Harms						
Insufficient data to assess						
Oxytocin versus Prostaglandin E₂ Induction in Trial of Labor: Other Harms						
Insufficient data to assess						
Mechanical Induction in Trial of Labor: Other Harms						
Insufficient data to assess						
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Trial of Labor versus Elective Repeat Cesarean Delivery	Low, Moderate, High
Maternal Outcomes: Hysterectomy						
16 402,059	Medium 14 cohort (4 Good, 10 Fair Quality); 1 case control (Good Quality)	Inconsistent	Direct	Precise	Overall: 0.537/1,000 (95% CI: -1.49/1,000 to 0.419/1,000) TOL: 1.73/1,000 (95% CI: 0.115/1,000 to 2.42/1,000) ERCD: 3.1/1,000 (95% CI: 0.172/1,000 to 4.88/1,000)	Moderate
Maternal Outcomes: Transfusion						
10 409,382	Medium 10 cohort (4 Good, 6 Fair Quality)	Consistent	Direct	Precise	Overall: -0.818/1,000 (95% CI: -0.339/1,000 to 1.76/1,000) TOL: 8.81/1,000 (95% CI: 4.2/1,000 to 15.1/1,000) ERCD: 11.6/1,000 (95% CI: 6.39/1,000 to 18.3/1,000)	Moderate
Maternal Outcomes: Blood Loss/Hemorrhage						
7 47,754	High 7 cohort (1 Good, 6 Fair Quality)	Inconsistent	Indirect	Imprecise	General trend toward increased blood loss with ERCD and RCD after a TOL when reported	Low
Maternal Outcomes: Effect of Induction on Hemorrhage						
Insufficient data to assess						

Appendix J. Strength of Evidence Table, continued

	Domains pertaining to strength of evidence				Magnitude of effect	Strength of Evidence
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Trial of Labor versus Elective Repeat Cesarean Delivery	Low, Moderate, High
Maternal Outcomes: Infection, All Definitions						
22 354,060	High 20 cohort (5 Good, 15 Fair Quality); 2 case control (Fair Quality)	Inconsistent	Indirect	Imprecise	Overall: 0.93% (95% CI: 0.068% to 1.8%) TOL: 6.3% (95% CI: 3.4% to 10.1%) ERCD: 3.9% (95% CI: 2.3% to 5.8%)	Low
Maternal Outcomes: Fever						
12;26,679	High 1 cohort (1 Good, 11 Fair Quality)	Inconsistent	Direct	Imprecise	Overall: -5.4% (95% CI: -9.9% to -0.80%) TOL: 6.6% (95% CI: 4.4% to 9.3%) ERCD: 10.2% (95% CI: 4.9% to 17.1%)	Low
Long Term Maternal Outcomes: Adhesions						
Insufficient data to assess						
Long Term Maternal Outcomes: Pelvic Pain						
Insufficient data to assess						
Long Term Maternal Outcomes: Reproductive Health						
Insufficient data to assess						
Infant Outcomes: Perinatal Mortality (infant death occurring ≥20 weeks-28 days life)						
5 76,899	Medium 4 cohort (3 Good, 1 Fair Quality)	Consistent	Indirect	Imprecise	TOL: 0.00133 (95% CI: 0.00059 to 0.00034) ERCD: 0.00050 (95% CI: 0.00007 to 0.00382)	Moderate
Infant Outcomes: Fetal Mortality (infant death occurring ≥20 weeks gestation, but prior to birth)						
2 63,646	Medium 2 cohort (Good Quality, 1 with AP/IP deaths; 1 IP only)	Consistent	Indirect	Imprecise	TOL (overall): 39/30,834 (1.3/1000) ERCD (overall): 23/32,806 (0.7/1000)	Low (2 cohort studies)
Infant Outcomes: Neonatal Mortality (infant death occurring after birth but ≤ 28 days of life)						
6 108,328	Medium 6 cohorts (3 Fair, 3 Good Quality)	Consistent	Indirect	Imprecise	TOL: 0.00114 (95% CI: 0.00063 to 0.00204) ERCD: 0.00055 (95% CI: 0.00020 to 0.00150)	Moderate
Term Infant Outcomes: Transient Tachypnea of the Newborn						
3 4,927	Medium 3 cohort (Fair Quality)	Inconsistent	Direct	Imprecise	TOL: 36.1/1,000 ERCD: 42/1,000	Low
Term Infant Outcomes: Neonatal Respiratory Morbidity with Bag & Mask Ventilation						
3 2,110	Medium 3 cohort (Fair Quality)	Inconsistent	Direct	Imprecise	TOL: 53.7/1000 ERCD: 25/1000	Low

Appendix J. Strength of Evidence Table, continued

	Domains pertaining to strength of evidence				Magnitude of effect	Strength of Evidence
# of Studies; # of Subjects	Risk of Bias (Design/Quality)	Consistency	Directness	Precision	Trial of Labor versus Elective Repeat Cesarean Delivery	Low, Moderate, High
<i>Term Infant Outcomes: Neonatal Respiratory Morbidity with Intubation for Meconium</i>						
2 1438	Medium 2 cohort (Fair Quality)	Consistent	Direct	Precise	TOL: 11.5% ERCD: 1.5%	Moderate
<i>Term Infant Outcomes: Hypoxic Ischemic Encephalopathy and Asphyxia</i>						
3 62,829	High (definition issues) 3 cohort (Fair Quality)	Inconsistent	Low	Imprecise	Cannot calculate summary estimate	Low
<i>Term Infant Outcomes: Neonatal Intensive Care Unit Admissions</i>						
*8 65,121	Medium 8 cohort (2 Good, 6 Fair Quality)	Inconsistent	Indirect	Imprecise	Cannot calculate summary estimate	Low
<i>Term Infant Outcomes: Short and Long Term Neurologic Outcomes</i>						
Insufficient data to assess						
<i>Term Infant Outcomes: Confirmed Sepsis</i>						
Insufficient data to assess	High (definition issues) 3 cohort (Fair Quality)	Inconsistent	Indirect	Imprecise	Cannot calculate summary estimate	Low
<i>Term Infant Outcomes: Trauma</i>						
2 41,899	High (definition issues) 2 cohort (Fair Quality)	Inconsistent	Indirect	Imprecise	Cannot calculate summary estimate	Insufficient
<i>Term Infant Outcomes: Breastfeeding</i>						
Insufficient data to assess						

*1 case series included 628 women with induced labor, number with augmentation not reported

Abbreviations: AP=anteartum; CI=confidence interval; ERCD=elective repeat cesarean delivery; IP=intrapartum; RCD=repeat cesarean delivery; TOL=trial of labor

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean

Introduction

A brief description on the predictors of trial of labor (TOL) and vaginal birth after cesarean (VBAC) is included in the text of the evidence report. Detailed descriptions of the studies and analyses conducted on these topics are included in this appendix.

Predictors of Trial of Labor

Three good quality retrospective cohort studies,¹⁻³ five fair quality retrospective cohort studies⁴⁻⁸ and one fair quality retrospective cross sectional study⁹ looked for factors known in the prenatal setting that may predict TOL. Predictors have been categorized into three categories as they relate to the likelihood of TOL: 1) nonclinical which includes the site of care and type of insurance 2) demographic which include maternal age, race and economic status and 3) past obstetric factors which include a history of a vaginal birth and the gestational age of the prior cesarean delivery. Unless otherwise noted, all results are presented in odds ratios. If studies reported relative risks (RR), these are noted in the tables.

Nonclinical Factors

Among the studies that reported factors related to TOL rates, location of delivery (volume), hospital level, and access to private insurance were considered nonclinical factors.

Three retrospective studies found that the location of delivery was associated with TOL^{1,2} or related to unnecessary RCDs.⁹ In a secondary analysis of the Agency for Healthcare Research and Quality's (AHRQ) 2001 Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample database, investigators reported that women had a reduced likelihood of TOL if they were delivered in rural or nonteaching urban hospitals (Table K-1).⁹ These investigators identified all women who had unnecessary (had no discharge indication, ICD-9 code, for a repeat cesarean delivery [RCD]) RCDs as a way to quantify the number of women who may not have been offered a TOL; the database includes data from 33 states. In this study, a prior cesarean alone was not considered as sufficient justification for a RCD. With this definition, 65 percent of RCDs were considered unnecessary and overall bed size of the hospital was not related to unnecessary RCDs.

In a study of Australian deliveries during 1998 to 2001,¹ predictors of TOL were evaluated for 14,350 charts of women eligible for TOL by the American College of Obstetricians and Gynecologists (ACOG) standards. Women had an increased likelihood of TOL if they delivered at a Level 5 or 6 hospital (metro district hospital for high-risk mothers/babies or perinatal center) and a decreased likelihood at a Level 4 or below (metro district for moderate-risk mothers/babies, rural, and private hospitals).¹ A study conducted in Nova Scotia, Canada, between 1986 and 1992, similarly found that women in community and regional hospitals were half as likely to have a TOL as women delivering in tertiary care centers.² Further examination of rural community hospitals suggest that women delivering at rural teaching hospitals with lower volumes of deliveries and women with private insurance had a decreased likelihood of TOL even when adjusting for race, employment and marital status.⁷ Interestingly, the only study to date that considered the volume of VBAC deliveries found no relationship between annual VBAC volume and rate of TOL (not shown as no odds ratio or RR were provided).⁵ In this secondary analysis⁵ of a large, retrospective cohort study,¹⁰ 55, 51, and 57 percent of women had

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

TOL in hospitals that had less than 70; 70 to 100, or more than 100 VBAC deliveries per year, respectively.

Table K-1. Nonclinical factors as predictors of trial of labor

Author, Year	Characteristic	Adjusted odds ratio for TOL	95% CI
<i>Site of Care (volume of deliveries)</i>			
Hueston, 1994 ⁷	252 women with prior CD/2y	1.00	Referent
	135 women with prior CD/2 y	0.46	0.29-0.74
	179 women with prior CD/2 y	0.57	0.38-0.85
	193 women with prior CD/2y	0.38	0.25-0.56
<i>Hospital Level</i>			
Cameron, 2004 ¹	Level 6 (Perinatal center)	1.00	Referent
	Level 5 (High-risk care)	1.22	1.09-1.37
	Level 4 (moderate-risk care)	0.90	0.81-0.99
	Level 1-3 (Rural)*	0.66	0.58-0.74
	Private	0.45	0.41-0.50
McMahon, 1996 ²	Tertiary Care	1.00	Referent
	Regional Hospital	0.50	0.50-0.60
	Community Hospital	0.40	0.30-0.50
<i>Private Insurance</i>			
Hueston, 1994 ⁷	Yes	0.52	0.35-70

*96 percent rural hospitals

Abbreviations: CD=cesarean delivery; CI=confidence interval; TOL=trial of labor; y=year(s)

Demographic and Pre-Existing Factors

Studies reported only maternal age, race and economic status as current demographic factors affecting rates of TOL.

Two studies provided evidence that advancing maternal age may change the likelihood of TOL (Table K-2).^{1,2} In the older of the two studies, conducted between 1986 and 1992, younger women (age 19 and younger) and older women (age 30 and older) were more likely to have a TOL compared with 25 to 29 year old women.² In the second study conducted between 1998 and 2001, older women were less likely to have a TOL.¹ In contrast to this more recent finding, women age 35 and older in a US study conducted in 2001 had a reduced likelihood of an unnecessary RCD (or increased likelihood of TOL).⁹ In this retrospective cross-sectional study 67 percent of women under age 35 had unnecessary RCDs compared with 60 percent of women age 35 and older, $p < 0.001$.

Two studies found that non-white women had an increased likelihood of a TOL compared with white women. In a study based in the United Kingdom (UK) that recorded the rate of TOL in 2007, 77 percent of Afro-Caribbean women, 68 percent of Asian women and 41 percent of white women chose a TOL.⁸ In a US study, 66 percent of white women had unnecessary RCDs compared with 62 percent of African American women, suggesting that white women had less

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

opportunity for a TOL ($p < 0.001$).⁹ Race in this study was an independent predictor of TOL even when type of insurance was included in a regressive model.

One retrospective study of women in Hong Kong conducted between 2002 and 2006 reported social economic factors influenced the decision. When the family monthly income was \$3,850 or less US dollars, the woman was less likely to choose a TOL (adjusted odds ratio 0.64; 95% CI: 0.43 to 0.97).³

Table K-2. Demographic factors as predictors of trial of labor

Author, Year Study Design	Characteristic	Adjusted odds ratio for TOL	95% CI
<i>Maternal Age</i>			
Cameron, 2004 ¹ Retrospective Cohort	<30 y	1.00	Referent
	30-39 y	0.86	0.80-0.92
	40 y and older	0.40	0.33-0.48
McMahon, 1996 ² Retrospective Cohort	≤19 y	1.40	1.00-2.10
	20-24 y	1.00	0.80-1.10
	25-29 y	1.00	Referent
	30-34 y	1.10	1.00-1.20
	≥35 y	1.20	1.00-1.40
<i>Race</i>			
Selo-Ojeme, 2008 ⁸ Retrospective Cohort	White	1.00	Referent
	Non-white (Afro-Caribbean, Asian)	3.5	1.90-6.10

Abbreviations: CI=confidence interval; TOL=trial of labor; y=year(s)

Past obstetric factors

The number of previous vaginal deliveries and gestational age (GA) at prior caesarean delivery are the past-obstetric factors that have been assessed for their influence on TOL rates

Careful attention is given to prior obstetric history in estimating likelihood of VBAC, which, in turn may influence the initial decision to have a TOL. Three retrospective cohort studies,¹⁻³ described above, and a secondary analysis⁶ of a large retrospective study¹⁰ examined whether obstetric factors such as number of prior vaginal deliveries or GA at the prior cesarean predicted TOL (Table K-3). The likelihood of TOL increased for women with prior vaginal deliveries¹⁻³ while it decreased for women who had a prior cesarean before 34 weeks GA.⁶

Table K-3. Past obstetric factors as predictors of trial of labor

Author, Year Study Design	Characteristic	Adjusted odds ratio or relative risk for VBAC	95% CI
<i>Number of previous vaginal deliveries</i>			
Cameron, 2004 ¹ Retrospective Cohort	1 Prior VD	1.51	1.35-1.68
	2 Prior VDs	2.35	1.92-2.86
	≥ 3 Prior VDs	2.94	2.23-3.88
McMahon, 1996 ² Retrospective Cohort	1 Prior VD	3.20	Not reported
	2 Prior VDs	4.00	Not reported
Pang, 2009 Retrospective Cohort	History of VD	6.67	2.70-16.67

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-3. Past obstetric factors as predictors of trial of labor

Author, Year Study Design	Characteristic	Adjusted odds ratio or relative risk for VBAC	95% CI
<i>Gestational age of prior cesarean delivery</i>			
Harper, 2009 ⁶ Retrospective Cohort	GA ≥ 34 wk	1	Referent
	GA < 34 wk	1.2 RR	1.1-1.2

Abbreviations: CI=confidence interval; GA=gestational age; RR=Relative Risk; VBAC=vaginal birth after cesarean; VD=vaginal delivery; wk=week(s)

Summary of Predictors of Trial of Labor

Trial of labor is more likely in hospitals with higher delivery volumes, tertiary care centers, and teaching hospitals. Women with a prior vaginal delivery or non-white women were more likely to have a TOL (odds ratio 1.51 to 6.67).

Predictors of Vaginal Birth After Cesarean

The impact of individual factors on VBAC discussed in the evidence report can overlap and interact with each other such that a factor found to have statistically significant influence on VBAC rate may no longer be significant when other key factors are taken into account. Studies that evaluate these factors in concert, using regression analyses for example, can provide a higher level of evidence on the residual influence of individual factors. Four prospective cohort studies,¹¹⁻¹⁴ 18 retrospective cohort studies,^{1, 5, 8, 15-29} and one case-control study³⁰ addressed predictive factors for VBAC. The key factors considered by these studies were demographic factors that included maternal age, ethnicity, race, and marital status; nonclinical factors that included insurance status, site of delivery, and volume of VBACs; past obstetric factors that included prior vaginal delivery and prior indications for cesarean; pre-existing and current factors that included maternal height, body mass index (BMI), substance abuse, and pre-existing maternal disease; and current obstetric factors related to the infant gender, age and size. Finally, the section folds in factors related to the labor experience (dilation, effacement, station, Bishop score, cervix position, type of labor and epidural use).

Demographic Factors

Maternal age, ethnicity, race and marital status have been examined for their ability to predict VBAC in women who attempt a TOL (Table K-4). Eight cohort studies provided inconsistent evidence on the effect of advancing age on the VBAC rate.^{1, 11-13, 19, 21, 24, 27} In five of the eight studies, younger women were more likely to have a VBAC, particularly women under age 40.^{1, 11, 12, 19, 24} In the other studies, there was no statistically significant relationship between maternal age and likelihood of VBAC.^{13, 21, 27} Taken as a group, the overall trend appears to be that younger women have a higher likelihood of a VBAC.

In all four cohort studies reporting on ethnicity and race, Hispanic and African American women had a reduced likelihood to have a VBAC compared with non-Hispanic and white women, respectively.^{12, 13, 19, 26} Two large prospective cohort studies reported reduced likelihood of VBAC for Hispanic and for African American women (Table K-4).^{12, 13} In both studies data were analyzed from the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (MFMU, Appendix G). While different subsets of data were

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

analyzed based on GA, both studies reached the same conclusions about the effects of race or ethnicity on likelihood of VBAC. In one study,¹³ the VBAC rate was evaluated for women with GAs of at least 20 weeks. In this study, Hispanic women were 35 percent less likely to have a VBAC and African American women were 31 percent less likely to have a VBAC compared with non-Hispanic and white women respectively.

It is interesting to note that non-white women were more likely to have a TOL but less likely to have a VBAC.⁸ This suggests that other factors related to patient preferences may be driving this result. In a prior systematic review,³¹ underlying cultural ideologies were found to influence the desire to go through the painful labor process. Non-white women in 100 structured interviews reported that labor was a painful process that did not relate to motherhood.³² By contrast, white women in the same cohort study viewed vaginal birth as an experience “not to be missed” in motherhood.³²

Additionally, unmarried women had a reduced likelihood of a VBAC.¹³ Finally, in a retrospective study of births in New York in 1989, women with more than 12 years of education had an increased likelihood of a VBAC.¹⁹

Table K-4. Demographic factors as predictors of vaginal birth after cesarean

Author, Year Study Design	Characteristic	Adjusted OR for VBAC	95% CI
<i>Maternal age</i>			
Flamm, 1997 ¹¹ Prospective Cohort	>40y	0.39	0.23-0.65
McNally, 1999 ²¹ Retrospective Cohort	Per y	1.18	0.98-1.40
Weinstein, 1996 ²⁷ Retrospective Cohort	>37 y	0.9	0.5-1.7
Smith, 2005 ²⁴ Retrospective Cohort	Per 5 y increase	0.82	0.78-0.86
King, 1994 ¹⁹ Retrospective Cohort	Per 5 y increase	0.85	0.81-0.90
Cameron, 2004 ¹ Retrospective Cohort	<30 y	1.0	referent
	30-39 y	0.86	0.77-0.95
	>40 y	0.59	0.43-0.82
Grobman, 2007 ¹² Prospective Cohort	Per yr	0.96	0.95-0.97
Landon, 2005 ¹³ Prospective Cohort	<17 y	0.84*	0.57-1.25
	18-34 y	1.0	referent
	>35 y	1.0*	0.91-1.10
<i>Ethnicity, race and marital status</i>			
<i>Hispanic</i>			
Grobman, 2007 ¹² Prospective Cohort	Referent: Non-Hispanic	0.51	0.44-0.59
Landon, 2005 ¹³ Prospective Cohort	Referent: Non-Hispanic	0.65*	0.59-0.72
Srinivas, 2007 ²⁶ Retrospective Cohort	Referent: White	0.69	0.56-0.84

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-4. Demographic factors as predictors of vaginal birth after cesarean

Author, Year Study Design	Characteristic	Adjusted OR for VBAC	95% CI
King, 1994 ¹⁹ Retrospective Cohort	Referent: White	0.61	0.51-0.73
<i>African American</i>			
Grobman, 2007 ¹² Prospective Cohort	Referent: White	0.51	0.44-0.59
Landon, 2005 ¹³ Prospective Cohort	Referent: White	0.69*	0.63-0.75
Srinivas, 2007 ²⁶ Retrospective Cohort	Referent: White	0.58	0.52-0.67
King, 1994 ¹⁹ Retrospective Cohort	Referent: White	0.80	0.70-0.93
<i>Afro-Caribbean</i>			
Selo-Ojeme, 2008 ⁸ Retrospective Cohort	Referent: White	3.22	1.5-7.14
<i>Asian</i>			
Srinivas, 2007 ²⁶ Retrospective Cohort	Referent: White	0.80	0.61-1.05
<i>Other</i>			
Landon, 2005 ¹³ Prospective Cohort	Referent: White	0.71*	0.60-0.84
<i>Unmarried</i>			
Landon, 2005 ¹³ Prospective Cohort	Referent: Married	0.88	0.82-0.95
<i>Education</i>			
King, 1994 ¹⁹ Retrospective Cohort	<12 y	1.0	Referent
	12 y	1.15	0.99-1.34
	13-15 y	1.36	1.16-1.60
	16 y	1.59	1.32-1.93
	17 y	2.00	1.64-2.45

*Only provided univariate odds ratio

Abbreviations: CI=confidence interval; OR=odds ratio; VBAC=vaginal birth after cesarean; y=year(s)

Nonclinical Factors

Nonclinical factors such as insurance and site of delivery play an important role in deciding what kind of birthing options are pursued. Women with non-private insurance or who were uninsured had a decreased likelihood for VBAC (Table K-5).¹³ However, women in Health Maintenance Organizations (HMO) had an increased likelihood of VBAC.¹⁹ The level of the hospital at which the birth takes place is also a major factor in the likelihood of VBAC. Women at rural and private hospitals that provide obstetric care for lower risk deliveries had a decreased likelihood of VBAC.¹ This finding is consistent with another finding by the same investigators¹ that women at rural and private hospitals were less likely to attempt a TOL. Private hospitals in this study had an average VBAC rate of 57 percent compared with a VBAC rate of 66 percent for level 6 hospitals.¹ Finally, in a secondary analysis⁵ of a retrospective cohort study,¹⁰ the annual VBAC volume at the hospital did not change the likelihood of VBAC.

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-5. Nonclinical factors as predictors of vaginal birth after cesarean

Author, Year Study Design	Characteristic	Adjusted OR for VBAC	95% CI
<i>Insurance Status</i>			
Landon, 2005 ¹³ Prospective Cohort	Private	1.00	Referent
	Non-private	0.88*	0.81-0.95
	Uninsured	0.74*	0.66-0.83
King, 1994 ¹⁹ Retrospective Cohort	Private	1.00	Referent
	HMO	1.15	1.02-1.30
	Self-pay	1.19	0.96-1.47
	Medicaid	1.01	0.89-1.15
<i>Hospital Level of Birth</i>			
Cameron, 2004 ¹ Retrospective Cohort	Level 6 (Perinatal center)	1.0	Referent
	Level 5 (High-risk care)	0.96	0.82-1.12
	Level 4 (Moderate-risk care)	1.02	0.89-1.19
	Level 1-3 (Rural [†])	0.79	0.65-0.95
	Private	0.72	0.62-0.84
<i>Volume of VBACs</i>			
Chang, 2008 ⁵ Retrospective Cohort	<70 per year	1.11	0.79-1.56
	70-100 per year	1.16	0.93-1.45
	>100 per year	1.00	Referent

*Only provided univariate odds ratio

[†]96 percent rural hospitals

Abbreviations: CI=confidence interval; HMO=health management organization; OR=odds ratio;

VBAC=vaginal birth after cesarean

Past obstetric Factors

There is particular interest in whether demographic factors, nonclinical and past obstetric factors may predict VBAC since these factors are known prenatally and would allow clinicians to provide information on prognosis early in pregnancy. Investigators from studies have explored prior vaginal delivery, years since prior cesarean delivery, prior labor experience and prior baby weight as potential factors for predicting VBAC. A prior history of vaginal delivery was consistently reported to increase likelihood of VBAC in all 13 cohort studies (Table K-6).^{1, 11-13, 15, 17, 18, 20, 21, 24, 26, 27, 33} in one case-control study³⁰ Women with a vaginal delivery after their prior cesarean (prior VBAC) were three to seven times more likely to have a VBAC for their current delivery^{11-13, 15, 17, 18, 30, 33} compared with women with no prior VDs. Women who had a vaginal delivery before their cesarean deliveries also had an increased likelihood to have a VBAC.^{11, 27}

One secondary analysis of a retrospective cohort study¹⁰ of 16 community and university hospitals that is not included in Table K-6 because it did not provide odds ratios³⁴ specifically examined the effect of prior vaginal delivery before a cesarean and of a prior VBAC on the current TOL. The VBAC rate for women with no history of vaginal delivery was 65 percent, 83 percent for women with a prior vaginal delivery before a cesarean, and 94 percent for women with a prior VBAC.³⁴ Finally, a secondary analysis of the MFMU cohort data reported that the likelihood of a VBAC increased with each prior VBAC.³⁵ Women with zero, one, two, three, and four or more prior VBACs had likelihoods of VBAC of 63.3, 87.6, 90.9, 90.6, and 91.6 percent (p<0.001), respectively.

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-6. Past obstetric factor as predictors of vaginal birth after cesarean: prior deliveries

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
<i>Multipara/vaginal delivery</i>			
Learman, 1996 ²⁰ Retrospective Cohort	Yes	03.45 RR	1.0-12.50 RR
<i>Prior vaginal delivery</i>			
McNally, 1999 ²¹ Retrospective Cohort	Yes	27.78	3.85-200
Grobman, 2007 ¹² Prospective Cohort	Yes	2.43	2.04-2.89
Landon, 2005 ¹³ Prospective Cohort	Yes	3.90	3.60-4.30
Smith, 2005 ²⁴ Retrospective Cohort	Yes	5.08	4.82-5.72
Cameron, 2004 ¹ Retrospective Cohort	1 prior	2.95	2.47-3.53
	2 prior	5.58	3.92-7.96
	3 prior	3.57	2.43-5.26
Bujold, 2004 ¹⁵ Retrospective Cohort	Yes	2.69	1.41-5.13
Srinivas, 2007 ²⁶ Retrospective Cohort	Yes	4.76	4.17-5.26
Gyamfi, 2004 ¹⁸ Retrospective Cohort	Spontaneous vaginal delivery	1.83	1.29-2.60
<i>Vaginal delivery before prior cesarean</i>			
Flamm, 1997 ¹¹ Prospective Cohort	Yes	1.53	1.12-2.10
Weinstein, 1996 ²⁷ Retrospective Cohort	Yes	1.8	1.1-3.1
<i>Vaginal delivery after prior cesarean</i>			
Flamm, 1997 ¹¹ Prospective Cohort	Yes	3.39	2.25-5.11
Macones, 2001 ³⁰ Case Control	Yes	7.69	3.23-20
Gonen, 2004 ¹⁷ Retrospective Cohort	Yes	7.20	2.10-24.80
Grobman, 2007 ¹² Prospective Cohort	Yes	2.73	2.21-3.36
Landon, 2005 ¹³ Prospective Cohort	No	1.0	referent
	Yes	4.76*	4.35-5.26
Bujold, 2004 ¹⁵ Retrospective Cohort	Yes	3.32	1.35-8.13
Gyamfi, 2004 ¹⁸ Retrospective Cohort	Yes	7.40	4.51-12.16

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-6. Past obstetric factor as predictors of vaginal birth after cesarean: prior deliveries

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
<i>Vaginal delivery after prior cesarean versus vaginal delivery before prior cesarean</i>			
Caughey, 1998 ³³ Retrospective Cohort	Yes	3.48	1.9-6.1
<i>Vaginal delivery before and vaginal delivery after prior cesarean</i>			
Flamm, 1997 ¹¹ Prospective Cohort	Yes	9.11	2.2-38.0

*Only provided univariate odds ratio

Abbreviations: CI=confidence interval; OR=odds ratio; RR=relative risk when odds ratio not reported; VBAC=vaginal birth after cesarean

In examining the indication for the prior cesarean delivery, the evidence suggested an association between a prior indication of breech and a VBAC (Table K-7). One retrospective study¹⁷ showed that a prior cesarean delivery due to malpresentation (breech) significantly increased likelihood of VBAC (adjusted odds ratio 7.4; 95% CI: 2.8 to 19.2, compared with an indication for failure to progress [FTP]) and a second retrospective study²⁷ suggested a relationship that was not statistically significant (adjusted odds ratio 1.0; 95% CI: 1.0 to 3.6 compared to a non-breech indication). Consistent with these findings, a third retrospective study²³ reported that women with a prior breech indication had the same risk of a RCD as a nulliparous woman's risk of a primary cesarean (risk of RCD odds ratio 0.95; 95% CI: 0.70 to 1.30).

This same study reported that women with a prior indication of FTP were four times (odds ratio 4.50; 95% CI: 3.60 to 5.50) as likely to have a RCD when compared with the risk of a nulliparous woman to have a primary cesarean.²³ This finding supports the trend shown in Table K-7 that a prior indication of FTP reduces the likelihood of a VBAC.^{11, 20, 27}

The evidence on prior indications for dystocia, FTP or for fetal concern was inconsistent in predicting VBAC.^{13, 15, 20, 25, 27} Cervical ripening with a Foley catheter was also reported in one study¹⁵ to reduce likelihood of VBAC (adjusted odds ratio 0.6; 95% CI: 0.40 to 0.89) compared with a fetal indication.

In considering other factors about the prior cesarean delivery, two studies found no relationship in the spacing of deliveries: less than 19 months³⁶ or less than 2 years¹³ compared to larger inter-delivery spacing. Compared with women who had an unknown scar, women with a LTCS had a reduced likelihood of VBAC (univariate odds ratio 0.71; 95% CI: 0.64 to 0.79).¹³ Finally, Women who delivered prior babies greater than 4,000 grams, were less likely to have a VBAC (adjusted odds ratio 0.52; 95% CI: 0.32 to 0.85).¹⁵

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-7. Past obstetric factor as predictors of vaginal birth after cesarean: prior indications

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
<i>Recurring versus nonrecurring</i>			
Weinstein, 1996 ²⁷ Retrospective Cohort	Referent: Nonrecurring	0.80	0.3-2.0
Grobman, 2007 ¹² Prospective Cohort	Referent: Nonrecurring indication for arrest in dilation or descent	0.53	0.48-0.60
Gyamfi, 2004 ¹⁸ Retrospective Cohort	Referent: Nonrecurring	0.42	0.31-0.57
<i>Mal-presentation (breech)</i>			
Weinstein, 1996 ²⁷ Retrospective Cohort	Yes	1.9	1.0-3.6
Gonen, 2004 ¹⁷ Retrospective Cohort	Referent: FTP	7.40	2.8-19.2
<i>Dystocia</i>			
Landon, 2005 ¹³ Retrospective Cohort	Referent: Breech	0.59	0.56-0.67
Bujold, 2004 ¹⁵ Retrospective Cohort	1st stage of labor Referent: fetal indication	0.5	0.34-0.74
Bujold, 2004 ¹⁵ Retrospective Cohort	2nd stage of labor Referent: fetal indication	0.97	0.50-1.88
<i>Cephalopelvic disproportion</i>			
Srinivas, 2007 ²⁶ Retrospective Cohort	Any CPD	0.69	0.63-0.77
<i>Failure to progress</i>			
Weinstein, 1996 ²⁷ Retrospective Cohort	FTP	0.81	0.3-2.0
Learman, 1996 ²⁰ Retrospective Cohort	FTP	0.83 (RR)	0.36-1.67
Flamm, 1997 ¹¹ Prospective Cohort	FTP	0.52	0.43-0.63
Spaans, 2002 Retrospective Study	FTE or suspected cephalic pelvic distortion	0.34	0.15-0.77
<i>Cervical ripening with foley catheter</i>			
Bujold, 2004 ¹⁵ Retrospective Cohort	Referent: fetal indication	0.60	0.40-0.89
<i>Fetal wellbeing</i>			
Landon, 2005 ¹³ Prospective Cohort	Non-reassuring fetal well-being Referent: Breech	0.51*	0.45-0.58

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-7. Past obstetric factor as predictors of vaginal birth after cesarean: prior indications

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
Weinstein, 1996 ²⁷ Retrospective Cohort	Fetal Distress	1.05	0.4-2.6

*Only univariate odds ratio provided

Abbreviations: CI=confidence interval; CPD=cephalopelvic disproportion; FTP=failure to progress; OR=odds ratio; RR=Relative Risk; VBAC=vaginal birth after cesarean

Pre-Existing and Current Obstetric Factors

Many pre-existing factors (maternal height, BMI, smoking and substance use, and maternal disease) greatly impact the likelihood of VBAC (Table K-8). In examining pre-existing factors, women with greater maternal height (for each 5 cm increase) had an increased likelihood of VBAC.²⁴ Increased BMI at the first prenatal visit (per BMI unit)¹² or an increased BMI at delivery (greater than 30) resulted in decreased likelihood of VBAC.¹³ Women who smoked or reported any substance abuse had an increased likelihood of VBAC but neither study adjusted for socioeconomic status.^{13, 30} However, in three of four cohort studies in Table K-8, women with a maternal disease (hypertension, diabetes, asthma, seizures, renal disease, thyroid disease, or collagen vascular disease) had a decreased likelihood of VBAC.^{13, 18, 26} By contrast, in a large prospective study by Grobman et al,¹² the presence of diabetes, asthma, chronic hypertension, renal disease or heart disease, was not significant in the study's multivariable logistic model.

Table K-8. Pre-existing maternal factors predicting vaginal birth after cesarean

Author, Year Study Design	Characteristic	Adjusted OR for VBAC	95% CI
<i>Maternal height</i>			
Smith, 2005 ²⁴ Retrospective Cohort	Per 5 cm increase	1.33	1.28-1.37
<i>BMI at first prenatal visit</i>			
Grobman, 2007 ¹² Prospective Cohort	Per BMI unit	0.94	0.93-0.95
<i>BMI at delivery</i>			
Landon, 2005 ¹³ Prospective Cohort	>30	0.55*	0.51-0.60
<i>Smoking</i>			
Landon, 2005 ¹³ Prospective Cohort	Smoker	1.15*	1.04-1.28
<i>Substance Abuse</i>			
Macones, 2001 ³⁰ Case Control	Yes	3.70	1.25-11.11
<i>Maternal disease</i>			
Srinivas, 2007 ²⁶ Retrospective Cohort	Chronic hypertension	0.70	0.56-0.86
Srinivas, 2007 ²⁶ Retrospective Cohort	Gestational diabetes	0.68	0.58-0.81
Grobman, 2007 ¹² Prospective Cohort	Diabetes	Not significant	Not significant
Gymafi, 2004 ¹⁸ Retrospective Cohort	Diabetes or gestational diabetes	0.42	0.28-0.62

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-8. Pre-existing maternal factors predicting vaginal birth after cesarean

Author, Year Study Design	Characteristic	Adjusted OR for VBAC	95% CI
Landon, 2005 ¹³ Prospective Cohort	Hypertension, diabetes, asthma, seizures, renal disease, thyroid disease, or collagen vascular disease.	0.83	0.71-0.71
Grobman, 2007 ¹²	Hypertension, cardiac disease, asthma, renal disease, or connective tissue disorder	Not reported	Not reported

*Only univariate odds ratio provided

Abbreviations: BMI=body mass index; CI=confidence interval; cm=centimeters; OR=odds ratio; VBAC=vaginal birth after cesarean

Many current obstetric factors related to the infant (GA, birth weight and infant gender) predicted VBAC or TOL followed by a cesarean delivery (Table K-9). Of these, the most consistent finding is that as infant weight increases the likelihood of VBAC decreases. Four of five studies reported that infants weighing more than 4 kilograms (kg) were less likely to be delivered vaginally.^{1, 13, 18, 27, 28} The oldest of these studies²⁷ found no relationship between a birth weight over 4,000 grams and likelihood of VBAC.

Table K-9. Current obstetric factors: infant gender, gestational age, and weight

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
<i>Gestational age</i>			
Srinivas, 2007 ²⁶ Retrospective Cohort	37-41 wk	1.00	Referent
	<32 wk	2.32	1.67-3.33
	32-37 wk	1.37	1.14-1.67
	>41 wk	1.25	1.10-1.41
Cameron, 2004 ¹ Retrospective Cohort	40 wk	1.00	Referent
	37 wk	0.43	0.34-0.54
	38 wk	0.51	0.44-0.60
	39 wk	0.74	0.65-0.85
Landon, 2005 ¹³ Prospective Cohort	37 0/7-40 6/7 wk/d	1.00	Referent
	>41 wk	0.61*	0.55-0.68
Smith, 2005 ²⁴ Retrospective Cohort	40 wk	1.00	Referent
	41 wk	0.77	0.7-0.85
	42 wk	0.72	0.62-0.85
Gonen, 2004 ¹⁷	≥41 wk	0.36	0.14-0.91
Learman, 1996 ²⁰ Retrospective Cohort	>41 wk	1.25 (*RR)	0.53-3.33
Quiñones, 2005 ²² Retrospective Cohort	33.9 wk	1.54	1.27-1.86
	39.2 wk	1.0	Referent
<i>Gestational age and labor</i>			
Zelop, 2001 ²⁸ Retrospective Cohort	>40wks spontaneous	0.67	0.56-0.83

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-9. Current obstetric factors: infant gender, gestational age, and weight

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
Zelop, 2001 ²⁸ Retrospective Cohort	>40wks induced	0.67	0.45-0.91
<i>Birth weight</i>			
Weinstein, 1996 ²⁷ Retrospective Cohort	>4000g	1.05	0.20-5.88
Zelop, 2001 ²⁸ Retrospective Cohort	>4000g	0.59	0.45-0.77
Gyamfi, 2004 ¹⁸ Retrospective Cohort	>4000g	0.49	0.30-0.78
Cameron, 2004 ¹ Retrospective Cohort	3000-3499g	1.0	Referent
	<2500g	0.66	0.45-0.97
	2500-2999g	0.93	0.78-1.10
	3500-3999g	0.75	0.66-0.85
Landon, 2005 ¹³ Prospective Cohort	>4000g	0.50	0.43-0.56
<i>Mean estimated fetal weight</i>			
Gonen, 2004 ¹⁷ Prospective Cohort	3360g ± 395	0.9	0.8-0.9
Learman, 1996 ²⁰ Retrospective Cohort	>3800g	0.53 (*RR)	0.24-1.11
<i>Sex of Infant</i>			
Smith, 2005 ²⁴ Retrospective Cohort	Female	1.18	1.08-1.28

*Only univariate odds ratio provided

Abbreviations: CI=confidence interval; d=day(s); g=gram(s); kg=kilogram(s); OR=odds ratio; RR=relative risk; VBAC=vaginal birth after cesarean; wk= week(s);

Obstetric factors related to the labor itself (dilation, effacement, station, Bishop score, cervix position) consistently predicted VBAC (Table K-10). Three prospective cohort studies,^{11, 13, 17} one retrospective study²⁰ and one case-control study³⁰ provided consistent evidence that women who were more dilated at admission or at rupture of membranes (ROM) were more likely to deliver vaginally. All three studies that examined effacement reported increased likelihood as effacement reached 75 to 100 percent.^{11, 17, 21} Similarly, all three studies that examined head position reported that as the baby's position was vertex, engaged or at a lower station, the likelihood of VBAC increased.^{14, 19, 20} Both studies that examined Bishop's score showed that as the score increased the likelihood of VBAC increased two¹⁵ to six times.²⁷

Table K-10. Current obstetric factors: cervical dilation, etc

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
<i>Cervical dilation at admission</i>			
Flamm, 1997 ¹¹ Prospective Cohort	>4cm	2.16	1.66-2.82
Landon, 2005 ¹³ Prospective Cohort	>4cm	2.56*	2.38-2.78

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-10. Current obstetric factors: cervical dilation, etc

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI
Macones, 2001 ³⁰ Case Control	Per cm increase	1.89	1.13-3.22
Gonen, 2004 ¹⁷ Prospective Cohort	>2cm	3.00	1.70-5.30
Learman, 1996 ²⁰ Retrospective Cohort	>2cm	1.69 (*RR)	0.80-3.45 RR
<i>Effacement</i>			
Flamm, 1997 ¹¹ Prospective Cohort	>75% Referent: <25%	2.72	2.00-3.71
Flamm, 1997 ¹¹ Prospective Cohort	25-75% Referent: <25%	1.79	1.31-2.44
McNally, 1999 ²¹ Retrospective Cohort	100%	5.0	1.28-19.2
<i>Head position and station</i>			
King, 1994 ¹⁹ Retrospective Cohort	Head in vertex position	7.69	5.26-12.5
Strong, 1996 ¹⁴ Prospective Cohort	Head engaged on admission	12.3	4.6-33.3
Learman, 1996 ²⁰ Retrospective Cohort	Lower than -3 cm	2.10 (*RR)	1.10-4.20 RR
<i>Bishop score</i>			
Weinstein, 1996 ²⁷ Retrospective Cohort	>4	6.00	3.5-10.4
Bujold, 2004 ¹⁵ Retrospective Cohort	>6: modified	2.07	1.28-3.35

*Only univariate odds ratio provided

Abbreviations: CI=confidence interval; cm=centimeters; OR=odds ratio; RR: relative risk; VBAC=vaginal birth after cesarean

Other obstetric factors related to interventions (augmentation, induction, or epidural use) were examined in predicting VBAC (Table K-11). Three studies consistently showed reduced likelihood of VBAC with augmentation.^{13, 17, 30} Two studies^{13, 20} showed that induction reduced the likelihood of VBAC and three more studies showed the same trend.^{17, 24, 25} One of these studies showed no effect when a non-prostaglandin was used but showed a reduced likelihood of VBAC if a prostaglandin was used.²⁴

The overall evidence suggests that epidurals reduced the likelihood of VBAC^{17, 21} but is not completely consistent with one study showing an increased likelihood of VBAC.¹³

Table K-11. Current obstetric factors: type of labor

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI or P value
<i>Augmentation</i>			
Macones, 2001 ³⁰ Case Control	Yes	0.47	0.25-0.88
Landon, 2005 ¹³ Prospective Cohort	Referent: Spontaneous	0.68*	0.62-0.75

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

Table K-11. Current obstetric factors: type of labor

Author, Year Study Design	Characteristic	Adjusted OR* or RR for VBAC	95% CI or P value
Gonen, 2004 ¹⁷ Prospective Cohort	Augmentation with oxytocin	0.29	0.16-0.53
Spaans, 2002 ²⁵ Retrospective Cohort	Yes	0.83	0.30-2.50
<i>Induction</i>			
Gonen, 2004 ¹⁷ Prospective Cohort	On admit Referent: in labor and ROM	0.6	0.3-1.5
Gonen, 2004 ¹⁷ Prospective Cohort	During labor	0.5	0.23-1.11
Landon, 2005 ¹³ Prospective Cohort	Referent: Spontaneous	0.5*	0.45-0.55
Learman, 1996 ²⁰ Retrospective Cohort	Yes	0.34 (*RR)	0.19-0.67 RR
Spaans, 2002 ²⁵ Retrospective Cohort	Yes	0.67	0.16-3.33
Smith, 2005 ²⁴ Retrospective Cohort	IOL: Non-prostaglandin Referent: Spontaneous	1.00	0.87-1.14
Smith, 2005 ²⁴ Retrospective Cohort	IOL: With prostaglandin Referent: Spontaneous	0.70	0.63-0.79
<i>Epidural use</i>			
McNally, 1999 ²¹ Retrospective Cohort	Yes	0.26	0.06-1.12
Landon, 2005 ¹³ Prospective cohort	Yes	2.70*	2.44-3.03
Gonen, 2004 ¹⁷ Prospective Cohort	Yes	0.17	0.09-0.35

*Only univariate odds ratio provided

Abbreviations: CI=confidence interval; IOL=induction of labor; OR=odds ratio; ROM=rupture of membranes; RR=relative risk; VBAC=vaginal birth after cesarean

Summary of Predictors of Vaginal Birth After Cesarean

With the exception of three studies,^{11, 12, 24} these prognostic studies of VBAC could be described as exploratory.³⁷ According to Simon and Altman, studies that report association and identify patients at risk but that have not yet had results confirmed in followup studies with pre-stated hypotheses, do not yet provide sufficient evidence to change clinical practice.³⁷ The three studies^{11, 12, 24} that provided this cross-validation evidence also proposed screening tools for VBAC and are discussed in detail in the section on Screening Tools for VBAC and in Appendix N.

Summary of Predictors

Hispanic and African American women were more likely to have a TOL but less likely to have a VBAC compared with non-Hispanic and white women, respectively. Women at rural and private hospitals had a decreased likelihood of TOL and a decreased likelihood of VBAC. A

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

prior history of vaginal delivery was consistently reported to increase likelihood of VBAC. Women delivering infants over 4 kg have a reduced likelihood of VBAC. Greater progress of labor--measured as greater dilation, lower station and higher Bishop score--predicts a higher likelihood of VBAC. The effect of epidural use on the likelihood of VBAC is uncertain.

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

References

1. Cameron CA, Roberts CL, Peat B. Predictors of labor and vaginal birth after cesarean section. *Int J Gynaecol Obstet.* 2004;85(3):267-269.
2. McMahon MJ, Luther ER, Bowes WA, Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section. *N Engl J Med.* 1996;335(10):689-695.
3. Pang MW, Law LW, Leung TY, Lai PY, La TK. Sociodemographic factors and pregnancy events associated with women who declined vaginal birth after cesarean section. *Eur J Obstet Gynecol Reprod Biol.* 2009;143(1):24-28.
4. Bujold E. Uterine rupture during a trial of labor after a one- versus two-layer closure of low transverse cesarean. *Am J Obstet Gynecol.* 2001;184(suppl)(S18).
5. Chang JJ, Stamilio DM, Macones GA. Effect of hospital volume on maternal outcomes in women with prior cesarean delivery undergoing trial of labor. *Am J Epidemiol.* 2008;167(6):711-718.
6. Harper LM, Cahill AG, Stamilio DM, Odibo AO, Peipert JF, Macones GA. Effect of gestational age at the prior cesarean delivery on maternal morbidity in subsequent VBAC attempt. *Am J Obstet Gynecol.* 2009;200(3):276.e271-276.
7. Hueston WJ, Rudy M. Factors predicting elective repeat cesarean delivery. *Obstet Gynecol.* 1994;83(5 Pt 1):741-744.
8. Selo-Ojeme D, Abulhassan N, Mandal R, Tirlapur S, Selo-Ojeme U. Preferred and actual delivery mode after a cesarean in London, UK. *Int J Gynaecol Obstet.* 2008;102(2):156-159.
9. Kabir AA, Pridjian G, Steinmann WC, Herrera EA, Khan MM. Racial differences in cesareans: an analysis of U.S. 2001 National Inpatient Sample Data. *Obstet Gynecol.* 2005;105(4):710-718.
10. Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. *Am J Obstet Gynecol.* 2005;193(5):1656-1662.
11. Flamm BL, Geiger AM. Vaginal birth after cesarean delivery: an admission scoring system. *Obstet Gynecol.* 1997;90(6):907-910.
12. Grobman WA, Lai Y, Landon MB, et al. Development of a nomogram for prediction of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2007;109(4):806-812.
13. Landon MB, Leindecker S, Spong CY, et al. The MFMU Cesarean Registry: factors affecting the success of trial of labor after previous cesarean delivery. *Am J Obstet Gynecol.* 2005;193(3 Pt 2):1016-1023.
14. Strong JM, McQuillan K. Factors affecting mode of delivery in labour following a single previous birth by cesarean. *Journal of Obs & Gyn.* 1996;16(5).
15. Bujold E, Blackwell SC, Hendler I, Berman S, Sorokin Y, Gauthier RJ. Modified Bishop's score and induction of labor in patients with a previous cesarean delivery. *Am J*

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

- Obstet Gynecol.* 2004;191(5):1644-1648.
16. Caughey AB, Shipp TD, Repke JT, Zelop CM, Cohen A, Lieberman E. Rate of uterine rupture during a trial of labor in women with one or two prior cesarean deliveries. *Am J Obstet Gynecol.* 1999;181(4):872-876.
 17. Gonen R, Tamir A, Degani S, Ohel G. Variables associated with successful vaginal birth after one cesarean section: a proposed vaginal birth after cesarean score. *Am J Perinatol.* 2004;21(8):447-453.
 18. Gyamfi C, Juhasz G, Gyamfi P, Stone JL. Increased success of trial of labor after previous vaginal birth after cesarean. *Obstet Gynecol.* 2004;104(4):715-719.
 19. King DE, Lahiri K. Socioeconomic factors and the odds of vaginal birth after cesarean delivery. *JAMA.* 1994;272(7):524-529.
 20. Learman LA, Evertson LR, Shiboski S. Predictors of repeat cesarean delivery after trial of labor: do any exist? *J Am Coll Surg.* 1996;182(3):257-262.
 21. McNally OM, Turner MJ. Induction of labour after 1 previous Caesarean section. *Aust N Z J Obstet Gynaecol.* 1999;39(4):425-429.
 22. Quinones JN, Stamilio DM, Pare E, Peipert JF, Stevens E, Macones GA. The effect of prematurity on vaginal birth after cesarean delivery: success and maternal morbidity. *Obstet Gynecol.* 2005;105(3):519-524.
 23. Shipp TD, Zelop CM, Repke JT, Cohen A, Caughey AB, Lieberman E. Labor after previous cesarean: influence of prior indication and parity. *Obstet Gynecol.* 2000;95(6 Pt 1):913-916.
 24. Smith GCS, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. *PLoS Med.* 2005;2(9):e252.
 25. Spaans WA, Sluijs MB, van Roosmalen J, Bleker OP. Risk factors at caesarean section and failure of subsequent trial of labour. *Eur J Obstet Gynecol Reprod Biol.* 2002;100(2):163-166.
 26. Srinivas SK, Stamilio DM, Stevens EJ, Odibo AO, Peipert JF, Macones GA. Predicting failure of a vaginal birth attempt after cesarean delivery. *Obstet Gynecol.* 2007;109(4):800-805.
 27. Weinstein D, Benshushan A, Tanos V, Zilberstein R, Rojansky N. Predictive score for vaginal birth after cesarean section. *Am J Obstet Gynecol.* 1996;174(1 Pt 1):192-198.
 28. Zelop CM, Shipp TD, Cohen A, Repke JT, Lieberman E. Trial of labor after 40 weeks' gestation in women with prior cesarean. *Obstet Gynecol.* 2001;97(3):391-393.
 29. Zelop CM, Shipp TD, Repke JT, Cohen A, Lieberman E. Outcomes of trial of labor following previous cesarean delivery among women with fetuses weighing >4000 g. *Am J Obstet Gynecol.* 2001;185(4):903-905.
 30. Macones GA, Hausman N, Edelstein R, Stamilio DM, Marder SJ. Predicting outcomes of trials of labor in women attempting vaginal birth

Appendix K. Detailed Evaluation of Predictors of Trial of Labor and Vaginal Birth After Cesarean, continued

- after cesarean delivery: a comparison of multivariate methods with neural networks. *Am J Obstet Gynecol.* 2001;184(3):409-413.
31. Eden KB, Hashima JN, Osterweil P, Nygren P, Guise J-M. Childbirth preferences after cesarean birth: a review of the evidence. *Birth.* 2004;31(1):49-60.
32. McClain CS. The making of a medical tradition: vaginal birth after cesarean. *Soc Sci Med.* 1990;31(2):203-210.
33. Caughey AB, Shipp TD, Repke JT, Zelop C, Cohen A, Lieberman E. Trial of labor after cesarean delivery: the effect of previous vaginal delivery. *Am J Obstet Gynecol.* 1998;179(4):938-941.
34. Elkousy MA, Sammel M, Stevens E, Peipert JF, Macones G. The effect of birth weight on vaginal birth after cesarean delivery success rates. *Am J Obstet Gynecol.* 2003;188(3):824-830.
35. Mercer BM, Gilbert S, Landon MB, et al. Labor outcomes with increasing number of prior vaginal births after cesarean delivery. *Obstet Gynecol.* 2008;111(2 Pt 1):285-291.
36. Huang WH, Nakashima DK, Rumney PJ, Keegan KA, Jr., Chan K. Interdelivery interval and the success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2002;99(1):41-44.
37. Simon R, Altman D. Statistical aspects of prognostic factor studies in oncology. *Br J Cancer.* 1994;69:979-985.

Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates

Introduction


A brief description on the vaginal birth after cesarean (VBAC) rate is included in the text of the evidence report. Detailed descriptions of the studies and analyses conducted on this topic are included in this appendix.

Vaginal Birth After Cesarean

Sixty-seven studies, 14 fair quality prospective cohort studies¹⁻¹⁴ and 53 retrospective cohort studies¹⁵⁻⁶⁷ provided an overall summary estimate for VBAC of 74 percent (95 percent CI: 72 to 75 percent). The heterogeneity of this meta-analysis of 67 observational studies that included 368,304 women was high, I^2 greater than 98 percent. To examine this heterogeneity, these studies were stratified and analyzed by study design (prospective versus retrospective; true cohort that included trial of labor (TOL) and elective repeat cesarean delivery (ERCD) versus studies of TOL only), country (United States [U.S.] versus non-U.S.), gestational age ([GA] term only versus all GAs) and by years when the data were collected (completed before 1996, during 1996, and started after 1996). None of these factors were found to result in statistically significant differences analysis of study design yielded a statistically significant association ($p < 0.05$). The summary estimate for VBAC for 14 prospective studies was 73 percent (95 percent CI: 71 to 74 percent) compared with 77 percent (95 percent CI: 75 to 79 percent) for the 53 retrospective studies. The VBAC rate did not differ between studies that included both TOL and ERCD groups and those that focused exclusively on TOL (73 percent; 95 percent CI: 71 to 75 percent versus 74 percent; 95 percent CI 71 to 77 percent). Similarly when studies were stratified by country (U.S. versus Non-U.S.) and by GA at enrollment (term versus non-term studies), no clear associations emerged (Figures L-1 and L-2). The summary estimates for rates of VBAC were similar: for the 43 studies conducted in the U.S., 74 percent (95 percent CI: 72 to 76 percent) versus 73 percent (95 percent CI: 71 to 74 percent) for the 24 studies conducted outside the U.S.. In examining the GA for enrolled patients, the summary estimates for rates of VBAC were again similar: for the 18 studies of term deliveries, 73 percent (95 percent CI: 71 to 75 percent) versus 74 percent (95 percent CI: 72 to 76 percent) for the 49 studies that included preterm and term deliveries.


Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued

Figure L-1. Vaginal birth after cesarean rates in United States studies



Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued

Figure L-2. Vaginal birth after cesarean rates in studies conducted outside the United States



Finally, when the studies were stratified by years of data collection, the summary estimates of VBAC again remained similar: 73 percent (95 percent CI: 70 to 77 percent) for the 31 studies completed before 1996;^{1, 2, 5, 8-14, 16, 26, 27, 30, 36-38, 43, 47-50, 53-55, 59, 61, 63, 65, 67, 68}; 74 percent (95 percent CI: 72 to 76 percent) for the 19 studies that included data collection during 1996^{3, 19, 22-25, 32-34, 42, 44-46, 52, 57, 58, 60, 62, 64} and 73 percent (95 percent CI: 70 to 75 percent) for the 17 studies started after 1996.^{4, 6, 7, 15, 17, 18, 20, 21, 28, 29, 31, 35, 39, 41, 51, 56, 66}

Summary of vaginal Birth After Cesarean Rate

The rates of VBAC are highly variable in these studies. Most evidence of VBAC rates are from studies based in large tertiary care centers. While TOL rates have dropped over time, VBAC rates reported in observational studies have remained constant for the women who have a TOL. In studies based in the U.S., 74 percent of women who had a TOL delivered vaginally.

Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued

References

1. Bais JM, van der Borden DM, Pel M, et al. Vaginal birth after caesarean section in a population with a low overall caesarean section rate. *Eur J Obstet Gynecol Reprod Biol.* 2001;96(2):158-162.
2. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol.* 1994;83(6):927-932.
3. Hendler I, Bujold E. Effect of prior vaginal delivery or prior vaginal birth after cesarean delivery on obstetric outcomes in women undergoing trial of labor. *Obstet Gynecol.* 2004;104(2):273-277.
4. Hibbard JU, Gilbert S, Landon MB, et al. Trial of labor or repeat cesarean delivery in women with morbid obesity and previous cesarean delivery. *Obstet Gynecol.* 2006;108(1):125-133.
5. Hook B, Kiwi R, Amini SB, Fanaroff A, Hack M. Neonatal morbidity after elective repeat cesarean section and trial of labor. *Pediatrics.* 1997;100(3 Pt 1):348-353.
6. Jakobi P, Weissman A, Peretz BA, Hocherman I. Evaluation of prognostic factors for vaginal delivery after cesarean section. *J Reprod Med.* 1993;38(9):729-733.
7. Landon MB, Spong CY, Thom E, et al. Risk of uterine rupture with a trial of labor in women with multiple and single prior cesarean delivery. *Obstet Gynecol.* 2006;108(1):12-20.
8. Lieberman E, Ernst EK, Rooks JP, Stapleton S, Flamm B. Results of the national study of vaginal birth after cesarean in birth centers. *Obstet Gynecol.* 2004;104(5 Pt 1):933-942.
9. Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after cesarean. *Am J Obstet Gynecol.* 1987;157(6):1510-1515.
10. Rozenberg P, Goffinet F, Philippe HJ, Nisand I. Thickness of the lower uterine segment: its influence in the management of patients with previous cesarean sections. *Eur J Obstet Gynecol Reprod Biol.* 1999;87(1):39-45.
11. Rozenberg P, Goffinet F, Phillippe HJ, Nisand I. Ultrasonographic measurement of lower uterine segment to assess risk of defects of scarred uterus. *Lancet.* 1996;347(8997):281-284.
12. Stovall TG, Shaver DC, Solomon SK, Anderson GD. Trial of labor in previous cesarean section patients, excluding classical cesarean sections. *Obstet Gynecol.* 1987;70(5):713-717.
13. Strong JM, McQuillan K. Factors affecting mode of delivery in labour following a single previous birth by cesarean. *Journal of Obs & Gyn.* 1996;16(5).
14. van Gelderen CJ, England MJ, Naylor GA, Katzeff TC. Labour in patients with a caesarean section scar. The place of oxytocin augmentation. *Samj, S.* 1986;70(9):529-532.
15. Cameron CA, Roberts CL, Peat B. Predictors of labor and vaginal birth

Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued

- after cesarean section. *Int J Gynaecol Obstet.* 2004;85(3):267-269.
16. Caughey AB, Shipp TD, Repke JT, Zelop CM, Cohen A, Lieberman E. Rate of uterine rupture during a trial of labor in women with one or two prior cesarean deliveries. *Am J Obstet Gynecol.* 1999;181(4):872-876.
 17. Costantine MM, Fox K, Byers BD, et al. Validation of the prediction model for success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2009;114(5):1029-1033.
 18. DeFranco EA, Rampersad R, Atkins KL, et al. Do vaginal birth after cesarean outcomes differ based on hospital setting? *Am J Obstet Gynecol.* 2007;197(4):400.e401-406.
 19. Delaney T, Young DC. Spontaneous versus induced labor after a previous cesarean delivery. *Obstet Gynecol.* 2003;102(1):39-44.
 20. DiMaio H, Edwards RK, Euliano TY, Treloar RW, Cruz AC. Vaginal birth after cesarean delivery: an historic cohort cost analysis. *Am J Obstet Gynecol.* 2002;186(5):890-892.
 21. Dinsmoor MJ, Brock EL. Predicting failed trial of labor after primary cesarean delivery. *Obstet Gynecol.* 2004;103(2):282-286.
 22. Durnwald C, Mercer B. Vaginal birth after Cesarean delivery: predicting success, risks of failure. *J Matern Fetal Neonatal Med.* 2004;15(6):388-393.
 23. Durnwald CP, Ehrenberg HM, Mercer BM. The impact of maternal obesity and weight gain on vaginal birth after cesarean section success. *Am J Obstet Gynecol.* 2004;191(3):954-957.
 24. Elkousy MA, Sammel M, Stevens E, Peipert JF, Macones G. The effect of birth weight on vaginal birth after cesarean delivery success rates. *Am J Obstet Gynecol.* 2003;188(3):824-830.
 25. El-Sayed YY, Watkins MM, Fix M, Druzin ML, Pullen KM, Caughey AB. Perinatal outcomes after successful and failed trials of labor after cesarean delivery. *Am J Obstet Gynecol.* 2007;196(6):583.e581-585; discussion 583.e585.
 26. Fisler RE, Cohen A, Ringer SA, Lieberman E. Neonatal outcome after trial of labor compared with elective repeat cesarean section. *Birth.* 2003;30(2):83-88.
 27. Flamm BL, Goings JR, Fuelberth NJ, Fischermann E, Jones C, Hersh E. Oxytocin during labor after previous cesarean section: results of a multicenter study. *Obstet Gynecol.* 1987;70(5):709-712.
 28. Gonen R, Nisenblat V, Barak S, Tamir A, Ohel G. Results of a well-defined protocol for a trial of labor after prior cesarean delivery. *Obstet Gynecol.* 2006;107(2 Pt 1):240-245.
 29. Goodall PT, Ahn JT, Chapa JB, Hibbard JU. Obesity as a risk factor for failed trial of labor in patients with previous cesarean delivery. *Am J Obstet Gynecol.* 2005;192(5):1423-1426.
 30. Gregory KD, Korst LM, Cane P, Platt LD, Kahn K. Vaginal birth after cesarean and uterine rupture rates in

Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued

- California. *Obstet Gynecol.* 1999;94(6):985-989.
31. Gregory KD, Korst LM, Fridman M, et al. Vaginal birth after cesarean: clinical risk factors associated with adverse outcome. *Am J Obstet Gynecol.* 2008;198(4):452.e451-410; discussion 452.e410-452.
 32. Gyamfi C, Juhasz G, Gyamfi P, Stone JL. Increased success of trial of labor after previous vaginal birth after cesarean. *Obstet Gynecol.* 2004;104(4):715-719.
 33. Hammoud A, Hendler I, Gauthier RJ, Berman S, Sansregret A, Bujold E. The effect of gestational age on trial of labor after Cesarean section. *J Matern Fetal Neonatal Med.* 2004;15(3):202-206.
 34. Hashima JN, Guise J-M. Vaginal birth after cesarean: a prenatal scoring tool. *Am J Obstet Gynecol.* 2007;196(5):e22-23.
 35. Hollard AL, Wing DA, Chung JH, et al. Ethnic disparity in the success of vaginal birth after cesarean delivery. *J Matern Fetal Neonatal Med.* 2006;19(8):483-487.
 36. Horenstein JM, Eglinton GS, Tahilramaney MP, Boucher M, Phelan JP. Oxytocin use during a trial of labor in patients with previous cesarean section. *J Reprod Med.* 1984;29(1):26-30.
 37. Horenstein JM, Phelan JP. Previous cesarean section: the risks and benefits of oxytocin usage in a trial of labor. *Am J Obstet Gynecol.* 1985;151(5):564-569.
 38. Hoskins IA, Gomez JL. Correlation between maximum cervical dilatation at cesarean delivery and subsequent vaginal birth after cesarean delivery. *Obstet Gynecol.* 1997;89(4):591-593.
 39. Huang WH, Nakashima DK, Rumney PJ, Keegan KA, Jr., Chan K. Interdelivery interval and the success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2002;99(1):41-44.
 40. Johnson C, Oriol N, Flood K. Trial of labor: a study of 110 patients. *J Clin Anesth.* 1991;3(3):216-218; discussion 214-215.
 41. Juhasz G, Gyamfi C, Gyamfi P, Tocce K, Stone JL. Effect of body mass index and excessive weight gain on success of vaginal birth after cesarean delivery. *Obstet Gynecol.* 2005;106(4):741-746.
 42. Kugler E, Shoham-Vardi I, Burstien E, Mazor M, Hershkovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. *Arch Gynecol Obstet.* 2008;277(4):339-344.
 43. Learman LA, Evertson LR, Shiboski S. Predictors of repeat cesarean delivery after trial of labor: do any exist? *J Am Coll Surg.* 1996;182(3):257-262.
 44. Locatelli A, Regalia AL, Ghidini A, Ciriello E, Biffi A, Pezzullo JC. Risks of induction of labour in women with a uterine scar from previous low transverse caesarean section. *BJOG.* 2004;111(12):1394-1399.
 45. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal

Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued


- morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
46. Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. *Am J Obstet Gynecol.* 2005;193(5):1656-1662.
47. McMahon MJ, Luther ER, Bowes WA, Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section. *N Engl J Med.* 1996;335(10):689-695.
48. Nguyen TV, Dinh TV, Suresh MS, Kinch RA, Anderson GD. Vaginal birth after cesarean section at the University of Texas. *J Reprod Med.* 1992;37(10):880-882.
49. Obara H, Minakami H, Koike T, Takamizawa S, Matsubara S, Sato I. Vaginal birth after cesarean delivery: results in 310 pregnancies. *J Obstet Gynaecol Res.* 1998;24(2):129-134.
50. Ouzounian JG, Miller DA, Paul RH. Amnioinfusion in women with previous cesarean births: a preliminary report. *Am J Obstet Gynecol.* 1996;174(2):783-786.
51. Pang MW, Law LW, Leung TY, Lai PY, La TK. Sociodemographic factors and pregnancy events associated with women who declined vaginal birth after cesarean section. *Eur J Obstet Gynecol Reprod Biol.* 2009;143(1):24-28.
52. Pathadey SD, Van Woerden HC, Jenkinson SD. Induction of labour after a previous caesarean section: a retrospective study in a district general hospital. *J Obstet Gynaecol.* 2005;25(7):662-665.
53. Pickhardt MG, Martin JN, Jr., Meydrech EF, et al. Vaginal birth after cesarean delivery: are there useful and valid predictors of success or failure? *Am J Obstet Gynecol.* 1992;166(6 Pt 1):1811-1815; discussion 1815-1819.
54. Raynor BD. The experience with vaginal birth after cesarean delivery in a small rural community practice. *Am J Obstet Gynecol.* 1993;168(1 Pt 1):60-62.
55. Sakala EP, Kaye S, Murray RD, Munson LJ. Oxytocin use after previous cesarean: why a higher rate of failed labor trial? *Obstet Gynecol.* 1990;75(3 Pt 1):356-359.
56. Selo-Ojeme D, Abulhassan N, Mandal R, Tirlapur S, Selo-Ojeme U. Preferred and actual delivery mode after a cesarean in London, UK. *Int J Gynaecol Obstet.* 2008;102(2):156-159.
57. Smith GCS, Pell JP, Cameron AD, Dobbie R. Risk of perinatal death associated with labor after previous cesarean delivery in uncomplicated term pregnancies. *JAMA.* 2002;287(20):2684-2690.
58. Smith GCS, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. *PLoS Med.* 2005;2(9):e252.
59. Socol ML, Peaceman AM. Vaginal birth after cesarean: an appraisal of

Appendix L. Detailed Evaluation of Vaginal Birth After Cesarean Rates, continued

- fetal risk. *Obstet Gynecol.* 1999;93(5 Pt 1):674-679.
60. Spaans WA, Sluijs MB, van Roosmalen J, Bleker OP. Risk factors at caesarean section and failure of subsequent trial of labour. *Eur J Obstet Gynecol Reprod Biol.* 2002;100(2):163-166.
61. Troyer LR, Parisi VM. Obstetric parameters affecting success in a trial of labor: designation of a scoring system. *Am J Obstet Gynecol.* 1992;167(4 Pt 1):1099-1104.
62. Vinueza CA, Chauhan SP, Barker L, Hendrix NW, Scardo JA. Predicting the success of a trial of labor with a simple scoring system. *J Reprod Med.* 2000;45(4):332-336.
63. Weinstein D, Benshushan A, Tanos V, Zilberstein R, Rojansky N. Predictive score for vaginal birth after cesarean section. *Am J Obstet Gynecol.* 1996;174(1 Pt 1):192-198.
64. Wen SW, Rusen ID, Walker M, et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(4):1263-1269.
65. Yetman TJ, Nolan TE. Vaginal birth after cesarean section: a reappraisal of risk. *Am J Obstet Gynecol.* 1989;161(5):1119-1123.
66. Yogev Y, Ben-Haroush A, Lahav E, Horowitz E, Hod M, Kaplan B. Induction of labor with prostaglandin E2 in women with previous cesarean section and unfavorable cervix. *Eur J Obstet Gynecol Reprod Biol.* 2004;116(2):173-176.
67. Zelop CM, Shipp TD, Cohen A, Repke JT, Lieberman E. Trial of labor after 40 weeks' gestation in women with prior cesarean. *Obstet Gynecol.* 2001;97(3):391-393.
68. Johnson KC, Gaskin IM. Vaginal delivery after cesarean section. Safety of single-layer suturing in caesarean sections must be proved. *BMJ.* 2001;323(7324):1307-1308.

Appendix M. Induction of Labor Additional Figures


Figure M-1. Proportion with vaginal birth after cesarean and any method of induction of labor



Abbreviations: NaN=Not a number; VBAC=vaginal birth after cesarean

Appendix M. Induction of Labor Additional Figures, continued


Figure M-2. Proportion with vaginal birth after cesarean after induction of labor with prostaglandin E₂



Abbreviations: N=total number; VRAC= vaginal birth after cesarean.

Appendix M. Induction of Labor Additional Figures, continued

Figure M-3. Vaginal birth after cesarean rates with oxytocin augmentation



Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean

Introduction

A brief description on the screening tools for predicting vaginal birth after cesarean (VBAC) is included in the text of the evidence report. Detailed description of the studies and analyses conducted on this topic is included in this appendix.

Screening Tools for Predicting Vaginal Birth After Cesarean

The purpose of a screening tool is to help providers and patients to better identify who will have a VBAC (and who is more likely to have a repeat cesarean delivery [RCD]). Two prospective cohort studies,^{1,2} ten retrospective cohort studies³⁻¹² and two case-control studies^{13, 14} that presented screening tools were identified. All included studies were either good or fair quality (Table N-1). These studies combined individual factors to predict the likelihood of VBAC (or cesarean delivery) when certain thresholds were reached. Predictive variables (historic, intrapartum or perinatal) of delivery route were first identified by univariate analyses. Significant variables ($p \leq 0.05$) were included in multiple logistic regression models and/or scored models.

In the strongest studies, the resulting models or scoring systems were then evaluated with a separate validation data set.¹⁵ Three of the scored models presented at the top of Table N-1 had one or more external validation studies (shaded) that tested the models with independent cohort data sets. The scored model by Flamm et al¹ was externally validated by one retrospective cohort study.⁵ The scored model by Grobman et al² was externally evaluated with a retrospective study.⁴ The Troyer model was externally validated by two retrospective studies.^{5, 11} In all validation studies, the scored model's performance was similar to the originally reported performance. In a retrospective cohort study that evaluated three scored models using the same data set,^{1, 10, 16} Dinsmoor et al reported that all three models were accurate at predicting which women would have a VBAC but were not accurate at predicting who would have a RCD after a TOL. Using the three models, 50 percent of women with unfavorable risk factors (in these three models) had vaginal deliveries suggesting that other factors may be needed to identify women at risk for cesarean. A previous decision analysis of VBAC¹⁷ suggested that a scored model would be most useful clinically if it achieved a sensitivity and specificity over 85 percent⁵ which none of these tools achieved.

In four studies, a cross-validation approach was taken.^{1, 2, 7, 9} The data in these studies were randomly divided to create a score development group and a validation group. In a multi-center prospective cohort study by Flamm,¹ 48 percent of women were assigned VBAC estimates either below 60 percent or greater than 80 percent suggesting that almost half of the women gained new information after the screening. After being screened by the tool that included maternal age, prior vaginal delivery history, prior cesarean delivery indication, cervical effacement and dilation, 18 percent of women in the validation group had a less than 60 percent likelihood of VBAC which might discourage some of these women from attempting a TOL. Thirty percent of the women in the validation group had an estimated 87% likelihood of VBAC, which might prove to encourage more of these women to attempt a TOL.

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

Table N-1. Screening tools for predicting vaginal birth after cesarean

Author/Year	Design Years Population	TOL/ Eligible	Score development	Predictors included (point values if provided)	Performance
Flamm, 1997 ¹⁸	Prospective cohort 1990-1992 Prior LTCS All GA	5003/ 5022	Half of the population for score development and the other for score validating. Logistic modeling of significant variables at the univariate level. Scores based on beta coefficients.	Age <40 years: 2 pts, prior vaginal delivery (prior to CD: 1pt, VBAC: 2 pts, both: 4 pts), prior cesarean indication (other than FTP: 1 pt), cervical effacement (25-75%: 1 pt, >75%: 2 pt), cervical dilation (>4cm at admission: 1pt) <u>to predict VBAC.</u>	In validation set <u>Score % with VD</u> 0 to 2 49.1 3 59.9 4 66.7 5 77.0 6 88.6 7 92.6 8 to 10 94.9
Dinsmoor, 2004 ⁵	Retrospective Cohort 1998 Prior CD All GA	153/153	Applied Flamm scored model (validation study)	Age <40 years: 2 pts, prior vaginal delivery (prior to CD: 1pt, VBAC: 2 pts, both: 4 pts), prior cesarean indication (other than FTP: 1 pt), cervical effacement (25-75%: 1 pt, >75%: 2 pt), cervical dilation (>4cm at admission: 1pt) <u>to predict VBAC.</u>	<u>Score % with VD</u> ≥7 100 <4 56
Grobman, 2007 ¹⁹	Prospective cohort 1999-2002 1 LTCS Term	11,856/ 11,856	Half of the population randomly selected for score development and the other for score validating. Logistic modeling of significant variables at the univariate level. Scores based on beta coefficients.	Maternal age, pre-pregnancy BMI, prior VD, prior VBAC, recurring indication for CD <u>to predict VBAC.</u>	In validation set, AUROC 75.0%
Costantine, 2009 ⁴	Retrospective 2002-2007 Prior CD GA > 36 wks	502/502	Applied Grobman 2007 scored model (validation study)	Maternal age, pre-preg BMI, prior VD, prior VBAC, recurring indication for CD <u>to predict VBAC.</u>	Correctly predicted 78% of women who had a VBAC and 60% of women who did not. AUROC 78%
Troyer, 1992 ¹⁰ Term	Retro cohort 1990-1991 Prior LTCS GA > 36 wks Vertex	264/567	Univariate analysis identified variables significantly associated with trial of labor outcome. One-point per variable.	Previous dysfunctional labor, no prior vaginal delivery, non-reassuring FHT at admission, induction (1 pt each) <u>to predict VBAC.</u>	Score % with VD 0 91.5 1 73.9 2 66.7 3-4 46.1

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

Table N-1. Screening tools for predicting vaginal birth after cesarean

Author/Year	Design Years Population	TOL/ Eligible	Score development	Predictors included (point values if provided)	Performance
Dinsmoor, 2004 ⁵	Retrospective Cohort 1998 Prior CD All GA	153/153	Applied Troyer scored model (validation study)	Previous dysfunctional labor, no prior vaginal delivery, non-reassuring FHT at admission, induction (1 pt each) <u>to predict VBAC.</u>	<u>Score % with VD</u> 0 97 3 56
Vinueza, 2000 ¹¹	Retro cohort 1992-1997 Prior LTCS All GA	236/236	Applied Troyer screening tool (validation study).	Previous dysfunctional labor, no prior vaginal delivery, non-reassuring FHT at admission, induction (1 pt each) <u>to predict VBAC.</u>	Score % with VD 0 98 1 69 2 40 3-4 33
Weinstein, 1996 ¹² Israel	Retro cohort 1981-1990 1 prior CD All GA	471/572	Logistic regression analysis to obtain weighted scores based on odds ratios.	Bishop score (≥ 4 : 4 pts), vaginal delivery before cesarean: 2 pts), prior cesarean indication (multiple grades ranging in values of 3-6 pts) <u>to predict VBAC.</u>	Score % with VD ≥ 4 58 ≥ 6 67 ≥ 8 78 ≥ 10 85 ≥ 12 88 For ≥ 10 points, Sens:85.6% / Spec:67.7% Accuracy: 80%
Jakobi, 1993 ⁸ Israel	Retro cohort Years NR 1 prior CD No oxytocin All GA	261/261	Univariate analysis coupled with multivariate analysis and discriminant analysis.	Prior breech, prior VBAC, station, admission without ROM, dilation at admission, prior failure to progress <u>to predict VBAC.</u>	PV for VBAC: 94.5% PV for CD: 33.3% Accuracy: 68%
Gonen, 2004 ⁶ Israel	Retro cohort 2000 1 LTCS All GA	339/475	Univariate analysis coupled with logistic regression analysis.	Indication of first CD (0-3 pts), previous VBAC (3 pts), dilation ≥ 2 cm (2 pts), gestation (≤ 41 wks, 2 pts) <u>to predict VBAC.</u>	Score % with VD 0-2 42 3-6 81 7-10 98 PV for score > 2 for VBAC: 88.2%; PV for CD: 58.1% Accuracy: 84.3%

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

Table N-1. Screening tools for predicting vaginal birth after cesarean

Author/Year	Design Years Population	TOL/ Eligible	Score development	Predictors included (point values if provided)	Performance
Hashima, 2007 ⁷	Retro cohort, 180-2002 1 LTCS Term	10, 828/ 10,828	Half of the population randomly selected for score development and the other for score validating. Logistic modeling of significant variables at the univariate level. Scores based on beta coefficients.	Non-recurrent prior CD indication, no history of macrosomic, no maternal anemia <u>to predict VBAC.</u>	In validation set <u>Score % with VD</u> 0 25.0 1 48.5 2 52.9 3 66.9
Smith, 2005 ⁹	Retro cohort 1985-2001 1 LTCS Term 40-42 wks	23,286/ 23,286	Half of the population randomly selected for score development and the other for score validating. Logistic modeling of significant variables at the univariate level. Scores based on beta coefficients.	Maternal age, prior vaginal delivery, GA (40, 41, 42), induction method, gender of infant to convert prior odds to <u>posterior odds of CD.</u>	In validation group, 36% of women predicted to be low risk for CD (<20% risk); Spec: 89.1%. 16.5% of women predicted to be high risk for CD (>40% risk); Sens: 47.7%, Spec: 89.1%. AUROC: 70.8%. When model applied to GA 37-39 weeks, AUROC: 69.2%
Bujold, 2004 ³	Retro cohort, 1988-2002 Induction after prior LTCS > 24 wks	685/685	Logistic modeling of significant variables at the univariate level. Scores based on beta coefficients.	Bishops score. Cervical dialation (0-6 points); effacement (0-3 points); fetal station (0-3 points) <u>to predict VBAC.</u>	Score % with VD 0-2 57.8 3-5 64.5 6-8 82.5 9-11 97.0
Macones, 2001 ¹³	Case Control 1994-1998 Prior CD all GA	400/400	Cases: TOL-CD Controls: VBAC Univariate analysis coupled with multivariate modeling.	History of substance abuse, prior VBAC, admission cervical dilation, need for labor augmentation <u>to predict CD.</u>	Sens:77% / Spec:65% AUROC: 77%
Pickhardt, 1992 ¹⁴	Case control 1989 Prior CD all GA	312/336	Cases: TOL-CD Controls: VBAC Univariate analysis coupled with stepwise regression, resulting in two different models.	Equation 1: EFW, number of prior cesarean <u>to predict CD.</u> Equation 2: number of prior cesarean, cervical dilation, estimated GA <u>to predict CD.</u>	Equation 1: Sens:60.4% / Spec:66% Accuracy: 63.4% Equation 2: Sens:38% / Spec:88% Accuracy: 71.9%

Abbreviations: AUROC=area under the Receiver Operating Characteristic curve; CD=cesarean delivery; FHT=fetal heart tones; GA=gestational age; LTCS=low transverse cesarean scar; VBAC=vaginal birth after cesarean section; VD=vaginal delivery; wks=weeks

NOTE: Shaded rows are validation studies of a scored model presented above them.

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

In a retrospective study designed to predict risk of cesarean delivery for women at 40 to 42 weeks gestational age (GA),⁹ 16.5 percent of women were assigned estimates of cesarean greater than 40 percent based on a screening tool that included maternal age, GA, induction method and gender of the infant. In the same study, 36 percent of women were assigned estimates of cesarean less than 20 percent, again suggesting that more than half of women gained knowledge after being screened.

The remaining two cross-validated studies^{2,7} evaluated tools based on factors that are known before labor begins in women who delivered at term. In a retrospective study of a statewide population database, women in this study with any of the following—recurrent cesarean delivery indication, history of a macrosomic infant, or current anemia—had a likelihood of VBAC of less than 55 percent. In the prospective cohort study,² women were screened based on maternal age, pre-pregnancy BMI, race, ethnicity, prior vaginal delivery history, and recurring indication for cesarean delivery. These factors were then used to create a graphical nomogram. This nomogram not only provided a point estimate for VBAC but also 95 percent confidence interval around the estimate. The authors present four case studies using the nomogram (two in which the women are assigned estimates in the expected range of 60 to 80 percent; and two in which the estimates are outside the quoted range). In one case, a 25 year-old African American woman of pre-pregnancy body mass index (BMI) of 25, with a prior vaginal delivery and a prior VBAC, was assigned an estimate of VBAC of 92.4 percent (95% CI: 91.1 to 93.6 percent). In a second case, a 35 year-old white woman with a pre-pregnancy BMI of 30, with no prior vaginal delivery and a recurring cesarean indication received an estimate of 49 percent (95% CI: 46.1 to 51.9 percent).

In evaluating the performance of screening tools, the studies report inconsistent accuracy for predicting overall delivery route (Gonen, 2004: 84.3 percent;⁶ Weinstein, 1996: 80 percent;¹² Macones, 2001: 71.9 percent;¹³ Jakobi, 1993: 68 percent⁸). It is important to note in looking at Table N-1, that most studies are designed to predict VBAC. The ability of these tools to identify women best suited for VBAC is noted by sensitivity levels¹² and positive predictive values.^{6,8} The only study to report sensitivity, the proportion of women who delivered vaginally who were correctly categorized to deliver vaginally, achieved a sensitivity of 85.5 percent.¹² Two studies reported high positive predictive values for VBAC (Jakobi, 1993: 94.5 percent⁸ and Gonen, 2004: 88.2 percent⁶), meaning that about 90 percent of women predicted to have a vaginal birth from the tools actually had a vaginal birth. These same studies were not as accurate at predicting cesarean delivery with predictive values (for cesarean) ranging from 33.3 percent⁸ to 58.1 percent.⁶

Other studies are modeled to predict cesarean delivery (RCD after a TOL).^{9,13,14} In these studies high levels of specificity mean the model is reasonable at estimating the proportion of women who had a VBAC who were identified to have a VBAC.^{9,13,14} Specificity across these studies ranged from 65 percent¹³ to 89 percent.⁹ These studies had inconsistent ability to identify women at risk for cesarean as shown by sensitivity levels ranging from 38¹⁴ to 77 percent.¹³

Three of the studies evaluated the screening tool performance by examining the area under the Receiver Operating Characteristic curve (AUROC).^{2,9,13} This curve is a plot of the true-positive rate (sensitivity) against the false-positive rate (1-specificity). Screening tools with more area under the ROC are considered better tests. The AUROC ranged from 69⁹ to 77 percent.¹³

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

Summary of Screening Tools to Predict Vaginal Birth After Cesarean

Since the last VBAC report,²⁰ five new scored models have been created and evaluated to identify women for VBAC (or for RCD).^{2, 3, 6, 7, 9} Two of the studies created scored tools that can be used the prenatal setting.^{2, 7} All scored models provide reasonable ability to identify women who are good candidates for VBAC but none have discriminating ability to consistently identify women who are at risk for cesarean.

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

References

1. Flamm BL, Geiger AM. Vaginal birth after cesarean delivery: an admission scoring system. *Obstetrics & Gynecology*. 1997;90(6):907-910.
2. Grobman WA, Lai Y, Landon MB, et al. Development of a nomogram for prediction of vaginal birth after cesarean delivery. *Obstetrics & Gynecology*. 2007;109(4):806-812.
3. Bujold E, Blackwell SC, Hendler I, Berman S, Sorokin Y, Gauthier RJ. Modified Bishop's score and induction of labor in patients with a previous cesarean delivery. *American Journal of Obstetrics & Gynecology*. 2004;191(5):1644-1648.
4. Costantine MM, Fox K, Byers BD, et al. Validation of the prediction model for success of vaginal birth after cesarean delivery. *Obstetrics and Gynecology*. 2009;114(5):1029-1033.
5. Dinsmoor MJ, Brock EL. Predicting failed trial of labor after primary cesarean delivery. *Obstetrics & Gynecology*. 2004;103(2):282-286.
6. Gonen R, Tamir A, Degani S, Ohel G. Variables associated with successful vaginal birth after one cesarean section: a proposed vaginal birth after cesarean section score. *American Journal of Perinatology*. 2004;21(8):447-453.
7. Hashima JN, Guise J-M. Vaginal birth after cesarean: a prenatal scoring tool. *American Journal of Obstetrics & Gynecology*. 2007;196(5):e22-23.
8. Jakobi P, Weissman A, Peretz BA, Hocherman I. Evaluation of prognostic factors for vaginal delivery after cesarean section. *Journal of Reproductive Medicine*. 1993;38(9):729-733.
9. Smith GCS, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. *PLoS Medicine / Public Library of Science*. 2005;2(9):e252.
10. Troyer LR, Parisi VM. Obstetric parameters affecting success in a trial of labor: designation of a scoring system. *American Journal of Obstetrics & Gynecology*. 1992;167(4 Pt 1):1099-1104.
11. Vinueza CA, Chauhan SP, Barker L, Hendrix NW, Scardo JA. Predicting the success of a trial of labor with a simple scoring system. *Journal of Reproductive Medicine*. 2000;45(4):332-336.
12. Weinstein D, Benshushan A, Tanos V, Zilberstein R, Rojansky N. Predictive score for vaginal birth after cesarean section. *American Journal of Obstetrics & Gynecology*. 1996;174(1 Pt 1):192-198.
13. Macones GA, Hausman N, Edelstein R, Stamilio DM, Marder SJ. Predicting outcomes of trials of labor in women attempting vaginal birth after cesarean delivery: a comparison of multivariate methods with neural networks. *American Journal of Obstetrics & Gynecology*. 2001;184(3):409-413.
14. Pickhardt MG, Martin JN, Jr., Meydrech EF, et al. Vaginal birth after cesarean delivery: are there useful and valid predictors of success or failure? *American Journal of Obstetrics & Gynecology*. 1992;166(6 Pt 1):1811-1815; discussion 1815-1819.
15. Altman D. Prognosis and prognostic research: validating prognostic model. *BMJ*. 2009;338:1430-1435.
16. Alamia VJ, Meyer BA, Selioutski O, Vohra N. Can a VBAC scoring system predict uterine rupture in patients attempting a trial of labor? Paper presented at: ACOG 47th Annual Clinical Meeting; May 19, 1999.
17. Macones GA. The utility of clinical tests of eligibility for a trial of labour following a caesarean section: a decision analysis. *British Journal of Obstetrics & Gynaecology*. 1999;106(7):642-646.
18. Flamm BL. Once a cesarean, always a controversy. *Obstetrics & Gynecology*. 1997;90(2):312-315.
19. Grobman WA, Gilbert S, Landon MB, et al. Outcomes of induction of labor after one prior cesarean. *Obstetrics & Gynecology*. 2007;109(2 Pt 1):262-269.

Appendix N. Detailed Evaluation of Screening Tools for Predicting Vaginal Birth After Cesarean, continued

20. Guise JM, McDonagh MS, Hashima J, et al. Vaginal birth after cesarean (VBAC). *Evidence Report: Technology Assessment*. 2003(71):1-8.

Appendix O. Detailed Maternal Mortality Table

Table O-1. Maternal mortality rates for trial of labor versus elective repeat cesarean delivery among any gestational age studies

Author, year	Study description	N	Overall maternal death (followed by death per 100,000)	Maternal death by delivery type (followed by death per 100,000)
<i>Term gestational age</i>				
Gregory, 2008 ¹	Retrospective cohort Low risk = absence of maternal complications High Risk = any maternal condition ICD9 codes	41,450	2/41,450 (0.005%) Overall: 5/100,000 Low-risk 1/29,126 (0.003%) 3/100,000 High-risk 1/12,324 (0.008%) 8/100,000	Low-risk TOL: 0/8,292 (0%) RCD: 1/20,834 (0.005%) 4.7/100,000 High-risk TOL: 0/3,188 (0%) ERCD: 1/9,136 (0.011%) 10.9/100,000
Loebel 2004 ²	Retrospective Cohort Community Teaching Hospital	1,408	0/1,408 (0%)	TOL: 0/927 ERCD: 0/481
Spong, 2007 ³	MFMU Network cohort 19 University hospitals	39,117	6/39,117 (0.015%) 15/100,000	TOL: 1/15,323 (0.007%) 6.5/100,000 ERCD: (no indication/no labor): 5/14,993 (0.033%) 33.3/100,000 All other groups: 0
Wen, 2004 ⁴	Retrospective cohort Canadian Registry ICD9 codes	308,755	12/308,755 (0.004%) 4/100,000	TOL: 2 /128,960 (0.002%) 15/100,000 ERCD: 10/179,795 (0.006%) 5.6/100,000
<i>Any gestational age</i>				
Bais, 2001 ⁵	Prospective Cohort Netherlands Regional hospital	252	0/252 (0%)	TOL: 0/184 ERCD: 0/68
Eglinton 1984 ⁶	Retrospective cohort University Hospital	871	1/871 (0.115%) 115/100,000	TOL: 0/308 ERCD: 1/563 117.6/100,000
Eriksen, 1989 ⁷	Retrospective Cohort Military Base	139	0/139 (0%)	TOL: 0/71 ERCD: 0/68
Flamm, 1994 ⁸	Prospective cohort 10 Kaiser Hospital in CA	7,229	1/7229 (0.014%) 14/100,000	TOL 1/5022 (0.020%) 20/100,000 ERCD: 0/2208 (0%)
Martin, 1983 ⁹	Prospective Cohort 2 University Centers	709	0/709 (0%)	TOL: 0/162 ERCD: 0/547

Appendix O. Detailed Maternal Mortality Table, continued

Table O-1. Maternal mortality rates for trial of labor versus elective repeat cesarean delivery among any gestational age studies

Author, year	Study description	N	Overall maternal death (followed by death per 100,000)	Maternal death by delivery type (followed by death per 100,000)
Obara, 1998 ¹⁰	Prospective Cohort University Hospital, Japan	310	0/310 (0%)	TOL: 0/214 ERCD:0/96
Phelan,1987 ¹¹	Prospective Cohort University hospital ≥2 prior CD only	2,643	2/2643 (0.076%) 76/100,000	TOL: 1/1796 (0.056%) 55.7/100,000 RCD: 1/847 (0.118%) 118/100,000
Zelop, 1999 ¹²	Retrospective Cohort University Hospital	2,774	0/2774 (0%)	Not reported

Abbreviations: CA=California; CD=cesarean delivery; ERCD=elective repeat cesarean delivery; ICD-9= International Classification of Diseases, 9th Edition/Revision; MFMU=Maternal Fetal Medicine Units; RCD=repeat cesarean delivery; TOL=trial of labor

Appendix O. Detailed Maternal Mortality Table

References

1. Gregory KD, Korst LM, Fridman M, et al. Vaginal birth after cesarean: clinical risk factors associated with adverse outcome. *Am J Obstet Gynecol.* 2008;198(4):452.e451-410; discussion 452.e410-452.
2. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
3. Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstet Gynecol.* 2007;110(4):801-807.
4. Wen SW, Rusen ID, Walker M, et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(4):1263-1269.
5. Bais JM, van der Borden DM, Pel M, et al. Vaginal birth after caesarean section in a population with a low overall caesarean section rate. *Eur J Obstet Gynecol Reprod Biol.* 2001;96(2):158-162.
6. Eglinton GS, Phelan JP, Yeh S, Diaz FP, Wallace TM, Paul RH. Outcome of a trial of labor after prior cesarean delivery. *J Reprod Med.* 1984;29(1):3-8.
7. Eriksen NL, Buttino L, Jr. Vaginal birth after cesarean: a comparison of maternal and neonatal morbidity to elective repeat cesarean section. *Am J Perinatol.* 1989;6(4):375-379.
8. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol.* 1994;83(6):927-932.
9. Martin JN, Jr., Harris BA, Jr., Huddleston JF, et al. Vaginal delivery following previous cesarean birth. *Am J Obstet Gynecol.* 1983;146(3):255-263.
10. Obara H, Minakami H, Koike T, Takamizawa S, Matsubara S, Sato I. Vaginal birth after cesarean delivery: results in 310 pregnancies. *J Obstet Gynaecol Res.* 1998;24(2):129-134.
11. Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after cesarean. *Am J Obstet Gynecol.* 1987;157(6):1510-1515.
12. Zelop CM, Shipp TD, Repke JT, Cohen A, Caughey AB, Lieberman E. Uterine rupture during induced or augmented labor in gravid women with one prior cesarean delivery. *Am J Obstet Gynecol.* 1999;181(4):882-886.

Appendix P. Predictive Tools of Uterine Rupture Table

Table P-2. Predictive tools of uterine rupture

Author, year, country	Study years/ Population	# UR/ population	Score development	Predictors included (point values if provided)	Factors , OR, and score	Score and UR
Shipp, 2008 ¹ US	Retrospective Cohort 1984-1996 TOL among prior cesarean (4% among women with >1 CD)	40/4,383 TOLs	Score development only	Maternal age (<30, 30-39; >40) interdelivery interval >18 months having > 1 prior cesarean number of prior VDs	<u>Factor OR (95%CI) Score</u> Age>40 5.8 (1.6-20.3) 2 Age 30-39 2.6 (1.1-6.0) 1 ≥2 prior CD 5.3 (2.1-12.9) 2 Interdelivery 2.4 (1.0-5.6) interval 1 Prior VD 0.3 (0.1-0.9) -1	<u>Score% w/ Score% UR (n)</u> -1 8.9% 0.26% (1) 0 36.8% 0.25 (4) 1 43.2% 1.11% (21) 2 8.4% 2.43% (9) 3 2.5% 3.70% (4) 4 0.2% 14.29% (1) <i>Overall UR rate: 0.91%</i>
Macones , 2006 ² USA	Secondary Analysis of Nested Case-Control (nested in retrospective cohort) identified by ICD9 code 1996-2000	134 cases UR (670 controls)/25 ,000 TOLs Cases: UR TOL Controls: no UR TOL	At least 17 factors examined and analyzed using Chi square, unpaired t-tests and the Mann-Whitney U test. Those significant at p<0.1 were included in two regression models using backwards stepwise elimination: antepartum and early intrapartum factors Final model selected by ROC characteristics	"No individual factors are sufficient"	<u>Factor OR (95%CI) Beta Coefficient</u> Mat Age 1.11 (1.05-1.17) 0.05 GA at deliv 1.12 (0.97-1.20) 0.11 Ethnicity .84 (.74-1.0) -0.43 Prior VD .40 (.20-.80) -0.83 Cerv dil >3cm .66 (.41-1.11) -0.39 IOL 1.94 (1.32-2.81) 0.59	Antepartum model AUC 0.67 Intrapartum + Antepartum model AUC 0.70 optimal cut point yield sensitivity of 75% and FP rate of 40% <i>Overall UR rate: 0.98%</i>

Appendix P. Predictors of Uterine Rupture Table, continued

Table P-2. Predictive tools of uterine rupture

Author, year, country	Study years/ Population	# UR/ population	Score development	Predictors included (point values if provided)	Factors , OR, and score	Score and UR
Smith, 2005 ³ Scotland	Retrospective Cohort 1985-2001 National Dataset hosp discharge and perinatal deaths Designed to look at unplanned CD (UR secondary) 40-43wks GA	101 UR/23,386 1 prior CD	Score Development and Validation Groups		<u>Factor for Emergent CD OR (95%CI)</u> Mat Age (5yr inc) 1.22 (1.16-1.28) Mat Ht (5cm inc) 0.75 (0.73-0.78) Male infant 1.18 (1.08-1.29) Prior VD 0.19 (0.17- 0.22) - 1/5.08 (4.52-5.72) GA .66	Predicted risk of UR associated with risk of Emergent CD Overall UR rate: 0.4-0.5%
Grobman , 2008 ⁴	Cohort MFMU Cesarean registry 1999-2002 1 prior LTCD ≥37 weeks looked for factors known prenatally or at admission	83 UR/11,855 LTCD TOL	Logistic Regression of factors associated with UR (20 factors) Divided population into development and testing populations ROC generated from regression and c statistic was determined Partitioned UR into 10 groups 0-0.5% 0.5-1.0% ... 4.5-5.0%	Maternal age, ethnicity, BMI, Medical HX: recurrent indication for CD, time since last CD, N prior VD, VD before CD, prior PTD, prior birth wt, GDM, asthma, CHTN, connective tissue disorder Intrapartum: IOL, IOL indication, cervical exam, EGA, PIH	"Predictive nomogram was not developed because it would have little clinical value" <u>Factor OR (95%CI)</u> Any prior VD 0.44 (0.27-0.71) IOL 1.71 (1.11-2.69) Best Model to predict UR $\exp(w)/[1+\exp(w)]$, where $w=-4.81-0.82(\text{previous VD}) + 0.55(\text{IOL})$	ROC - 0.627 (0.568-0.686) "predicted probabilities do not reflect empiric probabilities that the pt experienced" <i>Overall UR rate: 0.7%</i>

Abbreviations: CD=cesarean delivery; CHTN=chronic hypertension; CI=confidence interval; cm=centimeter; EGA= estimated gestational age; GA=gestational age; GDM=gestational diabetes mellitus; IOL=induction of labor; LTCD=low transverse cesarean delivery; MFMU=Maternal-Fetal Medicine Units Network; Ob HX= obstetric history; OR=odds ratio; PIH=pregnancy induced hypertension; PTD=permanently and totally disabled; ROC= receiver operating characteristic; TOL=trial of labor; UR= uterine rupture; VD=vaginal delivery; wks=weeks; wt=weight; y=year(s)

Appendix P. Predictors of Uterine Rupture Table, continued

References

1. Shipp TD, Zelop C, Lieberman E. Assessment of the rate of uterine rupture at the first prenatal visit: a preliminary evaluation. *J Matern Fetal Neonatal Med.* 2008;21(2):129-133.
2. Macones GA, Cahill AG, Stamilio DM, Odibo A, Peipert J, Stevens EJ. Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted?[see comment]. *Am J Obstet Gynecol.* 2006;195(4):1148-1152.
3. Smith GCS, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section.[see comment]. *PLoS Med.* 2005;2(9):e252.
4. Grobman WA, Lai Y, Landon MB, et al. Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. *Am J Obstet Gynecol.* 2008;199(1):30.e31-35.

Appendix Q. Detailed Transfusion/Hemorrhage Table

Table Q-1. Transfusion rates for trial of labor versus elective repeat cesarean delivery among any gestational age studies

Author, year	Study description	N	Blood transfusion	Blood Transfusion per 10,000	Hemorrhage	Hemorrhage Rate per 10,000
<i>Term gestational age</i>						
Gregory, 2008 ¹	Retrospective cohort Low-risk = absence of maternal complications High-risk = any maternal condition ICD-9 codes	41,450	Low-risk TOL: 38/8292 (0.46%) ERCD: 69/20,834 (0.33%) High-risk TOL: 25/3188 (0.78%) ERCD: 84/9136 (0.92%)	Low-risk TOL: 46 ERCD: 33 High-risk TOL: 78 ERCD: 92	Low-risk TOL: 196/8292 (2.36%) ERCD: 142/2083 (6.82%) High-risk TOL: 104/3188 (3.26%) ERCD: 144/9136 (1.57%)	Low-risk TOL:236 ERCD: 682 High-risk TOL:326 ERCD: 157
Loebel, 2004 ²	Retrospective Cohort Community Teaching Hospital	1,408 TOL: 927 ERCD: 481	TOL: 12/927 (1.29%) ERCD: 3/481 (0.62%)	TOL: 129 ERCD: 62	Not reported	Not reported
Spong 2007 ³	MFMU study 19 Academic centers	39,117	TOL: 227/15,323 (1.48%) ERCD: no labor: 138/14,993 (0.92%) ERCD + labor: 45/2721 (1.65%) IRCD no labor: 107/5002 (2.14%) IRCD + labor: 23/1078 (2.13%)	TOL: 148 ERCD: no labor: 92 ERCD + labor: 165 IRCD no labor: 214 IRCD + labor: 213	Not reported	Not reported
Wen, 2004 ⁴	Retrospective cohort Canadian Registry ICD-9 codes	308,755	TOL: 245/128,960 (0.19%) ERCD: 268/179,795 (0.15%), adjusted odds ratio 1.67 (1.39-2.00)	TOL: 19 ERCD: 15 adjusted odds ratio 1.67 (1.39-2.00)	Not reported	Not reported

Appendix Q. Detailed Transfusion/Hemorrhage Table, continued

Table Q-1. Transfusion rates for trial of labor versus elective repeat cesarean delivery among any gestational age studies

Author, year	Study description	N	Blood transfusion	Blood Transfusion per 10,000	Hemorrhage	Hemorrhage Rate per 10,000
<i>Any gestational age</i>						
Bais, 2001 ⁵	Prospective Cohort Netherlands Regional hospital	252	TOL: 8/184 (4.35%) ERCD: 4/68 (5.88%)	TOL: 435 ERCD: 588	Hemorrhage >500 mL TOL: 31/184 (16.85%) ERCD: 20/68 (29.41%) Hemorrhage >1000 mL TOL: 9/184 (4.89%) ERCD: 6/68 (8.83%)	Hemorrhage >500 mL TOL: 168.5 ERCD: 294.1 Hemorrhage >1000 mL TOL: 489 ERCD: 8.83%
Flamm, 1994 ⁶	Prospective cohort 10 Kaiser Hospital in CA	7229	VBAC: 25/3516 (0.71%) ERCD: 38/2208 (1.72%) (p=.0001)	VBAC: 71 ERCD: 172 (p=.0001)	Not reported	Not reported
Hibbard, 2001 ⁷	Prospective Cohort University Hospital	2450	ERCD: 6/431 (1.40%) TOL: 11/1,324 (0.83%) VBAC: 4/908 (0.44%) TOL-CD: 7/416 (1.68%)	ERCD: 140 TOL: 83 VBAC: 44 TOL-CD: 168	>1,000mL ERCD: 32/431 (7.42%) TOL: 46/1,324 (3.47%) VBAC: 7/908 (0.77%) TOL-CD: 39/416 (9.37%) >2,000mL ERCD: 5/431 (1.16%) TOL: 8/1,324 (0.60%) VBAC: 3/908 (0.33%) TOL-CD: 5/416 (1.20%)	>1,000mL ERCD: 742 TOL: 347 VBAC: 77 TOL-CD: 937 >2,000mL ERCD: 116 TOL: 60 VBAC: 33 TOL-CD: 120
Kugler, 2008 ⁸	Retrospective cohort Israel University Grand Multiparous women	1102	ERCD: 18/328 (5.49%) TOL: 8/155 (5.16%) VBAC: 6/619 (1.0%) p<0.001	ERCD: 549 TOL: 516 VBAC: 100 p<0.001	ERCD: 3/328 (0.91%), TOL: 1/155 (0.64%), VBAC: 5/619 (0.81%) p<0.001	ERCD: 91 TOL: 64 VBAC: 81 p<0.001
Martin, 1983 ⁹	Prospective Cohort 2 University Centers	709	Not reported	Not reported	VBAC: 6/101 (5.94%) TOL-CD: 9/61 (14.75%) ERCD: 57/547 (10.42%)	VBAC: 594 TOL-CD: 1475 ERCD: 1042

Appendix Q. Detailed Transfusion/Hemorrhage Table, continued

Table Q-1. Transfusion rates for trial of labor versus elective repeat cesarean delivery among any gestational age studies

Author, year	Study description	N	Blood transfusion	Blood Transfusion per 10,000	Hemorrhage	Hemorrhage Rate per 10,000
McMahon, 1996 ¹⁰	Retrospective cohort Population based Longitudinal study Canada	6,138	TOL: 36/3429 (1.05%) ERCD: 39/2889 (1.35%)	TOL: 105 ERCD: 135	Not reported	
Obara, 1997 ¹¹	Prospective Cohort University Hospital, Japan	310	Not reported	Not reported	ERCD: 4/96 (4.17%) TOL: 3/214 (1.40%)	ERCD: 417 TOL: 140

Abbreviations: CA=California; ERCD=elective repeat cesarean delivery; IRCD=indicated repeat cesarean delivery; MFMU=Maternal-Fetal Medicine Units Network; mL=milliliter; TOL=trial of labor; TOL-CD=trial of labor followed by a cesarean delivery; VBAC=vaginal birth after cesarean

Appendix Q. Detailed Transfusion/Hemorrhage Table, continued

References

1. Gregory KD, Korst LM, Fridman M, et al. Vaginal birth after cesarean: clinical risk factors associated with adverse outcome. *Am J Obstet Gynecol.* 2008;198(4):452.e451-410; discussion 452.e410-452.
2. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
3. Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstet Gynecol.* 2007;110(4):801-807.
4. Wen SW, Rusen ID, Walker M, et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(4):1263-1269.
5. Bais JM, van der Borden DM, Pel M, et al. Vaginal birth after caesarean section in a population with a low overall caesarean section rate. *Eur J Obstet Gynecol Reprod Biol.* 2001;96(2):158-162.
6. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol.* 1994;83(6):927-932.
7. Hibbard JU, Ismail MA, Wang Y, Te C, Karrison T. Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. *Am J Obstet Gynecol.* 2001;184(7):1365-1371; discussion 1371-1363.
8. Kugler E, Shoham-Vardi I, Burstien E, Mazor M, HersHKovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. *Arch Gynecol Obstet.* 2008;277(4):339-344.
9. Martin JN, Jr., Harris BA, Jr., Huddleston JF, et al. Vaginal delivery following previous cesarean birth. *Am J Obstet Gynecol.* 1983;146(3):255-263.
10. McMahon MJ, Luther ER, Bowes WA, Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section.[see comment]. *N Engl J Med.* 1996;335(10):689-695.
11. Obara H, Minakami H, Koike T, Takamizawa S, Matsubara S, Sato I. Vaginal birth after cesarean delivery: results in 310 pregnancies. *J Obstet Gynaecol Res.* 1998;24(2):129-134.

Q

Appendix R. Detailed Infection Table

Table R-1. Infection rates for trial of labor versus elective repeat cesarean delivery

Author, year	Study description	N	Fever	Fever per 10,000	Endometritis Chorio- amnionitis	Endometritis or Chorio- amnionitis per 10,000	Wound/Other	Wound/ Other per 10,000
<i>Term gestational age</i>								
Eriksen, 1989 ¹	Retrospective cohort military base	139	TOL: 4/71 (5.6%) ERCD: 7/68 (10.2%) (p:NS)	TOL: 560 ERCD: 1020 (p:NS)	TOL: 2/71 (2.8%) ERCD: 1/68 (1.5%) (p:NS)	TOL: 280 ERCD: 150	Not reported	
Hook, 1997 ²	Prospective cohort level 1, 2, & 3 hospital included	989	Maternal fever TOL: 38/492 (8%) ERCD: 0/497 (0%) (p=<0.0002)	Maternal fever TOL: 80 ERCD: 0 (p=<0.0002)	Not reported	Not reported	Not reported	Not reported
Loebel, 2004 ³	Retrospective cohort community teaching hospital	1,408	Not reported	Not reported	Not reported	Not reported	"Infection" ERCD: 11/481 (1.9%) VBAC 14/749 (2.3%) TOL-CD 9/178 (5.1%) (p:NS)	"Infection" ERCD: 190 VBAC 230 TOL-CD 510 (p:NS)
Spong, 2007 ⁴	MFMU network cohort 19 university hospitals	39,117	Not reported	Not reported	TOL: 442/15,323 (2.9%) ERCD no labor: 260/14,993(1.7%) ERCD + labor: 101/2721 (3.7%) IRCD no labor 137/5002 (2.7%) IRCD + labor: 54/1078 (5.0%)	TOL: 290 ERCD no labor: 170 ERCD + labor: 370 IRCD no labor 270 IRCD + labor: 500	Not reported	Not reported

Appendix R. Detailed Infection Table, continued

Table R-1. Infection rates for trial of labor versus elective repeat cesarean delivery

Author, year	Study description	N	Fever	Fever per 10,000	Endometritis Chorio- amnionitis	Endometritis or Chorio- amnionitis per 10,000	Wound/Other	Wound/ Other per 10,000
Wen, 2004 ⁵	Retrospective cohort Canadian registry ICD-9 codes	308,755	Not reported	Not reported	Not reported	Not reported	“Postpartum Infection” TOL: 487/128,960 (0.38%) ERCD: 837/179,795 (0.47%); Adjusted odds ratio: 0.86 (0.77-0.97)	“Postpartum Infection” TOL: 380 ERCD: 470 Adjusted odds ratio: 0.86 (0.77-0.97)
<i>All gestational ages</i>								
Bais, 2001 ⁶	Prospective cohort Netherlands regional hospital	252	TOL: 16/184 (9%) ERCD: 7/68 (10%)	TOL: 900 ERCD: 1000	Not reported	Not reported	Not reported	Not reported
Cahill, 2006 ⁷	Retrospective cohort 16 university & community hospitals	6,619	TOL: 329/5041 (6.52%) ERCD: 294/1578(18.63%)	TOL: 652 ERCD: 1863	Not reported	Not reported	Not reported	Not reported

Appendix R. Detailed Infection Table, continued

Table R-1. Infection rates for trial of labor versus elective repeat cesarean delivery

Author, year	Study description	N	Fever	Fever per 10,000	Endometritis Chorio- amnionitis	Endometritis or Chorio- amnionitis per 10,000	Wound/Other	Wound/ Other per 10,000
Durnwald, 2004 ⁸	Retrospective cohort university hospital	768	TOL: 27/522(5.2%) VBAC: 7/344(2.0%) TOL-CD: 20/178 (11.2%) ERCD: 6/246 (2.4%)	TOL: 520 VBAC: 200 TOL-CD: 1120 ERCD: 240	Chorio- amnionitis TOL: 31/522(5.9%) VBAC: 18/344(5.2%) TOL-CD: 13/178(7.3%) ERCD: 0/246(0%) Endometritis TOL: 24/522 (4.6%) VBAC: 7/344(2%) TOL-CD: 17/178(9.6%) ERCD: 5/246(2%)	Chorio- amnionitis TOL: 590 VBAC: 520 TOL-CD: 730 ERCD: 0 Endometritis TOL: 460 VBAC: 200 TOL-CD: 960 ERCD: 200	Not reported	Not reported
Flamm, 1994 ⁹	Prospective cohort 10 Kaiser hospital in California	7,229	TOL: 638/5022 (12.7%) ERCD: 362/2208 (16.4%)	TOL: 1270 ERCD: 1640	Not reported	Not reported	Not reported	Not reported
McMahon, 1996 ¹⁰	Retrospective cohort population based longitudinal study Canada	6,138	TOL: 171/3424 (5.3%) ERCD: 185/2889 (6.4%)	TOL: 530 ERCD: 640	Not reported	Not reported	Wound TOL 43/3424 (1.3%) ERCD 63/2889 (2.2%)	Wound TOL 130 ERCD 220

Appendix R. Detailed Infection Table, continued

Table R-1. Infection rates for trial of labor versus elective repeat cesarean delivery

Author, year	Study description	N	Fever	Fever per 10,000	Endometritis Chorio- amnionitis	Endometritis or Chorio- amnionitis per 10,000	Wound/Other	Wound/ Other per 10,000
Phelan, 1987 ¹¹	Prospective Cohort University hospital ≥2 prior CD only	2,643	Planned TOL 159/ 1,796 (8.9%)* VBAC: 53/1465 (3.6%) TOL-CD: 106/331 (32%) No Planned TOL 163/847 (19.2%) VBAC: 4/69 (5.8%) ERCD: 56/314 (18%) IRCD: 103/464 (22%)	Planned TOL 890* VBAC: 360 TOL-CD: 320 No Planned TOL 1920 VBAC: 580 ERCD: 1800 IRCD: 2200	Not reported	Not reported	Not reported	Not reported
Kugler, 2008 ¹²	Retrospective cohort Israel University grand multiparous women	1,102	IRCD [†] 10/328 (3%), TOL: 9/619(1.5%), VBAC: 1/155(0.6%)	IRCD [†] 300 TOL: 150 VBAC: 60	Amnionitis IRCD ^a 4/328(1.2%) TOL: 5/619 (0.8%), VBAC: 14/155 (9.0%)	Amnionitis IRCD ^a 120 TOL: 80 VBAC: 900	Not reported	Not reported
Eglinton, 1984 ¹³	Retrospective cohort university hospital	871	VBAC: 6/240(2.5%) TOL-CD: 27/136 (19.8%) ERCD: 176/495 (35.5%)	VBAC: 250 TOL-CD: 1980 ERCD: 3550	Not reported	Not reported	Not reported	Not reported
Chauhan, 2001 ¹⁴		69	Not reported	Not reported	TOL: 9/30 (30%) ERCD: 7/39 (18%)	TOL: 300 ERCD: 1800	Wound TOL: 8/30(27%) ERCD: 3/39(8%)	Wound TOL: 2700 ERCD: 800

Appendix R. Detailed Infection Table, continued

Table R-1. Infection rates for trial of labor versus elective repeat cesarean delivery

Author, year	Study description	N	Fever	Fever per 10,000	Endometritis Chorio- amnionitis	Endometritis or Chorio- amnionitis per 10,000	Wound/Other	Wound/ Other per 10,000
Hibbard, 2001 ¹⁵	Prospective cohort university hospital	2,450	Not reported	Not reported	Endometritis ERCD: 38/431 (8.8%) TOL: 108/1,324 (8.2%) VBAC: 31/908 (3.4%) TOL-CD: 77/416 (18.5%) Chorio- amnionitis ERCD: 18/431 (4.2%) TOL: 169/1,324 (12.8%) VBAC: 102/908 (11.2%) TOL-CD: 67/416 (16%)	Endometritis ERCD: 880 TOL: 820 VBAC: 340 TOL-CD: 1850 Chorio- amnionitis ERCD: 420 TOL: 1280 VBAC: 1120 TOL-CD: 1600	Not reported	Not reported

Appendix R. Detailed Infection Table, continued

Table R-1. Infection rates for trial of labor versus elective repeat cesarean delivery

Author, year	Study description	N	Fever	Fever per 10,000	Endometritis Chorio- amnionitis	Endometritis or Chorio- amnionitis per 10,000	Wound/Other	Wound/ Other per 10,000
Martin, 1983 ¹⁶	Prospective cohort 2 university centers	709	Not reported	Not reported	Endometritis VBAC: 1/101(1%) TOL-CD: 7/61 (11.5%) ERCD: 42/547 (7.7%) TOL: 8/162 = 4.9%	Endometritis VBAC: 100 TOL-CD: 1150 ERCD: 770 TOL: 490	Wound VBAC: 0/101 TOL-CD: 3/61 (4.9%) ERCD: 12/547 (2.2%) Any TOL: 3/162 (1.9%) Pulmonary: VBAC: 5/101 (5%) TOL-CD: 1/61 (1.6%) ERCD: 31/547 (5.7%) Other: VBAC: 3/101 (3%) TOL-CD: 2/61 (3.2%) ERCD:36/547(6.6%)	Wound VBAC: 0 TOL-CD: 490 ERCD: 220 Any TOL: 190 Pulmonary VBAC: 500 TOL-CD: 160 ERCD: 570 Other: VBAC: 300 TOL-CD: 320 ERCD: 660

*p < .05; † includes both ERCD as well as emergency CD

Abbreviations: ERCD=elective repeat cesarean delivery; IRCD=indicated repeat cesarean delivery; NS=not significant; TOL=trial of labor; TOL-CD=trial of labor followed by a cesarean delivery; UTI=urinary tract infection; VBAC=vaginal birth after cesarean

Appendix R. Detailed Infection Table, continued

References

1. Eriksen NL, Buttino L, Jr. Vaginal birth after cesarean: a comparison of maternal and neonatal morbidity to elective repeat cesarean section. *Am J Perinatol.* 1989;6(4):375-379.
2. Hook B, Kiwi R, Amini SB, Fanaroff A, Hack M. Neonatal morbidity after elective repeat cesarean section and trial of labor. *Pediatrics.* 1997;100(3 Pt 1):348-353.
3. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
4. Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and adverse perinatal outcome at term after cesarean delivery. *Obstet Gynecol.* 2007;110(4):801-807.
5. Wen SW, Rusen ID, Walker M, et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. *Am J Obstet Gynecol.* 2004;191(4):1263-1269.
6. Bais JM, van der Borden DM, Pel M, et al. Vaginal birth after caesarean section in a population with a low overall caesarean section rate. *Eur J Obstet Gynecol Reprod Biol.* 2001;96(2):158-162.
7. Cahill AG, Stamilio DM, Odibo AO, et al. Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery? *Am J Obstet Gynecol.* 2006;195(4):1143-1147.
8. Durnwald C, Mercer B. Vaginal birth after Cesarean delivery: predicting success, risks of failure. *J Matern Fetal Neonatal Med.* 2004;15(6):388-393.
9. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol.* 1994;83(6):927-932.
10. McMahon MJ, Luther ER, Bowes WA, Jr., Olshan AF. Comparison of a trial of labor with an elective second cesarean section.[see comment]. *N Engl J Med.* 1996;335(10):689-695.
11. Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after cesarean. *Am J Obstet Gynecol.* 1987;157(6):1510-1515.
12. Kugler E, Shoham-Vardi I, Burstien E, Mazor M, Hershkovitz R. The safety of a trial of labor after cesarean section in a grandmultiparous population. *Arch Gynecol Obstet.* 2008;277(4):339-344.
13. Eglinton GS, Phelan JP, Yeh S, Diaz FP, Wallace TM, Paul RH. Outcome of a trial of labor after prior cesarean delivery. *J Reprod Med.* 1984;29(1):3-8.
14. Chauhan SP, Magann EF, Carroll CS, Barrilleaux PS, Scardo JA, Martin JN, Jr. Mode of delivery for the morbidly obese with prior cesarean delivery: vaginal versus repeat cesarean section. *Am J Obstet Gynecol.* 2001;185(2):349-354.

Appendix R. Detailed Infection Table, continued

15. Hibbard JU, Ismail MA, Wang Y, Te C, Karrison T. Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. *Am J Obstet Gynecol.* 2001;184(7):1365-1371; discussion 1371-1363.
16. Martin JN, Jr., Harris BA, Jr., Huddleston JF, et al. Vaginal delivery following previous cesarean birth. *Am J Obstet Gynecol.* 1983;146(3):255-263.

Appendix S. Detailed Hospital Stay Table

Table S-1. Length of stay: all studies from the United States

Author, year	Study description	N	Length of stay (days)	
<i>Term gestational age</i>				
Gregory, 2008 ¹	Retrospective cohort -Low risk: absence of maternal complications -High Risk: any maternal condition ICD-9 codes	41,450	Low-risk-TOL: 2.25 High-risk TOL: 2.86	Low-risk ERCD: 3.02 High-risk ERCD: 3.26
Loebel, 2004 ²	Retrospective cohort community teaching hospital	1,408	TOL: 2.02	ERCD: 3.14
Hook, 1997 ³	Prospective cohort level 1, 2, & 3 hospitals included	989	TOL only: 3.6(±1) VBAC: 3.1; (+2) TOL-CD: 4.8; (+2)*	ERCD: 4.5(±1) [†]
<i>Any gestational age</i>				
Eglinton, 1984 ⁴	Retrospective cohort university hospital	871	VBAC 2.4(1.0) TOL-CD 5(1.4)	ERCD-VD :2.3 (0.7) ERCD no labor:4.9 (1.6) ERCD labor:4.9 (1.5)
Eriksen, 1989 ⁵	Retrospective cohort military base	139	TOL: 3.1 ± 1.6	ERCD: 5.4 days ± 2.0 [‡]
Flamm, 1994 ⁶	Prospective cohort 10 Kaiser hospitals in California	7,229	TOL: 57.2 hours ± 31.1	ERCD: 84.9 hours ±26.3 [§]
Hibbard, 2001 ⁷	Prospective cohort university hospital	2,450	TOL: 3.26 ± 2.61 VBAC: 2.34 ± 1.85 TOL-CD: 5.31 ± 2.88	ERCD: 5.04 ± 3.09
Phelan, 1987 ⁸	Prospective cohort university hospital ≥2 prior CD only	2,643	VBAC: 2.2 TOL-CD: 4.2	ERCD: 4.2

* p <0.01

† p =0.002

‡ p=0.001

§ p<0.001

Abbreviations: CD=cesarean delivery; ERCD=elective repeat cesarean delivery; TOL=trial of labor; TOL-CD=trial of labor followed by a cesarean delivery; VBAC=vaginal birth after a cesarean

Appendix S. Detailed Hospital Stay Table, continued

References

1. Gregory KD, Korst LM, Fridman M, et al. Vaginal birth after cesarean: clinical risk factors associated with adverse outcome. *Am J Obstet Gynecol.* 2008;198(4):452.e451-410; discussion 452.e410-452.
2. Loebel G, Zelop CM, Egan JFX, Wax J. Maternal and neonatal morbidity after elective repeat Cesarean delivery versus a trial of labor after previous Cesarean delivery in a community teaching hospital. *J Matern Fetal Neonatal Med.* 2004;15(4):243-246.
3. Hook B, Kiwi R, Amini SB, Fanaroff A, Hack M. Neonatal morbidity after elective repeat cesarean section and trial of labor. *Pediatrics.* 1997;100(3 Pt 1):348-353.
4. Eglinton GS, Phelan JP, Yeh S, Diaz FP, Wallace TM, Paul RH. Outcome of a trial of labor after prior cesarean delivery. *J Reprod Med.* 1984;29(1):3-8.
5. Eriksen NL, Buttino L, Jr. Vaginal birth after cesarean: a comparison of maternal and neonatal morbidity to elective repeat cesarean section. *Am J Perinatol.* 1989;6(4):375-379.
6. Flamm BL, Goings JR, Liu Y, Wolde-Tsadik G. Elective repeat cesarean delivery versus trial of labor: a prospective multicenter study. *Obstet Gynecol.* 1994;83(6):927-932.
7. Hibbard JU, Ismail MA, Wang Y, Te C, Karrison T. Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. *Am J Obstet Gynecol.* 2001;184(7):1365-1371; discussion 1371-1363.
8. Phelan JP, Clark SL, Diaz F, Paul RH. Vaginal birth after cesarean. *Am J Obstet Gynecol.* 1987;157(6):1510-1515.